Clustering O 0 5.7598340390541125e-06
of O 0 8.595646932008094e-07
missense O 0 5.34096079718438e-06
mutations O 0 1.3128367015724507e-07
in O 0 1.5847490431042388e-08
the O 0 4.2607513250914053e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.3375513390201377e-06
in O 0 3.317801500202222e-08
a O 0 1.702514218493434e-08
sporadic B-Disease 0 3.7980603337928187e-06
T I-Disease 0 0.00017735185974743217
- I-Disease 0 8.60250074765645e-05
cell I-Disease 1 0.9994542002677917
leukaemia I-Disease 1 0.9999996423721313
. O 0 1.0348244359192904e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999867677688599
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.2070486266633225e-09
is O 0 5.618674414620273e-10
a O 0 1.5783893081433575e-09
recessive B-Disease 0 1.2553078931887285e-07
multi I-Disease 0 2.63545098277973e-06
- I-Disease 0 1.171137796518451e-06
system I-Disease 0 3.578187346420236e-08
disorder I-Disease 0 3.958445176976966e-06
caused O 0 4.171158352050952e-08
by O 0 4.725626001622629e-10
mutations O 0 3.1297593405810176e-09
in O 0 6.357934179135327e-10
the O 0 6.11863848476446e-09
ATM O 0 1.3390905451160506e-06
gene O 0 8.719794664102665e-08
at O 0 2.960261724638258e-07
11q22 O 0 1.7741209603627794e-06
- O 0 9.462436878493463e-07
q23 O 0 3.1462734568776796e-06
( O 0 4.8557783571823165e-08
ref O 0 3.0936812436266337e-06
. O 0 7.579458838335995e-08
3 O 0 6.003672865517728e-07
) O 0 3.912771973091367e-08
. O 0 4.0087945762934396e-07

The O 0 1.3308750794749358e-06
risk O 0 3.4123977457056753e-06
of O 0 6.366603884089272e-07
cancer B-Disease 0 8.356319995073136e-06
, O 0 1.1527985677162178e-08
especially O 0 6.031620358726286e-08
lymphoid B-Disease 0 0.16747061908245087
neoplasias I-Disease 1 0.9994920492172241
, O 0 7.39388594794832e-09
is O 0 1.5349949089582537e-09
substantially O 0 4.4878891714006386e-08
elevated O 0 3.2477709055456216e-07
in O 0 1.289222772982157e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.038383505961974e-07
and O 0 2.0985945425877617e-08
has O 0 9.474413475984989e-10
long O 0 1.7972685839584557e-10
been O 0 1.0414100831690476e-10
associated O 0 5.668451041884737e-09
with O 0 1.3457083447576679e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.5753165573405568e-06

By O 0 2.6921219387077144e-07
analysing O 0 2.9221027944004163e-06
tumour B-Disease 1 0.9991230368614197
DNA O 0 1.5206011028112698e-07
from O 0 7.785526001669041e-09
patients O 0 4.0537703749343734e-10
with O 0 3.6998598629267576e-10
sporadic B-Disease 0 4.757955309742101e-07
T I-Disease 0 4.444692876859335e-06
- I-Disease 0 2.182065600209171e-06
cell I-Disease 0 0.02555808611214161
prolymphocytic I-Disease 1 0.9786152839660645
leukaemia I-Disease 1 0.9993671774864197
( O 0 4.595236902105171e-08
T B-Disease 0 6.438473064918071e-06
- I-Disease 0 4.852046913583763e-06
PLL I-Disease 0 9.001599210023414e-06
) O 0 2.6069937320016834e-09
, O 0 4.3204290145482105e-10
a O 0 7.425979275943462e-10
rare O 0 1.3074036964155766e-08
clonal B-Disease 0 5.19941409038438e-07
malignancy I-Disease 0 6.840935498075851e-07
with O 0 1.2367811219604619e-09
similarities O 0 2.2870800364671595e-08
to O 0 3.971356132836945e-09
a O 0 2.914154784150469e-08
mature B-Disease 0 1.490236058998562e-07
T I-Disease 0 1.666267166910984e-06
- I-Disease 0 6.559805569850141e-07
cell I-Disease 0 1.5900284324743552e-06
leukaemia I-Disease 0 2.4084160031634383e-05
seen O 0 2.7747402597810833e-08
in O 0 2.325928338819949e-09
A B-Disease 1 1.0
- I-Disease 0 0.08018060773611069
T I-Disease 1 1.0
, O 0 8.071490142924631e-09
we O 0 6.400519003690874e-10
demonstrate O 0 1.9123078676130945e-09
a O 0 2.0490726893029887e-09
high O 0 9.427083114132984e-09
frequency O 0 7.462644724398615e-09
of O 0 1.4371734025075966e-08
ATM O 0 9.231142939825077e-06
mutations O 0 9.099771887122188e-07
in O 0 6.773995551156986e-07
T B-Disease 1 0.8952576518058777
- I-Disease 0 0.33783644437789917
PLL I-Disease 0 0.004818473011255264
. O 0 5.127451004227623e-06

In O 0 2.8426713427620598e-08
marked O 0 1.932306474827783e-07
contrast O 0 1.3087409378442771e-08
to O 0 2.0202544082081886e-09
the O 0 1.0639237935095025e-08
ATM O 0 1.2548786116894917e-06
mutation O 0 3.237077805806621e-08
pattern O 0 6.376325956125584e-08
in O 0 6.1129457051833924e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 1.2220184864020212e-08
the O 0 4.472352266304824e-09
most O 0 5.897031196688829e-10
frequent O 0 7.695844517208172e-10
nucleotide O 0 2.4299298129193403e-09
changes O 0 1.5365767547237397e-09
in O 0 6.478029779266592e-10
this O 0 6.665908269809506e-09
leukaemia B-Disease 0 0.0001842521596699953
were O 0 1.1117148801531584e-07
missense O 0 8.818768037599511e-06
mutations O 0 2.40186341216031e-06
. O 0 1.5075062265168526e-06

These O 0 2.9647989663317276e-07
clustered O 0 1.0692659770938917e-06
in O 0 2.595953452200206e-09
the O 0 5.416740833652511e-09
region O 0 6.697271182076747e-09
corresponding O 0 7.694131554103478e-09
to O 0 2.8509177241176076e-09
the O 0 2.591912817706543e-08
kinase O 0 6.787394681850856e-07
domain O 0 3.4686671313011175e-08
, O 0 2.884776639788811e-09
which O 0 6.308275568578381e-10
is O 0 2.5758634114581014e-10
highly O 0 1.3420934363850279e-09
conserved O 0 6.897974635933224e-09
in O 0 1.4527191671831474e-09
ATM O 0 1.382041887154628e-06
- O 0 1.932173745444743e-07
related O 0 4.257265828755408e-08
proteins O 0 4.662073838090919e-09
in O 0 1.2864954657132444e-09
mouse O 0 1.3688360667174493e-08
, O 0 2.8336564206199455e-09
yeast O 0 1.0374583325756248e-07
and O 0 5.3308529146534056e-08
Drosophila O 0 6.097170626162551e-07
. O 0 5.069958888270776e-07

The O 0 1.2357605783108738e-06
resulting O 0 1.0288366638633306e-06
amino O 0 3.180806800173741e-07
- O 0 9.736784534197795e-08
acid O 0 1.9831874809028704e-08
substitutions O 0 2.7526745327577373e-08
are O 0 1.3644820828773163e-09
predicted O 0 3.096473832897573e-08
to O 0 3.208957766176468e-09
interfere O 0 1.24077303098602e-07
with O 0 2.0687876300939934e-08
ATP O 0 0.0002053500502370298
binding O 0 4.954799806000665e-07
or O 0 9.611221685190685e-08
substrate O 0 1.2625562249013456e-06
recognition O 0 1.6930476931520388e-06
. O 0 1.9701030851138057e-06

Two O 0 5.953702952865569e-07
of O 0 7.046058385640208e-07
seventeen O 0 1.1722104318323545e-06
mutated O 0 2.1341422780096764e-06
T B-Disease 0 3.931162609660532e-06
- I-Disease 0 1.1437115290391375e-06
PLL I-Disease 0 1.860310817392019e-06
samples O 0 1.0576052034139138e-08
had O 0 6.2076472850947084e-09
a O 0 1.737082810926438e-09
previously O 0 5.210678999389984e-09
reported O 0 6.205128499914281e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9995779395103455
T I-Disease 1 1.0
allele O 0 8.778885785432067e-06
. O 0 9.207985272041697e-07

In O 0 1.0991612242605697e-07
contrast O 0 1.794055037862563e-07
, O 0 6.867728163939546e-09
no O 0 5.0244222116191395e-09
mutations O 0 9.65767377181237e-09
were O 0 2.910731211613893e-09
detected O 0 6.834380616993485e-09
in O 0 5.97102867150312e-10
the O 0 1.1635565400069936e-08
p53 O 0 6.349117143145122e-08
gene O 0 1.4349958554760178e-08
, O 0 8.749611701830418e-09
suggesting O 0 1.3072964044624769e-08
that O 0 3.1967381519670823e-10
this O 0 5.3680921929810665e-09
tumour B-Disease 1 1.0
suppressor O 0 1.839365722844377e-05
is O 0 1.4494119238150915e-09
not O 0 7.868539708688616e-10
frequently O 0 4.761511629425286e-09
altered O 0 1.1335718141936013e-08
in O 0 2.81483503172808e-09
this O 0 3.816974825099351e-08
leukaemia B-Disease 0 0.008823640644550323
. O 0 1.1947877283091657e-06

Occasional O 0 2.7154264898854308e-06
missense O 0 5.378710284276167e-06
mutations O 0 1.4494864331027202e-07
in O 0 1.3853147962095136e-08
ATM O 0 1.1203576832485851e-05
were O 0 6.22807263539471e-08
also O 0 2.8312254762852263e-09
found O 0 1.5331865776957443e-09
in O 0 1.268068205995121e-09
tumour B-Disease 1 0.9999855756759644
DNA O 0 4.584714119459932e-08
from O 0 5.7059397207126494e-09
patients O 0 7.767070320241487e-10
with O 0 1.1386224185727656e-09
B B-Disease 0 1.4159847978589823e-06
- I-Disease 0 2.94872620543174e-07
cell I-Disease 0 0.0008791980799287558
non I-Disease 1 0.9999964237213135
- I-Disease 1 0.9997594952583313
Hodgkins I-Disease 1 0.9999994039535522
lymphomas I-Disease 0 1.3090678294247482e-05
( O 0 2.0681918400100585e-08
B B-Disease 0 1.5526550214417512e-06
- I-Disease 0 8.459062428300967e-08
NHL I-Disease 0 0.0018012637738138437
) O 0 8.440053100855494e-10
and O 0 1.5738887970684345e-09
a O 0 1.194275345284268e-08
B B-Disease 0 1.277458295589895e-06
- I-Disease 0 1.2199788557154534e-07
NHL I-Disease 0 0.002658009994775057
cell O 0 6.322564149741083e-05
line O 0 1.8461912986822426e-05
. O 0 6.115875521572889e-07

The O 0 7.815926039711485e-08
evidence O 0 8.99123762110321e-08
of O 0 2.542284960327379e-08
a O 0 8.524488892547311e-10
significant O 0 4.4190002768118575e-09
proportion O 0 1.207615785148164e-08
of O 0 4.101627482100412e-09
loss O 0 1.965882390209117e-08
- O 0 2.8351609060450755e-08
of O 0 1.315775080001913e-06
- O 0 1.010634349540851e-07
function O 0 2.636044271753235e-09
mutations O 0 1.6209932285349282e-09
and O 0 3.0942509665621287e-10
a O 0 2.420035283279276e-10
complete O 0 1.0340318601365084e-09
absence O 0 1.5504679140576627e-07
of O 0 4.31452917837305e-08
the O 0 5.546686665525158e-09
normal O 0 2.2860759951726095e-09
copy O 0 3.843902973699187e-09
of O 0 5.340467623682343e-09
ATM O 0 5.232723196968436e-07
in O 0 8.784254990068519e-10
the O 0 4.641365070057191e-09
majority O 0 9.612534102032555e-10
of O 0 9.618462470939448e-09
mutated O 0 2.082918399537448e-06
tumours B-Disease 1 0.9999985694885254
establishes O 0 4.165140055079064e-08
somatic O 0 2.0355398078208964e-07
inactivation O 0 2.5697573846628075e-07
of O 0 4.638081918528769e-09
this O 0 1.603954052908918e-10
gene O 0 8.318367661352966e-10
in O 0 1.5128177599521564e-09
the O 0 1.097932944560398e-08
pathogenesis O 0 4.726740371552296e-06
of O 0 6.537092644975928e-08
sporadic B-Disease 0 5.54220196136157e-06
T I-Disease 0 9.913363464875147e-05
- I-Disease 0 0.00026155164232477546
PLL I-Disease 0 0.11023315042257309
and O 0 3.187049202324488e-08
suggests O 0 8.19722068001738e-09
that O 0 6.657963069756079e-10
ATM O 0 8.159706794685917e-07
acts O 0 3.043796326096526e-08
as O 0 7.550629277375265e-08
a O 0 1.9751060165162926e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0008217977010644972
. O 0 2.0497011519182706e-06

As O 0 2.5188714403157064e-07
constitutional O 0 1.541874468102833e-07
DNA O 0 1.32870979996369e-07
was O 0 3.153754235540873e-08
not O 0 1.8366778931078187e-10
available O 0 2.8041713395765555e-09
, O 0 5.396865732087974e-10
a O 0 3.105415036230852e-09
putative O 0 3.3586513836780796e-06
hereditary O 1 0.996961772441864
predisposition O 1 0.9999459981918335
to O 0 5.21977199241519e-06
T B-Disease 1 0.9999988079071045
- I-Disease 1 0.9759644865989685
PLL I-Disease 0 0.00011988540063612163
will O 0 9.5487635576319e-09
require O 0 7.696538517620866e-09
further O 0 3.7036407718460396e-08
investigation O 0 1.1456816650934343e-07
. O 0 3.843479134957306e-08
. O 0 2.685782760636357e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 3.788270987570286e-05
kinase O 0 6.144150574982632e-06
is O 0 6.260655993628461e-09
involved O 0 8.974182508225681e-10
in O 0 5.352811596748275e-11
the O 0 2.806823939938141e-10
modulation O 0 1.9452848221135355e-09
of O 0 8.135830897870733e-10
the O 0 2.3606374632834104e-09
Ca2 O 0 2.156015597165606e-07
+ O 0 6.504276939267584e-07
homeostasis O 0 6.912490562172025e-07
in O 0 7.195439621909827e-08
skeletal O 0 0.013195597566664219
muscle O 0 1.3083439625916071e-05
cells O 0 5.360735485737678e-06
. O 0 4.96062511956552e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9953364729881287
DM B-Disease 1 1.0
) O 0 8.735475631738154e-08
, O 0 2.788916209084391e-09
the O 0 1.8923012046201393e-09
most O 0 2.4840736134734698e-09
prevalent O 0 2.140603783118422e-06
muscular B-Disease 1 0.9794908165931702
disorder I-Disease 1 0.9317547082901001
in O 0 2.242055874290827e-09
adults O 0 2.346720817669734e-09
, O 0 2.2210412675693902e-10
is O 0 1.5209875026123143e-10
caused O 0 5.249744639002074e-09
by O 0 5.5366977669280004e-09
( O 0 2.0462538330434654e-08
CTG O 0 3.3742671803338453e-06
) O 0 2.055613901319475e-09
n O 0 1.0844630082829099e-08
- O 0 2.213414518337231e-08
repeat O 0 1.2904676438552087e-08
expansion O 0 2.904632090405812e-08
in O 0 8.173283161383438e-10
a O 0 1.1224309259816323e-09
gene O 0 9.22726617336167e-10
encoding O 0 6.917025618946582e-09
a O 0 3.321695629665555e-08
protein O 0 6.254535378502624e-07
kinase O 0 5.502702606463572e-06
( O 0 2.878886391499691e-07
DM B-Disease 1 0.9999998807907104
protein O 0 7.325184014916886e-07
kinase O 0 8.623991902823036e-07
; O 0 3.171265205992313e-08
DMPK O 0 0.0023768432438373566
) O 0 5.576141215435371e-10
and O 0 3.134997539344653e-10
involves O 0 4.907841910650745e-10
changes O 0 6.447840594780985e-10
in O 0 5.335122565952588e-09
cytoarchitecture O 0 4.911348696623463e-06
and O 0 1.1209813521873002e-07
ion O 0 2.9329768949537538e-05
homeostasis O 0 3.558287789928727e-05
. O 0 1.0274374290020205e-05

To O 0 2.351471373174263e-08
obtain O 0 1.909080538098351e-07
clues O 0 1.6850099200382829e-06
to O 0 5.706919381509579e-09
the O 0 1.5217667126421475e-08
normal O 0 4.537267628279551e-08
biological O 0 2.843043489519914e-07
role O 0 3.2063287136452345e-08
of O 0 1.420048363343085e-07
DMPK O 0 0.0561634823679924
in O 0 1.4577911322533055e-08
cellular O 0 1.813538119677105e-07
ion O 0 3.814860519923968e-06
homeostasis O 0 7.749717951810453e-07
, O 0 2.7683014991453092e-08
we O 0 8.66332605653497e-09
have O 0 2.227210638139354e-09
compared O 0 1.5458489599495806e-08
the O 0 1.892959211602374e-08
resting O 0 2.4407708565377106e-07
[ O 0 3.961130090601728e-08
Ca2 O 0 4.26682618126506e-08
+ O 0 5.474378284020531e-08
] O 0 2.2268549670911852e-08
i O 0 1.3195943004973287e-08
, O 0 1.6000926139625449e-09
the O 0 2.367211315856821e-09
amplitude O 0 1.2682139782782542e-08
and O 0 2.364787921038669e-09
shape O 0 4.495325711673104e-08
of O 0 7.044325656124784e-08
depolarization O 0 1.502816644460836e-07
- O 0 6.303590680545312e-07
induced O 0 6.077269745219382e-07
Ca2 O 0 2.648752115419484e-07
+ O 0 1.3677001220457896e-07
transients O 0 1.630150592291102e-07
, O 0 2.255037934162374e-09
and O 0 8.863930700542255e-10
the O 0 4.921492990916931e-09
content O 0 3.026544703743639e-08
of O 0 9.06303583292356e-08
ATP O 0 8.845933734846767e-06
- O 0 9.715558917378075e-07
driven O 0 1.0017809017881518e-06
ion O 0 3.3994953696492303e-07
pumps O 0 1.0698539654185879e-07
in O 0 1.0849636744580948e-08
cultured O 0 1.2076120583515149e-06
skeletal O 0 2.1444125195557717e-06
muscle O 0 9.906541720283712e-08
cells O 0 8.991941058411612e-08
of O 0 1.1575559710763628e-07
wild O 0 1.480894784577913e-08
- O 0 9.963367020304759e-09
type O 0 1.724887610521364e-08
and O 0 1.2409405947266805e-08
DMPK O 0 1.414631333318539e-05
[ O 0 7.593450845888583e-08
- O 0 5.979075012874091e-07
/ O 0 9.368004612042569e-07
- O 0 5.155296548764454e-06
] O 0 4.607787502663996e-07
knockout O 0 2.131539258698467e-05
mice O 0 1.1815350262622815e-06
. O 0 5.14135876983346e-07

In O 0 1.4165210586725152e-06
vitro O 0 4.616065780282952e-06
- O 0 3.851445853797486e-06
differentiated O 0 3.965321866417071e-06
DMPK O 0 0.00022966868709772825
[ O 0 8.909260600376001e-07
- O 0 1.1518729934323346e-06
/ O 0 7.447985694852832e-07
- O 0 6.541707762153237e-07
] O 0 1.1560534574073245e-07
myotubes O 0 9.419336493010633e-07
exhibit O 0 1.8824385605853422e-08
a O 0 7.157588743922361e-09
higher O 0 4.159939592796036e-08
resting O 0 1.1350954309818917e-07
[ O 0 1.7922827666438934e-08
Ca2 O 0 2.07726884582371e-08
+ O 0 3.511650348286821e-08
] O 0 2.6348292436750853e-08
i O 0 8.578251886603994e-09
than O 0 1.2929108894610408e-09
do O 0 1.867624499496401e-09
wild O 0 2.3213601707539055e-08
- O 0 9.135752598865565e-09
type O 0 1.8547570590499163e-08
myotubes O 0 3.738228997463011e-07
because O 0 4.26589608082395e-09
of O 0 7.552368508356722e-09
an O 0 1.5409556963774662e-09
altered O 0 3.076175092431299e-09
open O 0 4.210475079702292e-09
probability O 0 5.869172259309607e-09
of O 0 1.3135875498448968e-08
voltage O 0 9.939470828612684e-07
- O 0 2.7851973527504015e-07
dependent O 0 2.9619840802297404e-07
l O 0 5.99427849579115e-08
- O 0 4.415446852590321e-08
type O 0 1.2655415382312185e-08
Ca2 O 0 6.204832914136205e-08
+ O 0 5.5721066871683433e-08
and O 0 2.3765682755083617e-08
Na O 0 9.336345385690947e-08
+ O 0 8.827024089441693e-08
channels O 0 1.746109887790226e-07
. O 0 2.0236072373336356e-07

The O 0 3.5205675885663368e-06
mutant O 0 4.199155682726996e-06
myotubes O 0 7.117904715414625e-06
exhibit O 0 1.526849473520997e-07
smaller O 0 2.5067258491162647e-08
and O 0 3.71763109185963e-09
slower O 0 5.467126129587996e-08
Ca2 O 0 8.904625303784997e-08
+ O 0 5.876086106582079e-08
responses O 0 1.1880932682117873e-08
upon O 0 8.825741026896594e-09
triggering O 0 1.7420738629425614e-08
by O 0 1.1761494000950279e-09
acetylcholine O 0 4.784373572874756e-07
or O 0 4.071736725563824e-08
high O 0 2.0360621988402272e-07
external O 0 4.756948328576982e-07
K O 0 2.2292999801720725e-06
+ O 0 1.454998823646747e-06
. O 0 7.181699857028434e-07

In O 0 8.123557648787028e-08
addition O 0 1.4646924739736278e-07
, O 0 1.4887595156665157e-08
we O 0 3.993795516521459e-09
observed O 0 3.0796682981559798e-09
that O 0 1.677687988532739e-10
these O 0 9.52216971938924e-10
Ca2 O 0 1.6754471232616197e-07
+ O 0 3.557724426173081e-07
transients O 0 4.7325497121164517e-07
partially O 0 4.1531137640049565e-08
result O 0 6.161454013664525e-09
from O 0 1.6581558348605085e-09
an O 0 9.980289927824515e-10
influx O 0 1.78549282026097e-08
of O 0 9.996393046662888e-09
extracellular O 0 5.585183515677272e-08
Ca2 O 0 5.5506156115825434e-08
+ O 0 4.946509335468363e-08
through O 0 8.567003106918492e-09
the O 0 2.6891191495792555e-08
l O 0 1.6214238840461803e-08
- O 0 2.3317127784139302e-08
type O 0 2.3571832485913546e-08
Ca2 O 0 1.768749058328467e-07
+ O 0 6.291974727901106e-07
channel O 0 1.1081672255386366e-06
. O 0 3.811831561506551e-07

Neither O 0 3.281055114712217e-06
the O 0 1.84716014928199e-07
content O 0 1.0828098595538904e-07
nor O 0 2.6288114440831123e-07
the O 0 1.602824184487872e-08
activity O 0 3.479215493484844e-08
of O 0 3.874451692809089e-08
Na O 0 9.68392583899913e-08
+ O 0 1.4779806178921717e-07
/ O 0 1.5311920265048684e-07
K O 0 3.463438247308659e-07
+ O 0 1.1004240718648362e-07
ATPase O 0 2.433359327369544e-07
and O 0 5.653391710325195e-08
sarcoplasmic O 0 1.5992991393432021e-06
reticulum O 0 1.3377234608924482e-06
Ca2 O 0 2.7265926405561913e-07
+ O 0 2.0662565702878055e-07
- O 0 1.9098344239409926e-07
ATPase O 0 1.3086017247587733e-07
are O 0 1.1816855272073212e-09
affected O 0 1.6736818153617605e-08
by O 0 1.3632133644136957e-08
DMPK O 1 0.982738196849823
absence O 0 1.5212264770525508e-05
. O 0 1.7366534166285419e-06

In O 0 1.758922252292905e-07
conclusion O 0 1.3188315506340587e-06
, O 0 1.5934842778619895e-08
our O 0 1.0529435989781177e-08
data O 0 1.0498172997586153e-08
suggest O 0 1.3174014767969311e-08
that O 0 2.849515290392901e-09
DMPK O 0 0.0004702119913417846
is O 0 2.5288242611054557e-09
involved O 0 1.0996676902408353e-09
in O 0 6.326699164560523e-10
modulating O 0 7.878970365027271e-08
the O 0 5.224412902293807e-09
initial O 0 4.755730032002248e-09
events O 0 2.3260260384461162e-09
of O 0 9.124885735900534e-09
excitation O 0 6.406811735359952e-06
- O 0 9.764057722350117e-06
contraction O 0 4.2207895489809744e-07
coupling O 0 5.024501774641976e-07
in O 0 7.020918957323374e-08
skeletal O 0 0.00017947405285667628
muscle O 0 6.457572908402653e-06
. O 0 4.262369088792184e-07
. O 0 5.083370524516795e-07

Constitutional O 0 9.383157157571986e-05
RB1 O 0 0.002561752451583743
- O 0 4.094597898074426e-06
gene O 0 1.3576688218108757e-07
mutations O 0 1.0852372867020676e-07
in O 0 3.1183067239481943e-09
patients O 0 2.134005194776023e-09
with O 0 1.6395630408894135e-09
isolated O 0 1.0547003057581605e-06
unilateral B-Disease 0 3.886663762386888e-06
retinoblastoma I-Disease 1 0.9999655485153198
. O 0 3.598742296162527e-06

In O 0 5.5413917010582736e-08
most O 0 1.4272844239826554e-08
patients O 0 3.5055920388771256e-09
with O 0 7.135720903050924e-10
isolated O 0 3.8670694380016357e-07
unilateral B-Disease 0 9.879423714664881e-07
retinoblastoma I-Disease 1 0.9999282360076904
, O 0 2.685290567683296e-08
tumor B-Disease 0 9.5385894383071e-07
development O 0 1.3491752604011253e-08
is O 0 1.7943571628542543e-10
initiated O 0 9.903491360319094e-10
by O 0 1.2978368379990002e-10
somatic O 0 7.365891718791318e-08
inactivation O 0 2.741300590969331e-07
of O 0 6.190408630146749e-09
both O 0 2.3488881950584073e-09
alleles O 0 1.1495972174202507e-08
of O 0 8.535836570899846e-08
the O 0 2.973205255329958e-07
RB1 O 0 0.000306576956063509
gene O 0 1.0182611731579527e-06
. O 0 3.7528100165218348e-06

However O 0 5.896485504308657e-07
, O 0 1.1584722514612622e-08
some O 0 2.7744848640764985e-09
of O 0 1.0537673844623896e-08
these O 0 2.6806119546307627e-09
patients O 0 1.0700959007792221e-09
can O 0 1.0572133168906817e-09
transmit O 0 4.840779297410336e-07
retinoblastoma B-Disease 1 0.5153303742408752
predisposition O 0 0.0027032694779336452
to O 0 3.715321739150568e-08
their O 0 2.4580944568697305e-07
offspring O 0 1.4289604223449714e-05
. O 0 2.237167336716084e-06

To O 0 1.267841565066874e-08
determine O 0 1.4526367664302597e-08
the O 0 1.201348531765234e-08
frequency O 0 1.4295512329454141e-08
and O 0 8.549874142005365e-10
nature O 0 6.272728558798235e-09
of O 0 9.821854440872357e-09
constitutional O 0 2.2851925507438864e-07
RB1 O 0 0.0005388287827372551
- O 0 5.069504709354078e-07
gene O 0 2.7073632224983157e-08
mutations O 0 2.0637195063955005e-08
in O 0 1.1026459745266948e-09
patients O 0 4.048585633409374e-10
with O 0 2.64507860059382e-10
isolated O 0 6.630823179420986e-08
unilateral B-Disease 0 1.4503216050343326e-07
retinoblastoma I-Disease 0 0.0002446586440782994
, O 0 4.657985108735829e-09
we O 0 1.5143998277622472e-09
analyzed O 0 3.85150578097182e-09
DNA O 0 8.85021744778669e-09
from O 0 9.926757194023139e-09
peripheral O 0 7.219439339678502e-06
blood O 0 2.782367403142416e-07
and O 0 4.385015017760452e-08
from O 0 1.554257949010207e-07
tumor B-Disease 0 1.48570152305183e-05
tissue O 0 3.172162678310997e-06
. O 0 1.1412492995077628e-06

The O 0 1.8511950372612773e-07
analysis O 0 1.4008939785981056e-07
of O 0 6.368328513417509e-07
tumors B-Disease 1 1.0
from O 0 1.0450688137098041e-07
54 O 0 1.3010000543545175e-07
( O 0 1.6000681890560031e-09
71 O 0 2.69374957895252e-08
% O 0 6.531042373580931e-10
) O 0 5.1448040272461526e-11
of O 0 3.63081964493972e-09
76 O 0 5.52055645641758e-08
informative O 0 2.9819876345982266e-08
patients O 0 2.0096011521530954e-09
showed O 0 1.4234837308890746e-08
loss O 0 2.30098109454957e-08
of O 0 5.255367341305828e-08
constitutional O 0 1.2501365063144476e-06
heterozygosity O 1 0.9999990463256836
( O 0 0.03379547595977783
LOH O 1 1.0
) O 0 1.490203374032717e-07
at O 0 5.305590207171917e-07
intragenic O 0 3.1137617042986676e-05
loci O 0 3.0362061806954443e-06
. O 0 1.4336027334138635e-06

Three O 0 1.982368758035591e-06
of O 0 1.4256949043556233e-06
13 O 0 3.255962838011328e-06
uninformative O 0 0.0005105542368255556
patients O 0 2.9064065643069625e-07
had O 0 5.796959001713731e-08
constitutional O 0 5.111984933137137e-07
deletions O 0 1.740970037644729e-05
. O 0 2.7511580356076593e-06

For O 0 7.804036954439653e-07
39 O 0 6.577617568837013e-06
randomly O 0 4.6036674916649645e-07
selected O 0 1.7842760371422628e-06
tumors B-Disease 1 1.0
, O 0 2.626565844821016e-07
SSCP O 1 0.9848588109016418
, O 0 6.802909524594725e-08
hetero O 0 4.301316778310138e-07
- O 0 1.2051725661876844e-07
duplex O 0 8.307672771934449e-08
analysis O 0 9.474526940778105e-09
, O 0 4.4618445049771083e-10
sequencing O 0 1.2865224441327427e-09
, O 0 5.014864079555537e-10
and O 0 8.396635609031478e-10
Southern O 0 1.1651066778028962e-08
blot O 0 9.518545596165495e-08
analysis O 0 5.0843076415674204e-09
were O 0 2.67509570051061e-09
used O 0 1.9971975184773783e-09
to O 0 5.168562022817014e-09
identify O 0 5.167027552488435e-07
mutations O 0 3.52244160239934e-06
. O 0 3.0413352760660928e-06

Mutations O 0 6.092624857956253e-07
were O 0 5.0298897491529715e-08
detected O 0 3.2359416479721403e-08
in O 0 1.341617483774371e-09
21 O 0 3.639682688572066e-08
( O 0 1.0307512621210435e-09
91 O 0 2.7675572056296005e-08
% O 0 1.0840964792535601e-09
) O 0 1.4942740100831742e-10
of O 0 3.023526673473498e-08
23 O 0 0.006177249830216169
tumors B-Disease 1 1.0
with O 1 0.9999992847442627
LOH O 1 1.0
. O 0 3.3148629881907254e-05

In O 0 3.6384616919349355e-07
6 O 0 1.9774781776504824e-06
( O 0 2.2354852191597274e-08
38 O 0 2.8391607997946267e-07
% O 0 2.5266981840132985e-09
) O 0 2.5610491505290156e-10
of O 0 1.3158167888605021e-08
16 O 0 1.4453786434387439e-06
tumors B-Disease 1 1.0
without O 1 0.9928296208381653
LOH O 1 1.0
, O 0 9.50508027841579e-09
one O 0 1.5695510446889216e-09
mutation O 0 1.0764644731153794e-09
was O 0 2.6473307990215744e-09
detected O 0 1.7791654816079472e-09
, O 0 3.5815020393847874e-10
and O 0 8.097715831212327e-10
in O 0 1.2976072438775077e-09
9 O 0 4.8631005000743244e-08
( O 0 1.1940606281513055e-09
56 O 0 3.9011769814578656e-08
% O 0 8.34937952109982e-10
) O 0 8.009937157993363e-11
of O 0 4.862133362593113e-09
the O 0 4.1526865857122175e-07
tumors B-Disease 1 1.0
without O 1 0.9249648451805115
LOH O 1 1.0
, O 0 4.95941385736387e-08
both O 0 2.3740401644545273e-08
mutations O 0 9.268991618682776e-08
were O 0 4.84395634714474e-08
found O 0 3.291894046242305e-08
. O 0 4.2845312009376357e-07

Thus O 0 4.06492432603045e-07
, O 0 9.757918917330244e-09
a O 0 3.5722662605763844e-09
total O 0 4.105493722761366e-09
of O 0 8.140305318704577e-09
45 O 0 1.516869474471605e-08
mutations O 0 1.025140328181351e-08
were O 0 7.411040670035618e-09
identified O 0 5.301437866478409e-08
in O 0 8.540800955358918e-09
tumors B-Disease 1 1.0
of O 0 7.5754128374683205e-06
36 O 0 1.45425519804121e-06
patients O 0 5.1302308179401734e-08
. O 0 3.6500418332252593e-07

Thirty O 0 8.074184734141454e-06
- O 0 4.210935458104359e-07
nine O 0 1.5263778152529994e-07
of O 0 3.8965065840557145e-08
the O 0 9.729038907835275e-09
mutations O 0 1.1795694199179252e-08
- O 0 3.081420629769127e-08
including O 0 5.383657075697101e-09
34 O 0 2.3586365216488048e-07
small O 0 2.48317508777518e-08
mutations O 0 2.135720578166911e-08
, O 0 3.928511294049031e-09
2 O 0 3.748306198758655e-08
large O 0 3.121843406006519e-08
structural O 0 3.3489621387161606e-07
alterations O 0 4.922659968542575e-07
, O 0 1.1997730808843698e-08
and O 0 1.0108325732005596e-08
hypermethylation O 0 1.3069298802292906e-05
in O 0 7.817163094614443e-08
3 O 0 2.7675682758854236e-06
tumors O 1 1.0
- O 0 1.2198090360016067e-07
were O 0 2.186370640089308e-09
not O 0 1.7260015638953519e-10
detected O 0 1.2094083512437237e-09
in O 0 6.895915782845208e-11
the O 0 6.416336351122709e-10
corresponding O 0 1.2926254733258702e-08
peripheral O 0 1.4779961929889396e-06
blood O 0 2.1330259869500878e-07
DNA O 0 1.8457423038853449e-06
. O 0 1.3999166412759223e-06

In O 0 3.880909389408771e-07
6 O 0 1.841227572185744e-06
( O 0 1.6901061883345392e-08
17 O 0 1.2909359270452114e-07
% O 0 8.948731200497662e-10
) O 0 4.282278004419382e-11
of O 0 1.41123124297593e-09
the O 0 5.5542139776321164e-09
36 O 0 3.292434058721483e-08
patients O 0 2.414867417144251e-09
, O 0 5.058536367563704e-10
a O 0 7.673462976143242e-10
mutation O 0 1.3203943494133341e-09
was O 0 2.876139992835647e-09
detected O 0 6.583458778131046e-10
in O 0 7.844829646996843e-11
constitutional O 0 2.233655704841908e-09
DNA O 0 1.7381575290187357e-08
, O 0 1.377722602668996e-09
and O 0 1.1485664641597282e-09
1 O 0 1.7183662492925578e-08
of O 0 6.906689886676531e-09
these O 0 2.223272010937194e-09
mutations O 0 7.95349475168905e-09
is O 0 9.54427981092465e-10
known O 0 8.630600678571909e-10
to O 0 1.285342721146776e-09
be O 0 4.08418721065118e-09
associated O 0 1.3602141279989155e-07
with O 0 3.6121026170121695e-08
reduced O 0 2.7691364721249556e-06
expressivity O 0 7.602957339258865e-05
. O 0 1.7638384406382102e-06

The O 0 2.2354305428962107e-07
presence O 0 7.86616212167246e-08
of O 0 5.2997091160023047e-08
a O 0 3.5407907716944464e-09
constitutional O 0 7.370090759906134e-09
mutation O 0 3.4240064117341262e-09
was O 0 2.4811568355431746e-09
not O 0 7.793436729297554e-11
associated O 0 3.106054746737641e-09
with O 0 1.9639839754503896e-10
an O 0 9.637445286259094e-10
early O 0 2.05260199948043e-08
age O 0 6.202158431278804e-08
at O 0 3.0369417203246485e-08
treatment O 0 1.6379172507186013e-07
. O 0 2.7706425953510916e-07

In O 0 7.686317360366957e-08
1 O 0 5.315339421940735e-07
patient O 0 8.444392562978464e-08
, O 0 9.90463000505315e-09
somatic O 0 1.0578740329947323e-05
mosaicism O 0 0.00014460706734098494
was O 0 8.099515014237113e-08
demonstrated O 0 3.645531210239028e-09
by O 0 2.0894301566709572e-10
molecular O 0 4.3890207024332994e-09
analysis O 0 1.048056086361271e-09
of O 0 2.2455437509449894e-09
DNA O 0 1.1225492535515968e-08
and O 0 4.408081899498484e-09
RNA O 0 2.6319619905734726e-07
from O 0 9.81137233679874e-08
peripheral O 0 0.0006217538611963391
blood O 0 4.905385139863938e-06
. O 0 1.2782955991497147e-06

In O 0 1.9905667159036966e-07
2 O 0 3.898964280324435e-07
patients O 0 4.686573351619927e-09
without O 0 2.640049512336873e-09
a O 0 2.4675270715590614e-09
detectable O 0 3.058082995721634e-07
mutation O 0 5.076265185977036e-09
in O 0 8.655031136228786e-10
peripheral O 0 1.3268702332425164e-06
blood O 0 7.635598109345665e-08
, O 0 6.9466685737040734e-09
mosaicism O 0 7.179849944805028e-06
was O 0 3.124535652432314e-08
suggested O 0 5.014503923206348e-09
because O 0 1.3304585211315612e-09
1 O 0 2.881808391919094e-08
of O 0 8.362484926749403e-09
the O 0 1.855652342896974e-08
patients O 0 3.497285661069327e-08
showed O 0 1.042168150888756e-06
multifocal O 1 0.9999988079071045
tumors B-Disease 1 1.0
and O 0 7.72899397816218e-08
the O 0 3.457081731994549e-08
other O 0 5.40916289537563e-09
later O 0 3.7467120961309774e-08
developed O 0 1.1824452172959354e-07
bilateral B-Disease 0 6.03432363277534e-06
retinoblastoma I-Disease 0 0.05623951181769371
. O 0 4.587986495607765e-06

In O 0 8.588177280444143e-08
conclusion O 0 6.787006441300036e-07
, O 0 1.496957224844664e-08
our O 0 1.5038999379157758e-08
results O 0 1.6647733858121683e-08
emphasize O 0 2.55605439036799e-08
that O 0 5.704489658420187e-10
the O 0 4.006811771262164e-09
manifestation O 0 2.0981707393730176e-07
and O 0 3.179949414899852e-09
transmissibility O 0 2.6354332476330455e-06
of O 0 4.0469760875794236e-08
retinoblastoma B-Disease 0 3.489504706521984e-06
depend O 0 1.0296596286707427e-07
on O 0 2.5749621102022502e-08
the O 0 3.2377427405805292e-09
nature O 0 8.72295036202786e-09
of O 0 8.251795691194275e-09
the O 0 7.088382325548537e-09
first O 0 1.9755754809835935e-09
mutation O 0 1.4776267986960079e-09
, O 0 4.5409601079349216e-10
its O 0 5.729547392085976e-10
time O 0 7.924870759623559e-10
in O 0 1.2833143436807859e-09
development O 0 2.526554965243122e-08
, O 0 1.1537768518365965e-09
and O 0 1.0894006807760093e-09
the O 0 4.045700663368734e-09
number O 0 4.880232218340552e-09
and O 0 1.2000929139333039e-09
types O 0 2.10714166115622e-08
of O 0 2.038571800255795e-08
cells O 0 9.872754169748532e-09
that O 0 2.163839329938355e-09
are O 0 1.3029692880195398e-09
affected O 0 2.726599745983549e-08
. O 0 2.218867223291454e-08
. O 0 4.5797673919878434e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.00013003505591768771
fifth I-Disease 0 3.563976406439906e-06
component I-Disease 0 8.084140858954925e-07
of I-Disease 0 4.1449624177403166e-08
complement I-Disease 0 5.874629493973771e-08
in O 0 4.042416534844051e-08
man O 0 1.9250874174758792e-05
. O 0 3.440641194174532e-06

I O 0 0.0393584705889225
. O 0 7.14571651769802e-05

Clinical O 0 1.684802191448398e-05
, O 0 2.398628282662685e-07
immunochemical O 0 0.00015463813906535506
, O 0 1.1670332611402046e-07
and O 0 5.268957536941343e-08
family O 0 1.860437066625309e-07
studies O 0 2.0680505485870526e-07
. O 0 3.420353493766015e-07

The O 0 2.859742664895748e-07
first O 0 2.1970400609916396e-08
recognized O 0 2.062420811910215e-08
human O 0 2.840156554384521e-08
kindred O 0 0.02326441928744316
with O 0 5.784288159560447e-09
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 4.390176763990894e-05
fifth I-Disease 0 1.0470255347172497e-06
component I-Disease 0 8.605990160504007e-07
of I-Disease 0 7.339105536630086e-07
complement I-Disease 0 1.5502920405197074e-06
( O 0 6.788948212488322e-07
C5 O 1 1.0
) O 0 2.4406235255014508e-08
is O 0 1.5298077471470606e-08
described O 0 2.195482124989212e-07
. O 0 8.64317598825437e-07

The O 0 3.330903382448014e-06
proband O 0 3.068229489144869e-05
, O 0 2.9530534462196556e-08
a O 0 1.0618823154118218e-08
20 O 0 2.484425642990118e-08
- O 0 6.34045038694353e-09
year O 0 2.6532807062551456e-09
- O 0 1.3190557979214645e-08
old O 0 1.426346187827221e-07
black O 0 1.1326274140799342e-08
female O 0 7.66492380677164e-09
with O 0 2.2291667178819807e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 8.504977813572623e-06
age O 0 2.0674208371929126e-06
11 O 0 1.411531371786623e-07
, O 0 4.775381867716533e-09
lacked O 0 1.6907003441701818e-07
serum O 0 2.2119590425973001e-07
hemolytic O 0 1.3897942153562326e-05
complement O 0 2.665420595349133e-07
activity O 0 4.43025214735826e-07
, O 0 1.2816980365926156e-08
even O 0 2.2047052183893356e-08
during O 0 5.666486657673886e-08
remission O 0 5.034843297835323e-07
. O 0 2.510501815322641e-07

C5 O 1 0.9877640604972839
was O 0 7.207710496004438e-06
undetectable O 0 1.2443225614333642e-06
in O 0 4.523784902232819e-09
her O 0 2.581333813367337e-09
serum O 0 1.281439043765431e-08
by O 0 2.8802793483606592e-09
both O 0 4.3087311496492475e-08
immunodiffusion O 0 0.0035374255385249853
and O 0 3.869245972509816e-07
hemolytic O 1 0.9884456396102905
assays O 0 1.5345442079706118e-05
. O 0 6.206688794918591e-06

Other O 0 5.3998466142957113e-08
complement O 0 2.5047805607414375e-08
components O 0 1.3342436488983367e-07
were O 0 5.174963568777002e-09
normal O 0 1.0259463500972288e-08
during O 0 1.6372941891162895e-09
remission O 0 4.0984854621228806e-08
of O 0 1.667958038353845e-08
lupus O 0 1.279819116462022e-06
, O 0 3.16608570471999e-08
but O 0 1.098258053389145e-07
C1 O 0 2.589127325336449e-05
, O 0 1.5704507916325383e-07
C4 O 0 0.00029680735315196216
, O 0 1.7315799993866676e-07
C2 O 0 3.125983994323178e-06
, O 0 9.408314838310616e-08
and O 0 7.520158646912023e-07
C3 O 1 0.9998548030853271
levels O 0 3.453438694123179e-05
fell O 0 0.00034431443782523274
during O 0 4.317509478823922e-07
exacerbations O 0 0.0005294071161188185
. O 0 2.9240595722512808e-06

A O 0 2.1272142475936562e-05
younger O 0 3.293953341199085e-06
half O 0 9.611907216822146e-07
- O 0 3.480427324120683e-07
sister O 0 3.119926930139627e-07
, O 0 7.756044695383935e-09
who O 0 1.7439422350662426e-08
had O 0 1.4140718818111964e-08
no O 0 1.3951178878812698e-08
underlying O 0 8.783155180935864e-07
disease O 0 1.4663742149423342e-06
, O 0 1.9014114727156084e-09
was O 0 1.7056930090575406e-08
also O 0 4.2801243105294873e-10
found O 0 5.692371018994891e-10
to O 0 3.3738165594598968e-09
lack O 0 3.508727240841836e-05
immunochemically O 1 0.998193085193634
detectable O 1 0.9989256262779236
C5 O 1 0.9983264803886414
. O 0 2.8999052119615953e-06

By O 0 8.0226976706399e-07
hemolytic O 0 0.00675200205296278
assay O 0 1.3764905816060491e-05
, O 0 1.8992091099789832e-07
she O 0 1.6392229795769708e-08
exhibited O 0 5.131503044708552e-08
1 O 0 3.7965065757816774e-08
- O 0 7.495439824367622e-09
2 O 0 1.587671683012104e-08
% O 0 2.2378635056163887e-10
of O 0 4.5360515343872976e-10
the O 0 9.825447122580044e-10
normal O 0 1.481262046354459e-08
serum O 0 5.002364389383729e-08
C5 O 0 9.808051800064277e-06
level O 0 5.982479223121118e-08
and O 0 2.1055457377627818e-09
normal O 0 9.623949637216356e-09
concentrations O 0 2.5724782304337168e-08
of O 0 8.344018809225417e-09
other O 0 5.145672776762922e-09
complement O 0 1.6685730486187822e-07
components O 0 3.500247203191975e-06
. O 0 9.319751939074195e-07

C5 O 0 0.0007363958866335452
levels O 0 1.7224589043962624e-07
of O 0 2.0202245210043657e-08
other O 0 2.3083428501990966e-09
family O 0 3.582521834744057e-09
members O 0 2.224967571295977e-10
were O 0 6.319993417491787e-10
either O 0 1.0250460480420998e-09
normal O 0 2.5181392526718582e-09
or O 0 3.241238111240108e-10
approximately O 0 6.260987284179009e-10
half O 0 3.599377462748521e-09
- O 0 6.732916446594572e-09
normal O 0 2.3300232854239766e-08
, O 0 1.2869323384734344e-09
consistent O 0 2.4325927938662062e-08
with O 0 1.7656093254103666e-09
autosomal O 0 3.410386568702961e-07
codominant O 0 3.244642584832036e-06
inheritance O 0 2.2430563717534824e-07
of O 0 1.8896260556289235e-08
the O 0 1.7481184499956726e-08
gene O 0 4.85112195747206e-07
determining O 0 0.004824535921216011
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 6.794493856432382e-06

Normal O 0 0.00012769282329827547
hemolytic O 1 0.9960149526596069
titers O 0 0.00018036803521681577
were O 0 1.514196128482581e-07
restored O 0 9.688064039892197e-08
to O 0 4.684455490178152e-09
both O 0 4.979489176548668e-08
homozygous O 0 1.1053333764721174e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.298510015767533e-06
C5D B-Disease 1 1.0
) O 0 6.772456817571992e-09
sera O 0 4.003498688120999e-08
by O 0 2.1203676314751618e-10
addition O 0 2.2645374464502765e-09
of O 0 1.868844101693412e-08
highly O 0 6.545413810954415e-08
purified O 0 2.515633070743206e-07
human O 0 9.881675850920146e-07
C5 O 1 0.9987144470214844
. O 0 1.4797535641264403e-06

In O 0 4.3599413857009495e-07
specific O 0 3.3493754472146975e-06
C5 O 0 0.0010761454468593001
titrations O 0 1.2553558008221444e-05
, O 0 2.9447852156749832e-08
however O 0 2.6790083040850732e-08
, O 0 2.236132390365242e-09
it O 0 7.321930284298617e-10
was O 0 1.1710329594905033e-08
noted O 0 3.3443765534713066e-09
that O 0 1.7685003461664905e-10
when O 0 5.034482830623688e-10
limited O 0 7.825345371692549e-10
amounts O 0 7.534297630229503e-09
of O 0 6.644166461455825e-08
C5 O 0 9.741740359459072e-05
were O 0 3.140590365546814e-08
assayed O 0 1.0515551451817373e-07
in O 0 1.1334329030887602e-09
the O 0 3.867597797579947e-09
presence O 0 1.808597893671049e-08
of O 0 4.099275230373678e-08
low O 0 1.9046323984639457e-07
dilutions O 0 2.427727395115653e-06
of O 0 1.36254314497819e-07
either O 0 2.2510805592901306e-06
C5D B-Disease 1 1.0
serum O 0 2.110707100655418e-06
, O 0 3.779780044510517e-08
curving O 0 5.69851351883699e-07
rather O 0 7.160101844760902e-09
than O 0 2.9105535759299528e-09
linear O 0 3.5893560124122814e-08
dose O 0 2.642403629238288e-08
- O 0 2.4137452925288017e-08
response O 0 1.2438458263375196e-08
plots O 0 7.657752831846665e-08
were O 0 1.1478706873901956e-08
consistently O 0 4.101830874958523e-09
obtained O 0 8.855722377631992e-09
, O 0 1.6827459425883262e-09
suggesting O 0 8.097904569126513e-09
some O 0 5.219153997870762e-09
inhibitory O 0 3.3030253234755946e-06
effect O 0 1.1806744169007288e-06
. O 0 1.156215944320138e-06

Further O 0 7.014988909759268e-07
studies O 0 6.707885091827848e-08
suggested O 0 1.9686215324554723e-08
that O 0 2.3488611056166064e-09
low O 0 1.0470321143429828e-07
dilutions O 0 5.175143087399192e-06
of O 0 4.0412413682133774e-07
C5D B-Disease 1 1.0
serum O 0 5.8171952588281783e-08
contain O 0 3.3695848333792355e-09
a O 0 2.2395130194752255e-09
factor O 0 1.3591270331403393e-08
( O 0 7.862538953240517e-10
or O 0 1.1664447185921745e-09
factors O 0 1.510373692781286e-08
) O 0 3.682091020973388e-10
interfering O 0 7.873978802308557e-09
at O 0 5.476182174390942e-09
some O 0 1.0575360587239402e-09
step O 0 5.1095838671244564e-09
in O 0 6.203123015247058e-10
the O 0 1.220271617086155e-08
hemolytic O 0 1.1811309377662838e-05
assay O 0 8.518968570569996e-07
of O 0 3.935116183129139e-06
C5 O 1 0.9998818635940552
, O 0 8.419621444488712e-09
rather O 0 3.488809463547682e-09
than O 0 2.7838884530950736e-09
a O 0 3.282226757050921e-08
true O 0 9.403620992998185e-07
C5 O 0 6.24815802439116e-05
inhibitor O 0 6.128078098299738e-07
or O 0 3.1072065098669555e-07
inactivator O 0 2.143738129234407e-05
. O 0 1.726081222841458e-06

Of O 0 1.3011939472562517e-06
clinical O 0 2.474641860317206e-06
interest O 0 1.5135161675061681e-06
are O 0 6.039400535229333e-09
( O 0 2.3652662051176776e-09
a O 0 5.769148714307448e-09
) O 0 1.7323570355998186e-10
the O 0 5.969150174145454e-10
documentation O 0 1.7113771377808007e-07
of O 0 1.951095924823676e-07
membranous O 1 0.9999916553497314
glomerulonephritis B-Disease 1 1.0
, O 0 5.316687747836113e-07
vasculitis B-Disease 1 1.0
, O 0 1.8965683068472572e-07
and O 0 2.5100903258135077e-06
arthritis B-Disease 1 1.0
in O 0 8.174456667120467e-09
an O 0 4.3527141890820076e-09
individual O 0 2.630781814616512e-08
lacking O 0 0.214999720454216
C5 O 1 0.9999994039535522
( O 0 1.637276270116672e-08
and O 0 2.755646377750054e-09
its O 0 2.711185942416705e-09
biologic O 0 2.9278641022756347e-07
functions O 0 5.83001025233898e-09
) O 0 4.979294199181084e-10
, O 0 6.741419644740176e-10
and O 0 1.2470948718146246e-09
( O 0 1.7775169114386813e-09
b O 0 1.2487712197639667e-08
) O 0 1.9382023763725442e-10
a O 0 9.6634911184168e-10
remarkable O 0 8.026462161581094e-09
propensity O 0 3.379769353273332e-08
to O 0 5.139316527902338e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.0111567966552002e-10
the O 0 1.8601233886528235e-09
proband O 0 4.556477222195099e-07
, O 0 1.0360079460980387e-09
even O 0 1.7886108150122482e-09
during O 0 2.5280866289278947e-09
periods O 0 4.007096876534888e-08
of O 0 3.4232115808663366e-08
low O 0 1.3342332749743946e-07
- O 0 2.2326984705500763e-08
dose O 0 3.3354027095811034e-08
or O 0 4.616423687764382e-09
alternate O 0 2.9035365400886803e-07
- O 0 4.0919525190474815e-07
day O 0 1.2917708147597295e-07
corticosteroid O 0 9.671253792475909e-06
therapy O 0 7.915238029454486e-07
. O 0 9.441884003535961e-07

Other O 0 1.7910359417783184e-07
observations O 0 3.2380319225921994e-07
indicate O 0 3.495758349458811e-08
that O 0 1.5910084361081545e-09
the O 0 2.1536374461561536e-08
C5D B-Disease 1 1.0
state O 0 3.415278948537548e-09
is O 0 2.2655213816058506e-10
compatible O 0 3.228739053895424e-09
with O 0 2.74858996673899e-10
normal O 0 7.204816299122285e-09
coagulation O 0 3.976057172394576e-08
function O 0 5.813265424592373e-09
and O 0 2.128155873748483e-09
the O 0 8.08269007279705e-09
capacity O 0 1.0331294042487116e-08
to O 0 3.965588746268622e-09
mount O 0 3.9276851566683035e-06
a O 0 4.537614017863234e-07
neutrophilic O 1 0.8933599591255188
leukocytosis O 0 0.0006239969516173005
during O 0 1.13120995592908e-06
pyogenic B-Disease 0 0.000399896438466385
infection I-Disease 0 9.855859843810322e-07
. O 0 4.370427930666665e-08
. O 0 2.3109306823698716e-07

Susceptibility O 0 1.6641673937556334e-05
to O 0 1.2528768138508894e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.9532052419890533e-07
twins O 0 5.090219588055334e-07
: O 0 1.9391870331730843e-09
the O 0 6.590258561089968e-09
role O 0 8.435019793751053e-09
of O 0 2.7660849610811056e-08
genes O 0 3.7000752683979954e-08
, O 0 2.257694298180013e-08
HLA O 0 0.00019344358588568866
, O 0 4.084835936168929e-08
and O 0 3.58315226378636e-08
the O 0 4.1902723069142667e-07
environment O 0 1.21499022043281e-06
. O 0 1.3113191243974143e-06

OBJECTIVE O 0 1.79777907760581e-05
To O 0 4.152525434619747e-09
determine O 0 1.0056997901131126e-08
the O 0 2.069887816702476e-09
relative O 0 9.545453139025994e-08
effects O 0 6.150678188987513e-08
of O 0 1.849644104545689e-09
genetic O 0 1.6314780637571857e-08
and O 0 1.136038707549858e-09
environmental O 0 5.858859619678469e-09
factors O 0 7.40075689620312e-09
in O 0 4.589521263032026e-10
susceptibility O 0 5.424341793514031e-07
to O 0 1.3125486475473735e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.623245952941943e-05
AS B-Disease 1 1.0
) O 0 5.57940218470776e-08
. O 0 2.9035751936135057e-07

METHODS O 0 1.3434046195470728e-05
Twins O 0 4.46914964413736e-06
with O 0 3.3933922338746925e-08
AS B-Disease 1 1.0
were O 0 4.228180028320594e-09
identified O 0 2.0584269844192704e-09
from O 0 3.126231773453725e-10
the O 0 1.3294108036632224e-09
Royal O 0 4.4098833029693196e-08
National O 0 1.1752221951155661e-07
Hospital O 0 0.00011930742766708136
for O 0 2.0953548229840635e-08
Rheumatic B-Disease 1 1.0
Diseases I-Disease 0 0.004209267441183329
database O 0 1.3420296909316676e-06
. O 0 5.412064183474286e-07

Clinical O 0 1.1213314792257734e-06
and O 0 2.5285702420774214e-08
radiographic O 0 7.003885116318997e-07
examinations O 0 7.459459538949886e-08
were O 0 1.775999614039847e-08
performed O 0 9.32526722507987e-10
to O 0 3.1277408440999466e-10
establish O 0 9.724289817825138e-09
diagnoses O 0 8.947372407419607e-06
, O 0 3.879974119769258e-09
and O 0 2.9506814769320044e-09
disease O 0 3.472729758868809e-06
severity O 0 2.3757633243803866e-05
was O 0 8.884567748168593e-09
assessed O 0 3.4843405938289607e-09
using O 0 2.4311247459607443e-10
a O 0 7.982062233402587e-10
combination O 0 6.794892648542827e-09
of O 0 2.4021437283749947e-08
validated O 0 1.6085029130863404e-07
scoring O 0 6.483883225882892e-07
systems O 0 2.792233999571181e-06
. O 0 2.9551856641774066e-06

HLA O 0 8.66100745042786e-05
typing O 0 9.696851748230984e-07
for O 0 1.780453686706096e-07
HLA O 0 8.015655112103559e-06
- O 0 3.540000307111768e-06
B27 O 0 3.2902296425163513e-06
, O 0 2.5711440088116433e-08
HLA O 0 3.320327834899217e-07
- O 0 1.7252010309221077e-07
B60 O 0 4.6061447278589185e-07
, O 0 3.3934166587812342e-09
and O 0 2.0844079795523385e-09
HLA O 0 4.829324780075694e-07
- O 0 1.1178070735695655e-06
DR1 O 0 5.3818901506019756e-05
was O 0 3.0100569148316936e-08
performed O 0 1.7111298489247417e-10
by O 0 8.79719422308689e-11
polymerase O 0 4.005115794569747e-09
chain O 0 6.240769678811375e-09
reaction O 0 4.48462689206508e-09
with O 0 4.2078077133744785e-10
sequence O 0 1.927769499587839e-09
- O 0 2.543631971718696e-09
specific O 0 1.9315531396557617e-09
primers O 0 7.071060537100493e-08
, O 0 5.808123315631519e-09
and O 0 9.491239794101602e-09
zygosity O 0 2.9426962555589853e-06
was O 0 1.245173280040035e-07
assessed O 0 1.0198944977446445e-07
using O 0 2.7031580529524035e-08
microsatellite O 0 4.731963144877227e-06
markers O 0 4.75817341794027e-06
. O 0 2.8702120289381128e-06

Genetic O 0 6.262067699935869e-07
and O 0 1.7407652208589752e-08
environmental O 0 3.8470144403390805e-08
variance O 0 1.8015056113540595e-08
components O 0 2.1414964024302208e-08
were O 0 1.8564230153117478e-09
assessed O 0 1.5172107126204537e-08
with O 0 3.532788506177553e-10
the O 0 4.9703392512867595e-09
program O 0 1.1821769119180203e-09
Mx O 0 1.8733837592321834e-08
, O 0 1.0559492863437825e-10
using O 0 2.4842324378160363e-11
data O 0 3.8341327335267295e-10
from O 0 3.7680722431154834e-10
this O 0 1.806375882207334e-10
and O 0 6.06217909204787e-10
previous O 0 4.013565924054774e-09
studies O 0 4.7363308830483675e-09
of O 0 1.942490079898107e-08
twins O 0 1.470471602260659e-06
with O 0 8.551823782454449e-08
AS B-Disease 1 1.0
. O 0 2.76704054158472e-06

RESULTS O 0 1.5845087546040304e-05
Six O 0 7.956651870699716e-07
of O 0 4.971081466464966e-07
8 O 0 1.6969887610684964e-06
monozygotic O 0 7.464336704288144e-06
( O 0 2.0576396764226956e-07
MZ O 0 0.0037815843243151903
) O 0 5.833884131334344e-08
twin O 0 1.1092172371718334e-06
pairs O 0 1.093077344194171e-07
were O 0 5.1259952726923075e-08
disease O 0 7.204597295640269e-06
concordant O 0 2.2614926820097025e-06
, O 0 1.0465639466161747e-09
compared O 0 7.731463802507221e-10
with O 0 3.105040391471192e-10
4 O 0 2.0716068860338055e-08
of O 0 2.2517811615330174e-08
15 O 0 4.763948524555417e-08
B27 O 0 4.190004574411432e-07
- O 0 1.2957461592577602e-07
positive O 0 3.745404697497179e-08
dizygotic O 0 2.898887714763987e-06
( O 0 5.967413585494796e-08
DZ O 0 1.98129109776346e-05
) O 0 3.839625506429911e-08
twin O 0 5.130456202095957e-07
pairs O 0 5.190575791402807e-08
( O 0 1.2165788376705677e-08
27 O 0 3.5447328627924435e-07
% O 0 2.4698720846316746e-09
) O 0 5.028136587648113e-11
and O 0 4.918543350385107e-10
4 O 0 1.2527505255377491e-08
of O 0 4.586620505619976e-08
32 O 0 2.523483544791816e-06
DZ O 0 0.021527055650949478
twin O 0 5.118949502502801e-06
pairs O 0 2.6633878746906703e-07
overall O 0 3.481224894130719e-06
( O 0 1.6746971809311617e-08
12 O 0 6.479209702092703e-08
. O 0 6.422192111443792e-09
5 O 0 7.410505986626958e-08
% O 0 4.175534140671289e-09
) O 0 1.3134116016999542e-09
. O 0 5.858940710368188e-08

Nonsignificant O 0 3.669822035590187e-05
increases O 0 2.303269468484359e-07
in O 0 3.365377976294326e-09
similarity O 0 2.65577320135435e-08
with O 0 5.980295147978154e-10
regard O 0 9.889603802548663e-09
to O 0 9.936261813336955e-10
age O 0 3.957746841365406e-08
at O 0 4.261146990813813e-09
disease O 0 5.532288227527715e-08
onset O 0 1.1874389116428574e-07
and O 0 2.6392224516946783e-10
all O 0 1.9942350548696197e-10
of O 0 9.26785204136138e-10
the O 0 1.911068192583798e-09
disease O 0 3.076622689945907e-08
severity O 0 3.977930873588775e-08
scores O 0 6.277108610674986e-09
assessed O 0 2.593257875105337e-08
were O 0 4.25757251676373e-09
noted O 0 7.807607893539625e-09
in O 0 1.7659125273183918e-09
disease O 0 2.8461334977691877e-07
- O 0 2.6140764930460136e-06
concordant O 0 0.003675251267850399
MZ O 1 0.9944209456443787
twins O 0 2.1096568616485456e-06
compared O 0 8.660918382474847e-08
with O 0 4.5793481007194714e-08
concordant O 0 0.14831586182117462
DZ O 1 0.9996829032897949
twins O 0 0.0003007599734701216
. O 0 1.1684798664646223e-05

HLA O 0 0.00015392067143693566
- O 0 1.817295742512215e-05
B27 O 0 8.494391295243986e-06
and O 0 2.1066394850777215e-08
B60 O 0 3.4679828786465805e-07
were O 0 2.0333554839879753e-09
associated O 0 4.290392041639279e-09
with O 0 3.7820840903535213e-10
the O 0 3.96230737109704e-09
disease O 0 1.2146074368502013e-07
in O 0 3.193696973546878e-10
probands O 0 3.096736236329889e-06
, O 0 3.8036709892885767e-10
and O 0 1.6176628092612333e-10
the O 0 1.4286292149279234e-09
rate O 0 6.554682130399669e-09
of O 0 3.2250953019286044e-09
disease O 0 2.630425477434528e-08
concordance O 0 1.5865516900248622e-08
was O 0 1.479166455986558e-09
significantly O 0 1.357799539469795e-09
increased O 0 8.028820275285398e-09
among O 0 1.0732426147797014e-07
DZ O 0 0.00014445808483287692
twin O 0 1.2521792314146296e-06
pairs O 0 2.2753713579959367e-08
in O 0 3.919148561237762e-09
which O 0 3.9769498805242165e-09
the O 0 3.126014291865431e-08
co O 0 7.736900187182982e-08
- O 0 5.623837182611169e-07
twin O 0 1.554980030959996e-06
was O 0 4.8423490994764506e-08
positive O 0 2.219898931343778e-09
for O 0 5.75137226732636e-09
both O 0 1.191115970300416e-07
B27 O 0 4.1493927710689604e-05
and O 0 2.1712260149797658e-06
DR1 O 0 0.28022271394729614
. O 0 3.8714788388460875e-06

Additive O 0 6.439391881940537e-07
genetic O 0 2.533267888793489e-07
effects O 0 2.393957174717798e-07
were O 0 3.6561014216118792e-09
estimated O 0 7.244871924605434e-10
to O 0 8.536948231663288e-11
contribute O 0 1.1457067516928987e-09
97 O 0 1.2924085801557794e-08
% O 0 1.6135151548191118e-10
of O 0 1.2456845277508677e-10
the O 0 1.0275085227107184e-09
population O 0 7.661616896470491e-10
variance O 0 7.649008892940401e-08
. O 0 2.1449245934945793e-07

CONCLUSION O 0 1.348783462162828e-05
Susceptibility O 0 9.718525006974232e-07
to O 0 6.461512214173126e-08
AS B-Disease 1 1.0
is O 0 4.885820636957305e-09
largely O 0 5.548718373660222e-09
genetically O 0 3.5461844571926804e-09
determined O 0 9.773528653056474e-09
, O 0 7.401628754344358e-10
and O 0 4.906138273419458e-10
the O 0 2.0531960576164465e-09
environmental O 0 2.8666667262200463e-08
trigger O 0 1.490443537477404e-07
for O 0 2.7594120322049775e-09
the O 0 8.008558438632463e-08
disease O 0 3.2702935186534887e-06
is O 0 6.901449189911091e-09
probably O 0 1.0494012769868277e-07
ubiquitous O 0 5.241680810286198e-06
. O 0 9.958305327018024e-07

HLA O 0 0.00017001255764625967
- O 0 1.1315345545881428e-05
B27 O 0 3.1395177302329103e-06
accounts O 0 8.435035780962608e-09
for O 0 3.215732680139638e-10
a O 0 9.173323767264208e-10
minority O 0 5.007753101082812e-10
of O 0 1.3891348071837228e-09
the O 0 2.678792299093402e-09
overall O 0 1.52215005044809e-08
genetic O 0 2.4070970994216623e-08
susceptibility O 0 1.6385672552132746e-07
to O 0 6.503130123292067e-08
AS B-Disease 1 1.0
. O 0 1.2753403098031413e-06

Cell O 0 5.057238013250753e-06
cycle O 0 1.676102215242281e-06
- O 0 4.2287794599360495e-07
dependent O 0 2.1616072842789436e-07
colocalization O 0 3.1091026357898954e-06
of O 0 1.3765917117325444e-07
BARD1 O 0 0.001543865306302905
and O 0 4.370936323994101e-08
BRCA1 O 0 1.7236182259239285e-08
proteins O 0 3.729136111019216e-09
in O 0 1.7033155996770688e-09
discrete O 0 1.2525418924269616e-07
nuclear O 0 5.895569302083459e-06
domains O 0 6.108162324380828e-06
. O 0 2.015123300225241e-06

Germ O 0 0.00011032864858862013
- O 0 6.284577921178425e-06
line O 0 5.903693249820208e-07
mutations O 0 5.924816903757346e-08
of O 0 8.505397630642619e-08
the O 0 7.450913130924164e-08
BRCA1 O 0 1.217895828631299e-07
gene O 0 2.2865348725531476e-08
predispose O 0 1.1746818927349523e-05
women O 0 2.3235529056364612e-08
to O 0 2.6245305928540574e-09
early O 0 8.121123187265766e-07
- O 0 9.26470966078341e-06
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.3225972539387953e-09
compromising O 0 2.5355827659723218e-08
the O 0 3.2013649509110564e-09
genes O 0 1.530271731553512e-08
presumptive O 0 3.001500488153397e-07
function O 0 1.7463454682342672e-08
as O 0 1.4058239905523351e-08
a O 0 5.9366605853483634e-08
tumor B-Disease 0 4.380803602543892e-06
suppressor O 0 0.00014375755563378334
. O 0 1.4674317299068207e-06

Although O 0 2.7916379963244253e-07
the O 0 8.04149777877683e-08
biochemical O 0 6.467495495598996e-06
properties O 0 2.3154361770139076e-06
of O 0 1.1863946838275297e-06
BRCA1 O 0 2.3137201310419186e-07
polypeptides O 0 1.772413327216782e-07
are O 0 1.2103315016886995e-09
not O 0 1.222516754495473e-09
understood O 0 1.4439325290993565e-08
, O 0 7.34726501860905e-10
their O 0 7.948440794436351e-10
expression O 0 1.0133671679568579e-08
pattern O 0 1.7369048421755906e-08
and O 0 2.8097715265573697e-09
subcellular O 0 1.4077445484872442e-06
localization O 0 3.7800907648488646e-07
suggest O 0 2.5505025647021284e-08
a O 0 1.260896098642661e-08
role O 0 3.279248161902615e-08
in O 0 8.031546094855457e-09
cell O 0 1.8168339011026546e-06
- O 0 1.9602885004132986e-06
cycle O 0 2.2362790730312554e-07
regulation O 0 7.243357913466753e-07
. O 0 6.549335580530169e-07

When O 0 1.2759522860505967e-06
resting O 0 4.808383437193697e-06
cells O 0 1.4442994711316715e-07
are O 0 1.5686860699304361e-09
induced O 0 2.2221536610800285e-08
to O 0 7.148117653343888e-10
proliferate O 0 1.2546157002191194e-08
, O 0 5.610674702616336e-10
the O 0 1.534204541187023e-09
steady O 0 5.886529663712281e-08
- O 0 1.6172749806031561e-09
state O 0 7.75394082275227e-10
levels O 0 5.9767635285368215e-09
of O 0 1.3418534727804854e-08
BRCA1 O 0 1.59153437095938e-08
increase O 0 2.098033302644353e-09
in O 0 1.6290891968750998e-09
late O 0 5.009611641071388e-07
G1 O 0 3.5609150472737383e-07
and O 0 1.2959624484665255e-09
reach O 0 4.1167540487663246e-09
a O 0 2.1470984989946373e-09
maximum O 0 2.8483373881726948e-08
during O 0 7.512117150554332e-08
S O 0 6.390464477590285e-06
phase O 0 2.2505309971165843e-06
. O 0 1.5948000964272069e-06

Moreover O 0 1.4253332665248308e-06
, O 0 2.897206918817119e-08
in O 0 1.4878539289497894e-08
S O 0 8.454769044874411e-07
phase O 0 1.2731877063743013e-07
cells O 0 1.1307520964010109e-07
, O 0 3.822890803917289e-08
BRCA1 O 0 1.0687465135106322e-07
polypeptides O 0 1.650075915904381e-07
are O 0 5.883361797742737e-09
hyperphosphorylated O 0 1.4793160971748875e-06
and O 0 7.024586690107526e-09
accumulate O 0 2.365028350936882e-08
into O 0 1.5572247491490998e-08
discrete O 0 1.4347389765134722e-07
subnuclear O 0 6.2241988416644745e-06
foci O 0 4.3318141251802444e-06
termed O 0 1.5501975667575607e-06
" O 0 6.917027803865494e-07
BRCA1 O 0 4.261793492332799e-06
nuclear O 0 2.890603536798153e-05
dots O 0 4.244565207045525e-05
. O 0 7.124797775759362e-06

" O 0 6.8415824898693245e-06
BRCA1 O 0 9.583957762515638e-06
associates O 0 2.96029156743316e-06
in O 0 3.0182373933484996e-08
vivo O 0 1.5083848836638936e-07
with O 0 9.074997975311305e-10
a O 0 8.748176405504182e-09
structurally O 0 1.2631473111923697e-07
related O 0 1.2053402542733238e-07
protein O 0 2.9971668027428677e-06
termed O 0 5.184825113246916e-06
BARD1 O 1 0.9993969202041626
. O 0 3.3299536426056875e-06

Here O 0 5.077585001345142e-07
we O 0 2.2714081282515508e-08
show O 0 7.4336350408543694e-09
that O 0 4.5896611511331287e-10
the O 0 3.125750325239096e-09
steady O 0 6.107971728397388e-08
- O 0 2.0813566425914587e-09
state O 0 4.407154641228317e-10
levels O 0 8.272439622203365e-09
of O 0 1.483826839177027e-08
BARD1 O 0 0.00018822425045073032
, O 0 1.210216149516441e-09
unlike O 0 9.637831643871664e-10
those O 0 1.111783887175477e-09
of O 0 3.6555036331265e-08
BRCA1 O 0 5.1147249990890487e-08
, O 0 2.8624362879980936e-09
remain O 0 1.0051053322968073e-08
relatively O 0 6.067619295890836e-09
constant O 0 2.2982968417295524e-08
during O 0 1.1413909817292733e-08
cell O 0 7.771550940560701e-07
cycle O 0 3.939859709589655e-07
progression O 0 3.000678816533764e-06
. O 0 5.670356699738477e-07

However O 0 9.484453471486631e-07
, O 0 1.7072790114980307e-07
immunostaining O 0 2.4383505660807714e-05
revealed O 0 1.3113100294503965e-07
that O 0 6.297999899373963e-09
BARD1 O 0 0.0034662389662116766
resides O 0 2.3343523025687318e-07
within O 0 1.0803834271655433e-08
BRCA1 O 0 9.131905898129844e-08
nuclear O 0 2.3728118492272188e-07
dots O 0 3.70747841316188e-08
during O 0 6.405151520283425e-09
S O 0 6.099089233657651e-08
phase O 0 9.578131177079285e-09
of O 0 5.988105566956392e-09
the O 0 3.6979426187855324e-09
cell O 0 2.6629809468659005e-08
cycle O 0 5.495916610698259e-09
, O 0 3.873088516570533e-10
but O 0 4.3629688750712603e-10
not O 0 9.229290665047074e-10
during O 0 1.507210889428734e-08
the O 0 1.1485632711583094e-07
G1 O 0 7.414701485686237e-06
phase O 0 1.5930579593259608e-06
. O 0 1.911392018882907e-06

Nevertheless O 0 5.03436203871388e-05
, O 0 1.0829363645825651e-06
BARD1 O 0 0.0005438828957267106
polypeptides O 0 1.5040411653899355e-06
are O 0 6.582971945334748e-09
found O 0 3.0979609988435186e-09
exclusively O 0 6.459365931021921e-09
in O 0 2.0878565543114291e-10
the O 0 1.194894405642799e-09
nuclear O 0 2.1080381884530652e-08
fractions O 0 1.8385582833957415e-08
of O 0 3.5182271318490166e-08
both O 0 2.188867043173559e-08
G1 O 0 1.075685986506869e-06
- O 0 2.827768526003638e-07
and O 0 1.2722023257083492e-07
S O 0 5.218726528255502e-06
- O 0 4.7102346911742643e-07
phase O 0 4.697037070400256e-07
cells O 0 7.523056524405547e-07
. O 0 7.282541218955885e-07

Therefore O 0 1.282531570723222e-06
, O 0 2.65222457329628e-08
progression O 0 1.0586349219465774e-07
to O 0 1.0623218749117314e-08
S O 0 4.084174349827663e-07
phase O 0 3.77502509252281e-08
is O 0 1.0918324022668457e-09
accompanied O 0 4.65703431373754e-09
by O 0 3.203580456467847e-10
the O 0 1.5743242265386925e-09
aggregation O 0 1.494324131101621e-08
of O 0 1.0225607027791739e-08
nuclear O 0 9.713187409943203e-07
BARD1 O 0 0.0012403175933286548
polypeptides O 0 2.7487244551593903e-06
into O 0 2.971598007661669e-07
BRCA1 O 0 3.093108944085543e-06
nuclear O 0 9.833263902692124e-06
dots O 0 1.5073688700795174e-05
. O 0 3.387031256352202e-06

This O 0 6.5141783522904e-08
cell O 0 6.341928155961796e-07
cycle O 0 1.8206672791620804e-07
- O 0 7.408697655364449e-08
dependent O 0 7.106497434961057e-08
colocalization O 0 1.1593517683650134e-06
of O 0 6.201010904760551e-08
BARD1 O 0 0.007031301502138376
and O 0 1.763156909362351e-08
BRCA1 O 0 6.574091315769692e-08
indicates O 0 1.3478712368453216e-08
a O 0 1.966196538916165e-09
role O 0 5.657930124414179e-09
for O 0 4.110633611276171e-09
BARD1 O 1 0.9022009968757629
in O 0 7.475127006273397e-08
BRCA1 O 0 9.245397450285964e-06
- O 0 3.8217152905417606e-05
mediated O 0 0.00034431443782523274
tumor B-Disease 0 4.161614197073504e-05
suppression O 0 2.0653771571232937e-05
. O 0 8.99363669759623e-07

Ethnic O 0 1.8930586520582438e-06
differences O 0 5.374814691094798e-07
in O 0 1.8725442529898828e-08
the O 0 1.4584507823656168e-07
HFE O 0 0.0002823943505063653
codon O 0 8.053766578086652e-06
282 O 0 6.9631196311092936e-06
( O 0 8.60574402850034e-07
Cys O 0 0.00030410895124077797
/ O 0 2.8751803256454878e-05
Tyr O 0 1.5969573723850772e-05
) O 0 3.021434125116684e-08
polymorphism O 0 6.113245945016388e-07
. O 0 1.1618842563621001e-06

Recent O 0 4.396396207084763e-07
studies O 0 3.27578497660852e-08
have O 0 1.2405044769181472e-09
shown O 0 3.361547928903974e-09
that O 0 1.0118317739227223e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9996553659439087
HH B-Disease 1 1.0
) O 0 2.6042654699409695e-09
is O 0 3.8952543968129305e-10
likely O 0 9.028865433080568e-10
to O 0 6.173214162075169e-10
be O 0 2.0644901344013533e-09
caused O 0 4.24750865590795e-08
by O 0 2.028563539369088e-09
homozygosity O 0 1.0114999895449728e-06
for O 0 2.308311985999012e-09
a O 0 1.4844750317877242e-08
Cys282Tyr O 0 7.807118436176097e-07
mutation O 0 1.2491762291233499e-08
in O 0 2.5302668849036536e-09
the O 0 7.895653908462918e-08
HFE O 0 4.801354953087866e-05
gene O 0 2.643634502419445e-07
located O 0 1.4173116369420313e-06
4 O 0 3.2113830457092263e-06
. O 0 7.236067176563665e-07

5 O 0 2.9456974516506307e-05
Mb O 0 9.988169949792791e-06
telomeric O 0 1.622535455680918e-05
to O 0 7.261963901328272e-07
HLA O 0 0.00010642511188052595
- O 0 2.0883739125565626e-05
A O 0 1.3997996575199068e-05
. O 0 8.687312629263033e-07

Population O 0 1.9747174562212422e-08
studies O 0 7.235732901733627e-09
of O 0 1.3607499571577364e-09
this O 0 1.6707966954410125e-10
polymorphism O 0 2.8812023877833326e-09
are O 0 3.313321006448433e-10
facilitated O 0 4.123622332485866e-09
by O 0 7.054214989921093e-10
the O 0 5.684518189497112e-09
fact O 0 2.2223221041173247e-09
that O 0 5.696584870484855e-10
the O 0 1.3510061513954952e-08
Cys282Tyr O 0 2.907204361690674e-06
mutation O 0 5.138740988286372e-08
creates O 0 1.279107522123013e-07
a O 0 8.536667905900686e-08
Rsal O 0 6.156367817311548e-06
restriction O 0 1.5588254882459296e-06
site O 0 5.4093688959255815e-06
. O 0 1.6784566696514958e-06

We O 0 4.2858471260842634e-07
have O 0 2.0537378020435426e-08
studied O 0 1.084717879962227e-07
the O 0 2.1462234656155488e-08
codon O 0 5.050487175140006e-07
282 O 0 1.3572457646660041e-06
( O 0 1.8301409454579698e-07
Cys O 0 4.9101879994850606e-05
/ O 0 3.342916670590057e-06
Tyr O 0 1.236826392414514e-06
) O 0 4.3481065969963595e-10
polymorphism O 0 7.68353936031474e-10
in O 0 1.8147433555881776e-10
different O 0 5.515593537452901e-10
ethnic O 0 9.703131631511042e-09
groups O 0 1.0957760032681563e-08
. O 0 1.4430629846629017e-07

In O 0 3.92882775201997e-08
agreement O 0 1.1983121339653735e-07
with O 0 3.19311999064098e-09
previous O 0 1.8420298175669814e-08
observations O 0 2.3786904890243932e-08
the O 0 7.627821929645506e-09
Tyr O 0 8.622182576800697e-07
allele O 0 2.4691292566103584e-08
appeared O 0 1.966688678578521e-08
to O 0 9.312541293660104e-10
be O 0 1.343384181673457e-09
rare O 0 1.2800514426203335e-08
or O 0 7.113276190295892e-09
absent O 0 1.31240611267458e-07
in O 0 2.6795996532769095e-09
Asiatic O 0 4.607291259617341e-07
( O 0 8.629810754889888e-10
Indian O 0 3.26578919462861e-09
, O 0 2.1790143023281416e-09
Chinese O 0 1.9460872024978926e-08
) O 0 2.605244020514874e-09
populations O 0 4.3884369915758725e-08
. O 0 3.402047923373175e-07

The O 0 2.836530370586843e-07
highest O 0 2.115655775014602e-07
allele O 0 6.818654441076433e-08
frequency O 0 4.259231900505256e-08
( O 0 1.9211696677956525e-09
7 O 0 1.7761960791062847e-08
. O 0 8.505194881713862e-10
5 O 0 8.517569760613242e-09
% O 0 7.19259263259886e-10
) O 0 6.763877652415928e-11
was O 0 2.57000998260537e-09
found O 0 1.3366775464263014e-09
in O 0 5.1611341866930616e-09
Swedes O 0 1.954041408680496e-06
. O 0 1.9182141386409057e-06

Saamis O 0 0.000231281403102912
( O 0 3.52770882727782e-07
2 O 0 5.457582119561266e-07
% O 0 7.318275763168458e-09
) O 0 2.727470749253058e-10
and O 0 1.566835106103781e-09
Mordvinians O 0 1.8771255838601064e-07
( O 0 1.0715582865472584e-09
1 O 0 9.67242108629307e-09
. O 0 7.095764531506177e-10
8 O 0 6.645013428396851e-09
% O 0 3.633159328941815e-10
) O 0 1.6519006648674228e-11
had O 0 2.3189945796975309e-10
significantly O 0 1.4083970656386668e-09
lower O 0 2.8745767988169746e-09
frequencies O 0 1.0684974682817483e-08
of O 0 1.6808350267183414e-08
the O 0 1.3035372603553697e-07
Tyr O 0 1.9413108020671643e-05
allele O 0 2.7685055101756006e-06
. O 0 1.1049919521610718e-06

Comparisons O 0 1.8531641217123251e-06
with O 0 2.2616854167267775e-08
allele O 0 1.09279596927081e-07
frequencies O 0 5.0985661914637603e-08
based O 0 1.2468625243400311e-08
on O 0 9.98993066048115e-09
prevalence O 0 3.0332540035260536e-08
estimates O 0 1.9134033024670316e-08
of O 0 2.319089809077468e-08
HH B-Disease 1 0.9999974966049194
showed O 0 9.532005265100452e-07
some O 0 2.6007175080167144e-08
disagreements O 0 6.33417926110269e-07
with O 0 2.2064499116680736e-09
the O 0 1.3673486343179775e-08
RFLP O 0 2.5226142952305963e-07
data O 0 5.099295918853386e-08
, O 0 9.103503728624673e-09
particularly O 0 2.232119200584748e-08
in O 0 2.9530870193639203e-08
Finns O 0 3.8919420148886275e-06
. O 0 1.6988152538033319e-06

The O 0 5.099858753965236e-06
newly O 0 1.1875122254423331e-05
described O 0 1.139522169069096e-06
HFE O 0 0.005646613892167807
marker O 0 1.6382374496970442e-06
provides O 0 4.088390070933201e-08
a O 0 3.818793281595845e-09
new O 0 1.927651815947229e-09
approach O 0 1.5682464216126846e-09
to O 0 2.9192365191832437e-10
the O 0 1.5753784943228766e-09
screening O 0 2.043086144709605e-09
of O 0 2.3702396489966304e-08
HH B-Disease 0 0.30259743332862854
as O 0 2.350677696938419e-08
well O 0 2.265522658362329e-09
as O 0 1.1161160884398669e-09
studies O 0 5.924324364414701e-10
of O 0 1.1818612755121194e-09
the O 0 6.432440802228712e-09
relationship O 0 8.889839975267932e-09
between O 0 4.7041652351254015e-08
the O 0 3.6518525803330704e-07
HFE O 0 0.0011078623356297612
Tyr O 0 8.360378160432447e-06
allele O 0 1.662486255327167e-07
and O 0 1.6417919468381115e-08
different O 0 1.3675787613465218e-07
disorders O 1 0.9999732971191406
including O 0 1.323219566984335e-05
cancer B-Disease 1 0.9999998807907104

Autosomal B-Disease 1 0.9997062087059021
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 0 0.0011365169193595648
associated O 0 7.794458412035965e-08
with O 0 3.4420526429101983e-09
a O 0 1.6612208497690517e-08
missense O 0 2.3926060066514765e-07
mutation O 0 1.8637928533848935e-08
encoding O 0 7.488140596478843e-08
Gly23 O 0 3.2967755032586865e-06
- O 0 6.735943429703184e-07
- O 0 1.1170184279762907e-06
> O 0 3.3822141176642617e-07
Val O 0 1.7953283304450451e-07
in O 0 1.679716454816571e-08
neurophysin O 0 1.6846573998918757e-05
II O 1 0.6539875268936157
. O 0 3.876834853144828e-06

Autosomal B-Disease 1 0.9965362548828125
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 4.840169935960148e-07
ADNDI B-Disease 1 1.0
) O 0 3.551321903216831e-09
is O 0 1.1914375042110237e-09
an O 0 6.308868538695833e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 5.895068966310646e-07
by O 0 6.706893929120383e-10
progressive O 0 0.00023611553478986025
degeneration O 1 1.0
of O 0 2.471876392462491e-08
the O 0 5.4452686804040695e-09
magnocellular O 0 3.3080093544413103e-06
neurons O 0 1.3506716811662045e-07
of O 0 2.9153165215234367e-08
the O 0 2.8636391036229725e-08
hypothalamus O 0 2.5063394559765584e-07
leading O 0 1.0508072989523498e-07
to O 0 2.632306150829322e-09
decreased O 0 2.8286414988087927e-08
ability O 0 1.336906918503189e-09
to O 0 3.0437714571007746e-09
produce O 0 7.545835245537091e-08
the O 0 1.3837784251791163e-07
hormone O 0 1.2152220278949244e-06
arginine O 0 5.956183940725168e-06
vasopressin O 0 2.1482981537701562e-05
( O 0 1.7161362393380841e-06
AVP O 0 0.00012022963346680626
) O 0 3.6649288404078106e-07
. O 0 9.541882945995894e-07

Affected O 0 2.7313893724567606e-07
individuals O 0 7.360524190147544e-09
are O 0 1.0610901046703702e-09
not O 0 9.169054959734524e-10
symptomatic O 0 1.759554152158671e-06
at O 0 7.144863367614107e-09
birth O 0 1.4223764388532345e-08
, O 0 1.2216683220600544e-09
but O 0 2.3497486179024918e-09
usually O 0 1.8558857561856712e-08
develop O 0 1.756682621589789e-07
diabetes B-Disease 1 0.9999982118606567
insipidus I-Disease 0 0.017736217007040977
at O 0 1.5639254513644119e-07
1 O 0 7.270050446095411e-07
- O 0 9.50994092363544e-07
6 O 0 3.5496077543939464e-06
yr O 0 1.1212352546863258e-05
of O 0 4.81915776617825e-07
age O 0 1.867769924501772e-06
. O 0 1.4810636912443442e-06

The O 0 2.3280428251837293e-07
genetic O 0 8.652511951368069e-07
locus O 0 3.289387677796185e-07
of O 0 9.328638128636157e-08
the O 0 4.2385416065826576e-08
disease O 0 2.212381787103368e-06
is O 0 2.5644231183008515e-09
the O 0 3.890617605861735e-08
AVP O 0 3.1036084692459553e-05
- O 0 3.1546685477223946e-06
neurophysin O 0 0.00011532925418578088
II O 1 0.9999983310699463
( O 0 2.512197454507259e-07
NPII O 0 0.02371855638921261
) O 0 2.562384082693825e-09
gene O 0 6.921301309859018e-09
, O 0 7.654346489971431e-09
and O 0 3.937911330353927e-09
mutations O 0 1.5888106830175275e-08
that O 0 1.0883083323420806e-09
cause O 0 1.669449716246163e-06
ADNDI B-Disease 1 0.9999871253967285
have O 0 4.271098585917343e-09
been O 0 2.9264237699777595e-09
found O 0 8.134201645582095e-10
in O 0 1.8583529159954537e-10
both O 0 7.622232844894938e-10
the O 0 5.204918274159809e-09
signal O 0 3.103983559071821e-08
peptide O 0 2.172292923319219e-08
of O 0 4.621306715080209e-08
the O 0 2.0117541055242327e-07
prepro O 0 0.00010911364370258525
- O 0 7.273397204698995e-05
AVP O 0 0.0004726876795757562
- O 0 2.546266114222817e-05
NPII O 0 0.08171334862709045
precursor O 0 3.2943992209766293e-06
and O 0 5.368064037725162e-08
within O 0 1.1908183950026796e-07
NPII O 1 0.9141624569892883
itself O 0 5.918344641031581e-07
. O 0 1.0013663995778188e-06

An O 0 1.4195447306519782e-07
affected O 0 4.975720457878197e-07
girl O 0 2.7112088218927965e-07
who O 0 1.7305291422076152e-08
presented O 0 5.796859525730724e-08
at O 0 1.789710424304758e-08
9 O 0 1.5470289937979942e-08
months O 0 1.43006861907935e-09
of O 0 3.852725249942068e-09
age O 0 2.825400713390991e-08
and O 0 6.217340420278106e-09
her O 0 2.7448927575335347e-09
similarly O 0 4.6723909186141555e-09
affected O 0 4.642525031073319e-09
younger O 0 7.583637540165e-08
brother O 0 2.3679582739077887e-07
and O 0 2.2406332789159933e-08
father O 0 2.683806314962567e-07
were O 0 1.2673434746091061e-08
all O 0 7.215621988798659e-10
found O 0 4.5165923778789363e-10
to O 0 3.0263855310685983e-10
have O 0 4.774859951872656e-10
a O 0 2.1855575127460725e-09
novel O 0 1.9020360397803415e-08
missense O 0 9.948710300022867e-08
mutation O 0 1.126970694542706e-08
( O 0 5.414633630351773e-09
G1758 O 0 2.5284549565185443e-07
- O 0 1.312638886474815e-07
- O 0 3.720896586401068e-07
> O 0 9.59962562774308e-08
T O 0 6.250743211921872e-08
) O 0 2.864444792471943e-10
encoding O 0 2.9776097143496827e-09
the O 0 1.569483032426433e-08
amino O 0 1.0645185177793337e-08
acid O 0 2.9466322715165916e-09
substitution O 0 3.412259630408698e-08
Gly23 O 0 1.9180092749593314e-06
- O 0 4.985267310075869e-07
- O 0 1.1910074135812465e-06
> O 0 1.2962025266460842e-06
Val O 0 9.354185408483318e-07
within O 0 5.74549744669639e-07
NPII O 0 0.015775732696056366
. O 0 1.548353566249716e-06

The O 0 8.742640034142823e-07
mutation O 0 1.7388944684171292e-07
was O 0 8.410877683218132e-08
confirmed O 0 1.0345373446796202e-08
by O 0 1.2391944137490896e-09
restriction O 0 9.375193599225895e-08
endonuclease O 0 1.50312780533568e-06
analysis O 0 2.1226280466635217e-07
. O 0 7.014052130216442e-07

A O 0 5.079465336166322e-05
T1 O 0 0.00012968065857421607
- O 0 1.6165530496436986e-06
weighted O 0 5.602948363048199e-07
magnetic O 0 7.291513526297422e-08
resonance O 0 4.820205745659223e-08
imaging O 0 5.365054107642209e-07
of O 0 4.5977577656231006e-07
the O 0 2.7680591756507056e-06
fathers O 0 0.020999334752559662
pituitary O 1 0.9970924854278564
gland O 0 7.192519115051255e-05
demonstrates O 0 1.1497372724988963e-06
an O 0 1.397179545392646e-07
attenuated O 0 0.00026536433142609894
posterior O 0 0.2850094139575958
pituitary O 1 0.9999650716781616
bright O 1 0.9999918937683105
spot O 0 0.0014821344520896673
. O 0 5.904695171921048e-06

This O 0 7.515040323369249e-08
mutation O 0 7.641732224783482e-08
may O 0 1.3421453282091989e-08
be O 0 2.6846029843596853e-09
valuable O 0 6.926547513330661e-08
for O 0 2.7136486391299286e-09
developing O 0 3.1492220387008274e-08
models O 0 1.1294458346355896e-07
of O 0 8.949233887278751e-08
dominantly B-Disease 0 0.00669975858181715
inherited I-Disease 1 0.999993085861206
neurodegeneration I-Disease 1 1.0
, O 0 6.880461711489261e-08
as O 0 5.162088978494239e-09
the O 0 1.3047872782223635e-09
early O 0 4.0291285863247595e-09
age O 0 4.557231036983467e-09
of O 0 3.797526293425335e-09
onset O 0 0.003913302905857563
of O 0 1.320780853575343e-07
symptoms O 0 2.639865670062136e-06
suggests O 0 4.465609659831671e-09
that O 0 8.318839367360553e-11
this O 0 9.473162532191992e-11
mutation O 0 9.796367050896038e-10
may O 0 1.1180486536588319e-09
be O 0 2.4926645192380192e-09
particularly O 0 1.145491079768135e-08
deleterious O 0 1.9025787878490519e-06
to O 0 2.8873213153701727e-08
the O 0 6.242474341888737e-07
magnocellular O 0 0.0002277269377373159
neuron O 0 3.197680780431256e-05
. O 0 3.5263769859739114e-07
. O 0 1.290673935727682e-06

Frequent O 0 2.4571877474954817e-06
inactivation O 0 3.802064020419493e-05
of O 0 2.930407845269656e-06
PTEN O 1 0.9999977350234985
/ O 1 0.934639573097229
MMAC1 O 1 1.0
in O 0 6.465111823672487e-07
primary O 1 1.0
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2642225328818313e-06

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 3.833595485502883e-08
the O 0 2.8508471139332414e-09
most O 0 9.917365817457835e-10
common O 0 3.987842944752629e-09
male B-Disease 0 3.747846921697828e-09
cancer I-Disease 0 2.3162505247142917e-09
in O 0 1.2645605396155446e-10
the O 0 3.5571721124227906e-09
Western O 0 2.87714012614515e-08
world O 0 2.018836875450347e-09
, O 0 2.705656809709467e-10
yet O 0 5.17349052486793e-10
many O 0 2.703541834847556e-10
of O 0 1.409797278917324e-09
the O 0 1.4687756566544863e-09
major O 0 7.989224393156746e-09
genetic O 0 7.246630406854138e-09
events O 0 1.4686299953936555e-09
involved O 0 1.6410490744078743e-09
in O 0 5.83561476918959e-10
the O 0 5.371430855660719e-09
progression O 0 2.5930901870196976e-07
of O 0 7.475579266724708e-09
this O 0 1.673961858017492e-09
often O 0 5.622915111302973e-08
fatal O 0 2.5171062588924542e-05
cancer B-Disease 0 9.786039299797267e-06
remain O 0 8.840267895493525e-08
to O 0 1.0450882825807639e-08
be O 0 9.755522256682525e-08
elucidated O 0 3.380349880899303e-05
. O 0 1.4533997045873548e-06

Numerous O 0 1.0801033567986451e-05
cytogenetic O 0 0.00015384085418190807
and O 0 3.7945670783301466e-07
allelotype O 0 1.0835225111804903e-05
studies O 0 2.0023554370141028e-08
have O 0 5.933710744976395e-10
reported O 0 3.8280258962686275e-09
frequent O 0 6.409832220555245e-09
loss O 0 3.0789824023713663e-08
of O 0 1.2524689907422726e-07
heterozygosity O 1 0.9999927282333374
on O 0 3.0920205063011963e-06
chromosomal O 0 9.856035467237234e-05
arm O 0 6.563969236594858e-06
10q O 0 1.3619363926409278e-05
in O 0 5.996405860742016e-08
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7859631498140516e-06

Deletion O 0 8.110844191833166e-07
mapping O 0 5.002736997994361e-07
studies O 0 7.128463153094344e-08
have O 0 2.527131837126717e-09
unambiguously O 0 1.1851400216755792e-07
identified O 0 1.6415164338923205e-08
a O 0 3.648187973936956e-09
region O 0 4.3847556696618994e-08
of O 0 2.614968153125119e-08
chromosome O 0 9.279057167077553e-08
10q23 O 0 2.1177875453304296e-07
to O 0 1.3889944749934102e-09
be O 0 1.4175439710939486e-09
the O 0 4.091937899630693e-09
minimal O 0 2.9002984547332744e-07
area O 0 2.310846838327052e-07
of O 0 6.91284753884247e-08
loss O 0 6.0585825849557295e-06
. O 0 3.08827497974562e-06

A O 0 1.0678783837647643e-05
new O 0 5.906188107474009e-07
tumor B-Disease 0 2.6878940388996853e-06
suppressor O 0 7.889292646723334e-06
gene O 0 1.9244022553266404e-07
, O 0 2.1848882170161232e-07
PTEN O 0 0.0005525018204934895
/ O 0 4.662592345994199e-06
MMAC1 O 1 0.9993014335632324
, O 0 1.2977045216189254e-08
was O 0 2.275675292651158e-08
isolated O 0 1.918102476849981e-08
recently O 0 1.6294932070337609e-09
at O 0 6.760811910311304e-10
this O 0 1.192635157298838e-10
region O 0 6.7309642304280715e-09
of O 0 1.154409279280344e-08
chromosome O 0 5.8988817386307346e-08
10q23 O 0 3.377914197244536e-07
and O 0 1.2658279979760323e-09
found O 0 4.924983199039445e-10
to O 0 4.2930423105325133e-10
be O 0 9.756946361960672e-10
inactivated O 0 5.718534534793207e-09
by O 0 5.939380931518912e-11
mutation O 0 1.0333595090727954e-09
in O 0 1.8052747075003595e-09
three O 0 1.6862829852470895e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 1.567951221659314e-05
lines O 0 4.905156174572767e-07
. O 0 2.2699101975831582e-07

We O 0 2.744774292295915e-06
screened O 0 9.218809282174334e-06
80 O 0 4.9246973503613845e-06
prostate B-Disease 0 6.006350668030791e-05
tumors I-Disease 1 1.0
by O 0 1.945544392256693e-09
microsatellite O 0 8.141721963283999e-08
analysis O 0 3.953972704806574e-09
and O 0 9.052523730623818e-10
found O 0 1.0300319486233889e-09
chromosome O 0 7.610180041695003e-09
10q23 O 0 7.337062868373323e-08
to O 0 1.8269797896763862e-09
be O 0 3.1844711312345453e-09
deleted O 0 5.527405022576204e-08
in O 0 9.630744202127062e-09
23 O 0 2.59762231280547e-07
cases O 0 6.135667973694581e-08
. O 0 4.4092362827541365e-07

We O 0 1.9499053394156363e-07
then O 0 4.77345345473168e-08
proceeded O 0 4.734616965151872e-08
with O 0 6.267986130126246e-11
sequence O 0 2.0618523555171464e-10
analysis O 0 6.947883934849131e-10
of O 0 2.120214892542549e-09
the O 0 1.1271211519670032e-08
entire O 0 3.5999224223814963e-07
PTEN O 0 0.0004447066457942128
/ O 0 1.0344988368160557e-06
MMAC1 O 0 5.59417776457849e-06
coding O 0 3.874954401794639e-08
region O 0 2.3806242310797643e-08
and O 0 1.118976689085116e-09
tested O 0 1.3246169716651934e-09
for O 0 1.7190602275007905e-09
homozygous O 0 1.880608380133708e-08
deletion O 0 1.444067443401309e-08
with O 0 2.6543891529229313e-09
new O 0 4.3989874853878064e-08
intragenic O 0 9.085714737011585e-06
markers O 0 1.747322500023074e-07
in O 0 2.6395763352837776e-09
these O 0 4.626190097667404e-09
23 O 0 5.83326134062645e-08
cases O 0 2.7027906579490946e-09
with O 0 7.98553390080059e-10
10q23 O 0 5.238312496658182e-06
loss O 0 4.1853917309708777e-07
of O 0 2.1517564618989127e-06
heterozygosity O 1 0.9991607666015625
. O 0 1.482589232182363e-05

The O 0 1.598995069684861e-08
identification O 0 6.668899033002162e-08
of O 0 9.716283955185645e-08
the O 0 3.605680376495002e-08
second O 0 1.7841897204107227e-07
mutational O 0 9.090004823519848e-06
event O 0 1.0922187243522785e-07
in O 0 2.9244890953350478e-08
10 O 0 1.3891758499084972e-07
( O 0 2.4137543519486826e-08
43 O 0 1.137082904278941e-06
% O 0 9.472759643358586e-08
) O 0 4.091612026968505e-08
tumors B-Disease 1 1.0
establishes O 0 5.136074378242483e-06
PTEN O 1 0.9921970367431641
/ O 0 1.553604488435667e-05
MMAC1 O 1 0.9748662710189819
as O 0 1.5125818819683445e-08
a O 0 3.507939716484998e-09
main O 0 4.4703757140496236e-08
inactivation O 0 1.1252142684270439e-07
target O 0 1.159577589504579e-08
of O 0 1.3458982373037998e-08
10q O 0 1.750976934999926e-06
loss O 0 2.7678774472406076e-07
in O 0 9.262753053462802e-08
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3443543878111086e-07
. O 0 2.1444601827624865e-07

Risk O 0 6.7791156652674545e-06
reversals O 0 5.2095274440944195e-06
in O 0 3.154077665712407e-09
predictive O 0 3.6859944430034375e-08
testing O 0 6.55293197482365e-09
for O 0 5.331259700369628e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1418316034905729e-06

The O 0 1.2365769919142622e-07
first O 0 7.331310225566767e-09
predictive O 0 9.229665032250978e-09
testing O 0 9.832683556254551e-10
for O 0 1.9238550308386948e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.453001605815189e-09
HD B-Disease 0 1.8058648265650845e-07
) O 0 8.569265436131346e-11
was O 0 8.314592347957728e-10
based O 0 3.6714595252895776e-10
on O 0 6.425668330756196e-10
analysis O 0 6.001881214245941e-10
of O 0 2.8759534753675098e-09
linked O 0 1.8046625527290416e-08
polymorphic O 0 2.2784114150908863e-08
DNA O 0 2.4548864274720472e-08
markers O 0 2.6661981067377383e-08
to O 0 5.971905747692574e-10
estimate O 0 1.985628905742942e-08
the O 0 1.3669985143849317e-09
likelihood O 0 4.413543663872588e-08
of O 0 2.038894564293514e-08
inheriting O 0 2.662199563019385e-07
the O 0 2.5450891172340562e-08
mutation O 0 1.1899052410058175e-08
for O 0 3.374796264665747e-08
HD B-Disease 0 0.00016073421284090728
. O 0 2.5450367502344307e-06

Limits O 0 1.4368669098985265e-07
to O 0 6.977608268954327e-09
accuracy O 0 8.423977959637341e-08
included O 0 4.331917047295519e-09
recombination O 0 3.923763536306524e-09
between O 0 7.090275033760918e-09
the O 0 4.195964464770441e-09
DNA O 0 4.41996341749018e-08
markers O 0 5.9598956880790865e-08
and O 0 7.804824342372285e-09
the O 0 3.603383902373025e-08
mutation O 0 3.059324882315195e-08
, O 0 5.402542857524395e-09
pedigree O 0 1.0895367097418784e-07
structure O 0 4.4118774411572304e-08
, O 0 5.036627115373449e-09
and O 0 1.796913062790395e-09
whether O 0 1.2452742170765418e-09
DNA O 0 8.149548591518396e-09
samples O 0 2.2776280861336318e-09
were O 0 6.42789932392418e-10
available O 0 3.6354417254358395e-09
from O 0 1.0672713379733523e-08
family O 0 9.883498108820277e-08
members O 0 4.738772929613333e-08
. O 0 8.955190651249723e-07

With O 0 9.804541178937143e-09
direct O 0 2.116506969684906e-08
tests O 0 4.800080888323066e-10
for O 0 1.3744758664557821e-09
the O 0 1.4473626741562384e-08
HD B-Disease 0 6.423015861400927e-07
mutation O 0 7.473954788395076e-09
, O 0 1.164386254082217e-09
we O 0 1.0529912497503346e-09
have O 0 3.072901377798587e-10
assessed O 0 8.298277620610861e-09
the O 0 1.5979607637106596e-09
accuracy O 0 1.0662584060128211e-07
of O 0 2.0003628975473475e-08
results O 0 1.0592323462788045e-08
obtained O 0 2.5958064142628245e-08
by O 0 3.4630194267748493e-09
linkage O 0 1.8836423976154038e-07
approaches O 0 4.7138833281223924e-08
when O 0 1.1735993288297664e-09
requested O 0 4.186068380818142e-09
to O 0 2.383512498482787e-09
do O 0 2.2185697723386966e-09
so O 0 1.77627657027557e-09
by O 0 1.0838896447040725e-09
the O 0 6.68760824495962e-09
test O 0 3.2513820524826542e-09
individuals O 0 2.5180348472986225e-08
. O 0 1.1360368716850644e-06

For O 0 1.0689809215591595e-07
six O 0 2.6077660919554546e-08
such O 0 1.484998235490309e-09
individuals O 0 3.385613123185749e-09
, O 0 1.6144949821494947e-09
there O 0 6.548230846448178e-10
was O 0 2.2263866306104774e-09
significant O 0 5.938423974782836e-09
disparity O 0 2.731368340391782e-07
between O 0 2.6242366502060577e-08
the O 0 5.521430779253933e-08
tests O 0 2.088754769147272e-08
. O 0 4.540557654308941e-07

Three O 0 4.833785851587891e-07
went O 0 1.3259477782412432e-07
from O 0 7.591478556889797e-09
a O 0 4.311409007584643e-09
decreased O 0 2.948348409859136e-08
risk O 0 1.4304259998709767e-09
to O 0 1.2334024079851957e-10
an O 0 3.892952071815614e-10
increased O 0 1.5115602103321635e-09
risk O 0 2.594602088734632e-09
, O 0 3.5497149664109884e-10
while O 0 7.211714558863491e-10
in O 0 4.5383882762983774e-10
another O 0 4.895138960847589e-09
three O 0 2.8154256703771807e-09
the O 0 1.3682095456601928e-08
risk O 0 9.659114397209123e-08
was O 0 1.030207741337108e-07
decreased O 0 3.370936951796466e-07
. O 0 3.21121319757367e-07

Knowledge O 0 5.97081793785037e-07
of O 0 1.1845242653407695e-07
the O 0 2.0493903463147944e-08
potential O 0 8.805097451158872e-08
reasons O 0 2.3582355623830153e-08
for O 0 4.668042064004396e-10
these O 0 4.2739731198615516e-10
changes O 0 7.276349522911119e-10
in O 0 3.359700295746393e-10
results O 0 1.7281469588681375e-09
and O 0 1.1780039166353617e-09
impact O 0 2.5465165975901982e-08
of O 0 2.1427497554071806e-09
these O 0 9.737221029482157e-10
risk O 0 2.036255786208585e-08
reversals O 0 1.1338100591729017e-07
on O 0 1.8294633363780122e-08
both O 0 2.0973009995373104e-09
patients O 0 7.608085828003652e-10
and O 0 1.575477748261278e-09
the O 0 6.177882205804508e-09
counseling O 0 9.065794226437163e-10
team O 0 1.423890227947311e-09
can O 0 3.9574257759689146e-10
assist O 0 5.3243699227323305e-08
in O 0 1.7450226819093473e-09
the O 0 1.7693322362788422e-08
development O 0 2.2039358782421914e-08
of O 0 5.996449115031055e-09
strategies O 0 4.145118470688658e-09
for O 0 1.4415240112697347e-09
the O 0 9.65130286800786e-09
prevention O 0 2.6681259868155394e-08
and O 0 2.852794445118434e-09
, O 0 9.066191686279979e-10
where O 0 1.639819502408102e-09
necessary O 0 1.993160836377683e-08
, O 0 1.7620835901510645e-09
management O 0 4.806862907713594e-09
of O 0 1.1288509682572112e-08
a O 0 6.7518715063386026e-09
risk O 0 4.6511068774179876e-08
reversal O 0 2.6726743485028237e-08
in O 0 4.6229947647802305e-10
any O 0 4.658233798693345e-09
predictive O 0 2.9503286924636996e-08
testing O 0 4.196012426405105e-09
program O 0 3.617197563698937e-08
. O 0 9.080650897885789e-08
. O 0 7.394692147499882e-07

A O 0 1.9786118627962423e-06
novel O 0 2.652235480127274e-07
common O 0 6.8276726494787e-08
missense O 0 1.1790855296567315e-06
mutation O 0 5.541624403804235e-08
G301C O 0 5.779922958026873e-07
in O 0 6.152881315557579e-09
the O 0 8.582413357771657e-08
N O 0 6.709483955091855e-07
- O 0 2.957056324248697e-07
acetylgalactosamine O 0 4.168007762928028e-06
- O 0 1.4391202967090067e-06
6 O 0 2.2333474589686375e-06
- O 0 7.058662276904215e-07
sulfate O 0 2.077173576253699e-06
sulfatase O 0 1.0412420124339405e-05
gene O 0 1.1933148869047727e-07
in O 0 1.6944015612807561e-07
mucopolysaccharidosis B-Disease 0 0.0049635423347353935
IVA I-Disease 1 0.9999996423721313
. O 0 1.1576698852877598e-05

Mucopolysaccharidosis B-Disease 0 0.003440226661041379
IVA I-Disease 1 1.0
( O 0 6.652739102719352e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 8.219723213187535e-08
is O 0 4.659637564685681e-09
an O 0 3.8957487902280263e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 2.387851600360591e-05
by O 0 3.604982146132585e-10
a O 0 6.919691042384102e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.092152051602625e-08
N O 0 3.4587117170303827e-07
- O 0 1.7808477537073486e-07
acetylgalactosamine O 0 6.548700639541494e-06
- O 0 2.3768097889842466e-06
6 O 0 3.4162565043516224e-06
- O 0 2.571828872532933e-06
sulfate O 0 9.386147212353535e-06
sulfatase O 0 7.556791388196871e-05
( O 0 1.4469563893726445e-06
GALNS O 0 0.16817054152488708
) O 0 3.9560873688060383e-07
. O 0 1.493998411206121e-06

In O 0 6.533814200793131e-08
previous O 0 7.650481848031632e-08
studies O 0 2.330916792914195e-08
, O 0 1.268220639616402e-09
we O 0 4.932372843491351e-10
have O 0 1.3367559836829912e-10
found O 0 5.254189860970371e-10
two O 0 2.305455271134349e-10
common O 0 2.3328225462471153e-10
mutations O 0 8.292309061630476e-10
in O 0 3.6051747698273573e-10
Caucasians O 0 1.1956063694640306e-08
and O 0 3.1571352199222247e-09
Japanese O 0 2.2248855202633422e-07
, O 0 1.4707779882883187e-08
respectively O 0 1.4939087122911587e-07
. O 0 8.146954542098683e-07

To O 0 9.967590841597485e-08
characterize O 0 5.610177140624728e-07
the O 0 9.38549931106536e-08
mutational O 0 3.901905984093901e-06
spectrum O 0 1.2020160511383438e-07
in O 0 7.022895043284905e-10
various O 0 2.0767092490103778e-09
ethnic O 0 4.329769875965894e-09
groups O 0 4.885500892726213e-10
, O 0 4.1111647419711517e-10
mutations O 0 1.4932777236964512e-09
in O 0 7.562065973409915e-10
the O 0 1.5292474841999137e-08
GALNS O 0 7.444616130669601e-06
gene O 0 1.974554519890148e-09
in O 0 4.013512189260382e-09
Colombian O 0 2.51662436312472e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 4.3337710309288013e-08
were O 0 9.400365819089984e-09
investigated O 0 2.148562217030303e-08
, O 0 1.4482345322974766e-09
and O 0 5.881607978430736e-10
genetic O 0 7.338501362141869e-09
backgrounds O 0 9.15077151830701e-08
were O 0 6.574978783646657e-09
extensively O 0 1.4151370075765612e-09
analyzed O 0 1.0840199848871634e-09
to O 0 1.1181482822975042e-10
identify O 0 5.510412570686185e-09
racial O 0 9.054185845513985e-09
origin O 0 7.916022504161901e-09
, O 0 1.0239751269125463e-09
based O 0 6.704569344151423e-09
on O 0 1.258935267145489e-08
mitochondrial O 0 5.608712072557864e-08
DNA O 0 2.503501264072838e-07
( O 0 8.162090381347298e-08
mtDNA O 0 2.776665724013583e-07
) O 0 2.1946735984101906e-08
lineages O 0 6.745078167114116e-07
. O 0 7.421631380566396e-07

Three O 0 5.024736537961871e-07
novel O 0 6.577113822459069e-07
missense O 0 3.2766340609668987e-06
mutations O 0 2.582463594080764e-07
never O 0 1.234482027712147e-07
identified O 0 4.89234146527906e-08
previously O 0 6.834875776462468e-09
in O 0 1.7605072955007017e-10
other O 0 5.543426273568741e-10
populations O 0 1.5178959200667919e-09
and O 0 5.861841012588798e-10
found O 0 3.804266068829776e-10
in O 0 2.980165281218916e-10
16 O 0 9.181958304793625e-09
out O 0 1.6350846232526806e-09
of O 0 3.84185039337126e-09
19 O 0 5.328098140466864e-08
Colombian O 0 2.23002712118614e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 2.768136084796424e-07
alleles O 0 1.3431082024339958e-08
account O 0 8.430983022833516e-09
for O 0 1.264402627043637e-08
84 O 0 1.3405357321971678e-06
. O 0 6.8996081381556e-07

2 O 0 1.8464783124727546e-06
% O 0 1.964570373047536e-08
of O 0 9.435826342496512e-09
the O 0 7.44764250271146e-09
alleles O 0 5.885022691387576e-09
in O 0 1.0418794715860713e-09
this O 0 1.7539456553805621e-09
study O 0 7.631983933720221e-09
. O 0 6.380449946163935e-08

The O 0 2.5638628358137794e-06
G301C O 0 1.4317514796857722e-05
and O 0 5.387049739624672e-08
S162F O 0 1.9487488316372037e-06
mutations O 0 5.701743432950934e-08
account O 0 1.919376124703831e-08
for O 0 2.0997557470536776e-08
68 O 0 1.919004716910422e-06
. O 0 6.959853067201038e-07

4 O 0 2.7546828277991153e-05
% O 0 2.566675902926363e-07
and O 0 7.916991506817794e-08
10 O 0 4.37450609069856e-07
. O 0 6.302905148913851e-07

5 O 0 3.374517973497859e-06
% O 0 3.360306166655391e-08
of O 0 1.6474571040703267e-08
mutations O 0 2.4799517106544045e-08
, O 0 7.029894444343654e-09
respectively O 0 1.0308952802517979e-08
, O 0 7.989937045316253e-10
whereas O 0 5.8412745751468265e-09
the O 0 2.9438753657018424e-08
remaining O 0 4.104143590666354e-05
F69V O 1 0.9977796673774719
is O 0 1.2152818751332006e-09
limited O 0 8.348329250118525e-10
to O 0 8.233979054139695e-10
a O 0 1.1421705359282441e-08
single O 0 4.500224193293434e-08
allele O 0 1.022665855998639e-06
. O 0 1.0726527079896186e-06

The O 0 4.4397603460311075e-07
skewed O 0 1.7346719687338918e-06
prevalence O 0 3.021270629233186e-07
of O 0 1.4052423225052735e-08
G301C O 0 1.5421832699757942e-07
in O 0 8.091802228271661e-10
only O 0 2.6957065468735664e-09
Colombian O 0 3.4757665190454645e-08
patients O 0 1.1695256985078117e-09
and O 0 2.5193150343660875e-10
haplotype O 0 3.15270631823239e-09
analysis O 0 2.4373369988950344e-10
by O 0 5.7716741108659875e-11
restriction O 0 3.99130506423262e-09
fragment O 0 1.8264683987467834e-08
length O 0 3.3331433169081492e-09
polymorphisms O 0 1.563349272259984e-08
in O 0 3.4912859270264107e-09
the O 0 1.0692868102069042e-07
GALNS O 0 0.000896228535566479
gene O 0 1.1715981962368005e-08
suggest O 0 1.734504628814193e-08
that O 0 1.634024693331071e-09
G301C O 0 8.925931638259499e-08
originated O 0 1.3668323362026058e-08
from O 0 2.6972082345366744e-09
a O 0 3.544831761459477e-09
common O 0 1.1379780673337336e-08
ancestor O 0 9.26044435800577e-07
. O 0 6.289203042797453e-07

Investigation O 0 6.484414143415052e-07
of O 0 2.278887905049487e-07
the O 0 2.620560302091235e-08
genetic O 0 3.184090147101415e-08
background O 0 1.006705474537739e-08
by O 0 3.6912112255649276e-10
means O 0 7.599649798351038e-09
of O 0 6.285327369681681e-09
mtDNA O 0 1.5305635869822254e-08
lineages O 0 1.5990316626357526e-08
indicate O 0 1.4513988233488817e-08
that O 0 1.1409703182252429e-09
all O 0 3.778538371079776e-09
our O 0 1.3429442446977191e-08
patients O 0 1.3605501170133039e-09
are O 0 2.611451610512461e-10
probably O 0 5.226495680688004e-09
of O 0 1.1768704233361404e-08
native O 0 4.642536666210617e-08
American O 0 1.020307422550104e-06
descent O 0 2.674384268175345e-05

Low O 0 1.0159701560041867e-06
frequency O 0 2.299527324112205e-07
of O 0 1.5937646935526573e-07
BRCA1 O 0 1.021326738737116e-06
germline O 0 1.5269791902028373e-06
mutations O 0 2.211827521136911e-08
in O 0 2.2343928929302592e-09
45 O 0 7.612157304492939e-08
German O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.232143524518506e-08
. O 0 4.289854516059677e-08

In O 0 8.280494512291625e-08
this O 0 6.022686349638207e-09
study O 0 2.1754014145614065e-09
we O 0 6.437788635516029e-10
investigated O 0 1.1852164583103786e-08
45 O 0 4.990033630747348e-08
German O 0 0.0019995025359094143
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.212952457535948e-10
for O 0 1.894741863406324e-10
germline O 0 4.5475257337557196e-08
mutations O 0 9.025237446280698e-09
in O 0 1.8310682969868708e-09
the O 0 8.589028510641583e-08
BRCA1 O 0 3.000424726451456e-07
gene O 0 2.1674966887985647e-07
. O 0 1.526454980194103e-06

We O 0 3.200063645181217e-07
identified O 0 6.140703021628724e-07
four O 0 4.6958188448797955e-08
germline O 0 4.466091013455298e-06
mutations O 0 1.7732823209826165e-07
in O 0 3.710711382609588e-08
three O 0 9.389796673531237e-08
breast B-Disease 0 5.121373192196188e-07
cancer I-Disease 0 1.0975920616829171e-07
families O 0 2.1742816436187695e-09
and O 0 1.1045994119385227e-09
in O 0 2.5530175751242723e-09
one O 1 0.9994344115257263
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3775840024266017e-08
. O 0 9.203146578151689e-11
among O 0 1.0963457225399154e-10
these O 0 1.1140673800147383e-10
were O 0 5.259363500265124e-10
one O 0 1.1035506952694618e-09
frameshift O 0 7.926223588583525e-08
mutation O 0 5.038010453262132e-09
, O 0 3.4174425511679374e-09
one O 0 9.886227836375383e-09
nonsense O 0 2.1719165488320868e-07
mutation O 0 3.5319967395253116e-08
, O 0 5.9774358796005345e-09
one O 0 6.978753575026531e-09
novel O 0 3.900819578461778e-08
splice O 0 7.009584805928171e-07
site O 0 6.4030530211312e-08
mutation O 0 1.0692517982135996e-08
, O 0 8.001301843307829e-09
and O 0 8.796884110040537e-09
one O 0 6.817678155357498e-08
missense O 0 1.1904194252565503e-05
mutation O 0 1.1448639725131216e-06
. O 0 1.853874778134923e-06

The O 0 9.410107395524392e-07
missense O 0 3.7487466215679888e-06
mutation O 0 1.2278553640499013e-07
was O 0 1.474913773336084e-07
also O 0 3.0872842060603034e-09
found O 0 3.023715944294736e-09
in O 0 7.249368216832863e-09
2 O 0 1.5175052112681442e-06
. O 0 8.603421974839875e-07

8 O 0 3.6642195482272655e-06
% O 0 1.68205360751017e-08
of O 0 1.0098920810719392e-08
the O 0 5.740434350087753e-09
general O 0 2.194062531657437e-08
population O 0 2.1987283105318056e-09
, O 0 2.7130933610841623e-10
suggesting O 0 1.7337297153474651e-09
that O 0 2.5047205975958775e-10
it O 0 2.0724269522709449e-10
is O 0 4.698197386687752e-10
not O 0 2.6754169990539367e-09
disease O 0 3.989956667282968e-07
associated O 0 2.038359752987162e-06
. O 0 1.7330120272163185e-06

The O 0 1.2541400451482332e-07
average O 0 2.0693320834652695e-08
age O 0 1.1999699012221754e-08
of O 0 1.03013073626812e-08
disease O 0 2.1496132376341848e-06
onset O 0 1.3333089555089828e-05
in O 0 2.9521043942715153e-10
those O 0 6.1012239704894e-10
families O 0 4.038569034747752e-09
harbouring O 0 2.228176754215383e-07
causative O 0 1.1242981656778284e-07
mutations O 0 2.3414507666075224e-08
was O 0 7.510727328963185e-08
between O 0 5.258947410879955e-08
32 O 0 4.787185389432125e-06
. O 0 1.9821757177851396e-06

3 O 0 5.2207244152668864e-05
and O 0 2.2207570964383194e-06
37 O 0 3.137617386528291e-05
. O 0 2.7815337944048224e-06

4 O 0 5.762240107287653e-06
years O 0 1.0781791104363947e-07
, O 0 4.770329020686859e-09
whereas O 0 9.183131588486049e-09
the O 0 7.194915330188678e-09
family O 0 1.7294272680601352e-08
harbouring O 0 2.277366917269319e-07
the O 0 8.111910254626764e-09
missense O 0 9.40348954259207e-08
mutation O 0 3.2251752379863774e-09
had O 0 3.2785585357686386e-09
an O 0 5.956548587704447e-10
average O 0 1.8762007503170253e-09
age O 0 3.3725620074420704e-09
of O 0 2.8135698215692173e-08
onset O 1 0.7777244448661804
of O 0 3.7333625186874997e-06
51 O 0 5.20516732649412e-06
. O 0 9.351259109280363e-07

2 O 0 8.328824333148077e-05
years O 0 3.771070623770356e-06
. O 0 4.441586952452781e-06

These O 0 1.6896589727366518e-07
findings O 0 4.018524464299844e-07
show O 0 5.273924585935674e-08
that O 0 8.63643467852171e-09
BRCA1 O 0 2.703220616240287e-07
is O 0 4.731454783524214e-09
implicated O 0 1.6031910021752083e-08
in O 0 4.770162598255467e-10
a O 0 6.09088779413014e-10
small O 0 3.5464869929668907e-10
fraction O 0 3.263138026454726e-08
of O 0 5.341801625036169e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.259317756971086e-10
suggesting O 0 3.852414776073232e-10
the O 0 1.0344770873249587e-10
involvement O 0 4.915786111503451e-10
of O 0 5.836215399845912e-10
another O 0 1.6062540186823071e-09
susceptibility O 0 3.699524953049149e-08
gene O 0 9.801384948104896e-08
( O 0 7.893061706454318e-07
s O 0 4.114167677471414e-05
) O 0 1.8731230966295698e-06

Paternal O 0 0.024746941402554512
transmission O 1 0.9998941421508789
of O 1 0.9999909400939941
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9762309193611145

We O 0 4.991023843103903e-07
report O 0 4.40245422339558e-08
a O 0 4.657513930084178e-09
rare O 0 7.735037499401187e-09
case O 0 1.822636797044197e-08
of O 0 3.632040801448966e-08
paternally O 1 0.9979920387268066
transmitted O 1 0.9999411106109619
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999310970306396
DM B-Disease 1 1.0
) O 0 2.2190117476839077e-07
. O 0 4.830403099731484e-07

The O 0 2.425551883789012e-06
proband O 0 8.1172889622394e-05
is O 0 2.8465398926869057e-08
a O 0 1.7160013854322642e-08
23 O 0 1.35108905396919e-07
year O 0 6.9016068415805876e-09
old O 0 3.898792783729732e-06
, O 0 4.757066278671118e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.9978698492050171
who O 0 1.394529363096808e-06
suffers O 1 0.9944597482681274
severe O 1 0.9999986886978149
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 6.515808308904525e-06

He O 0 3.43188418128193e-07
presented O 0 1.5958148935624195e-07
with O 0 8.107734039697334e-09
respiratory O 1 0.9999995231628418
and O 0 1.3140041232873045e-07
feeding O 0 1.0566922355792485e-05
difficulties O 0 0.45599737763404846
at O 0 1.963823251571739e-06
birth O 0 1.6921350834309123e-05
. O 0 2.7490127649798524e-06

His O 0 6.566154297615867e-06
two O 0 1.8880896277551074e-06
sibs O 1 0.9998356103897095
suffer O 0 0.00014410946459975094
from O 0 1.290189175051637e-06
childhood O 1 0.7710171341896057
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 6.187487997522112e-06

Their O 0 7.514810818065598e-08
late O 0 3.6273099794925656e-06
father O 0 6.311139486570028e-07
had O 0 1.0949403161930604e-08
the O 0 4.2097503261118163e-10
adult O 0 2.6591412405352344e-10
type O 0 1.686891404339974e-09
of O 0 3.045794016998116e-08
DM B-Disease 1 1.0
, O 0 3.4685545102774995e-08
with O 0 6.2204716932967585e-09
onset O 1 0.9999125003814697
around O 0 2.8604729251924255e-08
30 O 0 1.3604008586298733e-07
years O 0 3.96090342746902e-08
. O 0 3.2452194886900543e-07

Only O 0 9.149601964963949e-08
six O 0 1.0138388795155606e-08
other O 0 2.9520819122552666e-10
cases O 0 2.570327284345808e-10
of O 0 7.416056102549362e-10
paternal O 0 5.7697629927133676e-06
transmission O 0 0.4050304889678955
of O 1 0.9826745390892029
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.1300678124825936e-05
been O 0 3.679103954823404e-08
reported O 0 3.704954920635828e-08
recently O 0 2.1875189659681382e-08
. O 0 9.32812156406726e-08

We O 0 1.0069054923178555e-07
review O 0 2.1055909016354235e-08
the O 0 5.287246640506282e-09
sex O 0 9.54246015538729e-10
related O 0 7.377643385098054e-09
effects O 0 3.710117013611125e-08
on O 0 8.386412453376124e-09
transmission O 0 1.9235192212363472e-06
of O 0 2.9694017484871438e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00031747366301715374

Decreased O 0 3.711544195539318e-06
fertility O 0 1.7617897185573383e-07
of O 0 1.0309817888298767e-08
males O 0 2.857939718214908e-10
with O 0 5.880450293371808e-11
adult O 0 3.1779545661692055e-09
onset O 0 6.13394104220788e-06
DM B-Disease 1 1.0
and O 0 2.035811963452261e-09
contraction O 0 1.2213334343869064e-08
of O 0 5.905295807906441e-09
the O 0 3.2066815869313814e-09
repeat O 0 4.338168491102579e-09
upon O 0 1.1358182838705488e-08
male O 0 1.7475875191408363e-09
transmission O 0 3.8594034634797936e-09
contribute O 0 3.687544714026103e-10
to O 0 4.2210468453873773e-10
the O 0 2.8788784689481872e-09
almost O 0 3.568881634663512e-09
absent O 0 1.54689896447735e-08
occurrence O 0 9.484579344132271e-09
of O 0 3.6109297774089555e-09
paternal O 0 7.245565939228982e-06
transmission O 0 0.00024797883816063404
of O 0 0.023269355297088623
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0003222564409952611

Also O 0 9.106146592330333e-08
the O 0 3.780905188932593e-08
fathers O 0 3.757278932425834e-07
of O 0 9.329847472372421e-08
the O 0 4.070323456062397e-08
reported O 0 7.62219727334923e-08
congenitally O 0 4.2963906707882416e-06
affected O 0 4.385123730799023e-08
children O 0 5.77465320006354e-09
showed O 0 1.3057838366137275e-08
, O 0 6.912511674173061e-10
on O 0 9.984635340742898e-09
average O 0 2.151198685851341e-08
, O 0 3.270501647278934e-09
shorter O 0 2.5947997528419364e-07
CTG O 0 9.535928256809711e-06
repeat O 0 1.471673698461018e-07
lengths O 0 7.014788252490689e-07
and O 0 4.408518883280976e-09
hence O 0 8.156406217096901e-09
less O 0 7.430899007232483e-09
severe O 0 3.8531098311977985e-07
clinical O 0 3.870994547128248e-08
symptoms O 0 2.2970608526406977e-08
than O 0 2.0531756850239447e-10
the O 0 2.4625717021109494e-09
mothers O 0 5.532876379277241e-09
of O 0 8.297059039819032e-09
children O 0 2.9072796792206645e-07
with O 0 7.330681455641752e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 7.894967711763456e-05

We O 0 6.771787752768432e-08
conclude O 0 1.0372426828553216e-07
that O 0 9.96644100581534e-10
paternal O 0 1.4139701534077176e-06
transmission O 0 5.549108664126834e-06
of O 0 2.8070737243979238e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.717220036809522e-08
rare O 0 5.393431479205901e-09
and O 0 2.5603652531458465e-10
preferentially O 0 7.616783315178566e-10
occurs O 0 2.793301423498207e-10
with O 0 8.101541659755185e-11
onset O 0 8.708498171472456e-07
of O 0 3.048648409276211e-07
DM B-Disease 1 1.0
past O 0 6.525818889713264e-07
30 O 0 6.139261898852055e-08
years O 0 2.0821666613102252e-09
in O 0 8.800891126981014e-10
the O 0 2.3275271487932514e-08
father O 0 3.89223629326807e-07
. O 0 6.239379501948861e-08
. O 0 5.645778173857252e-07

The O 0 4.577750587486662e-06
RB1 O 0 0.00017362010839860886
gene O 0 1.167240313293405e-07
mutation O 0 3.108237578430817e-08
in O 0 2.677157828756549e-09
a O 0 1.5809149545020773e-08
child O 0 5.334830461833917e-07
with O 0 7.860040227569698e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 5.470918767969124e-05

The O 0 8.708591849426739e-06
RB1 O 0 0.00020266980573069304
gene O 0 1.5142047971039574e-07
mutation O 0 7.806211499428173e-08
was O 0 5.216270793084732e-08
investigated O 0 1.416069128623576e-08
in O 0 3.8712419381248253e-10
a O 0 4.362463279505846e-09
child O 0 1.296646132686874e-07
with O 0 1.8214350916423427e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 0.9999998807907104
retinoblastoma I-Disease 0 7.884057595219929e-06
using O 0 1.3160947887058683e-09
DNA O 0 8.104688475896182e-09
obtained O 0 7.3497496977381616e-09
from O 0 3.167207607290834e-09
both O 0 4.699382660788842e-09
the O 0 3.4093709189164656e-08
pineal B-Disease 0 0.0001602236006874591
and I-Disease 0 7.914395183661327e-08
retinal I-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
of O 0 2.1681966245523654e-05
the O 0 8.599549801147077e-07
patient O 0 2.2811652797827264e-06
. O 0 1.3046656022197567e-06

A O 0 3.997587555204518e-06
nonsense O 0 1.4408095694307121e-06
mutation O 0 3.485305910544412e-08
in O 0 9.617306950815419e-09
exon O 0 2.8984595701331273e-07
17 O 0 3.634099243754463e-07
( O 0 1.0237374503674346e-08
codon O 0 1.0531528715773675e-07
556 O 0 1.1396293331245033e-07
) O 0 9.724452354475943e-10
of O 0 2.9689797287346664e-08
the O 0 1.8964037451496552e-07
RB1 O 0 5.248618981568143e-05
gene O 0 8.69809646530939e-09
was O 0 4.995975544375142e-08
found O 0 2.550709088389169e-10
to O 0 7.806796181730746e-11
be O 0 4.048809343348836e-10
present O 0 2.639334750753619e-09
homozygously O 0 9.90041939985531e-07
in O 0 1.141525318715253e-09
both O 0 7.897955178748362e-09
the O 0 5.381011192184815e-08
retinal B-Disease 0 0.0002163195313187316
and I-Disease 0 1.4666549930097972e-07
the I-Disease 0 3.093613258897676e-06
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 3.0616536150773754e-06

The O 0 2.1333677580059884e-07
same O 0 1.4807366000013644e-08
mutation O 0 5.863130425609597e-09
was O 0 6.356869697299317e-09
present O 0 1.7886243597331486e-09
heterozygously O 0 1.1593633786333157e-07
in O 0 3.6928660129831314e-10
the O 0 7.92032217589167e-10
DNA O 0 2.5410666903979973e-09
from O 0 1.75381842382194e-09
the O 0 1.7658047246627007e-09
constitutional O 0 4.856183455359542e-09
cells O 0 4.198286163159537e-09
of O 0 7.0494441395396734e-09
the O 0 3.9575942523129015e-09
patient O 0 7.352259689952234e-09
, O 0 9.393442690353027e-10
proving O 0 2.4062341452690816e-08
it O 0 2.5259214164741195e-10
to O 0 6.225430171369339e-10
be O 0 7.570598370421067e-09
of O 0 1.2041799379858276e-07
germline O 0 2.145321195712313e-05
origin O 0 2.414225491520483e-06
. O 0 1.6951028101175325e-06

The O 0 2.433888255382044e-07
initial O 0 1.1699528812414428e-07
mutation O 0 8.206278323541483e-09
was O 0 1.538377958354431e-08
shown O 0 2.2085287765261086e-10
to O 0 3.7497896454574686e-10
have O 0 3.202438036975508e-10
occurred O 0 2.7162494475874155e-08
in O 0 7.030936388652265e-10
the O 0 1.4406479564854635e-08
paternally O 0 4.006243671028642e-06
derived O 0 9.659221404945129e-07
RB1 O 0 0.0005012533511035144
allele O 0 2.3700465590081876e-06
. O 0 1.0472473377376446e-06

The O 0 1.7472193292178417e-07
mutation O 0 3.6424051330641305e-08
is O 0 1.7502863602913976e-09
in O 0 2.342891436413197e-10
an O 0 7.067885166023302e-10
area O 0 6.751665893034442e-09
of O 0 2.8704623122877138e-09
the O 0 5.480894849085871e-09
gene O 0 2.9647682087130534e-09
that O 0 2.3563639928170232e-09
encodes O 0 8.169313225891983e-09
the O 0 6.400632912573201e-09
protein O 0 1.062479970670438e-08
- O 0 6.944893105043093e-09
binding O 0 1.2368148283314895e-08
region O 0 1.2333053689417284e-07
known O 0 1.4265605585705998e-08
as O 0 3.3931253362595726e-09
the O 0 3.1301115033244287e-09
pocket O 0 2.4135208605002845e-06
region O 0 1.4743372389602882e-07
and O 0 2.366761187033717e-08
has O 0 1.964112206209734e-09
been O 0 4.481691961988332e-10
detected O 0 9.188085292599624e-10
in O 0 8.080924124298505e-11
other O 0 5.041891903978524e-10
cases O 0 4.431027100793017e-09
of O 0 7.917293487480492e-08
retinoblastoma B-Disease 0 0.0001629144826438278
. O 0 2.527806657326437e-07
. O 0 1.5893825775492587e-06

Low O 0 3.3786272979341447e-06
levels O 0 1.503418758375119e-07
of O 0 2.0734290728796623e-08
beta O 0 4.688471477720668e-08
hexosaminidase O 0 3.765867120364419e-07
A O 0 3.749621768633915e-08
in O 0 5.340922704100137e-10
healthy O 0 2.4964135203475735e-09
individuals O 0 4.0332939765796993e-10
with O 0 1.6728989304937159e-09
apparent O 0 0.11429686844348907
deficiency O 1 0.9999901056289673
of O 0 7.1540134740644135e-06
this O 0 1.5623237814565982e-08
enzyme O 0 6.472178483818425e-06
. O 0 7.171413471951382e-07

Appreciable O 0 5.084772055852227e-05
beta O 0 3.989289780292893e-06
hexosaminidase O 0 1.7692833353066817e-05
A O 0 2.7101200430479366e-06
( O 0 5.381996714959314e-08
hex O 0 2.1199223283474566e-06
A O 0 3.5856547242474335e-07
) O 0 1.3413000710116307e-09
activity O 0 1.561340745581674e-08
has O 0 4.282263432742184e-10
been O 0 3.1419233881280206e-10
detected O 0 2.652314146089907e-09
in O 0 5.455453866431981e-10
cultured O 0 2.927554305642843e-07
skin O 0 6.3163901131702e-07
fibroblasts O 0 6.857310950181272e-07
and O 0 1.0954524753969963e-07
melanoma B-Disease 0 2.8751269383064937e-06
tissue O 0 6.611639946640935e-08
from O 0 2.5741078601981826e-08
healthy O 0 5.1294160030579405e-09
individuals O 0 2.1300310126814992e-10
previously O 0 1.4031417139293012e-09
reported O 0 1.407349792259538e-09
as O 0 1.2056082798750367e-09
having O 0 6.562050014480292e-09
deficiency B-Disease 0 0.0001031632928061299
of I-Disease 0 0.0015880853170529008
hex I-Disease 0 0.0001069648569682613
A I-Disease 0 3.098539309576154e-07
activity O 0 2.214030914160503e-08
indistinguishable O 0 5.457384588680725e-08
from O 0 1.0812405415450144e-09
that O 0 9.15273135060346e-11
of O 0 1.0083192059084922e-09
patients O 0 1.4616492460817199e-09
with O 0 8.496269288116309e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.0828347260248847e-05
TSD B-Disease 1 0.9999991655349731
) O 0 1.4336831100081326e-07
. O 0 6.099356824051938e-07

Identification O 0 2.6885146553468076e-07
and O 0 4.1625352054097675e-08
quantitation O 0 9.923067409545183e-05
of O 0 2.4600843971711583e-05
hex O 0 0.0002593498211354017
A O 0 9.191945537168067e-06
, O 0 3.658977476561631e-08
amounting O 0 9.372475773261613e-08
to O 0 3.182129049150717e-08
3 O 0 2.2637109395873267e-06
. O 0 1.0669862149370601e-06

5 O 0 2.987427797052078e-05
% O 0 4.646948355002678e-07
- O 0 8.177281074495113e-07
6 O 0 2.7876415060745785e-06
. O 0 5.803613021271303e-07

9 O 0 2.8957542781427037e-06
% O 0 2.4083739447178232e-08
of O 0 1.5567970024221722e-08
total O 0 9.223541042047145e-09
beta O 0 4.558528488018965e-08
hexosaminidase O 0 5.488606689141307e-07
activity O 0 3.457840236364973e-08
, O 0 2.0632342501158973e-09
has O 0 5.935318347916052e-10
been O 0 4.5901080159005403e-10
obtained O 0 6.403197083670875e-09
by O 0 6.586325262958326e-09
cellulose O 0 1.742813765304163e-06
acetate O 0 1.1190036275365856e-06
gel O 0 3.3652258935035206e-07
electrophoresis O 0 8.064583312261675e-08
, O 0 4.313887203011291e-08
DEAE O 0 1.3050256711721886e-05
- O 0 4.0628856368130073e-07
cellulose O 0 1.7365656503898208e-06
ion O 0 1.7059750234693638e-06
- O 0 1.0328278676752234e-06
exchange O 0 2.762221242846863e-07
chromatography O 0 1.5901756000857858e-07
, O 0 1.7143330310886995e-08
radial O 0 1.0447653266965062e-06
immunodiffusion O 0 8.389298272959422e-06
, O 0 8.239705806545317e-08
and O 0 2.9322930572561745e-07
radioimmunoassay O 0 0.002586864400655031
. O 0 9.636380127631128e-06

Previous O 0 4.035448000649922e-06
family O 0 1.8039439453332307e-07
studies O 0 2.482853034280197e-08
suggested O 0 2.982190938638496e-09
that O 0 4.6038891449162733e-11
these O 0 1.0698871649728048e-10
individuals O 0 1.2436973673146667e-10
may O 0 9.04158303782765e-10
be O 0 4.719770685390756e-10
compound O 0 9.759892449778818e-09
heterozygotes O 0 1.782015779383528e-08
for O 0 2.692005784954432e-10
the O 0 1.8728469886042376e-09
common O 0 3.124367653484228e-09
mutant O 0 1.337584052407692e-07
TSD B-Disease 0 1.8708379911913653e-06
gene O 0 8.813090701664805e-09
and O 0 8.473478807502488e-09
a O 0 1.9024426478608802e-08
rare O 0 1.1033517210989885e-07
( O 0 2.2439820668296306e-08
allelic O 0 7.478904535673792e-07
) O 0 1.6545046221949633e-08
mutant O 0 5.094347557133005e-07
gene O 0 5.667469622494536e-07
. O 0 2.453502020216547e-06

Thus O 0 5.956724180578021e-07
, O 0 1.7980452682309078e-08
the O 0 1.2195503273915165e-08
postulated O 0 9.158800935438194e-07
rate O 0 1.4735972442281309e-08
mutant O 0 1.9645778337462616e-08
gene O 0 6.045577816138348e-09
appears O 0 1.027166085521003e-08
to O 0 1.7456976142415925e-10
code O 0 1.103333327479028e-10
for O 0 2.8009197738931846e-10
the O 0 1.8780623722847167e-09
expression O 0 7.183383221587292e-09
of O 0 1.484650624661299e-08
low O 0 4.773544759473225e-08
amounts O 0 2.9160284853446683e-08
of O 0 1.859053639918784e-07
hex O 0 2.001652137550991e-05
A O 0 7.086842742864974e-06
. O 0 2.409597300356836e-06

Heterozygotes O 0 2.3021018478175392e-06
for O 0 3.403445703042962e-08
the O 0 2.030112966622255e-08
rare O 0 2.0015688662056164e-08
mutant O 0 4.543788989508357e-08
may O 0 2.1829662522065973e-09
be O 0 4.6180417823116215e-10
indistinguishable O 0 4.1649254711728645e-08
from O 0 1.623295164954186e-09
heterozygotes O 0 3.696237982353523e-08
for O 0 2.8414066655102488e-09
the O 0 4.204899539672624e-08
common O 0 1.8912132304649276e-07
TSD B-Disease 0 0.000115131915663369
mutant O 0 6.3629231590311974e-06
. O 0 2.309825276824995e-06

However O 0 2.591752661373903e-07
, O 0 1.0037029873899428e-08
direct O 0 2.4716973356930794e-08
visualization O 0 4.2026468349831703e-07
and O 0 1.5304292944051667e-08
quantitation O 0 0.00010920013301074505
of O 0 1.8074953914037906e-05
hex O 0 1.7644339095568284e-05
A O 0 2.0692421287549223e-07
by O 0 1.244395697597156e-09
the O 0 1.564678830945354e-09
methods O 0 3.610640675333343e-09
described O 0 2.7503637145542825e-09
may O 0 1.3030065915131672e-09
prevent O 0 1.1418395118312219e-08
false O 0 9.912136533785088e-08
- O 0 6.619791292905575e-08
positive O 0 1.610515987238159e-08
prenatal O 0 5.829813076729806e-08
diagnosis O 0 6.267145380434158e-08
of O 0 1.0571901043476828e-07
TSD B-Disease 0 0.048007458448410034
in O 0 4.697673716691497e-08
fetuses O 0 2.0492737462518562e-07
having O 0 5.162305694028646e-09
the O 0 4.844739276421706e-09
incomplete O 0 6.175310431899561e-07
hex B-Disease 0 5.478312687046127e-06
A I-Disease 0 9.936723017744953e-07
deficiency I-Disease 0 0.0001068973433575593
of O 0 2.3419474928232376e-06
the O 0 2.6790489826566954e-08
type O 0 3.6445317874722605e-08
described O 0 9.70227986840655e-09
in O 0 2.976065394122429e-09
the O 0 3.262871075548901e-07
four O 0 3.099206935530674e-07
healthy O 0 1.9823517050099326e-06
individuals O 0 6.130860583652975e-07

The O 0 3.434844984440133e-06
tumor B-Disease 0 2.0417670384631492e-05
suppressor O 0 3.0361707104020752e-05
gene O 0 5.593237233370019e-07
Smad4 O 0 4.492979132919572e-05
/ O 0 7.376801249847631e-07
Dpc4 O 0 8.560935498280742e-07
is O 0 7.199166818239178e-10
required O 0 2.709065194395066e-10
for O 0 4.126972374951521e-10
gastrulation O 0 1.349543907736006e-07
and O 0 2.6470381442322832e-09
later O 0 1.2853384134814405e-08
for O 0 4.565652744759063e-09
anterior O 0 5.207602384871279e-07
development O 0 4.053712387985797e-08
of O 0 3.367562584344341e-08
the O 0 5.115681389611382e-08
mouse O 0 1.5490580551613675e-07
embryo O 0 2.2249882931646425e-06
. O 0 8.151586712301651e-07

Mutations O 0 1.4824867093921057e-06
in O 0 1.4722577645898127e-07
the O 0 9.258678801415954e-07
SMAD4 O 1 0.9999996423721313
/ O 0 0.00011836351040983573
DPC4 O 0 0.0007809874950908124
tumor B-Disease 0 1.4167467270453926e-06
suppressor O 0 1.0709212574511184e-06
gene O 0 7.79112596660525e-09
, O 0 1.5180118273505627e-09
a O 0 1.5518956120175176e-09
key O 0 6.648565431532916e-08
signal O 0 1.467952301936748e-07
transducer O 0 9.742543483071131e-08
in O 0 4.470330772221587e-09
most O 0 1.7429314880246238e-08
TGFbeta O 0 1.5531007875324576e-06
- O 0 8.465841716542855e-08
related O 0 1.2686113848303648e-07
pathways O 0 2.035503001707184e-07
, O 0 1.443606900686234e-09
are O 0 1.186257897467513e-10
involved O 0 3.8330139062736635e-10
in O 0 2.718392455580698e-10
50 O 0 1.7437093546845972e-08
% O 0 1.2493811318847747e-08
of O 0 1.708370263031611e-07
pancreatic B-Disease 1 0.9999988079071045
cancers I-Disease 1 0.9984525442123413
. O 0 1.7309208715232671e-06

Homozygous O 0 5.28244936504052e-06
Smad4 O 0 5.909882020205259e-05
mutant O 0 2.224805939476937e-06
mice O 0 1.8725323513990588e-07
die O 0 2.074806673135754e-07
before O 0 2.9237975596174692e-08
day O 0 3.60198875171136e-08
7 O 0 4.0234596099253395e-07
. O 0 2.268953664952278e-07

5 O 0 2.788274832710158e-05
of O 0 3.152009867335437e-06
embryogenesis O 0 5.208629590924829e-05
. O 0 6.6217626226716675e-06

Mutant O 0 1.265712398890173e-06
embryos O 0 5.403049954111339e-07
have O 0 1.0764012792208177e-08
reduced O 0 2.797260378883948e-08
size O 0 1.7757285419861546e-08
, O 0 2.8089246484341857e-09
fail O 0 2.1553962170628438e-08
to O 0 1.5585142065788204e-08
gastrulate O 0 6.277341981331119e-06
or O 0 1.3422553735153997e-08
express O 0 5.598437713416615e-09
a O 0 3.5948355403547794e-09
mesodermal O 0 7.416091420964221e-07
marker O 0 7.940884074741916e-07
, O 0 2.2456733361764236e-08
and O 0 7.141827751411256e-08
show O 0 5.846164299327938e-07
abnormal O 0 1.2278673239052296e-05
visceral O 0 0.07229743897914886
endoderm O 0 0.11170029640197754
development O 0 2.08910096262116e-05
. O 0 3.0896035241312347e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.7008358554448932e-05
the O 0 2.46987639229701e-07
Smad4 O 0 1.6397583749494515e-05
- O 0 5.677342187482282e-07
deficient O 0 7.565809312382044e-08
embryos O 0 1.738038157839128e-08
results O 0 3.90683396744862e-09
from O 0 2.8526800921468976e-09
reduced O 0 9.89447102028862e-09
cell O 0 4.173394430040389e-08
proliferation O 0 1.190775265058619e-07
rather O 0 1.1061385141175606e-09
than O 0 5.043757633771406e-10
increased O 0 8.53617532214912e-09
apoptosis O 0 4.245293894200586e-07
. O 0 3.8290068005153444e-07

Aggregation O 0 2.3599779979122104e-06
of O 0 5.355066718948365e-07
mutant O 0 2.346020437471452e-06
Smad4 O 0 8.795307076070458e-05
ES O 0 1.78108639374841e-05
cells O 0 1.5970869071679772e-08
with O 0 2.8503521765088635e-09
wild O 0 5.100180899830775e-08
- O 0 5.514337075851472e-08
type O 0 7.171722415932891e-08
tetraploid O 0 9.111885447055101e-06
morulae O 0 1.0364321497036144e-05
rescues O 0 2.0157997369096847e-06
the O 0 1.0994085641868878e-07
gastrulation B-Disease 0 2.1169536921661347e-05
defect I-Disease 0 1.3871195733372588e-05
. O 0 3.0603691811847966e-06

These O 0 1.0105322445497222e-07
results O 0 1.3623639461002313e-07
indicate O 0 1.432832874570522e-07
that O 0 5.7127134134304924e-09
Smad4 O 0 1.6932415292103542e-06
is O 0 8.386824013051353e-10
initially O 0 3.6926123270220046e-10
required O 0 6.485110365384017e-11
for O 0 2.450827873978767e-10
the O 0 2.376294938599699e-09
differentiation O 0 5.385118129197508e-08
of O 0 2.278424382495814e-08
the O 0 1.5022830979205537e-08
visceral O 0 1.290483169213985e-06
endoderm O 0 2.201840970883495e-06
and O 0 2.5176638551727137e-09
that O 0 3.666462689011496e-10
the O 0 6.176656519585322e-09
gastrulation B-Disease 0 5.016285626879835e-07
defect I-Disease 0 6.702487809207014e-08
in O 0 2.6697537514053238e-09
the O 0 2.4482281091309233e-08
epiblast O 0 8.01997521193698e-06
is O 0 9.481757601292884e-09
secondary O 0 1.641720643874578e-07
and O 0 1.5774871187090866e-08
non O 0 4.380436166684376e-06
- O 0 2.3262991817318834e-06
cell O 0 0.0036529048811644316
autonomous O 0 9.078429866349325e-05
. O 0 1.8299016346645658e-06

Rescued O 0 1.1836726116598584e-05
embryos O 0 2.015619202211383e-06
show O 0 8.186543709598482e-07
severe O 0 0.0025142147205770016
anterior O 0 0.0010501521173864603
truncations O 0 0.00047124625416472554
, O 0 1.5549925791447095e-08
indicating O 0 5.104316613824267e-08
a O 0 4.460348979051787e-09
second O 0 1.2705600127560501e-08
important O 0 1.962091289442469e-08
role O 0 1.873666199969648e-08
for O 0 2.7157781801179226e-08
Smad4 O 0 0.011224056594073772
in O 0 2.0909557463255624e-07
anterior O 0 0.002990927081555128
patterning O 0 1.6911639249883592e-05
during O 0 7.114105642358481e-07
embryogenesis O 0 9.817896170716267e-06
. O 0 2.1464011297211982e-06

Prevalence O 0 6.8054664552619215e-06
of O 0 3.34589742578828e-07
p16 O 0 9.516473369330924e-07
and O 0 1.4201012277226255e-07
CDK4 O 1 0.981355607509613
germline O 0 5.6944072639453225e-06
mutations O 0 1.2010512762117287e-07
in O 0 1.1467415461652308e-08
48 O 0 4.226283749630966e-07
melanoma B-Disease 0 3.94065182263148e-06
- O 0 1.3485788485922967e-07
prone O 0 1.0888989265822602e-07
families O 0 6.741757374584267e-09
in O 0 7.48478257150964e-09
France O 0 4.942435225530062e-07
. O 0 6.401398309208162e-07

The O 0 4.1694943320180755e-06
French O 0 0.00020006495469715446
Familial B-Disease 0 0.00012130116374464706
Melanoma I-Disease 0 3.770233161048964e-05
Study O 0 3.4987269970088164e-08
Group O 0 2.4202545745311e-08
. O 0 9.651379428987639e-08

Germline O 0 6.454172398662195e-05
mutations O 0 9.963044931282639e-07
in O 0 4.6942609799316415e-08
the O 0 4.773034589788949e-08
p16 O 0 2.9861598704883363e-07
and O 0 1.0057804367136214e-08
CDK4 O 0 1.3637716619996354e-05
genes O 0 7.767770426880816e-09
have O 0 1.2089563794503988e-09
been O 0 4.700779210331518e-10
reported O 0 5.420810467171577e-10
in O 0 4.7268321201610064e-11
a O 0 4.0103881326913893e-10
subset O 0 2.439636936912848e-08
of O 0 3.867422648795582e-08
melanoma B-Disease 0 1.143162080552429e-06
pedigrees O 0 1.8040850591205526e-07
, O 0 3.4990523811728735e-09
but O 0 2.588640635181605e-09
their O 0 8.763775483089375e-09
prevalence O 0 8.013323054001376e-07
is O 0 5.985396067664794e-10
not O 0 1.0931932026281288e-09
well O 0 1.9614329715977874e-08
known O 0 1.4489846478227264e-07
. O 0 8.91033096195315e-07

We O 0 9.81043726255848e-08
searched O 0 1.8956731651087466e-07
for O 0 3.946709181690267e-09
such O 0 1.3187489322774582e-08
germline O 0 2.276214672747301e-06
mutations O 0 8.005061147287051e-08
in O 0 5.945949510532955e-09
48 O 0 1.5050254376092198e-07
French O 0 2.1419884888018714e-06
melanoma B-Disease 0 2.680429815882235e-06
- O 0 6.197050339551424e-08
prone O 0 2.2031624524743165e-08
families O 0 1.7141883468241303e-09
selected O 0 1.7680289454702347e-09
according O 0 2.2512808284247399e-10
to O 0 2.8136634688813444e-10
two O 0 4.869983305511028e-10
major O 0 4.8074682013066194e-09
criteria O 0 3.109552171309815e-09
families O 0 6.482170356036931e-10
with O 0 1.7641239857812963e-10
at O 0 2.286690614639042e-09
least O 0 1.1625888030053488e-09
three O 0 9.500037423393337e-10
affected O 0 1.0109964421189943e-08
members O 0 1.2869396659453969e-09
( O 0 1.6716199535693477e-09
n O 0 9.779570042667274e-09
= O 0 1.9818186203224286e-08
20 O 0 1.3067705140201724e-08
) O 0 6.962153770162516e-11
or O 0 1.5133248820742295e-10
families O 0 3.1345728790377336e-10
with O 0 1.2265240212361306e-10
two O 0 3.967477735233871e-10
affected O 0 3.6295455529966603e-09
members O 0 4.1669476202876865e-10
, O 0 2.75469896893199e-10
one O 0 3.7717393097658203e-10
of O 0 2.065604798318077e-09
them O 0 4.756235405523057e-10
affected O 0 7.952523972676317e-09
before O 0 2.1887864853908923e-09
the O 0 1.6400321101173176e-09
age O 0 4.266644815231757e-09
of O 0 1.2624941092553854e-08
50 O 0 1.3432516432487773e-08
( O 0 2.4289659172893607e-09
n O 0 1.4422865568519683e-08
= O 0 7.993845940745814e-08
28 O 0 1.8194141659932939e-07
) O 0 9.897070940567687e-10
, O 0 1.3398273601694655e-09
and O 0 1.1278066258668673e-09
one O 0 1.148952155638483e-09
additional O 0 5.938254332704673e-09
minor O 0 2.9227447839730303e-07
criterion O 0 6.856002437416464e-05
. O 0 1.6653949614919838e-06

Sixteen O 0 6.52619382890407e-06
different O 0 2.0527475896869873e-07
p16 O 0 3.897387159668142e-06
germline O 0 1.7683624946585041e-06
mutations O 0 1.0396134797474588e-07
were O 0 5.764947186293057e-09
found O 0 3.9230957371572117e-10
in O 0 1.5626740179630616e-10
21 O 0 4.687172427964015e-09
families O 0 1.6365512278682104e-09
, O 0 5.674007930167591e-10
while O 0 1.431585960887105e-09
one O 0 4.715724699622115e-09
germline O 0 8.699077511664655e-07
mutation O 0 4.615483817360655e-08
, O 0 7.80232412012083e-09
Arg24His O 0 1.587149881743244e-06
, O 0 6.4570007118902595e-09
was O 0 2.4821426691801207e-08
detected O 0 8.472233581358068e-09
in O 0 2.544719102104409e-09
the O 0 7.750784192239735e-08
CDK4 O 0 0.022068673744797707
gene O 0 1.3998111398905166e-06
. O 0 3.132101255687303e-06

The O 0 1.2074940514139598e-07
frequency O 0 1.5218689952689601e-07
of O 0 3.7471622249540815e-08
p16 O 0 5.343842701677204e-08
gene O 0 8.99380658836435e-09
mutation O 0 8.215863545046886e-09
in O 0 1.5119293594878513e-09
our O 0 4.4746646388205136e-09
sample O 0 2.1868962196691655e-09
( O 0 9.375596965455202e-10
44 O 0 3.096781142630789e-08
% O 0 5.152702153843336e-10
) O 0 1.8686916597454584e-11
is O 0 4.313789950249891e-11
among O 0 2.4938662246398735e-10
the O 0 9.489786734206973e-10
highest O 0 1.2167622465142358e-08
rates O 0 2.6391031582306823e-09
yet O 0 9.144499601987377e-10
reported O 0 6.614941927551854e-09
and O 0 8.177930554964519e-10
the O 0 6.6507190865650045e-09
CDK4 O 0 1.2248523489688523e-05
mutation O 0 3.970326289959303e-09
is O 0 4.30414343055574e-10
the O 0 7.646536182015495e-10
second O 0 1.904169710797987e-09
mutation O 0 2.676070476326231e-09
detected O 0 3.6653320378832177e-09
in O 0 2.0254620203274953e-10
this O 0 6.045401956811247e-10
gene O 0 2.946414490168081e-08
worldwide O 0 9.243551346571621e-08
. O 0 6.357296911119192e-07

In O 0 8.036943910383343e-08
summary O 0 3.743473143913434e-06
, O 0 2.5312774099006674e-08
our O 0 2.4627702543966734e-08
results O 0 4.599007041861114e-08
show O 0 1.135255267570301e-08
frequent O 0 1.3958125322233172e-08
involvement O 0 1.635313218173451e-08
of O 0 9.498628550375088e-09
the O 0 9.427083114132984e-09
p16 O 0 5.692767501841445e-08
gene O 0 8.29674284830162e-09
in O 0 7.712232630296967e-09
familial B-Disease 0 1.2601732350958628e-06
melanoma I-Disease 0 5.567962375607749e-07
and O 0 3.4336183896144234e-10
confirm O 0 4.6787764773625895e-09
the O 0 5.5385780406425056e-09
role O 0 7.10901737477343e-09
of O 0 8.738908263694611e-08
the O 0 1.5827953347979928e-07
CDK4 O 1 0.9994213581085205
gene O 0 4.989805191257801e-08
as O 0 8.832245157464058e-08
a O 0 8.671612761190772e-08
melanoma B-Disease 0 3.899662260664627e-06
- O 0 1.360345436296484e-06
predisposing O 0 1.1209476724616252e-05
gene O 0 2.438725914544193e-07
. O 0 4.401959188271576e-07
. O 0 1.6321711200362188e-06

Progression O 0 1.97422195924446e-05
of O 0 1.9311212327011162e-06
somatic O 0 0.00044556529610417783
CTG O 0 0.0001420312182744965
repeat O 0 2.6139016995330167e-07
length O 0 1.560804818723227e-08
heterogeneity O 0 1.6102541167128948e-07
in O 0 1.245918035408522e-09
the O 0 5.690984128392529e-09
blood O 0 1.8342362295697967e-08
cells O 0 1.0962907026623725e-07
of O 0 6.562659109476954e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.4454018128162716e-05
. O 0 7.291429255928961e-07

The O 0 6.59905339261968e-08
genetic O 0 1.855306095421838e-07
basis O 0 2.1412436979062477e-07
of O 0 2.1637336544699792e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0026453309692442417
DM B-Disease 1 1.0
) O 0 2.0283934532017156e-09
is O 0 2.2666971077889286e-10
the O 0 7.34181604400419e-10
expansion O 0 2.369787566181003e-08
of O 0 1.8920280453471605e-08
an O 0 4.2842369651907575e-08
unstable O 0 0.00012631439312826842
CTG O 0 8.750167035032064e-05
repeat O 0 9.70731903748856e-08
in O 0 6.656518891645646e-09
the O 0 5.1547520030226224e-08
34 O 0 2.967746581816755e-07
UTR O 0 0.00026462788810022175
of O 0 4.226771181947697e-07
the O 0 7.731352411610715e-07
DM B-Disease 1 1.0
protein O 0 2.1187563561397837e-06
kinase O 0 1.4514590702674468e-06
gene O 0 1.2321508791046654e-07
on O 0 8.724766189516231e-07
chromosome O 0 2.1108603505126666e-06
19 O 0 3.889159415848553e-06
. O 0 7.442745300068054e-07

One O 0 3.676053381695965e-07
of O 0 1.580472428486246e-07
the O 0 7.592524298161152e-08
principal O 0 7.778350550324831e-07
features O 0 9.72822356004599e-09
of O 0 2.8713838418070736e-08
the O 0 3.234566179344256e-07
DM B-Disease 1 1.0
mutation O 0 7.316129568835095e-08
is O 0 1.148047434895716e-09
an O 0 1.261978188615842e-09
extraordinarily O 0 2.0641762077389103e-08
high O 0 2.953943400996195e-08
level O 0 4.391861807562236e-08
of O 0 1.1027646706907035e-07
somatic O 0 0.18847045302391052
mosaicism O 0 0.0002663033956196159
, O 0 4.143426934888339e-09
due O 0 5.4220330447662946e-09
to O 0 5.043623296785427e-10
an O 0 7.236861665482763e-10
extremely O 0 2.0223516195017055e-09
high O 0 2.045624558633108e-09
degree O 0 6.660024087778993e-09
of O 0 2.569098489502153e-09
somatic O 0 1.0539749382587615e-05
instability O 0 5.60808530281065e-07
both O 0 4.226841543442106e-09
within O 0 7.448594629977379e-09
and O 0 2.674320098705607e-09
between O 0 7.252106026811589e-09
different O 0 2.1639683822627376e-08
tissues O 0 3.937030669476371e-06
. O 0 1.0519779607420787e-06

This O 0 2.3825167261293245e-07
instability O 0 4.578868356475141e-06
appears O 0 6.137271668649191e-08
to O 0 2.6181958823201512e-09
be O 0 3.2743652234046294e-09
biased O 0 7.705870075369603e-08
towards O 0 7.993613770906904e-09
further O 0 2.3529238557529197e-09
expansion O 0 1.095610979717776e-08
and O 0 9.337745021653632e-10
continuous O 0 8.864813771936042e-09
throughout O 0 1.7691557108179268e-09
the O 0 4.770893458072578e-09
life O 0 4.554016275193362e-09
of O 0 8.855181476974394e-09
an O 0 1.8688433023328344e-09
individual O 0 1.2242389324512715e-09
, O 0 9.945001488986804e-10
features O 0 3.665345804648723e-09
that O 0 3.248956659263058e-10
could O 0 2.610685889692377e-09
be O 0 1.1344321038109229e-09
associated O 0 1.4207116372233486e-08
with O 0 1.8387679157072512e-09
the O 0 9.792396582497531e-08
progressive O 0 4.001638444606215e-06
nature O 0 3.055849262523225e-08
of O 0 2.7330250063073436e-08
the O 0 1.402337659328623e-07
disease O 0 2.2233507479541004e-06
. O 0 3.3788933251344133e-07

Although O 0 3.783689450642669e-08
increasing O 0 2.5009567750089445e-08
measured O 0 8.45641245916795e-09
allele O 0 1.128392490556962e-08
size O 0 4.262772801411074e-09
between O 0 5.774785538648075e-09
patients O 0 3.182443197857765e-09
clearly O 0 6.9663319557378145e-09
correlates O 0 9.82181713737873e-09
with O 0 1.925584865170027e-11
an O 0 4.743983678112684e-11
increased O 0 2.764431183965854e-10
severity O 0 3.155343009098033e-08
of O 0 8.615835156433604e-09
symptoms O 0 2.3059243403622531e-07
and O 0 4.724382551835049e-10
an O 0 3.554227190338821e-10
earlier O 0 6.694905185788969e-10
age O 0 3.0317084398490124e-09
of O 0 4.759868055259631e-09
onset O 0 1.4237612333545258e-07
, O 0 3.435452478051104e-10
this O 0 8.533920098363623e-11
correlation O 0 1.5564012301183539e-09
is O 0 1.249711167883305e-10
not O 0 2.123014125610112e-10
precise O 0 5.574317540890661e-08
and O 0 7.373338384297767e-09
measured O 0 2.168211388209329e-08
allele O 0 2.3957197115009876e-08
length O 0 2.8605260382619235e-09
cannot O 0 4.444213885790305e-09
be O 0 2.343258698189743e-09
used O 0 3.4813578686510027e-09
as O 0 1.5989393142845643e-09
an O 0 4.5944081872306697e-10
accurate O 0 2.94298843073193e-08
predictor O 0 2.513194658604334e-06
of O 0 1.9564080844247655e-07
age O 0 4.300383352529025e-06
of O 0 7.3880069066945e-06
onset O 1 0.9528106451034546
. O 0 2.1503594780369895e-06

In O 0 2.4627231809404293e-08
order O 0 7.842667848478868e-09
to O 0 1.4677730142409473e-09
further O 0 6.535182617284363e-09
characterize O 0 4.5975511397955415e-08
the O 0 1.1321975357247993e-08
dynamics O 0 9.590200278353223e-08
of O 0 2.3240410484959284e-07
DM B-Disease 1 1.0
CTG O 0 0.00010478970216354355
repeat O 0 2.4339627202607517e-07
somatic O 0 7.569390618300531e-06
instability O 0 1.0268565802107332e-06
, O 0 4.885997384462826e-09
we O 0 1.9757526725783237e-09
have O 0 7.859690120959328e-10
studied O 0 9.372757681092025e-09
repeat O 0 6.123179741024387e-09
length O 0 1.3367743578740487e-09
changes O 0 1.7158957588137014e-09
over O 0 2.4683557420246416e-09
time O 0 2.7411257708109815e-09
in O 0 3.780715296386461e-09
111 O 0 3.717921117640799e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.303689931679401e-09
with O 0 1.8616487518219316e-10
varying O 0 7.377165101019045e-09
clinical O 0 1.2745722699492035e-08
severity O 0 1.1328788787068333e-06
and O 0 4.7080156662104855e-08
CTG O 0 5.5645828069827985e-06
repeat O 0 2.4577772705924872e-08
size O 0 2.2594994320002115e-08
over O 0 8.399956286098131e-09
time O 0 5.157188454063544e-09
intervals O 0 2.4551253474669466e-08
of O 0 4.6132573316981507e-08
1 O 0 6.247846613405272e-07
- O 0 5.373400426833541e-07
7 O 0 9.960261877495213e-07
years O 0 1.8158605996632105e-07
. O 0 8.21240291770664e-07

We O 0 1.7512546435227705e-07
have O 0 4.5291033146099835e-09
found O 0 1.4612561161087e-09
a O 0 8.650244964769627e-10
direct O 0 6.680698216854353e-09
progression O 0 8.190754385850596e-08
of O 0 1.2919649350351392e-08
the O 0 6.7577210494107476e-09
size O 0 1.887047318405166e-08
heterogeneity O 0 3.139985835787229e-07
over O 0 4.975385436978286e-09
time O 0 1.6345109710158567e-09
related O 0 7.850974981238323e-09
to O 0 4.827296784526425e-09
initial O 0 1.7582010514161084e-07
CTG O 0 2.5058282062673243e-06
repeat O 0 1.7900962490102756e-08
size O 0 1.4744519383214083e-08
and O 0 7.032616711200035e-09
the O 0 1.667620885825727e-08
time O 0 1.2371263125032783e-08
interval O 0 8.076944624235693e-08
and O 0 2.0751581786271345e-08
always O 0 4.7765137622945986e-08
biased O 0 9.832783689489588e-07
towards O 0 3.2810692118800944e-07
further O 0 1.8272424995302572e-07
expansion O 0 3.310915872134501e-06
. O 0 2.679734734556405e-06

Attempts O 0 2.2103269259332592e-07
to O 0 1.1578889846930451e-08
mathematically O 0 1.415073427324387e-07
model O 0 5.44412941394512e-08
the O 0 4.3385096404335854e-08
dynamics O 0 1.8348700336900947e-07
have O 0 5.7728470892470796e-09
proved O 0 2.8716803512907063e-07
only O 0 9.029800018822698e-09
partially O 0 9.225268371437778e-08
successful O 0 3.5763363381846602e-09
suggesting O 0 5.732895935750548e-09
that O 0 8.431279979737027e-11
individual O 0 2.2363061402685958e-10
specific O 0 2.585319958114951e-09
genetic O 0 3.218669064608548e-08
and O 0 8.732823353341246e-09
/ O 0 5.305868455707241e-08
or O 0 1.8786643352086685e-09
environmental O 0 2.0112127074867203e-08
factors O 0 2.6181972145877808e-08
also O 0 1.1813903189050734e-09
play O 0 4.83385687033433e-09
a O 0 1.779302039039976e-08
role O 0 4.242496842721266e-08
in O 0 2.997029824314268e-08
somatic O 0 0.00019497053290251642
mosaicism O 0 0.00022442277986556292
. O 0 4.2053326865243434e-07
. O 0 1.6353745877495385e-06

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 3.3601893392187776e-06
Palestinian O 0 0.006551325786858797
Arabs O 0 2.323566695849877e-05
. O 0 2.3637219328520587e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.04832844063639641
AGU B-Disease 1 1.0
) O 0 3.5331222392187556e-08
is O 0 1.4338378262479523e-09
a O 0 2.1410788697551197e-09
rare O 0 9.61822763656528e-08
disorder B-Disease 1 0.9999996423721313
of I-Disease 0 0.0048781041987240314
glycoprotein I-Disease 0 6.477123861259315e-06
metabolism I-Disease 0 2.4435314571746858e-06
caused O 0 9.93966366991117e-08
by O 0 5.293783189586065e-10
the O 0 3.7378683259703394e-08
deficiency B-Disease 1 0.9999839067459106
of I-Disease 0 0.00013122196833137423
the I-Disease 0 3.347014398968895e-07
lysosomal I-Disease 0 1.5723237083875574e-05
enzyme I-Disease 0 9.511333701084368e-06
aspartylglucosaminidase I-Disease 0 0.0001487039844505489
( O 0 1.1739832217472213e-07
AGA O 0 0.0014526289887726307
) O 0 2.0488477048274945e-07
. O 0 1.1869706213474274e-06

AGU B-Disease 1 1.0
is O 0 5.366794084693538e-07
inherited O 0 1.8663897208170965e-05
as O 0 9.224177688338386e-08
an O 0 2.1767391444882378e-08
autosomal O 0 2.9476902909664204e-06
recessive O 0 3.3763465125957737e-06
trait O 0 2.3848423325034673e-07
and O 0 7.469831975193131e-10
occurs O 0 2.1163108765431815e-10
with O 0 3.1509538034324436e-11
a O 0 3.121483072021647e-10
high O 0 1.9581722909833843e-09
frequency O 0 1.20527254843239e-09
in O 0 2.368312213008039e-10
Finland O 0 1.8574581872599083e-08
because O 0 1.9647654170285023e-08
of O 0 2.9759203812318447e-07
a O 0 1.3032325796302757e-07
founder O 0 1.973499138330226e-06
effect O 0 2.702408437471604e-06
. O 0 1.9297312974231318e-06

While O 0 5.908914886276762e-07
very O 0 4.338543035942166e-08
few O 0 3.746176346908214e-08
patients O 0 1.0334762379216045e-08
with O 0 1.1246473974324545e-08
AGU B-Disease 1 1.0
have O 0 7.825319947585285e-09
been O 0 1.4669614412099463e-09
reported O 0 3.4102149992776276e-09
from O 0 1.6594625673604924e-09
non O 0 1.3182761549046518e-08
- O 0 3.3589970804825953e-09
Finnish O 0 5.164298144677559e-08
origin O 0 1.8818893110505996e-08
, O 0 5.035435624023421e-09
we O 0 1.7259145224102213e-08
diagnosed O 0 8.787729370851594e-07
the O 0 5.0473616397539445e-08
disorder O 0 1.946135910202429e-07
in O 0 1.3208452109836344e-09
8 O 0 5.0105550819523614e-09
patients O 0 1.396623372507122e-10
originating O 0 1.5749068715820158e-09
from O 0 4.771746331400095e-10
3 O 0 2.7021516135761203e-09
unrelated O 0 4.669086006714451e-09
families O 0 9.57768864218167e-10
, O 0 2.419550670929027e-10
all O 0 4.528202535158954e-10
Palestinian O 0 7.476715495613462e-07
Arabs O 0 2.7866205343229922e-08
from O 0 2.6764992444583413e-09
the O 0 7.033166493641829e-09
region O 0 3.098872625173499e-08
of O 0 1.1577724734479489e-07
Jerusalem O 0 8.307835378218442e-05
. O 0 3.4532904464867897e-06

The O 0 2.177806948111538e-07
clinical O 0 3.9762323922332143e-07
diagnosis O 0 1.0123558240593411e-05
of O 0 0.11840447038412094
AGU B-Disease 1 1.0
is O 0 8.53945252288213e-08
often O 0 6.017117026857477e-09
difficult O 0 1.0050938747951932e-08
, O 0 9.777215703721254e-10
in O 0 2.2840611346719442e-10
particular O 0 2.1136978833879994e-09
early O 0 6.302325772367112e-09
in O 0 2.1893699353459084e-10
the O 0 1.9699275544127204e-09
course O 0 1.877886957046826e-09
of O 0 4.731454783524214e-09
the O 0 9.593892791315284e-09
disease O 0 3.3979326019561995e-08
, O 0 2.7059152141184484e-10
and O 0 1.4283614568899594e-10
most O 0 2.8438182364531883e-10
of O 0 5.970861138848704e-09
the O 0 6.711862177155581e-09
patients O 0 3.564874617723035e-09
are O 0 2.021310452349212e-09
diagnosed O 0 1.510898073320277e-08
after O 0 4.092874927863477e-09
the O 0 6.161148480288148e-09
age O 0 4.325727331888629e-08
of O 0 6.404127361747669e-08
5 O 0 2.1703263541894557e-07
years O 0 6.912412686688185e-08
. O 0 7.828068646631436e-07

However O 0 1.793727960830438e-06
, O 0 4.085303118017691e-08
since O 0 1.1828451995654632e-08
these O 0 6.940099606111971e-09
patients O 0 2.7375415267982817e-09
excrete O 0 2.6550996068408494e-08
early O 0 5.964600369168238e-09
large O 0 7.455925321586676e-10
amounts O 0 4.653074814342517e-09
of O 0 1.4867645781180272e-08
aspartylglucosamine O 0 9.82560322881909e-07
in O 0 2.810505828065857e-09
urine O 0 5.616063170066354e-09
, O 0 6.351146275562769e-10
biochemical O 0 1.4826500027709244e-08
screening O 0 2.7212574416068946e-09
is O 0 9.797562761093559e-10
easy O 0 2.320381753406764e-08
by O 0 2.7414721159857436e-08
urine O 0 1.7259053208817932e-07
chromatography O 0 8.718993740330916e-07
. O 0 2.3801207760243415e-07
. O 0 1.3705886203752016e-06

Detection O 0 3.671925981052482e-07
of O 0 7.295561488263047e-08
heterozygous O 0 1.5334681080503287e-08
carriers O 0 9.209513152086402e-09
of O 0 1.8075150265417506e-08
the O 0 3.326387911783968e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.279790795815643e-06
ATM O 0 5.7083467254415154e-05
) O 0 3.1569666880670866e-09
gene O 0 3.5508136431161574e-09
by O 0 6.3394098859248516e-09
G2 O 0 2.2559268018085277e-06
phase O 0 1.1032695823587346e-07
chromosomal O 0 7.710933118687535e-07
radiosensitivity O 0 1.0767887943075038e-05
of O 0 4.1797520111686026e-07
peripheral O 0 0.009365109726786613
blood O 0 3.925605051335879e-05
lymphocytes O 0 1.1239181731070857e-05
. O 0 8.020571726774506e-07

In O 0 3.669094212455093e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999815225601196
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.9244431321018283e-09
patients O 0 2.075861704753379e-09
, O 0 1.802706872666704e-10
mutations O 0 3.5333005965476616e-10
in O 0 1.0215245316302912e-10
a O 0 2.662978171308339e-10
single O 0 1.6158957505396643e-10
gene O 0 3.180621044318599e-10
, O 0 9.386242894038332e-10
ATM O 0 1.3496595840933878e-07
, O 0 3.9489508885104385e-10
result O 0 7.716010053115951e-10
in O 0 3.694486383487572e-10
an O 0 7.472025345123257e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.9412381035976978e-08
embraces O 0 1.7837058052805332e-08
a O 0 7.697062986977699e-10
variety O 0 3.796142955536652e-09
of O 0 8.120734307226485e-09
clinical O 0 1.8627446252139634e-08
features O 0 1.3330984316439753e-08
and O 0 4.535240627490111e-09
manifests O 0 8.688036245985131e-08
extreme O 0 3.7315501799639605e-07
radiosensitivity O 0 4.820095455215778e-06
and O 0 2.0148908319583825e-08
a O 0 5.904093569597535e-08
strong O 0 5.308136223902693e-07
pre O 0 3.3924654871952953e-06
- O 0 3.2539142011955846e-06
disposition O 0 4.760041701956652e-05
to O 0 3.3000486610035296e-07
malignancy B-Disease 0 0.0002544111921451986
. O 0 9.616932175049442e-07

Heterozygotes O 0 3.878484676533844e-06
for O 0 3.7913615358320385e-08
the O 0 5.6530680581090564e-08
ATM O 0 1.3065831581116072e-06
gene O 0 3.271282977834744e-08
have O 0 5.0130308792972755e-09
no O 0 2.506375551547535e-09
clinical O 0 3.415630889236354e-09
expression O 0 3.1617213291923463e-09
of O 0 1.8427296311074315e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 2.3730358122975304e-07
may O 0 2.242660102069749e-08
be O 0 1.063380139498804e-08
cancer B-Disease 0 8.402507489790878e-08
prone O 0 1.6673219249696558e-08
with O 0 3.737978537809994e-10
a O 0 3.656519753647558e-09
moderate O 0 1.2670889759647253e-07
increase O 0 2.7507782718316776e-09
in O 0 1.3776726426328878e-09
in O 0 8.708239462862366e-09
vitro O 0 1.3774470062344335e-06
radiosensitivity O 0 3.850167922792025e-05
. O 0 1.3234214293333935e-06

We O 0 5.255107566881634e-07
performed O 0 1.0094900204649093e-07
a O 0 5.958804649708327e-08
blind O 0 4.861190063820686e-07
chromosomal O 0 5.867921117896913e-07
analysis O 0 1.100854447599886e-07
on O 0 8.81474235825408e-08
G2 O 0 2.2314268335321685e-06
- O 0 9.366024755763647e-08
phase O 0 8.824734720747074e-08
lymphocytes O 0 4.732973835075427e-08
from O 0 5.391981083846531e-09
7 O 0 3.0971531117529594e-08
unrelated O 0 6.902702125444193e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.500121164596749e-08
, O 0 1.701166318923697e-09
13 O 0 5.486323395587078e-09
obligate O 0 1.6380204215238336e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 1.8878087075790972e-06
( O 0 1.9568953124604604e-09
parents O 0 2.5034039285998233e-09
of O 0 9.169269787889789e-09
the O 0 1.8364372245116556e-09
patients O 0 1.9258135364186302e-10
) O 0 4.653886304106791e-11
, O 0 2.8692126452511957e-10
and O 0 1.0734668709488915e-09
14 O 0 2.398902054778773e-08
normal O 0 1.8300985615837817e-08
controls O 0 1.0692986052163178e-08
following O 0 5.2558362106935874e-09
X O 0 2.2750377581814973e-07
- O 0 4.552185828288202e-08
irradiation O 0 1.391106110304463e-07
with O 0 4.454805413445229e-09
1 O 0 1.287279616235537e-07
Gy O 0 1.1710931175912265e-06
in O 0 7.596775986051796e-10
order O 0 2.3676629545832384e-09
to O 0 2.044653335531166e-09
evaluate O 0 1.4168742623610342e-08
this O 0 2.24976237639396e-09
cytogenetic O 0 8.263776294370473e-07
method O 0 3.204995380201581e-08
as O 0 5.62964075356831e-09
a O 0 1.9046344501560952e-09
tool O 0 2.066508208997675e-08
for O 0 5.907230260504548e-10
detection O 0 6.524424378540061e-08
of O 0 8.383329941352713e-08
ATM O 0 0.0005292163696140051
carriers O 0 5.363210220821202e-06
. O 0 2.9274358439579373e-06

Both O 0 4.650140908779576e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 1.0286687938787509e-05
and O 0 2.7430411719819858e-08
heterozygotes O 0 3.185566868069145e-07
showed O 0 1.0477908318762275e-08
significantly O 0 1.2268358551281722e-09
increased O 0 2.0327894922900214e-09
levels O 0 1.871625521232545e-09
of O 0 3.1073703610218217e-09
radiation O 0 1.275678528145363e-06
- O 0 1.993306000258599e-07
induced O 0 1.2052361171299708e-06
chromatid O 0 9.44104726841033e-07
damage O 0 6.020862883815425e-07
relative O 0 2.969149726084197e-08
to O 0 7.188395989565777e-10
that O 0 4.085681237775418e-10
of O 0 1.0716386000808598e-08
normal O 0 1.2225331147419638e-07
controls O 0 6.110046228968713e-07
. O 0 7.889464086474618e-07

These O 0 1.0018710128179009e-07
results O 0 1.570019634300479e-07
show O 0 3.576133167371154e-08
that O 0 3.147653027113506e-09
the O 0 5.956179904842429e-08
G2 O 0 4.555110081128078e-06
- O 0 3.2315136877514306e-07
phase O 0 3.898138913882576e-07
chromosomal O 0 1.0574477755653788e-06
radiosensitivity O 0 1.2669707984969136e-06
assay O 0 6.86517651615759e-08
can O 0 2.0958734747722474e-09
be O 0 9.777737508542828e-10
used O 0 4.624776395178998e-10
for O 0 1.995338477778219e-10
the O 0 2.596427794987477e-10
detection O 0 1.396915294549217e-08
of O 0 1.6653139311983978e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0016746337059885263
. O 0 4.263261416781461e-06

In O 0 5.750453979658232e-08
combination O 0 1.5364756222879805e-07
with O 0 5.67184699207246e-09
molecular O 0 1.6184830542442796e-07
genetic O 0 5.6320065056070234e-08
analyses O 0 2.2838543500824926e-08
, O 0 2.583243619014297e-10
this O 0 6.674527597283486e-11
test O 0 2.385694697348839e-10
may O 0 1.4972276751734626e-09
be O 0 1.2652077163721742e-09
of O 0 2.776882945809689e-09
value O 0 4.458749813807117e-09
in O 0 2.1878003575448446e-10
studies O 0 1.2887868550137682e-09
of O 0 5.122229751464147e-09
familial B-Disease 0 1.439697996374889e-07
and I-Disease 0 3.1617712892284544e-08
sporadic I-Disease 0 1.5698049537604675e-05
cancers I-Disease 0 1.2158351637481246e-05
aimed O 0 1.3100189732995204e-07
at O 0 5.719364093437207e-09
determination O 0 8.065195622464216e-09
of O 0 8.245156557507016e-09
the O 0 6.250156392439976e-09
potential O 0 4.8292701393393145e-08
involvement O 0 6.498677862509794e-08
of O 0 1.0112437820453124e-07
ATM O 0 0.0009268655558116734
mutations O 0 4.1531382066750666e-07
in O 0 2.0196541328232342e-08
tumor B-Disease 0 1.4524378457281273e-05
risk O 0 2.7938349944633956e-07
or O 0 9.034416770248299e-09
development O 0 5.8301022676232606e-08
. O 0 1.2508929003729463e-08
. O 0 1.5397144181861222e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.5245477413827757e-07
identification O 0 3.791991076695922e-08
and O 0 1.4420766802913931e-09
detection O 0 6.024434640039544e-08
of O 0 7.621077457997671e-08
founder O 0 8.115432024169422e-07
- O 0 1.4698194661377784e-07
effect O 0 1.163338438914252e-07
mutations O 0 2.314229341493501e-08
in O 0 8.604991164062881e-10
the O 0 3.998482878131426e-09
ATM O 0 3.062022528865782e-07
gene O 0 5.80945291872581e-09
in O 0 3.064579701117509e-09
ethnic O 0 2.4547318844270194e-08
populations O 0 2.5940591896755905e-08
. O 0 9.272404355442632e-08

To O 0 3.286699623572531e-08
facilitate O 0 1.0825001339753726e-07
the O 0 1.0481666201656026e-08
evaluation O 0 3.662678338400838e-08
of O 0 4.2284888479571237e-08
ATM O 0 0.00016125354159157723
heterozygotes O 0 5.230764600128168e-06
for O 0 1.1358573637210156e-08
susceptibility O 0 2.1416686024622322e-07
to O 0 5.145957437946436e-09
other O 0 2.2104483576868006e-08
diseases O 0 0.00018520859885029495
, O 0 1.1600680416279374e-09
such O 0 2.0541832679299432e-09
as O 0 6.448468070630042e-07
breast B-Disease 0 1.1909983186342288e-06
cancer I-Disease 0 1.0883783261306235e-06
, O 0 1.509442681957296e-09
we O 0 9.751923712997268e-10
have O 0 5.290653470879647e-10
attempted O 0 5.747720077664553e-09
to O 0 1.1441716463167495e-09
define O 0 9.96253124441182e-09
the O 0 8.5092226598249e-09
most O 0 4.0666043865655865e-09
common O 0 1.737334609508423e-09
mutations O 0 1.3960141931335102e-09
and O 0 3.239964962986619e-10
their O 0 4.914220697038729e-10
frequencies O 0 4.540609310765831e-08
in O 0 1.4233099143723393e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8226576447486877
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.873760417467565e-08
homozygotes O 0 7.39882580091944e-07
from O 0 1.4760923150447525e-08
10 O 0 1.7903660776141805e-08
ethnic O 0 2.6274218356547863e-08
populations O 0 9.656959321091563e-08
. O 0 2.2913248187705904e-07

Both O 0 2.937843532890838e-07
genomic O 0 6.242962626856752e-07
mutations O 0 1.3581090740899526e-07
and O 0 1.070218935694811e-08
their O 0 2.4799315934131982e-09
effects O 0 7.642854882305983e-08
on O 0 2.65871769045134e-08
cDNA O 0 2.41871845219066e-07
were O 0 5.844865924586884e-08
characterized O 0 2.449340286148072e-07
. O 0 4.1050265053854673e-07

Protein O 0 4.48660648544319e-06
- O 0 8.646440505799546e-07
truncation O 0 5.536246021620173e-07
testing O 0 1.3634656070848905e-08
of O 0 3.7428051768984005e-08
the O 0 2.1266963301513897e-08
entire O 0 3.7111998807404234e-08
ATM O 0 5.891201908525545e-07
cDNA O 0 1.4921060653705354e-07
detected O 0 4.230537697935688e-08
92 O 0 6.084309944753841e-08
( O 0 1.4594678798829364e-09
66 O 0 2.597336745679968e-08
% O 0 1.938240457022289e-09
) O 0 2.2753603168279568e-10
truncating O 0 1.725572040811585e-08
mutations O 0 5.981781736608127e-09
in O 0 1.1881288175530358e-09
140 O 0 1.4705592299435466e-08
mutant O 0 8.53119885846354e-08
alleles O 0 8.463032230565659e-08
screened O 0 5.366527489059081e-07
. O 0 4.1679462015054014e-07

The O 0 7.358364086940128e-07
haplotyping O 0 4.858486136072315e-05
of O 0 2.9696207093365956e-07
patients O 0 6.382431916307496e-09
with O 0 3.6703390327019747e-10
identical O 0 8.54932480365278e-09
mutations O 0 1.2544504990330552e-08
indicates O 0 1.3041410618086502e-08
that O 0 5.512246215033656e-11
almost O 0 9.134528133891706e-10
all O 0 1.1713378877953318e-10
of O 0 3.670506953934449e-10
these O 0 9.734226619206865e-11
represent O 0 8.962293684966482e-10
common O 0 2.0150128232643283e-09
ancestry O 0 1.1805957988997307e-08
and O 0 2.3856139286237976e-09
that O 0 2.0882520157528006e-09
very O 0 9.166384096204183e-09
few O 0 6.225602078302472e-08
spontaneously O 0 3.171054174799792e-07
recurring O 0 4.5606506660078594e-07
ATM O 0 1.9072012946708128e-05
mutations O 0 1.207836589856015e-06
exist O 0 9.67912114901992e-07
. O 0 2.4689986730663804e-06

Assays O 0 5.269591270007368e-07
requiring O 0 1.2445296704299835e-07
minimal O 0 5.133006197866052e-07
amounts O 0 1.104568809751072e-07
of O 0 2.6835035527028595e-08
genomic O 0 2.1122279036944747e-08
DNA O 0 4.419078081241423e-08
were O 0 3.0375599813226017e-09
designed O 0 2.329115789123648e-09
to O 0 2.878179916621093e-10
allow O 0 8.647704219377772e-10
rapid O 0 1.6022433158013882e-08
screening O 0 7.07948810685366e-10
for O 0 5.373364531102709e-10
common O 0 8.238522752890276e-09
ethnic O 0 4.275021225907949e-08
mutations O 0 5.760464318882441e-07
. O 0 4.6004115006326174e-07

These O 0 1.6393175883422373e-07
rapid O 0 1.2000795095445937e-06
assays O 0 1.782689622586986e-07
detected O 0 5.691519078254714e-08
mutations O 0 4.515216200928762e-09
in O 0 5.78300518583319e-10
76 O 0 2.5903215572498084e-08
% O 0 4.209622095352472e-10
of O 0 1.3964989165060615e-09
Costa O 0 2.204902926905561e-08
Rican O 0 7.170668681055758e-08
patients O 0 1.5146771614737986e-09
( O 0 5.802804903254355e-10
3 O 0 1.2711199204318291e-08
) O 0 1.625946738359474e-10
, O 0 2.3328583509396594e-10
50 O 0 1.7569155019714344e-09
% O 0 2.869234572155932e-10
of O 0 1.4921843760618003e-09
Norwegian O 0 1.5738062586478918e-07
patients O 0 2.292717571350522e-09
( O 0 1.1054424042811206e-09
1 O 0 3.739094722732261e-08
) O 0 4.128467845365691e-10
, O 0 7.612004915280579e-10
25 O 0 4.398096109525795e-09
% O 0 3.4471225873744515e-10
of O 0 1.1680031386518408e-09
Polish O 0 1.6054409002208558e-07
patients O 0 6.752438608259581e-09
( O 0 2.0586783389120455e-09
4 O 0 4.456643409866956e-08
) O 0 5.126215008033341e-10
, O 0 6.187914070032718e-10
and O 0 1.3158237832655573e-09
14 O 0 1.3146954636056307e-08
% O 0 6.842829081143975e-10
of O 0 1.7252289596925152e-09
Italian O 0 4.290713562227211e-08
patients O 0 1.1592451443220853e-09
( O 0 7.016147107741233e-10
1 O 0 2.390105890981431e-08
) O 0 4.12506750979702e-10
, O 0 4.835200573261034e-10
as O 0 1.6660940405088809e-09
well O 0 1.0404833661326052e-09
as O 0 2.5766115907543963e-09
in O 0 6.946187514067503e-10
patients O 0 1.8842911675420737e-09
of O 0 2.0165826342122273e-08
Amish O 0 5.546963848246378e-07
/ O 0 4.7551475290674716e-07
Mennonite O 0 2.790727421597694e-06
and O 0 5.054240403978838e-08
Irish O 0 6.92051287387585e-08
English O 0 8.190441747046862e-08
backgrounds O 0 1.5735256511106854e-06
. O 0 1.3643158354170737e-06

Additional O 0 7.268379818015092e-07
mutations O 0 4.615748423475452e-07
were O 0 9.390960542532412e-08
observed O 0 1.8586595373903947e-08
in O 0 2.2776236452415333e-09
Japanese O 0 3.8492235177045586e-08
, O 0 1.595222953731934e-09
Utah O 0 1.3758877592806584e-08
Mormon O 0 3.543021875884733e-08
, O 0 1.8404030521779191e-09
and O 0 4.15814449539198e-09
African O 0 2.0139841794275526e-08
American O 0 4.925486152274061e-08
patients O 0 5.287209248194813e-08
. O 0 2.2796420751092228e-07

These O 0 9.930965205739994e-08
assays O 0 1.161085094736336e-07
should O 0 5.758902243968578e-09
facilitate O 0 9.83760362061048e-09
screening O 0 4.943940812296432e-09
for O 0 1.1701912328021535e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
heterozygotes O 0 8.258702450802957e-07
in O 0 2.3690813755194995e-09
the O 0 8.070058399312074e-09
populations O 0 7.47498152264825e-09
studied O 0 2.3728405906808803e-08
. O 0 1.3840049106761398e-08
. O 0 2.842205901743e-07

The O 0 2.3411450456478633e-05
von B-Disease 1 0.9999841451644897
Hippel I-Disease 1 0.9999996423721313
- I-Disease 1 0.9999158382415771
Lindau I-Disease 1 0.988761842250824
tumor I-Disease 0 3.965344149037264e-05
suppressor O 0 2.620706027300912e-06
gene O 0 5.034801908720965e-09
is O 0 2.590071768171498e-10
required O 0 1.1167244906573615e-10
for O 0 3.298012141161877e-10
cell O 0 4.100534312101445e-08
cycle O 0 2.0279998125261045e-08
exit O 0 6.61364509824125e-08
upon O 0 6.352218662186715e-08
serum O 0 6.48613422526978e-07
withdrawal O 0 3.7061820421513403e-06
. O 0 2.090067482640734e-06

The O 0 1.6359362007278833e-06
inactivation O 0 7.137291686376557e-05
of O 0 1.2805895721612615e-06
the O 0 9.745328952703858e-07
von B-Disease 1 0.9999998807907104
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 0.00034362482256256044
VHL I-Disease 1 1.0
) I-Disease 0 2.900669073824247e-07
tumor I-Disease 0 5.918541319260839e-06
suppressor O 0 8.835124390316196e-06
gene O 0 5.371331468495555e-08
predisposes O 0 1.006146021609311e-06
affected O 0 1.5125500851809193e-08
individuals O 0 1.1299829821842522e-10
to O 0 3.330167530624095e-10
the O 0 5.46528822198411e-09
human O 0 4.7354938033095095e-06
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9997511506080627
and O 0 8.821158803407059e-10
is O 0 8.63741439482979e-11
associated O 0 1.8050473338249162e-09
with O 0 3.700129980188649e-09
sporadic B-Disease 1 0.9999996423721313
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.4031903447175864e-05
RCC B-Disease 1 1.0
) O 0 9.750908702699235e-08
and O 0 4.262246875441633e-07
brain B-Disease 1 0.9999977350234985
hemangioblastomas I-Disease 1 0.9999042749404907
. O 0 1.5364242926807492e-06

VHL O 1 0.7086386680603027
- O 0 0.00024784670677036047
negative O 0 4.003566573373973e-06
786 O 0 5.513029464054853e-06
- O 0 1.5406324109790148e-06
0 O 0 9.531860314382357e-07
RCC B-Disease 0 1.946000338648446e-05
cells O 0 8.851571919876733e-08
are O 0 4.476234938266543e-09
tumorigenic O 0 5.036581114836736e-06
in O 0 1.9787327332210225e-08
nude O 0 4.741946497688332e-07
mice O 0 4.158088984240749e-09
which O 0 2.569004176056211e-10
is O 0 1.564660206954116e-10
suppressed O 0 4.3898915613738154e-09
by O 0 6.327266488526107e-10
the O 0 9.415761503817066e-09
reintroduction O 0 1.988844815059565e-06
of O 0 3.6556713212121394e-07
VHL B-Disease 1 0.956775426864624
. O 0 7.078338967403397e-06

Remarkably O 0 2.6716694264905527e-05
, O 0 1.3896046091588232e-08
this O 0 3.539492587911752e-10
occurs O 0 5.295580640662934e-10
without O 0 1.2114584890809965e-09
affecting O 0 7.726102424499004e-09
the O 0 2.6592845703277135e-09
growth O 0 2.159699530324133e-09
rate O 0 1.4897103550737256e-09
and O 0 3.903033451990723e-10
cell O 0 2.1692786233984407e-08
cycle O 0 1.5931316710293686e-08
profile O 0 1.6368016275691843e-08
of O 0 2.711932189924937e-08
these O 0 4.295173994250945e-09
cells O 0 1.839691421423595e-08
in O 0 3.479731169875322e-09
culture O 0 1.5632753047611914e-07
. O 0 2.2438887015141518e-07

The O 0 6.27999452262884e-06
786 O 0 1.1258769518462941e-05
- O 0 5.022460527470685e-07
0 O 0 1.389083195135754e-07
cell O 0 1.195219283545157e-07
line O 0 3.498180376482196e-07
, O 0 2.1800952154649167e-09
like O 0 1.5184896673403614e-09
many O 0 4.714753032430963e-09
cancer B-Disease 0 5.479988018919357e-08
cells O 0 9.325432870355144e-09
, O 0 4.755682514456794e-10
fails O 0 2.9697431180863987e-09
to O 0 8.512432980722906e-10
exit O 0 5.320968909927615e-08
the O 0 5.798515445576413e-09
cell O 0 5.6887078159206794e-08
cycle O 0 2.1923893811504058e-08
upon O 0 6.126768425929185e-08
serum O 0 4.12707180430516e-07
withdrawal O 0 2.1122216367075453e-06
. O 0 2.261738700326532e-06

Here O 0 2.2796864413976436e-06
, O 0 4.21414085849392e-08
it O 0 1.8476484786589253e-09
is O 0 7.925974321310036e-10
shown O 0 3.1850405646238755e-10
that O 0 1.1124769161430237e-10
reintroduction O 0 7.892807474263464e-08
of O 0 1.4565403105848418e-08
the O 0 3.500929679489673e-08
wild O 0 2.2748294270513725e-07
- O 0 3.73825400856731e-07
type O 0 5.397816948971013e-07
VHL B-Disease 0 0.0007747971685603261
gene O 0 1.0864074084793174e-07
restores O 0 1.453771233173029e-06
the O 0 2.0929583399720286e-08
ability O 0 1.8719051197990666e-08
of O 0 4.417864829520113e-07
VHL O 1 1.0
- O 1 0.9999513626098633
negative O 0 9.169917029794306e-05
RCC B-Disease 1 0.9997019171714783
cancer I-Disease 0 2.4013107235987263e-07
cells O 0 1.435353613743473e-09
to O 0 3.3139910260437944e-10
exit O 0 8.881094082369145e-09
the O 0 7.506180121907846e-10
cell O 0 1.042555908270515e-08
cycle O 0 9.3223020414257e-09
and O 0 4.494354222117636e-09
enter O 0 3.38810565381209e-07
G0 O 0 8.934438665164635e-05
/ O 0 2.1818700588482898e-06
quiescence O 0 3.4503245842643082e-06
in O 0 7.590366379872648e-08
low O 0 2.056150151474867e-06
serum O 0 1.513497409177944e-06
. O 0 7.205052270364831e-07

Both O 0 1.0175837815040722e-05
VHL O 1 0.9997883439064026
- O 0 7.813911361154169e-05
positive O 0 5.291244633554015e-07
and O 0 1.3511613872196904e-07
VHL O 1 0.9994049072265625
- O 0 4.756719863507897e-05
negative O 0 1.8912468249254744e-06
RCC B-Disease 0 0.0001140415552072227
cells O 0 1.8780065147439018e-07
exit O 0 1.1561041901586577e-07
the O 0 3.830026962248212e-09
cell O 0 1.3792456954320187e-08
cycle O 0 4.72406069818021e-09
by O 0 2.2093979978876632e-09
contact O 0 1.5809909825748036e-07
inhibition O 0 2.574025074864039e-06
. O 0 6.8013389409316e-07

The O 0 4.116310719837202e-06
cyclin O 0 1.6139396393555216e-05
- O 0 6.805271823395742e-06
dependent O 0 3.1856961868470535e-06
kinase O 0 3.0272776712081395e-06
inhibitor O 0 5.400175382419548e-07
, O 0 1.8975283566646794e-08
p27 O 0 3.3461017778790847e-07
, O 0 1.64537117264274e-09
accumulates O 0 1.8908735910372343e-08
upon O 0 2.736429527416817e-09
serum O 0 5.026262517304758e-09
withdrawal O 0 9.545614076955644e-09
, O 0 5.826172322365153e-10
only O 0 3.764207556766763e-10
in O 0 1.9826409958234592e-10
the O 0 2.4360180539417797e-09
presence O 0 2.766601880921371e-08
of O 0 2.707926967104868e-07
VHL B-Disease 1 0.9999992847442627
, O 0 9.885548379884312e-09
as O 0 2.2333788152195666e-09
a O 0 9.108084286779672e-10
result O 0 2.7736171137604515e-09
of O 0 5.5348077232508786e-09
the O 0 4.97472107952035e-09
stabilization O 0 5.028096552450734e-07
of O 0 1.4390639080374967e-07
the O 0 2.923441684288264e-07
protein O 0 8.657796570332721e-06
. O 0 1.3989330227559549e-06

We O 0 7.463643925120778e-08
propose O 0 3.345616050864919e-08
that O 0 3.0418794150222084e-09
the O 0 1.2700948737176532e-08
loss O 0 7.949357438974403e-08
of O 0 5.424901416972716e-08
wild O 0 1.8255443023917906e-07
- O 0 2.8812044661208347e-07
type O 0 7.096352305779874e-07
VHL B-Disease 0 0.008655291050672531
gene O 0 1.4197119924119761e-08
results O 0 2.589866987534606e-08
in O 0 5.262634772407182e-10
a O 0 6.479104475154429e-10
specific O 0 5.963827209853889e-09
cellular O 0 2.5575329232196964e-07
defect O 0 1.0372842496053636e-07
in O 0 4.349967053229875e-09
serum O 0 7.853374484056985e-08
- O 0 3.868500755288551e-07
dependent O 0 2.635096507219714e-06
growth O 0 4.6796532870985175e-08
control O 0 2.3479486799260485e-08
, O 0 3.5166687339938107e-09
which O 0 1.854494335873369e-09
may O 0 2.3756799194529776e-08
initiate O 0 3.053746411296743e-07
tumor B-Disease 0 1.7815569663071074e-05
formation O 0 4.5009464884060435e-06
. O 0 2.951712986032362e-06

This O 0 6.561213439226776e-08
is O 0 1.0726098231828018e-08
corrected O 0 5.1359972275122345e-08
by O 0 8.921906546888181e-10
the O 0 5.4701896345932255e-09
reintroduction O 0 2.4298830680891115e-07
of O 0 3.574544393813994e-08
wild O 0 5.839606274093967e-07
- O 0 1.844668986450415e-06
type O 0 1.5165247532422654e-05
VHL B-Disease 1 1.0
, O 0 4.7134338387877506e-07
implicating O 0 0.0037403013557195663
VHL B-Disease 1 1.0
as O 0 1.9191605815649382e-07
the O 0 1.6619116749438945e-08
first O 0 6.357100179599229e-09
tumor B-Disease 0 7.367929555357478e-08
suppressor O 0 4.180106714102294e-07
involved O 0 1.260828108584633e-09
in O 0 3.6926547930526965e-10
the O 0 2.9586164629336054e-09
regulation O 0 1.0398470529082715e-08
of O 0 2.98352382799294e-08
cell O 0 1.1871422600506776e-07
cycle O 0 2.4918195506984375e-08
exit O 0 2.377402630315828e-08
, O 0 8.02832578195023e-10
which O 0 2.4261403996916897e-10
is O 0 3.0465230338450056e-10
consistent O 0 5.754828613646623e-09
with O 0 3.532262815575393e-10
its O 0 2.6207338521544443e-09
gatekeeper O 0 7.378997679552413e-08
function O 0 4.020606958476947e-09
in O 0 4.441095935447947e-09
the O 0 1.1698925561631768e-07
kidney O 0 2.156253503926564e-05
. O 0 8.790799910229907e-08
. O 0 4.0054544570011785e-07

Piebaldism B-Disease 1 1.0
with O 1 0.5753809809684753
deafness B-Disease 1 1.0
: O 0 2.833188545992016e-07
molecular O 0 3.1554878887618543e-07
evidence O 0 8.739075241237515e-08
for O 0 2.0196917471793085e-09
an O 0 7.95832022504328e-09
expanded O 0 2.873625248867029e-07
syndrome O 1 0.917140007019043
. O 0 7.172282039391575e-07

In O 0 2.0696559133170922e-08
a O 0 1.7869066226694486e-08
South O 0 2.1787121440297597e-08
African O 0 1.1403768596096597e-08
girl O 0 3.4917402302880873e-08
of O 0 1.0708355979716089e-08
Xhosa O 0 7.59698579599899e-08
stock O 0 3.018277894284438e-08
with O 0 5.174349282377477e-10
severe O 0 3.5044047308474546e-07
piebaldism B-Disease 0 4.95666972710751e-05
and O 0 1.6815988601592835e-07
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.842283942707581e-07
identified O 0 1.756789025364469e-08
a O 0 1.0904753766638464e-09
novel O 0 2.1443646858188004e-09
missense O 0 2.1181868703479267e-08
substitution O 0 3.790175995277423e-08
at O 0 3.231506795486894e-08
a O 0 5.960699933638125e-09
highly O 0 1.1516799958144475e-08
conserved O 0 2.29152092856566e-08
residue O 0 1.0439113395932509e-07
in O 0 2.4543469478999214e-09
the O 0 1.570839636144683e-08
intracellular O 0 2.1063868871351588e-07
kinase O 0 9.311738153883198e-07
domain O 0 1.6050948659085407e-07
of O 0 2.9279004820637056e-07
the O 0 8.159597655321704e-07
KIT O 0 0.0004131327150389552
proto O 0 6.176865281304345e-05
- O 0 1.485690245317528e-05
oncogene O 0 6.635005411226302e-05
, O 0 3.643513935003284e-07
R796G O 0 2.2876376533531584e-05
. O 0 2.494778755135485e-06

Though O 0 1.6659699895171798e-06
auditory B-Disease 0 0.0007819798192940652
anomalies I-Disease 0 3.3594100386835635e-05
have O 0 6.225195470221934e-09
been O 0 6.408194419549318e-09
observed O 0 1.0645489822991294e-08
in O 0 6.713049560680417e-10
mice O 0 3.1133029487762087e-09
with O 0 9.830696257040472e-10
dominant O 0 2.266445790155558e-06
white O 0 9.1776371391461e-08
spotting O 0 9.036968549480662e-06
( O 0 2.983939140221992e-08
W O 0 0.09343567490577698
) O 0 3.116189972729444e-09
due O 0 7.687973635484013e-08
to O 0 5.745779851906718e-09
KIT O 0 0.043828897178173065
mutations O 0 7.2946399995998945e-06
, O 0 1.304057377637946e-06
deafness B-Disease 1 1.0
is O 0 1.1702470104069107e-08
not O 0 1.1330092419825633e-09
typical O 0 6.127118723497915e-08
in O 0 4.607363379705021e-09
human O 0 2.9534177770074166e-07
piebaldism B-Disease 0 0.00010721657599788159
. O 0 1.4332309774545138e-06

Thus O 0 1.6270318781153037e-07
, O 0 2.850798042075553e-09
the O 0 9.88482740105212e-10
occurrence O 0 1.2129613935485395e-07
of O 0 7.461443942702317e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.279767781805276e-07
this O 0 8.421608965747396e-10
patient O 0 1.7403858354470003e-09
extends O 0 9.167201997506425e-10
considerably O 0 1.6311443307159834e-09
the O 0 6.093199833578922e-10
phenotypic O 0 1.5717747103849433e-08
range O 0 4.292350652690402e-08
of O 0 1.790181514138567e-08
piebaldism B-Disease 0 1.5552557215414708e-06
due O 0 3.746662358139474e-08
to O 0 5.8920757162184145e-09
KIT O 0 5.863194019184448e-07
gene O 0 4.442019196915226e-09
mutation O 0 4.839096234832141e-09
in O 0 5.746105813386748e-10
humans O 0 3.043109542133493e-09
and O 0 1.3759656747325266e-09
tightens O 0 1.2623110556830852e-08
the O 0 2.1452195575477617e-09
clinical O 0 6.0175535665507596e-09
similarity O 0 1.8869032558654908e-08
between O 0 2.3776109969730896e-08
piebaldism B-Disease 0 2.528987533878535e-05
and O 0 4.929534558328896e-09
the O 0 1.1917170583686243e-09
various O 0 2.4383794983151574e-09
forms O 0 2.7963642068584704e-08
of O 0 5.06459514326707e-07
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999980926513672
. O 0 1.7871357727017312e-07
. O 0 8.406416327488841e-07

Cycloheximide O 0 4.6948716772021726e-05
facilitates O 0 4.754780320581631e-07
the O 0 8.634194692547226e-09
identification O 0 4.870517145150188e-08
of O 0 8.908107673732957e-08
aberrant O 0 4.564549271890428e-07
transcripts O 0 3.2682558526175853e-07
resulting O 0 1.9217907265556278e-07
from O 0 1.9456789956961984e-08
a O 0 6.3494538515840304e-09
novel O 0 2.665674259105799e-08
splice O 0 5.394210234044294e-07
- O 0 6.12180386383443e-08
site O 0 4.330267344698768e-08
mutation O 0 8.194548151152503e-09
in O 0 3.744531351657088e-09
COL17A1 O 0 0.08796603232622147
in O 0 2.7468094465632475e-09
a O 0 6.853673628626211e-09
patient O 0 3.8753089626197834e-08
with O 0 1.4048134211464003e-08
generalized O 1 0.9999970197677612
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9983077049255371
. O 0 1.3590380149253178e-05

Patients O 0 6.657086260020151e-07
with O 0 7.894148268405843e-08
generalized O 1 0.9999812841415405
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.1560404896736145
often O 0 5.229200894518726e-08
show O 0 1.9317051069833724e-08
decreased O 0 1.0373574355071469e-07
expression O 0 1.6022189797126885e-08
of O 0 2.938557130960362e-08
type O 0 4.820711296815716e-07
XVII O 0 0.0017381974030286074
collagen O 0 6.9721436375402845e-06
, O 0 1.021370152898271e-07
a O 0 1.0577992526350499e-07
transmembrane O 0 1.3776202649751212e-06
hemidesmosomal O 0 1.615147652955784e-06
protein O 0 1.2087313905340125e-07
encoded O 0 4.267412023750694e-08
by O 0 8.410042795503614e-08
COL17A1 O 1 0.9763540029525757
. O 0 2.056722678389633e-06

This O 0 1.1534698529658272e-07
report O 0 5.830491289771089e-08
documents O 0 1.3340273596895713e-07
a O 0 5.071370878795278e-08
novel O 0 8.420428088129484e-08
splice O 0 1.2206229484945652e-06
- O 0 7.224648612691453e-08
site O 0 1.8146966596077618e-08
mutation O 0 3.5099410045091872e-09
in O 0 1.519289138940394e-09
COL17A1 O 1 0.7886722087860107
in O 0 1.3070066140485892e-09
a O 0 2.3990198716461464e-09
patient O 0 5.282549508933698e-09
with O 0 3.0864837352595487e-09
generalized O 1 0.9999856948852539
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 0 0.009768752381205559
, O 0 8.250568228618249e-09
and O 0 1.1660264975787982e-09
applies O 0 1.4193573427689898e-08
a O 0 2.2415898026650893e-09
new O 0 1.0383363058252826e-09
methodology O 0 3.835802342422312e-09
to O 0 9.071951523331734e-10
define O 0 2.5749230303517834e-08
and O 0 2.1988677545436985e-08
characterize O 0 3.438416626977414e-07
the O 0 1.1082829587394372e-07
resulting O 0 2.993864995914919e-07
mRNA O 0 3.3852518299681833e-06
splice O 0 1.1490530596347526e-05
variants O 0 6.574877261300571e-06
. O 0 5.648267233482329e-06

Mutational O 0 0.0001757338468451053
analysis O 0 1.1222301736779627e-06
of O 0 3.0227311071939766e-06
COL17A1 O 1 0.9890472292900085
identified O 0 5.367433573155722e-07
a O 0 4.94247274218651e-08
maternally O 0 6.360674547067902e-07
inherited O 0 2.6983784096046293e-07
G O 0 1.0844153166544857e-06
- O 0 2.130793745891424e-07
to O 0 5.445022210892603e-08
- O 0 2.284544052599813e-06
T O 0 4.145977527514333e-06
transversion O 0 4.619959327101242e-06
at O 0 2.4943160426005306e-08
the O 0 4.220380489527997e-09
- O 0 4.354333338341121e-09
1 O 0 7.396382173396887e-09
position O 0 1.4324253783115637e-08
of O 0 1.1784494269306833e-08
exon O 0 6.599569246645842e-08
32 O 0 8.017917707547895e-07
. O 0 7.102269705683284e-07

This O 0 1.0433340946747194e-07
acceptor O 0 5.178600304134306e-07
splice O 0 1.058309953805292e-05
- O 0 5.383412826631684e-07
site O 0 7.245196087524164e-08
mutation O 0 5.990893114926621e-09
led O 0 8.22364043528978e-09
to O 0 1.0447609444241834e-09
the O 0 6.679577335688691e-09
formation O 0 4.8478938197149546e-08
of O 0 7.102744348230772e-08
aberrant O 0 3.2280576078846934e-07
transcripts O 0 2.1554522788846953e-07
present O 0 9.857009786173876e-08
at O 0 2.8450966738091665e-07
extremely O 0 3.725064914306131e-07
low O 0 2.6777420316648204e-06
levels O 0 8.781689189163444e-07
. O 0 5.348446734387835e-07

Based O 0 1.3588362435257295e-06
on O 0 3.4161874395977065e-07
our O 0 5.040867634420465e-08
recent O 0 9.407880696699067e-09
finding O 0 1.988247610995586e-08
that O 0 3.348557653382045e-09
cycloheximide O 0 3.402119773454615e-06
stabilized O 0 2.266013325424865e-06
mutant O 0 2.993185432842438e-07
COL17A1 O 0 1.4782789548917208e-05
transcripts O 0 8.704672893600218e-08
in O 0 4.326847324875871e-09
keratinocytes O 0 3.778901316309202e-07
homozygous O 0 9.095242781143043e-09
for O 0 1.932828341821846e-09
a O 0 7.573862426113465e-09
frameshift O 0 2.3509113589170738e-07
mutation O 0 6.078437753131993e-09
, O 0 9.339329309909772e-10
the O 0 3.8761500675832394e-09
effects O 0 3.50699565387913e-07
of O 0 2.394267539784778e-07
the O 0 6.83965168946088e-08
splice O 0 1.1863764939334942e-06
- O 0 1.394639497220851e-07
site O 0 4.936848441161601e-08
mutation O 0 3.5391298780496072e-09
on O 0 9.191437833067084e-09
splicing O 0 5.477344089399594e-08
of O 0 1.6684742831785115e-07
COL17A1 O 0 0.00010146076238015667
transcripts O 0 2.475264579970826e-07
were O 0 1.4849621088330878e-08
determined O 0 5.494869004252223e-09
using O 0 3.25426730007905e-09
reverse O 0 4.905198025539903e-08
transcriptase O 0 3.535380344033001e-08
polymerase O 0 2.5447979723480785e-08
chain O 0 4.07947133851394e-08
reaction O 0 5.029659533306585e-08
of O 0 8.464727585533183e-08
total O 0 1.175867492264615e-08
RNA O 0 8.993261246814654e-08
from O 0 4.541415066228183e-08
keratinocytes O 0 9.295102358919394e-07
incubated O 0 7.226618663480622e-07
for O 0 1.8606352014671756e-08
2 O 0 1.1064787486247951e-06
. O 0 6.743367180206405e-07

5 O 0 3.1136246434471104e-06
h O 0 2.2846130320886004e-07
in O 0 6.256501983159524e-09
the O 0 1.2597134002589883e-08
presence O 0 2.783550101526089e-08
or O 0 1.4218610289162825e-08
absence O 0 1.3243393368611578e-06
of O 0 2.5555652882758295e-07
10 O 0 1.4480329468824493e-07
microg O 0 2.2444961359724402e-05
cycloheximide O 0 7.777759492455516e-06
per O 0 2.188508432254821e-07
ml O 0 1.24590303585137e-06
. O 0 4.809699589714e-07

Using O 0 1.287993800502818e-08
this O 0 3.5663842989919203e-09
approach O 0 3.67575125892472e-08
, O 0 6.602538515920742e-09
an O 0 1.9147870844449244e-08
abnormally O 0 3.330911511056911e-07
spliced O 0 6.408379817912646e-07
transcript O 0 7.489082918255008e-07
was O 0 1.296519940297003e-07
identified O 0 1.3212566152276395e-08
that O 0 5.556330395783959e-10
contains O 0 1.946594885282593e-09
an O 0 1.7064177848524764e-09
extra O 0 4.241022200091038e-09
264 O 0 1.6366330513051253e-08
bases O 0 3.392977987459744e-08
upstream O 0 2.1320497012311534e-07
from O 0 2.302974344559061e-08
exon O 0 4.5926256575512525e-08
32 O 0 6.637935001663209e-08
, O 0 1.0778101744435276e-09
resulting O 0 4.664341801685623e-09
in O 0 7.47053030547562e-10
a O 0 1.4315758356531205e-08
premature O 0 8.683130090503255e-07
termination O 0 1.2453506315068807e-06
codon O 0 2.3574721126351506e-06
27 O 0 3.9681590351392515e-06
bp O 0 1.9221220100007486e-06
downstream O 0 9.247706657333765e-06
from O 0 2.4861850533852703e-07
the O 0 3.717470633546327e-07
cryptic O 0 3.7048248486826196e-06
splice O 0 1.9496856111800298e-05
site O 0 7.310016826522769e-06
. O 0 2.573696065155673e-06

Three O 0 4.293873985261598e-07
other O 0 3.644406731950767e-08
splice O 0 9.797092843655264e-07
variants O 0 1.0718208187654454e-07
, O 0 5.290434312854586e-09
including O 0 7.833603765661223e-10
one O 0 5.749724030224002e-10
derived O 0 2.6881383785593016e-09
from O 0 3.0805551443080503e-09
the O 0 8.170793819317623e-09
skipping O 0 3.027358630447452e-08
of O 0 2.5752568078019067e-08
exon O 0 3.8656676082382546e-08
32 O 0 2.434338739476516e-07
, O 0 1.3824536182482916e-08
were O 0 3.9071188950856595e-08
also O 0 2.5730475528007446e-08
identified O 0 2.8285694497753866e-07
. O 0 5.736824846280797e-07

These O 0 1.0303983088988389e-07
results O 0 1.0543025297238273e-07
indicate O 0 1.2182024988760531e-07
the O 0 1.4251191338132685e-08
usefulness O 0 2.0573531855916372e-07
of O 0 1.1998280591285493e-08
cycloheximide O 0 1.960662814326497e-07
treatment O 0 3.8565630688935926e-09
in O 0 1.8903452414509303e-10
evaluating O 0 7.879147112532792e-09
the O 0 4.9594870432656535e-09
abnormal O 0 1.8492571030037652e-08
processing O 0 6.964381782381679e-08
of O 0 4.862896574309161e-08
mRNA O 0 3.7182255141487985e-07
due O 0 1.0928187776926279e-07
to O 0 1.1507533592691743e-08
splice O 0 1.8058595969705493e-06
- O 0 2.038463549070002e-07
site O 0 7.422077175078812e-08
mutations O 0 8.73950423141423e-09
, O 0 4.154109944920492e-09
because O 0 2.0777246589887e-08
( O 0 2.4492647909823972e-08
i O 0 9.748026030820256e-08
) O 0 4.4009240696141205e-09
aberrant O 0 5.648228906807162e-08
splicing O 0 5.3731447735572146e-08
often O 0 5.527264868021575e-09
generates O 0 8.625010039509107e-09
a O 0 6.328030099922444e-09
premature O 0 2.61422087532992e-07
termination O 0 2.2247370168315683e-07
codon O 0 3.5928843544752453e-07
, O 0 2.011722877170996e-08
( O 0 2.75930167603633e-09
ii O 0 5.186172415960755e-07
) O 0 3.3730058746073155e-09
transcripts O 0 5.1018737678987236e-08
with O 0 5.804025704492233e-09
premature O 0 3.778364430218062e-07
termination O 0 5.9157827081435244e-08
codons O 0 3.574953666429792e-08
can O 0 1.3280803123905116e-09
occur O 0 1.4302877104910294e-08
at O 0 2.3127288528712597e-08
low O 0 1.3598017289950803e-07
or O 0 3.5458731506565755e-09
undetectable O 0 7.614641361897156e-08
levels O 0 4.1821897056593116e-09
due O 0 7.0939010221593435e-09
to O 0 3.5337741621788155e-09
nonsense O 0 1.440324268742188e-07
- O 0 7.558237768989784e-08
mediated O 0 2.070963631695122e-07
mRNA O 0 8.360367331761154e-08
decay O 0 9.989725668901883e-08
, O 0 1.60232815904493e-09
and O 0 1.4393398695133897e-09
( O 0 6.038129995999952e-10
iii O 0 1.3485067995588906e-07
) O 0 1.4734783393421935e-09
the O 0 6.844816269335752e-09
levels O 0 8.980197030439285e-09
of O 0 6.064264201910419e-09
these O 0 9.767857633846688e-10
transcripts O 0 1.1933326327095983e-08
can O 0 1.1599352589541922e-09
be O 0 2.224145534412969e-09
increased O 0 1.6263083324474792e-08
by O 0 1.6922610868164156e-08
cycloheximide O 0 6.165884406073019e-05
. O 0 2.351963757973863e-06

A O 0 1.110159132622357e-06
deletion O 0 1.4400619363641454e-07
mutation O 0 4.471672099271018e-08
in O 0 9.238858567073294e-09
COL17A1 O 0 0.002140405820682645
in O 0 2.8454092415586274e-09
five O 0 3.942239867882336e-09
Austrian O 0 1.755558827198911e-07
families O 0 6.861312407124842e-09
with O 0 2.632517315248606e-09
generalized O 1 0.9999175071716309
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.0010867526289075613
represents O 0 5.562263183378491e-08
propagation O 0 2.3383472580462694e-07
of O 0 2.9644361632108485e-08
an O 0 6.095969951047664e-09
ancestral O 0 4.0025753378358786e-07
allele O 0 6.645617531830794e-07
. O 0 4.420511459102272e-07

Patients O 0 4.6085875737844617e-07
with O 0 6.226029114486664e-08
generalized O 1 0.9999992847442627
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998507499694824
, O 0 4.124104080460711e-08
a O 0 7.571465232558694e-09
usually O 0 4.172612033670475e-09
nonlethal O 0 9.974187378247734e-07
form O 0 4.5031605111489625e-08
of O 0 1.2630536048163776e-06
junctional B-Disease 1 0.9999988079071045
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9983545541763306
, O 0 2.208826401783881e-07
have O 0 3.451152252864631e-08
generalized O 0 3.443162086114171e-06
blistering B-Disease 0 8.03535476734396e-06
, O 0 2.1394963312104665e-07
nail B-Disease 1 0.9979544878005981
dystrophy I-Disease 1 0.9999997615814209
, O 0 6.78759315633215e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.7828604541136883e-05
and O 1 0.9938526153564453
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9957953691482544

Skin B-Disease 1 0.9982637763023376
fragility I-Disease 0 0.0001568542793393135
in O 0 4.429996369736955e-09
most O 0 1.4956834659685114e-09
cases O 0 9.289531921474747e-10
is O 0 1.5399030661722435e-10
due O 0 1.4123622271711156e-09
to O 0 4.970431843887013e-10
mutations O 0 4.864118441361143e-09
in O 0 5.317097873103194e-10
the O 0 2.5273150239257802e-09
gene O 0 4.297140421272161e-09
encoding O 0 1.0012674067638727e-07
type O 0 1.431933014828246e-06
XVII O 0 0.3763003945350647
collagen O 0 2.3254444386111572e-05
( O 0 2.616228584884084e-06
COL17A1 O 1 0.9999810457229614
) O 0 3.5704363199329237e-07
. O 0 8.608215011918219e-07

Recently O 0 2.1082548755657626e-06
, O 0 3.179872365421943e-08
we O 0 5.671370928439501e-09
reported O 0 1.4487049782019312e-08
five O 0 1.7721648593038708e-09
Austrian O 0 2.318095368991635e-07
families O 0 1.8141914637226364e-08
with O 0 6.03455285741461e-09
generalized O 1 0.9999346733093262
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998636245727539
who O 0 8.398357920214039e-08
share O 0 9.040501680601665e-09
the O 0 5.2000559414011605e-09
same O 0 1.587520337409387e-08
COL17A1 O 0 0.0002272486744914204
mutation O 0 5.356435508474533e-07
. O 0 5.643608460559335e-07

Affected O 0 2.6417492904329265e-07
individuals O 0 1.834767116015712e-09
in O 0 7.953672165328385e-10
three O 0 2.9200050710720404e-10
families O 0 4.764616479135952e-10
are O 0 8.275335278140616e-11
homozygous O 0 1.346388001088883e-09
for O 0 2.3583828223650016e-09
4003delTC O 0 2.233435907328385e-07
, O 0 2.273895072235632e-09
whereas O 0 4.182005852726434e-09
those O 0 1.6627924592782506e-09
in O 0 1.415736305965254e-09
two O 0 8.548884267156609e-09
others O 0 2.0951709700511856e-08
are O 0 5.364571453725375e-09
compound O 0 7.578054805890133e-07
heterozygotes O 0 1.2108099326724187e-05
. O 0 2.3680177037022077e-06

To O 0 1.4094269751296906e-08
determine O 0 3.611895849076063e-08
if O 0 7.092493703453329e-09
the O 0 7.0995582746036234e-09
occurrence O 0 3.1989127791121064e-08
of O 0 8.388044037133113e-09
4003delTC O 0 3.8538299662604913e-08
in O 0 2.2094893969981655e-10
these O 0 2.6658139584689877e-10
unrelated O 0 7.156455872348033e-09
families O 0 7.34582228378855e-10
signifies O 0 8.123367756240896e-09
propagation O 0 2.6118478047010285e-08
of O 0 5.638839617461144e-09
an O 0 3.113991953185291e-09
ancestral O 0 1.846279502615289e-07
allele O 0 7.889075703815251e-08
or O 0 7.649034294843204e-09
a O 0 1.876165889314052e-08
mutational O 0 5.6777007557684556e-06
hot O 0 2.1343619209801545e-06
spot O 0 7.02712100064673e-07
, O 0 3.5476523940758398e-09
haplotypes O 0 9.021058389180325e-08
were O 0 3.8787386635874554e-09
determined O 0 9.202664408292094e-09
for O 0 5.95961990867977e-09
polymorphisms O 0 5.015922397433314e-07
both O 0 1.2059497578320588e-07
within O 0 3.082514297148009e-07
and O 0 1.1443574976510718e-06
flanking O 0 0.01297761034220457
COL17A1 O 1 1.0
. O 0 9.007678272610065e-06

Five O 0 3.4552735996840056e-06
intragenic O 0 3.044236837013159e-05
polymorphisms O 0 2.0132024474150967e-06
were O 0 5.0844263910221343e-08
chosen O 0 3.0331207767630985e-08
based O 0 5.6963518346719866e-08
on O 0 7.839037152734818e-08
their O 0 4.865243496965377e-08
informativeness O 0 0.0001698649430181831
. O 0 2.2196263671503402e-06

One O 0 3.1585105375597777e-07
of O 0 1.6476150221933494e-07
these O 0 1.5889378701672285e-08
, O 0 3.7675276232107535e-09
not O 0 1.3747118998708174e-09
previously O 0 9.258899424935407e-09
reported O 0 1.3205159632434516e-08
, O 0 7.740789675914073e-10
was O 0 2.2652903552966563e-08
2988 O 0 6.344263283608598e-07
A O 0 2.714867264330678e-07
or O 0 1.67477374191094e-08
C O 0 1.1952025715800119e-06
that O 0 1.4600914921558683e-09
introduces O 0 3.421996908059555e-08
a O 0 2.85393175758486e-09
new O 0 4.1412779872018746e-09
restriction O 0 4.0533027600986316e-08
site O 0 1.2017524397833768e-07
for O 0 5.549557258177629e-08
Eco0109 O 0 4.8322643124265596e-05
I O 0 9.01391395018436e-05
. O 0 7.306030056497548e-06

All O 0 1.149823560808727e-07
the O 0 1.1565364133048206e-07
4003delTC O 0 1.1828078640974127e-06
alleles O 0 3.981308793754579e-08
showed O 0 2.050934888586653e-08
the O 0 2.743793414694551e-09
same O 0 7.869230267409932e-10
haplotype O 0 5.4869538246293814e-08
for O 0 3.808217741152475e-09
these O 0 1.3622152295056367e-08
five O 0 4.6847798529370266e-08
polymorphic O 0 5.344638225324161e-07
markers O 0 7.960439688758925e-06
. O 0 4.364739652373828e-06

Fourteen O 0 1.1293093848507851e-05
microsatellite O 0 1.5056040183480945e-06
polymorphisms O 0 5.841355346092314e-07
were O 0 2.7454175821617355e-08
selected O 0 7.29036964131069e-09
based O 0 5.074716202813079e-09
on O 0 5.269990221989929e-09
their O 0 2.6613191650426415e-09
high O 0 7.005495490375324e-07
heterozygosity O 0 0.004391946364194155
and O 0 4.995737512558662e-08
their O 0 1.931561399715065e-08
location O 0 1.3446597222355194e-06
within O 0 1.598516945477968e-07
10q23 O 0 2.0001580196549185e-05
- O 0 5.603254521702183e-06
q25 O 0 9.041926386998966e-05
near O 0 3.1929212127579376e-05
COL17A1 O 0 0.03497251868247986
. O 0 8.10539313533809e-06

Three O 0 2.2833933144283947e-07
families O 0 5.107043676844114e-08
shared O 0 3.210122301311458e-08
microsatellite O 0 5.213177587393147e-07
polymorphisms O 0 6.625475066357467e-07
covering O 0 7.735231406513776e-07
at O 0 5.24306287275067e-08
most O 0 6.8575052303287976e-09
19 O 0 7.198281082310132e-08
cM O 0 5.98424847453316e-08
, O 0 8.792116479305889e-10
whereas O 0 4.274529619152645e-09
the O 0 6.699238941365593e-09
others O 0 5.933623370424357e-09
shared O 0 3.6378557943805845e-09
smaller O 0 3.372581103278094e-09
regions O 0 3.3330478377280315e-09
consistent O 0 2.4823888722380616e-08
with O 0 1.0631017177686886e-09
cross O 0 6.985055023278619e-08
- O 0 1.243106311221709e-07
over O 0 2.0856735005736482e-08
events O 0 5.588409290879781e-09
during O 0 2.407169352736105e-09
passage O 0 1.4604070841528483e-08
of O 0 2.472945626053047e-09
this O 0 2.8353583370055446e-10
mutation O 0 1.7863538426254877e-09
through O 0 3.0096189984618604e-09
several O 0 1.2429160811677775e-08
generations O 0 3.472516993952013e-07
. O 0 1.0122024605152546e-06

These O 0 1.3070376780888182e-07
results O 0 9.33191230956254e-08
indicate O 0 9.150335245067254e-08
that O 0 2.928540299151905e-09
4003delTC O 0 8.449741528693266e-08
occurs O 0 2.9554974023682234e-09
on O 0 5.250966328418372e-09
a O 0 2.237360963164292e-09
single O 0 1.1678076283772043e-08
ancestral O 0 3.917551794074825e-07
allele O 0 3.4533522352830914e-07
. O 0 7.614815444867418e-08
. O 0 4.71218442044119e-07

The O 0 5.079966285848059e-06
haptoglobin O 0 7.283238664967939e-05
- O 0 1.9131425688101444e-06
gene O 0 1.5370822836757725e-07
deletion O 0 2.222896142711761e-07
responsible O 0 1.1946971767429204e-07
for O 0 6.767888294234581e-08
anhaptoglobinemia B-Disease 0 0.00012482679449021816
. O 0 1.8140377733288915e-06

We O 0 2.502603706489026e-07
have O 0 5.848967088439849e-09
found O 0 2.1764889890363293e-09
an O 0 8.886648084072135e-10
allelic O 0 7.798548296023e-08
deletion O 0 3.961923411566204e-08
of O 0 1.0349048551461237e-07
the O 0 1.1008817324409392e-07
haptoglobin O 0 2.7732125090551563e-05
( O 0 4.030883005157193e-08
Hp O 0 5.058078755837414e-08
) O 0 2.778757224319861e-10
gene O 0 8.326924150203752e-10
from O 0 2.00927630089609e-08
an O 0 3.439716067532572e-09
individual O 0 2.709381830001689e-09
with O 0 2.441834290323186e-08
anhaptoglobinemia B-Disease 0 0.03266939893364906
. O 0 1.6729640037738136e-06

The O 0 1.4499538565360126e-06
Hp O 0 1.395890336652883e-07
gene O 0 1.0568893316076355e-08
cluster O 0 5.6388209657143307e-08
consists O 0 1.6357648568998684e-09
of O 0 7.329335471872866e-10
coding O 0 1.705286400977002e-08
regions O 0 3.626765376907315e-08
of O 0 7.99034580722946e-07
the O 0 8.119870642531168e-08
alpha O 0 1.475616606683161e-08
chain O 0 5.152124948892833e-09
and O 0 5.572494132799477e-10
beta O 0 7.585500227946795e-09
chain O 0 5.843725947585199e-09
of O 0 7.84642306683736e-09
the O 0 3.402056947265919e-08
haptoglobin O 0 7.712308729423967e-07
gene O 0 1.1370538288701937e-08
( O 0 4.245408913305937e-09
Hp O 0 9.143422907698096e-09
) O 0 6.141361724720795e-11
and O 0 1.4922975355435852e-10
of O 0 4.2394212584895286e-09
the O 0 6.9241141709142084e-09
alpha O 0 8.040374588347277e-09
chain O 0 2.785619956924279e-09
and O 0 9.246575727317463e-10
beta O 0 9.950946733283672e-09
chain O 0 9.850183779747113e-09
of O 0 1.840126451213564e-08
the O 0 3.59737519772807e-08
haptoglobin O 0 1.3540446843762766e-06
- O 0 1.2813880800877087e-07
related O 0 7.470836749234877e-08
gene O 0 2.1924728699218576e-08
( O 0 1.477041422504044e-08
Hpr O 0 3.5870093029188865e-07
) O 0 1.3145142752080119e-09
, O 0 9.354073071676794e-10
in O 0 9.467368000670717e-10
tandem O 0 6.715399791801246e-08
from O 0 2.6329503910460517e-08
the O 0 1.4785219093482738e-07
5 O 0 4.897794383396104e-07
side O 0 2.860009317373624e-06
. O 0 2.3298737232835265e-06

Southern O 0 5.488436727318913e-06
blot O 0 3.1906915864965413e-06
and O 0 1.8436011828271148e-08
PCR O 0 1.1349936812621308e-07
analyses O 0 2.628755346734124e-08
have O 0 7.644829769226646e-10
indicated O 0 3.8673619862095165e-09
that O 0 1.0732800065360593e-10
the O 0 4.5602110976261656e-10
individual O 0 2.0913998310945203e-10
with O 0 3.937488668448452e-10
anhaptoglobinemia B-Disease 0 1.3777149661109434e-06
was O 0 4.933334629697583e-09
homozygous O 0 4.43300285368764e-10
for O 0 3.709342277780081e-10
the O 0 2.045745572942792e-09
gene O 0 1.3609369187150833e-09
deletion O 0 5.592077467753143e-09
and O 0 4.633446681889808e-10
that O 0 3.783758306674656e-10
the O 0 3.1398039723740112e-09
gene O 0 1.7615929825964827e-09
deletion O 0 3.897686617904128e-09
was O 0 7.18957915424312e-09
included O 0 7.957056680218955e-10
at O 0 2.926262121505374e-09
least O 0 1.180291087088392e-09
from O 0 2.2823116729853155e-09
the O 0 3.871871268046334e-09
promoter O 0 1.2664619930546905e-07
region O 0 5.5769337592437296e-08
of O 0 6.475033842434641e-08
Hp O 0 3.612977650391258e-08
to O 0 4.820432941698982e-09
Hpr O 0 4.953855068379198e-07
alpha O 0 2.154122213937626e-08
but O 0 1.5458100355303372e-09
not O 0 9.699482328429099e-10
to O 0 1.5731123070850117e-08
Hpr O 0 3.961995389545336e-06
beta O 0 9.326286658506433e-07
( O 0 1.1217599649171461e-07
Hpdel O 0 8.0168556451099e-06
) O 0 7.72203918586456e-08
. O 0 4.6373855866477243e-07

In O 0 4.1917509463473834e-08
addition O 0 3.799571146601011e-08
, O 0 4.9916493161106246e-09
we O 0 1.024791917991763e-09
found O 0 5.008011227936038e-10
seven O 0 7.934762846772969e-10
individuals O 0 1.7982149103090705e-10
with O 0 3.738563347788215e-10
hypohaptoglobinemia B-Disease 0 4.486716989049455e-07
in O 0 5.626031307492951e-10
three O 0 5.241497791352856e-10
families O 0 7.772167909259053e-10
, O 0 2.5893159838474844e-10
and O 0 2.6170363098820815e-10
the O 0 4.401091935335444e-09
genotypes O 0 2.8237963078936446e-07
of O 0 1.3269699650209077e-07
six O 0 1.5882774206943395e-08
of O 0 7.362071841043871e-08
the O 0 4.074774295759198e-08
seven O 0 5.581219042483099e-09
individuals O 0 1.313366415622852e-09
were O 0 1.7039305078014877e-08
found O 0 3.090371514247181e-09
to O 0 7.042885385999398e-09
be O 0 8.248762384255315e-08
Hp2 O 0 0.00015968625666573644
/ O 0 3.200951687176712e-05
Hpdel O 0 0.0001154621786554344
. O 0 2.9419218208204256e-06

The O 0 6.388615361174743e-07
phenotypes O 0 2.404017550361459e-06
and O 0 3.7885712345087086e-08
genotypes O 0 8.253497867372062e-07
in O 0 4.308565060284764e-09
one O 0 3.503212386846144e-09
of O 0 2.0973451864136905e-09
these O 0 6.016953602028252e-10
three O 0 1.2286882622447592e-09
families O 0 5.414964032723901e-09
showed O 0 2.0286188728846355e-08
the O 0 9.915725129872044e-09
father O 0 3.2872701893893463e-08
to O 0 3.881698962260316e-09
be O 0 2.354154915451545e-08
hypohaptoglobinemic B-Disease 0 1.2659522326430306e-05
( O 0 2.537179000228207e-08
Hp2 O 0 1.0907942851190455e-06
) O 0 3.6569800521135676e-09
and O 0 1.8953002722810197e-08
Hp2 O 0 5.023537596571259e-06
/ O 0 3.222373550215707e-07
Hpdel O 0 6.065150046197232e-06
, O 0 1.0042162656986875e-08
the O 0 6.17835524963084e-08
mother O 0 2.294643586253642e-08
to O 0 5.544412484681516e-09
be O 0 1.5673560227469352e-08
Hp2 O 0 2.3927959773573093e-06
- O 0 2.206203220112002e-07
1 O 0 2.2193333393261128e-07
and O 0 4.2164646885112234e-08
Hp1 O 0 3.6656349493568996e-06
/ O 0 1.3308149959812e-07
Hp2 O 0 7.267409500855138e-07
, O 0 1.877202837619052e-09
one O 0 1.7927400675077365e-09
of O 0 7.983679495282558e-09
the O 0 9.769427933292718e-09
two O 0 3.217623723017482e-09
children O 0 2.254160635928315e-09
to O 0 3.1601357086685766e-09
be O 0 5.716760043128488e-08
hypohaptoglobinemic B-Disease 0 5.470496398629621e-05
( O 0 5.0239837179333335e-08
Hp2 O 0 4.9565474000701215e-06
) O 0 3.277576876570265e-09
and O 0 1.0797283067631724e-08
Hp2 O 0 5.680983122147154e-06
/ O 0 1.9837574427583604e-07
Hpdel O 0 5.864223112439504e-06
, O 0 4.335703351898701e-09
and O 0 2.2972919122565827e-09
the O 0 5.749331677407099e-09
other O 0 5.696848770497809e-09
child O 0 9.585258808897379e-09
to O 0 2.420313283124642e-09
be O 0 1.6173098416061293e-08
Hp1 O 0 6.4982705225702375e-06
and O 0 4.87383502445482e-08
Hp1 O 0 3.180270505254157e-05
/ O 0 1.5275063560693525e-06
Hpdel O 0 2.0578629118972458e-05
, O 0 1.1049708703581018e-08
showing O 0 3.63093910493717e-08
an O 0 3.4264169279651924e-09
anomalous O 0 8.320722599819419e-07
inheritance O 0 1.0141154689335963e-06
of O 0 7.053938020362693e-07
Hp O 0 3.5589187064033467e-07
phenotypes O 0 2.0423591706730804e-07
in O 0 4.9732031826010825e-09
the O 0 3.636088408143223e-08
child O 0 8.57230233464179e-08
with O 0 2.281368338685752e-08
Hp1 O 0 0.0005702596972696483
. O 0 3.1495580969931325e-06

The O 0 9.611241694074124e-06
Hp2 O 0 0.0003016156842932105
/ O 0 4.310615622671321e-06
Hpdel O 0 3.737530278158374e-06
individuals O 0 7.1377392885096924e-09
had O 0 9.632562303352188e-09
an O 0 1.46501799580534e-09
extremely O 0 4.963007338432135e-09
low O 0 4.616796189793604e-08
level O 0 8.030400522329728e-08
of O 0 1.5079592685651733e-07
Hp O 0 8.112502314361336e-08
( O 0 4.026332156570334e-09
mean O 0 4.2524295196244566e-08
+ O 0 8.288142083756611e-08
/ O 0 6.840225097448638e-08
- O 0 1.2008473504465655e-07
SD O 0 1.137910658144392e-06
= O 0 2.9635239684466796e-07
0 O 0 1.3884832128496782e-07
. O 0 1.5137075592974725e-08
049 O 0 3.1761629770699074e-07
+ O 0 5.744424314002572e-08
/ O 0 4.570220824007265e-08
- O 0 7.849315863950324e-08
0 O 0 8.594223288582725e-08
. O 0 1.3448102187396671e-08
043 O 0 6.043644020792271e-07
mg O 0 3.6558807892106415e-07
/ O 0 2.0290213953444436e-08
ml O 0 9.17714260140201e-09
; O 0 1.6608272535023616e-09
n O 0 3.4836624696055196e-09
= O 0 8.246792582156104e-09
6 O 0 1.6597702767739975e-08
) O 0 4.954716845140261e-11
, O 0 6.914670919178079e-11
compared O 0 1.359799772782111e-10
with O 0 1.888729624088814e-11
the O 0 1.6150801807057746e-09
level O 0 6.8867476166190045e-09
( O 0 2.3171067842220339e-10
1 O 0 6.370707072989035e-09
. O 0 8.755851599318021e-10
64 O 0 8.861839262408466e-09
+ O 0 5.783692191840828e-09
/ O 0 6.415654230096379e-09
- O 0 1.454735709671695e-08
1 O 0 1.335643506905626e-08
. O 0 2.466868265216249e-09
07 O 0 3.48865114574437e-08
mg O 0 1.0884815537792747e-07
/ O 0 7.610151619985572e-09
ml O 0 2.113286878824283e-09
) O 0 3.021441083439491e-11
obtained O 0 1.1284326806304534e-09
from O 0 3.783615643015992e-09
52 O 0 4.650912188708389e-08
healthy O 0 1.2131518012381548e-08
volunteers O 0 1.176320640894346e-08
having O 0 7.340755114881858e-09
phenotype O 0 2.1660110860466375e-07
Hp2 O 0 9.174589195026783e-07
, O 0 2.3363238010887244e-09
whereas O 0 5.615516940338239e-09
the O 0 3.937671078091398e-09
serum O 0 2.202103743798034e-08
Hp O 0 1.2705600127560501e-08
level O 0 4.088850147354606e-08
of O 0 1.603496890822953e-08
an O 0 1.8452817052150294e-09
individual O 0 1.472385546819055e-09
with O 0 6.190397083827293e-09
Hp1 O 0 4.0328413888346404e-05
/ O 0 1.9284159407106927e-06
Hpdel O 0 6.652936917816987e-06
was O 0 5.143909334037744e-07
0 O 0 1.5138683693294297e-06
. O 0 9.300653118771152e-07

50 O 0 3.5717412174562924e-06
mg O 0 4.585956958180759e-06
/ O 0 9.613899010219029e-08
ml O 0 3.878770016285671e-08
, O 0 6.356017934194824e-10
which O 0 1.6673712410764097e-10
was O 0 1.484955713948466e-09
approximately O 0 3.8691161385884243e-10
half O 0 6.441301381165943e-10
the O 0 1.3714852586943493e-09
level O 0 3.230477929605513e-08
of O 0 3.071445320301791e-08
Hp O 0 2.6959957821759417e-08
in O 0 1.2540575244912588e-09
control O 0 1.3494094730504003e-08
sera O 0 3.2363803370571986e-07
from O 0 1.9469847956088415e-09
the O 0 1.7637253435509592e-08
Hp1 O 0 2.86257977677451e-06
phenotype O 0 1.6603536323600565e-07
( O 0 6.274271768802464e-09
1 O 0 1.0058459309902901e-07
. O 0 2.1387778659232026e-08
26 O 0 1.9634134673651715e-07
+ O 0 4.907846573587449e-08
/ O 0 6.683007569563415e-08
- O 0 9.762576524963151e-08
0 O 0 1.0067826394788426e-07
. O 0 9.93312099240029e-09
33 O 0 9.651748200667498e-08
mg O 0 1.1642541153378261e-07
/ O 0 1.2718645692189057e-08
ml O 0 1.1756386975037003e-08
; O 0 2.3024551154549044e-09
n O 0 8.472137658088741e-09
= O 0 2.7760107101926224e-08
9 O 0 6.56871392834546e-08
) O 0 5.612290632228678e-10
, O 0 1.5343449843996382e-09
showing O 0 1.2590312792326586e-08
a O 0 6.782332473420638e-09
gene O 0 1.6479882347653074e-08
- O 0 3.2144731676453375e-07
dosage O 0 7.890201345617243e-07
effect O 0 8.055019407038344e-07
. O 0 4.742403518775973e-07

The O 0 2.5705415396259923e-07
other O 0 5.952750115056915e-08
allele O 0 3.1071175499164383e-07
( O 0 1.2250617409392817e-08
Hp2 O 0 8.066566579145729e-07
) O 0 8.053140376773626e-10
of O 0 2.4582917923510195e-09
individuals O 0 4.0979342141866937e-10
with O 0 2.3766304479977407e-09
Hp2 O 0 2.267979107273277e-05
/ O 0 2.0196549144202436e-07
Hpdel O 0 1.313965526605898e-06
was O 0 1.2759246992288809e-08
found O 0 1.2127943094242255e-10
to O 0 1.1127315735492971e-10
have O 0 2.270457155617578e-10
, O 0 4.32150065732273e-10
in O 0 5.048213513880739e-10
all O 0 4.142620912972461e-09
exons O 0 1.2045819630657206e-07
, O 0 1.0446219889104214e-08
no O 0 1.1264506660779716e-08
mutation O 0 4.000000775050694e-09
, O 0 7.066159324331522e-10
by O 0 6.480798120378495e-10
DNA O 0 1.1087375639817765e-07
sequencing O 0 5.367080007090408e-07
. O 0 1.0944538644253043e-06

On O 0 3.2843689723449643e-07
the O 0 1.1038248537431627e-08
basis O 0 2.1012141360188252e-08
of O 0 5.031566718827207e-09
the O 0 4.268704500987042e-09
present O 0 2.052812364539136e-09
study O 0 6.968215449099091e-10
, O 0 1.7439737154401058e-10
the O 0 7.200059437550976e-10
mechanism O 0 1.9671427153866716e-08
of O 0 2.3559607598144794e-08
anhaptoglobinemia B-Disease 0 8.314729711855762e-06
and O 0 5.090265542406769e-09
the O 0 7.730405648942451e-09
mechanism O 0 6.886199344080524e-08
of O 0 2.1299436880894973e-08
anomalous O 0 4.726447059510974e-06
inheritance O 0 1.1153078958159313e-06
of O 0 7.649518352081941e-07
Hp O 0 4.5928098302283615e-07
phenotypes O 0 1.8523548988014227e-06
were O 0 1.7065562474272156e-07
well O 0 1.5588389601361996e-07
explained O 0 2.346637984373956e-06
. O 0 2.2794276901549893e-06

However O 0 1.830619112297427e-06
, O 0 5.407711256566472e-08
the O 0 2.8677384023012564e-08
mechanism O 0 8.634360142423247e-07
of O 0 5.760981025559886e-07
hypohaptoglobinemia B-Disease 1 0.931759238243103
remains O 0 5.423798211268149e-05
unknown O 0 0.0003414727689232677

ATM O 0 0.00015184930816758424
mutations O 0 4.217343757773051e-06
and O 0 1.6255181378710404e-07
phenotypes O 0 2.4006976673263125e-06
in O 0 9.732346484270238e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 4.4951201516596484e-07
in O 0 9.68785274224615e-10
the O 0 2.1750155010380468e-09
British O 0 2.096985030064502e-09
Isles O 0 5.06630204455405e-09
: O 0 3.703764239748608e-10
expression O 0 2.887187600109087e-09
of O 0 5.819156267961034e-09
mutant O 0 2.021612210967305e-08
ATM O 0 6.451672902585415e-07
and O 0 6.249273987180004e-09
the O 0 8.663458395119505e-09
risk O 0 7.545201441416793e-08
of O 0 1.0210545298150464e-07
leukemia B-Disease 1 0.9999997615814209
, O 0 5.234097898210166e-06
lymphoma B-Disease 1 1.0
, O 1 0.9999493360519409
and O 1 0.9999998807907104
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 5.288417014526203e-06

We O 0 1.236562923168094e-07
report O 0 4.109609008651205e-08
the O 0 8.53765680375318e-09
spectrum O 0 1.3824990219291067e-07
of O 0 4.085482530058471e-08
59 O 0 1.7132060747826472e-07
ATM O 0 2.5586505216779187e-06
mutations O 0 1.0300957598019522e-07
observed O 0 4.841305667468987e-08
in O 0 1.003136507193858e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.99992835521698
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.932271675997299e-09
patients O 0 9.729740346742233e-10
in O 0 3.3218000572432516e-10
the O 0 5.4508282332221825e-09
British O 0 1.4267400594292212e-08
Isles O 0 2.4437312617919815e-07
. O 0 3.2473622013640124e-07

Of O 0 8.767181498114951e-06
51 O 0 6.384019798133522e-06
ATM O 0 1.4300906514108647e-05
mutations O 0 1.9034121123695513e-07
identified O 0 4.0001705059466985e-08
in O 0 7.20580206614585e-10
families O 0 1.1928814602768512e-09
native O 0 4.0502615150650456e-10
to O 0 3.6850628104545535e-10
the O 0 6.07163652688314e-09
British O 0 1.1269405852942782e-08
Isles O 0 5.6156270744622816e-08
, O 0 7.264704837695035e-09
11 O 0 8.629819348016099e-08
were O 0 5.914248646377018e-08
founder O 0 2.71817839347932e-07
mutations O 0 1.9512386373321533e-08
, O 0 4.233312367318831e-09
and O 0 2.2406920763273774e-09
2 O 0 4.887332849534687e-08
of O 0 1.6839154071135454e-08
these O 0 3.7024594501389174e-09
11 O 0 3.228654321674185e-08
conferred O 0 2.985618507977961e-08
a O 0 2.5202007147839822e-09
milder O 0 2.0207608031341806e-07
clinical O 0 5.560361504564071e-09
phenotype O 0 1.2679188365893879e-08
with O 0 4.487534233099666e-10
respect O 0 8.385485195105957e-09
to O 0 1.729522836058095e-08
both O 0 5.707923378395208e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 2.6288236654181674e-07
cellular O 0 1.3951066648587584e-06
features O 0 9.984722737499396e-07
. O 0 1.066508048097603e-06

We O 0 2.5236755618607276e-07
report O 0 1.7031776167186763e-07
, O 0 2.8425124476427754e-09
in O 0 1.4225004507650851e-09
two O 0 1.829798357277923e-08
A B-Disease 1 1.0
- I-Disease 1 0.9796099662780762
T I-Disease 1 1.0
families O 0 1.2758522416334017e-07
, O 0 3.4736702403392883e-09
an O 0 4.396293107333804e-09
ATM O 0 4.609198356320121e-07
mutation O 0 3.1972778202771224e-08
( O 0 3.625864719580818e-09
7271T O 0 1.2624789746951137e-07
- O 0 3.926588121316854e-08
- O 0 6.900675231236164e-08
> O 0 2.465016635255779e-08
G O 0 1.094708963478297e-07
) O 0 3.4194946874066545e-10
that O 0 1.6371372313361832e-10
may O 0 3.9752950931060127e-10
be O 0 1.4823967053878562e-10
associated O 0 1.7027959042792418e-09
with O 0 1.1108527986358752e-10
an O 0 3.6855760110476865e-10
increased O 0 4.8585180323357235e-09
risk O 0 2.9659799949399712e-08
of O 0 3.1274637990463816e-07
breast B-Disease 0 9.158852662949357e-06
cancer I-Disease 0 4.55547819910862e-07
in O 0 4.777246931375601e-10
both O 0 3.4623854894277883e-09
homozygotes O 0 1.4808559001266985e-07
and O 0 3.539426751686392e-09
heterozygotes O 0 9.168713432927689e-08
( O 0 2.3653428105063767e-09
relative O 0 4.340695340943057e-07
risk O 0 4.246034635002616e-08
12 O 0 3.55864635537273e-08
. O 0 4.643304407636606e-09
7 O 0 6.406192198937788e-08
; O 0 1.9280756546891098e-08
P O 0 1.686768769104674e-06
= O 0 1.2439436147815286e-07
. O 0 1.2451513597966368e-08
0025 O 0 4.574681895519461e-07
) O 0 4.666270703168607e-10
, O 0 2.539800869616471e-10
although O 0 3.6036210127043944e-10
there O 0 4.0633926778887997e-10
is O 0 8.787065519655357e-11
a O 0 1.485989109539787e-10
less O 0 1.0770497826939618e-09
severe O 0 4.616699698090088e-06
A B-Disease 1 1.0
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
phenotype O 0 1.3794561937174876e-08
in O 0 8.020469705050104e-11
terms O 0 7.90732646027692e-10
of O 0 4.6263995412409997e-10
the O 0 7.615258423854243e-10
degree O 0 4.700532585388828e-08
of O 0 8.966644315933081e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 9.332638001069427e-06

This O 0 2.9444800020428374e-07
mutation O 0 1.8738882090474362e-07
( O 0 3.296864647950315e-08
7271T O 0 3.9594539202880696e-07
- O 0 9.744606188633043e-08
- O 0 7.874312757394364e-08
> O 0 2.537353260834152e-08
G O 0 1.0248886184172079e-07
) O 0 3.110025015296003e-10
also O 0 5.297982538787771e-11
allows O 0 6.378287481512146e-11
expression O 0 1.2617855649210696e-09
of O 0 3.734375031427817e-09
full O 0 4.461608416050922e-09
- O 0 8.058767875240846e-09
length O 0 1.7970502863562388e-09
ATM O 0 1.4866871822505345e-07
protein O 0 6.519088202594503e-08
at O 0 1.2464369092413108e-08
a O 0 9.739766770877623e-10
level O 0 4.285934718240014e-09
comparable O 0 5.616180853706965e-09
with O 0 1.3263759535142583e-10
that O 0 3.4802341564166284e-10
in O 0 1.7453056777583242e-09
unaffected O 0 4.1436908304604003e-07
individuals O 0 1.065412291723078e-08
. O 0 6.96559027346666e-07

In O 0 6.245082317946071e-08
addition O 0 2.464471293706083e-08
, O 0 6.247617978516473e-09
we O 0 2.0683486035011356e-09
have O 0 7.656912881515154e-10
studied O 0 1.8743095964168788e-08
18 O 0 1.746727775753243e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.692916881296696e-08
, O 0 1.011538075523788e-09
in O 0 4.19671464246818e-10
15 O 0 1.0661603155881494e-08
families O 0 5.203419028987355e-09
, O 0 2.1617767576032065e-09
who O 0 4.1983820864288646e-09
developed O 0 3.8328860085812266e-08
leukemia B-Disease 1 0.9999996423721313
, O 0 1.7452554175179102e-06
lymphoma B-Disease 1 1.0
, O 0 5.158509566172143e-07
preleukemic O 1 0.9273338317871094
T O 0 0.00027488256455399096
- O 0 1.0084485438710544e-05
cell O 0 0.003729079617187381
proliferation O 1 0.8192089796066284
, O 0 1.0588081522655557e-08
or O 0 1.5447149337433075e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.7839942617902125e-07
mostly O 0 3.025771277975764e-08
in O 0 4.369566930506608e-09
childhood O 0 3.5669618227984756e-06
. O 0 1.1342053767293692e-06

A O 0 8.03658076620195e-06
wide O 0 1.1124695902253734e-06
variety O 0 1.350832832258675e-07
of O 0 6.091695325949331e-08
ATM O 0 1.6311533954649349e-06
mutation O 0 1.1932370647116386e-08
types O 0 8.03523914072457e-09
, O 0 6.790716877702607e-10
including O 0 6.38661734608803e-10
missense O 0 2.619746339860285e-07
mutations O 0 3.519502200788338e-08
and O 0 2.1611636924490085e-08
in O 0 9.343200879641245e-09
- O 0 1.5924945273582125e-07
frame O 0 1.1057983329010312e-06
deletions O 0 4.763548986375099e-07
, O 0 2.6385910345538832e-08
were O 0 5.286815607519202e-08
seen O 0 4.924340402112648e-08
in O 0 2.5327488994975056e-09
these O 0 1.3615608196460016e-08
patients O 0 1.0206476019902766e-07
. O 0 6.656489404122112e-07

We O 0 3.326178443785466e-07
also O 0 2.949056998602373e-08
show O 0 2.9780868882056666e-09
that O 0 2.6286722798474216e-10
25 O 0 3.741190468531386e-09
% O 0 3.194872699729956e-10
of O 0 1.023385487464168e-09
all O 0 1.8914290578209147e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.4456279018304485e-07
carried O 0 2.375770691287471e-08
in O 0 3.342278676043975e-09
- O 0 8.817365682034506e-08
frame O 0 5.527773510038969e-07
deletions O 0 4.0104771414917195e-07
or O 0 2.7021270554428156e-08
missense O 0 2.2208577377114125e-07
mutations O 0 1.6608565189812907e-08
, O 0 1.4892614919048697e-09
many O 0 5.878041386964128e-10
of O 0 2.74539524447448e-09
which O 0 2.997043724306536e-10
were O 0 1.1716154713070637e-09
also O 0 2.067941373695703e-10
associated O 0 1.8611667762513662e-09
with O 0 3.2998620502766585e-10
expression O 0 5.800177405035356e-08
of O 0 1.2512894898009108e-07
mutant O 0 6.972368851165811e-07
ATM O 0 3.863139863824472e-05
protein O 0 2.0916328139719553e-05
. O 0 2.0364479951240355e-06

The O 0 2.397126536379801e-06
DMPK O 0 0.0021420277189463377
gene O 0 5.639702749249409e-07
of O 0 1.7703907815302955e-06
severely O 1 0.997512698173523
affected O 1 0.7451199889183044
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.56783042056486e-05
is O 0 5.7484328408463625e-09
hypermethylated O 0 8.227344210354204e-07
proximal O 0 1.0152747336178436e-06
to O 0 1.2579750574559512e-08
the O 0 1.0963429986077244e-07
largely O 0 2.0051956539646199e-07
expanded O 0 1.738324044708861e-07
CTG O 0 3.068516525672749e-05
repeat O 0 2.8219969863130245e-06
. O 0 2.9753457511105807e-06

Using O 0 5.494483161783137e-07
methylation O 0 3.655507725852658e-06
- O 0 3.018986035385751e-06
sensitive O 0 2.8021847242598596e-07
restriction O 0 4.049099189273875e-08
enzymes O 0 2.9609212859327272e-08
, O 0 3.5969345280051357e-09
we O 0 7.340835717073446e-10
characterized O 0 1.3226527650900266e-09
the O 0 2.904531060110571e-09
methylation O 0 4.5453667496531125e-08
pattern O 0 1.63809545483673e-07
on O 0 2.1826341622954715e-08
the O 0 5.2610311662704135e-09
5 O 0 1.1210664396799075e-08
side O 0 2.1250745163570173e-08
of O 0 2.807383658876006e-08
the O 0 1.252762871217783e-07
CTG O 0 1.9527746189851314e-05
repeat O 0 3.0396307693081326e-08
in O 0 3.904986556335643e-09
the O 0 2.4997598657705566e-08
DMPK O 0 1.0362502507632598e-05
gene O 0 4.131857522793325e-09
of O 0 2.1738346234201344e-08
normal O 0 8.043856247752501e-09
individuals O 0 2.650993036201754e-10
and O 0 1.164968344014028e-09
of O 0 3.133139969691001e-09
patients O 0 1.4759593547353234e-09
affected O 0 2.8554252295975857e-08
with O 0 5.269480141123495e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.1006984474734054e-08
showing O 0 4.292007105277662e-08
expansions O 0 1.1775039610029125e-07
of O 0 1.0674854422632052e-07
the O 0 1.1057512949719239e-07
repetitive O 0 7.38827736768144e-07
sequence O 0 3.844418472453981e-07
. O 0 1.5186966493274667e-06

The O 0 1.5704239331171266e-06
gene O 0 2.6929023988486733e-07
segment O 0 3.3105641250585904e-07
analyzed O 0 2.8107377758601615e-08
corresponds O 0 1.625716095077223e-08
to O 0 2.422608558205752e-09
the O 0 2.7198993279853312e-08
genomic O 0 6.108024308559834e-07
SacI O 0 1.2636242900043726e-05
- O 0 4.377661184662429e-07
HindIII O 0 2.4515140921721468e-06
fragment O 0 2.044647118282228e-07
carrying O 0 1.7803110097247554e-07
exons O 0 7.04252499872382e-07
11 O 0 1.6013152617233573e-06
- O 0 9.626153314457042e-07
15 O 0 1.1370253787390538e-06
. O 0 8.617208777650376e-07

There O 0 4.817907779397501e-07
is O 0 3.83927378777571e-08
constitutive O 0 1.190630314340524e-06
methylation O 0 1.3872313502361067e-06
in O 0 2.5158033167826943e-07
intron O 0 1.79776889126515e-05
12 O 0 1.3873609532311093e-06
at O 0 3.4417585226265146e-08
restriction O 0 2.5452056462427208e-08
sites O 0 2.1080541756646198e-08
of O 0 3.165246553749057e-08
SacII O 0 2.1286173250700813e-06
and O 0 5.293415128448942e-08
HhaI O 0 4.063213964400347e-06
, O 0 1.0014924001211511e-08
localized O 0 2.9991315386723727e-07
1 O 0 9.304914527774599e-08
, O 0 2.639717333607905e-09
159 O 0 1.5263307062696185e-08
- O 0 2.1991992227299306e-08
1 O 0 4.7989139773108036e-08
, O 0 4.038946510576125e-09
232 O 0 1.790266956902542e-08
bp O 0 2.0512478826617553e-08
upstream O 0 1.1194899229849398e-07
of O 0 3.416225524688343e-08
the O 0 1.915627905191286e-07
CTG O 0 8.021084795473143e-06
repeat O 0 5.879673636854932e-08
, O 0 3.46796391603732e-09
whereas O 0 2.3265140924877414e-09
most O 0 2.147262367913072e-09
, O 0 2.074467542190206e-10
if O 0 3.979930551789579e-10
not O 0 5.755714793664879e-10
all O 0 2.0701798053579523e-09
, O 0 1.4720289431835454e-09
of O 0 7.244281174934031e-09
the O 0 5.169705552532378e-09
other O 0 1.9194006384282147e-09
sites O 0 5.367285993429505e-08
of O 0 1.2802081528207054e-07
SacII O 0 3.069588274229318e-06
, O 0 2.7765402421664476e-08
HhaI O 0 3.0884164061717456e-06
, O 0 1.4354748500977621e-08
and O 0 1.3500710771552349e-08
HpaII O 0 9.0174944489263e-07
in O 0 2.090866590975793e-09
this O 0 9.318742444364148e-10
region O 0 1.9796237538116657e-08
are O 0 2.416747468814151e-09
unmethylated O 0 6.077281113903155e-07
, O 0 2.5793749358626883e-09
in O 0 6.834363630581208e-10
normal O 0 4.680490217623401e-09
individuals O 0 2.202488053049123e-10
and O 0 1.1744233363586432e-09
most O 0 2.4914854623858673e-09
of O 0 1.656146331185937e-08
the O 0 3.735502218660258e-08
patients O 0 6.117345208167535e-08
. O 0 3.7396156926661206e-07

In O 0 3.641606127757768e-08
a O 0 6.219736281565247e-09
number O 0 7.538810464779999e-09
of O 0 6.897740689737475e-08
young O 0 9.636424636028096e-08
and O 0 2.403839438613886e-08
severely O 0 1.9242832422605716e-05
affected O 0 5.663201463335099e-08
patients O 0 2.7652287126755937e-09
, O 0 1.982932013033789e-10
however O 0 1.4792173042010859e-09
, O 0 1.9541306073289633e-10
complete O 0 1.3992478287150334e-09
methylation O 0 3.810529847214639e-08
of O 0 7.221962050607544e-08
these O 0 3.4379712410270713e-09
restriction O 0 2.3612511057535812e-08
sites O 0 3.772549206360054e-08
was O 0 1.6181768813794406e-08
found O 0 8.138686391490069e-10
in O 0 8.823901609389395e-10
the O 0 1.049234743533134e-08
mutated O 0 3.8279151226561225e-07
allele O 0 1.063775584952964e-06
. O 0 9.015078603624715e-07

In O 0 4.583349877407272e-08
most O 0 1.1522050868961742e-08
of O 0 1.1916450048943261e-08
these O 0 1.3647580843212381e-09
patients O 0 8.074488300202631e-10
, O 0 1.4765273725902972e-10
the O 0 8.497541559293609e-10
onset O 0 0.0004612445191014558
of O 0 1.2148536399081422e-08
the O 0 3.424151628905747e-08
disease O 1 0.9932310581207275
was O 0 2.6862573577091098e-05
congenital O 1 1.0
. O 0 4.016105322079966e-06

Preliminary O 0 5.660508122673491e-06
in O 0 3.8817455561002134e-07
vivo O 0 3.301114020359819e-06
footprinting O 0 1.1237123544560745e-05
data O 0 8.241622850846397e-08
gave O 0 5.0478529800557226e-08
evidence O 0 3.5676784193583444e-08
for O 0 3.138965976035024e-09
protein O 0 2.2650354480902024e-08
- O 0 5.87002313423568e-09
DNA O 0 8.61264837226372e-09
contact O 0 1.9391805494706205e-08
in O 0 1.7571099020230463e-09
normal O 0 1.425592728310221e-07
genes O 0 3.278059779177056e-08
at O 0 3.05948830714442e-08
an O 0 8.660584249753356e-09
Sp1 O 0 2.992928500589187e-07
consensus O 0 4.10332710032435e-08
binding O 0 2.5887604948593435e-08
site O 0 1.248038330459167e-07
upstream O 0 6.265227057156153e-07
of O 0 1.0985135645569244e-07
the O 0 4.1645051851446624e-07
CTG O 0 6.41636288492009e-05
repeat O 0 6.996188517405244e-08
and O 0 3.755832977958562e-09
for O 0 3.889938371415269e-10
a O 0 5.679573478190036e-10
significant O 0 3.3791360820600858e-09
reduction O 0 1.037248154034387e-08
of O 0 3.223189048995323e-09
this O 0 6.03453842451529e-10
interaction O 0 1.7432672194672705e-08
in O 0 2.19613793817075e-09
cells O 0 8.150932373496289e-09
with O 0 1.0970616637351327e-09
a O 0 4.402202335995753e-08
hypermethylated O 0 1.2086768947483506e-05
DMPK O 0 6.490303348982707e-05
gene O 0 7.180851469001936e-08
. O 0 1.5435280431574938e-07
. O 0 6.870743050058081e-07

The O 0 1.33623161673313e-05
hemochromatosis B-Disease 1 1.0
gene O 0 8.985406338979374e-07
product O 0 1.9209184642932087e-07
complexes O 0 6.259380569417772e-08
with O 0 1.4974304018977591e-09
the O 0 1.567744689623396e-08
transferrin O 0 1.0024480161519023e-06
receptor O 0 4.293945494282525e-06
and O 0 3.410971416428765e-08
lowers O 0 1.6791308610208944e-07
its O 0 2.7332058838425155e-09
affinity O 0 1.490171541718155e-08
for O 0 4.62368499043464e-09
ligand O 0 1.9631734176073223e-06
binding O 0 2.857915205822792e-06
. O 0 3.828477019851562e-06

We O 0 6.083747052798572e-07
recently O 0 1.5330944336255925e-07
reported O 0 2.715617419823957e-08
the O 0 1.8057084716360805e-09
positional O 0 1.3544266153076023e-07
cloning O 0 3.149582283867858e-08
of O 0 1.855524800475905e-08
a O 0 5.2683617468574084e-09
candidate O 0 1.6400203861621776e-08
gene O 0 2.398078713383711e-08
for O 0 9.034685035658185e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999932050704956
HFE O 1 0.9999991655349731
. O 0 3.5334840049472405e-06

The O 0 4.2977984548997483e-07
gene O 0 4.8739465796643344e-08
product O 0 1.5037026912523288e-07
, O 0 3.1926450372310455e-09
a O 0 2.6638635741704775e-09
member O 0 4.3395256277278804e-09
of O 0 7.677306257392047e-08
the O 0 1.0247888582171072e-07
major O 0 4.872673571298947e-07
histocompatibility O 0 1.4425858125832747e-06
complex O 0 4.3189177745261986e-07
class O 0 2.6658115714894848e-08
I O 0 3.3636572993600566e-07
- O 0 6.72938753609742e-08
like O 0 8.000417217601807e-09
family O 0 3.089076372475574e-08
, O 0 2.2607398175722437e-09
was O 0 4.6825974209241394e-09
found O 0 2.41784342547291e-10
to O 0 6.721543877041825e-10
have O 0 1.518970393910024e-09
a O 0 1.0197035216208405e-08
mutation O 0 1.7763383652891207e-08
, O 0 1.726250253852868e-08
Cys O 0 1.3460801255860133e-06
- O 0 5.939660923104384e-07
282 O 0 7.011136062828882e-07
- O 0 8.000647540029604e-07
- O 0 1.0431037935632048e-06
> O 0 3.801731622843363e-07
Tyr O 0 2.24314931074332e-06
( O 0 6.268518148999647e-09
C282Y O 0 1.3417388800007757e-07
) O 0 2.4324975367306934e-10
, O 0 9.647207338536745e-11
in O 0 7.65638316635453e-11
85 O 0 4.887740434611487e-09
% O 0 4.539513764889591e-10
of O 0 1.097473889544176e-09
patient O 0 1.3476553206714925e-08
chromosomes O 0 5.600373356173804e-07
. O 0 7.723540420556674e-07

This O 0 4.2350670526047907e-08
mutation O 0 1.837531726778252e-07
eliminates O 0 1.933505927809165e-06
the O 0 2.4540673493333998e-08
ability O 0 1.492395718116768e-08
of O 0 6.689435281259648e-07
HFE O 0 0.007095359265804291
to O 0 9.37590840521807e-08
associate O 0 6.049600642654696e-07
with O 0 1.1196346960673509e-08
beta2 O 0 0.00016599254740867764
- O 0 8.745294508116785e-06
microglobulin O 0 0.0001017521062749438
( O 0 3.928086300675204e-08
beta2m O 0 3.0332596452353755e-06
) O 0 3.0782529858441876e-09
and O 0 3.899917722094415e-09
prevents O 0 3.83392446678954e-08
cell O 0 2.307579507032642e-06
- O 0 1.7002610093186377e-06
surface O 0 7.312290108529851e-06
expression O 0 6.378722332556208e-07
. O 0 2.924568320850085e-07

A O 0 5.9209237406321336e-06
second O 0 1.0958579821362946e-07
mutation O 0 1.9887520963379757e-08
that O 0 1.4877226117704367e-09
has O 0 1.2796065318454453e-09
no O 0 2.372920748783258e-09
effect O 0 2.8207807645230787e-08
on O 0 5.941735281567162e-08
beta2m O 0 5.961628176009981e-06
association O 0 9.634752728970852e-08
, O 0 2.3723472963865788e-08
H63D O 1 0.9351610541343689
, O 0 7.784708877522917e-09
was O 0 2.0244211640374488e-08
found O 0 5.053734097870688e-10
in O 0 2.3366836243710054e-10
eight O 0 3.362522704719595e-09
out O 0 2.2602482108169397e-09
of O 0 5.941800385045326e-09
nine O 0 9.243001031222775e-09
patients O 0 1.3474130700075193e-09
heterozygous O 0 2.2422139700495336e-09
for O 0 2.369515250677523e-09
the O 0 7.608586827245745e-08
C282Y O 0 5.268925178825157e-06
mutant O 0 2.539329898354481e-06
. O 0 1.223156232299516e-06

In O 0 5.5954835431748506e-08
this O 0 1.0893493218588901e-08
report O 0 2.7458993301365808e-08
, O 0 2.1721675569352783e-09
we O 0 1.1020278023465835e-09
demonstrate O 0 1.1961765800094781e-08
in O 0 5.907830669116265e-09
cultured O 0 2.004901347163468e-07
293 O 0 7.862396955715667e-08
cells O 0 4.552967425297538e-08
overexpressing O 0 1.2626285297301365e-06
wild O 0 1.1006318345607724e-07
- O 0 3.4763765199841146e-08
type O 0 2.6905402350507757e-08
or O 0 1.814160199842263e-08
mutant O 0 1.2870366106199072e-07
HFE O 0 1.0636152865117765e-06
proteins O 0 3.23790327882989e-09
that O 0 1.0357253943382716e-09
both O 0 1.7047913081214006e-09
the O 0 1.1702335989127732e-08
wild O 0 2.781008134888907e-08
- O 0 3.576426621521023e-08
type O 0 1.9280835772406135e-07
and O 0 4.989291255697026e-07
H63D O 1 0.9999589920043945
HFE O 0 6.0428614233387634e-05
proteins O 0 7.578981353617564e-08
form O 0 4.4632617601791935e-08
stable O 0 2.8120683737142826e-07
complexes O 0 2.9456277417239107e-08
with O 0 2.8002908880608857e-09
the O 0 5.7435041611597626e-08
transferrin O 0 5.124625204189215e-06
receptor O 0 2.4402092094533145e-05
( O 0 2.4733532200116315e-07
TfR O 0 9.502919056103565e-06
) O 0 5.710896644472996e-08
. O 0 4.329701823735377e-07

The O 0 1.6763003714004299e-06
C282Y O 0 1.413273457728792e-05
mutation O 0 1.059895566868363e-07
nearly O 0 3.279554761093095e-08
completely O 0 1.3809303922585059e-08
prevents O 0 4.760221994359881e-09
the O 0 1.6652108580927916e-09
association O 0 1.9551233965131587e-09
of O 0 1.7890277703713764e-08
the O 0 3.1715980952640166e-08
mutant O 0 3.608529084431211e-07
HFE O 0 1.0657460734364577e-05
protein O 0 1.8976014359850524e-07
with O 0 1.1493823670605252e-08
the O 0 5.961475721960596e-07
TfR O 0 5.2016217523487285e-05
. O 0 1.3543043451136327e-06

Studies O 0 1.2204925496916985e-06
on O 0 2.732942334660038e-07
cell O 0 2.523016178201942e-07
- O 0 1.1477705186280218e-07
associated O 0 8.554123809290104e-08
transferrin O 0 9.996660992328543e-07
at O 0 2.3437516816215975e-08
37 O 0 1.5284630450196346e-08
degrees O 0 1.4100534961869471e-08
C O 0 2.0369704145650758e-08
suggest O 0 1.0582826837080006e-09
that O 0 1.9213666768713722e-10
the O 0 8.588566302591971e-09
overexpressed O 0 8.498601573592168e-07
wild O 0 1.273839984605729e-07
- O 0 1.6238804789736605e-07
type O 0 1.2055080844675103e-07
HFE O 0 2.6051743589050602e-06
protein O 0 1.1704851488048007e-07
decreases O 0 1.719248032827636e-08
the O 0 1.1809329070189278e-09
affinity O 0 1.2827326756337243e-08
of O 0 1.7202026469931297e-08
the O 0 6.440706101784599e-08
TfR O 0 1.249236674993881e-06
for O 0 1.5042614265325938e-08
transferrin O 0 1.8309145161765628e-05
. O 0 1.7215144225701806e-06

The O 0 1.9657116354210302e-05
overexpressed O 0 0.0003295668284408748
H63D O 0 0.0003866941842716187
protein O 0 3.576931817406148e-07
does O 0 4.3815595596186085e-09
not O 0 9.97448457162875e-10
have O 0 2.1080924506033938e-10
this O 0 9.828816233126147e-11
effect O 0 5.456539220460854e-09
, O 0 1.9193886757751244e-10
providing O 0 1.4047323304566817e-09
the O 0 6.896826443281157e-10
first O 0 4.6475731596551384e-10
direct O 0 2.177319213814144e-09
evidence O 0 6.1940461648646306e-09
for O 0 5.135022407287693e-10
a O 0 2.5148034765720695e-09
functional O 0 1.1559784951487018e-07
consequence O 0 2.5045352458619163e-07
of O 0 4.81113993089366e-08
the O 0 2.9064841555737075e-07
H63D O 0 0.002001238986849785
mutation O 0 1.6265150861727307e-06
. O 0 1.0572732662694762e-06

Addition O 0 8.311268402394489e-07
of O 0 1.4600863096347894e-06
soluble O 0 2.3455069822375663e-05
wild O 0 3.423493581067305e-06
- O 0 1.9997046365460847e-06
type O 0 3.2454718166263774e-06
HFE O 1 0.9388384819030762
/ O 0 1.4120477317192126e-05
beta2m O 0 6.9592824729625136e-06
heterodimers O 0 8.340775252690946e-07
to O 0 9.10076014548622e-09
cultured O 0 7.601972384918554e-08
cells O 0 7.604695539953354e-09
also O 0 6.388420348280022e-10
decreased O 0 1.979638009075302e-09
the O 0 1.3154967393180783e-10
apparent O 0 6.401914998122038e-09
affinity O 0 1.6192883478538533e-08
of O 0 1.4798415826078326e-08
the O 0 1.1913177111466666e-08
TfR O 0 8.073001822594961e-08
for O 0 3.478295984571389e-10
its O 0 6.892289516891026e-10
ligand O 0 7.58742828566028e-08
under O 0 1.143382544199767e-08
steady O 0 8.180215615993802e-08
- O 0 3.887351773812497e-09
state O 0 7.32986671359015e-10
conditions O 0 7.610357499743259e-08
, O 0 1.93052196451049e-09
both O 0 1.103159230630979e-09
in O 0 1.0387086746277419e-09
293 O 0 6.230018279040905e-09
cells O 0 2.6335518210629516e-09
and O 0 3.5234630768599118e-09
in O 0 1.313998509999692e-08
HeLa O 0 4.843674105359241e-06
cells O 0 1.0514925179450074e-06
. O 0 1.3402084277913673e-06

Furthermore O 0 2.1298844785633264e-06
, O 0 6.597845469968888e-08
at O 0 4.1861341060212e-08
4 O 0 2.6742602798890402e-08
degrees O 0 9.493252406400643e-08
C O 0 3.7363932392509014e-07
, O 0 2.45390685549296e-09
the O 0 2.0010954671079162e-08
added O 0 8.950036090027425e-08
soluble O 0 8.798849648883333e-07
complex O 0 1.662705102489781e-07
of O 0 5.713020527764456e-07
HFE O 1 0.9995998740196228
/ O 0 4.162400000495836e-05
beta2m O 0 1.413406880601542e-05
inhibited O 0 1.2275813787709922e-07
binding O 0 5.308652006874581e-08
of O 0 7.948478497610267e-08
transferrin O 0 1.248597186531697e-06
to O 0 4.0767957898424356e-08
HeLa O 0 2.0645520635298453e-06
cell O 0 2.887638856918784e-07
TfR O 0 8.700454259269463e-07
in O 0 1.9689885277784924e-09
a O 0 7.561650861021008e-09
concentration O 0 4.741449401990394e-07
- O 0 3.9214617686411657e-07
dependent O 0 4.419103731834184e-07
manner O 0 1.0455288474986446e-06
. O 0 1.0161290902033215e-06

Scatchard O 0 0.0002799532958306372
plots O 0 2.943319486803375e-06
of O 0 9.412892865157119e-08
these O 0 3.90123444660162e-09
data O 0 2.3384112424196246e-08
indicate O 0 3.34259269152426e-08
that O 0 2.3470565491123807e-09
the O 0 5.109576761697099e-08
added O 0 1.3090897255096934e-07
heterodimer O 0 1.5540518916168367e-07
substantially O 0 1.582447417547428e-08
reduced O 0 5.8299542970985385e-09
the O 0 2.093220707877208e-09
affinity O 0 4.102278694517736e-08
of O 0 4.8875474334408864e-08
TfR O 0 2.5053404897334985e-06
for O 0 1.0822544993516203e-07
transferrin O 0 0.00012597159366123378
. O 0 5.7232136896345764e-06

These O 0 2.1915160175467463e-07
results O 0 1.160613507522612e-07
establish O 0 4.206046710919509e-08
a O 0 1.0536427730301057e-08
molecular O 0 1.0000821504263513e-07
link O 0 1.0731423571996856e-07
between O 0 5.907360289825192e-08
HFE O 0 0.014510520733892918
and O 0 3.8527421253320426e-08
a O 0 2.963842504755121e-08
key O 0 1.7647626293637586e-07
protein O 0 5.518398538129077e-08
involved O 0 3.818429128443768e-09
in O 0 2.258283338107958e-09
iron O 0 7.212140076262585e-07
transport O 0 7.034000759631454e-07
, O 0 2.678102628550505e-09
the O 0 2.61347228303066e-08
TfR O 0 2.655599018908106e-06
, O 0 1.9453625377252592e-09
and O 0 1.5563685895614299e-09
raise O 0 6.066947833005543e-09
the O 0 8.987324662257379e-09
possibility O 0 3.1292294977447455e-08
that O 0 2.841443191847759e-10
alterations O 0 1.3884653426998739e-08
in O 0 1.2250557512860638e-10
this O 0 9.50771752994406e-11
regulatory O 0 7.1977837023951e-09
mechanism O 0 6.985227685163409e-08
may O 0 7.121299105961043e-09
play O 0 1.507320135374357e-08
a O 0 1.1390899778973562e-08
role O 0 6.509108807506436e-09
in O 0 6.931761276085524e-10
the O 0 9.520357835413051e-09
pathogenesis O 1 0.6225116848945618
of O 0 3.6030244245921494e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.1921230654697865e-05
. O 0 9.143057582150504e-07

Genomic O 0 3.3486310258012963e-06
organization O 0 4.993804054720385e-07
of O 0 5.348768468138587e-07
the O 0 6.644527843491232e-07
UBE3A O 0 0.0005112554645165801
/ O 0 3.48705293617968e-06
E6 O 0 7.692484359722584e-05
- O 0 1.6050045132942614e-06
AP O 0 2.8424596166587435e-05
gene O 0 2.25841372269997e-08
and O 0 1.4027063066635037e-08
related O 0 2.699320305055153e-07
pseudogenes O 0 1.0060365639219526e-05
. O 0 1.2057051890224102e-06

The O 0 9.02621013665339e-06
UBE3A O 0 0.0001972371101146564
gene O 0 4.665269557335705e-07
encodes O 0 1.2680321788138826e-06
the O 0 7.904391168267466e-07
E6 O 0 4.716545663541183e-05
- O 0 2.4864439183147624e-06
AP O 0 2.2932426873012446e-05
ubiquitin O 0 8.221900316129904e-07
- O 0 1.6814288983368897e-07
protein O 0 2.9748921548389262e-08
ligase O 0 8.256459693711804e-08
and O 0 1.90712921011027e-08
has O 0 1.5602503733447293e-09
recently O 0 1.7315453515465151e-09
been O 0 1.0501827185649404e-10
shown O 0 6.717772865760807e-11
to O 0 2.9474835766540863e-11
be O 0 1.107611433126543e-10
mutated O 0 5.591280327621462e-08
in O 0 2.9387365430011414e-08
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 4.3978971575597825e-08
who O 0 3.875565646183077e-09
lack O 0 7.210799424228753e-08
15q11 O 0 1.725745505609666e-06
- O 0 6.529223810503026e-07
q13 O 0 2.3286431769520277e-06
deletions O 0 3.012478089203796e-07
or O 0 4.3443144193133776e-08
chromosome O 0 1.1353286026860587e-06
15 O 0 2.3115662770578638e-06
paternal O 0 0.11248733848333359
uniparental B-Disease 1 0.9983348250389099
disomy I-Disease 0 0.0025123930536210537
. O 0 6.274068255152088e-06

Previous O 0 6.285261406446807e-06
UBE3A O 0 4.510838698479347e-05
cDNA O 0 5.283641257847194e-07
analysis O 0 5.435890670923982e-08
has O 0 2.2602311133823605e-09
shown O 0 5.67619451441459e-10
a O 0 5.256374779882833e-10
coding O 0 6.634707006014651e-08
region O 0 5.3272547262395165e-08
of O 0 5.119048651636149e-08
approximately O 0 8.932624950830359e-08
2 O 0 1.5124570609259536e-06
. O 0 7.161729058680066e-07

6 O 0 3.631408617366105e-05
kb O 0 2.0560504708555527e-05
and O 0 1.1927619425478042e-07
a O 0 1.4247854096538504e-07
3 O 0 4.945731006955612e-07
- O 0 3.084682020926266e-07
untranslated O 0 0.00017618013953324407
region O 0 1.966466101066544e-07
( O 0 1.1650621800640693e-08
UTR O 0 3.119060420431197e-05
) O 0 4.2704879632537995e-09
of O 0 5.901931743323985e-08
< O 0 1.699971079460738e-07
50 O 0 1.1663233578929066e-07
bp O 0 4.9742396868168726e-08
, O 0 9.342162599068615e-10
whereas O 0 3.2273965722140474e-09
Northern O 0 6.84345868862124e-09
analysis O 0 1.921638848045859e-09
has O 0 1.1251917175769677e-09
indicated O 0 5.912024203524879e-09
mRNA O 0 3.5183344238021164e-08
sizes O 0 2.6268614305990923e-07
of O 0 3.677553763736796e-07
5 O 0 1.810099547583377e-06
- O 0 2.9103887300152564e-06
8 O 0 4.466091013455298e-06
kb O 0 6.420029239961877e-05
. O 0 3.1999798011383973e-06

We O 0 3.8562788517992885e-07
have O 0 6.518774853248033e-09
analyzed O 0 1.4643538825964697e-08
additional O 0 4.274660181380341e-09
cDNA O 0 8.524236960738563e-08
clones O 0 1.5706545752891543e-07
and O 0 3.564575301595596e-09
provide O 0 2.8743245561457798e-09
evidence O 0 2.1836253694118568e-08
for O 0 1.7181817080214046e-09
an O 0 2.9398787848577967e-09
additional O 0 1.3820529609631649e-08
0 O 0 1.0473452221049229e-06
. O 0 6.175293378873903e-07

5 O 0 1.3379352822084911e-05
kb O 0 4.194652501610108e-05
of O 0 5.133983449923107e-06
5 O 0 2.6962584342982154e-06
- O 0 8.879978850018233e-07
UTR O 0 0.00013603684783447534
and O 0 4.945282938706441e-08
> O 0 1.8847565286250756e-07
2 O 0 1.8144793045848928e-07
kb O 0 1.826520929171238e-06
of O 0 1.0017866998168756e-06
3 O 0 3.853473572235089e-06
- O 0 4.829993031307822e-06
UTR O 0 0.006990976631641388
. O 0 5.34813261765521e-06

We O 0 3.1519871868113114e-07
have O 0 8.642992987972775e-09
established O 0 2.43406859112838e-08
the O 0 8.526151340504384e-09
genomic O 0 6.10025239211609e-08
organization O 0 3.181049024192362e-08
of O 0 5.2436927688859214e-08
UBE3A O 0 0.0002116299292538315
and O 0 2.85028303181889e-08
the O 0 2.165450752045217e-08
sequence O 0 3.0210539847530526e-08
of O 0 1.8675119406452723e-07
intron O 0 3.2326433938578703e-06
- O 0 3.257549906265922e-06
exon O 0 6.260383429435024e-07
borders O 0 2.2680198981106514e-06
. O 0 3.539034878485836e-06

We O 0 6.475743816736212e-07
have O 0 4.892714500215334e-08
also O 0 3.549650884338007e-08
mapped O 0 1.0584329857010744e-07
two O 0 1.1959553347651308e-08
highly O 0 2.855436065374306e-08
homologous O 0 3.768651168911674e-08
processed O 0 3.2010495942813577e-07
pseudogenes O 0 1.5415508869409678e-06
, O 0 1.7898059923027176e-08
UBE3AP1 O 0 0.00010304000170435756
and O 0 4.1043527687634196e-08
UBE3AP2 O 0 0.0009216496255248785
, O 0 4.062557845685433e-09
to O 0 3.209581933560912e-09
chromosomes O 0 1.557156359410783e-08
2 O 0 3.9430840814702606e-08
and O 0 2.9245099675279107e-09
21 O 0 5.3911712427634484e-08
, O 0 2.537202004049277e-09
respectively O 0 3.6479235188124903e-09
, O 0 1.3931361619867744e-09
and O 0 1.8373725874099023e-09
determined O 0 2.4574303481017523e-08
their O 0 2.998196180215018e-08
genomic O 0 1.2035064855808741e-06
organization O 0 9.53887933974329e-07
. O 0 1.2666542943406967e-06

These O 0 1.713474091502576e-07
results O 0 9.121339417106356e-08
will O 0 2.240666541197811e-09
form O 0 1.323563814104034e-09
the O 0 1.7158761078661655e-09
basis O 0 1.9245438576120932e-09
for O 0 1.8126090906012138e-10
studies O 0 2.102038765272596e-09
of O 0 2.226548057038258e-09
mutation O 0 7.422244596710925e-09
and O 0 1.2150274564248775e-08
imprinting O 0 1.3160852176952176e-05
of O 0 7.071416348480852e-06
UBE3A O 1 0.999066174030304
. O 0 1.1939201613131445e-05

Mutation O 0 4.3006934902223293e-07
spectrum O 0 9.981713446904905e-07
and O 0 3.027104611419418e-08
genotype O 0 4.4679595134766714e-07
- O 0 5.931532882641477e-07
phenotype O 0 1.8290627679107274e-07
analyses O 0 4.98722627639836e-08
in O 0 3.968577466650913e-09
Cowden B-Disease 0 6.551984552061185e-05
disease I-Disease 0 7.756432751193643e-06
and O 0 5.8589858298319086e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.2155346002250553e-08
two O 0 2.8198018142688852e-08
hamartoma B-Disease 1 0.9999949932098389
syndromes I-Disease 1 0.99104905128479
with O 0 1.942910557772848e-06
germline O 1 1.0
PTEN O 1 1.0
mutation O 0 3.1857860449235886e-05
. O 0 2.5723907128849532e-06

The O 0 2.0014975234516896e-05
tumour B-Disease 1 1.0
suppressor O 0 0.002181354211643338
gene O 0 7.127081062208163e-06
PTEN O 1 0.9881139397621155
, O 0 4.787066032463372e-08
which O 0 2.4895190353646512e-09
maps O 0 2.1615392142848577e-07
to O 0 6.552097175926974e-08
10q23 O 0 0.00012692800373770297
. O 0 4.685191470343852e-06

3 O 0 7.066704256430967e-06
and O 0 5.965740967894817e-08
encodes O 0 8.402427198461737e-08
a O 0 3.335886233912788e-08
403 O 0 3.627671674166777e-08
amino O 0 1.719192255222879e-08
acid O 0 1.879145550276462e-08
dual O 0 1.0455832466504944e-07
specificity O 0 4.122500456560374e-07
phosphatase O 0 2.628665060910862e-05
( O 0 2.7136869107380335e-07
protein O 0 1.465725404159457e-06
tyrosine O 0 9.357040084978507e-07
phosphatase O 0 2.6176437586400425e-06
; O 0 6.979368549764331e-08
PTPase O 0 1.0152166396437678e-06
) O 0 8.670529849652553e-10
, O 0 5.90381743492685e-10
was O 0 4.032965073008654e-09
shown O 0 3.77361031311807e-10
recently O 0 2.778068330933081e-10
to O 0 2.5548527182728265e-10
play O 0 6.186371415140002e-09
a O 0 2.4147444932509643e-08
broad O 0 2.77057381481427e-07
role O 0 1.591391551869492e-08
in O 0 9.992256799762345e-09
human O 0 6.478950353994151e-07
malignancy B-Disease 0 0.08382216840982437
. O 0 6.518814643641235e-07

Somatic O 0 0.0004248163604643196
PTEN O 0 0.0008468743180856109
deletions O 0 2.7129362933919765e-06
and O 0 3.0984235621644984e-08
mutations O 0 7.958445280564774e-08
were O 0 4.806514741773071e-09
observed O 0 2.9368412146624223e-09
in O 0 9.276570622773761e-10
sporadic B-Disease 0 9.870036592474207e-06
breast I-Disease 0 1.0350689990445971e-05
, I-Disease 0 3.228457501336379e-08
brain I-Disease 1 0.9999997615814209
, I-Disease 0 1.5217209465845372e-06
prostate I-Disease 1 1.0
and I-Disease 0 0.440162718296051
kidney I-Disease 1 1.0
cancer I-Disease 0 0.00017830001888796687
cell O 0 9.511628036307229e-07
lines O 0 5.3897526441915034e-08
and O 0 8.119986905086307e-10
in O 0 5.464430574697587e-10
several O 0 1.3423629319220254e-08
primary O 0 1.994284502870869e-06
tumours B-Disease 1 1.0
such O 0 1.0608903089348587e-08
as O 0 1.5905804957583314e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 0.005018077790737152
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.608726754260715e-05

In O 0 7.558078607416974e-08
addition O 0 1.594293621565157e-07
, O 0 5.871380892585876e-08
PTEN O 0 0.0011763194343075156
was O 0 6.794441986812672e-08
identified O 0 8.89923779112678e-09
as O 0 4.777611084527678e-10
the O 0 3.9286965347606895e-10
susceptibility O 0 5.5969646695075426e-09
gene O 0 1.0856234800016296e-09
for O 0 3.465860931584075e-09
two O 0 9.318038962646824e-08
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999128580093384
( O 0 3.2732366150867165e-08
CD B-Disease 0 3.144446236547083e-05
; O 0 1.134933000912497e-07
MIM O 0 9.219917046721093e-06
158350 O 0 2.588420557003701e-06
) O 0 5.894998711397648e-09
and O 0 2.1663595362042543e-08
Bannayan B-Disease 0 7.923711382318288e-05
- I-Disease 0 0.00011883125262102112
Zonana I-Disease 1 0.9642763137817383
( I-Disease 0 9.078431162379275e-07
BZS I-Disease 0 0.0003916921268682927
) I-Disease 0 3.225558486974478e-08
or I-Disease 0 3.231864553754349e-08
Ruvalcaba I-Disease 0 6.59114357404178e-06
- I-Disease 0 1.0355362292102654e-06
Riley I-Disease 0 1.4528007341141347e-05
- I-Disease 1 0.9995976090431213
Smith I-Disease 1 0.7941715717315674
syndrome I-Disease 1 1.0
( O 0 2.6848358174902387e-05
MIM O 0 0.3574739098548889
153480 O 0 0.00011354274465702474
) O 0 1.2115658876155067e-07
. O 0 5.939480161032407e-07

Constitutive O 0 3.2520031254534842e-06
DNA O 0 6.593605803573155e-07
from O 0 2.534176530843979e-07
37 O 0 2.5605638143133547e-07
CD B-Disease 0 1.4169073381253838e-07
families O 0 1.0852865273136558e-08
and O 0 5.5720290603744616e-09
seven O 0 4.022189514785168e-08
BZS B-Disease 0 5.830105146742426e-05
families O 0 2.2797413734565453e-08
was O 0 3.971911155531416e-08
screened O 0 3.333996900778402e-08
for O 0 1.9279470464539372e-08
germline O 0 0.0005879480158910155
PTEN O 0 0.09105105698108673
mutations O 0 1.6175576092791744e-05
. O 0 4.007913503301097e-06

PTEN O 0 0.0008996567921712995
mutations O 0 1.95576217265625e-06
were O 0 9.091620256640454e-08
identified O 0 1.3098722995152912e-08
in O 0 5.684970827424252e-10
30 O 0 6.605636926337866e-09
of O 0 7.600315932165813e-09
37 O 0 5.694798232980247e-08
( O 0 2.462759551846716e-09
81 O 0 7.857479999984207e-08
% O 0 4.5944612003800955e-10
) O 0 2.425805910311052e-11
CD B-Disease 0 6.3735510202889145e-09
families O 0 1.458922427310938e-09
, O 0 4.534356223828695e-10
including O 0 3.951362015364168e-10
missense O 0 3.2149330309039215e-07
and O 0 3.054578812111686e-08
nonsense O 0 4.4333373239169305e-07
point O 0 2.5065639874810586e-07
mutations O 0 1.8891611830440524e-08
, O 0 9.109356824410497e-09
deletions O 0 1.4570855455531273e-07
, O 0 1.4773485546015763e-08
insertions O 0 2.792239683913067e-07
, O 0 1.2600114729366396e-08
a O 0 3.3229184737137984e-08
deletion O 0 2.0624648300326953e-07
/ O 0 6.860254870844074e-07
insertion O 0 2.2906039021108882e-07
and O 0 1.8741491203400074e-07
splice O 0 2.1446829123306088e-05
site O 0 3.625621957326075e-06
mutations O 0 2.593473482193076e-06
. O 0 3.2723992262617685e-06

These O 0 1.1934241683775326e-07
mutations O 0 1.0174153430853039e-07
were O 0 1.8167920501355184e-08
scattered O 0 3.1748118800578595e-08
over O 0 1.2503913460193417e-09
the O 0 1.4841006201748996e-09
entire O 0 5.110996958990199e-09
length O 0 1.459988463459183e-09
of O 0 7.903198984138271e-09
PTEN O 0 1.2755952411680482e-05
, O 0 2.3701796081354587e-09
with O 0 1.5255025020977087e-10
the O 0 3.703787498920974e-09
exception O 0 5.832212046641416e-09
of O 0 7.226588660813604e-09
the O 0 8.703058718140255e-09
first O 0 1.1631660079558515e-08
, O 0 5.0967647879929245e-09
fourth O 0 2.6202013714282657e-07
and O 0 4.4394127485247736e-08
last O 0 4.660191450511775e-07
exons O 0 2.752618456725031e-05
. O 0 7.192638349806657e-06

A O 0 3.0695460736751556e-05
hot O 0 1.4812085282756016e-05
spot O 0 2.427285153316916e-06
for O 0 5.966082028407982e-08
PTEN O 0 1.6188416338991374e-05
mutation O 0 9.250708643548933e-09
in O 0 2.009984401141196e-09
CD B-Disease 0 2.8342643076939567e-07
was O 0 4.4265355825245933e-08
identified O 0 5.580389039749889e-09
in O 0 5.683756798546824e-10
exon O 0 1.397368265543264e-08
5 O 0 2.276691013491927e-08
that O 0 2.3693785822231916e-10
contains O 0 1.2298230211982286e-09
the O 0 8.964281761336679e-09
PTPase O 0 1.6173364656424383e-06
core O 0 2.592091448150313e-07
motif O 0 9.651324717196985e-08
, O 0 1.1505925101573666e-09
with O 0 8.082038371881595e-10
13 O 0 2.982158164854809e-08
of O 0 5.595355645482414e-08
30 O 0 9.406305423453887e-08
( O 0 7.038373439627321e-09
43 O 0 1.1772727503966962e-07
% O 0 1.5047197932105405e-09
) O 0 1.4146531168712784e-10
CD B-Disease 0 4.787613860912643e-08
mutations O 0 2.0713381232440042e-08
identified O 0 2.7884921038889843e-08
in O 0 3.100053325155727e-09
this O 0 1.085534950817646e-08
exon O 0 8.111996976367664e-07
. O 0 9.060959200724028e-07

Seven O 0 2.301256927239592e-06
of O 0 7.020569796623022e-07
30 O 0 2.0387746246797178e-07
( O 0 4.404888009901242e-09
23 O 0 7.048237193885143e-08
% O 0 8.992910860428083e-10
) O 0 3.419786329117436e-11
were O 0 3.990138497389495e-10
within O 0 1.6936034796799504e-09
the O 0 8.974477161416416e-09
core O 0 5.880312770045748e-08
motif O 0 1.81315016334338e-08
, O 0 3.4591954300999816e-10
the O 0 8.761765202258687e-10
majority O 0 4.0352637897811405e-10
( O 0 3.593380593081008e-10
five O 0 4.133276387818796e-09
of O 0 2.414772026781975e-08
seven O 0 6.055294932139077e-09
) O 0 1.8528140133255988e-10
of O 0 7.2652310834087075e-09
which O 0 2.2018002976409434e-09
were O 0 1.5134014930140438e-08
missense O 0 5.311554218678793e-07
mutations O 0 6.179982392495731e-08
, O 0 5.2616737633570665e-09
possibly O 0 5.460008623003887e-08
pointing O 0 2.3411432437114854e-07
to O 0 2.056512071746397e-09
the O 0 8.245156557507016e-09
functional O 0 9.352011431928986e-08
significance O 0 9.747765972178968e-08
of O 0 1.8244177724113797e-08
this O 0 1.0407775974385913e-08
region O 0 4.2497376284700294e-07
. O 0 1.0785580570882303e-06

Germline O 0 0.0019250644836574793
PTEN O 0 0.0008798660710453987
mutations O 0 2.0156981008767616e-06
were O 0 9.630967667817458e-08
identified O 0 2.052410152941775e-08
in O 0 1.1794967225142727e-09
four O 0 2.2899466767256627e-09
of O 0 9.638829290281592e-09
seven O 0 1.1776405628438624e-08
( O 0 3.59319041187689e-09
57 O 0 2.522612021493842e-07
% O 0 9.245980869820869e-09
) O 0 3.4776943547143446e-09
BZS B-Disease 0 0.0003542728372849524
families O 0 2.2274713273873203e-07
studied O 0 9.228274961969873e-07
. O 0 4.319255424434232e-07

Interestingly O 0 2.6485297439649003e-06
, O 0 4.176221324314611e-08
none O 0 7.098099530367108e-08
of O 0 2.021766398740965e-08
these O 0 3.521078317803017e-09
mutations O 0 6.859195167407961e-08
was O 0 3.104830526012847e-08
observed O 0 3.37182215481846e-09
in O 0 1.4562118177963157e-09
the O 0 8.133510931429555e-08
PTPase O 0 7.507009286200628e-05
core O 0 5.39053098691511e-06
motif O 0 4.619051651388872e-06
. O 0 8.42963345348835e-07

It O 0 7.750843167286803e-08
is O 0 6.71601130264321e-09
also O 0 1.1418520573514002e-09
worthy O 0 5.481597753487222e-08
of O 0 1.1454779347275235e-08
note O 0 5.505254030424567e-09
that O 0 3.1584945769935757e-10
a O 0 1.725459330970125e-09
single O 0 4.7559205462732734e-09
nonsense O 0 8.614787816441094e-08
point O 0 7.473074248309786e-08
mutation O 0 7.962951187323597e-09
, O 0 2.4654382979605316e-09
R233X O 0 2.56317321145616e-07
, O 0 4.5503694146020734e-09
was O 0 1.1420944190376758e-08
observed O 0 2.610188065688135e-09
in O 0 1.124968562749018e-09
the O 0 1.7438024357829818e-08
germline O 0 2.4186169866879936e-07
DNA O 0 7.029012039083682e-08
from O 0 2.5141909887338443e-08
two O 0 4.630957395335145e-09
unrelated O 0 2.0087208341124096e-08
CD B-Disease 0 2.1626279078645894e-07
families O 0 2.00829930463442e-08
and O 0 1.1621636986092199e-08
one O 0 1.4606389697746636e-07
BZS B-Disease 0 0.2813311815261841
family O 0 3.1214021873893216e-06
. O 0 3.1498582302447176e-06

Genotype O 0 2.6343579975218745e-06
- O 0 1.162819899036549e-06
phenotype O 0 7.106362431841262e-08
studies O 0 6.39003250313408e-09
were O 0 1.1744614170083878e-09
not O 0 3.158771855193976e-10
performed O 0 7.496822607144793e-10
on O 0 1.8974986026876195e-09
this O 0 3.6857022989167376e-10
small O 0 6.179767808589531e-09
group O 0 4.395722896788357e-09
of O 0 1.1246842746004404e-07
BZS B-Disease 1 0.9999431371688843
families O 0 2.3661868908675388e-06
. O 0 1.8534151422500145e-06

However O 0 7.231913627947506e-07
, O 0 6.028480470376962e-08
genotype O 0 2.1822020812578558e-07
- O 0 5.047150466452877e-07
phenotype O 0 8.205766022229e-08
analysis O 0 1.9284142283026995e-08
inthe O 0 2.7920214051846415e-07
group O 0 3.663291003874747e-09
of O 0 9.247497878561717e-09
CD B-Disease 0 1.3564578011937556e-06
families O 0 2.698506307297066e-08
revealed O 0 4.237175588173159e-08
two O 0 1.6836834149103197e-09
possible O 0 8.42424707769851e-09
associations O 0 1.148790573779479e-08
worthy O 0 5.330497288014158e-07
of O 0 6.618149939185969e-08
follow O 0 3.05679357381905e-08
- O 0 4.8380190520447286e-08
up O 0 9.014174295884914e-09
in O 0 2.2377322217437268e-09
independent O 0 3.661015668399159e-08
analyses O 0 4.137791052016837e-07
. O 0 6.349323484755587e-07

The O 0 1.8991216848007753e-06
first O 0 2.2115118269994127e-07
was O 0 1.7435073118576838e-07
an O 0 3.1354174812037172e-09
association O 0 3.7818983500415015e-09
noted O 0 2.198721027468764e-08
in O 0 1.0348841783525131e-09
the O 0 9.975232195813533e-09
group O 0 1.0979868125815528e-09
of O 0 4.84973172731884e-09
CD B-Disease 0 0.0001346205099252984
families O 0 4.433305548445787e-06
with O 0 2.2808933863416314e-05
breast B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999819993972778
. O 0 6.063804107725446e-07

A O 0 1.8291515289092786e-06
correlation O 0 4.561298965199967e-07
was O 0 4.468372338806148e-08
observed O 0 5.7218949578441425e-09
between O 0 1.4709399254186906e-09
the O 0 2.940361065739694e-09
presence O 0 7.030325832602102e-08
/ O 0 2.7281791403765965e-07
absence O 0 5.723218237108085e-07
of O 0 8.799590744956731e-08
a O 0 4.2159900459637356e-08
PTEN O 0 1.4037940673006233e-05
mutation O 0 9.875579465301598e-09
and O 0 1.3862339054426798e-09
the O 0 9.817635593378782e-10
type O 0 2.3279799421516145e-08
of O 0 8.741742618667558e-08
breast O 0 1.296247091886471e-06
involvement O 0 1.5332158227465698e-06
( O 0 2.3256994552411925e-07
unaffected O 1 0.7723908424377441
versus O 0 0.20652279257774353
benign O 1 0.9999833106994629
versus O 0 5.630419764202088e-05
malignant O 0 1.574368798173964e-05
) O 0 7.791263101353252e-08
. O 0 4.041823444822512e-07

Specifically O 0 2.4950873012130614e-07
and O 0 1.2618801115138467e-08
more O 0 1.6684982284687067e-09
directly O 0 2.6334777913916696e-08
, O 0 6.617387193763591e-10
an O 0 4.77524242370464e-10
association O 0 2.5038766615637087e-09
was O 0 6.492991388995506e-08
also O 0 7.285792524847068e-10
observed O 0 1.0281829831981781e-09
between O 0 1.346477818131575e-09
the O 0 3.457304220688684e-09
presence O 0 1.0220245094672009e-08
of O 0 1.2678897931550637e-08
a O 0 4.374864559508751e-08
PTEN O 1 0.9996325969696045
mutation O 0 0.00012449776113498956
and O 1 0.504289448261261
malignant B-Disease 1 1.0
breast I-Disease 1 0.9999992847442627
disease I-Disease 1 0.9997459053993225
. O 0 8.990840569822467e-07

Secondly O 0 1.0053920050268061e-05
, O 0 9.32959807187217e-08
there O 0 2.9757718067457972e-08
appeared O 0 3.76352211617359e-08
to O 0 1.7822222586616476e-09
be O 0 2.763942186234658e-09
an O 0 5.9792721884832645e-09
interdependent O 0 6.712825211252493e-07
association O 0 6.141697639350241e-08
between O 0 1.9697037600963085e-07
mutations O 0 9.30251587760722e-07
upstream O 0 2.4754090190981515e-06
and O 0 7.595302164986606e-09
within O 0 1.4460050934417268e-08
the O 0 9.143670354205824e-08
PTPase O 0 1.1237616490689106e-05
core O 0 5.896530979043746e-07
motif O 0 3.09258467723339e-07
, O 0 6.16733286662452e-09
the O 0 1.8337324547701428e-08
core O 0 1.659736170722681e-07
motif O 0 2.9085351016533423e-08
containing O 0 2.5857389562844446e-09
the O 0 3.3057225845567473e-09
majority O 0 1.0659056970396819e-09
of O 0 1.6936237301479196e-08
missense O 0 1.563266494031268e-07
mutations O 0 7.2065069467441845e-09
, O 0 1.1640000074919499e-09
and O 0 5.694716920245924e-10
the O 0 6.891215154070096e-09
involvement O 0 3.120962333014177e-08
of O 0 8.111526739185138e-08
all O 0 3.9547569663511695e-09
major O 0 4.902878814050382e-08
organ O 0 2.2304525373328943e-06
systems O 0 1.1963908264078782e-06
( O 0 3.3107721009173474e-08
central O 0 2.7964284527115524e-05
nervous O 0 7.052861292322632e-06
system O 0 1.557472933200188e-05
, O 0 8.855050026568279e-08
thyroid O 1 0.9834296703338623
, O 0 1.3786270756099839e-06
breast O 1 0.9864588379859924
, O 0 3.1786523777554976e-06
skin O 1 1.0
and O 1 0.9999047517776489
gastrointestinal O 1 1.0
tract O 1 0.9995371103286743
) O 0 1.4086266730828356e-07
. O 0 2.620491159177618e-06

However O 0 1.0264394632031326e-06
, O 0 1.747761757542321e-08
these O 0 2.1973574071409985e-09
observations O 0 3.164443995729016e-08
would O 0 6.175499001059848e-10
need O 0 2.574420676637601e-09
to O 0 3.1869382688398673e-09
be O 0 4.0461709538419655e-09
confirmed O 0 1.4948971838180114e-08
by O 0 1.2648698755057808e-09
studying O 0 4.401595976588624e-09
a O 0 4.96339302991089e-10
larger O 0 2.7994793150298847e-09
number O 0 4.6863322111789785e-09
of O 0 1.512633929223739e-08
CD B-Disease 0 3.1998515623854473e-06
families O 0 5.849706212757155e-07
. O 0 1.4010317954671336e-06

Molecular O 0 0.00026203837478533387
defects O 1 0.9997028708457947
leading O 0 1.006450247587054e-06
to O 0 1.995773324381389e-09
human O 0 1.7384161665745523e-08
complement B-Disease 0 4.2861333326982276e-07
component I-Disease 1 0.9999985694885254
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.1534474203832588e-09
an O 0 2.333357729256136e-09
African O 0 6.5316063668774405e-09
- O 0 1.534784921375376e-08
American O 0 2.2939435240232342e-08
family O 0 7.741136442973584e-08
. O 0 2.1942805972230417e-07

Complement B-Disease 0 2.2834616174804978e-05
component I-Disease 1 0.6280353665351868
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.1462627703149337e-07
C6D B-Disease 1 0.9533696174621582
) O 0 5.039528794270609e-09
was O 0 1.1522406850872358e-07
diagnosed O 0 1.3245823105023646e-08
in O 0 2.82313561417169e-10
a O 0 1.742568200846506e-09
16 O 0 6.156849252647589e-09
- O 0 2.0103831932516414e-09
year O 0 1.7617945990977546e-09
- O 0 4.583609491959351e-09
old O 0 9.285872692998964e-08
African O 0 1.2494002277207983e-08
- O 0 1.7278708241974527e-08
American O 0 4.145593202053988e-09
male O 0 4.2326182558838354e-09
with O 0 1.4190048025497504e-09
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.9753096580643614e-07

The O 0 4.341995349932404e-07
patients O 0 2.8836778298568788e-08
father O 0 2.950003192836448e-07
and O 0 1.496095158870503e-08
two O 0 2.089607598065868e-08
brothers O 0 6.987386313994648e-07
also O 0 2.930245734944492e-08
had O 0 2.634889639807625e-08
C6D B-Disease 1 0.9997605681419373
, O 0 2.2068793459339986e-09
but O 0 1.5328824876092995e-09
gave O 0 1.100041746582292e-08
no O 0 2.175136071258521e-09
history O 0 1.130311755304092e-08
of O 0 5.5581800495474454e-08
meningitis B-Disease 1 1.0
or O 0 2.1258122373524202e-08
other O 0 4.626880922842247e-08
neisserial B-Disease 0 0.00036142702447250485
infection I-Disease 0 1.8108747781298007e-06
. O 0 2.974819324208511e-07

By O 0 1.0872034295061894e-07
using O 0 2.7103084221380414e-08
exon O 0 9.361095010262943e-08
- O 0 2.955510147728546e-08
specific O 0 5.769280608802774e-09
polymerase O 0 2.7935175950233315e-08
chain O 0 2.1462806643057775e-08
reaction O 0 2.4959101452282084e-08
( O 0 1.199832011522517e-09
PCR O 0 1.1299667868058805e-08
) O 0 8.42597880357232e-10
/ O 0 2.737176041378575e-09
single O 0 3.7036882449825725e-09
- O 0 1.1469121652396552e-08
strand O 0 1.0138776040946595e-08
conformation O 0 2.703414381244329e-09
polymorphism O 0 7.04045044486179e-10
as O 0 7.775177723878812e-10
a O 0 3.5879699211704974e-10
screening O 0 1.690291656641918e-10
step O 0 1.0540441852668891e-09
and O 0 2.6205576597604363e-10
nucleotide O 0 1.2235851221120697e-09
sequencing O 0 3.0141917850556865e-09
of O 0 1.2796536275061499e-08
target O 0 2.648650543335407e-08
exons O 0 8.236924031734816e-08
, O 0 5.055529328501507e-09
we O 0 1.895089640768788e-09
determined O 0 8.871884560335275e-09
that O 0 2.308972568698664e-09
the O 0 3.537444470680384e-08
proband O 0 2.875083055187133e-06
was O 0 3.9589096445524774e-08
a O 0 3.9004901530859115e-09
compound O 0 2.991558289977547e-08
heterozygote O 0 5.701318173123582e-07
for O 0 1.5892288374175223e-08
two O 0 1.164318490509686e-07
C6 O 0 0.0016497106989845634
gene O 0 1.0899810831688228e-06
mutations O 0 4.96471329824999e-06
. O 0 2.5111198738159146e-06

The O 0 1.2436878478183644e-06
first O 0 1.284464019590814e-07
, O 0 2.17881179764845e-08
1195delC O 0 6.3864769117572e-07
located O 0 9.254453203766388e-08
in O 0 5.242480227707347e-09
exon O 0 1.7073180913484975e-07
7 O 0 3.152028966724174e-07
, O 0 3.2044622511051557e-09
is O 0 4.5071604781732333e-10
a O 0 5.994501561801258e-10
novel O 0 3.0492917080238158e-09
mutation O 0 5.457389540275415e-10
, O 0 4.1071521184044e-10
while O 0 5.92190685377858e-10
the O 0 8.049581445845888e-09
second O 0 6.942432406731314e-08
, O 0 4.202580061729577e-09
1936delG O 0 5.5197350690150415e-08
in O 0 3.903183998232862e-09
exon O 0 4.3599534649274574e-08
12 O 0 1.2291417306187213e-07
, O 0 1.1484662998384465e-08
has O 0 3.218458832776605e-09
been O 0 2.638509188912508e-09
described O 0 2.306393298567855e-09
before O 0 2.3771291601804023e-09
to O 0 2.905173879241829e-09
cause O 0 3.6847791307081934e-06
C6D B-Disease 1 0.9999492168426514
in O 0 2.488047323723208e-09
an O 0 1.7572238109053728e-09
unrelated O 0 2.2506949193257242e-08
African O 0 8.927119488078006e-09
- O 0 3.473751775118217e-08
American O 0 1.4447755880553359e-08
individual O 0 2.3510855484687454e-08
. O 0 6.197162747412222e-07

Both O 0 2.454596881307225e-07
mutations O 0 2.564972874097293e-07
result O 0 1.0304062669774794e-07
in O 0 1.3850637969881063e-08
premature O 0 3.444630237936508e-06
termination O 0 9.062133585757692e-07
codons O 0 2.417261839582352e-06
and O 0 6.435928980863537e-07
C6 O 0 0.21173995733261108
null O 0 2.6126006559934467e-05
alleles O 0 1.5445338021891075e-06
. O 0 1.6589181086601457e-06

Allele O 0 4.6131341946420434e-07
- O 0 1.3150145150575554e-07
specific O 0 7.220058773071969e-09
PCR O 0 6.87512269337276e-08
indicated O 0 1.414152794865231e-08
that O 0 2.73318895294139e-10
the O 0 4.101377015786056e-09
probands O 0 1.0402259249531198e-06
two O 0 1.4939166348426625e-08
brothers O 0 2.467041895215516e-07
also O 0 7.368586629752372e-09
inherited O 0 5.981909367847038e-08
the O 0 8.673975315787175e-09
1195delC O 0 2.8342094893218928e-08
mutation O 0 6.595159418587571e-10
from O 0 9.029175185304439e-10
their O 0 8.386791816583639e-10
heterozygous O 0 4.837545919400554e-09
mother O 0 1.1861120086109622e-08
and O 0 1.980801300760504e-09
the O 0 5.369341860017585e-09
1936delG O 0 1.6458647777994884e-08
mutation O 0 1.7135409757784714e-09
from O 0 4.298632561017257e-09
their O 0 7.206493179978679e-09
homozygous O 0 8.634132342422163e-08
father O 0 1.4354400263982825e-06
. O 0 1.5889021653947566e-07
. O 0 9.602662203178625e-07

PAX6 O 0 0.014948061667382717
mutations O 0 8.695484575582668e-05
reviewed O 0 3.0116359994281083e-05
. O 0 8.149198947648983e-06

Mutations O 0 2.4047901661106152e-06
in O 0 2.461817416588019e-07
PAX6 O 0 0.0003422065929044038
are O 0 8.849812438427307e-09
responsible O 0 1.2209188327005904e-08
for O 0 2.610208049702578e-09
human O 0 2.179801725787911e-07
aniridia B-Disease 1 1.0
and O 0 4.595894154135749e-08
have O 0 5.435906169637406e-10
also O 0 6.315896139419408e-10
been O 0 2.224594258803947e-10
found O 0 1.6579052020126994e-10
in O 0 7.245765792918135e-11
patients O 0 1.1296553970030487e-10
with O 0 1.0555248897148317e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.8311253547362867e-07
with O 0 0.3456791937351227
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 7.195931630121777e-06
with O 0 2.7432767168988903e-08
autosomal B-Disease 1 0.8789196014404297
dominant I-Disease 1 0.9999991655349731
keratitis I-Disease 1 1.0
, O 0 2.69502908878394e-08
and O 0 1.0400731831339272e-08
with O 0 3.156570826945426e-08
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0009326915605925024

No O 0 8.783791827227105e-07
locus O 0 1.3215822036727332e-07
other O 0 7.031677906610412e-09
than O 0 3.360189015921833e-09
chromosome O 0 7.635947696371659e-08
11p13 O 0 8.903739399102051e-07
has O 0 4.878035753108634e-09
been O 0 5.786538803675967e-09
implicated O 0 2.1194640709154555e-08
in O 0 8.353716829390123e-09
aniridia B-Disease 1 1.0
, O 0 1.8305524207562485e-08
and O 0 1.6882923503658276e-08
PAX6 O 0 0.09134361892938614
is O 0 1.1019568368908494e-08
clearly O 0 4.6775831208378804e-08
the O 0 1.7097221416406683e-08
major O 0 7.526070362473547e-07
, O 0 4.954683774371915e-09
if O 0 3.2518039372320118e-09
not O 0 3.3941867094711142e-09
only O 0 2.6846349143738735e-08
, O 0 7.179095984355399e-09
gene O 0 6.563466570241872e-08
responsible O 0 9.647970955484197e-07
. O 0 1.919125452332082e-06

Twenty O 0 7.673186701140366e-06
- O 0 4.3058480514446273e-07
eight O 0 8.128625950121204e-08
percent O 0 9.753155616465392e-09
of O 0 4.146154530815238e-09
identified O 0 4.3868467969332414e-08
PAX6 O 0 4.821460606763139e-06
mutations O 0 7.937116208722728e-08
are O 0 7.567840576427898e-09
C O 0 6.436409603338689e-05
- O 0 1.2414219781931024e-05
T O 0 1.0566742275841534e-05
changes O 0 2.8358369874581513e-08
at O 0 3.4583479191496735e-08
CpG O 0 7.705105531385925e-08
dinucleotides O 0 4.1193564470631827e-07
, O 0 2.367572582429034e-09
20 O 0 4.174124601519225e-09
% O 0 2.5581686768916256e-10
are O 0 4.040560247497993e-11
splicing O 0 8.609461588093836e-09
errors O 0 3.3630831808295625e-07
, O 0 4.367974870689295e-09
and O 0 9.632171726892125e-10
more O 0 5.161466254399727e-10
than O 0 6.569623178798167e-10
30 O 0 1.2393416071176944e-08
% O 0 5.028830130093809e-10
are O 0 8.586067967719657e-11
deletion O 0 1.2087743028743603e-09
or O 0 2.412597899237312e-09
insertion O 0 2.2650224806852748e-08
events O 0 1.1617873951763613e-07
. O 0 2.4708192540856544e-06

There O 0 2.2620785955496103e-07
is O 0 1.2411062400019546e-08
a O 0 1.3328669723478015e-08
noticeably O 0 7.057719813019503e-07
elevated O 0 3.4351029398749233e-07
level O 0 9.943774692544594e-09
of O 0 2.885403915797724e-09
mutation O 0 1.1947395295308638e-09
in O 0 6.185825740523399e-10
the O 0 7.579108007860214e-09
paired O 0 4.544610021639528e-09
domain O 0 2.5300159745000883e-09
compared O 0 1.0827511109923194e-09
with O 0 1.7676909935815388e-10
the O 0 3.084871025293978e-09
rest O 0 2.42977336029071e-08
of O 0 2.8498318371816822e-08
the O 0 6.449889156101563e-08
gene O 0 1.375391036617657e-07
. O 0 2.0621278054022696e-06

Increased O 0 1.9123787353692023e-07
mutation O 0 2.7490331788726508e-08
in O 0 2.83361334396659e-09
the O 0 1.0640373915293821e-08
homeodomain O 0 8.058954108491889e-07
is O 0 1.224023993273704e-09
accounted O 0 9.094582864577205e-09
for O 0 1.3597581394186875e-10
by O 0 6.103295646653351e-10
the O 0 4.803648678830541e-08
hypermutable O 0 9.91600154520711e-06
CpG O 0 7.347410928559839e-07
dinucleotide O 0 1.0966291483782697e-06
in O 0 4.340835957350464e-08
codon O 0 3.101503580182907e-06
240 O 0 9.407110042047861e-07
. O 0 7.824068575246201e-07

Very O 0 4.713074304163456e-07
nearly O 0 1.3959063949187112e-07
all O 0 4.158422495237346e-09
mutations O 0 6.21691320645823e-09
appear O 0 2.5102890877093387e-09
to O 0 4.3588599396571226e-10
cause O 0 3.999499043061405e-08
loss O 0 2.0641524045572623e-08
of O 0 8.624961189696023e-09
function O 0 2.484718208961567e-09
of O 0 1.5495745131488547e-08
the O 0 2.958283396026218e-09
mutant O 0 5.031653316223128e-09
allele O 0 4.044605095288034e-09
, O 0 4.0614867025112744e-10
and O 0 2.1083779166986005e-10
more O 0 2.3111303149025986e-10
than O 0 3.473509535556474e-10
80 O 0 6.414014652733613e-09
% O 0 6.114784789623684e-10
of O 0 1.6787707890486558e-09
exonic O 0 1.30863782032975e-07
substitutions O 0 3.349389743334541e-08
result O 0 5.6452989838362555e-08
in O 0 2.4859899028228938e-08
nonsense O 0 1.7122569033745094e-06
codons O 0 8.807103768049274e-06
. O 0 3.11388612317387e-06

In O 0 5.9371810579023077e-08
a O 0 2.928134001933813e-08
gene O 0 1.1092573970472586e-08
with O 0 3.151467753426118e-09
such O 0 8.455283584396511e-09
extraordinarily O 0 5.165441052668029e-07
high O 0 1.2622827227914968e-07
sequence O 0 1.878005306821251e-09
conservation O 0 3.917160817934473e-09
throughout O 0 1.4851306295859956e-10
evolution O 0 1.3993705083592545e-09
, O 0 1.4974610440532388e-10
there O 0 4.444143941739753e-10
are O 0 8.416726759996607e-10
presumed O 0 5.793642685603118e-07
undiscovered O 0 1.881205662357388e-06
missense O 0 1.3641840723721543e-07
mutations O 0 1.5322459745448214e-08
, O 0 1.293769313903681e-09
these O 0 1.5681566045699924e-09
are O 0 1.3876306770299607e-09
hypothesized O 0 2.367637108591225e-08
to O 0 1.634529733784973e-09
exist O 0 1.512639613565625e-08
in O 0 8.088242076098595e-09
as O 0 7.444833727277e-08
- O 0 1.068489652311655e-07
yet O 0 9.414095103466025e-08
unidentified O 0 3.08370431412186e-06
phenotypes O 0 3.525576630636351e-07
. O 0 4.9314557770685497e-08
. O 0 3.058190714000375e-07

Genetic O 0 5.939609764027409e-06
heterogeneity O 0 7.791850293870084e-06
and O 0 4.822927479608552e-08
penetrance O 0 1.18240632218658e-06
analysis O 0 2.7807377733779504e-08
of O 0 2.690068079402863e-08
the O 0 8.249455163422681e-08
BRCA1 O 0 7.635320002918888e-07
and O 0 3.242280968152045e-07
BRCA2 O 0 4.909634299110621e-06
genes O 0 1.2279880365895224e-06
in O 0 6.148977718112292e-07
breast B-Disease 1 0.9620839357376099
cancer I-Disease 0 0.334626168012619
families O 0 3.5009671250918473e-07
. O 0 5.5386647090927e-07

The O 1 0.5913516879081726
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 3.094995190622285e-05
Consortium O 0 1.8708914240050944e-06
. O 0 2.8787655992346117e-07

The O 0 1.7868937618459313e-07
contribution O 0 9.854640126150116e-08
of O 0 1.6082972820186114e-07
BRCA1 O 0 1.3503822628990747e-06
and O 0 2.69059228230617e-07
BRCA2 O 0 2.33255595958326e-05
to O 0 2.750093017311883e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 8.716651933582398e-08
assessed O 0 6.503846350369713e-09
by O 0 3.3934083321085495e-10
linkage O 0 1.4374850820786378e-07
and O 0 7.13451020484257e-10
mutation O 0 1.2262346693603376e-09
analysis O 0 5.155808557866237e-10
in O 0 2.7674648683806424e-10
237 O 0 3.395028480568385e-09
families O 0 1.900515744779341e-09
, O 0 3.91023158297088e-10
each O 0 3.5255454111648987e-10
with O 0 4.792853336432756e-10
at O 0 9.506023523897511e-09
least O 0 2.9111530963632504e-09
four O 0 1.5654849638835344e-09
cases O 0 1.199100463367131e-08
of O 0 8.042937338359479e-07
breast B-Disease 0 3.2158359317691065e-06
cancer I-Disease 0 1.3272710930323228e-07
, O 0 8.698854969679815e-10
collected O 0 4.0282754909526375e-09
by O 0 4.607785264454378e-09
the O 0 3.880090662278235e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 1.3868530004401691e-06
Consortium O 0 2.1956957141355815e-07
. O 0 1.3369363216497732e-07

Families O 0 1.0697988983565665e-07
were O 0 8.062304601708092e-09
included O 0 1.3860859127134972e-09
without O 0 7.674078039698884e-10
regard O 0 3.367637946283253e-09
to O 0 2.6718408041581654e-10
the O 0 2.2509984987095777e-09
occurrence O 0 5.977929049549857e-07
of O 0 3.036640464415541e-06
ovarian B-Disease 1 1.0
or I-Disease 0 3.645565448096022e-05
other I-Disease 0 4.9244999900111e-06
cancers I-Disease 1 0.982163667678833
. O 0 9.170075259135047e-07

Overall O 0 4.3180705688428134e-05
, O 0 1.5714876155925595e-07
disease O 0 6.772550477762707e-06
was O 0 6.519063333598751e-08
linked O 0 2.5282229643153187e-08
to O 0 2.2950450428993463e-09
BRCA1 O 0 2.1350606616010737e-08
in O 0 3.9365122272982944e-10
an O 0 5.356532439826367e-10
estimated O 0 6.131146701449097e-10
52 O 0 2.771686880009838e-09
% O 0 1.2226095136291804e-10
of O 0 5.129325297836829e-10
families O 0 2.749870775531349e-09
, O 0 1.2694281181779843e-09
to O 0 4.0922656374675626e-09
BRCA2 O 0 3.12037862215675e-08
in O 0 1.0360672320075537e-09
32 O 0 1.519327597065967e-08
% O 0 5.253568691188093e-10
of O 0 7.835651572030145e-10
families O 0 1.2328008613948782e-09
, O 0 5.460388252664927e-10
and O 0 7.251881317671405e-10
to O 0 2.7137934122123397e-09
neither O 0 2.68585385043707e-08
gene O 0 3.3170535207460716e-09
in O 0 4.653109897390095e-09
16 O 0 7.091238529710608e-08
% O 0 1.5172042511224504e-09
( O 0 2.2328154603012962e-10
95 O 0 9.087612440339399e-09
% O 0 2.090160711176736e-09
confidence O 0 2.1637497127358074e-08
interval O 0 8.775772641911317e-08
[ O 0 4.6057755298534175e-07
CI O 0 2.0810834030271508e-05
] O 0 1.9395214678752382e-07
6 O 0 3.4896402212325484e-07
% O 0 1.1890135986902806e-08
- O 0 1.3808302945506057e-08
28 O 0 5.074941356042473e-08
% O 0 1.5519132645636091e-09
) O 0 6.4755437123587e-11
, O 0 1.9549768748294838e-10
suggesting O 0 3.860574082636958e-09
other O 0 8.353541858241442e-09
predisposition O 0 3.519350502756424e-05
genes O 0 2.0971635876776418e-06
. O 0 1.5532547195107327e-06

The O 0 6.900003199916682e-07
majority O 0 4.162669853258194e-08
( O 0 8.915922222740846e-09
81 O 0 1.999146661546547e-07
% O 0 1.0329554989141343e-09
) O 0 3.8440015059926225e-11
of O 0 2.7292728077554784e-09
the O 0 2.501002882127068e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.935819308826694e-09
were O 0 3.4731914566599187e-10
due O 0 6.2234356557056e-10
to O 0 5.400304647906751e-10
BRCA1 O 0 7.05875446982418e-09
, O 0 5.477505671258598e-10
with O 0 1.977380204021273e-10
most O 0 2.784408925649018e-09
others O 0 6.521759576827435e-09
( O 0 1.927342951901778e-09
14 O 0 6.29419503184181e-08
% O 0 2.547938970920427e-09
) O 0 1.8292731218672031e-10
due O 0 1.9541138485124065e-08
to O 0 1.3272558874177776e-07
BRCA2 O 0 2.5207071303157136e-05
. O 0 1.7811801171774277e-06

Conversely O 0 2.5086496862058993e-06
, O 0 1.8956148650772775e-08
the O 0 7.672530166757952e-09
majority O 0 5.604310904239185e-10
of O 0 2.632125406520913e-09
families O 0 2.058662573745096e-09
with O 0 7.152617942374206e-10
male B-Disease 0 4.797669816980488e-07
and I-Disease 0 1.1290338761682506e-06
female I-Disease 0 0.009347744286060333
breast I-Disease 0 0.01079090777784586
cancer I-Disease 1 0.9643130898475647
were O 0 2.342956229028914e-08
due O 0 7.599826545856558e-08
to O 0 2.1181303822004338e-08
BRCA2 O 0 3.338566614274896e-07
( O 0 5.355339727231012e-09
76 O 0 2.49962710086038e-07
% O 0 1.062929921857858e-08
) O 0 2.8441287103220247e-09
. O 0 1.1031139024453296e-07

The O 0 6.96063636951294e-07
largest O 0 3.8300660776258155e-07
proportion O 0 6.641113259320264e-08
( O 0 1.3299993328885762e-09
67 O 0 9.907161313549295e-09
% O 0 1.3768970685834603e-10
) O 0 2.0058221576746416e-12
of O 0 1.3270035070789277e-10
families O 0 1.1323778026373077e-10
due O 0 1.4137556680893226e-09
to O 0 1.8487966713109927e-10
other O 0 5.712143535951952e-10
genes O 0 2.0184094395858665e-09
was O 0 3.078663768363299e-09
found O 0 1.0738369915497259e-10
in O 0 6.705726252054234e-11
families O 0 5.052269158589695e-10
with O 0 2.6456234425431546e-10
four O 0 1.736512933447898e-09
or O 0 3.2770750002519833e-10
five O 0 2.952385835808258e-10
cases O 0 2.9979199123175704e-09
of O 0 1.8315323586648447e-06
female O 1 0.9999446868896484
breast B-Disease 1 0.9889984726905823
cancer I-Disease 0 7.055680180201307e-05
only O 0 1.0060992394755885e-07
. O 0 3.815134164142364e-07

These O 0 8.210572133293681e-08
estimates O 0 2.6938940322907e-07
were O 0 5.366822541930105e-09
not O 0 5.647770584538137e-10
substantially O 0 1.7296580168135733e-08
affected O 0 2.0637853648253213e-09
either O 0 3.168426354616116e-10
by O 0 3.692570138547069e-10
changing O 0 4.528420749494444e-09
the O 0 4.793825336690816e-09
assumed O 0 1.0283560669677172e-08
penetrance O 0 6.113251060924085e-08
model O 0 4.788743623862501e-09
for O 0 2.74989697679473e-09
BRCA1 O 0 2.8674158158992213e-08
or O 0 1.5304577605235181e-09
by O 0 1.0048862852940488e-09
including O 0 2.65686606049087e-09
or O 0 4.1404430106695145e-08
excluding O 0 6.44409112737776e-07
BRCA1 O 0 1.6954700754467922e-07
mutation O 0 3.138811877079206e-08
data O 0 2.52794421840008e-07
. O 0 8.429762488049164e-07

Among O 0 1.6579643613567896e-07
those O 0 1.1275210987093942e-08
families O 0 6.619207848501674e-09
with O 0 3.3092284468239086e-10
disease O 0 6.131900818218128e-07
due O 0 1.2421719652877528e-08
to O 0 1.0109111325817821e-09
BRCA1 O 0 1.056784437736269e-08
that O 0 3.376260937493214e-10
were O 0 2.24418109096014e-10
tested O 0 1.4984553875496687e-10
by O 0 1.3385981212366005e-10
one O 0 8.338653101347404e-10
of O 0 2.610566429694927e-09
the O 0 1.4291633432250705e-09
standard O 0 7.233121879224313e-10
screening O 0 1.7453814782353305e-10
methods O 0 1.3316847624622596e-09
, O 0 1.0180220000322038e-09
mutations O 0 4.6917700835535925e-09
were O 0 6.1724874100832494e-09
detected O 0 9.034416770248299e-09
in O 0 4.6250847596240874e-10
the O 0 5.869507990752254e-09
coding O 0 3.849656948773372e-08
sequence O 0 1.715539887925388e-08
or O 0 4.401259801056767e-09
splice O 0 8.140169427406363e-08
sites O 0 1.7158638954128946e-08
in O 0 9.780815046767088e-10
an O 0 1.68558556001841e-09
estimated O 0 4.559022048766792e-09
63 O 0 2.456427594665911e-08
% O 0 1.1083770568021123e-09
( O 0 3.594353981117848e-10
95 O 0 4.396219921432021e-08
% O 0 1.2535823046277983e-08
CI O 0 1.0799898291224963e-06
51 O 0 9.053361083033451e-08
% O 0 8.442326837609926e-09
- O 0 2.3718946806638996e-08
77 O 0 9.191072791736588e-08
% O 0 5.878123321423345e-09
) O 0 1.4932464154071567e-09
. O 0 7.58818075041745e-08

The O 0 2.738744910857349e-07
estimated O 0 5.5592192182984945e-08
sensitivity O 0 3.326875841480614e-08
was O 0 9.586703875186231e-09
identical O 0 1.2975552854399552e-09
for O 0 1.7813139852052018e-10
direct O 0 2.6196642632925204e-09
sequencing O 0 1.3252746455805209e-08
and O 0 7.115351863262731e-09
other O 0 9.037536052858286e-09
techniques O 0 6.967609351704596e-07
. O 0 1.0001733699027682e-06

The O 0 2.0048451006005052e-06
penetrance O 0 0.00015315850032493472
of O 0 9.22698927752208e-06
BRCA2 O 0 2.089348299705307e-06
was O 0 5.1135643275301845e-08
estimated O 0 2.7107516231694717e-09
by O 0 5.663217672591259e-10
maximizing O 0 1.4576137630228914e-07
the O 0 3.9917711802672784e-08
LOD O 0 0.00027669340488500893
score O 0 1.3136407517322368e-07
in O 0 1.624943912759136e-08
BRCA2 O 0 3.109655040134385e-07
- O 0 3.399967951622784e-08
mutation O 0 7.848997896076071e-09
families O 0 7.8902608890985e-09
, O 0 1.1990861636945738e-09
over O 0 1.2153769102241085e-09
all O 0 2.5935433800583496e-09
possible O 0 1.698985698794786e-07
penetrance O 0 1.7044014384737238e-05
functions O 0 4.2335167904639093e-07
. O 0 8.504616744176019e-07

The O 0 4.7572473960144634e-08
estimated O 0 1.7853190925620765e-08
cumulative O 0 6.575784539109009e-08
risk O 0 6.829795751173151e-08
of O 0 1.459026748307224e-07
breast B-Disease 0 2.3997224616323365e-06
cancer I-Disease 0 4.785614464708488e-07
reached O 0 8.62373070731337e-08
28 O 0 3.722819741369676e-08
% O 0 3.7893194138050035e-10
( O 0 1.1706878522144137e-10
95 O 0 1.9132720296966e-08
% O 0 3.762745226509878e-09
CI O 0 4.3672824290297285e-07
9 O 0 3.908326462465084e-08
% O 0 1.7455188405790523e-09
- O 0 3.4149663097338134e-09
44 O 0 9.803624578808012e-09
% O 0 2.637984553022221e-10
) O 0 3.747769455886285e-12
by O 0 5.4923586512156675e-11
age O 0 2.118088815450392e-09
50 O 0 1.939475469114882e-09
years O 0 6.139959096707059e-10
and O 0 1.6371599631526124e-09
84 O 0 2.797804476983856e-08
% O 0 4.910594708640303e-10
( O 0 8.130567052955229e-11
95 O 0 7.820977643291371e-09
% O 0 2.0555159796487033e-09
CI O 0 2.482669003711635e-07
43 O 0 1.8349570751752253e-08
% O 0 1.020232121007325e-09
- O 0 1.448209663301725e-09
95 O 0 4.723610391721422e-09
% O 0 2.2729659820974746e-10
) O 0 6.1308714181806945e-12
by O 0 8.60262416857438e-11
age O 0 1.7492791215545367e-08
70 O 0 4.525271535271713e-08
years O 0 3.298908879401097e-08
. O 0 2.2973769375767006e-07

The O 0 1.9635085664049257e-06
corresponding O 1 0.9999997615814209
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 6.274810402828734e-06
were O 0 8.643223914361897e-09
0 O 0 2.0456536731217057e-07
. O 0 8.500159509594596e-08

4 O 0 1.1107648788311053e-05
% O 0 7.030084248071944e-08
( O 0 3.460669084631718e-09
95 O 0 4.377201534566666e-08
% O 0 5.937031311020746e-09
CI O 0 3.1433714298145787e-07
0 O 0 2.0053901650385342e-08
% O 0 1.9058119526960127e-09
- O 0 1.6604978503309553e-09
1 O 0 5.7450240120715534e-09
% O 0 1.4473833243044965e-10
) O 0 2.104619213280645e-12
by O 0 1.1387362407189183e-11
age O 0 4.517074769783136e-10
50 O 0 4.5995116049191154e-10
years O 0 2.2696909629527084e-10
and O 0 7.912999144821242e-10
27 O 0 1.790181514138567e-08
% O 0 7.680506231011464e-10
( O 0 1.134262683777365e-10
95 O 0 6.9514665135272935e-09
% O 0 2.257533937566336e-09
CI O 0 1.481319173990414e-07
0 O 0 7.659545886440355e-09
% O 0 1.0127928495862193e-09
- O 0 1.7441609267976332e-09
47 O 0 1.0505743830435677e-08
% O 0 2.1479330813978237e-10
) O 0 6.959574843506955e-12
by O 0 6.495955162666434e-11
age O 0 8.785700167379673e-09
70 O 0 1.4312482754519351e-08
years O 0 9.72792602027539e-09
. O 0 1.0136498218571433e-07

The O 0 6.435683417294058e-07
lifetime O 0 3.2813679808896268e-06
risk O 0 0.004291628021746874
of O 0 0.3502286970615387
breast B-Disease 1 0.999556839466095
cancer I-Disease 0 2.951202441181522e-05
appears O 0 2.467178905618539e-09
similar O 0 2.8782991615128317e-11
to O 0 9.016676294493209e-11
the O 0 2.7146735970262625e-09
risk O 0 8.349702262933079e-09
in O 0 1.630052759438172e-09
BRCA1 O 0 1.4362635525344558e-08
carriers O 0 4.46336168025141e-09
, O 0 8.517987981626618e-10
but O 0 1.3441607826791824e-09
there O 0 2.2951458511499823e-09
was O 0 4.4710128932479165e-09
some O 0 3.727740338632657e-10
suggestion O 0 3.1512652043375056e-08
of O 0 6.524695894682964e-09
a O 0 7.191636175463145e-09
lower O 0 7.38081311624228e-08
risk O 0 1.605614663446886e-08
in O 0 2.5920396939937973e-09
BRCA2 O 0 2.9824086311691644e-08
carriers O 0 3.89406817902227e-09
< O 0 2.8573102994755573e-08
50 O 0 1.6286737292148246e-08
years O 0 8.759696967786113e-09
of O 0 6.412793851495735e-08
age O 0 7.29865803350549e-07
. O 0 7.754138664495258e-07

Eye B-Disease 0 0.0734255388379097
movement I-Disease 0 6.90685337758623e-05
abnormalities I-Disease 0 4.0745988371782005e-05
correlate O 0 1.782191532129218e-07
with O 0 1.595782950225555e-09
genotype O 0 2.1554708951043722e-07
in O 0 8.573476151241266e-09
autosomal O 0 0.0012422550935298204
dominant O 1 0.999996542930603
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 8.628528121334966e-06

We O 0 7.927280307740148e-07
compared O 0 9.377587275594124e-07
horizontal O 0 2.2636273570242338e-05
eye O 0 0.00027264311211183667
movements O 0 6.5144163272634614e-06
( O 0 8.182509958487572e-08
visually O 0 3.1412380963047326e-07
guided O 0 5.857376095264044e-07
saccades O 0 3.6748651837115176e-06
, O 0 4.664175179414087e-08
antisaccades O 0 3.0246112601162167e-06
, O 0 1.533977034284817e-08
and O 0 9.21200804526734e-09
smooth O 0 4.817430010461976e-08
pursuit O 0 4.847542456332121e-08
) O 0 5.535554792324149e-10
in O 0 1.0241548720202331e-09
control O 0 2.9278433899548872e-08
subjects O 0 1.4350770527471468e-07
( O 0 4.101329942329812e-09
n O 0 1.937520544004201e-08
= O 0 4.277141485431457e-08
14 O 0 2.2366453578115397e-08
) O 0 3.1048685844581314e-10
and O 0 4.88962148548211e-10
patients O 0 2.3144652860906945e-10
with O 0 3.5398552145071704e-11
three O 0 1.4296860917362153e-10
forms O 0 7.55012141695488e-09
of O 0 7.980973038002048e-08
autosomal O 0 0.0022434040438383818
dominant O 1 0.9997370839118958
cerebellar B-Disease 1 1.0
ataxias I-Disease 0 0.016156291589140892
type I-Disease 0 0.00016417042934335768
I I-Disease 0 0.00269871111959219
spinocerebellar B-Disease 0 0.0011363785015419126
ataxias I-Disease 0 1.682241418166086e-05
1 I-Disease 0 7.311622880479263e-07
and I-Disease 0 3.363627598673702e-08
2 I-Disease 0 4.1380278048563923e-07
( O 0 2.4338181248140245e-08
SCA1 B-Disease 0 0.00026244542095810175
, O 0 4.910449646899906e-08
n O 0 5.341070874465004e-08
= O 0 1.557201443347367e-07
11 O 0 1.1508053887610004e-07
; O 0 1.9186110478131013e-08
SCA2 B-Disease 0 1.9743310986086726e-05
, O 0 1.5322401125672513e-08
n O 0 1.9076312085530844e-08
= O 0 5.031214200812428e-08
10 O 0 2.6008862619164574e-08
) O 0 1.2484062672513119e-09
and O 0 1.3929693842840152e-08
SCA3 B-Disease 1 1.0
/ O 0 2.2724927930539707e-06
Machado B-Disease 0 7.870564218137588e-07
- I-Disease 0 6.449015472753672e-07
Joseph I-Disease 0 7.249049758684123e-06
disease I-Disease 1 0.9998144507408142
( O 0 2.7331299179422786e-07
MJD B-Disease 1 1.0
) O 0 1.8578479199504727e-08
( O 0 5.007278147672878e-09
n O 0 2.99478379872653e-08
= O 0 2.279503092950108e-07
16 O 0 4.855861561736674e-07
) O 0 2.1496074253946063e-08
. O 0 1.9895456659924093e-07

In O 0 1.4371536281032604e-06
SCA1 B-Disease 0 0.001323990523815155
, O 0 8.187802080783513e-08
saccade O 0 3.0497824354824843e-07
amplitude O 0 4.6134772446748684e-08
was O 0 9.533204448075594e-09
significantly O 0 6.887194370364114e-09
increased O 0 4.885923221564781e-09
, O 0 6.560569865143862e-10
resulting O 0 1.4793703151383397e-08
in O 0 8.927051098339689e-09
hypermetria B-Disease 0 4.967230779584497e-05
. O 0 1.3221914514360833e-06

The O 0 2.239673449366819e-06
smooth O 0 1.329971610175562e-06
pursuit O 0 1.3968480061521404e-06
gain O 0 2.0619015685952036e-06
was O 0 7.956727472446801e-07
decreased O 0 1.512591211394465e-06
. O 0 4.998044573767402e-07

In O 0 1.2452437658794224e-06
SCA2 B-Disease 0 0.0067384629510343075
, O 0 1.3841928137026116e-07
saccade O 0 1.6713549939595396e-06
velocity O 0 9.698210305941757e-07
was O 0 3.617463733007753e-07
markedly O 0 1.6878661881492008e-06
decreased O 0 1.1208984460608917e-06
. O 0 3.81385348191543e-07

The O 0 6.38353640169953e-07
percentage O 0 1.387702468491625e-06
of O 0 1.5379590934117005e-07
errors O 0 2.162876626243815e-06
in O 0 5.17586471460163e-08
antisaccades O 0 2.9337825253605843e-05
was O 0 3.371669521357035e-08
greatly O 0 6.6140337651177106e-09
increased O 0 1.5358031513201809e-09
and O 0 8.493393210962097e-10
was O 0 1.604046562242445e-09
significantly O 0 1.0028662345007433e-09
correlated O 0 1.6088796073177036e-08
with O 0 3.050441843566176e-10
age O 0 1.4037719608950283e-07
at O 0 6.313445055639022e-08
disease O 0 1.4984675544837955e-06
onset O 0 7.736729457974434e-06
. O 0 3.631462561770604e-07

In O 0 8.626773961850631e-08
addition O 0 2.4144449994878414e-08
, O 0 2.0530865896262185e-09
a O 0 1.9240959936439594e-09
correlation O 0 1.8577097193883674e-08
between O 0 6.526351459257285e-09
smooth O 0 2.8083263714506757e-08
pursuit O 0 3.888451161060402e-08
gain O 0 4.007738851896647e-08
and O 0 1.0834947383742133e-09
the O 0 1.9468213707796167e-09
number O 0 1.8117189526378752e-08
of O 0 1.2469021726246865e-07
trinucleotide O 0 2.8523680157377385e-05
repeats O 0 6.5920966108024e-07
was O 0 2.083749848225125e-07
found O 0 4.695855082559319e-08
. O 0 4.145730372329126e-07

In O 0 3.6627800454880344e-06
SCA3 B-Disease 1 1.0
, O 0 2.188033704442205e-06
gaze B-Disease 0 0.0001244953746208921
- I-Disease 0 4.206690846331185e-06
evoked I-Disease 0 4.661981438403018e-05
nystagmus I-Disease 0 5.298061660141684e-05
was O 0 1.5264330954778416e-07
often O 0 2.43681741451951e-09
present O 0 3.179324581381593e-09
as O 0 8.728709310901195e-09
was O 0 3.315631502687211e-08
saccade O 0 6.090754141041543e-07
hypometria O 0 3.0008275189175038e-06
and O 0 3.806447423926329e-08
smooth O 0 1.7031939592015988e-07
pursuit O 0 6.870389483992767e-07
gain O 0 8.32437308417866e-07
was O 0 5.04886429553153e-07
markedly O 0 4.013853867945727e-06
decreased O 0 2.2103192804934224e-06
. O 0 3.7549577314166527e-07

Three O 0 6.434652277675923e-07
major O 0 7.123420004973013e-07
criteria O 0 2.175907383161757e-07
, O 0 2.4812717214217628e-08
saccade O 0 7.609514227624459e-07
amplitude O 0 1.468911534630024e-07
, O 0 6.399497376463614e-09
saccade O 0 2.0663591726588493e-07
velocity O 0 1.4012829296916607e-07
, O 0 5.661147106650333e-09
and O 0 4.439757894658669e-09
presence O 0 2.457524601595651e-07
of O 0 3.1357802072307095e-05
gaze B-Disease 1 0.9176452159881592
- I-Disease 0 1.9159297153237276e-05
evoked I-Disease 0 0.00010356345592299476
nystagmus I-Disease 0 4.96152279083617e-06
, O 0 3.3588689607455535e-09
permitted O 0 7.083273523278422e-09
the O 0 5.048745421731837e-09
correct O 0 1.8734553464128112e-08
assignment O 0 2.000317067540891e-08
of O 0 8.395790729309738e-09
90 O 0 4.462138392113957e-08
% O 0 2.5866566666365998e-09
of O 0 5.050460050171068e-09
the O 0 2.571369783765931e-08
SCA1 B-Disease 0 4.321744927437976e-05
, O 0 1.833123097760847e-09
90 O 0 7.422697123615762e-09
% O 0 6.569221833174765e-10
of O 0 1.4023230354709426e-09
the O 0 1.3442306823208128e-08
SCA2 B-Disease 0 3.32675117533654e-05
, O 0 1.7866672585853394e-09
and O 0 1.1543052069740156e-09
93 O 0 1.3263469433866248e-08
% O 0 2.0186663451937648e-10
of O 0 3.758826583322161e-10
the O 0 1.3389791497786518e-09
patients O 0 1.1112262221502078e-09
with O 0 7.0495920212465535e-09
SCA3 B-Disease 1 1.0
to O 0 5.917111689512922e-09
their O 0 2.9726219263892517e-09
genetically O 0 1.87928161921036e-08
confirmed O 0 1.6929519119912584e-08
patient O 0 5.86096104981948e-09
group O 0 1.961042883635855e-09
and O 0 1.3837930801230414e-09
, O 0 1.0413012674348465e-09
therefore O 0 1.1880818107101732e-08
, O 0 3.3900331430913866e-09
may O 0 5.710534267677758e-09
help O 0 1.234131303817776e-07
orient O 0 0.0003803343861363828
diagnoses O 0 8.972184878075495e-05
of O 0 2.9709738100791583e-06
SCA1 B-Disease 1 0.9999990463256836
, O 0 3.232746337289427e-07
SCA2 B-Disease 1 0.9997245669364929
, O 0 7.485213160407511e-08
and O 0 3.342300090025674e-07
SCA3 B-Disease 1 1.0
at O 0 2.667554213076073e-07
early O 0 8.051136290987415e-08
clinical O 0 2.5236941425532677e-08
stages O 0 9.651158450196817e-08
of O 0 8.998203071541866e-08
the O 0 2.713992159897316e-07
diseases O 0 2.0468785805860534e-05
. O 0 1.0259584115601683e-07
. O 0 5.354361860554491e-07

Genetic O 0 8.287886998914473e-07
basis O 0 3.229548042327224e-07
and O 0 3.0531792649668432e-09
molecular O 0 1.7101469040881057e-07
mechanism O 0 8.062336291914107e-07
for O 0 3.9235789017766365e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.999622106552124

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.9994468092918396
causes O 0 3.1562351068714634e-05
more O 0 2.2175374869704e-09
than O 0 1.7042604827377517e-10
300 O 0 9.130069478224812e-10
, O 0 9.267034362103743e-11
000 O 0 4.683025967011645e-09
sudden O 0 7.402281454460535e-09
deaths O 0 3.994557129516352e-09
each O 0 3.0114893911914464e-10
year O 0 6.560457177506862e-10
in O 0 7.26550486440658e-10
the O 0 4.195030456344284e-08
USA O 0 5.715276643059042e-07
alone O 0 1.988225477589367e-07
. O 0 4.028896682939376e-07

In O 0 1.4890129307332245e-07
approximately O 0 5.101153632836031e-08
5 O 0 9.332570272135854e-08
- O 0 1.3182208213891045e-08
12 O 0 1.6086186604979957e-08
% O 0 3.006117854642554e-10
of O 0 1.0276667711250909e-10
these O 0 3.607243323489051e-11
cases O 0 3.2006061689848764e-10
, O 0 1.1110350139897918e-10
there O 0 7.878026703211916e-11
are O 0 4.7982291750958694e-11
no O 0 4.723862634392617e-09
demonstrable O 0 1.127366067521507e-05
cardiac O 0 4.159019226790406e-05
or O 0 3.897094416061009e-07
non O 1 0.9999966621398926
- O 0 0.0004182409029453993
cardiac O 0 0.20016160607337952
causes O 0 1.3217561445344472e-07
to O 0 3.842068052595238e-10
account O 0 1.0913514536525781e-09
for O 0 7.038477023435519e-10
the O 0 2.9604636964108977e-08
episode O 0 1.0795100813254521e-08
, O 0 1.514479930353474e-10
which O 0 3.713870877497527e-11
is O 0 1.1258904399069625e-11
therefore O 0 1.7873889868180726e-10
classified O 0 2.7169630989476445e-09
as O 0 3.575922136178633e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.8444628119468689
IVF B-Disease 1 1.0
) O 0 1.6748224140883394e-07
. O 0 3.963647543514526e-07

A O 0 1.7954463373826002e-06
distinct O 0 2.0602709582817624e-07
group O 0 1.4885635835071298e-08
of O 0 9.105608000936627e-08
IVF B-Disease 1 1.0
patients O 0 1.1794168841561259e-07
has O 0 1.3452097213928482e-09
been O 0 1.8737678075808617e-10
found O 0 9.531576222743254e-11
to O 0 7.106935179246321e-11
present O 0 1.3702459167319603e-09
with O 0 7.986478145483034e-10
a O 0 2.419428390965095e-08
characteristic O 0 1.905069893837208e-06
electrocardiographic O 0 1.4569187442248221e-05
pattern O 0 2.2480662664747797e-06
. O 0 5.290725084705628e-07

Because O 0 1.6054546847499296e-07
of O 0 4.5353212385634833e-07
the O 0 3.176326046627764e-08
small O 0 7.061514928352608e-09
size O 0 6.2573968229173715e-09
of O 0 5.4689901496374205e-09
most O 0 1.1576940517343814e-09
pedigrees O 0 1.96292990750635e-08
and O 0 1.980363206754987e-09
the O 0 6.631099225273829e-09
high O 0 1.5122118668386975e-07
incidence O 0 7.419479857162514e-07
of O 0 2.2189940551697873e-08
sudden B-Disease 0 5.773509883510997e-07
death I-Disease 0 1.2667425153267686e-06
, O 0 5.343177900130058e-09
however O 0 1.312876207748559e-08
, O 0 9.593777994254538e-10
molecular O 0 6.855477963085832e-09
genetic O 0 8.311013210970941e-09
studies O 0 3.178166840811514e-09
of O 0 2.7852655293258977e-08
IVF B-Disease 1 1.0
have O 0 8.501014114870031e-09
not O 0 2.332832593765488e-09
yet O 0 3.1491861562926715e-08
been O 0 1.793551440698593e-08
done O 0 1.3366761208999378e-07
. O 0 1.2451249631340033e-06

Because O 0 1.3889814454159932e-06
IVF B-Disease 1 1.0
causes O 0 0.001408599317073822
cardiac O 0 0.022424479946494102
rhythm O 0 7.1805206971475855e-06
disturbance O 0 0.00010941798245767131
, O 0 2.5570185968604164e-09
we O 0 1.1125835808201145e-09
investigated O 0 7.831307158312484e-09
whether O 0 4.648098350656937e-09
malfunction O 0 2.414324399069301e-06
of O 0 2.0415679813368115e-08
ion O 0 2.5797018565754115e-07
channels O 0 4.464504854695406e-08
could O 0 5.5651785402233145e-09
cause O 0 7.948612505970232e-07
the O 0 1.2314972153149029e-08
disorder O 0 1.7916368832970875e-08
by O 0 2.624624406699638e-10
studying O 0 1.199012999997251e-09
mutations O 0 7.3354189389363e-10
in O 0 3.0759036984129295e-10
the O 0 1.1374660324747765e-08
cardiac O 0 8.811924772089696e-07
sodium O 0 5.403382601798512e-06
channel O 0 7.808444024703931e-07
gene O 0 6.78788694585819e-07
SCN5A O 0 0.38817092776298523
. O 0 3.8129733184177894e-06

We O 0 4.1887344082169875e-07
have O 0 2.3208864163848375e-08
now O 0 1.009027617016045e-08
identified O 0 2.2493086504482562e-08
a O 0 7.732972484575384e-09
missense O 0 2.3805702653589833e-07
mutation O 0 1.3910287144369704e-08
, O 0 2.9404845225400322e-09
a O 0 3.819798699566945e-09
splice O 0 4.015551553493424e-07
- O 0 6.699279708755057e-08
donor O 0 2.417117705988403e-08
mutation O 0 7.354854059116178e-09
, O 0 7.559210479790579e-10
and O 0 3.9045303101836737e-10
a O 0 1.3739831494774535e-09
frameshift O 0 2.7869926810808465e-08
mutation O 0 5.83127490738633e-10
in O 0 1.6735109131804649e-10
the O 0 6.77710498830919e-10
coding O 0 3.0078531665367336e-08
region O 0 2.9342837493118168e-08
of O 0 7.557905945532184e-08
SCN5A O 0 0.32816046476364136
in O 0 1.3701629164586393e-08
three O 0 1.0503744363177248e-07
IVF B-Disease 1 1.0
families O 0 5.093288564239629e-07
. O 0 5.888960572519863e-07

We O 0 3.063167355321639e-07
show O 0 5.7986508039675755e-08
that O 0 1.749752120971948e-09
sodium O 0 1.7616107683693372e-08
channels O 0 2.460731174380726e-09
with O 0 1.1227515445133562e-10
the O 0 2.2324759818559414e-09
missense O 0 9.057246330712587e-08
mutation O 0 3.0080349322503253e-09
recover O 0 1.9265280926106243e-08
from O 0 9.669801848133375e-09
inactivation O 0 1.0492031776720978e-07
more O 0 3.4199709730842187e-10
rapidly O 0 2.8513200689417317e-09
than O 0 9.540925688389379e-11
normal O 0 9.683640556090722e-10
and O 0 2.1338940336956824e-10
that O 0 1.9339188583877842e-10
the O 0 5.165299743481455e-09
frameshift O 0 1.6033263250392338e-07
mutation O 0 9.130457279127313e-09
causes O 0 1.6086556087202553e-08
the O 0 7.653325084788776e-09
sodium O 0 5.228821819969198e-08
channel O 0 8.137075901970547e-09
to O 0 1.9160100173110095e-09
be O 0 1.639038416101357e-08
non O 0 2.038684442595695e-06
- O 0 2.1059699975012336e-06
functional O 0 8.002838512766175e-06
. O 0 1.305746081925463e-06

Our O 0 9.132390914601274e-07
results O 0 2.2792987408593035e-07
indicate O 0 1.3212394378570025e-07
that O 0 1.5721427493176066e-09
mutations O 0 1.0413971907041741e-08
in O 0 2.7570552507683033e-09
cardiac O 0 1.0153254947908863e-07
ion O 0 1.6976330243778648e-06
- O 0 2.5480530894128606e-06
channel O 0 2.5827633365338443e-08
genes O 0 1.2173650976166073e-09
contribute O 0 6.062074731083555e-10
to O 0 2.0538454270635498e-10
the O 0 1.6110528466839469e-09
risk O 0 9.000705070150161e-09
of O 0 7.359836295961486e-09
developing O 0 1.1558417867263415e-07
IVF B-Disease 1 1.0
. O 0 8.64852154336404e-08
. O 0 3.3086956818806357e-07

Molecular O 0 4.872310910286615e-06
heterogeneity O 0 6.837512501078891e-06
in O 0 7.432134907503496e-08
mucopolysaccharidosis B-Disease 0 0.00023723072081338614
IVA I-Disease 1 0.999992847442627
in O 0 1.7766568660704252e-08
Australia O 0 1.6425302229450267e-09
and O 0 1.918650349708173e-09
Northern O 0 3.090037026254322e-08
Ireland O 0 1.0134561634345118e-08
: O 0 5.690159454729837e-09
nine O 0 3.4180050789700545e-08
novel O 0 1.479392963688042e-08
mutations O 0 8.85791795468549e-09
including O 0 1.8200304596760475e-09
T312S O 0 1.0147965667783865e-06
, O 0 1.3526840758615322e-09
a O 0 1.461677112679638e-09
common O 0 2.3034916196706945e-09
allele O 0 1.2435801721721873e-08
that O 0 7.419098113636835e-10
confers O 0 1.4106431933669228e-07
a O 0 4.628319416610793e-08
mild O 0 1.9041943914999138e-06
phenotype O 0 2.4104799649649067e-06
. O 0 1.4496138192043873e-06

Mucopolysaccharidosis B-Disease 0 0.0010535537730902433
IVA I-Disease 1 1.0
( O 0 1.5129998246266041e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 4.942359765891524e-08
is O 0 3.967177253372256e-09
an O 0 4.054477642512211e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.00010660611587809399
by O 0 7.436609661404248e-10
a O 0 8.083953950688283e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.811890968487887e-09
N O 0 1.5173648648669769e-07
- O 0 1.3656197950240312e-07
acetylgalactosamine O 0 2.0343923097243533e-06
- O 0 9.888358363241423e-07
6 O 0 2.3436500669049565e-06
- O 0 1.6237655700024334e-06
sulfate O 0 8.48235322337132e-06
sulfatase O 0 5.5027685448294505e-05
( O 0 7.226046818686882e-07
GALNS O 0 0.20642340183258057
) O 0 2.274126842394253e-07
. O 0 1.1886482980116853e-06

Previous O 0 5.21937579378573e-07
studies O 0 3.030721273944437e-08
of O 0 6.810514818766933e-09
patients O 0 9.007364298874165e-10
from O 0 1.2374772317969018e-09
a O 0 8.372567084080629e-10
British O 0 3.0202287337743883e-09
- O 0 4.583189827656042e-09
Irish O 0 1.68600033934041e-09
population O 0 2.2571926272529907e-10
showed O 0 4.174409429236192e-10
that O 0 2.0944966247493646e-11
the O 0 4.774368123072747e-10
I113F O 0 3.1810973410983934e-08
mutation O 0 8.1768386506198e-10
is O 0 2.584731872978807e-10
the O 0 3.6852104701168287e-10
most O 0 3.413531957097149e-10
common O 0 1.2325322706896458e-10
single O 0 1.1755074691421896e-10
mutation O 0 1.1279013278908678e-09
among O 0 8.240801818715227e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.5319047008688358e-07
and O 0 3.6664644653683354e-09
produces O 0 1.1957797418915561e-08
a O 0 4.82831863379829e-09
severe O 0 7.105562076503702e-07
clinical O 0 3.668033627945988e-07
phenotype O 0 3.0820312986179488e-06
. O 0 7.571532023575855e-07

We O 0 3.2633568025630666e-07
studied O 0 2.703937411752122e-07
mutations O 0 3.769492096239446e-08
in O 0 4.130927599987899e-09
the O 0 2.1638651759303684e-08
GALNS O 0 1.4806209946982563e-05
gene O 0 5.637248001733042e-09
from O 0 6.6165575240972885e-09
23 O 0 2.5726892616262376e-08
additional O 0 3.891374689146687e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 4.487093718807955e-08
( O 0 1.3592350578406354e-09
15 O 0 8.554071229127658e-09
from O 0 3.749291099808261e-09
Australia O 0 2.427515133351932e-10
, O 0 3.378232138473436e-10
8 O 0 2.9319158212359753e-09
from O 0 1.6141378234024728e-09
Northern O 0 9.618719154502742e-09
Ireland O 0 2.8634847826225496e-09
) O 0 5.336941444333831e-10
, O 0 3.045674823454192e-10
with O 0 9.330083927672206e-11
various O 0 5.15435605308312e-09
clinical O 0 2.4763176043052226e-07
phenotypes O 0 2.002028122660704e-05
( O 0 7.294726600548529e-08
severe O 0 0.09818968176841736
, O 0 1.5789741070193486e-08
16 O 0 4.4920685837723795e-08
cases O 0 4.226083483160892e-09
; O 0 2.3502593204938194e-09
intermediate O 0 1.0655935511749703e-07
, O 0 2.506710394811762e-09
4 O 0 1.1875584959852858e-08
cases O 0 3.884861321523658e-09
; O 0 1.2035870078364042e-08
mild O 0 2.425306036002439e-07
, O 0 3.808333648436246e-09
3 O 0 2.137896970566544e-08
cases O 0 1.2658552428490566e-08
) O 0 1.2488641232266673e-08
. O 0 2.676514156974008e-07

We O 0 1.0812186701514293e-07
found O 0 2.134816412535656e-08
two O 0 4.456760294146989e-09
common O 0 2.613196992129474e-09
mutations O 0 3.5518297192282944e-09
that O 0 2.0710359815989676e-10
together O 0 2.7954760728476913e-10
accounted O 0 5.564318783513045e-09
for O 0 2.450028513401037e-10
32 O 0 2.4233679951635168e-08
% O 0 5.328143481975189e-10
of O 0 9.823910573913963e-10
the O 0 3.0824949259766754e-09
44 O 0 3.652186464364604e-08
unrelated O 0 2.614180338866845e-08
alleles O 0 3.6518499335613797e-09
in O 0 1.1228720175893159e-09
these O 0 8.18383316669724e-09
patients O 0 3.854609076370252e-08
. O 0 2.9650533406311297e-07

One O 0 3.624553244208073e-07
is O 0 1.7534047103140438e-08
the O 0 3.285339289504918e-08
T312S O 0 1.756871483848954e-06
mutation O 0 3.252065994274744e-08
, O 0 2.7653290768370198e-09
a O 0 1.8043933014411095e-09
novel O 0 4.471746528622589e-09
mutation O 0 1.477260536120184e-09
found O 0 6.30371699283927e-10
exclusively O 0 1.5637420247571754e-09
in O 0 5.1795034927693e-10
milder O 0 1.3006950894123293e-06
patients O 0 3.719817343039722e-08
. O 0 2.71733313184086e-07

The O 0 6.571659127985185e-07
other O 0 8.239940996190853e-08
is O 0 6.345531211593425e-09
the O 0 1.682817263315428e-08
previously O 0 2.7555531190159854e-08
described O 0 1.744141897574991e-08
I113F O 0 2.639155525230308e-07
that O 0 7.432823245778764e-10
produces O 0 6.745268787966552e-09
a O 0 8.097071457768834e-09
severe O 0 1.7811307770898566e-06
phenotype O 0 3.4484066873119446e-06
. O 0 9.84162056738569e-07

The O 0 3.052196461794665e-06
I113F O 0 2.2484358851215802e-05
and O 0 1.1632996432808795e-07
T312S O 0 1.3403899856712087e-06
mutations O 0 8.302730236664502e-08
accounted O 0 8.833593057033795e-08
for O 0 5.129249469604247e-09
8 O 0 6.169500466057798e-08
( O 0 2.870828907930445e-09
18 O 0 2.515284336368495e-08
% O 0 9.147709256751568e-10
) O 0 2.9919757643659395e-11
and O 0 4.644365170225484e-10
6 O 0 1.3298274481599037e-08
( O 0 5.799021263186432e-10
14 O 0 1.445255115584132e-08
% O 0 7.609972652034003e-10
) O 0 3.325462474834673e-11
of O 0 1.436153196365808e-09
44 O 0 1.6030686111889736e-08
unrelated O 0 2.5704084194444476e-08
alleles O 0 2.864644166322705e-08
, O 0 2.823800571150059e-08
respectively O 0 1.027417297905231e-07
. O 0 4.218870230943139e-07

The O 0 1.161651539405284e-06
relatively O 0 1.1864580073961406e-06
high O 0 1.2266023077245336e-06
residual O 0 8.994894596980885e-05
GALNS O 0 0.06755900382995605
activity O 0 1.7379991845700715e-07
seen O 0 2.2824391265885424e-08
when O 0 1.8554885405919208e-09
the O 0 2.81557621661932e-09
T312S O 0 6.636796001657785e-08
mutant O 0 1.0061737221178646e-08
cDNA O 0 4.337731951409296e-08
is O 0 3.5147240673438773e-09
overexpressed O 0 2.15694299754432e-07
in O 0 1.0428576890930685e-09
mutant O 0 1.5933354191588478e-08
cells O 0 2.1182504639227773e-09
provides O 0 1.1252646592296855e-09
an O 0 6.09546371710401e-11
explanation O 0 1.1243764808099854e-09
for O 0 2.1539475758558524e-10
the O 0 4.348183590963117e-09
mild O 0 1.3842139878761373e-07
phenotype O 0 1.8401371093546004e-08
in O 0 4.173645040683738e-10
patients O 0 4.322440183557319e-10
with O 0 2.4024987554938093e-10
this O 0 3.06893133128483e-09
mutation O 0 1.6057255436408013e-07
. O 0 3.837191400180018e-07

The O 0 7.114201139302168e-08
distribution O 0 2.1633081104255325e-08
and O 0 1.6823993309600382e-09
relative O 0 1.275598648931009e-08
frequencies O 0 1.0252537485655466e-08
of O 0 1.0577786646592813e-08
the O 0 1.176930997104364e-08
I113F O 0 3.261160372858285e-07
and O 0 6.154148746162491e-09
T312S O 0 2.1547020878642797e-07
mutations O 0 6.2593663585630566e-09
in O 0 1.110683767180376e-09
Australia O 0 3.130712911136868e-10
corresponded O 0 2.75231082369487e-09
to O 0 6.190853940601926e-10
those O 0 2.4968900280697426e-09
observed O 0 4.669290731840192e-09
in O 0 3.756533140109042e-10
Northern O 0 6.6182987978891106e-09
Ireland O 0 8.834864506646056e-10
and O 0 2.558365075344682e-09
are O 0 2.844409430213801e-10
unique O 0 5.759646648506589e-10
to O 0 2.7411087288875535e-10
these O 0 1.0647169812472157e-09
two O 0 2.031955936843133e-09
populations O 0 4.426423672043711e-09
, O 0 7.555203129783195e-10
suggesting O 0 6.269594621244323e-09
that O 0 1.4198656694830447e-09
both O 0 7.442998661844058e-09
mutations O 0 1.4751382337863106e-08
were O 0 9.807739509426483e-09
probably O 0 3.519191826839574e-09
introduced O 0 6.043822664558718e-10
to O 0 8.019295782979441e-10
Australia O 0 5.40107736313189e-10
by O 0 9.06527519717315e-10
Irish O 0 2.07181223288444e-08
migrants O 0 4.1893450486441e-08
during O 0 5.563745464343128e-09
the O 0 2.523915654251141e-08
19th O 0 9.558841611578828e-07
century O 0 2.1557309537456604e-06
. O 0 1.4039048892300343e-06

Haplotype O 0 3.6709839150717016e-06
analysis O 0 2.746157008459704e-07
using O 0 8.193848088922095e-08
6 O 0 9.091930337490339e-07
RFLPs O 0 1.3079320524411742e-06
provides O 0 4.335140690869821e-09
additional O 0 8.727689682075379e-10
data O 0 4.582263901653505e-09
that O 0 3.264330195040799e-10
the O 0 4.284340882065862e-09
I113F O 0 1.301631584738061e-07
mutation O 0 1.0221643531593827e-09
originated O 0 2.5472441933516166e-09
from O 0 1.8050335670594109e-09
a O 0 5.349775289431591e-09
common O 0 1.804717797426747e-08
ancestor O 0 1.7599218153918628e-06
. O 0 1.189358158626419e-06

The O 0 1.1196387958989362e-06
other O 0 1.6688976245404774e-07
9 O 0 2.823629188242194e-07
novel O 0 1.5046833112819513e-08
mutations O 0 1.4988714269748016e-08
identified O 0 8.516562566285302e-09
in O 0 1.7612628022689591e-10
these O 0 4.5963280403960027e-10
23 O 0 8.630078873750335e-09
patients O 0 6.275274189171398e-10
were O 0 1.099493607270574e-09
each O 0 1.4142376159043124e-10
limited O 0 6.793981488506518e-10
to O 0 1.0726215471379419e-09
a O 0 1.3818763022754865e-08
single O 0 3.145974147855668e-08
family O 0 2.3585420194649487e-07
. O 0 6.088652071412071e-07

These O 0 1.0174210984814636e-07
data O 0 9.468587336414203e-08
provide O 0 1.523012471693619e-08
further O 0 8.979014864962664e-09
evidence O 0 1.916449399175235e-08
for O 0 1.862168197419578e-09
extensive O 0 2.791866116069741e-08
allelic O 0 3.0698939212925325e-07
heterogeneity O 0 4.690734556334064e-07
in O 0 1.8662047907014312e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 1.1341254158026004e-08
British O 0 3.370595536011933e-08
- O 0 5.462946361944887e-08
Irish O 0 9.81275416478411e-09
patients O 0 1.392418846890564e-09
and O 0 2.7654173395674775e-10
provide O 0 5.208729003669532e-10
evidence O 0 1.0125866367616254e-08
for O 0 5.757054277744089e-10
their O 0 8.819796004644331e-10
transmission O 0 7.330932749738395e-09
to O 0 4.0609129947632994e-10
Australia O 0 1.223589285448412e-10
by O 0 9.339240492067802e-10
British O 0 1.923899084488312e-08
- O 0 5.491560273185314e-08
Irish O 0 3.5417112798086237e-08
migrants O 0 9.237189146915625e-08
. O 0 1.900621882100495e-08
. O 0 3.37547646722669e-07

Identification O 0 8.376422329092748e-07
of O 0 1.1654921081571956e-06
constitutional O 0 1.521655940450728e-05
WT1 O 0 0.06438742578029633
mutations O 0 1.930988673848333e-06
, O 0 1.4963690730951384e-08
in O 0 6.285492126778536e-10
patients O 0 6.55166643159788e-10
with O 0 6.412714248504869e-10
isolated O 0 1.3218726962804794e-05
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.2155378359988163e-09
and O 0 9.686165758360232e-11
analysis O 0 4.0246103671925937e-10
of O 0 5.306685313399839e-09
genotype O 0 3.8732923712814227e-07
/ O 0 3.574402285266842e-07
phenotype O 0 3.4579720420424565e-08
correlations O 0 2.5650310320202152e-08
by O 0 5.989232998437899e-10
use O 0 3.789791147568167e-09
of O 0 3.704220219447052e-08
a O 0 1.0924558146996333e-08
computerized O 0 2.3574312990604085e-07
mutation O 0 4.917301055229473e-08
database O 0 3.7435839317367936e-07
. O 0 1.0859253052331042e-06

Constitutional O 0 5.7856641433318146e-06
mutations O 0 2.5255153559555765e-06
of O 0 1.4976674265199108e-06
the O 0 4.420250547809701e-07
WT1 O 0 1.3497035979526117e-05
gene O 0 5.573955874638159e-08
, O 0 1.1529921017938705e-08
encoding O 0 3.83448757190763e-08
a O 0 1.664245559140909e-07
zinc O 0 6.398615255420737e-07
- O 0 2.3678002492033556e-07
finger O 0 2.1406903272236377e-07
transcription O 0 3.609527254866407e-07
factor O 0 8.934856765563381e-08
involved O 0 1.0009691742141058e-08
in O 0 7.225982923131369e-09
renal O 1 1.0
and O 0 7.408796227537096e-05
gonadal O 1 0.9963723421096802
development O 0 4.1557286749593914e-05
, O 0 1.7820726005979282e-09
are O 0 2.0962080682362938e-10
found O 0 4.801408715060518e-10
in O 0 2.8449304023681066e-10
most O 0 1.656796366766855e-09
patients O 0 8.307871057766647e-10
with O 0 8.917504068506332e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.8150993128074333e-05
DDS B-Disease 1 1.0
) O 0 1.5842172018665224e-08
, O 0 5.5335727111582855e-09
or O 0 5.8161521820920825e-08
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.0068630444948212e-06
DMS B-Disease 0 4.245925447321497e-05
) O 0 2.191016923447364e-09
associated O 0 3.283215832539099e-08
with O 0 9.602862505175835e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.3321905498742126e-06
/ O 0 1.4370999451784883e-05
or O 0 1.139898245128279e-06
Wilms B-Disease 1 0.9629261493682861
tumor I-Disease 0 0.041375961154699326
( O 0 1.3393408835327136e-06
WT B-Disease 1 1.0
) O 0 1.891923915309235e-07
. O 0 6.310302751444397e-07

Most O 0 1.9218822444599937e-07
mutations O 0 4.809562028640357e-07
in O 0 5.491602550478092e-08
DDS B-Disease 1 1.0
patients O 0 4.5284403427103825e-07
lie O 0 1.7592444123692985e-07
in O 0 6.467107294128027e-09
exon O 0 1.3165353607291763e-07
8 O 0 1.6830234983444825e-07
or O 0 6.331906110546015e-09
exon O 0 6.087710602287189e-08
9 O 0 1.7119322137659765e-07
, O 0 3.785679769663375e-09
encoding O 0 1.6078801934327203e-07
zinc O 0 7.517228368669748e-06
finger O 0 4.434954462340102e-06
2 O 0 7.800110324751586e-06
or O 0 9.994049605666078e-07
zinc O 0 4.363703283161158e-06
finger O 0 1.68013502843678e-06
3 O 0 6.538159027513757e-07
, O 0 9.441082582384297e-09
respectively O 0 1.4578967366674078e-08
, O 0 1.2340477528738347e-09
with O 0 1.1027763147097858e-09
a O 0 3.596620246071325e-08
hot O 0 1.578734918439295e-05
spot O 0 4.590135176840704e-06
( O 0 1.4767091549572342e-08
R394W O 0 9.62705257734342e-07
) O 0 4.919071372455619e-09
in O 0 1.6952203196751725e-08
exon O 0 8.102572337520542e-07
9 O 0 5.823072569910437e-06
. O 0 1.4534705314872554e-06

We O 0 9.032335412939574e-08
analyzed O 0 7.840607452180848e-08
a O 0 9.011734469765997e-09
series O 0 4.683008203443251e-09
of O 0 6.602638880082168e-09
24 O 0 2.257048414833207e-08
patients O 0 9.859727478911395e-10
, O 0 1.0378432557800465e-09
10 O 0 4.262301178670214e-09
with O 0 2.881477056959625e-09
isolated B-Disease 0 0.00128699722699821
DMS I-Disease 1 1.0
( O 0 1.280053538721404e-06
IDMS B-Disease 1 0.9999688863754272
) O 0 8.916194005337275e-09
, O 0 3.751615906821826e-09
10 O 0 7.135874557917532e-09
with O 0 5.983675777088138e-09
DDS B-Disease 1 1.0
, O 0 1.4865660702412242e-08
and O 0 6.958815745861102e-09
4 O 0 1.731847589780955e-07
with O 0 3.985730501199214e-08
urogenital B-Disease 1 0.9999384880065918
abnormalities I-Disease 1 0.9999319314956665
and O 0 2.8355229005683213e-05
/ O 1 0.9982380867004395
or O 0 0.002912756986916065
WT B-Disease 1 1.0
. O 0 5.959218015050283e-06

We O 0 9.273179557567346e-07
report O 0 1.2172866945547867e-06
WT1 O 0 0.00018889359489548951
heterozygous O 0 1.9437098330854496e-07
mutations O 0 7.84041276347125e-08
in O 0 5.584019469040413e-09
16 O 0 4.338360781730444e-08
patients O 0 1.845521180321441e-09
, O 0 1.129914606323723e-09
4 O 0 2.611230165427969e-08
of O 0 5.633037858387979e-08
whom O 0 3.2188538057198457e-07
presented O 0 1.2001230516034411e-06
with O 0 3.8934427948333905e-07
IDMS B-Disease 1 1.0
. O 0 1.284615518670762e-05

One O 0 7.889283324402641e-07
male O 0 2.1028623109486944e-07
and O 0 9.801680356247289e-09
two O 0 1.2517354264218739e-08
female O 0 1.359046990501156e-07
IDMS B-Disease 1 0.9285531044006348
patients O 0 9.035074555185929e-08
with O 0 8.245239513371416e-08
WT1 O 1 1.0
mutations O 1 0.7223166227340698
underwent O 0 2.4859011318767443e-05
normal O 0 7.361814823525492e-06
puberty O 0 1.223955496243434e-05
. O 0 5.354096401788411e-07

Two O 0 1.639217401816495e-07
mutations O 0 1.9724819821931305e-07
associated O 0 7.191925988081493e-07
with O 0 4.586760482538921e-08
IDMS B-Disease 1 0.9999998807907104
are O 0 3.0949547369374386e-09
different O 0 1.5949704890161343e-09
from O 0 8.47676062676328e-09
those O 0 1.8648267374743455e-09
described O 0 1.768465018869847e-08
in O 0 1.5923236063031254e-08
DDS B-Disease 1 1.0
patients O 0 4.776290438712749e-07
. O 0 4.304378080632887e-07

No O 0 3.9602045944775455e-06
WT1 O 0 0.00014610242214985192
mutations O 0 3.1579503456669045e-07
were O 0 2.0119530930173823e-08
detected O 0 1.2094644397109278e-08
in O 0 3.8401926083508897e-10
the O 0 1.8562530401666777e-09
six O 0 3.5983411805773358e-09
other O 0 1.0805833561278178e-08
IDMS B-Disease 1 1.0
patients O 0 4.848374857147064e-08
, O 0 1.208652067319349e-09
suggesting O 0 7.835894599850235e-09
genetic O 0 1.0324187371679727e-07
heterogeneity O 0 1.1587412700464483e-05
of O 0 2.176038123025137e-07
this O 0 2.5266128744760863e-08
disease O 0 9.669593964645173e-06
. O 0 4.3783168734989886e-07

We O 0 2.1592728671748773e-07
analyzed O 0 5.045764055466861e-07
genotype O 0 1.0603804412312456e-06
/ O 0 3.8572278526771697e-07
phenotype O 0 1.437494603351297e-07
correlations O 0 3.407649273867719e-07
, O 0 1.4335314046931558e-09
on O 0 1.2143041017154133e-09
the O 0 4.66247151997834e-10
basis O 0 2.9480431429362852e-09
of O 0 1.3146296273802704e-09
the O 0 2.0754342688888983e-09
constitution O 0 5.83220094441117e-09
of O 0 3.3075910010893494e-08
a O 0 1.888916223435899e-08
WT1 O 0 3.6938672565156594e-06
mutation O 0 4.14055145725456e-09
database O 0 1.3682930344316446e-08
of O 0 3.686592009444212e-08
84 O 0 1.1975033942235314e-07
germ O 0 2.331687483092537e-06
- O 0 2.4650953491800465e-06
line O 0 3.120033170489478e-06
mutations O 0 1.0495710078828324e-08
, O 0 3.9801656415150433e-10
to O 0 1.3403275711532103e-10
compare O 0 3.4514402447172188e-09
the O 0 2.4939721399164227e-09
distribution O 0 6.086942061500622e-09
and O 0 9.774567821807523e-10
type O 0 2.581753655306329e-08
of O 0 4.936848441161601e-08
mutations O 0 1.298061036436593e-08
, O 0 9.647836973769586e-10
according O 0 1.2797846116185951e-09
to O 0 1.5696407507093113e-09
the O 0 2.005221944045843e-08
different O 0 4.47473524900488e-08
symptoms O 0 1.8653472579899244e-05
. O 0 4.720271249425423e-07

This O 0 5.507021327844086e-08
demonstrated O 0 1.219353151782343e-07
( O 0 8.126901818172882e-09
1 O 0 4.9461792883676026e-08
) O 0 3.697926687085129e-10
the O 0 2.345163618855395e-09
association O 0 8.579397636765407e-09
between O 0 1.4243989987505756e-08
mutations O 0 1.8693468106789624e-08
in O 0 4.251567098378928e-09
exons O 0 1.0094996127918421e-07
8 O 0 9.933769007375304e-08
and O 0 8.776857463033139e-09
9 O 0 7.122428513639534e-08
and O 0 2.7742533603714037e-08
DMS B-Disease 0 1.0087611372000538e-05
; O 0 4.641323414489307e-08
( O 0 6.194648793922397e-09
2 O 0 1.0099830660692533e-07
) O 0 6.016104281414414e-10
among O 0 2.561587608695959e-09
patients O 0 7.138062363409858e-10
with O 0 1.5812217091237812e-09
DMS B-Disease 0 0.000330812152242288
, O 0 1.0009514328501723e-09
a O 0 7.385946854121528e-10
higher O 0 3.6402363345899857e-09
frequency O 0 3.913546375855503e-09
of O 0 6.426922105617905e-09
exon O 0 1.4989458563263724e-08
8 O 0 2.9226098874346462e-08
mutations O 0 5.4468682897379495e-09
among O 0 7.322129125242327e-09
46 O 0 1.1300189584062537e-07
, O 0 6.7191376906805544e-09
XY O 0 5.615531790681416e-06
patients O 0 1.313952835424459e-09
with O 0 7.391766643216613e-10
female O 0 4.617322080235908e-09
phenotype O 0 1.7477509439700611e-09
than O 0 1.493447865374975e-10
among O 0 1.1802888666423428e-09
46 O 0 3.987160113183563e-08
, O 0 6.563865007080949e-09
XY O 0 2.124234197253827e-05
patients O 0 2.1911965575327486e-09
with O 0 6.63287924584921e-10
sexual O 0 2.4361668238270795e-09
ambiguity O 0 1.3241630014704242e-08
or O 0 2.6002797692825652e-09
male O 0 2.6964468435863864e-09
phenotype O 0 9.546141654936946e-09
; O 0 1.809984162548517e-09
and O 0 8.181210375823866e-09
( O 0 6.61812205038359e-09
3 O 0 9.050874894001026e-08
) O 0 8.188293931787882e-10
statistically O 0 1.5658560670317456e-08
significant O 0 4.524113084158898e-09
evidence O 0 1.9556127384134925e-08
that O 0 1.8648125266196303e-09
mutations O 0 1.4445550533537244e-08
in O 0 6.5278329408613445e-09
exons O 0 8.732194345384414e-08
8 O 0 1.8814377256148873e-07
and O 0 1.8401021151248642e-08
9 O 0 7.876385410554576e-08
preferentially O 0 2.6240766004548277e-08
affect O 0 3.153405359057615e-08
amino O 0 3.3678965394301486e-08
acids O 0 1.2601027776781848e-08
with O 0 6.737408964063718e-10
different O 0 2.0111194931615728e-09
functions O 0 9.856949034769968e-09
. O 0 1.475608168988174e-08
. O 0 1.2619599942809145e-07

The O 0 2.4021221634029644e-06
185delAG O 0 1.450356012355769e-05
BRCA1 O 0 5.244223189038166e-07
mutation O 0 7.577272143066693e-09
originated O 0 5.490290444498669e-09
before O 0 5.006129399909298e-10
the O 0 3.4344829757948503e-10
dispersion O 0 1.209123112744237e-08
of O 0 2.0602179962025957e-09
Jews O 0 4.041627921225199e-09
in O 0 2.9734936735081874e-10
the O 0 3.3457101533684863e-09
diaspora O 0 1.3916125141122393e-08
and O 0 2.328262915796131e-09
is O 0 5.821740312050849e-10
not O 0 7.133190149666291e-10
limited O 0 1.613276801037955e-08
to O 0 4.973850664669044e-08
Ashkenazim O 0 0.00015681776858400553
. O 0 4.363453626865521e-06

The O 0 6.444920472858939e-07
185delAG O 0 1.946841166500235e-06
mutation O 0 9.234035758254322e-08
in O 0 1.6549654091591037e-08
BRCA1 O 0 9.435055403628212e-08
is O 0 3.36204819539887e-09
detected O 0 5.180375683977445e-09
in O 0 3.350881516706039e-10
Ashkenazi O 0 1.8851478600367955e-08
Jews O 0 1.1549774470154262e-08
both O 0 1.1115590670129905e-09
in O 0 1.310118902253521e-09
familial B-Disease 1 0.8800877928733826
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.6554507764610094e-09
in O 0 1.8364255949254726e-10
the O 0 1.4442568252448496e-09
general O 0 9.221746921639351e-09
population O 0 5.798935998058141e-09
. O 0 5.5212304062024486e-08

All O 0 1.4438450079978793e-07
tested O 0 3.7346044479136253e-08
Ashkenazi O 0 4.0899113429304634e-08
mutation O 0 2.748161476162636e-09
carriers O 0 1.6748177289471755e-09
share O 0 7.656898448615834e-10
the O 0 6.190700174713015e-10
same O 0 9.812823886790056e-10
allelic O 0 2.279902986401794e-07
pattern O 0 3.1228026386997954e-07
at O 0 8.939339579683292e-08
the O 0 2.40491118574937e-07
BRCA1 O 0 3.1380839118355652e-06
locus O 0 1.0019472256317385e-06
. O 0 1.156694565906946e-06

Our O 0 9.375816034662421e-07
previous O 0 8.07267852565019e-08
study O 0 4.023537947261957e-09
showed O 0 6.071254166073459e-09
that O 0 1.949205657991726e-10
this O 0 4.683104459779486e-10
Ashkenazi O 0 1.861252840740235e-08
mutation O 0 1.2769123536315874e-09
also O 0 1.779028868664767e-10
occurs O 0 2.0870841166420462e-10
in O 0 1.3460406400600533e-10
Iraqi O 0 3.616528658767493e-07
Jews O 0 1.775228213318769e-07
with O 0 5.645907630302816e-10
a O 0 1.9601678058478456e-09
similar O 0 4.0250114352602395e-09
allelic O 0 1.662979343564075e-06
pattern O 0 1.842197093537834e-06
. O 0 1.102707415157056e-06

We O 0 3.56329309170178e-07
extended O 0 2.3687037753461482e-07
our O 0 1.6842429673147308e-08
analysis O 0 4.033326561625472e-09
to O 0 1.488528744708617e-09
other O 0 3.913710688863148e-09
non O 0 1.3697558642888907e-07
- O 0 8.846102872439587e-08
Ashkenazi O 0 6.065561564128075e-08
subsets O 0 2.413128363798478e-08
354 O 0 2.6593061974722332e-08
of O 0 3.842810514242956e-09
Moroccan O 0 1.0742399325636143e-07
origin O 0 2.689801448241269e-08
, O 0 6.342868896780374e-09
200 O 0 1.8563319770237285e-08
Yemenites O 0 4.523873542439105e-07
and O 0 5.126491231521868e-09
150 O 0 2.1908091341060754e-08
Iranian O 0 7.465821454388788e-07
Jews O 0 9.331108685728395e-07
. O 0 1.1492177236505086e-06

Heteroduplex O 0 4.323443499743007e-05
analysis O 0 1.622402123757638e-07
complemented O 0 1.0581564424683165e-07
by O 0 2.4573916235226534e-09
direct O 0 2.568428669746936e-08
DNA O 0 7.211390595784906e-08
sequencing O 0 2.3134663251767051e-07
of O 0 4.368702661849966e-07
abnormally O 0 8.93933815859782e-07
migrating O 0 6.627017512528255e-08
bands O 0 4.567745648387245e-08
were O 0 4.382464524610441e-08
employed O 0 2.3284290762148885e-07
. O 0 3.2563184504397213e-07

Four O 0 4.6651271645714587e-07
of O 0 1.5844776157791784e-07
Moroccan O 0 2.2812478164269123e-06
origin O 0 6.028331256402453e-08
( O 0 2.069410198757282e-09
1 O 0 7.3622370422299355e-09
. O 0 5.782233025719563e-10
1 O 0 6.881810676873101e-09
% O 0 2.2669650878714975e-10
) O 0 1.070376513118143e-11
and O 0 7.365558163385799e-11
none O 0 3.37872330113953e-09
of O 0 3.738372722494887e-09
the O 0 1.7794988593777816e-08
Yemenites O 0 6.104210115154274e-07
or O 0 7.304553406584091e-09
Iranians O 0 2.8695714249238335e-08
was O 0 1.503372359934474e-08
a O 0 1.3461439740680703e-09
carrier O 0 7.3746324602552704e-09
of O 0 8.689275077244929e-09
the O 0 8.90831159949812e-08
185delAG O 0 8.043037269089837e-06
mutation O 0 1.563742216603714e-06
. O 0 1.999687356146751e-06

BRCA1 O 0 1.355329732177779e-05
allelic O 0 5.291626166581409e-06
patterns O 0 6.003896260153851e-07
were O 0 1.0918620674260637e-08
determined O 0 5.71310554420279e-09
for O 0 1.3582398539213614e-09
four O 0 2.6980675471577342e-09
of O 0 3.179179364209972e-09
these O 0 2.851449076857193e-10
individuals O 0 1.9764299918900718e-10
and O 0 1.0255153393146088e-09
for O 0 6.054275414335564e-10
12 O 0 7.762023912505356e-09
additional O 0 1.1256387821845237e-08
non O 0 3.988210437455564e-07
- O 0 2.2031841240277572e-07
Ashkenazi O 0 7.542180213704341e-08
185delAG O 0 3.626336564366284e-08
mutation O 0 4.914232576425093e-09
carriers O 0 1.0363147673331241e-08
who O 0 4.493577066000398e-08
had O 0 1.500799317000201e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5029557971502072e-06

Six O 0 3.344616288813995e-06
non O 0 6.592086265300168e-06
- O 0 8.626533372080303e-07
Ashkenazi O 0 1.0530745697678867e-07
individuals O 0 7.743905516832683e-10
shared O 0 2.5491930788490436e-09
the O 0 8.318415400943024e-10
common O 0 1.127047566384931e-09
Ashkenazi O 0 7.482598540775598e-09
haplotype O 0 2.3490507317092124e-08
, O 0 2.1327071220156313e-09
four O 0 2.953232325353383e-09
had O 0 4.0069649820395625e-09
a O 0 7.491990916541624e-10
closely O 0 2.6812035924805855e-10
related O 0 3.6062355324162354e-09
pattern O 0 3.2700853580536204e-08
, O 0 5.871721997507962e-10
and O 0 5.537624803153562e-10
the O 0 1.0816122220091984e-08
rest O 0 6.484328451961119e-08
( O 0 4.913257800609472e-09
n O 0 2.6343519365923385e-08
= O 0 1.5422538979237288e-07
6 O 0 1.1149361967000004e-07
) O 0 4.563909250521192e-10
displayed O 0 1.5783840012772998e-08
a O 0 5.222978050056781e-09
distinct O 0 4.164361655512039e-08
BRCA1 O 0 8.195627856366627e-07
allelic O 0 3.3580238323338563e-06
pattern O 0 1.5255584457918303e-06
. O 0 1.4907476497683092e-06

We O 0 1.3343759519557352e-07
conclude O 0 2.1201074673626863e-07
that O 0 2.743819393913327e-09
the O 0 3.072247878321832e-08
185delAG O 0 1.0352518984291237e-06
BRCA1 O 0 5.215703779981595e-08
mutation O 0 1.8548268476692442e-09
occurs O 0 8.188137945452922e-10
in O 0 2.096720019828524e-10
some O 0 9.86732806573798e-10
non O 0 1.9106869331153575e-07
- O 0 7.749689956426664e-08
Ashkenazi O 0 5.2564907093710644e-08
populations O 0 4.948375043056785e-09
at O 0 1.5088468252599796e-09
rates O 0 6.439409561131981e-10
comparable O 0 6.977528776985764e-09
with O 0 2.0160767499888266e-10
that O 0 1.6232456490072877e-09
of O 0 1.8909895516117103e-07
Ashkenazim O 0 3.0552422686014324e-05
. O 0 1.7334019730697037e-06

The O 0 6.030493864273012e-07
majority O 0 3.3333673599145186e-08
of O 0 1.2273800109596777e-07
Jewish O 0 5.844765382789774e-07
185delAG O 0 2.09847499377247e-07
mutation O 0 5.082698262270924e-09
carriers O 0 2.8539535179561426e-09
have O 0 4.978752965456579e-10
a O 0 1.7529490081713561e-09
common O 0 3.3673877020135023e-09
allelic O 0 1.8451845562594826e-07
pattern O 0 2.2765310347949708e-07
, O 0 4.483686311118618e-09
supporting O 0 1.5832414490546398e-08
the O 0 4.689947274982842e-08
founder O 0 2.956853393243364e-07
effect O 0 1.1243046316167238e-07
notion O 0 1.146848092048458e-07
, O 0 1.7632065807404729e-09
but O 0 1.0983555176480309e-09
dating O 0 7.535332358088453e-09
the O 0 4.491235383596859e-09
mutations O 0 2.7021358484091706e-09
origin O 0 2.339927140937448e-09
to O 0 1.8087522590803928e-09
an O 0 3.5632565786869463e-09
earlier O 0 4.873479397815572e-09
date O 0 8.441912058287926e-08
than O 0 6.139985408992743e-09
currently O 0 3.783834046089396e-08
estimated O 0 1.9084252755874331e-07
. O 0 6.046180374141841e-07

However O 0 5.315187081578188e-07
, O 0 1.0095358327077975e-08
the O 0 1.9530621564456396e-09
different O 0 5.324689578145581e-10
allelic O 0 1.8397726364582923e-07
pattern O 0 8.822361508009635e-08
at O 0 1.47025911445553e-08
the O 0 3.137231630034876e-08
BRCA1 O 0 5.307589034941884e-08
locus O 0 6.170933541937984e-09
even O 0 1.1965273216674177e-09
in O 0 3.518559055226689e-10
some O 0 1.0100728031758877e-09
Jewish O 0 1.919097947222781e-08
mutation O 0 2.8503850391103924e-09
carriers O 0 2.522354991540965e-09
, O 0 5.930576585377878e-10
might O 0 2.532241527575252e-09
suggest O 0 1.2321950570992612e-08
that O 0 1.5303526224030861e-09
the O 0 1.640996671881112e-08
mutation O 0 9.468168471471472e-09
arose O 0 1.647554448425126e-08
independently O 0 3.729827824372478e-08
. O 0 4.916147844369334e-08
. O 0 6.15941246451257e-07

Crystal O 0 3.5359083994990215e-05
structure O 0 5.937106379860779e-06
of O 0 7.442515197908506e-06
the O 0 2.264423528686166e-06
hemochromatosis B-Disease 1 1.0
protein O 0 0.1422075480222702
HFE O 1 0.9996755123138428
and O 0 1.4929424807519354e-08
characterization O 0 1.7956125475393492e-07
of O 0 2.9547212676561685e-08
its O 0 4.100907613491245e-09
interaction O 0 4.402017594884455e-08
with O 0 8.08861244649961e-09
transferrin O 0 2.6914085538010113e-05
receptor O 0 0.0001502871309639886
. O 0 2.5868660031846957e-06

HFE O 0 0.0357852578163147
is O 0 8.199576200240699e-07
an O 0 1.5164707178882963e-07
MHC O 0 7.84637359174667e-06
- O 0 2.2919462026038673e-06
related O 0 4.0570546389062656e-07
protein O 0 3.523109626257792e-07
that O 0 5.494865673583149e-10
is O 0 1.6897241938984564e-10
mutated O 0 3.780665114305748e-09
in O 0 1.362557622286431e-09
the O 0 1.608466106972628e-07
iron B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9988334774971008

HFE O 0 0.000573299010284245
binds O 0 4.956051270710304e-06
to O 0 3.179924306095927e-07
transferrin O 0 1.3424953976937104e-05
receptor O 0 9.268527719541453e-06
( O 0 1.3226765815943509e-07
TfR O 0 1.170628593172296e-06
) O 0 1.7426713405654937e-09
and O 0 1.7307595356896854e-09
reduces O 0 2.298082080187669e-08
its O 0 3.5333764802913947e-09
affinity O 0 3.7928369778228443e-08
for O 0 3.5208721271828836e-08
iron O 0 4.497960162552772e-06
- O 0 6.625487571909616e-07
loaded O 0 2.9649108910234645e-06
transferrin O 0 8.209261068259366e-06
, O 0 1.6488881726672844e-07
implicating O 0 7.75590306147933e-05
HFE O 1 0.9999957084655762
in O 0 6.139921424619388e-06
iron O 1 0.99986732006073
metabolism O 1 0.9972182512283325
. O 0 1.1739428373402916e-05

The O 0 1.988482108572498e-05
2 O 0 4.8139125283341855e-05
. O 0 4.736342361866264e-06

6 O 0 0.0003255211340729147
A O 0 3.5370077966945246e-05
crystal O 0 0.00011071425979025662
structure O 0 1.3985133591631893e-05
of O 0 0.00022345683828461915
HFE O 1 0.9999998807907104
reveals O 0 7.131896495593537e-07
the O 0 9.782591625651094e-09
locations O 0 4.343055337585611e-08
of O 0 2.453206775498984e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00016074709128588438
and O 0 2.0328627670096466e-07
a O 0 3.202954701464478e-08
patch O 0 1.3955697113487986e-06
of O 0 7.862154234317131e-07
histidines O 0 4.1091534512816e-06
that O 0 6.966913157491206e-10
could O 0 2.3887007927214654e-09
be O 0 3.7719853906992284e-09
involved O 0 9.426579516969014e-09
in O 0 1.9981053256401538e-08
pH O 0 3.658716423160513e-06
- O 0 1.1480848115752451e-05
dependent O 0 1.4945178918424062e-05
interactions O 0 4.0596041799290106e-06
. O 0 2.679798399185529e-06

We O 0 8.285927606266341e-07
also O 0 6.091938331564961e-08
demonstrate O 0 5.578529282956879e-08
that O 0 1.79104908681893e-08
soluble O 0 6.660701274086023e-06
TfR O 0 9.630059139453806e-06
and O 0 1.0712363263110092e-07
HFE O 0 2.6192812583758496e-05
bind O 0 2.4573091650381684e-07
tightly O 0 2.2560206502930669e-07
at O 0 5.034016936633634e-08
the O 0 1.0818371087850664e-08
basic O 0 3.0844017118170086e-08
pH O 0 3.6753167620418026e-08
of O 0 1.5564229016717945e-08
the O 0 1.6617342168956384e-08
cell O 0 5.07622885947967e-08
surface O 0 6.545477049257897e-08
, O 0 9.112254284460164e-10
but O 0 6.081658510126431e-10
not O 0 1.4824597105445037e-09
at O 0 3.022586980705455e-08
the O 0 6.651102069099579e-08
acidic O 0 4.267967597115785e-06
pH O 0 2.0449642761377618e-06
of O 0 1.3195009387345635e-06
intracellular O 0 3.536070289555937e-05
vesicles O 0 0.0002097908582072705
. O 0 6.668894002359593e-06

TfR O 0 0.005604041274636984
HFE O 0 0.001716401195153594
stoichiometry O 0 5.9160400269320235e-05
( O 0 5.39639700036787e-07
2 O 0 8.424827910857857e-07
1 O 0 2.1771175795493036e-07
) O 0 8.591707345573241e-10
differs O 0 4.896922867203557e-09
from O 0 6.4930878451718854e-09
TfR O 0 3.1446370485355146e-07
transferrin O 0 2.7155198267792e-07
stoichiometry O 0 1.697134734968131e-07
( O 0 6.66912569613487e-09
2 O 0 3.417952854078976e-08
2 O 0 3.806011861229308e-08
) O 0 5.884974729752912e-10
, O 0 7.940545443396729e-10
implying O 0 6.720714651464732e-09
a O 0 6.128013096962093e-10
different O 0 3.560509942435175e-10
mode O 0 1.834691154556367e-08
of O 0 3.6072538289744216e-09
binding O 0 4.707620959720771e-08
for O 0 1.003069911575949e-07
HFE O 0 0.00031871735700406134
and O 0 1.5425509047872765e-07
transferrin O 0 1.952752427314408e-06
to O 0 7.014708103270095e-08
TfR O 0 7.2445295700163115e-06
, O 0 1.2450800390695349e-08
consistent O 0 1.2789342918040347e-07
with O 0 3.715051155595006e-09
our O 0 9.733832229130712e-08
demonstration O 0 2.5700023797980975e-07
that O 0 1.1054007487132367e-08
HFE O 0 2.643960942805279e-05
, O 0 3.955980787395674e-08
transferrin O 0 2.8800448035326554e-06
, O 0 2.8652181072175154e-08
and O 0 2.9179702210058167e-08
TfR O 0 1.8330036937186378e-06
form O 0 1.9251837457545662e-08
a O 0 5.829757654396417e-08
ternary O 0 1.5240519815051812e-06
complex O 0 8.666751455166377e-06
. O 0 3.937623660021927e-06

Identification O 0 2.896522630635445e-07
of O 0 5.26982717019564e-07
three O 0 1.9153459263065997e-08
novel O 0 1.705709351540463e-08
mutations O 0 6.822449716281653e-09
and O 0 6.179103895220805e-10
a O 0 8.719087118969071e-10
high O 0 3.85532761271179e-09
frequency O 0 2.439426216582774e-09
of O 0 3.5957270494435534e-09
the O 0 1.0838530073442598e-08
Arg778Leu O 0 5.919620207350818e-07
mutation O 0 4.1729784072686016e-09
in O 0 8.6661317011405e-10
Korean O 0 1.1113798592532476e-07
patients O 0 2.3648512037510727e-09
with O 0 4.637622286196574e-09
Wilson B-Disease 0 6.320752845567768e-07
disease I-Disease 0 7.393072155537084e-05
. O 0 3.881427232954593e-07

Four O 0 6.022624347679084e-06
mutations O 0 1.998305378947407e-06
- O 0 2.809666057146387e-06
- O 0 3.1185693387669744e-06
R778L O 0 7.573802122351481e-06
, O 0 2.4206977755625303e-08
A874V O 0 8.094215786513814e-07
, O 0 8.029064524350815e-09
L1083F O 0 2.448737461691053e-07
, O 0 2.350743599777161e-09
and O 0 1.7230059601303083e-09
2304delC O 0 5.476456266251262e-08
- O 0 2.2027085933018498e-08
- O 0 3.282664806647517e-08
in O 0 8.449640986896156e-09
the O 0 1.1917977360553778e-07
copper O 0 9.852291782408429e-08
- O 0 1.3586396896414499e-08
transporting O 0 1.7313281475139775e-08
enzyme O 0 1.62571911488385e-08
, O 0 1.1475729699839121e-08
P O 0 3.925128453374782e-07
- O 0 3.3765989115863704e-08
type O 0 3.9013254848896395e-08
ATPase O 0 3.9267760598704626e-07
( O 0 7.339257646066244e-09
ATP7B O 0 8.75873229233548e-06
) O 0 2.373494456531233e-10
, O 0 1.525508330768588e-10
were O 0 3.091843725488985e-10
identified O 0 7.393303746994206e-10
in O 0 1.471130023356082e-10
Korean O 0 2.3516596669992396e-08
Patients O 0 8.889598501760076e-10
with O 0 1.923054160357651e-09
Wilson B-Disease 0 3.7716753809036163e-07
disease I-Disease 0 0.003155219368636608
. O 0 5.828667326568393e-07

Arg778Leu O 0 0.0002704971993807703
, O 0 1.022038489395527e-07
the O 0 2.8863411216661916e-08
most O 0 2.9530686784795535e-09
frequently O 0 1.9543813234434992e-09
reported O 0 1.1508339836652226e-09
mutation O 0 6.462529400508288e-10
of O 0 1.3772207818618654e-09
this O 0 1.4707147999448722e-10
enzyme O 0 6.516537087719598e-09
, O 0 1.0633247615743358e-09
was O 0 3.9373855287294646e-09
found O 0 4.953226162562885e-10
in O 0 1.9841239762286023e-10
six O 0 3.2816740436203418e-09
of O 0 6.276246633518667e-09
eight O 0 6.6935297304837604e-09
unrelated O 0 3.252065994274744e-08
patients O 0 2.0885548845939184e-09
studied O 0 9.705759751454934e-09
, O 0 2.3892510192524696e-10
an O 0 2.7084554043987907e-10
allele O 0 4.353295501857701e-09
frequency O 0 1.861952370063591e-08
of O 0 6.507844574343835e-08
37 O 0 3.0927608349884395e-06
. O 0 1.8065692302116076e-06

5 O 0 6.700239737256197e-06
% O 0 7.210950059288734e-08
, O 0 1.7696146770163068e-09
which O 0 4.83424189567927e-10
is O 0 1.3643564056309287e-10
considerably O 0 4.3099457336381874e-09
higher O 0 4.9148698444412275e-09
than O 0 9.423837404876068e-11
those O 0 1.3296079515168202e-10
in O 0 1.672990773693428e-10
other O 0 1.9485080215986272e-09
Asian O 0 1.0451600473970757e-08
populations O 0 3.254821479004022e-08
. O 0 1.2662687254305638e-07

The O 0 2.871882998078945e-07
novel O 0 1.1928301546504372e-07
single O 0 7.656653977505812e-09
nucleotide O 0 5.384039880595992e-08
deletion O 0 3.8513388034289164e-08
, O 0 7.021800474404927e-09
2304delC O 0 1.306830768044165e-07
, O 0 3.740962206677523e-09
was O 0 1.3440204504888698e-08
found O 0 1.3589732672514288e-09
in O 0 6.049646339434389e-10
one O 0 1.1057212923049065e-08
patient O 0 1.538898146691281e-07
. O 0 7.03256489487103e-07

Since O 0 2.514483981030935e-07
a O 0 5.1263182143657104e-08
mutation O 0 4.351014837311595e-08
at O 0 3.4721619357469535e-08
cDNA O 0 2.2358740636718721e-07
nucleotide O 0 8.479220241497387e-07
2302 O 0 1.183112726721447e-05
( O 0 2.0617680007717354e-08
2302insC O 0 2.179161526782991e-07
) O 0 1.4555009419936482e-09
had O 0 5.745648401500603e-09
been O 0 2.1388992799131756e-09
previously O 0 5.426792348828258e-09
described O 0 3.899173872667916e-09
, O 0 1.2325229725718145e-10
this O 0 8.917376559391954e-11
region O 0 1.0567180019904754e-08
of O 0 1.704951380077091e-08
the O 0 1.749079814317156e-07
ATP7B O 1 0.9984642267227173
gene O 0 3.114569580020543e-08
may O 0 3.8246557920729174e-08
be O 0 5.151741255815523e-09
susceptible O 0 1.89337868050643e-07
to O 0 7.619548547666e-09
gene O 0 5.492497621162329e-07
rearrangements O 0 0.011635521426796913
causing O 1 0.9886730313301086
Wilson B-Disease 0 1.181196239485871e-05
disease I-Disease 0 0.0002449805033393204
. O 0 7.28923225778999e-07

Disruption O 0 4.684371015173383e-05
of O 0 1.128237386183173e-06
splicing O 0 9.52749758198479e-07
regulated O 0 2.764049895631615e-07
by O 0 3.8401964275180944e-08
a O 0 1.7187339551583136e-07
CUG O 0 5.51808116142638e-05
- O 0 2.0138656964263646e-07
binding O 0 1.2460617426768295e-07
protein O 0 1.5050642332425923e-06
in O 0 1.4149843252653227e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00012013418017886579

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9619484543800354
DM B-Disease 1 1.0
) O 0 6.340404468119232e-08
is O 0 2.6458668589413037e-09
caused O 0 3.3021322565218725e-08
by O 0 1.4291633432250705e-09
a O 0 2.5579078410942202e-08
CTG O 0 9.936165042745415e-06
expansion O 0 6.291254806001234e-08
in O 0 2.2672084210029197e-09
the O 0 8.521095828939451e-09
3 O 0 4.589508151298105e-08
untranslated O 0 2.5927001843228936e-05
region O 0 6.716360445579994e-08
of O 0 1.4706270690112433e-07
the O 0 2.7719213449017843e-06
DM B-Disease 1 1.0
gene O 0 6.294643299042946e-06
. O 0 7.4456243055465166e-06

One O 0 5.8738336861097196e-08
model O 0 1.0997651855859658e-07
of O 0 6.800677283536061e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9976620674133301
suggests O 0 2.070216531535607e-08
that O 0 3.5173916557162954e-10
RNAs O 0 4.353461147132975e-09
from O 0 1.9593977551579655e-09
the O 0 1.9520491889579716e-09
expanded O 0 1.6980541417410677e-09
allele O 0 1.3245488039714814e-09
create O 0 5.847491379995517e-10
a O 0 2.2121302567512657e-09
gain O 0 2.562282830353979e-08
- O 0 2.7040501393571503e-08
of O 0 7.680205982296684e-08
- O 0 3.7299987099004284e-08
function O 0 2.587278169485785e-09
mutation O 0 6.497544169370428e-10
by O 0 3.730756259479051e-10
the O 0 4.973089051674151e-09
inappropriate O 0 7.738047536065551e-09
binding O 0 2.3028162488003545e-08
of O 0 4.55176056846085e-08
proteins O 0 7.62843299639826e-09
to O 0 1.4485862287472173e-08
the O 0 4.952357812726405e-07
CUG O 1 0.9992789626121521
repeats O 0 4.835620075027691e-06
. O 0 1.5853195236559259e-06

Data O 0 9.3849234872323e-07
presented O 0 6.380402055583545e-07
here O 0 3.9071338164831104e-08
indicate O 0 9.252370603007876e-08
that O 0 2.9263289569314566e-09
the O 0 2.356625827815151e-08
conserved O 0 4.0798028067001724e-07
heterogeneous O 0 1.557425775899901e-06
nuclear O 0 5.6857957133615855e-06
ribonucleoprotein O 0 6.61930171190761e-05
, O 0 4.384174587812595e-07
CUG O 0 6.75729097565636e-05
- O 0 4.3820972450703266e-07
binding O 0 2.573499671143509e-07
protein O 0 1.2569794307637494e-06
( O 0 7.476467800415776e-08
CUG O 0 0.00025859352899715304
- O 0 2.686848347366322e-06
BP O 0 2.0389625206007622e-06
) O 0 2.0095627384364434e-09
, O 0 1.452849396343936e-09
may O 0 2.9707116766530817e-09
mediate O 0 1.577885058168249e-07
the O 0 1.0813878503768137e-07
trans O 0 1.0929564098205446e-07
- O 0 7.584910832747482e-08
dominant O 0 1.224274939204406e-07
effect O 0 1.1853152415142176e-07
of O 0 3.290525896204599e-08
the O 0 3.6405090497737547e-08
RNA O 0 1.093896571546793e-06
. O 0 4.59387024420721e-07

CUG O 1 0.9680331945419312
- O 0 0.0002983461890835315
BP O 0 6.575456791324541e-05
was O 0 1.6533191171674844e-07
found O 0 7.686236092041554e-10
to O 0 1.8736320828161013e-10
bind O 0 1.651351055897976e-09
to O 0 1.0733951505415007e-09
the O 0 1.4426167815884128e-08
human O 0 2.94392151545253e-07
cardiac O 1 0.8938775062561035
troponin O 0 5.948647594777867e-05
T O 0 0.00030510654323734343
( O 0 7.70653088011386e-08
cTNT O 0 7.485291462216992e-07
) O 0 2.2339752270283952e-09
pre O 0 5.952034598522005e-08
- O 0 2.006270172216773e-08
messenger O 0 4.7309519857208215e-08
RNA O 0 7.303010818304756e-08
and O 0 8.458590272653055e-09
regulate O 0 5.894998711397648e-09
its O 0 5.6754179134088645e-09
alternative O 0 1.1266595834058535e-07
splicing O 0 2.0431261873454787e-06
. O 0 1.7665353198026423e-06

Splicing O 0 3.850373559544096e-06
of O 0 6.276156909734709e-06
cTNT O 0 3.264247425249778e-05
was O 0 7.728771720394434e-07
disrupted O 0 2.658748826434021e-06
in O 0 7.813555669144989e-08
DM B-Disease 1 1.0
striated O 0 3.239405032218201e-06
muscle O 0 2.0248235443887097e-07
and O 0 1.498328394688997e-08
in O 0 1.905281266090242e-09
normal O 0 6.765435500710737e-08
cells O 0 4.5790248037747006e-08
expressing O 0 7.784322519910347e-09
transcripts O 0 1.9039054777181263e-08
that O 0 1.45251144445524e-09
contain O 0 1.4432832529109874e-07
CUG O 0 0.0004926075926050544
repeats O 0 2.974398285005009e-06
. O 0 1.103534373214643e-06

Altered O 0 2.1839352939423406e-06
expression O 0 1.2379263125694706e-06
of O 0 3.9403144569405413e-07
genes O 0 1.218956668935789e-07
regulated O 0 6.546712683075384e-08
posttranscriptionally O 0 9.848155286817928e-07
by O 0 2.138786037164664e-08
CUG O 1 0.9128898978233337
- O 0 4.7136768444033805e-06
BP O 0 1.446801775273343e-06
therefore O 0 1.4696394323721051e-08
may O 0 2.03048378111248e-09
contribute O 0 1.338821498109155e-08
to O 0 5.168613981254566e-08
DM B-Disease 1 1.0
pathogenesis O 1 0.532348096370697
. O 0 1.0384501791804723e-07
. O 0 3.293729093911679e-07

Identification O 0 5.208198672335129e-07
of O 0 2.782924468647252e-07
a O 0 2.7613406672344354e-08
novel O 0 5.4992540299281245e-08
nonsense O 0 9.945637202690705e-08
mutation O 0 5.594210872317262e-09
and O 0 9.478282603225807e-10
a O 0 1.7533201557284883e-09
missense O 0 2.8177426614206524e-08
substitution O 0 1.3635098383701916e-08
in O 0 2.784382280296427e-09
the O 0 1.905100610599675e-08
vasopressin O 0 2.257367839320068e-07
- O 0 1.8123053280305612e-07
neurophysin O 0 1.3012521549171652e-06
II O 0 6.686783763143467e-06
gene O 0 4.111214035873445e-09
in O 0 2.518480313185023e-09
two O 0 3.94095422961982e-09
Spanish O 0 1.5527260188719083e-07
kindreds O 0 3.2902357816055883e-06
with O 0 2.4363771444768645e-08
familial B-Disease 0 0.017717652022838593
neurohypophyseal I-Disease 1 0.9999998807907104
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999936819076538
. O 0 4.246538992447313e-06

Familial B-Disease 1 0.999868631362915
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 5.116186912346166e-06
FNDI B-Disease 1 1.0
) O 0 1.342677879989651e-08
is O 0 1.310928809949985e-09
an O 0 2.9737332596369015e-09
autosomal B-Disease 0 0.0005682370392605662
dominant I-Disease 1 0.9947476983070374
disease I-Disease 1 0.9986697435379028
caused O 0 2.2281641065546864e-07
by O 0 1.4947766358019976e-09
deficiency O 1 0.7445093989372253
in O 0 6.449837108846168e-09
the O 0 3.9542618424093234e-07
antidiuretic O 0 1.172767269963515e-06
hormone O 0 2.1218185963789438e-07
arginine O 0 3.909535166712885e-07
vasopressin O 0 9.255774102712166e-07
( O 0 4.408066800465349e-08
AVP O 0 1.050157720783318e-06
) O 0 5.982508377577744e-10
encoded O 0 2.32403030153705e-09
by O 0 9.193541927743354e-09
the O 0 4.715052170922718e-07
AVP O 0 2.0632669475162402e-05
- O 0 1.6436551959486678e-06
neurophysin O 0 1.641247763473075e-05
II O 1 0.9999858140945435
( O 0 1.901004452520283e-06
AVP O 0 0.0001942637172760442
- O 0 1.525299740023911e-05
NPII O 0 0.04517574980854988
) O 0 2.0543490464319802e-08
gene O 0 4.4458609238517965e-08
on O 0 5.709545689569495e-07
chromosome O 0 2.0652314560720697e-06
20p13 O 0 4.364987398730591e-05
. O 0 2.0739810224768007e-06

In O 0 3.219596322878715e-08
this O 0 3.98224075937037e-09
study O 0 4.65623495315981e-09
, O 0 8.651944716220328e-10
we O 0 6.212121372861645e-10
analyzed O 0 7.152498593399059e-09
two O 0 9.085198704461561e-10
families O 0 2.277532384908909e-09
with O 0 1.0799873217948175e-09
FNDI B-Disease 1 1.0
using O 0 1.3240460949859312e-09
direct O 0 1.2519573822089569e-08
automated O 0 7.250311284678901e-08
fluorescent O 0 1.4648071555711795e-07
, O 0 6.762594928488852e-09
solid O 0 7.922565714579832e-08
phase O 0 8.295290854221093e-08
, O 0 4.66236738105863e-09
single O 0 5.483101084280406e-09
- O 0 2.3138850835380254e-08
stranded O 0 6.902439508849056e-08
DNA O 0 7.86306841860096e-09
sequencing O 0 8.979101018269375e-09
of O 0 5.006669567819699e-08
PCR O 0 9.448306741433043e-07
- O 0 1.656418498896528e-05
amplified O 0 2.5042201741598547e-05
AVP O 0 0.00015018942940514535
- O 0 1.5508894648519345e-05
NPII O 0 0.00024017594114411622
DNA O 0 4.190227173239691e-06
. O 0 3.11164171762357e-06

In O 0 6.311626776778212e-08
one O 0 2.168533974611364e-08
of O 0 2.5129729408490675e-08
the O 0 4.852850121750407e-09
families O 0 2.8509721250458142e-09
, O 0 3.03559510861362e-10
affected O 0 5.978880723844782e-10
individuals O 0 7.22986323586916e-11
presented O 0 7.0981776012502e-09
a O 0 1.934576498996421e-09
novel O 0 1.1118162390744146e-08
nonsense O 0 1.6141017411541725e-08
mutation O 0 1.7609212976665845e-09
in O 0 9.727699756822972e-10
exon O 0 1.529133797362192e-08
3 O 0 4.7707501948934805e-08
of O 0 3.0903020586947605e-08
the O 0 2.7239330790962413e-08
gene O 0 3.569773587841496e-09
, O 0 1.2895465806295192e-09
consisting O 0 5.594570917644148e-10
in O 0 4.95346264006713e-10
a O 0 4.651814489164963e-09
G O 0 2.654375919064478e-07
to O 0 9.310080173463575e-08
T O 0 2.4656274035805836e-05
transition O 0 2.4129033704411995e-07
at O 0 7.250200440012122e-08
nucleotide O 0 6.457545254079378e-08
2101 O 0 1.6945565448622801e-06
, O 0 1.7576462507662427e-09
which O 0 1.998964882510279e-10
produces O 0 5.698801985865032e-10
a O 0 4.083881566252501e-10
stop O 0 2.708632651504672e-09
signal O 0 3.110960022922882e-08
in O 0 3.6041176709744605e-09
codon O 0 7.401027914966107e-07
82 O 0 3.7042809708509594e-06
( O 0 1.5284317100849876e-07
Glu O 0 2.870561002055183e-05
) O 0 4.675477782711823e-08
of O 0 1.059706050909881e-06
NPII O 1 0.9999555349349976
. O 0 8.17667842056835e-06

The O 0 1.5002749478298938e-06
premature O 0 1.450840227334993e-05
termination O 0 8.665113000461133e-07
eliminates O 0 7.310256933124037e-07
part O 0 3.172675278051429e-08
of O 0 6.261637963689282e-08
the O 0 5.278402781527802e-08
C O 0 2.319564828212606e-06
- O 0 1.5687355414684134e-07
terminal O 0 2.42507695702443e-07
domain O 0 1.7708986277398253e-08
of O 0 4.521415064573375e-08
NPII O 0 0.015560541301965714
, O 0 6.715461076112206e-09
including O 0 1.7437219446136965e-09
a O 0 6.191435808489132e-09
cysteine O 0 3.4424134653932015e-09
residue O 0 6.473712943488863e-08
in O 0 2.2159816204236904e-09
position O 0 4.033744005482731e-08
85 O 0 4.5446643781588136e-08
, O 0 4.937323327958154e-10
which O 0 1.24473695239935e-10
could O 0 4.5223594313803517e-10
be O 0 8.884987190427296e-10
involved O 0 2.909282592611362e-09
in O 0 3.2788398662830787e-09
the O 0 7.014186564902047e-08
correct O 0 1.4266007610785891e-06
folding O 0 5.858186341356486e-06
of O 0 4.0053245697890816e-07
the O 0 1.4416176554732374e-06
prohormone O 0 0.00371617847122252
. O 0 5.870199402124854e-06

In O 0 5.6481425758647674e-08
the O 0 1.4662019509614765e-07
second O 0 7.522812950355728e-08
family O 0 1.498980140013373e-08
, O 0 9.121992050609151e-10
a O 0 2.3643684787799657e-09
G279A O 0 6.771606564370813e-08
substitution O 0 1.940212790429996e-08
at O 0 1.964742857296642e-08
position O 0 2.187869441172552e-08
- O 0 7.030403814667352e-09
1 O 0 2.006373556184826e-08
of O 0 1.0721925569612267e-08
the O 0 5.4723399145473195e-09
signal O 0 9.510811693758114e-09
peptide O 0 5.4095132817622016e-09
was O 0 5.290353932707603e-09
observed O 0 8.474104196132259e-10
in O 0 2.1485475898419537e-10
all O 0 1.587725284579733e-09
affected O 0 2.7332855978556836e-08
individuals O 0 2.0224373287192066e-08
. O 0 7.144844857975841e-07

This O 0 2.671023935363337e-07
missense O 0 1.3564663277065847e-05
mutation O 0 3.6711412576551083e-07
, O 0 3.903767265001079e-08
which O 0 1.8822124303596866e-08
replaces O 0 3.108782266281196e-06
Ala O 0 2.712144578254083e-06
with O 0 5.482957377012099e-08
Thr O 0 5.5437553783121984e-06
, O 0 6.3408367445561e-09
is O 0 5.844414396882769e-10
frequent O 0 3.035145024199437e-09
among O 0 1.0695782037828394e-08
FNDI B-Disease 1 1.0
patients O 0 4.771259796143568e-07
and O 0 1.3113796271113642e-08
is O 0 5.688615689614096e-10
thought O 0 3.537198034475608e-10
to O 0 2.532994092252494e-10
reduce O 0 4.173702716769867e-09
the O 0 4.5008743398966544e-09
efficiency O 0 9.871627781876668e-08
of O 0 2.9146438151883558e-08
cleavage O 0 3.5250386076768336e-07
by O 0 1.944862759728494e-08
signal O 0 9.445709110877942e-06
peptidases O 0 2.8424243282643147e-05
. O 0 5.300947805153555e-07
. O 0 2.7404219054005807e-06

Genetic O 0 3.823288807325298e-06
heterogeneity O 0 3.789972834056243e-05
of O 0 8.248955055023544e-06
Saethre B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999992847442627
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.206818614629128e-09
due O 0 1.7551679221128325e-08
to O 0 3.275258286805638e-09
TWIST O 0 0.000298018945613876
and O 0 3.6376775369717507e-07
FGFR O 1 0.999788224697113
mutations O 0 6.861890597065212e-06
. O 0 1.9624096694315085e-06

Thirty O 0 5.4801508667878807e-05
- O 0 3.2414757242804626e-06
two O 0 3.1989983995117655e-08
unrelated O 0 9.667058264994921e-08
patients O 0 1.4927935554354121e-09
with O 0 1.1295045454495778e-10
features O 0 3.754579758208365e-09
of O 0 4.3291770168707444e-08
Saethre B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.89797660815816e-09
a O 0 9.968627034950828e-10
common O 0 3.6223115618128077e-09
autosomal B-Disease 0 6.195897981342569e-07
dominant I-Disease 0 2.454261266393587e-05
condition I-Disease 0 3.43622082255024e-06
of O 0 2.8101808879910095e-07
craniosynostosis B-Disease 1 0.9967247843742371
and O 0 3.435034159338102e-07
limb B-Disease 1 0.9998433589935303
anomalies I-Disease 0 0.0034543012734502554
, O 0 2.1108222725274572e-08
were O 0 7.63524532487736e-09
screened O 0 5.3119713072646846e-09
for O 0 6.5046618091813e-10
mutations O 0 9.532423739244678e-09
in O 0 5.825230520173363e-09
TWIST O 0 2.4743614631006494e-05
, O 0 6.746132896751078e-08
FGFR2 O 1 0.9698014259338379
, O 0 9.117512433931552e-08
and O 0 4.1056688360185944e-07
FGFR3 O 1 0.9996843338012695
. O 0 4.784752491104882e-06

Nine O 0 1.5261639418895356e-06
novel O 0 1.750002525113814e-07
and O 0 2.35822223970672e-08
three O 0 1.239982339029666e-08
recurrent O 0 6.059376005396189e-07
TWIST O 0 1.8890801811721758e-06
mutations O 0 6.520244255625585e-08
were O 0 1.2873552002190536e-08
found O 0 2.9309317195469475e-09
in O 0 1.7255514794811688e-09
12 O 0 5.3898556728881886e-08
families O 0 6.061583235350554e-08
. O 0 4.826203507946047e-07

Seven O 0 4.395775761167897e-07
families O 0 3.5390101515986316e-08
were O 0 1.3747701643751498e-08
found O 0 1.610681032993e-09
to O 0 7.643124466660822e-10
have O 0 1.3546076482739977e-09
the O 0 1.8645573973685714e-08
FGFR3 O 0 6.59157958580181e-05
P250R O 0 6.948439477127977e-07
mutation O 0 1.1016837220267917e-08
, O 0 1.783534875343662e-09
and O 0 7.4681083539474e-10
one O 0 1.2290211071075419e-09
individual O 0 1.7042189881522063e-09
was O 0 5.996874108404882e-08
found O 0 1.48921597276086e-09
to O 0 1.8035745119604485e-09
have O 0 5.057583685186273e-09
an O 0 5.83970667378253e-08
FGFR2 O 0 0.00023185613099485636
VV269 O 0 7.2763396019581705e-06
- O 0 1.990381633731886e-06
270 O 0 7.384248306152585e-07
deletion O 0 7.722244390606647e-07
. O 0 1.0724185131039121e-06

To O 0 4.003575071465093e-08
date O 0 4.7648936174482515e-07
, O 0 6.057374157819595e-09
our O 0 1.9871888579103825e-09
detection O 0 7.290912762414337e-09
rate O 0 2.3969843887527986e-09
for O 0 6.323224721604959e-10
TWIST O 0 1.2193884231237462e-06
or O 0 3.504376877572213e-08
FGFR O 0 3.91438661608845e-05
mutations O 0 2.292753720212204e-08
is O 0 1.7566339494123895e-09
68 O 0 2.2689269130182765e-08
% O 0 5.033627958894726e-10
in O 0 1.888449674414261e-10
our O 0 1.7519903749985133e-08
Saethre B-Disease 1 0.6283103823661804
- I-Disease 1 0.9676717519760132
Chotzen I-Disease 1 0.999992847442627
syndrome I-Disease 1 0.9247204661369324
patients O 0 4.2022594293200655e-09
, O 0 5.545753301028356e-10
including O 0 8.593346034757587e-10
our O 0 4.317780621931888e-08
five O 0 4.976068890272245e-09
patients O 0 1.8602405171819214e-09
elsewhere O 0 1.2608913024791946e-08
reported O 0 1.3281949762244949e-08
with O 0 2.6197943814310065e-09
TWIST O 0 2.0279308955650777e-05
mutations O 0 1.3514001011571963e-06
. O 0 1.1423566093071713e-06

More O 0 4.801578157298536e-08
than O 0 5.685841131253255e-09
35 O 0 1.9426158459623366e-08
different O 0 1.1969564228664353e-09
TWIST O 0 1.23126994822087e-07
mutations O 0 1.1458014093079782e-08
are O 0 1.0418277351931238e-09
now O 0 1.2058106735324259e-09
known O 0 1.5236247818961601e-09
in O 0 6.667608687394022e-10
the O 0 1.6182477580173327e-08
literature O 0 2.1288741436364944e-07
. O 0 2.944797472537175e-07

The O 0 2.51715675858577e-07
most O 0 1.4450401764065646e-08
common O 0 5.088615306902966e-09
phenotypic O 0 2.0060443972624853e-08
features O 0 1.6998081164842915e-08
, O 0 7.737896434711899e-10
present O 0 1.1810500355480258e-09
in O 0 2.406745913674513e-10
more O 0 1.956879380760057e-10
than O 0 2.2664203847000408e-10
a O 0 1.273628758013956e-09
third O 0 6.5793570591665684e-09
of O 0 1.2471573995753715e-08
our O 0 3.432096207234281e-08
patients O 0 4.533182274002456e-09
with O 0 3.4900073941912524e-09
TWIST O 0 1.1353816262271721e-05
mutations O 0 1.0674060035853472e-07
, O 0 1.5036706102478092e-08
are O 0 1.0878937750646855e-08
coronal B-Disease 0 0.10315462201833725
synostosis I-Disease 0 0.0005200200830586255
, O 0 1.2187602749236248e-07
brachycephaly B-Disease 0 0.001702374778687954
, O 0 1.0635443459250382e-06
low B-Disease 1 0.9999765157699585
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 5.51275616089697e-06
facial B-Disease 1 1.0
asymmetry I-Disease 1 1.0
, O 0 7.662392818019725e-06
ptosis B-Disease 1 0.9983330368995667
, O 0 4.1757115809559764e-07
hypertelorism B-Disease 1 0.7402320504188538
, O 0 8.62198533013725e-07
broad B-Disease 1 0.9967061877250671
great I-Disease 1 0.9999998807907104
toes I-Disease 1 0.9999926090240479
, O 0 1.5952319927237113e-06
and O 0 2.465779516569455e-06
clinodactyly B-Disease 1 0.9996391534805298
. O 0 1.0241485142614692e-05

Significant O 0 6.187829967529979e-06
intra O 0 5.648802107316442e-05
- O 0 1.0470415645613684e-06
and O 0 1.063836485570846e-08
interfamilial O 0 1.6924891497183125e-06
phenotypic O 0 1.377080280917653e-07
variability O 0 5.660295983034302e-07
is O 0 8.343807866850739e-10
present O 0 6.461802204427158e-10
for O 0 8.908710436017486e-10
either O 0 2.4538051590639043e-08
TWIST O 0 7.885065315349493e-06
mutations O 0 5.093599497740797e-07
or O 0 2.818012205807463e-07
FGFR O 0 0.00043723310227505863
mutations O 0 2.6011002773884684e-06
. O 0 1.7523333326607826e-06

The O 0 8.091467975646083e-07
overlap O 0 2.895268664815376e-07
in O 0 4.401394360087352e-09
clinical O 0 1.0928726368319985e-08
features O 0 3.6981400164393108e-09
and O 0 6.232795946026215e-10
the O 0 2.7022906134988034e-09
presence O 0 1.2846570918156885e-08
, O 0 7.955068270781851e-10
in O 0 2.238922380826125e-10
the O 0 2.4434263501404985e-09
same O 0 9.273917744856419e-10
genes O 0 2.6163289312819415e-09
, O 0 8.879837420927572e-10
of O 0 4.904306738495734e-09
mutations O 0 2.24179497188004e-09
for O 0 1.4646688306640954e-09
more O 0 1.182636988339425e-09
than O 0 4.833782707436285e-09
one O 0 3.0554179630826184e-08
craniosynostotic B-Disease 0 1.9905071440007305e-06
condition I-Disease 0 3.0611084866905003e-07
- O 0 1.0545398509975712e-07
such O 0 1.561876850075805e-08
as O 0 1.2863789322636876e-07
Saethre B-Disease 0 5.497174242918845e-06
- I-Disease 0 6.723730052726751e-07
Chotzen I-Disease 0 4.439262283995049e-06
, I-Disease 0 1.497762625035648e-08
Crouzon I-Disease 0 2.8564877538883593e-06
, I-Disease 0 4.150943766489945e-08
and I-Disease 0 1.762382879633151e-07
Pfeiffer I-Disease 0 0.00010191408364335075
syndromes I-Disease 0 0.029402971267700195
- O 0 8.86540874489583e-06
support O 0 2.6422429755257326e-07
the O 0 4.5452278385482714e-08
hypothesis O 0 1.5474244108304447e-08
that O 0 2.1521116833067566e-10
TWIST O 0 2.464720978423429e-07
and O 0 3.894884859079184e-09
FGFRs O 0 2.8707327714982966e-07
are O 0 3.638110368520131e-10
components O 0 6.574919098056853e-08
of O 0 1.619677547637366e-08
the O 0 4.4094692341900554e-09
same O 0 9.756723207132723e-10
molecular O 0 2.1065831745659125e-08
pathway O 0 3.023901840037979e-08
involved O 0 7.72332864329428e-10
in O 0 2.743812954619784e-10
the O 0 1.4771251999334822e-09
modulation O 0 1.4801895531491027e-07
of O 0 1.6094604404770507e-07
craniofacial O 1 1.0
and O 1 0.7339767813682556
limb O 1 1.0
development O 0 3.465748477538e-06
in O 0 5.49179857145532e-09
humans O 0 2.8429587572986748e-08
. O 0 2.1111768333526015e-08
. O 0 1.916758947118069e-07

Mutation O 0 1.7115958428348677e-07
analysis O 0 3.363884104601311e-08
of O 0 1.2840352781040565e-07
UBE3A O 1 0.9999995231628418
in O 0 9.948002843884751e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.6297279216814786e-05
. O 0 4.5984810981281043e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.01156842801719904
AS B-Disease 1 1.0
) O 0 7.0231664928144255e-09
is O 0 2.079459937576189e-09
caused O 0 3.240685231276075e-08
by O 0 6.604994773340422e-09
chromosome O 0 5.198849066800904e-07
15q11 O 0 5.4481561164720915e-06
- O 0 4.5593111508424045e-07
q13 O 0 1.1244155757594854e-06
deletions O 0 9.585153293301119e-08
of O 0 2.1626481938596953e-08
maternal O 0 1.9246884619406046e-07
origin O 0 2.5555669580512586e-08
, O 0 2.7863533702543464e-09
by O 0 9.60370538649613e-09
paternal O 1 0.9999746084213257
uniparental B-Disease 1 0.9999995231628418
disomy I-Disease 1 0.9999877214431763
( O 0 4.297706254874356e-06
UPD B-Disease 1 1.0
) O 0 1.495176604748849e-08
15 O 0 5.096446642482988e-08
, O 0 5.694694715785431e-10
by O 0 1.065271537648016e-09
imprinting O 0 0.0001223091094288975
defects O 1 0.8959060311317444
, O 0 5.474782849290705e-09
and O 0 7.297141224604786e-10
by O 0 8.521026106933505e-10
mutations O 0 2.534702758794083e-08
in O 0 4.731563141291417e-09
the O 0 2.6356516968917276e-07
UBE3A O 0 0.0010285440366715193
gene O 0 2.450592774039251e-06
. O 0 4.81590541312471e-06

UBE3A O 0 0.0018106951611116529
encodes O 0 4.105952939426061e-06
a O 0 5.651364176628704e-07
ubiquitin O 0 2.0320171643106733e-06
- O 0 6.609760703213396e-07
protein O 0 1.5189661439762858e-07
ligase O 0 5.798661391054338e-07
and O 0 2.3453621622593346e-07
shows O 0 1.7949002995010233e-07
brain O 0 4.580178938340396e-06
- O 0 5.100346243125387e-07
specific O 0 2.12466147786472e-07
imprinting O 0 2.323021544725634e-05
. O 0 9.661506510383333e-07

Here O 0 1.3530661817640066e-06
we O 0 1.2678516725372901e-07
describe O 0 4.153328347911156e-07
UBE3A O 0 4.835499930777587e-05
coding O 0 2.500876689737197e-06
- O 0 2.8063025183655554e-06
region O 0 9.123809974198593e-08
mutations O 0 2.6589917823116593e-08
detected O 0 1.3061126402647005e-08
by O 0 1.1082629258751808e-09
SSCP O 0 5.046369096817216e-06
analysis O 0 3.6372103107140674e-09
in O 0 1.3611133331536962e-09
13 O 0 1.039159442939308e-07
AS B-Disease 1 1.0
individuals O 0 1.2605541055421554e-09
or O 0 1.3018919275964436e-08
families O 0 2.490289574552662e-08
. O 0 1.9454270727692347e-07

Two O 0 4.5422093535307795e-06
identical O 0 7.569830358988838e-06
de O 0 1.4866624042042531e-05
novo O 0 8.82686254044529e-06
5 O 0 3.0126414003461832e-06
- O 0 1.4106191201790352e-06
bp O 0 8.167671126102505e-07
duplications O 0 7.358813718383317e-07
in O 0 3.3507184582504124e-08
exon O 0 2.3533384307938832e-07
16 O 0 8.619625191386149e-07
were O 0 6.66546569050297e-08
found O 0 6.490292037142353e-08
. O 0 2.5242533752134477e-07

Among O 0 1.2073426205461146e-06
the O 0 1.3500509510322445e-07
other O 0 5.953964787863697e-08
11 O 0 4.9987782801963476e-08
unique O 0 5.838511896172349e-09
mutations O 0 1.9661147376837107e-08
, O 0 5.298149474697311e-09
8 O 0 4.8847422107201055e-08
were O 0 1.3199266568619805e-08
small O 0 1.4338138676350809e-08
deletions O 0 7.894855258427924e-08
or O 0 1.24605410434242e-08
insertions O 0 1.774524207576178e-07
predicted O 0 7.15196932787876e-08
to O 0 9.255614052960937e-09
cause O 0 2.9445548079820583e-06
frameshifts O 0 1.6546202459721826e-05
, O 0 5.169281891426181e-09
1 O 0 4.95081344809023e-08
was O 0 1.547571848448115e-08
a O 0 7.915867406005361e-10
mutation O 0 5.259634394683133e-10
to O 0 1.0574351394510018e-09
a O 0 6.486045034392873e-09
stop O 0 1.4347413035409318e-08
codon O 0 1.3020935796248523e-07
, O 0 1.0541894468474311e-08
1 O 0 6.740936697724464e-08
was O 0 3.422936956098965e-08
a O 0 3.830479933242259e-09
missense O 0 8.068983703424237e-08
mutation O 0 4.4497951989797e-09
, O 0 1.1525583820670704e-09
and O 0 9.556047064762652e-10
1 O 0 5.4082576639302715e-08
was O 0 3.3337997251692286e-08
predicted O 0 1.4402413484049248e-08
to O 0 8.299572140657574e-10
cause O 0 2.2487338213750263e-08
insertion O 0 5.1014360735734954e-08
of O 0 1.5699508537636575e-07
an O 0 5.7363987338021616e-08
isoleucine O 0 4.802513103641104e-06
in O 0 6.29276453167904e-09
the O 0 3.3432367985142264e-08
hect O 0 1.530911617919628e-06
domain O 0 6.02919314474093e-08
of O 0 7.420661773949178e-08
the O 0 1.6307804173720797e-07
UBE3A O 0 6.570131972694071e-06
protein O 0 1.7611731095712457e-07
, O 0 2.3861326248209025e-09
which O 0 2.806299359559006e-10
functions O 0 1.398188675949541e-09
in O 0 1.644530289723889e-09
E2 O 0 5.039502752879343e-07
binding O 0 2.3347388022898485e-08
and O 0 3.41749633037125e-08
ubiquitin O 0 1.4773451084693079e-06
transfer O 0 1.683135087660048e-05
. O 0 3.2242469387711026e-06

Eight O 0 7.331704523494409e-07
of O 0 1.1238372366051408e-07
the O 0 6.9717818185210945e-09
cases O 0 5.302779992888418e-09
were O 0 3.2414564365979004e-09
familial O 0 2.0699479463814896e-08
, O 0 1.846866104493472e-09
and O 0 3.0266471551243512e-09
five O 0 1.7881271574538005e-08
were O 0 2.925895081773433e-08
sporadic O 0 3.419353106437484e-06
. O 0 1.1179871535205166e-06

In O 0 1.8423378378429334e-07
two O 0 5.312582374017438e-08
familial O 0 2.3763921319641668e-07
cases O 0 1.1916426956304349e-08
and O 0 8.201955781217407e-10
one O 0 5.505188527266114e-10
sporadic O 0 2.2004496003091845e-08
case O 0 4.519472796005175e-09
, O 0 2.028764933825755e-09
mosaicism O 0 4.161934612056939e-06
for O 0 3.463880204890302e-08
UBE3A O 0 5.7273879065178335e-05
mutations O 0 8.388399663772361e-08
was O 0 1.5985010648478237e-08
detected O 0 1.0531259198032217e-09
in O 0 7.471552543325544e-11
the O 0 2.099550311385201e-09
mother O 0 5.146232329167333e-09
of O 0 1.3717475155772263e-08
three O 0 1.834096075015168e-08
AS B-Disease 1 1.0
sons O 0 6.333790224744007e-06
, O 0 3.1702718228387994e-09
in O 0 4.5905718115690775e-10
the O 0 9.081149165979241e-09
maternal O 0 7.113413857950945e-07
grandfather O 0 1.8799754570864025e-06
of O 0 1.5660971257602796e-06
two O 0 8.510216531476544e-08
AS B-Disease 1 1.0
first O 0 3.46272415185922e-08
cousins O 0 8.318136934803988e-08
, O 0 4.251834884172467e-09
and O 0 1.9521384508891515e-09
in O 0 1.9408594731373796e-09
the O 0 8.854645017208895e-08
mother O 0 4.0711006477067713e-07
of O 0 6.50259607937187e-07
an O 0 5.824816753374762e-07
AS B-Disease 1 1.0
daughter O 0 0.0018745759734883904
. O 0 7.294834631466074e-06

The O 0 2.560544487550942e-07
frequencies O 0 6.702219224052897e-08
with O 0 8.390663719382019e-10
which O 0 3.4558916839344533e-10
we O 0 7.656300038405561e-10
detected O 0 2.6839679367895997e-09
mutations O 0 1.4183878516149662e-09
were O 0 3.1027627134250224e-09
5 O 0 1.0556139962147881e-08
( O 0 5.864637109276316e-10
14 O 0 1.760559342756096e-08
% O 0 5.796223501164377e-10
) O 0 2.111495700507504e-11
of O 0 1.2123092529847668e-09
35 O 0 5.771261690767915e-09
in O 0 5.607690423126144e-10
sporadic O 0 5.2206999612280924e-08
cases O 0 1.6254392276593421e-09
and O 0 1.9386618976824366e-09
8 O 0 2.202826365760302e-08
( O 0 6.990446554944185e-10
80 O 0 1.1322839554850361e-08
% O 0 5.227769328541854e-10
) O 0 3.827189606897541e-11
of O 0 1.886585554444764e-09
10 O 0 9.649720134063955e-09
in O 0 1.8558636849519417e-09
familial O 0 3.1296174540784705e-08
cases O 0 1.1651867026785112e-08
. O 0 2.3956191697038776e-08
. O 0 2.459264294429886e-07

The O 0 2.9671300580957904e-05
hemochromatosis B-Disease 1 1.0
845 O 0 2.6662122763809748e-05
G O 0 4.299412012187531e-06
- O 0 6.458173515966337e-07
- O 0 2.2353835049671034e-07
> O 0 6.256276918747972e-08
A O 0 1.1685767731250962e-07
and O 0 1.7502728155704972e-09
187 O 0 1.4559395911106776e-09
C O 0 1.2316218267471868e-08
- O 0 2.8319708800239596e-09
- O 0 7.258111889285601e-09
> O 0 5.341516562396009e-09
G O 0 5.817627979354256e-08
mutations O 0 6.6221881311889774e-09
: O 0 1.6929834201206972e-09
prevalence O 0 8.470617984812634e-09
in O 0 6.368335303541528e-10
non O 0 9.643228082722999e-08
- O 0 7.812542435203795e-08
Caucasian O 0 3.654206892633738e-08
populations O 0 1.836101759522535e-08
. O 0 3.9147874275613503e-08

Hemochromatosis B-Disease 1 0.9723157286643982
, O 0 6.372715120050998e-07
the O 0 7.310669025173411e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 0.9999992847442627
metabolism I-Disease 1 0.9992300271987915
, O 0 4.219288385343134e-08
leads O 0 7.6304204412736e-05
, O 0 1.1605511218704123e-08
if O 0 1.2827159423522971e-07
untreated O 1 1.0
, O 0 1.9819084151606603e-09
to O 0 8.102864157422118e-09
progressive O 1 0.9999470710754395
iron B-Disease 1 0.999990701675415
overload I-Disease 1 1.0
and O 0 9.387785212311428e-06
premature B-Disease 0 0.001680940156802535
death I-Disease 0 9.436897380510345e-05
. O 0 1.9015938050870318e-06

The O 0 1.7699279851512983e-05
hemochromatosis B-Disease 1 1.0
gene O 0 4.4068918214179575e-05
, O 0 3.1672384466219228e-06
HFE O 1 0.9999853372573853
, O 0 7.819056691005244e-08
recently O 0 1.3351289851470938e-08
has O 0 5.431770588870677e-10
been O 0 1.6093290589047626e-10
identified O 0 1.0356305812919686e-09
, O 0 1.723747949933241e-10
and O 0 2.2545336431090135e-10
characterization O 0 3.842292173317219e-08
of O 0 2.986666558513207e-08
this O 0 8.108472226986407e-10
gene O 0 4.739330705660905e-09
has O 0 2.0689285840091998e-09
shown O 0 4.323751079393645e-10
that O 0 7.14159911763268e-11
it O 0 5.193171934148033e-11
contains O 0 9.427774533277145e-11
two O 0 2.4772167650510823e-10
mutations O 0 1.0160181584950578e-09
that O 0 5.381128875825425e-10
result O 0 1.2674014726599125e-08
in O 0 5.2094271119074165e-09
amino O 0 1.3711250801407004e-08
acid O 0 6.511815975329682e-09
substitutions O 0 9.773304832094709e-09
- O 0 4.015796406520167e-08
cDNA O 0 1.0940869543674125e-07
nucleotides O 0 2.815303723480156e-08
845 O 0 1.0219663693078473e-07
G O 0 2.2964044887885393e-07
- O 0 1.0656728477442812e-07
- O 0 9.192913807964942e-08
> O 0 6.508378902481127e-08
A O 0 4.5575464469038707e-07
( O 0 5.093130361899512e-09
C282Y O 0 2.0384518961691356e-07
) O 0 5.759931975823918e-10
and O 0 9.229730868476338e-10
187 O 0 3.597037334657216e-09
C O 0 4.293038458058618e-08
- O 0 1.5996509006299675e-08
- O 0 8.355011260618994e-08
> O 0 1.668098832396936e-07
G O 0 5.773252269136719e-06
( O 0 1.7602110347070266e-07
H63D O 0 0.0017435869667679071
) O 0 7.115422562264939e-08
. O 0 2.580878231128736e-07

Although O 0 3.619458766479511e-06
hemochromatosis B-Disease 1 1.0
is O 0 6.558999388062148e-08
common O 0 1.3753997052390332e-08
in O 0 2.807403642890449e-09
Caucasians O 0 6.740422264783774e-08
, O 0 5.005549752468141e-09
affecting O 0 3.108545953978137e-08
> O 0 3.468911913273587e-08
= O 0 7.221066766760487e-08
1 O 0 8.258049888354435e-08
/ O 0 7.626163700535926e-09
300 O 0 2.1662676097378153e-09
individuals O 0 9.463428651823591e-11
of O 0 2.1253163673407016e-09
northern O 0 3.2540996564023317e-09
European O 0 2.097293227976138e-09
origin O 0 1.931878301775214e-08
, O 0 9.53256362734578e-10
it O 0 2.6221777527091206e-10
has O 0 3.4338670795719395e-10
not O 0 2.7015215064984943e-10
been O 0 7.87556686532298e-10
recognized O 0 1.3310930135901344e-09
in O 0 5.462836294434226e-10
other O 0 5.235844646733767e-09
populations O 0 3.8923545275793003e-08
. O 0 1.9007492824130168e-07

The O 0 4.6844269263601745e-07
present O 0 2.7815227454652813e-08
study O 0 1.5645953421739023e-09
used O 0 5.967237814985538e-10
PCR O 0 1.682820460757739e-08
and O 0 2.9350493147006773e-09
restriction O 0 3.118909219779198e-08
- O 0 2.2646078789989588e-08
enzyme O 0 6.491750692561027e-09
digestion O 0 6.98402624621508e-09
to O 0 2.691153411227276e-10
analyze O 0 1.6383564505062509e-09
the O 0 1.3553596023285763e-09
frequency O 0 7.194380202690809e-09
of O 0 8.115748073578288e-09
the O 0 1.771601532141176e-08
845 O 0 9.288370961257897e-08
G O 0 1.0559064378412586e-07
- O 0 6.599821489317037e-08
- O 0 7.884758446152773e-08
> O 0 2.622005190744403e-08
A O 0 8.732676803901995e-08
and O 0 2.267243059961288e-09
187 O 0 2.1917443415730986e-09
C O 0 7.113764688426727e-09
- O 0 3.2515432568658298e-09
- O 0 9.122536503980427e-09
> O 0 9.4223544522265e-09
G O 0 8.887538172075438e-08
mutations O 0 1.224821044587543e-08
in O 0 4.31195212868829e-09
HLA O 0 1.630197346003115e-07
- O 0 3.5224569927549965e-08
typed O 0 3.599830877831778e-09
samples O 0 3.93799937103978e-10
from O 0 1.286210915552033e-09
non O 0 1.1403007427190914e-08
- O 0 5.088828913812904e-09
Caucasian O 0 2.7030069293942915e-09
populations O 0 1.3264677134472436e-09
, O 0 1.043147582202586e-10
comprising O 0 1.5764027583298201e-10
Australian O 0 1.617364464578941e-09
Aboriginal O 0 4.1389562888127784e-09
, O 0 7.379652444683416e-10
Chinese O 0 1.1724544002333914e-08
, O 0 3.072387011471278e-09
and O 0 1.868316701347794e-08
Pacific O 0 2.0376103293529013e-07
Islanders O 0 9.377408218824712e-07
. O 0 4.65776565761189e-07

Results O 0 3.899141574947862e-06
showed O 0 5.776021225756267e-07
that O 0 1.007765870753019e-08
the O 0 6.949109376819251e-08
845 O 0 1.8837646109659545e-07
G O 0 2.489701387276e-07
- O 0 9.920439225652444e-08
- O 0 7.918713862409277e-08
> O 0 2.202645532634051e-08
A O 0 2.1099086922049537e-08
mutation O 0 1.055919574000086e-09
was O 0 1.1378472608569723e-09
present O 0 5.872995839650841e-11
in O 0 3.135850953905894e-11
these O 0 1.214803813098797e-10
populations O 0 6.378753081293098e-10
( O 0 1.5785660278933022e-10
allele O 0 1.6081823650537785e-09
frequency O 0 1.8397783296819625e-09
0 O 0 2.1312431819353606e-09
. O 0 5.861081064928442e-10
32 O 0 1.4424735184093151e-08
% O 0 9.448823945490403e-10
) O 0 4.698418737403287e-11
, O 0 2.9867602835409457e-10
and O 0 5.189332852317818e-10
, O 0 6.450104339528195e-10
furthermore O 0 8.32218027824183e-09
, O 0 1.0805353278797725e-09
it O 0 8.864403655550745e-10
was O 0 5.2658229776625376e-08
always O 0 5.935049784966395e-09
seen O 0 1.3613659533007194e-08
in O 0 7.11488701288232e-10
conjunction O 0 1.079975486817375e-08
with O 0 9.747781248847787e-09
HLA O 0 8.215315756388009e-05
haplotypes O 0 1.1102015378128272e-06
common O 0 1.234340363254205e-08
in O 0 2.8262940876544462e-09
Caucasians O 0 5.148502779661612e-08
, O 0 3.117807345631718e-09
suggesting O 0 1.2375322100410813e-08
that O 0 2.4306019419384484e-09
845 O 0 4.4703671875367945e-08
G O 0 1.5021490185063158e-07
- O 0 1.3554694078266039e-07
- O 0 2.1297798014074942e-07
> O 0 1.393594430965095e-07
A O 0 1.4783345250179991e-06
may O 0 9.959567393025281e-09
have O 0 8.399407280812454e-10
been O 0 4.382827989424243e-10
introduced O 0 9.849703691555689e-11
into O 0 1.2492870626878982e-10
these O 0 5.7409545867193046e-11
populations O 0 6.475497360547422e-10
by O 0 3.546982263458176e-09
Caucasian O 0 4.0557085867476417e-07
admixture O 0 4.2440692595846485e-06
. O 0 7.197580771389767e-07

187 O 0 2.2775959678256186e-06
C O 0 1.0583941048025736e-06
- O 0 5.009400894095961e-08
- O 0 4.307046808094128e-08
> O 0 1.6178743678096907e-08
G O 0 9.775229159458831e-08
was O 0 1.1895330054301212e-08
present O 0 5.270148206726333e-10
at O 0 7.328077034074454e-10
an O 0 7.971453358512903e-11
allele O 0 5.161929217400996e-10
frequency O 0 2.4337285520203977e-09
of O 0 1.1116295439705937e-08
2 O 0 4.4664042775366397e-07
. O 0 6.618755605813931e-07

68 O 0 3.7664271985704545e-06
% O 0 7.560294612574125e-09
in O 0 3.292242589658656e-10
the O 0 2.1868669097813154e-09
two O 0 3.638568613073545e-10
populations O 0 8.135505047413005e-10
analyzed O 0 3.638917611681336e-09
( O 0 4.903743522355342e-10
Australian O 0 4.0016487901084474e-09
Aboriginal O 0 8.319117839050705e-09
and O 0 4.293028155188949e-09
Chinese O 0 4.593510638528642e-08
) O 0 1.2011285299706742e-08
. O 0 2.5073865117519745e-07

In O 0 7.779784283457047e-08
the O 0 1.3735441939388693e-07
Australian O 0 3.295412298598421e-08
Aboriginal O 0 1.4987998397941737e-08
samples O 0 3.739307086192412e-09
, O 0 2.060540404968947e-09
187 O 0 5.541769265704488e-09
C O 0 2.984901215086211e-08
- O 0 8.715267618697453e-09
- O 0 1.8481568275774407e-08
> O 0 1.886097322767455e-08
G O 0 1.4186298358254135e-07
was O 0 1.514799130575284e-08
found O 0 1.6044987560803747e-10
to O 0 8.517723332213123e-11
be O 0 4.001768916239712e-10
associated O 0 1.0584769505328495e-08
with O 0 2.988043812379715e-09
HLA O 0 0.0038488677237182856
haplotypes O 0 9.535005460747925e-07
common O 0 6.402793850668331e-09
in O 0 1.2517872294282029e-09
Caucasians O 0 2.034722079713447e-08
, O 0 6.136809393986198e-10
suggesting O 0 1.9900032732778072e-09
that O 0 2.5035076789414745e-10
it O 0 2.344017757671679e-10
was O 0 3.1854856530344478e-09
introduced O 0 6.924084083870241e-10
by O 0 1.8999033457589576e-09
recent O 0 5.438680972247312e-08
admixture O 0 6.2774856814939994e-06
. O 0 7.42794725283602e-07

In O 0 1.48552928180834e-07
the O 0 6.302472144170679e-08
Chinese O 0 2.406991583825402e-08
samples O 0 3.6791374391498266e-09
analyzed O 0 8.653913141642988e-09
, O 0 1.6210489617307644e-09
187 O 0 3.4682021698984045e-09
C O 0 1.5019965715623584e-08
- O 0 3.1138016609588703e-09
- O 0 7.444873162398835e-09
> O 0 1.1755085793652142e-08
G O 0 1.0954107665384072e-07
was O 0 2.3666258286425546e-08
present O 0 1.4500312062182275e-09
in O 0 3.4136363180614637e-10
association O 0 1.127086202146188e-09
with O 0 4.3172659891510534e-10
a O 0 2.339213045488009e-09
wide O 0 6.719214962203068e-09
variety O 0 3.232966561128592e-09
of O 0 2.9440887061582544e-08
HLA O 0 4.089391222805716e-05
haplotypes O 0 6.856709546809725e-07
, O 0 5.284061188604028e-09
showing O 0 7.321849793129331e-09
this O 0 3.556736016818718e-10
mutation O 0 2.774398766280939e-10
to O 0 1.8409497537508202e-10
be O 0 7.01191937846346e-10
widespread O 0 2.9651767263771944e-08
and O 0 1.9492512048913113e-09
likely O 0 6.2738529926775755e-09
to O 0 4.192508562539388e-09
predate O 0 6.718986469422816e-07
the O 0 2.976498514328796e-08
more O 0 4.112484575102826e-09
genetically O 0 4.715277412969954e-08
restricted O 0 5.136320879728373e-08
845 O 0 9.545962598167534e-08
G O 0 4.210802728721319e-07
- O 0 4.867554821430531e-07
- O 0 9.37600418637885e-07
> O 0 2.630581832363532e-07
A O 0 4.989871627003595e-07
mutation O 0 1.3862603509551263e-07
. O 0 1.5252661000886292e-07

Genotype O 0 3.413522426853888e-05
- O 0 1.667506694502663e-05
phenotype O 0 2.913710204666131e-06
correlations O 0 1.818107875806163e-06
in O 0 1.3620703498418152e-07
attenuated B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 5.020391199650476e-06

Germ O 0 0.00023467824212275445
- O 0 4.1784987843129784e-05
line O 0 2.1632602056342876e-06
mutations O 0 1.0157807395216878e-07
of O 0 1.3524194741876272e-07
the O 0 2.9035964743684417e-08
tumor B-Disease 0 1.5837600813028985e-06
suppressor O 0 1.9012431948794983e-05
APC O 0 2.443129858420434e-07
are O 0 1.1552897527522532e-09
implicated O 0 2.8458774892214933e-08
in O 0 1.6122800872153675e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00047814796562306583
AAPC B-Disease 1 1.0
) O 0 5.004222813909109e-09
, O 0 3.456860631079195e-10
a O 0 4.0724551508830586e-10
variant O 0 6.841144681857259e-07
of O 0 0.00011750075645977631
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.729919677018188e-05
FAP B-Disease 0 6.516094435937703e-05
) O 0 5.484787379828049e-08
. O 0 2.9342905349949433e-07

AAPC B-Disease 1 1.0
is O 0 3.7968469257521065e-08
recognized O 0 1.8067773055463476e-08
by O 0 2.01134975341688e-09
the O 0 6.893345005920537e-09
occurrence O 0 5.648390555279548e-08
of O 0 3.165276751815327e-08
< O 0 4.282541965494602e-07
100 O 0 2.663392990598368e-07
colonic B-Disease 0 2.437381408526562e-05
adenomas I-Disease 0 5.303189936967101e-06
and O 0 2.890388817178291e-09
a O 0 1.338233635017616e-09
later O 0 1.0857752030801748e-08
onset O 0 0.2757646143436432
of O 0 0.17045576870441437
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.971077745466232e-09
age O 0 3.7853045142810515e-09
> O 0 1.276499084212901e-08
40 O 0 3.568760931216275e-08
years O 0 1.034706986757783e-08
) O 0 9.342969065073703e-09
. O 0 1.2325904208410066e-07

The O 0 2.759130097729212e-07
aim O 0 3.252885392157623e-07
of O 0 3.0356268609921244e-08
this O 0 5.55654189327015e-10
study O 0 5.482450049498766e-10
was O 0 1.7643705385594899e-09
to O 0 5.010753478806862e-10
assess O 0 1.3952701749531116e-07
genotype O 0 1.1456853599156602e-06
- O 0 3.5620939797809115e-06
phenotype O 0 1.2576028893818147e-06
correlations O 0 3.611866077335435e-06
in O 0 4.138718452395551e-07
AAPC B-Disease 1 1.0
families O 0 3.2114658097270876e-06
. O 0 2.5690565053082537e-06

By O 0 1.1767720309308061e-07
protein O 0 1.01753130365978e-06
- O 0 4.6798498942735023e-07
truncation O 0 6.562327143910807e-07
test O 0 2.588814851378629e-08
( O 0 4.589867330651032e-08
PTT O 0 5.652495929098222e-07
) O 0 1.770241730980615e-10
assay O 0 8.705748122395107e-09
, O 0 4.829928124117089e-10
the O 0 7.614996411220432e-10
entire O 0 2.615560434904296e-09
coding O 0 2.1827382568062603e-08
region O 0 2.0108060994061816e-08
of O 0 1.980046704375127e-08
the O 0 2.4942066190192236e-08
APC B-Disease 0 4.66849172653383e-08
gene O 0 3.9547418673180346e-09
was O 0 6.214497005885278e-08
screened O 0 5.129249469604247e-09
in O 0 2.750047967126079e-10
affected O 0 2.589519709772503e-09
individuals O 0 1.0996488164494167e-09
from O 0 9.1270131008514e-08
11 O 0 1.9516464817570522e-06
AAPC B-Disease 1 1.0
kindreds O 0 9.340420547232497e-06
, O 0 7.84905829220861e-09
and O 0 4.469154379904694e-09
their O 0 7.543327740222594e-09
phenotypic O 0 9.534205105410365e-07
differences O 0 2.1564876533375354e-06
were O 0 4.193686606868141e-07
examined O 0 4.441252713149879e-06
. O 0 2.7568994482862763e-06

Five O 0 1.0804822068166686e-06
novel O 0 6.657994049419358e-07
germ O 0 1.3339601537154522e-05
- O 0 5.217442776483949e-06
line O 0 1.963527211046312e-06
APC B-Disease 0 1.9611603363500762e-07
mutations O 0 2.8794898909723088e-08
were O 0 7.379543198737792e-09
identified O 0 6.952924902492441e-09
in O 0 3.2300324637191125e-09
seven O 0 8.78047785590752e-08
kindreds O 0 3.2403379009338096e-05
. O 0 1.3702174328500405e-06

Mutations O 0 9.754757002156111e-07
were O 0 1.2856797582116997e-07
located O 0 4.55914594965634e-08
in O 0 5.19884357785827e-10
three O 0 1.5125226071610598e-10
different O 0 9.585286037117058e-11
regions O 0 2.434438872711553e-09
of O 0 2.341611349265804e-08
the O 0 6.730992652137502e-08
APC B-Disease 0 8.300924747572935e-08
gene O 0 5.172477113291052e-09
( O 0 2.648179231456993e-09
1 O 0 7.281160208094661e-08
) O 0 4.0829700731492835e-10
at O 0 7.533277113225267e-09
the O 0 6.318526590831652e-09
5 O 0 3.12567429716637e-08
end O 0 2.6727814628202395e-08
spanning O 0 3.3528152698636404e-08
exons O 0 1.2827085527078452e-07
4 O 0 8.419608832355152e-08
and O 0 1.0832350127998325e-08
5 O 0 6.857010959038234e-08
, O 0 1.0614570555844693e-08
( O 0 2.4787727426200945e-09
2 O 0 4.147896603967638e-08
) O 0 5.83067483184152e-10
within O 0 3.0942288731239387e-09
exon O 0 3.107087565012989e-08
9 O 0 5.4677105509881585e-08
, O 0 2.7704976091058597e-09
and O 0 4.3074801503451e-09
( O 0 1.133270810527165e-09
3 O 0 2.285183242634048e-08
) O 0 3.1897764984911703e-10
at O 0 9.236357456643418e-09
the O 0 1.4389178737417296e-08
3 O 0 6.37329833352851e-08
distal O 0 5.212103815210867e-07
end O 0 7.186606154618858e-08
of O 0 1.2369827118163812e-07
the O 0 6.308714262104331e-08
gene O 0 1.3399665022006957e-07
. O 0 1.6006969190129894e-06

Variability O 0 1.1451214959379286e-05
in O 0 1.1549598610827161e-08
the O 0 8.79009132148667e-09
number O 0 2.9252365862930674e-08
of O 0 6.398086497938493e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.3460934589204498e-08
most O 0 3.507369117361492e-10
apparent O 0 1.0193534905056367e-08
in O 0 2.0390521215940538e-10
individuals O 0 2.5086030475129917e-10
with O 0 4.505733564030834e-10
mutations O 0 7.969743087699044e-09
in O 0 2.118177633292362e-09
region O 0 2.1988553200458227e-08
1 O 0 1.4755637778307573e-07
, O 0 8.81120865159346e-09
and O 0 3.969600825826092e-08
upper O 0 0.0006213925080373883
- O 0 0.11605900526046753
gastrointestinal O 1 0.9993287324905396
manifestations O 0 0.3196382224559784
were O 0 2.4513633789524647e-08
more O 0 3.4424987305214927e-09
severe O 0 1.7200504771608394e-06
in O 0 6.695572540849071e-09
them O 0 1.220841312488119e-07
. O 0 1.0315462759535876e-06

In O 0 2.9207599894220948e-08
individuals O 0 4.048927415567505e-09
with O 0 1.4698798844747785e-09
mutations O 0 4.772513051420901e-09
in O 0 5.630754196239707e-10
either O 0 3.1297593405810176e-09
region O 0 1.4192598207785068e-08
2 O 0 1.0544589201799681e-08
or O 0 1.2951371086700192e-09
region O 0 1.4656365010523587e-08
3 O 0 1.5082664006627056e-08
, O 0 5.246998946439874e-10
the O 0 1.98783345339848e-09
average O 0 5.7747633341875826e-09
number O 0 5.576004991070249e-09
of O 0 6.466579804964567e-08
adenomas B-Disease 0 1.7100439890782582e-06
tended O 0 3.62748515669864e-08
to O 0 1.6681863668210895e-09
be O 0 3.6182099538706325e-09
lower O 0 2.4056101111114003e-08
than O 0 4.59442622835482e-10
those O 0 5.032111394243088e-10
in O 0 1.2930483073159138e-10
individuals O 0 1.5422103871731707e-10
with O 0 3.856737706975366e-10
mutations O 0 2.102014784455264e-09
in O 0 6.042761846458689e-10
region O 0 1.5034840927796722e-08
1 O 0 3.7877040170997134e-08
, O 0 1.1819266676482698e-09
although O 0 2.812034161081556e-09
age O 0 8.05917110824339e-08
at O 0 2.8408122076939435e-08
diagnosis O 0 7.474399410511978e-08
was O 0 2.814192434641427e-08
similar O 0 3.60515777231285e-08
. O 0 4.860402214035275e-07

In O 0 6.719954512846016e-07
all O 0 4.771419298776891e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.00020501314429566264
, O 0 1.3048178537644617e-08
a O 0 1.5463060165643583e-08
predominance O 0 2.3366437744698487e-05
of O 0 2.307585600647144e-05
right O 1 1.0
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0008889134041965008
rectal B-Disease 1 0.9999568462371826
polyp I-Disease 0 6.396762728400063e-06
sparing O 0 1.46515242249734e-06
was O 0 4.7396858349202375e-07
observed O 0 2.3379904234843707e-07
. O 0 3.231094467537332e-07

No O 0 4.1824216168606654e-05
desmoid B-Disease 1 0.9999865293502808
tumors I-Disease 1 1.0
were O 0 1.0689728213719718e-07
found O 0 4.849741053192247e-09
in O 0 1.7800818596924728e-09
these O 0 2.6424237020705732e-08
kindreds O 0 6.035121623426676e-05
. O 0 1.97416557057295e-06

Our O 0 8.607032668805914e-07
data O 0 3.3257660447816306e-07
suggest O 0 9.07460773191815e-08
that O 0 4.0572065707067395e-09
, O 0 2.751979977233532e-09
in O 0 7.086219611096567e-09
AAPC B-Disease 1 1.0
families O 0 2.5448269269645607e-08
, O 0 6.476176817038493e-10
the O 0 1.212591360655324e-09
location O 0 8.004695217778135e-08
of O 0 2.7678474623371585e-08
the O 0 1.7359036519337678e-07
APC B-Disease 0 1.2947767800142174e-06
mutation O 0 5.4652286252121485e-08
may O 0 2.0466442762767656e-08
partially O 0 9.507314757684071e-08
predict O 0 2.080099648082978e-08
specific O 0 3.0853197330316107e-08
phenotypic O 0 7.802324830663565e-07
expression O 0 2.478033138686442e-06
. O 0 3.391417294551502e-06

This O 0 4.868046943329318e-08
should O 0 1.8092777054334874e-08
help O 0 1.1759257567689474e-08
in O 0 2.4273079102243855e-09
the O 0 5.352817300519064e-09
design O 0 7.901800103127243e-08
of O 0 3.7265923680251944e-08
tailored O 0 2.816389326198987e-07
clinical O 0 1.3583577640474687e-07
- O 0 2.845140159024595e-07
management O 0 7.542089619505532e-09
protocols O 0 1.6806426472726343e-08
in O 0 4.6701792433268e-10
this O 0 4.089953931085688e-10
subset O 0 2.998447357072109e-08
of O 0 4.628831717923276e-08
FAP B-Disease 0 2.7330045213602716e-06
patients O 0 1.3459495740164584e-08
. O 0 3.2296707530576896e-08
. O 0 3.754596207272698e-07

Wilms B-Disease 0 0.014997020363807678
' I-Disease 0 2.3125776351662353e-05
tumor I-Disease 0 2.211500031989999e-06
1 O 0 9.849263733485714e-07
and O 0 3.934084702450491e-08
Dax O 0 9.214814781444147e-05
- O 0 1.1353660767099427e-07
1 O 0 7.527076206770289e-08
modulate O 0 7.721538253235849e-08
the O 0 2.6035365863208426e-08
orphan O 0 9.623898478139381e-08
nuclear O 0 1.4083339294757025e-07
receptor O 0 9.664731805969495e-07
SF O 0 5.344706733012572e-05
- O 0 3.1035460779094137e-07
1 O 0 1.1839561153692557e-07
in O 0 1.743991395741773e-09
sex O 0 8.214872670997408e-10
- O 0 4.895783334291082e-09
specific O 0 3.1766456132231724e-09
gene O 0 4.5176911100952566e-08
expression O 0 5.263955245027319e-07
. O 0 7.73459703395929e-07

Products O 0 2.490048473191564e-06
of O 0 1.713465508146328e-06
steroidogenic O 0 5.9225196309853345e-05
factor O 0 1.5690181953686988e-06
1 O 0 1.0496269169379957e-06
( O 0 3.385078883866299e-08
SF O 0 5.070821862318553e-05
- O 0 6.294723675637215e-07
1 O 0 4.0744251350588456e-07
) O 0 4.0501246800772606e-09
and O 0 2.3897229084468563e-08
Wilms B-Disease 0 6.705046416755067e-06
tumor I-Disease 0 9.254944188796799e-07
1 O 0 5.542743792830152e-07
( O 0 8.60086135645588e-09
WT1 O 0 1.4027565384822083e-06
) O 0 4.867958813825624e-10
genes O 0 1.1468502814082626e-09
are O 0 1.3115385166795335e-10
essential O 0 1.1948807498995961e-09
for O 0 4.906119954739552e-10
mammalian O 0 2.2429108526011987e-07
gonadogenesis O 0 2.945322705727449e-07
prior O 0 1.0551651996593137e-08
to O 0 3.573990658978232e-09
sexual O 0 2.8212220115619857e-08
differentiation O 0 1.1773731785069685e-06
. O 0 9.98898030957207e-07

In O 0 1.6277334680125932e-07
males O 0 2.5094045952300803e-08
, O 0 1.7875134261657877e-08
SF O 0 4.850250843446702e-05
- O 0 1.351106220681686e-06
1 O 0 7.358799507528602e-07
participates O 0 1.0952557971677379e-08
in O 0 6.100270288911247e-10
sexual O 0 6.404158314765596e-10
development O 0 5.117266610454863e-10
by O 0 1.2555383122059283e-10
regulating O 0 7.241614863318091e-09
expression O 0 1.941930527493696e-08
of O 0 1.942552962930222e-08
the O 0 3.801847370255018e-08
polypeptide O 0 1.5099953998287674e-06
hormone O 0 1.8404008983452513e-07
Mullerian O 0 4.150412223680178e-06
inhibiting O 0 4.620548850198247e-07
substance O 0 5.997160883453034e-07
( O 0 7.387079676846042e-07
MIS O 0 0.001088347053155303
) O 0 2.1833594132658618e-07
. O 0 6.990425731601135e-07

Here O 0 1.1405126087993267e-06
, O 0 9.362148745140075e-08
we O 0 3.068605280986958e-08
show O 0 2.991558289977547e-08
that O 0 9.893036612140804e-09
WT1 O 0 5.906423757551238e-05
- O 0 6.686470896966057e-06
KTS O 0 9.622034849599004e-05
isoforms O 0 1.7533548088977113e-06
associate O 0 1.0533170780036016e-06
and O 0 2.0152675972440193e-08
synergize O 0 1.3953501820651582e-06
with O 0 3.825319794259485e-08
SF O 0 0.00042689076508395374
- O 0 1.7095075008910499e-06
1 O 0 3.369124499386089e-07
to O 0 2.083923789086839e-08
promote O 0 4.986513317817298e-07
MIS O 0 0.00027570570819079876
expression O 0 1.025318283609522e-06
. O 0 9.53906237555202e-07

In O 0 2.0090010366402566e-07
contrast O 0 1.2771355386576033e-06
, O 0 2.687240794330137e-07
WT1 O 0 0.0003047655045520514
missense O 0 5.559013516176492e-06
mutations O 0 2.3176576746664068e-07
, O 0 6.725394907647342e-09
associated O 0 2.1963444396533305e-08
with O 0 4.11383416221156e-09
male B-Disease 0 9.312528277405363e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 6.418422771048427e-08
Denys B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3873832926947216e-07
fail O 0 1.3552444499964622e-07
to O 0 3.0737368206246174e-08
synergize O 0 3.7821785099367844e-06
with O 0 1.574430825712625e-07
SF O 1 0.9998461008071899
- O 0 0.00017458760703448206
1 O 0 5.6025153753580526e-05
. O 0 2.5053573153854813e-06

Additionally O 0 2.091341684717918e-06
, O 0 4.4357644668480134e-08
the O 0 6.857167988982837e-08
X O 0 5.762338787462795e-06
- O 0 1.596568381501129e-06
linked O 0 2.125951596099185e-06
, O 0 7.57106022319931e-09
candidate O 0 1.0720862420043886e-08
dosage O 0 5.6274213733331635e-08
- O 0 2.9185603267478655e-08
sensitive O 0 4.103875284044989e-08
sex O 0 3.6859084673324105e-09
- O 0 2.1873853839338153e-08
reversal O 0 2.5804588688060903e-08
gene O 0 8.722618183298891e-09
, O 0 2.0407348699791328e-08
Dax O 0 1.714746031211689e-05
- O 0 5.9521479300883584e-08
1 O 0 9.769916431423553e-08
, O 0 6.61521948330801e-09
antagonizes O 0 1.106580498344556e-07
synergy O 0 5.518492685041565e-08
between O 0 8.298329134959204e-08
SF O 0 6.0521004343172535e-05
- O 0 8.783824796410045e-07
1 O 0 5.499379653883807e-07
and O 0 5.70352725048906e-08
WT1 O 0 1.7317599485977553e-05
, O 0 4.628396332861939e-09
most O 0 9.407608025924219e-10
likely O 0 1.688455708581671e-09
through O 0 1.136727448280972e-10
a O 0 5.913689538061817e-10
direct O 0 1.0500956548753493e-08
interaction O 0 3.874525589253608e-08
with O 0 3.920608548924065e-08
SF O 1 0.9996784925460815
- O 0 0.00027320286608301103
1 O 0 5.085571683594026e-05
. O 0 1.942540166055551e-06

We O 0 3.2546387274123845e-07
propose O 0 2.684446087641845e-07
that O 0 3.590246322460189e-08
WT1 O 0 6.197787297423929e-05
and O 0 5.030878469369782e-07
Dax O 0 0.0043188114650547504
- O 0 4.1133895933853637e-07
1 O 0 1.7177607958274166e-07
functionally O 0 7.599507512168202e-08
oppose O 0 2.4347546201397563e-09
each O 0 6.109818762034536e-10
other O 0 2.4169364287729422e-09
in O 0 2.879773752795245e-09
testis O 0 5.949900128143781e-07
development O 0 2.2023726842235192e-08
by O 0 5.957983439941472e-09
modulating O 0 6.768281082258909e-07
SF O 0 0.00013817250146530569
- O 0 2.098520099025336e-06
1 O 0 2.716931248869514e-06
- O 0 7.024802926025586e-07
mediated O 0 3.4060090001730714e-06
transactivation O 0 4.287517185730394e-06
. O 0 7.152774372798376e-08
. O 0 2.438163164697471e-07

A O 0 4.7765324779902585e-06
mouse O 0 2.249815480581674e-07
model O 0 9.094516428831412e-08
for O 0 1.9016847829789185e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999982118606567
centre O 1 0.8885084390640259
mutations O 0 4.762503976962762e-06
. O 0 1.1786179356931825e-06

Imprinting O 0 1.5464023817912675e-05
in O 0 1.9049231525514188e-07
the O 0 2.9727718242611445e-07
15q11 O 0 6.087425390433054e-06
- O 0 5.966822413938644e-07
q13 O 0 1.421570345883083e-06
region O 0 4.380826723604514e-08
involves O 0 7.527919620997636e-09
an O 0 7.261933721025571e-09
imprinting O 0 7.160076620493783e-07
centre O 0 1.1007384728145553e-06
( O 0 7.721093098211895e-09
IC O 0 0.00013937242329120636
) O 0 2.994473780049134e-09
, O 0 6.96140034506243e-10
mapping O 0 3.471007925526237e-09
in O 0 7.7674405796202e-10
part O 0 1.556808126856879e-09
to O 0 2.076321115040969e-09
the O 0 5.73720839724956e-08
promoter O 0 1.4203289993020007e-06
and O 0 4.737218617378858e-08
first O 0 7.244214828006079e-08
exon O 0 7.667616728213034e-07
of O 0 4.996718416805379e-06
SNRPN O 1 0.9999830722808838
. O 0 2.0224228137522005e-05

Deletion O 0 9.648763352743117e-07
of O 0 2.3769632662151707e-07
this O 0 8.45825098849673e-09
IC O 0 1.0316070984117687e-05
abolishes O 0 2.5719687073433306e-06
local O 0 1.407184555546337e-07
paternally O 0 3.1441751957572706e-07
derived O 0 4.687673360592726e-09
gene O 0 1.2417212813531364e-09
expression O 0 4.202387771101712e-09
and O 0 6.553753095772663e-10
results O 0 4.744368897746654e-09
in O 0 2.274043708894169e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 1.842270989982353e-06
. O 0 8.693130553183437e-07

We O 0 1.587000184599674e-07
have O 0 5.0364441506189905e-09
created O 0 1.1430946855739421e-08
two O 0 3.2954858841804935e-09
deletion O 0 1.1509530217779229e-08
mutations O 0 1.8070807072945172e-08
in O 0 1.4727646879819645e-09
mice O 0 2.5819837379259525e-09
to O 0 1.6848077377673576e-09
understand O 0 4.7136046532614273e-07
PWS B-Disease 1 1.0
and O 0 4.2841715952590675e-08
the O 0 6.5515570746299545e-09
mechanism O 0 3.295123107704967e-08
of O 0 1.7101331906133055e-08
this O 0 1.4139262205503655e-08
IC O 0 0.0011549398768693209
. O 0 4.3653144530253485e-06

Mice O 0 2.065239277726505e-05
harbouring O 0 5.422422691481188e-05
an O 0 7.801642709637235e-08
intragenic O 0 2.2725664621248143e-06
deletion O 0 3.1875476480536236e-08
in O 0 5.360234922591189e-09
Snrpn O 0 2.475873998264433e-06
are O 0 7.200365192971958e-09
phenotypically O 0 2.235270403616596e-05
normal O 0 4.1450266508036293e-07
, O 0 8.996272615746648e-10
suggesting O 0 1.85862325530195e-09
that O 0 2.1057294796733572e-10
mutations O 0 9.681502710634504e-09
of O 0 7.95061652070217e-08
SNRPN O 1 0.998857855796814
are O 0 2.0669606026757492e-09
not O 0 2.9921500832585934e-09
sufficient O 0 2.690915437142394e-07
to O 0 1.2303320318096667e-07
induce O 0 0.04104660451412201
PWS B-Disease 1 1.0
. O 0 3.789604306803085e-05

Mice O 0 8.248815674960497e-07
with O 0 4.584422619302586e-09
a O 0 6.2819713875228445e-09
larger O 0 1.2095890511432117e-08
deletion O 0 5.409286796265178e-09
involving O 0 8.48863646041309e-09
both O 0 5.6091584710316056e-09
Snrpn O 0 1.998469087993726e-06
and O 0 2.998949311106003e-09
the O 0 1.7806124574804016e-08
putative O 0 4.988633463653969e-06
PWS O 1 1.0
- O 0 2.3941884137457237e-06
IC O 0 0.0005992382066324353
lack O 0 2.478245448855887e-07
expression O 0 1.2510073865712457e-08
of O 0 2.5009187609725814e-08
the O 0 4.242059858938774e-08
imprinted O 0 1.9635183434729697e-07
genes O 0 1.321740938919902e-07
Zfp127 O 0 8.800302566669416e-06
( O 0 1.7583310807367525e-08
mouse O 0 6.659899298711025e-08
homologue O 0 7.754671287329984e-07
of O 0 1.9596740230554133e-07
ZNF127 O 0 0.00023151659115683287
) O 0 2.136804511110313e-08
, O 0 5.241142986278646e-08
Ndn O 0 1.435620833944995e-05
and O 0 4.03259790004995e-08
Ipw O 0 4.766575784742599e-06
, O 0 3.6737887398885505e-08
and O 0 8.518056482387237e-09
manifest O 0 1.0806125771978259e-07
several O 0 1.4238096035512626e-08
phenotypes O 0 1.116250587074319e-06
common O 0 1.0286075990961763e-07
to O 0 9.256965540771489e-07
PWS B-Disease 1 1.0
infants O 1 0.9999986886978149
. O 0 4.6473169277305715e-06

These O 0 3.177374452434378e-08
data O 0 4.716230250778608e-08
demonstrate O 0 1.583226350021505e-08
that O 0 1.0864873445370904e-09
both O 0 1.1209503325559922e-09
the O 0 2.665947462787699e-09
position O 0 3.2054585652474543e-09
of O 0 4.543414089397402e-09
the O 0 6.0895084530443455e-09
IC O 0 6.483830020442838e-06
and O 0 4.1496512892535975e-09
its O 0 1.6778424205554643e-09
role O 0 2.6833844035678567e-09
in O 0 4.710849488276381e-10
the O 0 2.699040102527306e-09
coordinate O 0 1.5241690576317524e-08
expression O 0 3.593630637510614e-08
of O 0 2.5308379392185998e-08
genes O 0 5.21895460181554e-09
is O 0 1.2520905423585305e-09
conserved O 0 1.1619597728440567e-08
between O 0 7.576419491783781e-09
mouse O 0 1.8768959719750455e-08
and O 0 2.5751181187416705e-09
human O 0 3.5335852022200243e-09
, O 0 7.880345265220967e-10
and O 0 1.9565211950567374e-10
indicate O 0 2.5336668318942657e-09
that O 0 4.296515365709297e-10
the O 0 8.277742935547394e-09
mouse O 0 3.758441557977221e-09
is O 0 1.960832329839235e-10
a O 0 1.8090998143982517e-10
suitable O 0 3.098339140805706e-09
model O 0 1.1960846757474997e-09
system O 0 6.230371218940434e-10
in O 0 1.8991558325964775e-10
which O 0 1.0256361038241124e-10
to O 0 3.857856256672676e-10
investigate O 0 7.833921955580081e-09
the O 0 6.97597180021603e-09
molecular O 0 3.3755238604271653e-08
mechanisms O 0 3.916295909789369e-08
of O 0 8.568359355365374e-09
imprinting O 0 5.2003663597588456e-08
in O 0 2.890282735368288e-10
this O 0 1.843261654421724e-10
region O 0 6.918477346573582e-09
of O 0 8.961682951280636e-09
the O 0 2.3195587672830698e-08
genome O 0 3.115644986451116e-08
. O 0 3.8042482941591516e-08
. O 0 4.3614923583845666e-07

Mutations O 0 1.471554583076795e-06
of O 0 5.786894803350151e-07
the O 0 6.811283270735657e-08
ATM O 0 1.4244146768760402e-06
gene O 0 1.7102635752053175e-08
detected O 0 2.306860835687985e-08
in O 0 1.3636027862418132e-09
Japanese O 0 1.8672408259590156e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 2.432268411212135e-05
: O 0 4.4656417452770825e-10
possible O 0 8.863022316063507e-09
preponderance O 0 2.376066731812898e-05
of O 0 1.352064913362483e-07
the O 0 9.97424649540335e-08
two O 0 1.723006981535491e-08
founder O 0 7.142862159525976e-07
mutations O 0 1.827903162165967e-07
4612del165 O 0 2.511603724997258e-06
and O 0 2.1101588743022148e-07
7883del5 O 0 2.39633081946522e-05
. O 0 2.4878577278286684e-06

The O 0 1.0869831612581038e-06
ATM O 0 0.00019130230066366494
( O 0 4.223876658215886e-06
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 1.8098401000088415e-08
mutated O 0 1.3235619711338131e-08
) O 0 4.0793116107273875e-10
gene O 0 1.0591206800469877e-09
on O 0 1.2912062530290314e-08
human O 0 2.8895469128542572e-08
chromosome O 0 5.034641503698367e-07
11q22 O 0 8.755025191931054e-06
. O 0 4.583822033055185e-07

3 O 0 1.5179427464317996e-05
has O 0 5.600149677320587e-08
recently O 0 8.777794491265922e-09
been O 0 5.957275783785576e-10
identified O 0 1.1943931399471808e-09
as O 0 2.866488713060278e-10
the O 0 9.255711475031347e-11
gene O 0 1.1625371498791282e-10
responsible O 0 5.2844612019598e-10
for O 0 1.1546458927869097e-10
the O 0 2.4281134880510535e-09
human O 0 5.315957309903752e-07
recessive B-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999995231628418
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999743700027466
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.3788160180847626e-07
. O 0 6.176099986987538e-07

In O 0 3.2601896293726895e-08
order O 0 4.61612650326515e-08
to O 0 8.752850000348644e-09
define O 0 4.5357879230323306e-08
the O 0 7.910317734172168e-09
types O 0 5.1621114494082576e-08
of O 0 4.5861394681878664e-08
disease O 0 3.996853763510444e-07
- O 0 6.55878622524142e-08
causing O 0 2.1886586409891606e-07
ATM O 0 4.980183234692959e-07
mutations O 0 3.2488902679261855e-09
in O 0 4.925077567996539e-10
Japanese O 0 2.2722232984051516e-07
A B-Disease 1 1.0
- I-Disease 1 0.999980092048645
T I-Disease 1 1.0
patients O 0 2.672679677573342e-08
as O 0 4.3521577453020655e-09
well O 0 5.627748267400534e-10
as O 0 9.144045520770305e-10
to O 0 6.305953537122377e-10
look O 0 4.967742661676766e-09
for O 0 1.419026340876428e-09
possible O 0 1.055322513821011e-07
mutational O 0 8.763929145061411e-06
hotspots O 0 7.297962270058633e-07
, O 0 1.2737411125840481e-08
reverse O 0 6.349105063918614e-08
- O 0 5.7760551896990364e-08
transcribed O 0 2.756147132743081e-08
RNA O 0 1.6353288501136376e-08
derived O 0 5.2667443739551345e-09
from O 0 2.146222533028208e-09
ten O 0 7.721151717987595e-09
patients O 0 3.7381997497476505e-10
belonging O 0 1.4395732383931659e-09
to O 0 4.031217581967894e-10
eight O 0 4.701857125866127e-09
unrelated O 0 2.8269802498925856e-08
Japanese O 0 3.18792530151768e-07
A B-Disease 1 1.0
- I-Disease 0 0.00018931318481918424
T I-Disease 1 1.0
families O 0 4.4157246748000034e-08
was O 0 1.0398311545145589e-08
analyzed O 0 2.4640469664660714e-09
for O 0 3.8189806872424015e-10
mutations O 0 3.984694796344002e-09
by O 0 2.8683715402877397e-09
the O 0 1.5494091343271066e-08
restriction O 0 7.361045817333434e-08
endonuclease O 0 3.362967504472181e-07
fingerprinting O 0 8.576702015261617e-08
method O 0 3.2490720514033455e-07
. O 0 1.2258351489435881e-06

As O 0 6.164008254927467e-07
has O 0 9.306455162061411e-09
been O 0 1.1666360100193174e-09
reported O 0 1.057386733727128e-09
by O 0 1.6134843461301784e-10
others O 0 2.3498649692754725e-09
, O 0 3.6954658777510474e-10
mutations O 0 1.4298832118342375e-09
that O 0 4.2764683461093966e-10
lead O 0 4.9435167071010255e-09
to O 0 5.170721184555305e-09
exon O 0 7.381574107512279e-08
skipping O 0 8.328710521254834e-08
or O 0 1.8847092775331475e-08
premature O 0 6.740923907955221e-08
protein O 0 6.690162734912519e-08
truncation O 0 3.775155335006275e-07
were O 0 1.6254338319754424e-08
also O 0 3.8898511078855336e-09
predominant O 0 5.8446541828516274e-08
in O 0 2.7835007632148745e-09
our O 0 1.8233154719382583e-07
mutants O 0 1.952163984242361e-06
. O 0 1.3461044545692857e-06

Six O 0 1.1388840448489645e-07
different O 0 4.643534445847308e-09
mutations O 0 8.074384716394434e-09
were O 0 2.6160393851171193e-09
identified O 0 5.416678661163132e-09
on O 0 3.150097516169126e-09
12 O 0 3.272897952655285e-09
of O 0 2.53637932878803e-09
the O 0 2.348477323721454e-08
16 O 0 1.8272496049576148e-07
alleles O 0 9.769543396487279e-08
examined O 0 6.497265871985292e-07
. O 0 7.925979161882424e-07

Four O 0 1.4512446568915038e-06
were O 0 1.492143013592795e-07
deletions O 0 2.3068987786700745e-07
involving O 0 3.468342768542243e-08
a O 0 1.438262042796623e-08
loss O 0 3.243530102281511e-07
of O 0 1.2680233396622498e-07
a O 0 2.7563416438169952e-08
single O 0 1.8869751983174865e-08
exon O 0 1.3076672189527017e-07
exon O 0 2.408397392628103e-07
7 O 0 9.335933555121301e-07
, O 0 3.3237679275543996e-08
exon O 0 1.2045566677443276e-07
16 O 0 6.262736178541672e-07
, O 0 2.673464649660673e-08
exon O 0 2.2576216451852815e-07
33 O 0 1.1783953368649236e-06
or O 0 4.549269405629275e-08
exon O 0 5.992267233523307e-07
35 O 0 2.7949301966145867e-06
. O 0 8.354427336598746e-07

The O 0 1.3853778000338934e-06
others O 0 2.4202918780247273e-07
were O 0 5.1075307538894776e-08
minute O 0 1.0281755749019794e-06
deletions O 0 8.146503773787117e-07
, O 0 1.9088687963630946e-08
4649delA O 0 2.7443897465673217e-07
in O 0 1.1574562641669672e-08
exon O 0 1.0418924034638621e-07
33 O 0 7.280812042154139e-07
and O 0 2.4816314336817413e-08
7883del5 O 0 2.2176627680892125e-06
in O 0 2.9207877005887894e-08
exon O 0 5.215151759330183e-07
55 O 0 3.628105332609266e-06
. O 0 1.2524515113909729e-06

The O 0 1.9523761238815496e-06
mutations O 0 7.558164156762359e-07
4612del165 O 0 1.945027861438575e-06
and O 0 1.1237939467889646e-08
7883del5 O 0 3.7855451751056535e-07
were O 0 4.902287020769336e-09
found O 0 7.703407911563431e-10
in O 0 1.4191582631273292e-10
more O 0 7.398406887126896e-11
than O 0 1.6105204669880635e-10
two O 0 1.546991840184475e-10
unrelated O 0 1.926843129496092e-09
families O 0 2.680549116007569e-10
; O 0 3.1550026480253734e-10
44 O 0 1.3054849645754985e-08
% O 0 3.145215199396034e-10
( O 0 4.366055086912901e-11
7 O 0 3.242117907475972e-09
of O 0 7.3497496977381616e-09
16 O 0 1.0201470779236388e-08
) O 0 9.995601568668633e-11
of O 0 1.6984299522349033e-09
the O 0 1.4728939179420308e-09
mutant O 0 4.646298901178625e-09
alleles O 0 1.4338131792968056e-09
had O 0 1.493257739682008e-09
one O 0 1.0369864966719433e-09
of O 0 4.828604627249433e-09
the O 0 1.69965250762516e-08
two O 0 4.642315332148428e-08
mutations O 0 9.92089098872384e-07
. O 0 1.7517886590212584e-06

The O 0 1.4713665450472035e-06
4612del165 O 0 1.512334392828052e-06
mutations O 0 2.1836504160432924e-08
in O 0 6.732681079313352e-10
three O 0 8.039584969976588e-11
different O 0 4.2506713426870846e-11
families O 0 2.320463682314866e-10
were O 0 3.4020922190514113e-10
all O 0 1.8458017059241882e-10
ascribed O 0 1.1802354649148583e-08
to O 0 8.201032630772431e-10
the O 0 8.235066850659223e-09
same O 0 9.62710711149839e-09
T O 0 1.1525175835913615e-07
- O 0 3.338890408599582e-08
- O 0 4.755406024514741e-08
> O 0 1.1827459012181407e-08
A O 0 1.2760536627354213e-08
substitution O 0 1.5515796647491698e-08
at O 0 1.5641186124071282e-08
the O 0 5.880612885533765e-09
splice O 0 2.1828263641054946e-07
donor O 0 4.988310919884498e-08
site O 0 2.2040204328277468e-07
in O 0 3.560459305163022e-08
intron O 0 3.977820597356185e-05
33 O 0 3.202398511348292e-05
. O 0 2.9906907457188936e-06

Microsatellite O 0 1.4359631677507423e-05
genotyping O 0 2.251452087875805e-06
around O 0 6.963757215316946e-08
the O 0 3.9696313791637294e-08
ATM O 0 5.94980338064488e-06
locus O 0 1.1442664771266209e-07
also O 0 3.641764223516475e-09
indicated O 0 2.881751948180522e-09
that O 0 1.519184222864567e-10
a O 0 5.543944192609729e-10
common O 0 6.153488274485142e-10
haplotype O 0 3.8483943143319266e-08
was O 0 8.830590481068157e-09
shared O 0 1.452813425117938e-09
by O 0 3.345363985829408e-10
the O 0 3.4136511395388425e-09
mutant O 0 3.432881712228664e-08
alleles O 0 4.403812869924195e-09
in O 0 3.6121559077173515e-09
both O 0 5.1229950059905605e-08
mutations O 0 1.3917856449552346e-06
. O 0 1.5863827229622984e-06

This O 0 3.983686269748432e-08
suggests O 0 8.494729542007917e-08
that O 0 8.094873660269286e-10
these O 0 3.5777487639165884e-09
two O 0 9.332532080463807e-09
founder O 0 1.8089244235852675e-07
mutations O 0 1.8932697187779013e-08
may O 0 2.5370907597022097e-09
be O 0 4.628412098028889e-10
predominant O 0 3.037949980466692e-08
among O 0 1.5468687442066198e-09
Japanese O 0 2.8039695010306787e-08
ATM O 0 2.59883631770208e-06
mutant O 0 9.876390549834468e-07
alleles O 0 5.94950847698783e-07
. O 0 1.113146481657168e-06

W474C O 0 7.560504309367388e-05
amino O 0 1.1350330169079825e-06
acid O 0 6.053149093077081e-08
substitution O 0 4.577112378001402e-08
affects O 0 1.326157139658335e-08
early O 0 5.364551025621722e-09
processing O 0 1.9476839696608295e-08
of O 0 2.255727338251745e-08
the O 0 1.4163230588337683e-08
alpha O 0 6.2521592347764e-09
- O 0 1.6921892775911829e-09
subunit O 0 1.5871317593507683e-09
of O 0 3.4295881690127317e-09
beta O 0 1.1368109120724057e-08
- O 0 1.3840418588983994e-08
hexosaminidase O 0 1.7739674262884364e-07
A O 0 8.493109504570384e-08
and O 0 1.819836170646738e-09
is O 0 2.997615489164218e-10
associated O 0 6.33242525083233e-09
with O 0 8.381263683077123e-09
subacute O 1 0.6842896342277527
G B-Disease 1 0.9999462366104126
( I-Disease 0 1.9618837541202083e-05
M2 I-Disease 1 0.9999973773956299
) I-Disease 0 3.7588239365504705e-07
gangliosidosis I-Disease 0 0.001504951505921781
. O 0 2.3339680410572328e-06

Mutations O 0 1.1877644965352374e-06
in O 0 5.100502065147339e-08
the O 0 2.3402233750857704e-07
HEXA O 0 9.790557669475675e-06
gene O 0 1.6565540050805794e-08
, O 0 2.6280020382074554e-09
encoding O 0 6.196953172832309e-09
the O 0 1.5011144327559123e-08
alpha O 0 3.944481186124449e-09
- O 0 1.7294592424832445e-09
subunit O 0 1.0858097754251617e-09
of O 0 3.407633730745374e-09
beta O 0 1.2848555996924915e-08
- O 0 2.7357943466199686e-08
hexosaminidase O 0 8.753987117415818e-07
A O 0 5.90414970247366e-07
( O 0 4.118183127843622e-09
Hex O 0 2.685137587832287e-07
A O 0 2.282622375560095e-07
) O 0 8.372471604900511e-10
, O 0 6.324117340916757e-10
that O 0 1.9275406271113127e-10
abolish O 0 3.571859252815557e-08
Hex O 0 3.24107816140895e-07
A O 0 3.973669038259686e-08
enzyme O 0 9.346447882307984e-08
activity O 0 1.1375532693591595e-07
cause O 0 0.02442927099764347
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 3.5631291694926404e-08
TSD B-Disease 0 0.0034474125131964684
) O 0 1.2166873064600736e-09
, O 0 8.100928816645592e-10
the O 0 1.321856490932305e-08
fatal O 0 7.967168471623154e-07
infantile B-Disease 0 1.410561253578635e-06
form I-Disease 0 1.7055596046589017e-08
of I-Disease 0 1.3087405932310503e-06
G I-Disease 0 0.20397590100765228
( I-Disease 0 2.379317947998061e-06
M2 I-Disease 1 0.8923499584197998
) I-Disease 0 6.660966533900137e-08
gangliosidosis I-Disease 0 1.0004127943830099e-05
, I-Disease 0 2.0248691612323455e-08
Type I-Disease 0 1.5799750485712138e-07
1 I-Disease 0 3.1126094199862564e-06
. O 0 1.1524202818691265e-06

Less O 0 3.3937988064280944e-06
severe O 0 0.000617482524830848
, O 0 2.1377587700044387e-07
subacute O 0 2.0864112229901366e-05
( O 0 2.0713816439865695e-08
juvenile O 0 1.909695583890425e-06
- O 0 5.947857744104112e-07
onset O 0 0.09522750973701477
) O 0 3.14343551188756e-09
and O 0 3.830627903766981e-08
chronic O 1 0.9998212456703186
( O 0 4.085839222511822e-09
adult O 0 1.347139573226741e-06
- O 0 2.917445272032637e-07
onset O 0 2.5282383830926847e-06
) O 0 2.2387174059002035e-10
variants O 0 2.952195821137593e-09
are O 0 1.6030059224458881e-10
characterized O 0 2.88360890721151e-10
by O 0 1.9257326289157106e-10
a O 0 1.626729417836259e-09
broad O 0 1.4039509999008715e-08
spectrum O 0 1.9486352087483283e-08
of O 0 3.4198357479198194e-09
clinical O 0 5.804722924551697e-09
manifestations O 0 4.412550680399363e-08
and O 0 1.2364013146637376e-09
are O 0 2.156738815317638e-10
associated O 0 5.059870300527791e-09
with O 0 1.0641343362038924e-09
residual O 0 0.02848830074071884
levels O 0 2.703081349864078e-07
of O 0 2.1234704661310388e-07
Hex O 0 4.454614554560976e-06
A O 0 4.993408424525114e-07
enzyme O 0 9.575283002050128e-07
activity O 0 1.5094972241058713e-06
. O 0 1.3962073808215791e-06

We O 0 3.659218634766148e-07
identified O 0 3.1496642804995645e-07
a O 0 1.333134349579268e-07
1422 O 0 6.6379998315824196e-06
G O 0 2.292777026013937e-06
- O 0 1.2125939292673138e-06
- O 0 1.0604612725728657e-06
> O 0 3.190334041391907e-07
C O 0 1.3518473451767932e-06
( O 0 3.461910091928644e-09
amino O 0 6.937783236793393e-09
acid O 0 2.748087979398406e-09
W474C O 0 9.964108649285208e-09
) O 0 4.746126235077863e-12
substitution O 0 1.498578344749646e-10
in O 0 6.544906283600938e-11
the O 0 5.871878538954434e-10
first O 0 1.433115959237341e-09
position O 0 1.4192761632614292e-08
of O 0 8.20587153782526e-09
exon O 0 2.619955630223103e-08
13 O 0 1.070443857997816e-07
of O 0 2.983023534852691e-07
HEXA O 0 0.007997809909284115
of O 0 7.348490385084006e-07
a O 0 5.0322888967002655e-08
non O 0 1.374691009914386e-06
- O 0 2.8888919700875704e-07
Jewish O 0 1.0504748388484586e-05
proband O 0 0.013113586232066154
who O 0 3.959272021347715e-08
manifested O 0 5.386987567135293e-08
a O 0 1.639332403158278e-08
subacute O 0 1.0517312603042228e-06
variant O 0 2.960397296192241e-07
of O 0 2.346230758121237e-06
G B-Disease 1 0.9885678291320801
( I-Disease 0 1.5352468835772015e-05
M2 I-Disease 1 0.9999871253967285
) I-Disease 0 4.6078406512606307e-07
gangliosidosis I-Disease 0 0.0005256364238448441
. O 0 2.8426063636288745e-06

On O 0 1.0011868880610564e-06
the O 0 1.4474075271664333e-07
second O 0 2.727994683482393e-07
maternally O 0 1.2718593325189431e-06
inherited O 0 9.71774625213584e-07
allele O 0 2.5160625227726996e-07
, O 0 6.882256986529001e-09
we O 0 1.6728575191748973e-09
identified O 0 7.06710689968304e-09
the O 0 1.1031597857424913e-08
common O 0 2.7219888920626545e-07
infantile O 1 0.999937891960144
disease O 0 0.03711853548884392
- O 0 2.5954554985219147e-06
causing O 0 0.00010433114948682487
4 O 0 4.16303828387754e-06
- O 0 5.541464815905783e-07
bp O 0 2.2277093592038e-07
insertion O 0 1.5918597284780844e-07
, O 0 2.6330006619446067e-08
+ O 0 4.862062041866011e-07
TATC O 0 0.00046066410141065717
1278 O 0 1.5934461771394126e-05
, O 0 3.345405374943766e-08
in O 0 1.8791597611311772e-08
exon O 0 1.180059712169168e-06
11 O 0 2.7070796022599097e-06
. O 0 1.3157700777810533e-06

Pulse O 0 3.6441888369154185e-05
- O 0 2.9592101782327518e-06
chase O 0 3.58061470251414e-07
analysis O 0 3.019527383685272e-08
using O 0 2.1989810861100523e-08
proband O 0 7.3257333497167565e-06
fibroblasts O 0 1.1127814332212438e-06
revealed O 0 9.51066994048233e-08
that O 0 2.047638725244383e-09
the O 0 1.3041510094069508e-08
W474C O 0 1.453188929190219e-07
- O 0 8.712043531033942e-09
containing O 0 4.393459818174961e-09
alpha O 0 4.526184316233639e-09
- O 0 1.929745030437857e-09
subunit O 0 1.5882705151071264e-09
precursor O 0 1.444026143104793e-08
was O 0 1.185306874873504e-08
normally O 0 6.352939285747539e-10
synthesized O 0 5.673318259624693e-09
, O 0 9.639320452947686e-10
but O 0 6.615102909890425e-10
not O 0 5.47010325924191e-10
phosphorylated O 0 2.7431459770355104e-08
or O 0 3.2989952991613336e-09
secreted O 0 1.4927374891726686e-08
, O 0 1.6622914156272373e-09
and O 0 3.0864129030305776e-09
the O 0 2.0228425157142738e-08
mature O 0 5.4459050602417847e-08
lysosomal O 0 4.939965947414748e-07
alpha O 0 5.3261167920481967e-08
- O 0 2.8584821620825096e-08
subunit O 0 1.5225332106183487e-08
was O 0 3.5616004367966525e-08
not O 0 3.7127132479497504e-09
detected O 0 2.154693987677092e-07
. O 0 1.4903568512636411e-07

When O 0 4.626139684660302e-07
the O 0 3.0198850708984537e-07
W474C O 0 1.342375412605179e-06
- O 0 3.455249242279024e-08
containing O 0 8.947302454487271e-09
alpha O 0 2.184391689752374e-08
- O 0 5.476558317951685e-09
subunit O 0 6.2140208534344765e-09
was O 0 2.0091038166469843e-08
transiently O 0 7.26168707387842e-08
co O 0 2.1272480665857074e-08
- O 0 1.1538677568978528e-08
expressed O 0 2.727378545230863e-09
with O 0 3.4935751513920366e-10
the O 0 1.5870591507649578e-09
beta O 0 8.706789733636811e-10
- O 0 2.8217034264699237e-10
subunit O 0 1.476386513044048e-10
to O 0 1.7166217058939282e-10
produce O 0 5.294876537220716e-09
Hex O 0 6.833730594735243e-07
A O 0 4.2161912006122293e-07
( O 0 7.639790133850966e-09
alphabeta O 0 3.684764919853478e-07
) O 0 7.040357186127721e-10
in O 0 2.3951427507995504e-09
COS O 0 1.6865737052285112e-05
- O 0 1.8213168573311123e-07
7 O 0 7.061814244480047e-08
cells O 0 8.503479698163119e-09
, O 0 2.4102244644552684e-09
the O 0 2.0960093660704615e-09
mature O 0 1.7275867403299117e-09
alpha O 0 1.5565230215841552e-09
- O 0 9.099957454239416e-10
subunit O 0 5.211283071737682e-10
was O 0 3.3985334546571266e-09
present O 0 3.591784092371597e-10
, O 0 2.4831772749145387e-10
but O 0 2.605501370211982e-10
its O 0 5.078780729306231e-10
level O 0 3.6954044269066344e-09
was O 0 3.6765765987212262e-09
much O 0 7.051054184969985e-10
lower O 0 1.6650394396577894e-09
than O 0 2.040444757600568e-10
that O 0 2.8305599530931147e-10
from O 0 3.1334446148889583e-09
normal O 0 1.0905861991261645e-08
alpha O 0 6.991570433712013e-09
- O 0 7.549458835853784e-09
subunit O 0 1.5106444095636107e-08
transfections O 0 2.0184842242088052e-07
, O 0 5.004430203570109e-10
although O 0 1.5107955164683773e-10
higher O 0 2.137121146716936e-09
than O 0 6.191890750129048e-11
in O 0 1.9613075052937745e-10
those O 0 6.485360581898192e-10
cells O 0 4.632901173806658e-09
transfected O 0 3.034729800788227e-08
with O 0 3.642429136085923e-10
an O 0 1.880055222613919e-09
alpha O 0 5.674833492008702e-09
- O 0 6.526537976725422e-09
subunit O 0 1.0521526760953748e-08
associated O 0 1.3311779412106262e-07
with O 0 1.416828894207356e-07
infantile O 1 0.9999970197677612
TSD B-Disease 1 0.9995121955871582
. O 0 3.751285476027988e-06

Furthermore O 0 1.8532595049691736e-06
, O 0 1.9110727222937385e-08
the O 0 8.642794924185182e-09
precursor O 0 2.583158220659243e-07
level O 0 1.2348564837338927e-07
of O 0 2.652346076104095e-08
the O 0 1.3182057223559696e-08
W474C O 0 1.1489444773360447e-07
alpha O 0 2.3393738057819746e-09
- O 0 9.726882632676848e-10
subunit O 0 7.950441971438238e-10
was O 0 1.879624900169574e-09
found O 0 1.0952860146629106e-10
to O 0 6.82793682704741e-11
accumulate O 0 8.553544539324776e-10
in O 0 1.549957245883249e-10
comparison O 0 8.650776983643027e-09
to O 0 1.8860566441958326e-09
the O 0 2.456071435119611e-08
normal O 0 7.720007033640286e-08
alpha O 0 7.094607212820847e-08
- O 0 7.029213122677902e-08
subunit O 0 1.112970835492888e-07
precursor O 0 9.089849868360034e-07
levels O 0 3.080460260207474e-07
. O 0 5.44789372725063e-07

We O 0 4.010744873994554e-07
conclude O 0 1.4563842114512227e-06
that O 0 1.988300724065084e-08
the O 0 1.6854633599905355e-07
1422 O 0 4.747919774672482e-06
G O 0 2.88694695882441e-06
- O 0 5.545746830648568e-07
- O 0 4.883810333922156e-07
> O 0 1.1453539627837017e-07
C O 0 8.221494596227785e-08
mutation O 0 6.301793531449107e-10
is O 0 6.328048501869077e-11
the O 0 1.5731287106302005e-10
cause O 0 1.1969137680978292e-08
of O 0 1.5546248732789536e-08
Hex B-Disease 0 4.103447736270027e-06
A I-Disease 0 9.302798389398959e-06
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.85314953885063e-08
the O 0 2.0542829304304178e-07
proband O 0 2.8336684408714063e-05
. O 0 4.3408647343312623e-07

The O 0 3.7563225419035007e-07
resulting O 0 4.290382378258073e-07
W474C O 0 1.3113017303112429e-06
substitution O 0 1.7080151337722782e-07
clearly O 0 1.366254309687065e-07
interferes O 0 2.9544391821900717e-08
with O 0 1.037730568143047e-09
alpha O 0 3.053121089280353e-09
- O 0 8.098735015948932e-10
subunit O 0 3.8056738316250005e-10
processing O 0 5.627514898520758e-09
, O 0 2.0226902097686406e-10
but O 0 8.313747607013866e-11
because O 0 1.5422957355681888e-10
the O 0 2.426469025706979e-10
base O 0 4.471863712662838e-10
substitution O 0 7.579657790302008e-09
falls O 0 2.5620050791985705e-07
at O 0 3.5652552021758765e-09
the O 0 5.000101221952491e-09
first O 0 4.905158501600226e-09
position O 0 4.353413984858889e-08
of O 0 7.142045177488399e-08
exon O 0 1.3912016072481492e-07
13 O 0 4.113311149467336e-07
, O 0 1.849849695645389e-08
aberrant O 0 4.7567940697490485e-08
splicing O 0 1.0127686067562536e-07
may O 0 2.8492502579524626e-08
also O 0 3.4833571582737477e-09
contribute O 0 9.529077971137667e-09
to O 0 2.730648773763278e-08
Hex B-Disease 0 0.001310657593421638
A I-Disease 0 0.00011321775673422962
deficiency I-Disease 0 0.00010470860433997586
in O 0 6.735690671888506e-09
this O 0 9.135230349954782e-09
proband O 0 1.6347916243830696e-05
. O 0 9.778604237453692e-08
. O 0 4.4997781856181973e-07

Two O 0 1.8652443145583675e-07
frequent O 0 5.019070954404015e-07
missense O 0 6.352409400278702e-06
mutations O 0 1.6276942460535793e-06
in O 0 8.550548500352306e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.6085094102891162e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.965110669743808e-07
an O 0 2.5298224500147626e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.513162015333364e-07
by O 0 7.813936164779989e-10
early O 0 1.5462906048924197e-06
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 0 3.438037674641237e-05

A O 0 4.604831701726653e-06
century O 0 3.788203457588679e-07
after O 0 1.1212289763307126e-08
its O 0 5.890185006407478e-10
recognition O 0 1.6530819380022876e-08
as O 0 1.2444438368675037e-08
a O 0 2.394057041499309e-08
syndrome O 0 2.2915870090400858e-07
by O 0 2.623814943092384e-09
Vaughan O 0 8.366938004655822e-07
Pendred O 0 0.00018385396106168628
, O 0 5.68248070820232e-09
the O 0 1.4173473061873665e-08
disease O 0 1.050390494583553e-07
gene O 0 3.4248767377675904e-08
( O 0 5.705224737084791e-08
PDS O 1 0.879793107509613
) O 0 2.0429302693969476e-09
was O 0 2.160293988140438e-08
mapped O 0 7.965092585493494e-09
to O 0 1.5740607040015675e-08
chromosome O 0 1.0526795222176588e-06
7q22 O 0 3.782376370509155e-05
- O 0 2.720153861446306e-05
q31 O 0 0.0001004646037472412
. O 0 2.528055347283953e-06

1 O 0 1.0457947610120755e-05
and O 0 3.4481726629564946e-07
, O 0 3.16537338562739e-08
recently O 0 2.5175305395919167e-08
, O 0 1.870005705839617e-09
found O 0 7.061955464848779e-10
to O 0 8.082531866016041e-10
encode O 0 3.882270860344761e-08
a O 0 9.672000800264868e-08
putative O 0 1.0183555787079968e-05
sulfate O 0 1.173187411040999e-05
transporter O 0 8.042919944273308e-05
. O 0 2.7234973458689637e-06

We O 0 1.924875903114298e-07
performed O 0 7.88350629221668e-09
mutation O 0 4.1844558928971765e-09
analysis O 0 3.4931106895896846e-09
of O 0 1.0205090106296666e-08
the O 0 5.057190932689082e-08
PDS B-Disease 0 6.272574682952836e-05
gene O 0 4.518128093877749e-09
in O 0 1.9809713869278767e-09
patients O 0 1.2759142631324494e-09
from O 0 5.368214761602985e-09
14 O 0 1.9374354565115937e-08
Pendred B-Disease 0 1.1062807914186124e-07
families O 0 1.0221213875283297e-09
originating O 0 1.1064169580521366e-09
from O 0 6.358552573360043e-10
seven O 0 5.072855469023807e-10
countries O 0 1.4713882889871854e-10
and O 0 3.319021724124127e-09
identified O 0 8.021230968324744e-08
all O 0 6.978476108088216e-08
mutations O 0 1.4171723705658223e-06
. O 0 1.21484652026993e-06

The O 0 3.7436194588735816e-07
mutations O 0 9.84019692396032e-08
include O 0 1.9994624622654555e-08
three O 0 9.032418368803974e-09
single O 0 7.902023035910588e-09
base O 0 3.825327254958211e-08
deletions O 0 1.7458701506711805e-07
, O 0 1.1158867607719003e-08
one O 0 6.963329912679228e-09
splice O 0 6.7222805455458e-07
site O 0 9.905445352842435e-08
mutation O 0 1.0245578607737116e-08
and O 0 1.0359531010806222e-08
10 O 0 1.9242406779085286e-07
missense O 0 1.1138963600387797e-05
mutations O 0 7.309640295716235e-06
. O 0 4.015714694105554e-06

One O 0 4.932330170959176e-07
missense O 0 6.065809429856017e-06
mutation O 0 2.4070610038506857e-07
( O 0 2.1317239529139442e-08
L236P O 0 4.336392294135294e-07
) O 0 6.515414874286307e-10
was O 0 3.582118601741513e-09
found O 0 1.0282844020714776e-10
in O 0 4.644008441689884e-11
a O 0 3.0687660745876144e-10
homozygous O 0 9.130103895138575e-10
state O 0 6.697919996412338e-10
in O 0 4.227613814578035e-10
two O 0 1.3947101251687855e-09
consanguineous O 0 6.386574824546187e-08
families O 0 2.2549087042023075e-09
and O 0 5.130812441578314e-10
in O 0 2.817411859368235e-10
a O 0 1.888356804258251e-09
heterozygous O 0 2.1306334474502364e-09
state O 0 1.4410044268942102e-09
in O 0 1.5609945558381355e-09
five O 0 4.509897344462388e-09
additional O 0 5.612018583178724e-08
non O 0 3.199949333065888e-06
- O 0 4.150535005464917e-06
consanguineous O 0 6.300757377175614e-05
families O 0 1.3564913388108835e-06
. O 0 1.971606707229512e-06

Another O 0 1.4065045661482145e-06
missense O 0 8.857684406393673e-06
mutation O 0 1.1588173975951577e-07
( O 0 1.7641594851625086e-08
T416P O 0 4.828072519558191e-07
) O 0 6.476596481341801e-10
was O 0 2.1981665376813453e-09
found O 0 1.1947889899666109e-10
in O 0 3.69030118962943e-11
a O 0 4.164556199892644e-10
homozygous O 0 8.3496987102194e-10
state O 0 3.6473371545220346e-10
in O 0 4.99375096829624e-10
one O 0 1.7036017041505147e-09
family O 0 1.749091538272296e-09
and O 0 4.265389430546662e-10
in O 0 1.576228314537076e-10
a O 0 9.875386064450709e-10
heterozygous O 0 8.292277420274274e-10
state O 0 8.30386315264775e-10
in O 0 2.3457986664254804e-09
four O 0 3.668032988457526e-08
families O 0 1.1334901017789889e-07
. O 0 4.7487077381447307e-07

Pendred B-Disease 0 0.0001528126304037869
patients O 0 1.2030056950607104e-07
in O 0 8.533929118925698e-09
three O 0 1.0922516224809442e-08
non O 0 2.4953351385192946e-07
- O 0 8.237348225748065e-08
consanguineous O 0 6.388475526364346e-07
families O 0 5.465997432452241e-09
were O 0 3.606730913929823e-09
shown O 0 4.379276941079979e-10
to O 0 3.7026906540837956e-10
be O 0 1.5822716470381692e-09
compound O 0 5.8484566523020476e-08
heterozygotes O 0 3.2070508382275875e-07
for O 0 1.887453926485705e-08
L236P O 0 2.4116802705975715e-06
and O 0 6.993160184265435e-08
T416P O 0 1.3719532944378443e-05
. O 0 1.563445380270423e-06

In O 0 3.626053413086083e-08
total O 0 2.3046617059208074e-08
, O 0 1.0967937669192906e-09
one O 0 5.565558014453131e-10
or O 0 3.921958313668483e-10
both O 0 7.187929695895434e-10
of O 0 2.7774498256860625e-09
these O 0 5.37924094157205e-10
mutations O 0 5.6346571852827765e-09
were O 0 2.822986067130273e-09
found O 0 1.0406758788050752e-09
in O 0 4.225130800783461e-10
nine O 0 9.216928553712478e-09
of O 0 1.7918965866670078e-08
the O 0 4.7746919307201097e-08
14 O 0 1.364415709304012e-07
families O 0 2.7908171773560753e-08
analyzed O 0 4.956265229338896e-07
. O 0 9.007352446133154e-07

The O 0 7.193518314352332e-08
identification O 0 1.9896670266916772e-07
of O 0 2.0001155576210294e-07
two O 0 2.1743199241086586e-08
frequent O 0 3.859877324430272e-07
PDS B-Disease 1 0.9988000392913818
mutations O 0 7.256661405108389e-08
will O 0 2.2819939271556677e-09
facilitate O 0 4.4118440456486496e-08
the O 0 5.3999675841964745e-09
molecular O 0 3.02346393254993e-07
diagnosis O 0 1.162047828984214e-05
of O 0 2.0741685148095712e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.032964615267701e-06

Insertional O 0 0.0001285363541683182
mutation O 0 2.1349207202092657e-07
by O 0 2.6573083289349597e-08
transposable O 0 3.076991788475425e-06
element O 0 2.300819232914364e-07
, O 0 1.819517869705578e-08
L1 O 0 4.824446023121709e-06
, O 0 4.153159149922203e-09
in O 0 1.949065353556989e-09
the O 0 2.0771824438270414e-07
DMD B-Disease 1 1.0
gene O 0 6.291326570817546e-08
results O 0 1.419456623352744e-07
in O 0 2.9004855406356e-08
X B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
linked I-Disease 1 0.9999998807907104
dilated I-Disease 1 0.9999696016311646
cardiomyopathy I-Disease 1 1.0
. O 0 2.8990343707846478e-05

X B-Disease 1 0.9996888637542725
- I-Disease 1 0.9995506405830383
linked I-Disease 1 0.9999535083770752
dilated I-Disease 1 0.9999904632568359
cardiomyopathy I-Disease 1 1.0
( O 0 1.3545067304221448e-05
XLDCM B-Disease 1 1.0
) O 0 1.6217663878492772e-09
is O 0 2.600258619533946e-10
a O 0 3.609743615129446e-10
clinical O 0 9.274169876505312e-09
phenotype O 0 1.3721040659220307e-07
of O 0 9.811410706106471e-08
dystrophinopathy B-Disease 0 1.7885584384202957e-05
which O 0 8.961200115287227e-10
is O 0 2.320228870145158e-10
characterized O 0 5.036701611338401e-10
by O 0 7.4293082796828e-10
preferential O 0 9.267521363653941e-07
myocardial B-Disease 1 0.5974692702293396
involvement I-Disease 0 2.9396728606911893e-08
without O 0 2.8541278229710088e-09
any O 0 4.07011979675076e-09
overt O 0 1.7632586946092488e-07
clinical O 0 5.964580651607321e-08
signs O 0 1.1787449238909176e-06
of O 0 9.154557005786046e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 4.680048368754797e-05

To O 0 9.375801823807706e-08
date O 0 1.5228605434458586e-06
, O 0 1.2145988215195302e-08
several O 0 4.297124434060606e-09
mutations O 0 2.109759833501812e-08
in O 0 6.099807769999188e-09
the O 0 1.0754674804047681e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999915361404419
gene O 0 0.0002811025478877127
, O 0 1.7963300251722103e-06
DMD O 1 1.0
, O 0 6.530373131141687e-09
have O 0 4.5927264769041187e-10
been O 0 7.864908724286579e-10
identified O 0 1.8777186472362928e-09
in O 0 2.731125048338612e-10
patients O 0 8.092249648150585e-10
with O 0 1.556131223878765e-09
XLDCM B-Disease 1 1.0
, O 0 4.810935649857129e-09
but O 0 8.989411992565977e-10
a O 0 8.61044235911379e-10
pathogenic O 0 1.8066808493699682e-08
correlation O 0 1.788185244322449e-08
of O 0 8.543276308614622e-09
these O 0 9.04709107629742e-09
cardiospecific O 0 2.2923834421817446e-06
mutations O 0 9.886287699600871e-08
in O 0 2.409058375008044e-08
DMD O 1 1.0
with O 0 7.742772645258356e-09
the O 0 1.9209990398394439e-07
XLDCM B-Disease 1 0.9999986886978149
phenotype O 0 4.4642072793976695e-07
has O 0 1.2708145646911362e-08
remained O 0 1.0010688100692278e-07
to O 0 4.565609224016498e-09
be O 0 7.711089011763761e-08
elucidated O 0 9.701433009468019e-05
. O 0 4.149656433583004e-06

We O 0 4.45444271690576e-07
report O 0 1.2695166162757232e-07
here O 0 8.183957511675999e-09
the O 0 1.9880683765904905e-09
identification O 0 2.487171002485411e-08
of O 0 1.713149799797975e-08
a O 0 7.98672594726213e-09
unique O 0 4.055955216131224e-08
de O 0 1.203511033054383e-06
novo O 0 1.9641154267446836e-06
L1 O 0 4.110936970391776e-06
insertion O 0 1.0603849176504809e-07
in O 0 1.6270094604919905e-08
the O 0 5.147226289636819e-08
muscle O 0 2.578481250736786e-08
exon O 0 2.4969102341287908e-08
1 O 0 6.22807263539471e-08
in O 0 3.5209104520816936e-09
DMD O 1 1.0
in O 0 7.231787613193319e-09
three O 0 1.3176276070225867e-08
XLDCM B-Disease 0 0.03403497487306595
patients O 0 4.153024146802409e-09
from O 0 6.206640978945188e-09
two O 0 3.3942775257145286e-09
unrelated O 0 7.22508985973036e-08
Japanese O 0 1.6397896729358763e-07
families O 0 4.614621218479442e-08
. O 0 2.5775426593099837e-07

The O 0 4.3090273038615123e-07
insertion O 0 3.5521506447366846e-07
was O 0 2.324998717995186e-07
a O 0 1.434894603136172e-08
5 O 0 7.987353711769174e-08
- O 0 1.2710011709771152e-08
truncated O 0 1.503730651108981e-08
form O 0 2.1414137130193467e-09
of O 0 9.363181341370819e-09
human O 0 3.222262634494655e-08
L1 O 0 3.4524214242992457e-06
inversely O 0 7.8091142086123e-07
integrated O 0 1.1499265895054123e-07
in O 0 3.2304143804395835e-09
the O 0 1.0695067942378955e-08
5 O 0 6.403517005537651e-08
- O 0 3.004493009939324e-08
untranslated O 0 1.9975996110588312e-05
region O 0 8.975611365258374e-08
in O 0 3.285926863938471e-09
the O 0 1.9408567197842785e-08
muscle O 0 2.3651185898643234e-08
exon O 0 1.8806012747063505e-08
1 O 0 3.6006632342378e-08
, O 0 1.7374265914860132e-10
which O 0 5.173814154879608e-11
affected O 0 5.476429865147736e-10
the O 0 7.507268140471979e-10
transcription O 0 7.630077902831545e-09
or O 0 8.849858068593619e-10
the O 0 6.499010662963656e-09
stability O 0 7.693430603694651e-08
of O 0 3.3997604731439424e-08
the O 0 5.714217099495045e-09
muscle O 0 3.2634479563142804e-09
form O 0 5.227144050934385e-09
of O 0 7.450700678646172e-08
dystrophin O 0 3.954548333240382e-07
transcripts O 0 4.413013598991711e-08
but O 0 1.7728613022072182e-09
not O 0 2.130169235448065e-10
that O 0 2.9265562195845973e-10
of O 0 1.4134785786268367e-08
the O 0 4.7480643416975e-08
brain O 0 9.577420314599294e-07
or O 0 2.1376033387809912e-08
Purkinje O 0 3.4152335501858033e-06
cell O 0 9.785637899994981e-08
form O 0 1.4709462980988519e-08
, O 0 2.8329540935345676e-09
probably O 0 3.083019706195955e-08
due O 0 2.896377893080171e-08
to O 0 1.5805402542312663e-09
its O 0 2.1881103595688955e-09
unique O 0 6.2459375449464005e-09
site O 0 3.4355213784920124e-08
of O 0 3.631527789593747e-08
integration O 0 8.353479756806337e-07
. O 0 2.141575805580942e-06

We O 0 1.5352773630183947e-07
speculate O 0 1.2689089601281012e-07
that O 0 6.38448571788075e-10
this O 0 1.944712307855312e-10
insertion O 0 1.7770636517866478e-08
of O 0 1.666355586849022e-08
an O 0 6.129314389369256e-09
L1 O 0 1.4662931562270387e-06
sequence O 0 1.0821776363911795e-08
in O 0 1.2570948726420283e-08
DMD O 1 1.0
is O 0 4.306806467013757e-09
responsible O 0 1.0740567324418748e-09
for O 0 2.9180674543383134e-10
some O 0 2.688660127869724e-10
of O 0 1.7251565731513097e-09
the O 0 4.976018486146927e-10
population O 0 1.9003154605456984e-10
of O 0 6.573220301397953e-10
Japanese O 0 2.09454764643624e-08
patients O 0 1.4983561058556916e-09
with O 0 4.149817822707291e-09
XLDCM B-Disease 1 0.9966126084327698
. O 0 1.3490341643773718e-07
. O 0 6.683753213110322e-07

Severe O 0 0.00013059881166554987
early O 0 7.366098725469783e-05
- O 0 0.000137670649564825
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 7.058124396053245e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.050637693988392e-06
red O 1 0.9997841715812683
hair O 0 0.00019828627409879118
pigmentation O 0 0.05774400755763054
caused O 0 1.648438410484232e-05
by O 0 9.066977924021558e-08
POMC O 1 0.9997749924659729
mutations O 0 3.6753169752046233e-07
in O 0 7.838659499270761e-09
humans O 0 1.1458958226739924e-07
. O 0 2.0403851408445917e-07

Sequential O 0 1.0946710972348228e-05
cleavage O 0 7.868629836593755e-06
of O 0 8.368438102479558e-07
the O 0 9.333087547247487e-08
precursor O 0 3.949814413317654e-07
protein O 0 3.4588433095450455e-07
pre O 0 5.164450840311474e-07
- O 0 4.5286560634849593e-07
pro O 0 8.066835107456427e-06
- O 0 2.3152852008934133e-05
opiomelanocortin O 0 7.704598101554438e-05
( O 0 1.4966623496093234e-07
POMC O 0 2.1849935365025885e-05
) O 0 6.370877159156407e-09
generates O 0 4.144954601770223e-08
the O 0 4.008311904613038e-08
melanocortin O 0 5.6417534324282315e-06
peptides O 0 6.576341888830939e-07
adrenocorticotrophin O 0 2.309496449015569e-05
( O 0 2.34099132967458e-07
ACTH O 0 5.799905920866877e-06
) O 0 1.1300013369464068e-08
, O 0 2.067008786355018e-08
melanocyte O 0 1.0752115485956892e-05
- O 0 1.7437316273571923e-05
stimulating O 0 2.129401082129334e-06
hormones O 0 4.090910579179763e-07
( O 0 2.9193062189847296e-08
MSH O 0 3.2574691886111395e-06
) O 0 1.0924677829038387e-09
alpha O 0 3.3672207244705987e-09
, O 0 1.869252391761833e-10
beta O 0 5.312090767262134e-10
and O 0 1.5979872980409482e-10
gamma O 0 3.4463030207376733e-09
as O 0 1.3808716392560427e-09
well O 0 1.160900375829499e-09
as O 0 3.2779019498718753e-09
the O 0 5.237562827886677e-09
opioid O 0 3.0916646664991276e-07
- O 0 1.0966064678541443e-07
receptor O 0 4.153027362008288e-07
ligand O 0 2.3386401153402403e-06
beta O 0 1.836997171267285e-06
- O 0 3.2666962397343013e-06
endorphin O 0 7.358439324889332e-05
. O 0 1.3713626003664103e-06

While O 0 7.432603155166362e-08
a O 0 2.5009412318865998e-09
few O 0 1.7821542019902381e-09
cases O 0 1.2173535512971512e-09
of O 0 9.017063540284198e-09
isolated O 0 0.16496895253658295
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999915361404419
have O 0 1.2046320385650233e-08
been O 0 4.000382247681955e-09
reported O 0 3.634826484244513e-08
( O 0 1.0926537896693844e-08
OMIM O 0 0.0005158254643902183
201400 O 0 4.034031917399261e-06
) O 0 3.368736622988422e-09
, O 0 2.3081183631035174e-09
an O 0 1.7390197726285805e-08
inherited O 1 0.9997875094413757
POMC O 1 1.0
defect O 1 0.9999955892562866
has O 0 3.099392742456075e-08
not O 0 1.4284547988907548e-09
been O 0 2.955407252258624e-09
described O 0 1.006290872851423e-08
so O 0 6.0040479255007995e-09
far O 0 1.555221729176992e-07
. O 0 5.113417955726618e-07

Recent O 0 4.2794101773324655e-07
studies O 0 4.570307510221028e-08
in O 0 8.349443914035248e-10
animal O 0 6.29554985920322e-09
models O 0 7.735287965715543e-09
elucidated O 0 2.1202004063525237e-07
a O 0 5.304682026974206e-09
central O 0 4.1526305949446396e-08
role O 0 2.3808693683236015e-08
of O 0 8.921948335682828e-08
alpha O 0 1.6386266565859842e-07
- O 0 2.6746130288302083e-07
MSH O 0 2.9900100344093516e-05
in O 0 1.957343398473199e-09
the O 0 5.097426036826391e-09
regulation O 0 1.3381372454546181e-08
of O 0 8.228314918312662e-09
food O 0 1.4715075380422604e-08
intake O 0 2.1970849584107555e-09
by O 0 7.806081475658644e-11
activation O 0 1.0509957348858734e-07
of O 0 3.1882171924735303e-07
the O 0 5.389288730839326e-07
brain O 0 4.6414570533670485e-06
melanocortin O 0 8.652529686514754e-06
- O 0 1.34549998165312e-06
4 O 0 7.639924319846614e-07
- O 0 3.052552699500666e-07
receptor O 0 9.211464089275978e-07
( O 0 7.36663707812113e-08
MC4 O 0 2.0681563910329714e-05
- O 0 5.192467256165401e-07
R O 0 2.342559071166761e-07
; O 0 1.53602357499949e-08
refs O 0 3.72394225678363e-07
3 O 0 1.0745822009994299e-07
- O 0 1.6706612981920443e-08
5 O 0 5.447263085045506e-09
) O 0 3.4129702536356277e-11
and O 0 7.963551346135134e-11
the O 0 4.970014400029754e-10
linkage O 0 1.605278470151461e-07
of O 0 2.354981454288918e-08
human O 0 9.872642294794787e-07
obesity B-Disease 1 1.0
to O 0 3.0789575333756147e-09
chromosome O 0 1.4002337067609005e-08
2 O 0 9.272170586882567e-09
in O 0 4.59179777534402e-10
close O 0 6.765200843972252e-09
proximity O 0 3.715818053251496e-08
to O 0 1.8093905262972498e-09
the O 0 6.228321325352226e-08
POMC O 0 2.247215888928622e-05
locus O 0 4.565977462789306e-08
, O 0 2.4785364871604543e-09
led O 0 6.369686555984799e-09
to O 0 1.035105223756716e-09
the O 0 6.451412293273506e-09
proposal O 0 1.3857112790560677e-08
of O 0 1.9590624233956078e-08
an O 0 4.418191146271511e-09
association O 0 4.390530250475422e-08
of O 0 1.773870098986663e-05
POMC O 1 1.0
with O 0 2.3294286677355558e-07
human O 1 0.9613322019577026
obesity B-Disease 1 1.0
. O 0 5.61838476187404e-07

The O 0 4.490801188694604e-07
dual O 0 9.022776339406846e-07
role O 0 2.2827096302080463e-07
of O 0 1.2146240351285087e-06
alpha O 0 2.451859927532496e-06
- O 0 2.6245727440254996e-06
MSH O 0 4.356001227279194e-05
in O 0 7.741177476816574e-09
regulating O 0 6.289539555837109e-08
food O 0 1.2259118875590502e-07
intake O 0 3.239183499204046e-08
and O 0 6.130974394835675e-09
influencing O 0 4.241956958139781e-06
hair O 0 0.0002001670654863119
pigmentation O 0 0.00022040535986889154
predicts O 0 1.4190966624028079e-07
that O 0 9.074010987042413e-10
the O 0 3.592313335687436e-09
phenotype O 0 3.065621712039501e-08
associated O 0 5.297957628158656e-09
with O 0 7.267472179606216e-10
a O 0 9.449206750389294e-09
defect O 0 3.5056348224316025e-07
in O 0 1.694037266020132e-08
POMC O 1 0.7405921220779419
function O 0 3.119748015478763e-08
would O 0 9.141434276216387e-09
include O 0 8.568314058265969e-08
obesity B-Disease 1 1.0
, O 0 8.636533266326296e-09
alteration O 0 2.733322901349311e-07
in O 0 2.63477399897738e-08
pigmentation O 1 0.9999997615814209
and O 1 0.8040863871574402
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 1.5689684005337767e-05

The O 0 1.9397268147258728e-07
observation O 0 7.32784337742487e-06
of O 0 3.203039966592769e-08
these O 0 2.9435105020070296e-08
symptoms O 0 0.11700502783060074
in O 0 2.583747438222872e-09
two O 0 7.431763648924061e-09
probands O 0 1.1437942703196313e-05
prompted O 0 4.773663064838729e-08
us O 0 3.115108615503459e-09
to O 0 3.6578223783223507e-10
search O 0 8.365164561041638e-09
for O 0 7.306569793641415e-10
mutations O 0 2.4560902645021088e-08
within O 0 3.092070954835435e-08
their O 0 5.338896471585031e-07
POMC O 1 0.9672209620475769
genes O 0 7.766269845888019e-06
. O 0 4.5652036533283535e-06

Patient O 0 1.0269868653267622e-06
1 O 0 7.270646733559261e-07
was O 0 4.5921964897388534e-08
found O 0 1.0713907538928424e-09
to O 0 3.0812705165139676e-10
be O 0 7.967003168296571e-10
a O 0 2.5136719372653715e-09
compound O 0 2.5572346018520875e-08
heterozygote O 0 1.8730912643150077e-07
for O 0 4.624134852804218e-09
two O 0 4.34228253354263e-09
mutations O 0 1.464270127371492e-08
in O 0 6.652292938724713e-09
exon O 0 8.718929223050509e-08
3 O 0 3.9459590084334195e-07
( O 0 1.393070458988177e-08
G7013T O 0 9.418960189577774e-07
, O 0 9.537679090954043e-09
C7133delta O 0 2.1325216437162453e-07
) O 0 2.59527871415699e-10
which O 0 1.0883243611869986e-10
interfere O 0 1.1653328302330124e-09
with O 0 2.0948293100175874e-10
appropriate O 0 7.473726526541213e-09
synthesis O 0 2.2394611676190834e-07
of O 0 5.010500103708182e-07
ACTH O 0 5.070067345513962e-05
and O 0 4.6724426283617504e-07
alpha O 0 6.440634479076834e-06
- O 0 2.5656368961790577e-05
MSH O 0 0.0022838276345282793
. O 0 4.206113317195559e-06

Patient O 0 2.5488600385870086e-06
2 O 0 9.623968253436033e-07
was O 0 9.501042086412781e-08
homozygous O 0 1.444698316532822e-08
for O 0 2.2603605653870318e-09
a O 0 6.023639809171755e-09
mutation O 0 7.960020198538587e-09
in O 0 2.3252408887231013e-09
exon O 0 7.982281857721318e-08
2 O 0 6.198835649229295e-07
( O 0 2.4430267586694754e-08
C3804A O 0 1.4024756183061982e-06
) O 0 3.4346154809128393e-09
which O 0 5.011883796868233e-09
abolishes O 0 4.645291937777074e-06
POMC O 0 0.00017008099530357867
translation O 0 5.210029485169798e-06
. O 0 2.9950122097943677e-06

These O 0 1.102529125773799e-07
findings O 0 7.527650325300783e-08
represent O 0 1.0786538773288612e-08
the O 0 4.341744297420291e-09
first O 0 4.727285229932932e-10
examples O 0 3.3801352827822484e-09
of O 0 1.4560340710900732e-09
a O 0 4.3968633178792516e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 1.47903174152475e-08
the O 0 2.513193564368521e-08
POMC O 0 2.334526698177797e-06
gene O 0 2.2162309765150212e-09
and O 0 1.1454577286684753e-09
define O 0 3.1223896801435558e-09
a O 0 2.7803490620925686e-09
new O 0 3.498553269309923e-08
monogenic B-Disease 1 0.9999971389770508
endocrine I-Disease 1 0.9999998807907104
disorder I-Disease 0 0.006597516592592001
resulting O 0 1.113635477167918e-07
in O 0 1.0292974250702969e-09
early O 0 4.283362784462952e-07
- O 0 3.3187716326210648e-06
onset O 1 0.9999998807907104
obesity B-Disease 1 1.0
, O 0 2.1880244105432212e-07
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.4771210551261902
red O 1 0.9999988079071045
hair O 0 0.0006384081207215786
pigmentation O 0 0.00011798375635407865
. O 0 3.131325740923785e-07
. O 0 1.2172877177363262e-06

A O 0 2.6923480618279427e-06
European O 0 9.827701887843432e-07
multicenter O 0 2.3210661311168224e-05
study O 0 5.771540045884649e-08
of O 0 9.249588401871733e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.157359884653488e-08
classification O 0 1.9462270017811534e-07
of O 0 6.001565822089105e-08
105 O 0 3.054998387597152e-08
mutations O 0 2.752126970761992e-09
and O 0 6.206010705334108e-10
a O 0 5.947602410572017e-10
general O 0 1.765084189919719e-09
system O 0 1.2902472146247845e-10
for O 0 2.0200530137515216e-10
genotype O 0 5.144200621032269e-09
- O 0 7.26510629434074e-09
based O 0 3.191591657625281e-09
prediction O 0 1.9590069655350817e-07
of O 0 6.455796608406672e-08
metabolic O 0 0.03293392434716225
phenotype O 0 8.05753097665729e-06
. O 0 1.4177279581417679e-06

Phenylketonuria B-Disease 0 0.0007808915106579661
( O 0 2.483010348441894e-06
PKU B-Disease 0 9.157665772363544e-05
) O 0 3.2091428181502124e-08
and O 0 3.114920232860641e-08
mild B-Disease 1 0.999819815158844
hyperphenylalaninemia I-Disease 1 1.0
( O 0 2.606622956591309e-06
MHP B-Disease 1 1.0
) O 0 4.689962640469503e-09
are O 0 1.9322237143626353e-09
allelic B-Disease 0 2.8181890229461715e-05
disorders I-Disease 0 0.02668118290603161
caused O 0 1.9746993018543435e-07
by O 0 7.008924551854534e-10
mutations O 0 1.0894011914786006e-08
in O 0 7.954385483621706e-10
the O 0 3.94616694876504e-09
gene O 0 1.8702991155805648e-08
encoding O 0 5.687052748726273e-07
phenylalanine O 0 4.543217073660344e-05
hydroxylase O 0 0.0002333646989427507
( O 0 3.093108944085543e-06
PAH O 1 1.0
) O 0 7.384551281575114e-07
. O 0 6.657968469880871e-07

Previous O 0 1.8471195062375045e-06
studies O 0 1.3187229797040345e-07
have O 0 2.554961353595786e-09
suggested O 0 5.6498423717243895e-09
that O 0 1.9520034200137815e-10
the O 0 1.354612755299911e-09
highly O 0 1.4296712258499156e-08
variable O 0 9.864349976851372e-07
metabolic O 0 0.34881171584129333
phenotypes O 0 0.009497701190412045
of O 1 0.7799918055534363
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.051837220788002014
with O 0 2.215946096839616e-06
PAH O 1 1.0
genotypes O 1 0.758691668510437
. O 0 2.537146201575524e-06

We O 0 1.317195881256339e-07
identified O 0 1.2501206470005854e-07
both O 0 3.4293542228169827e-08
causative O 0 8.983417956187623e-07
mutations O 0 9.797927447152688e-08
in O 0 8.451059407832417e-09
686 O 0 5.598610641754931e-07
patients O 0 4.728117009022981e-09
from O 0 1.564578155921481e-08
seven O 0 1.3663161269050761e-08
European O 0 1.264456273020187e-07
centers O 0 2.9709124760302075e-07
. O 0 5.226967232374591e-07

On O 0 2.963207634820719e-07
the O 0 6.965349186316416e-09
basis O 0 1.2517568315217886e-08
of O 0 2.261870024611312e-09
the O 0 1.6202884589588962e-09
phenotypic O 0 3.344907995028734e-08
characteristics O 0 8.185070043964515e-08
of O 0 5.7561599930977536e-08
297 O 0 1.9934959993861412e-07
functionally O 0 5.256480903881311e-07
hemizygous O 0 9.9955354926351e-07
patients O 0 2.5197488540129598e-09
, O 0 5.673271852302264e-10
105 O 0 1.5728513602653038e-08
of O 0 5.778906242426274e-09
the O 0 7.035165339175364e-09
mutations O 0 3.523127345417265e-09
were O 0 1.6865149277123237e-09
assigned O 0 3.6771921618772296e-10
to O 0 3.2788693982155337e-10
one O 0 2.4334361192757115e-09
of O 0 1.68358784691236e-08
four O 0 8.689474029210942e-09
arbitrary O 0 9.15344855911826e-07
phenotype O 0 2.3545333078800468e-06
categories O 0 1.591527279742877e-06
. O 0 9.980885806726292e-07

We O 0 1.8268313795033464e-07
proposed O 0 1.0369281255862006e-07
and O 0 9.437931325351201e-09
tested O 0 3.110180779586358e-09
a O 0 5.931063418174176e-10
simple O 0 2.7224292264982353e-10
model O 0 5.585316098510873e-10
for O 0 2.1642634906449132e-10
correlation O 0 8.889601943451453e-09
between O 0 3.051281449728549e-09
genotype O 0 7.385234823686915e-08
and O 0 1.2478094113532734e-08
phenotypic O 0 2.4547654220441473e-07
outcome O 0 2.9313694085431052e-06
. O 0 2.98113445751369e-06

The O 0 4.5200010845292127e-07
observed O 0 1.398077813519194e-07
phenotype O 0 3.408611348731938e-07
matched O 0 2.407722377029131e-07
the O 0 1.8593439676806156e-08
predicted O 0 9.35172579374921e-08
phenotype O 0 9.402875811304057e-09
in O 0 6.219448289712659e-10
79 O 0 1.8151570913005344e-08
% O 0 2.633439855070918e-10
of O 0 2.2921391173991168e-10
the O 0 3.787368196839225e-10
cases O 0 9.419816038302997e-10
, O 0 5.366984079380188e-10
and O 0 6.271768104859632e-10
in O 0 3.359469646913027e-10
only O 0 9.995529959283544e-10
5 O 0 7.676189461847116e-09
of O 0 2.3352901834527984e-09
184 O 0 5.392721380559351e-09
patients O 0 7.747406605140839e-10
was O 0 4.5392387626463915e-09
the O 0 2.2016490852649895e-09
observed O 0 6.364901494748665e-09
phenotype O 0 5.421784798897988e-09
more O 0 4.808584641580183e-10
than O 0 6.768204885432283e-10
one O 0 1.9567236719808534e-09
category O 0 7.162095805313129e-09
away O 0 1.738900223813289e-08
from O 0 1.1656535292559056e-08
that O 0 3.496616995946056e-09
expected O 0 3.375621133727691e-07
. O 0 1.184016582556069e-06

Among O 0 9.981381481338758e-07
the O 0 9.293208336202952e-08
seven O 0 2.6097117356016497e-08
contributing O 0 1.6143111736255378e-08
centers O 0 5.959745141836947e-09
, O 0 2.0411611290072074e-10
the O 0 5.011384085484849e-10
proportion O 0 4.749230342326882e-09
of O 0 4.750641546813483e-10
patients O 0 9.822162527761691e-11
for O 0 2.8375710114936226e-10
whom O 0 2.3872081200693174e-08
the O 0 1.0506646219710092e-08
observed O 0 3.590011843357388e-09
phenotype O 0 3.962284278458128e-09
did O 0 1.0980748532674056e-09
not O 0 7.037241900320623e-10
match O 0 1.6671725333594622e-08
the O 0 2.9109772370361497e-08
predicted O 0 1.392000541500238e-07
phenotype O 0 3.3200485916040634e-08
was O 0 2.920208252987777e-08
4 O 0 2.4633573403320952e-08
% O 0 2.4581698898629156e-09
- O 0 1.3700636181113168e-08
23 O 0 1.1333020211168332e-07
% O 0 6.062552238006447e-09
( O 0 2.524578546214684e-09
P O 0 3.9327457557192247e-07
< O 0 4.024790811740786e-08
. O 0 4.6154378097185145e-09
0001 O 0 2.2052903148050973e-07
) O 0 1.1441738667627988e-09
, O 0 8.986309474323662e-10
suggesting O 0 5.929798874149128e-09
that O 0 4.841235745622896e-10
differences O 0 4.7041446293860645e-09
in O 0 1.6206028186083188e-10
methods O 0 5.349201637194767e-10
used O 0 1.3349697736142474e-10
for O 0 1.298143814665309e-10
mutation O 0 2.633802953511122e-09
detection O 0 2.091505812984451e-08
or O 0 5.992824458900259e-09
phenotype O 0 6.69238318096177e-08
classification O 0 2.1011338446896843e-08
may O 0 2.252656283729948e-09
account O 0 3.037357254598305e-09
for O 0 4.3923181758387386e-10
a O 0 1.4452929963937322e-09
considerable O 0 2.3251576664051754e-08
proportion O 0 2.9559384273625255e-08
of O 0 2.4735129500186304e-08
genotype O 0 2.042929281742545e-06
- O 0 3.3198739401996136e-05
phenotype O 0 9.39822075451957e-06
inconsistencies O 0 1.956350024556741e-05
. O 0 4.263004939275561e-06

Our O 0 2.936482417226216e-07
data O 0 1.484886240632477e-07
indicate O 0 3.867437570193033e-08
that O 0 2.8784448158347686e-09
the O 0 3.026342554335315e-08
PAH O 1 0.9249042868614197
- O 0 1.6245697054273478e-07
mutation O 0 2.8817628283661634e-09
genotype O 0 2.1646855419277244e-09
is O 0 9.870559924962663e-11
the O 0 4.878368820016021e-10
main O 0 2.8766242721189883e-08
determinant O 0 6.470984317274997e-07
of O 0 7.924500522449307e-08
metabolic O 1 0.818219006061554
phenotype O 0 6.448929070757004e-07
in O 0 4.535448461240321e-09
most O 0 2.1302446029380917e-08
patients O 0 9.738678130588596e-08
with O 0 1.8650430320121814e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.026745880022644997

In O 0 5.4042565977852064e-08
the O 0 2.528666698253801e-08
present O 0 7.2655361726958745e-09
study O 0 9.191678529418823e-10
, O 0 1.6887674592069857e-10
the O 0 2.906447027495318e-10
classification O 0 7.271372837180934e-09
of O 0 2.8821052211469578e-08
105 O 0 9.951422725862358e-07
PAH O 1 0.9999370574951172
mutations O 0 8.172261800609704e-08
may O 0 1.8254678879614517e-09
allow O 0 7.882510200118986e-10
the O 0 1.4705584527874294e-09
prediction O 0 5.880683318082447e-08
of O 0 2.2744157668341813e-09
the O 0 4.2931755928066195e-09
biochemical O 0 3.1904374964142335e-07
phenotype O 0 3.3080706174359875e-08
in O 0 1.90093274454739e-09
> O 0 3.7286117304802247e-08
10 O 0 3.797114800363488e-08
, O 0 2.232859230844042e-09
000 O 0 3.325403952203487e-08
genotypes O 0 6.777563754667426e-08
, O 0 2.1728387977759667e-09
which O 0 3.8105696376078413e-10
may O 0 5.779730027910546e-10
be O 0 3.97227833959235e-10
useful O 0 8.672817131127886e-09
for O 0 8.686304453497939e-10
the O 0 1.022812323725475e-08
management O 0 9.73453406771796e-09
of O 0 2.915679147008632e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 8.196599310394959e-08
newborns O 0 1.7070735793822678e-06
. O 0 6.91002583153022e-07

Somatic O 0 3.5995028156321496e-05
instability O 0 4.113838076591492e-05
of O 0 9.180908477901539e-07
the O 0 3.082808746057708e-07
CTG O 0 0.00010518194903852418
repeat O 0 5.679373771272367e-08
in O 0 3.0627564928664697e-09
mice O 0 3.7035046140942995e-09
transgenic O 0 1.1988992909550689e-08
for O 0 5.862836327530374e-10
the O 0 2.601858639650345e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.3616757996715023e-06
is O 0 1.7487179482245097e-09
age O 0 2.4852775393213733e-09
dependent O 0 6.2698335412392225e-09
but O 0 7.963236181574018e-10
not O 0 3.739640541677858e-10
correlated O 0 8.839993625997522e-09
to O 0 6.546232445003852e-10
the O 0 7.3533672484416e-09
relative O 0 7.845130198802508e-07
intertissue O 0 4.119672667002305e-06
transcription O 0 1.9904880446119932e-06
levels O 0 9.194104109155887e-07
and O 0 4.430860656157165e-07
proliferative O 1 0.9999980926513672
capacities O 0 0.00033907510805875063
. O 0 7.666266355954576e-06

A O 0 0.00041624344885349274
( O 0 3.060439212276833e-06
CTG O 0 0.00021688871493097395
) O 0 3.316776542305888e-08
nexpansion O 0 2.6458587853994686e-06
in O 0 7.234160381841548e-09
the O 0 3.2206525446554224e-08
3 O 0 2.2929731358090066e-07
- O 0 1.9082068547504605e-07
untranslated O 0 0.00016640775720588863
region O 0 3.560622872100794e-07
( O 0 1.6697661919806706e-08
UTR O 0 0.0003904175537172705
) O 0 5.974484018622661e-09
of O 0 6.426004972581723e-08
the O 0 6.601407562811801e-07
DM O 1 1.0
protein O 0 3.160841515637003e-06
kinase O 0 2.1040109459136147e-06
gene O 0 1.5967769684266386e-07
( O 0 5.714306325899088e-07
DMPK O 1 1.0
) O 0 1.5637718897565378e-09
is O 0 2.3689897266088167e-10
responsible O 0 4.95085583640531e-10
for O 0 1.6316391571180588e-09
causing O 1 0.9803529977798462
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9971053004264832
DM B-Disease 1 1.0
) O 0 3.546274740529043e-07
. O 0 6.111724815127673e-07

Major O 0 5.6412009143969044e-05
instability O 0 0.0015484823379665613
, O 0 5.7690858312753335e-08
with O 0 5.252369206232288e-09
very O 0 5.835328220626934e-09
large O 0 1.3373565366237017e-08
expansions O 0 3.090024947027814e-08
between O 0 1.0103891945334453e-08
generations O 0 5.4018865824900786e-08
and O 0 6.439044852868392e-09
high O 0 3.1622718665857974e-08
levels O 0 1.0714893861063501e-08
of O 0 1.5562330091256626e-08
somatic O 0 7.3142423389072064e-06
mosaicism O 0 3.004774043802172e-05
, O 0 1.233309543380301e-08
is O 0 2.159790346567547e-09
observed O 0 1.0773995917645607e-08
in O 0 6.890742199061606e-09
patients O 0 4.0319594774018697e-08
. O 0 4.470090573249763e-07

There O 0 1.1140370759221696e-07
is O 0 8.194657397098126e-09
a O 0 6.601959423591097e-09
good O 0 1.021357931563216e-08
correlation O 0 1.0704005681816398e-08
between O 0 1.0092009006257285e-08
repeat O 0 2.8189145240276048e-08
size O 0 1.2221728695749334e-07
( O 0 5.737938568728396e-09
at O 0 1.26887202966941e-08
least O 0 2.1091954849339345e-09
in O 0 1.0760436985890465e-09
leucocytes O 0 2.470821129918477e-07
) O 0 3.954453153820481e-10
, O 0 1.9765129810611626e-10
clinical O 0 2.330626802660163e-09
severity O 0 3.9653110661674873e-07
and O 0 1.0927746707523056e-08
age O 0 3.173649929522071e-07
of O 0 8.19856722955592e-07
onset O 0 0.3599165380001068
. O 0 1.8221001027995953e-06

The O 0 1.8500350051908754e-06
trinucleotide O 0 0.004056508652865887
repeat O 0 2.6276034077454824e-06
instability O 0 2.217798055426101e-06
mechanisms O 0 1.317598048444779e-07
involved O 0 5.242060119314829e-09
in O 0 2.762224227126353e-09
DM B-Disease 1 1.0
and O 0 4.4310102254030426e-09
other O 0 3.051124464192867e-09
human O 0 7.49268394883984e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.093462098644693e-09
unknown O 0 4.311723955652269e-07
. O 0 1.1673938615786028e-07

We O 0 2.07877974389703e-07
studied O 0 3.164613247008674e-07
somatic O 0 1.6106116618175292e-06
instability O 0 3.2288767215504777e-07
by O 0 5.583423057231585e-09
measuring O 0 3.387424101219949e-07
the O 0 7.205794361198059e-08
CTG O 0 9.794908692128956e-06
repeat O 0 4.673248810149744e-08
length O 0 7.309738148109091e-09
at O 0 6.9569310312544985e-09
several O 0 2.0330646055555235e-09
ages O 0 1.1787101961147073e-08
in O 0 2.250550995563927e-10
various O 0 1.5633574435014452e-09
tissues O 0 6.623719173148856e-08
of O 0 4.484817495153948e-08
transgenic O 0 2.64980315023422e-07
mice O 0 7.01811808667685e-09
carrying O 0 2.0691269142503188e-08
a O 0 4.693929867016777e-08
( O 0 7.26796471894886e-08
CTG O 0 3.701803871081211e-05
) O 0 2.5668466463457662e-08
55expansion O 0 2.080611466226401e-06
surrounded O 0 8.457061539957067e-08
by O 0 1.95282368053995e-09
45 O 0 4.58735556208012e-08
kb O 0 8.149814334501571e-07
of O 0 1.2253823911123618e-07
the O 0 4.358556537908953e-08
human O 0 6.064833542041015e-07
DM B-Disease 1 1.0
region O 0 2.363342446187744e-07
, O 0 2.75149703021782e-09
using O 0 3.583758845238094e-09
small O 0 3.3630247031624094e-08
- O 0 3.991254118318466e-07
pool O 0 7.782899160702073e-07
PCR O 0 2.103437054756796e-06
. O 0 1.946712927747285e-06

These O 0 2.859557355350262e-07
mice O 0 1.0351437396138863e-07
have O 0 3.29203087012786e-09
been O 0 8.802670814489488e-10
shown O 0 5.604415542759256e-11
to O 0 1.8328694464941897e-11
reproduce O 0 1.871140131726179e-09
the O 0 1.4323563446438925e-09
intergenerational O 0 2.0599284056288525e-08
and O 0 8.139494078740483e-10
somatic O 0 7.101889991645294e-07
instability O 0 5.929100552748423e-07
of O 0 1.0285408791332884e-07
the O 0 1.3036888901751809e-07
55 O 0 5.092763899483543e-07
CTG O 0 1.3944833881396335e-05
repeat O 0 1.2504412438829604e-07
suggesting O 0 8.929149686309756e-08
that O 0 2.8518423178525154e-09
surrounding O 0 1.0270779782217687e-08
sequences O 0 3.904033096802095e-09
and O 0 3.982331797658389e-09
the O 0 8.103652859858812e-09
chromatin O 0 3.483432635675854e-07
environment O 0 6.571082877826484e-08
are O 0 1.5385591689565103e-09
involved O 0 3.5500959949530397e-09
in O 0 5.075800224574323e-09
instability O 0 2.451696218486177e-06
mechanisms O 0 7.582611942780204e-06
. O 0 2.393003569522989e-06

As O 0 3.810167186202307e-07
observed O 0 5.1515968380044797e-08
in O 0 7.053744255358652e-10
some O 0 1.4047270013861635e-09
of O 0 9.791066624131872e-09
the O 0 5.229417787688817e-09
tissues O 0 1.1121284160253708e-07
of O 0 7.611401429130638e-07
DM B-Disease 1 1.0
patients O 0 1.204188659897909e-08
, O 0 6.200969737690798e-10
there O 0 4.521919227951088e-10
is O 0 1.6136567082547515e-10
a O 0 4.130508157729196e-10
tendency O 0 3.600819642457509e-09
for O 0 1.023008899814215e-09
repeat O 0 1.436126595422138e-08
length O 0 7.574729288251092e-09
and O 0 4.796760766367925e-09
somatic O 0 1.5211332993203541e-06
mosaicism O 0 6.501281859527808e-07
to O 0 9.49090916968487e-10
increase O 0 9.082270491234112e-10
with O 0 1.2620064715473944e-10
the O 0 2.085410066854365e-09
age O 0 1.6212723608077795e-08
of O 0 1.8522504419138386e-08
the O 0 4.408386899967809e-08
mouse O 0 3.82269490728504e-07
. O 0 8.734589869163756e-07

Furthermore O 0 3.2507814466953278e-06
, O 0 5.117564683132514e-08
we O 0 5.387868817763319e-09
observed O 0 5.785953938186594e-09
no O 0 1.9095560688242585e-09
correlation O 0 6.3197318489471854e-09
between O 0 6.297035670677076e-10
the O 0 2.0573751591257405e-09
somatic O 0 6.384382231772179e-07
mutation O 0 2.1739966271638878e-08
rate O 0 5.469720676387624e-09
and O 0 2.937440513051115e-09
tissue O 0 7.604276675010624e-07
proliferation O 0 0.11273312568664551
capacity O 0 2.161227030228474e-06
. O 0 4.2426592017363873e-07

The O 0 4.300701732518064e-07
somatic O 0 3.664086534627131e-06
mutation O 0 4.917779250490639e-08
rates O 0 5.2375526138348505e-09
in O 0 1.6273740688355076e-10
different O 0 4.2403244804312124e-10
tissues O 0 1.522440307155648e-08
were O 0 3.753548583063093e-09
also O 0 2.7892232967730024e-10
not O 0 8.58852433616164e-11
correlated O 0 2.7753526143925455e-09
to O 0 3.3162167456524116e-10
the O 0 5.929595925380227e-09
relative O 0 1.2066162753399112e-06
inter O 0 1.166405672847759e-05
- O 0 4.255106773598527e-07
tissue O 0 7.097503385011805e-08
difference O 0 6.108449213115819e-08
in O 0 3.028602924004531e-10
transcriptional O 0 3.595330966277288e-08
levels O 0 2.2385188813700552e-08
of O 0 1.5922751117614098e-08
the O 0 2.154450839952915e-08
three O 0 8.746725121966392e-09
genes O 0 3.595728870209314e-08
( O 0 2.4658440622715716e-08
DMAHP O 0 0.010821294970810413
, O 0 6.370515137632538e-08
DMPK O 0 0.0011347249383106828
and O 0 3.7665238039608084e-08
59 O 0 1.9409462481689843e-07
) O 0 1.5285089860483936e-09
surrounding O 0 7.152474523763885e-08
the O 0 7.549073899326686e-08
repeat O 0 2.3659696068989433e-07
. O 0 8.21337593492899e-08
. O 0 4.937540438731958e-07

A O 0 2.3643440272280714e-06
novel O 0 4.930956833959499e-07
missense O 0 1.2866355518781347e-06
mutation O 0 2.4154306998980246e-08
in O 0 1.281147521403625e-09
patients O 0 1.3265587517352628e-09
from O 0 2.805840670916382e-09
a O 0 9.871474304645744e-09
retinoblastoma B-Disease 0 3.9688664401182905e-05
pedigree O 0 6.217425720933534e-07
showing O 0 3.462261943809608e-08
only O 0 4.793577979000929e-09
mild O 0 7.288162606755577e-08
expression O 0 6.2837690606443175e-09
of O 0 1.780924918648452e-08
the O 0 7.253035505527805e-08
tumor B-Disease 0 2.9892707971157506e-06
phenotype O 0 9.253990924662503e-07
. O 0 4.889458864454355e-07

We O 0 1.6408660030720057e-07
have O 0 4.47114967272455e-09
used O 0 5.0218544878077864e-09
single O 0 9.731489392095227e-09
strand O 0 2.0311430759534232e-08
conformation O 0 2.5047841578640373e-09
polymorphism O 0 1.3024996636801234e-09
analysis O 0 7.687878111894975e-10
to O 0 7.206255592251409e-10
study O 0 9.63500057515887e-10
the O 0 4.661220298629587e-09
27 O 0 7.520044675857207e-08
exons O 0 2.5461434915996506e-07
of O 0 8.693009334592716e-08
the O 0 1.9529444728050294e-07
RB1 O 0 1.773306939867325e-05
gene O 0 4.478865722745695e-09
in O 0 1.1791189136189928e-09
individuals O 0 3.1244731801827186e-10
from O 0 1.8860746298088316e-09
a O 0 1.4651130308962479e-09
family O 0 3.902432599289796e-09
showing O 0 7.487937381256415e-09
mild O 0 3.424230143878049e-08
expression O 0 7.204102203672846e-09
of O 0 1.3018348177240568e-08
the O 0 9.410055668013229e-08
retinoblastoma B-Disease 0 8.330412674695253e-05
phenotype O 0 1.9891995179932564e-06
. O 0 8.687139256835508e-07

In O 0 3.742134424555843e-08
this O 0 4.474323134218139e-09
family O 0 1.787711134682013e-08
affected O 0 6.685669795558624e-09
individuals O 0 4.047103208115743e-10
developed O 0 2.871181159491698e-08
unilateral B-Disease 0 6.358097266456753e-07
tumors I-Disease 1 1.0
and O 0 4.540122056084783e-09
, O 0 1.648964437217515e-10
as O 0 2.2585577852396455e-10
a O 0 1.2241074820451558e-10
result O 0 8.507985427286258e-10
of O 0 4.886733684372757e-09
linkage O 0 1.3065640303011605e-07
analysis O 0 2.3479129751535766e-08
, O 0 6.586061918056885e-09
unaffected O 0 7.499347276507251e-08
mutation O 0 2.0705115399977103e-09
carriers O 0 8.164220410833423e-09
were O 0 1.2437936014464412e-08
also O 0 5.813265424592373e-09
identified O 0 2.644808816398836e-08
within O 0 2.067580417985937e-08
the O 0 2.3316111708027165e-07
pedigree O 0 1.3578539437730797e-05
. O 0 2.2871599867357872e-06

A O 0 8.424478437518701e-06
single O 0 6.757968407100634e-08
band O 0 3.214282529029333e-08
shift O 0 2.803595400280301e-08
using O 0 1.2378603919671605e-08
SSCP O 0 0.00013894356379751116
was O 0 8.834350495590115e-08
identified O 0 8.782550686703416e-09
in O 0 1.7060793888745707e-09
exon O 0 1.9457495170627226e-08
21 O 0 5.259358459852592e-08
which O 0 3.8419364911668197e-10
resulted O 0 1.2906989255156986e-08
in O 0 9.413315682493817e-10
a O 0 1.4161015471358951e-08
missense O 0 5.015883743908489e-07
mutation O 0 1.7015208797488413e-08
converting O 0 5.939605074445353e-08
a O 0 5.203591157965093e-08
cys O 0 2.5323115551145747e-06
- O 0 7.968786803758121e-07
- O 0 1.011850258691993e-06
> O 0 2.4294635636579187e-07
arg O 0 1.7239511862499057e-07
at O 0 2.1125865501403496e-08
nucleotide O 0 4.647710838412422e-08
position O 0 1.3081324823360774e-07
28 O 0 1.6753033094119019e-07
in O 0 3.2111620029695587e-09
the O 0 9.403453304912546e-08
exon O 0 8.313948001159588e-07
. O 0 8.172494290192844e-07

The O 0 1.5735917031634017e-06
mutation O 0 1.0304244142389507e-06
destroyed O 0 9.533583579468541e-06
an O 0 9.344308438130611e-08
NdeI O 0 2.9959776384202996e-06
restriction O 0 3.6564313177223084e-07
enzyme O 0 1.1538630815266515e-06
site O 0 2.999173830176005e-06
. O 0 9.018182822728704e-07

Analysis O 0 1.516570478088397e-07
of O 0 2.1216445134086825e-07
all O 0 1.9936514661367255e-08
family O 0 2.7364256638406914e-08
members O 0 7.56427309678287e-10
demonstrated O 0 2.6294360022660612e-09
that O 0 1.149576336900715e-10
the O 0 1.2200406240836514e-09
missense O 0 6.562765975104412e-08
mutation O 0 2.214090066843255e-08
co O 0 1.68123477806148e-07
- O 0 5.454563734019757e-07
segregated O 0 4.6965713096369655e-08
with O 0 2.2287742762472362e-09
patients O 0 2.7597293339454154e-08
with O 0 6.368060923023222e-08
tumors B-Disease 1 1.0
or O 0 0.00020419905195012689
who O 0 3.8528199297616084e-07
, O 0 7.072928909224174e-10
as O 0 8.824860842082671e-10
a O 0 4.783903273519741e-10
result O 0 5.348857357034831e-09
of O 0 1.070080113407812e-08
linkage O 0 1.2068264254594396e-07
analysis O 0 2.2911974539852054e-08
had O 0 1.9762058656169756e-08
been O 0 3.1806286493463176e-09
predicted O 0 1.0709275244380478e-08
to O 0 9.880926077343588e-10
carry O 0 2.4568493017795845e-08
the O 0 1.2199463128581556e-07
predisposing O 0 7.878873293520883e-05
mutation O 0 5.0357643885945436e-06
. O 0 2.3139439235819736e-06

These O 0 2.1317124776487617e-07
observations O 0 7.05517663845967e-07
point O 0 9.055899141685586e-08
to O 0 6.047142786513859e-10
another O 0 5.109155321036951e-09
region O 0 1.433461171984618e-08
of O 0 2.3468114562774645e-08
the O 0 9.259626665425458e-08
RB1 O 0 4.425941369845532e-05
gene O 0 1.0163637043092422e-08
where O 0 1.0700964558907344e-08
mutations O 0 1.5691080657020962e-09
only O 0 2.7750018949390665e-10
modify O 0 1.644580471804602e-09
the O 0 1.7270463947838266e-09
function O 0 9.32756205607177e-10
of O 0 3.834185857698458e-09
the O 0 5.41529443509603e-09
gene O 0 1.6148030690388282e-09
and O 0 6.444696776242154e-09
raise O 0 9.078222618086329e-09
important O 0 1.1913903641413981e-08
questions O 0 9.887641816419546e-09
for O 0 9.199009887161935e-10
genetic O 0 1.1273791677979261e-08
counseling O 0 2.6633961702771103e-09
in O 0 5.350140330762088e-10
families O 0 1.1794653032026758e-09
with O 0 5.42289935179241e-10
these O 0 4.46919701246884e-09
distinctive O 0 1.1887963324852535e-07
phenotypes O 0 4.63395082306306e-07
. O 0 9.881726015237291e-08
. O 0 4.866338940701098e-07

Maternal B-Disease 0 0.0005303616635501385
disomy I-Disease 0 0.0013676858507096767
and O 0 1.616129702597391e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.0006353955832310021
with O 0 5.672279534962854e-09
gamete O 0 8.767387953412253e-07
complementation O 0 4.763812455621519e-07
in O 0 5.168273031763704e-10
a O 0 1.032045671145454e-09
case O 0 6.035991706454524e-09
of O 0 1.76851564503977e-08
familial O 0 4.5942812221255735e-08
translocation O 0 4.376751405743562e-07
( O 0 1.5208033943281407e-08
3 O 0 1.1434767088758235e-07
; O 0 6.007289776732705e-09
15 O 0 5.815619985582998e-08
) O 0 1.954772788081982e-09
( O 0 3.069505316588561e-09
p25 O 0 4.158596027536987e-07
; O 0 1.2500390056402466e-08
q11 O 0 5.742670623476442e-07
. O 0 1.2611679700569312e-08
2 O 0 1.942134986165911e-07
) O 0 2.173403679250896e-08
. O 0 1.9193545597318007e-07

Maternal B-Disease 1 0.9968806505203247
uniparental I-Disease 1 0.9999899864196777
disomy I-Disease 1 0.9999862909317017
( I-Disease 0 3.9419795939465985e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.7271986507694237e-08
for I-Disease 0 7.282878744518939e-09
chromosome I-Disease 0 5.832171012798426e-08
15 I-Disease 0 3.509581247840288e-08
is O 0 6.23848139813532e-10
responsible O 0 1.2380462210970222e-09
for O 0 4.3993275689047096e-10
an O 0 1.211222899755171e-09
estimated O 0 2.2331658744434435e-09
30 O 0 4.162707512023189e-09
% O 0 1.5497503280670344e-10
of O 0 1.1584710274403776e-10
cases O 0 7.387158107441394e-10
of O 0 2.586343157418014e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 7.295881232494139e-07
. O 0 6.752736680937232e-07

We O 0 3.374909738340648e-07
report O 0 1.674273164553597e-07
on O 0 2.5256975177967433e-08
an O 0 7.741497998203783e-10
unusual O 0 2.2023713963648106e-09
case O 0 6.9637549060530546e-09
of O 0 2.310568625318865e-08
maternal B-Disease 0 0.00022429015371017158
disomy I-Disease 0 0.016056517139077187
15 I-Disease 0 2.226640987146311e-07
in O 0 1.5208847514713852e-08
PWS B-Disease 1 1.0
that O 0 4.263886577149378e-09
is O 0 1.0945702122455714e-09
most O 0 1.3144140220688882e-09
consistent O 0 3.1021372137729486e-08
with O 0 1.3854331015750176e-09
adjacent O 0 1.3794763731311832e-07
- O 0 4.725361080204493e-08
1 O 0 1.3687974842468975e-07
segregation O 0 3.834092865417915e-08
of O 0 6.592748125200387e-09
a O 0 1.3707641244309343e-08
paternal O 0 2.0146351289440645e-06
t O 0 8.108681015528418e-08
( O 0 8.812015117598548e-09
3 O 0 9.184151394947548e-08
; O 0 6.406653874080348e-09
15 O 0 3.276772275739859e-08
) O 0 1.2568329710305193e-09
( O 0 1.6705107297454447e-09
p25 O 0 1.8907731202943978e-07
; O 0 3.462768516371284e-09
q11 O 0 9.636682563041177e-08
. O 0 5.508297151735064e-10
2 O 0 3.3057097059696616e-09
) O 0 2.029312308471365e-11
with O 0 2.5195059580318535e-11
simultaneous O 0 1.3587795777425526e-08
maternal O 0 7.09299683876452e-07
meiotic O 0 2.7588457669480704e-06
nondisjunction O 0 1.4631984413426835e-05
for O 0 5.964534466329496e-08
chromosome O 0 1.2942953162564663e-06
15 O 0 2.3618786144652404e-06
. O 0 9.041881980920152e-07

The O 0 4.266073574399343e-07
patient O 0 2.51223582381499e-07
( O 0 2.3527004344714442e-08
J O 0 9.332033528153261e-07
. O 0 8.919630367643094e-09
B O 0 1.0884919987574904e-07
. O 0 4.671765196917477e-10
) O 0 6.374006877862826e-11
, O 0 2.1554516504984633e-10
a O 0 1.0004036488098222e-09
17 O 0 9.534495859497838e-09
- O 0 5.114049184129499e-09
year O 0 6.6229461914701915e-09
- O 0 6.923324491481253e-08
old O 0 4.571285444399109e-06
white O 0 3.3015275846537406e-08
male O 0 1.1704635483056336e-08
with O 0 1.991970366432838e-09
PWS B-Disease 1 1.0
, O 0 1.2893013767723005e-08
was O 0 7.653208733415795e-09
found O 0 1.2073197996897989e-10
to O 0 3.667484094194151e-10
have O 0 1.0688189222562983e-09
47 O 0 3.5664879050045784e-08
chromosomes O 0 4.50032455745486e-09
with O 0 1.1797487431408626e-09
a O 0 2.041622515491781e-08
supernumerary O 0 8.050234100664966e-06
, O 0 4.8459895651831175e-08
paternal O 0 0.00013960545766167343
der O 0 7.543464744230732e-05
( O 0 1.2836038898456081e-08
15 O 0 6.761643334129985e-08
) O 0 2.3073688792951685e-10
consisting O 0 1.6282877268736229e-09
of O 0 1.5592455326896015e-08
the O 0 7.483943420538708e-08
short O 0 2.728675418950388e-08
arm O 0 4.862766544988517e-08
and O 0 1.109490188611062e-08
the O 0 3.656815010799619e-07
proximal O 1 0.9892287254333496
long O 0 3.47182805171542e-07
arm O 0 6.589155532310542e-07
of O 0 4.783533995578182e-07
chromosome O 0 1.7852262601536495e-07
15 O 0 1.164717673418636e-06
, O 0 3.607888743317744e-08
and O 0 2.7122277401758765e-07
distal O 0 0.03114885464310646
chromosome O 0 0.0006872083176858723
arm O 0 0.0034337167162448168
3p O 0 0.012824052013456821
. O 0 1.2712960597127676e-05

The O 0 1.5306099157896824e-05
t O 0 1.0280431297360337e-06
( O 0 3.7466264757313184e-08
3 O 0 5.607086350778445e-08
; O 0 1.5153532872957953e-09
15 O 0 8.072398749447984e-09
) O 0 7.406454616276648e-11
was O 0 1.353120171465605e-09
present O 0 1.9108593873884416e-10
in O 0 1.3577730606506577e-10
the O 0 8.813288432385491e-10
balanced O 0 1.1911898134542298e-09
state O 0 1.4728876451819417e-10
in O 0 3.5251418450954475e-10
the O 0 4.3509462699375945e-09
patients O 0 1.4360355127251978e-09
father O 0 1.0457009125275363e-07
and O 0 2.9950523838806475e-08
a O 0 1.7831793286404718e-07
sister O 0 4.6812701839371584e-06
. O 0 1.536008198854688e-06

Fluorescent O 0 8.650847121316474e-06
in O 0 8.749716329248258e-08
situ O 0 3.5222967653680826e-07
hybridization O 0 5.980298478647228e-09
analysis O 0 1.5642372952484607e-09
demonstrated O 0 4.806257614120568e-09
that O 0 5.440013439717006e-10
the O 0 1.7402141949673933e-08
PWS B-Disease 1 1.0
critical O 0 4.162909306160145e-07
region O 0 5.4621335010551775e-08
resided O 0 2.836900989677815e-07
on O 0 1.2233384971693795e-08
the O 0 5.944067460461611e-09
derivative O 0 1.5593318636319964e-08
chromosome O 0 8.862700795475575e-09
3 O 0 2.062263604329928e-08
and O 0 8.667982998034063e-10
that O 0 3.041901175393491e-10
there O 0 1.2945788885332377e-09
was O 0 8.50516634898213e-09
no O 0 1.0764028557375127e-09
deletion O 0 1.5001290210037155e-09
of O 0 4.385037666310154e-09
the O 0 4.096273897857827e-08
PWS B-Disease 1 1.0
region O 0 5.578177706411225e-07
on O 0 4.326799540876891e-08
the O 0 1.3464940273877346e-08
normal O 0 4.4088825035260015e-08
pair O 0 4.022450283969192e-08
of O 0 4.05188025354164e-08
15s O 0 1.4613093526349985e-06
present O 0 8.629950087879479e-08
in O 0 1.0069554434721795e-07
J O 0 0.0005421449313871562
. O 0 3.3196297408721875e-06

B O 0 0.010734681971371174
. O 0 4.2361865780549124e-05

Methylation O 0 3.2350028504879447e-06
analysis O 0 5.477720037561085e-07
at O 0 1.3423967004655424e-07
exon O 0 7.110674005161854e-08
alpha O 0 4.0401193501793387e-08
of O 0 1.956164830119178e-08
the O 0 1.00875823250135e-08
small O 0 1.701397600584187e-08
nuclear O 0 2.5821091753641667e-07
ribonucleoprotein O 0 1.7234807501154137e-06
- O 0 1.4942663995043404e-07
associated O 0 1.1441770197961887e-07
polypeptide O 0 1.3431001661956543e-06
N O 0 5.387614123719686e-07
( O 0 9.903080133710773e-09
SNRPN O 0 9.386299097968731e-06
) O 0 3.7024294741172525e-10
gene O 0 9.383664956175153e-10
showed O 0 2.8659763451344134e-09
a O 0 2.2294152635105036e-10
pattern O 0 1.563643770019496e-09
characteristic O 0 2.8823896602858667e-09
of O 0 1.6345171882647946e-09
only O 0 9.570821912774363e-10
the O 0 8.255416794611392e-09
maternal O 0 1.229621716447582e-06
chromosome O 0 1.6016666393170453e-07
15 O 0 7.677436428821238e-07
in O 0 1.0167382669123981e-07
J O 0 0.0003725272254087031
. O 0 2.7815497105621034e-06

B O 0 0.006869073957204819
. O 0 3.4648557630134746e-05

Maternal B-Disease 0 0.0012742765247821808
disomy I-Disease 0 0.0003605449746828526
was O 0 3.7392237572930753e-07
confirmed O 0 2.1404632732924256e-08
by O 0 6.971233035280022e-10
polymerase O 0 2.6286150145438114e-08
chain O 0 8.545884888633282e-09
reaction O 0 9.09853881125855e-09
analysis O 0 7.879748409322929e-09
of O 0 1.1877374639368554e-08
microsatellite O 0 5.370183089326019e-07
repeats O 0 3.26884190826604e-07
at O 0 8.097815396013175e-08
the O 0 4.3612178757257425e-08
gamma O 0 5.819741772938869e-07
- O 0 2.9375831900324556e-07
aminobutyric O 0 1.5632142549293349e-06
acid O 0 1.541209826427803e-07
receptor O 0 1.5878993053775048e-06
beta3 O 0 3.630822675404488e-06
subunit O 0 3.4477912436159386e-07
( O 0 1.6929236323903751e-07
GABRB3 O 0 0.00013550514995586127
) O 0 7.370276478013693e-08
locus O 0 7.328852120735974e-07
. O 0 1.1380755040590884e-06

A O 0 3.8694997783750296e-05
niece O 0 2.9790837288601324e-05
( O 0 1.133877205461431e-07
B O 0 1.0354789310440538e-06
. O 0 3.2642946123928596e-09
B O 0 5.433631145024265e-08
. O 0 3.2084238044127744e-10
) O 0 3.053770084027185e-11
with O 0 5.3353505641284826e-11
45 O 0 4.592395796976234e-09
chromosomes O 0 1.4146485094457262e-09
and O 0 4.92100193927314e-10
the O 0 9.719872684499364e-10
derivative O 0 2.2996198278946167e-09
3 O 0 2.1645163439387716e-09
but O 0 2.8139104935043235e-10
without O 0 2.2294717183513058e-09
the O 0 3.474354670629509e-08
der O 0 1.406888259225525e-06
( O 0 2.6603397262903172e-09
15 O 0 1.5111572437831455e-08
) O 0 3.483993094022253e-10
demonstrated O 0 4.256817121017775e-09
a O 0 3.0606659429111005e-09
phenotype O 0 2.691587397407602e-08
consistent O 0 2.749651883959814e-08
with O 0 3.94099752831778e-10
that O 0 5.190797791598811e-10
reported O 0 4.006353471197599e-09
for O 0 6.886324288579715e-10
haploinsufficiency O 0 1.5154751963564195e-05
of O 0 6.090649549150839e-07
distal O 0 6.460452277678996e-05
3 O 0 4.850061304750852e-05
p O 0 2.9764423743472435e-05
. O 0 2.237598437204724e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 5.37477217221749e-06
with O 0 3.192549158370639e-08
unbalanced O 0 1.3514887541532516e-05
segregation O 0 4.3153440287824196e-07
of O 0 2.593075407730794e-07
non O 0 2.528985987737542e-06
- O 0 8.329598699674534e-07
Robertsonian O 0 5.404047442425508e-06
translocations O 0 3.952331155687716e-07
has O 0 3.8018019843377715e-09
been O 0 6.47658426888853e-10
reported O 0 4.084950600002912e-09
previously O 0 2.424365153075314e-09
but O 0 4.385980745258422e-10
has O 0 3.5048947077953585e-10
not O 0 1.3602718951233328e-10
, O 0 3.629640754621022e-10
to O 0 6.76775302466126e-10
our O 0 8.522087036055837e-09
knowledge O 0 1.8559059355993668e-07
, O 0 4.2775636366343406e-09
been O 0 1.9205763646112928e-09
observed O 0 3.812461901731012e-09
in O 0 6.369683669404935e-10
a O 0 5.862861751637638e-09
case O 0 1.4141075155293947e-07
of O 0 2.332454869247158e-06
PWS B-Disease 1 1.0
. O 0 1.2250614418007899e-05

Furthermore O 0 6.2243948377727065e-06
, O 0 1.4133848935671267e-07
our O 0 8.990551236820465e-08
findings O 0 6.041383926458366e-08
are O 0 1.0595146981984271e-09
best O 0 2.9865512285454088e-09
interpreted O 0 1.006072025688809e-08
as O 0 3.6718252882650404e-09
true O 0 5.732843888495154e-08
gamete O 0 2.46971671913343e-06
complementation O 0 3.835135430563241e-06
resulting O 0 3.0629803404735867e-07
in O 0 8.37560989452868e-08
maternal B-Disease 1 0.999943733215332
UPD I-Disease 1 1.0
15 I-Disease 0 0.002759307622909546
and O 0 4.023138899356127e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9974606037139893
- I-Disease 1 0.9999990463256836
Jampel I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999771118164062
type I-Disease 0 1.7059685433196137e-06
2 I-Disease 0 1.451769321647589e-06
and O 0 5.260121227479431e-08
Stuve B-Disease 1 0.9221075773239136
- I-Disease 1 0.9686836004257202
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 7.3427157687433464e-09
a O 0 3.3757667772249533e-09
case O 0 5.356228349739922e-09
for O 0 1.970393626038458e-09
" O 0 1.970499852177454e-08
lumping O 0 3.134146027150564e-07
" O 0 3.0849142262923124e-07
. O 0 6.960994483051763e-07

Recent O 0 1.4272741566401237e-07
studies O 0 2.0392368682564666e-08
demonstrated O 0 7.738814922220172e-09
the O 0 1.8235957188750263e-09
existence O 0 7.511368416146524e-09
of O 0 3.2780207437355102e-09
a O 0 1.4722592034388526e-09
genetically O 0 1.282671480140607e-08
distinct O 0 6.8906897965348435e-09
, O 0 3.7120173601579154e-10
usually O 0 6.089014709109719e-11
lethal O 0 1.1918626086071527e-09
form O 0 4.375477757889712e-10
of O 0 5.755871335111351e-09
the O 0 3.415932425809842e-08
Schwartz B-Disease 0 0.0523664653301239
- I-Disease 1 0.999997615814209
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.891685077585862e-07
SJS B-Disease 1 0.7899346947669983
) O 0 1.5794380914258e-08
of O 0 0.00020225397020112723
myotonia B-Disease 1 1.0
and O 1 0.9999685287475586
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.3032218905427726e-06
which O 0 3.140440796300936e-08
we O 0 2.5240938228421328e-08
called O 0 1.126184727695545e-07
SJS B-Disease 0 9.299701196141541e-05
type I-Disease 0 1.6162746760528535e-05
2 I-Disease 0 2.4074377506622113e-05
. O 0 8.220645781875646e-07

This O 0 1.0416300710858195e-07
disorder O 0 0.4887547492980957
is O 0 9.08899888685255e-09
reminiscent O 0 1.772156394963531e-07
of O 0 1.7045644895574696e-08
another O 0 4.5918526758725875e-09
rare O 0 8.78144490457089e-09
condition O 0 7.126369183652059e-08
, O 0 1.5473172743085684e-09
the O 0 5.513440370918943e-09
Stuve B-Disease 0 0.005287133622914553
- I-Disease 1 0.9918320775032043
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00044561922550201416
SWS B-Disease 1 0.9998550415039062
) O 0 1.9817838481372974e-09
, O 0 6.998050472439843e-10
which O 0 4.971237865802891e-10
comprises O 0 8.273481455489673e-09
campomelia B-Disease 0 0.0002126844337908551
at O 0 2.731722759108379e-07
birth O 0 2.6219953724648803e-05
with O 0 4.958487238582165e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 8.582312602811726e-07
contractures B-Disease 1 0.9999631643295288
, O 0 6.924882711700775e-08
and O 0 1.2902263257785762e-08
early B-Disease 0 1.0286953511240426e-06
death I-Disease 0 1.2441679245966952e-05
. O 0 1.7798743101593573e-06

To O 0 3.313450847031163e-08
test O 0 4.426947253222124e-09
for O 0 1.3889758232465965e-09
possible O 0 3.703096851381815e-08
nosologic O 0 4.549440291157225e-06
identity O 0 4.695666788734343e-08
between O 0 7.46837116594179e-08
these O 0 4.463764113893376e-08
disorders O 0 3.6471226394496625e-06
, O 0 3.1999485283762397e-09
we O 0 6.241527850114892e-10
reviewed O 0 5.120344592768333e-09
the O 0 2.623794959077941e-09
literature O 0 2.7704236682524197e-09
and O 0 1.8041376725896896e-10
obtained O 0 2.6581790102397918e-09
a O 0 8.627539238581505e-10
follow O 0 1.5414377552147585e-09
- O 0 5.8193450058752205e-09
up O 0 7.19292581052855e-09
of O 0 5.628019383863148e-09
the O 0 1.2555294581773069e-09
only O 0 1.231212465313547e-09
two O 0 1.3438609114402311e-09
surviving O 0 9.743360607217255e-08
patients O 0 1.6048729012396734e-09
, O 0 1.24413934710077e-09
one O 0 6.9643388833640074e-09
with O 0 1.3577304613932029e-08
SJS B-Disease 0 6.930730251042405e-06
type I-Disease 0 3.73427013755645e-07
2 I-Disease 0 3.0022189889677975e-07
at O 0 1.4095909328659673e-08
age O 0 7.695966530718579e-09
10 O 0 1.9078050250698197e-09
years O 0 1.118560466473184e-09
and O 0 8.105843218864095e-10
another O 0 5.857965668099041e-09
with O 0 1.2513081237841561e-08
SWS B-Disease 0 0.0005719891050830483
at O 0 1.5389510110708216e-07
age O 0 4.1672424799799046e-07
7 O 0 4.716500541235291e-07
years O 0 9.839220638241386e-08
. O 0 8.294339295389364e-07

Patients O 0 3.061000484194665e-07
reported O 0 1.0516694715079211e-07
as O 0 8.982954824432454e-09
having O 0 1.1130468102749091e-08
either O 0 2.0280971568809036e-07
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 1.2517551112978254e-05
SWS B-Disease 0 0.0843694880604744
presented O 0 9.970400505210364e-09
a O 0 4.2270653644038703e-10
combination O 0 1.0688108176282185e-09
of O 0 1.4933175807030352e-09
a O 0 2.0087120855549756e-09
severe O 0 1.5283923460174265e-07
, O 0 4.713889723007014e-09
prenatal O 0 1.287950453843223e-06
- O 0 1.568494008097332e-05
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 4.613380610862805e-07
with O 0 8.379946052627929e-07
congenital B-Disease 1 1.0
joint I-Disease 0 0.0041525037959218025
contractures I-Disease 1 1.0
, O 0 2.589373764294578e-07
respiratory O 1 1.0
and O 0 4.023041526579618e-07
feeding O 0 1.4147581168799661e-05
difficulties O 0 0.10802119225263596
, O 0 8.491971570379064e-09
tendency O 0 8.38929636870489e-08
to O 0 5.355410781504588e-09
hyperthermia B-Disease 0 0.012840940617024899
, O 0 2.304840984734824e-09
and O 0 7.286987679933077e-10
frequent O 0 3.4763414369365364e-09
death O 0 1.873411150654647e-07
in O 0 1.1325949955676151e-08
infancy O 0 7.292164355021669e-06
) O 0 1.288228967943894e-09
with O 0 9.17304343595049e-10
a O 0 1.07990132391933e-08
distinct O 0 2.543498283102963e-07
campomelic B-Disease 0 0.016991814598441124
- I-Disease 0 0.11247614026069641
metaphyseal I-Disease 1 0.9999129772186279
skeletal I-Disease 1 0.9999961853027344
dysplasia I-Disease 1 0.9999957084655762
. O 0 5.914629946346395e-05

The O 0 1.753566039042198e-07
similarity O 0 6.680497222077975e-07
of O 0 5.593167884399008e-07
the O 0 8.805936602129805e-08
clinical O 0 1.0927792715165197e-07
and O 0 1.2046917241548272e-08
radiographic O 0 1.0153629773412831e-05
findings O 0 1.1452185333382658e-07
is O 0 4.493317273812636e-09
so O 0 1.2372342039768114e-09
extensive O 0 2.5810891202127095e-08
that O 0 2.6557160914819633e-09
these O 0 5.071273889711847e-08
disorders O 0 5.159235570317833e-06
appear O 0 2.0387506793895227e-08
to O 0 1.7117575135117136e-09
be O 0 3.80660569732072e-09
a O 0 1.1347270678641053e-08
single O 0 3.5641829043697726e-08
entity O 0 1.2133575637562899e-06
. O 0 1.5908990462776273e-06

The O 0 7.904632184363436e-07
follow O 0 1.4405853221433063e-07
- O 0 1.1263479393619491e-07
up O 0 6.338660263338625e-09
observation O 0 2.970872969854099e-07
of O 0 3.387473412885811e-09
an O 0 7.55905227300957e-10
identical O 0 1.6585923745537912e-09
and O 0 4.799357578022523e-10
unique O 0 3.816594595917877e-09
pattern O 0 4.0779005416879954e-07
of O 0 7.830278718756745e-07
progressive O 1 1.0
bone B-Disease 1 0.999998927116394
dysplasia I-Disease 1 0.9999982118606567
in O 0 2.16242117545562e-08
the O 0 1.1525374077336892e-07
two O 0 3.5217098126594237e-09
patients O 0 1.8502192000724449e-09
( O 0 8.302817877670066e-10
one O 0 7.534901591554899e-09
with O 0 8.278280283491313e-09
SJS B-Disease 0 3.788318736042129e-06
type I-Disease 0 1.0381055659536287e-07
2 I-Disease 0 3.347876429415919e-07
, O 0 2.8743629698624318e-09
one O 0 4.4929659992476445e-09
with O 0 1.0166021802149316e-08
SWS B-Disease 0 4.3712185288313776e-05
) O 0 3.839447426656761e-09
surviving O 0 1.0002525414165575e-05
beyond O 0 3.6273929708841024e-06
infancy O 0 3.22460982715711e-06
adds O 0 4.614225090904256e-08
to O 0 2.447521518789131e-09
the O 0 2.751712413484597e-09
evidence O 0 1.5491607996409584e-08
in O 0 1.1559025958618463e-09
favor O 0 2.984536706662766e-08
of O 0 3.24158762055049e-08
identity O 0 1.937950031560831e-07
. O 0 6.466925128734147e-07

The O 0 7.820711402928282e-07
hypothesis O 0 2.322849695701734e-06
that O 0 7.704193905055945e-08
SWS B-Disease 0 2.2830412490293384e-05
and O 0 1.2766699342137144e-07
SJS B-Disease 0 3.977896994911134e-06
type I-Disease 0 1.0943352890535607e-07
2 I-Disease 0 3.4332427389927034e-07
are O 0 5.349854448333247e-10
the O 0 3.1848235160225613e-09
same O 0 3.798757752804249e-09
disorder O 0 1.3481545124705008e-07
should O 0 1.145009975722644e-09
be O 0 7.265490986618772e-10
testable O 0 4.3020222051382007e-08
by O 0 7.681121849678618e-10
molecular O 0 2.8804290508332997e-08
methods O 0 3.789669733578194e-08
. O 0 4.2606131955835735e-08
. O 0 4.699887199421937e-07

A O 0 3.268690534241614e-06
mouse O 0 1.2445595132248854e-07
model O 0 5.7893569049838334e-08
of O 0 4.6796888142353055e-08
severe O 0 0.19510194659233093
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9984102249145508
defects O 1 1.0
in O 0 2.141999289051455e-07
hemostasis O 0 0.05607609450817108
and O 0 1.0692893965824624e-06
thrombosis B-Disease 0 7.232562347780913e-05
. O 0 1.7697830116958357e-06

von B-Disease 1 0.7363399267196655
Willebrand I-Disease 1 0.9999994039535522
factor I-Disease 0 0.16890384256839752
( I-Disease 0 6.280571687966585e-05
vWf I-Disease 1 0.9999897480010986
) I-Disease 0 1.0398021004220936e-05
deficiency I-Disease 1 1.0
causes O 1 1.0
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.734296972699667e-07
humans O 0 2.3355212874776043e-07
. O 0 4.200835235224076e-08

We O 0 1.3761665229594655e-07
generated O 0 1.039298211935602e-07
a O 0 9.336858397546166e-09
mouse O 0 5.444209527638577e-09
model O 0 5.503931088668423e-09
for O 0 3.847245577670577e-10
this O 0 6.080858594437188e-10
disease O 0 7.120402045757146e-09
by O 0 3.7767353133766335e-10
using O 0 1.4107576218336249e-09
gene O 0 1.576217911747335e-08
targeting O 0 9.745151601237012e-07
. O 0 5.232299145063735e-07

vWf B-Disease 0 0.0036890218034386635
- I-Disease 0 0.005959881469607353
deficient I-Disease 0 9.652019798522815e-05
mice O 0 3.270048409831361e-07
appeared O 0 1.9328334133206226e-07
normal O 0 3.961507744065784e-08
at O 0 3.8051606310318675e-09
birth O 0 3.2464060328862843e-09
; O 0 4.2065559369142136e-10
they O 0 4.3059006360479657e-10
were O 0 5.884483567086818e-09
viable O 0 1.0638872254276066e-06
and O 0 1.2781393365912663e-07
fertile O 0 2.6503352273721248e-05
. O 0 1.6540208207516116e-06

Neither O 0 0.0002715173177421093
vWf O 0 0.008701326325535774
nor O 0 0.0005754445446655154
vWf O 0 0.004387770313769579
propolypeptide O 0 0.001026070793159306
( O 0 1.4283949667515117e-06
von B-Disease 0 0.0042925202287733555
Willebrand I-Disease 0 0.0007609036983922124
antigen O 0 4.437763436726527e-06
II O 1 0.99998939037323
) O 0 1.6306133332477657e-08
were O 0 1.2840152940896132e-08
detectable O 0 1.0363330460450015e-07
in O 0 1.303558372356406e-09
plasma O 0 7.599116713663534e-08
, O 0 1.1011264122728903e-09
platelets O 0 5.080238807408932e-08
, O 0 8.544054908021792e-10
or O 0 8.192762024350486e-10
endothelial O 0 1.3622075023533853e-08
cells O 0 4.304539835686683e-09
of O 0 1.4359184952184023e-08
the O 0 2.033895718511758e-08
homozygous O 0 5.224874044529315e-08
mutant O 0 1.583947323524626e-06
mice O 0 5.313910378390574e-07
. O 0 4.104697950424452e-07

The O 0 1.121684476856899e-06
mutant O 0 5.409998266259208e-06
mice O 0 5.533337343877065e-07
exhibited O 0 2.2426916075346526e-06
defects O 0 6.63708169668098e-06
in O 0 8.772270909673807e-09
hemostasis O 0 7.164461521824705e-07
with O 0 7.290490988687282e-10
a O 0 5.1684234669835405e-09
highly O 0 6.441381117383571e-08
prolonged O 0 0.0004568773729261011
bleeding O 0 2.4396624212386087e-05
time O 0 2.7313467043654782e-08
and O 0 3.652590052638516e-08
spontaneous O 0 5.845771011081524e-05
bleeding O 0 1.0105279216077179e-05
events O 0 3.7077454440037627e-09
in O 0 8.929004757796122e-10
approximately O 0 1.9353625368978555e-09
10 O 0 4.457712421412907e-09
% O 0 2.410592392365629e-09
of O 0 1.0974724240497835e-08
neonates O 0 3.315330104669556e-06
. O 0 1.4101914302955265e-06

As O 0 3.1452577786694746e-07
in O 0 1.0178885290201833e-08
the O 0 2.0625940067020565e-08
human O 0 2.3681428373834024e-08
disease O 0 1.6695200599770033e-07
, O 0 2.612268734658585e-10
the O 0 4.0001130185984834e-10
factor O 0 6.968165600085285e-09
VIII O 0 4.804634045285638e-06
level O 0 2.1637873715008027e-07
in O 0 2.1724866350325556e-09
these O 0 6.3264611327440434e-09
mice O 0 1.0244875170428713e-08
was O 0 5.78860337441256e-09
reduced O 0 3.860773034602971e-09
strongly O 0 1.0876193279329982e-09
as O 0 5.640170552823065e-10
a O 0 3.3512395636314807e-10
result O 0 3.078728383343332e-09
of O 0 8.52263948303289e-09
the O 0 1.3609428251015743e-08
lack O 0 1.1930417542771465e-07
of O 0 1.8164454829161514e-08
protection O 0 1.6003046710011404e-07
provided O 0 1.7003569041662558e-07
by O 0 8.031702947164376e-08
vWf O 0 0.00032729055965319276
. O 0 5.44847853234387e-06

Defective O 0 0.0001509530993644148
thrombosis B-Disease 0 1.3771153135166969e-05
in O 0 2.307846536098168e-08
mutant O 0 1.1636335983666868e-07
mice O 0 1.2955430506167431e-08
was O 0 1.068619770450141e-08
also O 0 2.792608921886597e-10
evident O 0 3.892241196012947e-09
in O 0 1.1698619850619707e-10
an O 0 4.400720343689102e-10
in O 0 1.4799275693810898e-10
vivo O 0 1.1226841678535493e-08
model O 0 1.4150944416257971e-08
of O 0 1.7907079552514915e-07
vascular B-Disease 1 0.9999974966049194
injury I-Disease 1 1.0
. O 0 0.0002525871677789837

In O 0 3.079299659702883e-08
this O 0 2.1091068891365694e-09
model O 0 4.5929933634170084e-08
, O 0 5.385505819077707e-09
the O 0 1.662479220954083e-08
exteriorized O 0 1.0059176020149607e-05
mesentery O 0 1.7814923921832815e-05
was O 0 2.9385526545411267e-07
superfused O 0 2.5059118797798874e-06
with O 0 1.655720005544481e-08
ferric O 0 3.0346081985044293e-06
chloride O 0 1.4483821360045113e-05
and O 0 2.995446948261815e-07
the O 0 1.203114692316376e-07
accumulation O 0 0.2184636890888214
of O 0 2.2992184312897734e-05
fluorescently O 0 1.656100903346669e-05
labeled O 0 8.491172138747061e-07
platelets O 0 1.6058710343713756e-06
was O 0 8.552753882895558e-08
observed O 0 1.16237650615858e-08
by O 0 6.137222285929056e-09
intravital O 0 9.531473551760428e-06
microscopy O 0 2.5459421522100456e-06
. O 0 1.2348275504336925e-06

We O 0 1.940242952969129e-07
conclude O 0 4.0444535898132017e-07
that O 0 5.10101472173119e-09
these O 0 7.329925999499665e-09
mice O 0 2.899357198771213e-08
very O 0 4.776119055804884e-09
closely O 0 1.569231677933658e-08
mimic O 0 5.2154553031869e-07
severe O 0 1.2103977496735752e-05
human O 0 1.423947537659842e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.592549097040319e-07
will O 0 6.964415155685799e-10
be O 0 6.260366669508244e-10
very O 0 7.192263451472058e-10
useful O 0 4.031896150280545e-09
for O 0 5.266360125766312e-10
investigating O 0 5.953734838470837e-09
the O 0 1.4799911518537101e-08
role O 0 1.8498745646411408e-08
of O 0 6.07463874757741e-08
vWf O 0 2.560730308687198e-06
in O 0 9.22382170642777e-09
normal O 0 3.9765848214301514e-07
physiology O 0 2.0934358246904594e-07
and O 0 9.22213327925192e-09
in O 0 4.201842873641226e-09
disease O 0 1.6864264296145848e-07
models O 0 7.223822251489764e-08
. O 0 2.768929796559405e-08
. O 0 2.699526078231429e-07

Oral O 0 2.6984243959304877e-06
contraceptives O 0 1.7431013930035988e-06
and O 0 7.20729032011036e-09
the O 0 1.3469152015943564e-08
risk O 0 5.117758519190829e-06
of O 1 0.9994656443595886
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1141440811334178e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 0 8.515962690580636e-07
Study O 0 6.6363750050868475e-09
Group O 0 6.585634704237009e-09
. O 0 3.154560701545961e-08

BACKGROUND O 0 0.000731702777557075
Women O 0 5.290366900112531e-08
with O 0 1.314476638647477e-09
mutations O 0 5.0811084228996606e-09
in O 0 5.462867380678915e-10
either O 0 2.5764739230993428e-09
the O 0 1.058549692345423e-08
BRCA1 O 0 3.622271904646368e-08
or O 0 2.58680454834348e-09
the O 0 1.2878021315998467e-08
BRCA2 O 0 3.0321260169330344e-08
gene O 0 1.1384682085946451e-09
have O 0 8.761231184983842e-10
a O 0 2.626969752839159e-09
high O 0 2.207351812444358e-08
lifetime O 0 4.990042867802913e-08
risk O 0 0.13119427859783173
of O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.841220637288643e-06

Oral O 0 2.476126974215731e-05
contraceptives O 0 0.00018074952822644264
protect O 0 0.0002760478528216481
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.621914019229621e-09
general O 0 1.4824773408861347e-08
, O 0 1.8557920478112777e-10
but O 0 1.1906804708861074e-10
it O 0 7.96631580146645e-11
is O 0 3.741158077774642e-11
not O 0 1.2836123830517465e-10
known O 0 1.304647945232773e-09
whether O 0 1.7474509617088074e-09
they O 0 2.276255850475195e-09
also O 0 1.5278940335150537e-09
protect O 0 1.5190689817146108e-09
against O 0 1.496968593528436e-08
hereditary B-Disease 1 0.9999998807907104
forms I-Disease 1 1.0
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.116413603900583e-07

METHODS O 0 4.018480922240997e-06
We O 0 5.0594099576528606e-08
enrolled O 0 1.5331997360590321e-07
207 O 0 3.8543593205986326e-08
women O 0 1.2510790625697155e-08
with O 0 1.0962572360995182e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.980766354911736e-10
161 O 0 9.022891878096573e-10
of O 0 8.392905259668737e-10
their O 0 2.164702195273094e-09
sisters O 0 7.071236041156226e-08
as O 0 1.914838243521899e-08
controls O 0 1.671595128982517e-08
in O 0 2.2459636372929026e-09
a O 0 6.141906538914554e-09
case O 0 2.794242170978123e-08
- O 0 1.307743247025428e-07
control O 0 7.354127973258073e-08
study O 0 5.189714613607066e-08
. O 0 1.5470899938918592e-07

All O 0 9.586250371285132e-08
the O 0 1.9338765255838553e-08
patients O 0 1.2213584588138815e-09
carried O 0 1.417105988110734e-09
a O 0 1.5388107454938904e-10
pathogenic O 0 2.1860662169359557e-09
mutation O 0 8.716061206115455e-10
in O 0 2.549298550036383e-10
either O 0 9.785260601802293e-09
BRCA1 O 0 4.464300573658875e-08
( O 0 2.1484012346917325e-09
179 O 0 2.012954958274804e-08
women O 0 3.827909100806437e-09
) O 0 1.6634585930930257e-09
or O 0 9.20398477433082e-08
BRCA2 O 0 1.5930428389765439e-06
( O 0 3.519119573525131e-08
28 O 0 5.641107691189973e-06
women O 0 2.8571039933922293e-07
) O 0 1.0487029555861227e-07
. O 0 1.2238622275617672e-06

The O 0 6.892236115163541e-07
control O 0 1.3402616616531304e-07
women O 0 1.695304341353676e-08
were O 0 5.839158045972681e-09
enrolled O 0 3.604021525660528e-09
regardless O 0 4.882914073078837e-09
of O 0 3.352801147826767e-09
whether O 0 9.367213671396257e-10
or O 0 2.0564452363203145e-09
not O 0 1.2321004216886422e-09
they O 0 3.597771636165703e-09
had O 0 1.6916994027837973e-08
either O 0 4.405940146057219e-08
mutation O 0 2.1175331710310275e-07
. O 0 4.123184851323458e-07

Lifetime O 0 1.2916689229314215e-06
histories O 0 1.34208096369548e-06
of O 0 1.031569809128996e-06
oral O 0 2.134362944161694e-07
- O 0 3.730617947894643e-08
contraceptive O 0 5.315011986084528e-09
use O 0 6.936139440583133e-10
were O 0 8.195762957186048e-10
obtained O 0 2.1070483136043094e-09
by O 0 8.080142666067047e-10
interview O 0 5.146320702920093e-09
or O 0 2.19173471038836e-10
by O 0 1.3838372114882702e-10
written O 0 1.8278152602579922e-10
questionnaire O 0 9.919744192732338e-11
and O 0 1.1153642592853785e-10
were O 0 3.644110846412474e-10
compared O 0 5.614175235812979e-10
between O 0 7.499597609594844e-10
patients O 0 4.5322115505008753e-10
and O 0 1.870612109655667e-09
control O 0 4.032866840475435e-08
women O 0 1.6625396170866225e-08
, O 0 1.5629012528606268e-09
after O 0 1.6461871865658395e-09
adjustment O 0 1.5192581415135464e-08
for O 0 7.963965042989685e-10
year O 0 1.6528509672042446e-09
of O 0 3.3603829052708534e-08
birth O 0 4.3421027839940507e-07
and O 0 2.0741578055094578e-07
parity O 0 8.894133316061925e-06
. O 0 3.4020031307591125e-06

RESULTS O 0 1.471808172937017e-05
The O 0 4.476707147205161e-07
adjusted O 0 2.066403794742655e-06
odds O 0 2.398475544396206e-06
ratio O 0 4.851593757848605e-07
for O 0 2.062953853965155e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.476439308589761e-07
with O 0 2.1703525088234699e-10
any O 0 1.2750434041919334e-09
past O 0 3.689319516553269e-09
use O 0 1.8772745580264427e-09
of O 0 1.8864426465370343e-08
oral O 0 1.238181965845797e-07
contraceptives O 0 1.1733468454622198e-06
was O 0 8.31521731470275e-07
0 O 0 2.6155275918426923e-06
. O 0 1.5090798797245952e-06

5 O 0 3.5501427646522643e-06
( O 0 3.622838562478137e-08
95 O 0 2.3767684353970253e-07
percent O 0 1.6227200916318907e-08
confidence O 0 1.2695644535654083e-08
interval O 0 1.3648003616140159e-08
, O 0 1.912475511289813e-09
0 O 0 1.1860033843902329e-08
. O 0 1.112681169423979e-09
3 O 0 7.901887144612374e-09
to O 0 4.8451367362645215e-09
0 O 0 7.594436368663082e-08
. O 0 1.4678353643660103e-08
8 O 0 2.408633861250564e-07
) O 0 1.8301159698808078e-08
. O 0 1.6430081473117752e-07

The O 0 7.609281738041318e-07
risk O 0 9.108923677558778e-07
decreased O 0 8.167960885430148e-08
with O 0 1.9406808104971418e-10
increasing O 0 2.3168162943676407e-09
duration O 0 8.038504084595388e-09
of O 0 1.7915265937418212e-09
use O 0 2.5703581485458926e-09
( O 0 3.6056577723542205e-09
P O 0 3.677957352010708e-07
for O 0 3.271425130790817e-09
trend O 0 9.863573069424092e-08
, O 0 1.9301020781625766e-09
< O 0 1.1998714910532726e-08
0 O 0 2.7282956338581243e-08
. O 0 4.3585375308907714e-09
001 O 0 1.1596952020909157e-07
) O 0 1.6868455243734815e-10
; O 0 8.637875137385009e-11
use O 0 1.8861709416562178e-10
for O 0 1.3404101162350912e-09
six O 0 5.531145763626455e-09
or O 0 7.717497196857437e-10
more O 0 4.3371900515509765e-10
years O 0 1.0514017434459788e-09
was O 0 2.0814878709529694e-09
associated O 0 1.3278903532309982e-09
with O 0 1.5752184279183012e-10
a O 0 1.208739663915992e-09
60 O 0 8.843265675295697e-09
percent O 0 1.3019805233938087e-09
reduction O 0 1.5810558418039022e-09
in O 0 1.5809834552626967e-09
risk O 0 3.481306976027554e-07
. O 0 4.878792765339313e-07

Oral O 0 1.781769242370501e-05
- O 0 1.291639364353614e-06
contraceptive O 0 5.716029605196127e-08
use O 0 8.94757512526212e-09
protected O 0 1.8889844795921817e-05
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 2.4759649885908175e-10
for O 0 1.3514989474772143e-11
carriers O 0 1.7217140213521276e-10
of O 0 1.0929845917218017e-09
the O 0 1.4143200388616606e-08
BRCA1 O 0 1.2530043136393942e-07
mutation O 0 2.896377893080171e-08
( O 0 1.7396068585640023e-08
odds O 0 4.770604391524103e-07
ratio O 0 3.849517682397163e-08
, O 0 4.1543160023138626e-09
0 O 0 2.029269019487856e-08
. O 0 1.5869986436101158e-09
5 O 0 6.452482548269245e-09
; O 0 9.729851369044695e-10
95 O 0 1.7592736156757383e-08
percent O 0 4.823670352038789e-09
confidence O 0 8.964008202383411e-09
interval O 0 2.4908976214987888e-08
, O 0 3.558190186936372e-09
0 O 0 1.4439187623338512e-08
. O 0 1.6030189398108519e-09
3 O 0 7.20346982063802e-09
to O 0 2.54853693704149e-09
0 O 0 2.262539666730845e-08
. O 0 1.8827897019235706e-09
9 O 0 1.5899626504278785e-08
) O 0 6.018809756147547e-11
and O 0 5.602919170288878e-11
for O 0 5.995939161840269e-11
carriers O 0 1.0730266675196276e-09
of O 0 4.814773024719443e-09
the O 0 1.4044282181657763e-07
BRCA2 O 0 1.3690445257452666e-06
mutation O 0 3.2982168107764664e-08
( O 0 1.9842055110075307e-08
odds O 0 6.963006171645247e-07
ratio O 0 7.134843116318734e-08
, O 0 8.201584300593368e-09
0 O 0 5.613238940327392e-08
. O 0 3.805051829175454e-09
4 O 0 1.6518558965117336e-08
; O 0 1.2939519455912318e-09
95 O 0 2.7646606781672745e-08
percent O 0 6.306462019267656e-09
confidence O 0 8.055448752486427e-09
interval O 0 1.948798811213237e-08
, O 0 1.939860272415217e-09
0 O 0 1.0961376695206582e-08
. O 0 1.284382045163568e-09
2 O 0 5.798670432710651e-09
to O 0 2.75305112040769e-09
1 O 0 4.283575094632397e-08
. O 0 4.301388134564377e-09
1 O 0 2.0741418893521768e-07
) O 0 1.6320321094553947e-08
. O 0 2.1083765489038342e-07

CONCLUSIONS O 0 0.0003332358901388943
Oral O 0 5.932974545430625e-06
- O 0 4.260194828020758e-07
contraceptive O 0 3.1313970083601816e-08
use O 0 6.089737603076628e-10
may O 0 5.983855078106615e-10
reduce O 0 9.96250637541607e-10
the O 0 1.5048690071850501e-09
risk O 0 3.776271455535607e-07
of O 1 0.8150036931037903
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.3280828659034682e-09
women O 0 1.586897974137358e-10
with O 0 3.4555205918884724e-11
pathogenic O 0 1.3431690204512847e-09
mutations O 0 1.8168846427357721e-09
in O 0 6.981945022133118e-10
the O 0 3.307502538518747e-08
BRCA1 O 0 3.0889289064361947e-06
or O 0 1.2111366913813981e-06
BRCA2 O 0 2.3643897293368354e-05
gene O 0 1.5609168258379214e-05

A O 0 4.356937552074669e-06
Japanese O 0 2.0657298591686413e-06
family O 0 1.2836680696182157e-07
with O 0 3.2525871773714243e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.3214724304286847e-09
a O 0 3.968100514839534e-09
codon O 0 7.21458235375394e-08
291 O 0 3.1372916708960474e-08
deletion O 0 5.8988227635836665e-09
: O 0 2.387662290104231e-09
a O 0 4.342630699483152e-09
clinical O 0 3.356583988534112e-08
, O 0 2.9957192282381584e-09
biochemical O 0 1.118649379350245e-06
, O 0 1.0427348762220845e-08
pathological O 0 6.753760681021959e-05
, O 0 3.393592962197545e-08
and O 0 2.1383781856343376e-08
genetic O 0 1.2885856222055736e-06
report O 0 4.554813415325043e-07
. O 0 8.412142733504879e-07

We O 0 2.8679170327450265e-07
report O 0 5.141564685118283e-08
a O 0 7.804302981639921e-09
Japanese O 0 1.0096884039967335e-07
family O 0 2.5339049969375083e-08
with O 0 1.6186831430786697e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 2.5254046249756357e-06
ALD B-Disease 1 1.0
) O 0 1.1239670305585037e-09
with O 0 2.5490312638432044e-10
a O 0 3.022020855780738e-09
three O 0 1.988940789843241e-09
base O 0 3.44055770540308e-08
pair O 0 3.7735134128524805e-08
deletion O 0 3.023324879336542e-08
( O 0 1.8931615386463818e-08
delGAG O 0 9.905745628202567e-07
291 O 0 7.288969072760665e-08
) O 0 6.922961648392345e-10
in O 0 2.82244760896333e-09
the O 0 4.702981186710531e-07
ALD B-Disease 1 1.0
gene O 0 3.099478135482059e-06
. O 0 2.444533492962364e-06

A O 0 2.3275949843082344e-06
variety O 0 2.298906736086792e-07
of O 0 1.505634230625219e-07
phenotypes O 0 4.5375011836767953e-07
were O 0 1.0872299505138017e-08
observed O 0 5.908799671772158e-09
within O 0 3.74718922557804e-09
this O 0 4.271147879819637e-09
family O 0 3.1525311783298093e-07
. O 0 4.791871219822497e-07

While O 0 6.026239702805469e-07
the O 0 4.2735945271488163e-07
proband O 0 2.0536635929602198e-05
( O 0 1.010387329358764e-08
patient O 0 1.8783678612521726e-08
1 O 0 8.81817285858233e-08
) O 0 5.955855808537081e-10
was O 0 7.170570359704698e-09
classified O 0 4.512220375119114e-09
as O 0 2.28068430807582e-09
having O 0 4.991294044742745e-10
a O 0 4.695796529397001e-10
rare O 0 1.4014619464930433e-09
intermediate O 0 7.460068118803065e-09
type O 0 6.775428218475099e-09
of O 0 1.548717598609528e-08
adult O 0 1.637180275793071e-07
cerebral O 0 9.757020052347798e-06
and O 0 1.2622321321487107e-07
cerebello O 1 0.5630693435668945
- O 0 5.2494349802145734e-05
brain O 0 9.872013833955862e-06
stem O 0 7.984901628788066e-08
forms O 0 1.1300745228481901e-08
, O 0 1.713272967940327e-09
his O 0 2.1905501412788908e-08
younger O 0 8.655879355501384e-07
brother O 0 1.3703225704375654e-05
( O 0 1.507495461794406e-08
patient O 0 4.7348969189897616e-08
2 O 0 1.0866312294410818e-07
) O 0 6.349511472159008e-10
and O 0 6.8421277532593194e-09
nephew O 0 3.4769833291647956e-05
( O 0 1.149667383515407e-08
patient O 0 5.104108140585595e-07
3 O 0 4.637793608708307e-06
) O 0 5.48516210230332e-09
had O 0 3.1717313220269716e-08
a O 0 5.013683690435755e-08
childhood O 0 4.621611151378602e-05
ALD B-Disease 1 1.0
type O 0 0.00012700838851742446
. O 0 2.6833556603378383e-06

Another O 0 1.8646944681677269e-06
nephew O 0 6.886832852615044e-05
( O 0 4.458828684050786e-08
patient O 0 7.100346977040317e-08
4 O 0 7.569504134607996e-08
) O 0 2.5837362804814745e-10
of O 0 4.5886392463501124e-09
patient O 0 1.160723783755202e-08
1 O 0 1.522766268635678e-07
was O 0 1.4797935321553268e-08
classified O 0 5.618848941679744e-09
as O 0 4.872977132919232e-09
having O 0 6.382334216681329e-09
an O 0 1.3428315348562592e-08
adolescent O 0 8.489092806485132e-08
form O 0 3.8188975537423175e-08
. O 0 7.892925850683241e-07

The O 0 5.098469273434603e-07
tau O 0 4.854588269154192e-07
level O 0 8.491781500197249e-08
in O 0 1.908198044020537e-09
the O 0 1.7970577914638852e-08
cerebrospinal O 0 2.876997541534365e-06
fluid O 0 1.5437120737260557e-06
( O 0 8.408920137981113e-08
CSF O 1 0.9999922513961792
) O 0 3.824201844082609e-09
in O 0 1.6433135963112022e-09
patient O 0 3.1750481355175e-08
1 O 0 2.1713573516990436e-07
was O 0 4.5870667264580334e-08
as O 0 2.019429956590102e-09
high O 0 1.9564037501140774e-08
as O 0 7.443591298894603e-10
that O 0 1.8327550588281838e-10
of O 0 3.616774879589002e-09
patients O 0 9.422120861302119e-09
with O 0 4.591154478816861e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.999911904335022
( O 0 2.290603262622426e-08
AD B-Disease 0 9.942780707206111e-06
) O 0 1.8056162787161156e-08
. O 0 1.387719379408736e-07

His O 0 5.0387043302180246e-06
brain O 0 6.472801487689139e-06
magnetic O 0 1.1243362223467557e-06
resonance O 0 1.736054286993749e-07
image O 0 2.0081907337043958e-07
( O 0 1.1107988306946481e-08
MRI O 0 9.279726782551734e-07
) O 0 3.7175107436837607e-09
showed O 0 5.526066004790664e-08
abnormalities B-Disease 0 1.6392769452977518e-07
in I-Disease 0 1.4339881504454866e-09
the I-Disease 0 1.552870543264362e-08
bilateral I-Disease 0 3.7173606415308313e-06
cerebellar I-Disease 1 1.0
hemispheres I-Disease 0 0.1550493836402893
and O 0 1.1286404344446055e-07
brain O 0 5.3091957852302585e-06
stem O 0 5.093599497740797e-07
, O 0 1.2307757035756595e-09
but O 0 6.721134204745738e-10
not O 0 2.461781334339719e-10
in O 0 7.457717776659933e-10
the O 0 3.339336274166271e-08
cerebral O 0 3.071979517699219e-05
white O 0 2.0301207825923484e-08
matter O 0 2.807137633453749e-08
, O 0 8.655691163816925e-10
where O 0 1.2352322498188073e-09
marked O 0 3.758828359679001e-09
reductions O 0 1.8875944363117014e-08
of O 0 1.6036558747600793e-08
the O 0 7.942628599266754e-08
cerebral O 0 1.786666643965873e-06
blood O 0 7.541561330981494e-08
flow O 0 1.2779759117620415e-07
and O 0 4.422305188711562e-09
oxygen O 0 4.651603902061652e-08
metabolism O 0 2.3565365836475394e-07
were O 0 3.0060292033340374e-08
clearly O 0 3.39841186303147e-08
demonstrated O 0 4.159866229258569e-09
by O 0 1.1971346136618877e-09
positron O 0 4.6213688165153144e-07
emission O 0 4.7107462819440116e-07
tomography O 0 4.4011531485921296e-07
( O 0 8.785101357489111e-08
PET O 0 1.0709124580898788e-05
) O 0 9.882064944122249e-08
. O 0 5.818892532261088e-07

In O 0 1.250941039643294e-07
patients O 0 2.5077921961269567e-08
2 O 0 9.049717419884473e-08
and O 0 4.017065791117602e-09
3 O 0 3.8124493784152946e-08
, O 0 7.162037629626639e-10
the O 0 1.1793077625554815e-09
autopsy O 0 5.940160008321982e-08
findings O 0 1.8685875957658027e-08
showed O 0 3.1771563158145e-08
massive O 0 1.6885073250705318e-07
demyelination B-Disease 1 1.0
of I-Disease 0 7.651118721696548e-06
the I-Disease 0 1.378469391966064e-06
cerebral I-Disease 0 0.2996944189071655
white I-Disease 0 8.512047955377966e-09
matter I-Disease 0 3.188002084542063e-09
with O 0 1.5043115364488102e-10
sparing O 0 1.9858031663488873e-08
of O 0 5.030436867059507e-08
the O 0 1.208129987162465e-07
U O 0 2.001562279474456e-05
- O 0 2.1056287096143933e-06
fibers O 0 7.4406416388228536e-06
, O 0 6.491292392496462e-09
compatible O 0 1.2879598898507538e-07
with O 0 1.0160646768397896e-09
the O 0 4.6294559297166415e-09
findings O 0 4.181410062642499e-08
of O 0 2.0423124169610674e-07
childhood O 0 0.24521303176879883
ALD B-Disease 1 1.0
. O 0 1.4286252735473681e-05

Oleic O 0 0.0001919747155625373
and O 0 1.0890573776123347e-06
erucic O 0 8.978852565633133e-05
acids O 0 1.5347050066338852e-06
( O 0 5.3549030099020456e-08
Lorenzos O 0 2.155140919057885e-06
Oil O 0 4.2777210751410166e-07
) O 0 1.8805634827145923e-10
were O 0 2.8107990934778115e-10
administered O 0 4.108575979433482e-11
to O 0 1.2956899442251313e-10
patients O 0 3.765931178012494e-10
1 O 0 1.1013937317727596e-08
and O 0 2.046986580239718e-09
4 O 0 1.668941429500137e-08
, O 0 4.3279427264231174e-10
but O 0 2.8785643313433695e-10
sufficient O 0 8.730308032056655e-09
effectiveness O 0 2.692393508141322e-08
was O 0 1.1823714451963951e-08
not O 0 2.3053641218240273e-09
obtained O 0 1.7061557855413412e-07
. O 0 4.4147273570160905e-07

The O 0 7.532015615652199e-07
findings O 0 1.548567638565146e-07
in O 0 1.9248118654502377e-09
this O 0 5.63657842622689e-10
family O 0 4.085433769063229e-09
suggest O 0 1.896297341374975e-09
that O 0 1.8122529865660653e-10
delGAG291 O 0 3.1142072032253054e-08
is O 0 2.5266971848125763e-10
part O 0 4.869221692516135e-10
of O 0 2.891464179199943e-09
the O 0 3.728524156088042e-09
cause O 0 2.7470267127682746e-07
of O 0 1.310414887711886e-07
Japanese O 0 1.3653097084898036e-05
ALD B-Disease 1 1.0
with O 0 1.098069102312138e-08
phenotypic O 0 3.477279051367077e-07
variations O 0 1.6197752756852424e-06
. O 0 1.1874744814122096e-06

Moreover O 0 3.082872126469738e-06
, O 0 1.5757731119947493e-08
although O 0 2.1173456321577078e-09
the O 0 9.324503391638927e-10
scale O 0 1.2429397955315835e-08
of O 0 5.5335518389654226e-09
the O 0 2.0464401284669975e-09
study O 0 3.5232128325901613e-10
is O 0 1.0087919388723776e-10
limited O 0 4.246492046888761e-10
, O 0 6.539244146175349e-10
there O 0 1.891824918942575e-09
is O 0 5.359209187538738e-10
a O 0 1.39400790910571e-09
possibility O 0 4.8515016004557765e-08
that O 0 6.594106150004109e-09
PET O 0 5.663687829837727e-07
can O 0 5.2318718246624485e-09
detect O 0 1.627606138754345e-07
an O 0 3.89974843528762e-08
insidious B-Disease 0 8.701602382643614e-06
lesion I-Disease 0 7.633007044205442e-06
which O 0 3.761905453814052e-09
is O 0 2.5526816216370207e-09
undetectable O 0 5.058917906808347e-08
by O 0 2.3803776727504555e-09
computed O 0 1.5957235177666007e-07
tomogram O 0 4.046550657221815e-06
( O 0 3.1325260607673044e-08
CT O 0 1.311498067479988e-06
) O 0 2.138246468774696e-09
or O 0 2.5756632382467615e-09
MRI O 0 8.821503882927573e-08
analysis O 0 5.641464628780568e-09
, O 0 6.034756583339629e-10
and O 0 2.9812793900241275e-10
that O 0 1.88563498149108e-10
the O 0 2.0127159938709838e-09
higher O 0 1.4558293237598718e-08
level O 0 1.7817404440734208e-08
of O 0 8.214657398752934e-09
tau O 0 3.1667621414044334e-08
reflects O 0 8.439075216415404e-09
the O 0 5.766417898733778e-10
process O 0 6.674152341901163e-09
of O 0 4.0767723419321555e-08
neuronal B-Disease 0 0.048555247485637665
degeneration I-Disease 1 1.0
in O 0 8.87434055130143e-07
ALD B-Disease 1 1.0
. O 0 6.028485131537309e-06

Lorenzos O 0 0.00012583183706738055
Oil O 0 5.0021158131130505e-06
should O 0 9.046194016093523e-09
be O 0 1.2227220347327261e-09
given O 0 3.2492246671012026e-09
in O 0 6.281800635221657e-10
the O 0 5.188820484391954e-09
early O 0 7.123230716388207e-08
stage O 0 3.614955801367614e-08
. O 0 3.5265646403104256e-08
. O 0 4.967735662830819e-07

Nonsense O 0 9.369163308292627e-06
mutation O 0 3.99506262738214e-07
in O 0 2.49848230993166e-08
exon O 0 1.9936595663239132e-07
4 O 0 1.92195926729255e-07
of O 0 1.9287194064077084e-08
human O 0 9.624097074834026e-09
complement O 0 1.7147392838978703e-07
C9 O 1 0.656375527381897
gene O 0 1.0134097117031615e-08
is O 0 1.6664913893293942e-09
the O 0 1.4051021457461843e-09
major O 0 1.393870530108643e-08
cause O 0 9.737508577245535e-08
of O 0 7.720331041127793e-08
Japanese O 0 1.7801459080146742e-06
complement B-Disease 0 5.152115772943944e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999980926513672
. O 0 1.0856180779228453e-05

Deficiency B-Disease 1 0.9455578327178955
of I-Disease 0 0.0018805328290909529
the I-Disease 0 1.0294097592122853e-06
ninth I-Disease 0 1.7988793388212798e-06
component I-Disease 0 3.980842393502826e-07
of I-Disease 0 1.3503647089407878e-08
human I-Disease 0 1.3296068246404502e-08
complement I-Disease 0 1.3371095519687515e-07
( O 0 2.0392134203461865e-08
C9 O 1 0.9999899864196777
) O 0 1.7650235717425744e-09
is O 0 2.1294135899019295e-10
the O 0 3.273558091265727e-10
most O 0 8.100093928931074e-10
common O 0 2.808251409192053e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.252834859945324e-09
Japan O 0 2.4414150701090875e-08
but O 0 1.4595847863674294e-09
is O 0 2.115874975228138e-10
rare O 0 9.181095883548096e-10
in O 0 7.29800386789492e-10
other O 0 4.643304407636606e-09
countries O 0 2.1008935036093135e-08
. O 0 5.210871449889964e-07

We O 0 2.941917500720592e-07
studied O 0 1.7474526714522653e-07
the O 0 4.201369918632736e-09
molecular O 0 4.253037744206267e-08
basis O 0 6.861628776277939e-08
of O 0 2.1737608335570258e-07
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9997020363807678
in O 0 9.983229887211564e-08
four O 0 5.5235794604868715e-08
Japanese O 0 1.2827065347664757e-06
C9 B-Disease 1 0.9999830722808838
- I-Disease 0 1.2982158295926638e-05
deficient I-Disease 0 1.0512899280001875e-06
patients O 0 8.596273204375393e-08
who O 0 2.5703398520704468e-08
had O 0 2.3051805797535962e-08
suffered O 0 1.3255220210339758e-06
from O 0 6.673174368643231e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.525185429178237e-07

Direct O 0 1.0290466434526024e-06
sequencing O 0 5.823222295475716e-07
of O 0 6.191167472024972e-07
amplified O 0 2.8329502583801514e-06
C9 O 0 8.095998782664537e-05
cDNA O 0 4.3312505226822395e-07
and O 0 1.8741770801966595e-08
DNA O 0 9.630673503124854e-08
revealed O 0 6.401563013014311e-08
a O 0 2.1892720525329423e-08
nonsense O 0 1.9060060196807171e-07
substitution O 0 1.7617290382077044e-07
( O 0 2.274434152127469e-08
CGA O 0 1.071773340299842e-06
- O 0 1.9211694279874791e-07
- O 0 2.841701700617705e-07
> O 0 1.1718869785681818e-07
TGA O 0 7.950159215397434e-07
) O 0 1.6608843189658273e-09
at O 0 6.623249504400519e-09
codon O 0 2.2824650613983977e-08
95 O 0 2.0977541481670414e-08
in O 0 1.746531252955208e-09
exon O 0 7.897503095932734e-09
4 O 0 4.570961920080663e-08
in O 0 4.8545998332372164e-09
the O 0 7.150509873099509e-08
four O 0 2.4767473405518103e-07
C9 B-Disease 1 0.9999595880508423
- I-Disease 0 0.00015819875989109278
deficient I-Disease 0 5.916306690778583e-06
individuals O 0 9.297907155314533e-08
. O 0 9.698663916424266e-07

An O 0 1.4878119714012428e-07
allele O 0 1.274183887289837e-07
- O 0 5.0887148717038144e-08
specific O 0 7.3760393348720754e-09
polymerase O 0 4.1364327074688845e-08
chain O 0 3.747548404930967e-08
reaction O 0 1.9411048768347428e-08
system O 0 2.446303604131117e-09
designed O 0 1.938343929808184e-09
to O 0 4.51358672659552e-10
detect O 0 5.47701795028388e-09
exclusively O 0 4.582823009968706e-09
only O 0 3.0364058489773527e-10
one O 0 3.416671667810789e-10
of O 0 1.4173411333473496e-09
the O 0 1.5330695601889488e-09
normal O 0 2.736184168128375e-09
and O 0 4.909714301781776e-10
mutant O 0 4.6675632248138754e-09
alleles O 0 1.0702755348646065e-09
indicated O 0 1.5071929260201955e-09
that O 0 1.4297078798630736e-10
all O 0 3.225598121936457e-10
the O 0 2.2387611764429494e-09
four O 0 1.2855462250271898e-09
patients O 0 6.437027577632648e-10
were O 0 2.65874700033919e-09
homozygous O 0 4.3155226059354845e-09
for O 0 1.9719803567852523e-09
the O 0 9.651633270379989e-09
mutation O 0 5.302466021817054e-09
in O 0 1.7378384287169979e-09
exon O 0 2.8796931061947362e-08
4 O 0 7.840233706701838e-08
and O 0 1.8492631870259402e-09
that O 0 3.7560887733434356e-10
the O 0 4.532318076400088e-09
parents O 0 6.680800357372618e-09
of O 0 1.779305414117971e-08
patient O 0 3.043082230647087e-08
2 O 0 7.229279503917496e-07
were O 0 2.0683937407284247e-07
heterozygous O 0 6.442609787882247e-07
. O 0 1.0079169214805006e-06

The O 0 4.722198241324804e-07
common O 0 8.417408992045239e-08
mutation O 0 5.2998906596712914e-08
at O 0 2.626930850624376e-08
codon O 0 1.4222032973520982e-07
95 O 0 1.1234428853867939e-07
in O 0 5.329792607255968e-09
exon O 0 6.247143602422511e-08
4 O 0 8.523618788558451e-08
might O 0 8.35301605661698e-09
be O 0 2.804288801172561e-09
responsible O 0 4.658420316161482e-09
for O 0 1.8829799941499914e-09
most O 0 3.00256814966815e-08
Japanese O 0 3.3454202821303625e-06
C9 B-Disease 1 0.9999998807907104
deficiency I-Disease 0 0.0016155067132785916
. O 0 2.946502490885905e-07
. O 0 9.289448144045309e-07

BRCA1 O 0 2.1000435026508057e-06
required O 0 1.0723811527668659e-07
for O 0 4.353828941816573e-08
transcription O 0 1.4356508472701535e-05
- O 0 2.30100195039995e-05
coupled O 0 2.3378897822112776e-05
repair O 0 3.68516202797764e-06
of O 0 3.979365601480822e-07
oxidative O 0 2.4566284992033616e-05
DNA O 0 3.5618457332020625e-05
damage O 1 0.9999358654022217
. O 0 2.0840966499235947e-06

The O 0 1.0985311746480875e-05
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 1.214021949635935e-06
gene O 0 5.813179981828398e-08
BRCA1 O 0 1.330563605961288e-07
encodes O 0 2.3003053684078623e-08
a O 0 2.369073648367248e-08
zinc O 0 5.054534426562896e-07
finger O 0 8.791169392452503e-08
protein O 0 1.114262246915132e-07
of O 0 2.323256467207102e-07
unknown O 0 4.150439963268582e-06
function O 0 1.3611769134058704e-07
. O 0 2.644718790634215e-07

Association O 0 1.8073792489303742e-06
of O 0 3.510215492497082e-06
the O 0 8.181625616998645e-07
BRCA1 O 0 1.5119336183033738e-07
protein O 0 3.662147207705857e-08
with O 0 6.08551098402188e-10
the O 0 4.519972840455466e-09
DNA O 0 4.8392930551699465e-08
repair O 0 3.3222855222447834e-07
protein O 0 5.909208198318083e-07
Rad51 O 0 7.188251061052142e-07
and O 0 2.8913702543320596e-09
changes O 0 2.0867947370106776e-09
in O 0 3.2564570484616695e-10
the O 0 1.808296956617994e-09
phosphorylation O 0 1.8477093632895958e-08
and O 0 1.5348835535888838e-09
cellular O 0 2.7256950474452424e-08
localization O 0 1.2152150929978234e-06
of O 0 1.4600763620364887e-07
the O 0 2.468620685647238e-08
protein O 0 8.150873753720589e-08
after O 0 1.1935283872333002e-08
exposure O 0 9.334721440268368e-09
to O 0 1.039556996040858e-09
DNA O 0 5.529830460204721e-08
- O 0 1.1317229819951535e-07
damaging O 0 4.838439053855836e-07
agents O 0 9.627584951488188e-09
are O 0 1.0064553634947515e-09
consistent O 0 1.3129212383944378e-08
with O 0 3.9305403376488357e-10
a O 0 4.20108969834132e-09
role O 0 6.319080814165545e-09
for O 0 2.0947394929748953e-08
BRCA1 O 0 6.977184625611699e-07
in O 0 2.2390100440361493e-08
DNA O 0 4.008582891401602e-06
repair O 0 0.0001327626232523471
. O 0 7.847324013710022e-06

Here O 0 6.71952420816524e-07
, O 0 1.126250914751381e-08
it O 0 4.780901785572667e-10
is O 0 2.1459592436379182e-10
shown O 0 2.0620333218701603e-10
that O 0 2.4076365900960184e-10
mouse O 0 4.0927812250401985e-09
embryonic O 0 2.9653577371391293e-08
stem O 0 4.1205581169379e-08
cells O 0 9.233204423253483e-09
deficient B-Disease 0 1.7648225991706568e-08
in I-Disease 0 1.192360543633697e-09
BRCA1 I-Disease 0 1.1584456949265132e-08
are O 0 3.250549551747639e-10
defective O 0 2.476940430540253e-08
in O 0 1.235833213542037e-09
the O 0 6.117051309928456e-09
ability O 0 1.295833884640274e-09
to O 0 2.4008326438007543e-09
carry O 0 1.183440989649398e-08
out O 0 1.4152536920164493e-08
transcription O 0 8.324896612066368e-07
- O 0 2.363938165217405e-06
coupled O 0 1.0418549209134653e-05
repair O 0 3.283615569671383e-06
of O 0 2.677844292975351e-07
oxidative O 0 1.2422310646797996e-06
DNA O 0 2.1816786102135666e-06
damage O 1 0.9735575318336487
, O 0 2.830103973394671e-08
and O 0 1.1230353536006987e-08
are O 0 3.8786498457454854e-09
hypersensitive O 0 3.2635855404805625e-06
to O 0 1.2325340037477872e-07
ionizing O 0 0.0002449919411446899
radiation O 0 9.176442108582705e-05
and O 0 7.194355333695057e-08
hydrogen O 0 5.871212351848953e-07
peroxide O 0 1.1408267710066866e-05
. O 0 1.4821883951299242e-06

These O 0 2.198356696681003e-07
results O 0 4.828063424611173e-07
suggest O 0 2.3171583052317146e-07
that O 0 4.336491343792659e-08
BRCA1 O 0 2.3103311264094373e-07
participates O 0 2.1642408754019016e-08
, O 0 2.8078857017277414e-09
directly O 0 7.969910953420367e-09
or O 0 2.7459974294430367e-09
indirectly O 0 3.455559038911815e-08
, O 0 1.013828798690497e-09
in O 0 5.805451119833549e-10
transcription O 0 9.428522389498539e-07
- O 0 1.8934540548798395e-06
coupled O 0 7.228367394418456e-06
repair O 0 3.7264258025970776e-06
of O 0 2.3072331600815232e-07
oxidative O 0 2.96900225293939e-06
DNA O 0 6.28391899226699e-06
damage O 1 0.7890920639038086
. O 0 1.2761587697696086e-07
. O 0 2.624482817736862e-07

Truncation O 0 2.6940408133668825e-05
mutations O 0 6.346199370454997e-07
in O 0 1.8190251083183284e-08
the O 0 3.6303092088019184e-08
transactivation O 0 4.9992922868113965e-06
region O 0 1.3877325955036213e-07
of O 0 1.5044427925658965e-07
PAX6 O 0 0.0001319163857260719
result O 0 2.08770799758895e-07
in O 0 2.1715306885994323e-08
dominant O 0 4.74388143629767e-05
- O 0 2.613184051369899e-06
negative O 0 2.3095029177966353e-07
mutants O 0 3.5485075500218954e-07
. O 0 2.559838776505785e-07

PAX6 O 0 0.0022019215393811464
is O 0 2.1875653999359201e-07
a O 0 6.159670107308557e-08
transcription O 0 5.142898658050399e-07
factor O 0 2.477578959769744e-07
with O 0 4.740686954107787e-09
two O 0 4.341495607462775e-09
DNA O 0 7.933120116376813e-08
- O 0 1.5023638866296096e-07
binding O 0 2.3404957971706608e-07
domains O 0 9.268670737583307e-07
( O 0 4.336135361882043e-08
paired O 0 8.067384271726041e-08
box O 0 9.035316139716087e-08
and O 0 4.9632249421449615e-09
homeobox O 0 4.362112520084338e-07
) O 0 2.7070314878585577e-09
and O 0 7.882935193492813e-09
a O 0 5.065850672281158e-08
proline O 0 4.4785434738514596e-07
- O 0 1.114981273531157e-06
serine O 0 5.928546897848719e-07
- O 0 2.7869079985975986e-06
threonine O 0 8.173944365807984e-07
( O 0 7.407976454487653e-08
PST O 0 4.238247129251249e-05
) O 0 2.7756243525800528e-08
- O 0 1.4276552917635854e-07
rich O 0 2.1143708295312535e-07
transactivation O 0 7.977707355166785e-06
domain O 0 1.037986294250004e-06
. O 0 1.0649042678778642e-06

PAX6 O 1 0.9994439482688904
regulates O 0 0.0001818838354665786
eye O 0 0.016220036894083023
development O 0 2.8645087013501325e-07
in O 0 2.8788620376474228e-09
animals O 0 2.5516302404327007e-09
ranging O 0 2.3820639682980982e-08
from O 0 3.919477631342261e-09
jellyfish O 0 1.8979908755767383e-09
to O 0 1.6278218772924902e-09
Drosophila O 0 1.0617607237861648e-08
to O 0 3.2232996272085757e-09
humans O 0 1.0932108551742203e-07
. O 0 6.181562071105873e-07

Heterozygous O 0 3.0885732371643826e-07
mutations O 0 1.1059621840558975e-07
in O 0 3.033258311191389e-09
the O 0 5.881207520985754e-09
human O 0 2.454694580933392e-08
PAX6 O 0 1.8720442312769592e-05
gene O 0 1.2893309531136765e-08
result O 0 2.371410978696531e-08
in O 0 5.918564527362946e-10
various O 0 7.725600603691873e-09
phenotypes O 0 1.7367466398354736e-07
, O 0 1.1655839626811826e-09
including O 0 1.9678247920040803e-09
aniridia B-Disease 1 1.0
, O 0 2.657172046838241e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.969360472590779e-08
autosomal B-Disease 0 2.4294133709190646e-06
dominant I-Disease 0 0.0022130273282527924
keratitis I-Disease 1 1.0
, O 0 2.2410870315070497e-07
and O 0 9.003754257719265e-07
familial B-Disease 1 0.9999997615814209
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.09950810670852661

It O 0 4.417552901259114e-08
is O 0 3.456954722480532e-09
believed O 0 8.967496079037574e-09
that O 0 1.961573126152416e-10
the O 0 1.0491021384950727e-09
mutated O 0 3.110989510446416e-08
allele O 0 8.987053945475054e-08
of O 0 8.802192041912349e-08
PAX6 O 0 4.8690573748899624e-05
produces O 0 4.875136383475365e-08
an O 0 7.158476922342061e-09
inactive O 0 1.4360691302783835e-08
protein O 0 5.093297872349467e-08
and O 0 1.0173139664004793e-08
aniridia B-Disease 1 1.0
is O 0 7.454108441606877e-09
caused O 0 1.5618954307683452e-07
due O 0 4.0425398140087054e-08
to O 0 2.115949726544386e-08
genetic O 0 1.3659817341249436e-05
haploinsufficiency O 0 0.0002578249550424516
. O 0 1.966476929737837e-06

However O 0 6.133644205874589e-07
, O 0 1.9617171886920914e-08
several O 0 1.1367502494863402e-08
truncation O 0 6.672200356661051e-07
mutations O 0 5.902550626046832e-08
have O 0 1.6636426680705085e-09
been O 0 1.0751737278269502e-09
found O 0 3.190512853912253e-10
to O 0 1.78154158092525e-10
occur O 0 4.311168366744056e-10
in O 0 4.845929213459499e-10
the O 0 6.9498491406250196e-09
C O 0 5.039152028984972e-07
- O 0 3.650500701724013e-08
terminal O 0 1.8864324147216394e-07
half O 0 7.755661002306624e-09
of O 0 1.527816095858725e-08
PAX6 O 0 2.3431002773577347e-06
in O 0 2.049166614170872e-09
patients O 0 1.1190961490825657e-09
with O 0 2.2850688008446696e-09
Aniridia B-Disease 1 1.0
resulting O 0 2.9887016239626973e-07
in O 0 1.2014075290167625e-09
mutant O 0 1.365815904819101e-08
proteins O 0 2.8827196185687853e-09
that O 0 7.498309750886278e-10
retain O 0 9.769521192026787e-09
the O 0 2.3876635779629396e-08
DNA O 0 5.944750824937728e-08
- O 0 4.2603204519764404e-08
binding O 0 2.8932751305887905e-08
domains O 0 2.6998758784202437e-08
but O 0 7.798172774187151e-09
have O 0 4.1328664934781045e-09
lost O 0 1.55018113900951e-07
most O 0 9.874411510679693e-09
of O 0 3.407512139119717e-08
the O 0 1.239524181073648e-07
transactivation O 0 2.1879124687984586e-05
domain O 0 3.798618536166032e-06
. O 0 2.331892119400436e-06

It O 0 5.3331309146642525e-08
is O 0 2.5769162359523534e-09
not O 0 3.147897775779285e-10
clear O 0 5.264404023819225e-09
whether O 0 1.5924808138834123e-09
such O 0 2.1910755432230644e-09
mutants O 0 9.031111858348595e-08
really O 0 1.5343516679422464e-08
behave O 0 9.267644429655775e-09
as O 0 1.677350525142174e-08
loss O 0 7.692740666698228e-08
- O 0 9.781476251191634e-08
of O 0 1.100608301385364e-06
- O 0 2.3546449767763988e-07
function O 0 1.6262337254602244e-08
mutants O 0 6.58876544434861e-08
as O 0 9.015034940773603e-09
predicted O 0 8.264384376843736e-08
by O 0 5.2358675617369954e-08
haploinsufficiency O 0 7.095495675457641e-05
. O 0 2.4947858037194237e-06

Contrary O 0 1.0164916375288158e-06
to O 0 7.784218603035242e-09
this O 0 1.264023330449504e-09
theory O 0 1.2855301179115486e-07
, O 0 1.345687117293437e-09
our O 0 1.916923952904881e-09
data O 0 1.723483578075502e-08
showed O 0 8.178465016328573e-09
that O 0 1.6600187890958296e-10
these O 0 6.689748754951097e-10
mutants O 0 2.046870761773789e-08
are O 0 1.3464727111056618e-09
dominant O 0 8.925863426156866e-08
- O 0 7.64428307320486e-08
negative O 0 1.5306103051671016e-08
in O 0 1.4542189674671135e-09
transient O 0 1.1592993587328237e-07
transfection O 0 2.514852681656521e-08
assays O 0 6.008011421698711e-09
when O 0 8.601107381878137e-09
they O 0 3.987584040743286e-09
are O 0 5.447658324442273e-09
coexpressed O 0 4.8852448344405275e-06
with O 0 1.5213373671940644e-08
wild O 0 8.855859050527215e-07
- O 0 2.470967729095719e-06
type O 0 1.265114769921638e-05
PAX6 O 0 0.024003544822335243
. O 0 7.36106994736474e-06

We O 0 1.2586116326929186e-07
found O 0 1.2096398549488185e-08
that O 0 2.5317103968802712e-09
the O 0 1.2019490291947932e-08
dominant O 0 2.5649825374784996e-07
- O 0 4.62059261963077e-08
negative O 0 6.89200385650679e-09
effects O 0 6.257265372511256e-09
result O 0 1.1493378471172377e-09
from O 0 1.1483255457633845e-09
the O 0 9.50380663056194e-10
enhanced O 0 2.0217885143836156e-09
DNA O 0 5.389462209848261e-09
binding O 0 7.232987542238334e-09
ability O 0 1.5939736641712443e-08
of O 0 9.67301616583427e-08
these O 0 4.0806231282886074e-08
mutants O 0 1.6510532532265643e-06
. O 0 1.1983182730546105e-06

Kinetic O 0 4.865299160883296e-06
studies O 0 1.0849537801504994e-07
of O 0 2.5135628689554324e-08
binding O 0 5.906830580215683e-08
and O 0 2.1249080717211655e-08
dissociation O 0 1.2168554519575991e-07
revealed O 0 1.0028457175792482e-08
that O 0 3.6577665896153633e-10
various O 0 3.307930152018912e-09
truncation O 0 2.917011272529635e-07
mutants O 0 3.282915272961873e-08
have O 0 4.31135971368235e-09
3 O 0 3.7036617328567445e-08
- O 0 1.4663886993560027e-08
5 O 0 5.236736910774198e-08
- O 0 3.350654509404194e-08
fold O 0 8.472287049698934e-08
higher O 0 1.8501321363828538e-08
affinity O 0 1.5582816148551615e-09
to O 0 4.222577010271067e-10
various O 0 2.148491384801332e-09
DNA O 0 8.31975199844237e-09
- O 0 2.6783579798461687e-09
binding O 0 1.6475254493997227e-09
sites O 0 5.426099125571682e-09
when O 0 1.2582336283983864e-09
compared O 0 1.1793437337814794e-09
with O 0 9.923604993300472e-11
the O 0 3.8787235645543205e-09
wild O 0 6.90309747142237e-08
- O 0 4.6427356892309035e-07
type O 0 2.2900585463503376e-06
PAX6 O 0 0.0007397233857773244
. O 0 5.079540187580278e-06

These O 0 1.220190739559257e-07
results O 0 4.103076989281362e-08
provide O 0 1.202373223208042e-08
a O 0 3.448347607459823e-09
new O 0 3.881935661809166e-09
insight O 0 1.0973718822526735e-08
into O 0 1.954358896938402e-09
the O 0 2.6987929668820243e-09
role O 0 8.649028160334638e-09
of O 0 4.399768016583039e-08
mutant O 0 2.007879857046646e-06
PAX6 O 0 0.00040900640306062996
in O 0 1.2065905252711673e-07
causing O 0 3.793708674493246e-05
aniridia B-Disease 1 1.0
. O 0 4.5021772621112177e-07
. O 0 1.1324814295221586e-06

Reversal O 0 1.9261633497080766e-05
of O 0 2.059439339063829e-06
severe O 1 0.9999973773956299
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 4.856166924582794e-06
excellent O 0 2.038309276031214e-06
neuropsychologic O 0 1.7660115190665238e-05
outcome O 0 1.6586838000876014e-06
in O 0 2.8225784376445517e-08
very B-Disease 0 8.452691702132142e-08
- I-Disease 0 3.9936796270012564e-07
long I-Disease 0 1.2318194819727069e-07
- I-Disease 0 1.9616878432771045e-07
chain I-Disease 0 1.6680003511737596e-07
acyl I-Disease 0 1.2361589369902504e-06
- I-Disease 0 7.483042736566858e-07
coenzyme I-Disease 0 6.970001891204447e-07
A I-Disease 0 9.596084055374376e-06
dehydrogenase I-Disease 0 0.000152238440932706
deficiency I-Disease 0 0.2701836824417114
. O 0 1.9660831185319694e-06

Very B-Disease 0 4.092747076356318e-06
- I-Disease 0 6.243234565772582e-06
long I-Disease 0 5.359204919841432e-07
- I-Disease 0 2.605002578093263e-07
chain I-Disease 0 1.3501951912076038e-07
acyl I-Disease 0 3.055861270695459e-07
- I-Disease 0 7.147946234908886e-08
coenzyme I-Disease 0 2.1154413332169497e-08
A I-Disease 0 9.018270930027938e-08
dehydrogenase I-Disease 0 1.6543316405659425e-07
( I-Disease 0 1.52425911892351e-08
VLCAD I-Disease 0 0.0005234531126916409
) I-Disease 0 2.5388335878062662e-09
deficiency I-Disease 0 1.1855107828750988e-07
is O 0 5.83610437754345e-10
a O 0 1.71339709087448e-09
disorder O 0 3.8265876355580986e-05
of O 0 5.497541224031011e-06
fatty O 0 2.0039071557675925e-07
acid O 0 3.420044247803844e-09
beta O 0 1.2889885825373426e-09
oxidation O 0 1.786278791549023e-09
that O 0 3.924817137956893e-10
reportedly O 0 4.5814685378786635e-09
has O 0 1.2873981047878402e-10
high O 0 2.2473347627283147e-09
rates O 0 2.3924535685893034e-09
of O 0 5.4717239628132575e-09
morbidity O 0 2.4337439754162915e-05
and O 0 1.359275216827882e-07
mortality O 0 2.142712037311867e-05
. O 0 5.594991989710252e-07

We O 0 6.780020100904949e-08
describe O 0 2.2486480233396833e-08
the O 0 1.489543510757585e-08
outcome O 0 1.6737126884436293e-07
of O 0 6.388133755308445e-08
a O 0 9.496128328123632e-09
5 O 0 2.3753717215413417e-08
- O 0 1.2407748606335645e-08
year O 0 9.098104492011316e-09
- O 0 7.916840871757813e-08
old O 0 1.5429939139721682e-06
girl O 0 1.9650244098556868e-07
with O 0 4.212573756490201e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.0361428571268334e-07
was O 0 1.3753787442283283e-08
first O 0 1.4680642257403065e-09
seen O 0 7.165416260335178e-09
at O 0 2.676509458510168e-09
5 O 0 4.5298289563788785e-09
months O 0 1.2624645773229304e-09
of O 0 2.7147148973227786e-09
age O 0 1.7960504195002613e-08
with O 0 4.047614687863188e-09
severe O 1 0.9999477863311768
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.6830005645751953
hepatomegaly B-Disease 1 1.0
, O 0 1.1047915904782712e-05
encephalopathy B-Disease 0 0.044757016003131866
, O 0 4.13232157825405e-07
and O 0 1.6131311895151157e-06
hypotonia B-Disease 1 0.9999574422836304
. O 0 3.0103437893558294e-05

Biochemical O 0 3.9152302633738145e-05
studies O 0 1.7478705558460206e-06
indicated O 0 0.00014324142830446362
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.048037302098237e-05
by O 0 2.6742232872578597e-09
a O 0 9.772931797158435e-09
stable O 0 4.060120204485429e-07
yet O 0 3.017661853732534e-08
inactive O 0 1.889013958589203e-07
enzyme O 0 5.678755314875161e-07
. O 0 5.13059774220892e-07

Molecular O 0 5.417869033408351e-07
genetic O 0 1.20102825462709e-07
analysis O 0 9.808977807779229e-08
of O 0 3.7085754911458935e-07
her O 0 1.2256067805083148e-07
VLCAD O 1 0.9999842643737793
gene O 0 1.6459172513805242e-07
revealed O 0 2.802761969178391e-07
a O 0 3.378480428750663e-08
T1372C O 0 1.3083088106213836e-06
( O 0 1.3385508701446724e-08
F458L O 0 7.269890716088412e-07
) O 0 5.7784657059301026e-09
missense O 0 4.129067576741363e-07
mutation O 0 6.77609008903346e-08
and O 0 4.352060400947266e-08
a O 0 3.7473631664397544e-07
1668 O 0 0.00033238905598409474
ACAG O 1 0.9993106126785278
1669 O 0 0.000310419563902542
splice O 0 0.00014846795238554478
site O 0 1.8265389371663332e-05
mutation O 0 9.573763236403465e-06
. O 0 5.038637027610093e-06

After O 0 2.3068460563990811e-07
initial O 0 1.900568094015398e-07
treatment O 0 2.4516625174442197e-08
with O 0 3.964847561377383e-09
intravenous O 0 8.59899529359609e-08
glucose O 0 4.074099138051679e-07
and O 0 1.4604349729552268e-08
carnitine O 0 9.139012604464369e-07
, O 0 2.0395625188740496e-09
the O 0 5.074483944156327e-09
patient O 0 1.4330784559035692e-08
has O 0 1.9897148373360096e-09
thrived O 0 3.886086119564425e-08
on O 0 1.6960612470029446e-08
a O 0 2.4992544922497473e-08
low O 0 6.892952910675376e-07
- O 0 1.8779350341446843e-07
fat O 0 4.444801504632778e-07
diet O 0 5.212869425008648e-08
supplemented O 0 3.221611066805963e-08
with O 0 1.8958852265882342e-09
medium O 0 3.1190702998173947e-07
- O 0 2.365006395166347e-07
chain O 0 2.4302653400809504e-07
triglyceride O 0 3.126365527350572e-06
oil O 0 1.6394470776504022e-06
and O 0 1.9062383671553107e-08
carnitine O 0 5.308136223902693e-07
and O 0 1.0970998332027193e-08
avoidance O 0 3.7824779042239243e-07
of O 0 3.678999007661332e-07
fasting O 0 1.390741658724437e-06
. O 0 1.7724348708725302e-06

Her O 0 4.305053153075278e-06
ventricular O 1 0.9988312125205994
hypertrophy O 1 0.9752546548843384
resolved O 0 1.1778269026763155e-06
significantly O 0 2.864360304499769e-08
over O 0 2.0312895809837528e-09
1 O 0 5.573591810303924e-09
year O 0 3.606522580579252e-10
, O 0 2.9649591115621377e-10
and O 0 7.896564513387716e-10
cognitively O 0 3.038622367057542e-07
, O 0 6.521883921806193e-09
she O 0 1.6546678471840437e-09
is O 0 3.490364941516333e-10
in O 0 4.415720289419056e-10
the O 0 7.1271828439023466e-09
superior O 0 6.943583912288886e-07
range O 0 3.087151014824485e-07
for O 0 1.3509906970909924e-08
age O 0 2.436852355458541e-06
. O 0 1.4200039686329546e-06

Clinical O 0 5.997126208967529e-07
recognition O 0 3.634844915723079e-06
of O 1 0.9999945163726807
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.2516006836781344e-08
important O 0 1.1250527620632056e-08
because O 0 9.41302813473044e-10
it O 0 1.8176046778783927e-10
is O 0 6.830268295399122e-11
one O 0 3.4359112777160306e-10
of O 0 3.8432137472455e-09
the O 0 5.63112267926158e-09
few O 0 1.2619259415203032e-08
directly O 0 4.7745917441943675e-08
treatable O 0 0.0003105856594629586
causes O 0 1.4310549545371032e-07
of O 0 5.688588444741072e-08
cardiomyopathy B-Disease 1 1.0
in O 0 3.2586910947429715e-08
children O 0 5.476988818031714e-08
. O 0 2.3041520691435835e-08
. O 0 2.378004069214512e-07

Cloning O 0 6.50083563868975e-07
of O 0 3.948933056108217e-07
a O 0 2.7387649481624976e-08
novel O 0 2.556590672497805e-08
member O 0 9.991455662827775e-09
of O 0 2.9309221716289358e-08
the O 0 1.5113829476831597e-07
low O 0 1.0116139037563698e-06
- O 0 2.1085394052988704e-07
density O 0 1.2887831246644055e-07
lipoprotein O 0 6.607443992834305e-06
receptor O 1 0.5085506439208984
family O 0 1.4722573723702226e-05
. O 0 1.4605208207285614e-06

A O 0 1.93942855730711e-06
gene O 0 3.9742072743820245e-08
encoding O 0 2.0345636642105092e-07
a O 0 1.300460326092434e-07
novel O 0 1.9182968458153482e-07
transmembrane O 0 2.3703353235760005e-07
protein O 0 1.0978705233810615e-07
was O 0 2.567522372487474e-08
identified O 0 1.4030079320548339e-09
by O 0 2.35825109440313e-10
DNA O 0 1.5558937471737977e-09
sequence O 0 5.57016655022835e-10
analysis O 0 5.115490808726975e-10
within O 0 3.622682986925696e-10
the O 0 3.1501816710743924e-09
insulin B-Disease 0 9.335718459624331e-06
- I-Disease 0 3.0416307708946988e-05
dependent I-Disease 1 0.9985312223434448
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.3913077623328718e-07
IDDM B-Disease 1 0.9441708922386169
) O 0 4.238564166314518e-09
locus O 0 7.381024857977536e-08
IDDM4 O 0 2.1127569198142737e-05
on O 0 1.6595383556250454e-07
chromosome O 0 8.240583611041075e-07
11q13 O 0 2.0367804609122686e-05
. O 0 1.2972413969691843e-06

Based O 0 5.994987759549986e-07
on O 0 1.2869482191035786e-07
its O 0 1.0980733655685526e-08
chromosomal O 0 9.450018865209131e-07
position O 0 7.443554750352632e-07
, O 0 3.3605991323071294e-09
this O 0 6.145958186820621e-10
gene O 0 1.9729509137533796e-09
is O 0 1.9237584858444734e-09
a O 0 1.565281793070028e-09
candidate O 0 7.877133612055331e-09
for O 0 1.3765379947017209e-09
conferring O 0 2.1437936936763435e-07
susceptibility O 0 4.181692020210903e-06
to O 0 2.4491112071700627e-07
diabetes B-Disease 1 0.9999977350234985
. O 0 1.9630556380434427e-06

The O 0 1.5543365634584916e-06
gene O 0 3.540516217981349e-07
, O 0 1.390697548231401e-07
termed O 0 7.485134005946747e-07
low O 0 9.235371862814645e-07
- O 0 9.788345067818227e-08
density O 0 2.6294474153587544e-08
lipoprotein O 0 3.4092482792402734e-07
receptor O 0 5.594399681285722e-07
related O 0 8.366636450318765e-08
protein O 0 2.781409307317517e-07
5 O 0 8.074356827592055e-08
( O 0 3.571748674602304e-09
LRP5 O 0 4.2261935959686525e-06
) O 0 5.606192732265924e-10
, O 0 3.9813805030597393e-10
encodes O 0 8.800387640839347e-10
a O 0 1.2645635649732867e-09
protein O 0 2.600529214191738e-08
of O 0 8.633127634993798e-08
1615 O 0 1.449754790883162e-06
amino O 0 7.818073299858952e-08
acids O 0 2.252966879723317e-08
that O 0 2.808864529857402e-10
contains O 0 7.837475113348091e-10
conserved O 0 2.368123475093853e-09
modules O 0 8.998847222940753e-10
which O 0 2.0488684360220333e-10
are O 0 1.4820913940560843e-10
characteristic O 0 1.558995776917982e-08
of O 0 2.176261659769807e-08
the O 0 1.1300534907832116e-07
low O 0 3.961643869843101e-06
- O 0 8.996570386443636e-07
density O 0 4.2715737436083145e-07
lipoprotein O 0 1.2757862350554205e-05
( O 0 1.884139464891632e-06
LDL O 1 0.9506040215492249
) O 0 7.072085139725459e-08
receptor O 0 9.256904013454914e-05
family O 0 1.19837318379723e-06
. O 0 4.792419758814503e-07

These O 0 9.644147525023072e-08
modules O 0 1.138847096626705e-07
include O 0 1.673011418290571e-08
a O 0 1.7515860761818658e-08
putative O 0 3.231448886253929e-07
signal O 0 9.351690266612422e-08
peptide O 0 1.0493187652116376e-08
for O 0 1.2337747490320794e-09
protein O 0 3.475116727713612e-08
export O 0 9.519489196918585e-08
, O 0 2.754206418487115e-09
four O 0 3.166615636374104e-09
epidermal O 0 3.0979276743892115e-07
growth O 0 2.8942134022713617e-08
factor O 0 4.5366444823002894e-08
( O 0 2.2097950136412692e-08
EGF O 0 7.890030246926472e-06
) O 0 2.9789275490799128e-09
repeats O 0 6.548733555433728e-09
with O 0 9.53009116066994e-10
associated O 0 7.521134648413863e-08
spacer O 0 6.064578883524518e-07
domains O 0 1.7873233559839719e-07
, O 0 1.9978310561441504e-08
three O 0 2.130077803030872e-08
LDL O 0 2.475751443853369e-06
- O 0 3.50186314790335e-06
receptor O 0 4.28278544859495e-05
( O 0 3.187721517861064e-07
LDLR O 1 0.999289870262146
) O 0 1.7483310355004278e-09
repeats O 0 8.492425429551531e-09
, O 0 5.227101529392542e-10
a O 0 2.4573165724461887e-09
single O 0 3.6927971791556047e-09
transmembrane O 0 3.8194219342813085e-08
spanning O 0 2.3284595584982526e-08
domain O 0 5.4704532459481925e-08
, O 0 1.5352064508533658e-08
and O 0 1.4788230195961205e-08
a O 0 6.221826964747379e-08
cytoplasmic O 0 7.582864782307297e-06
domain O 0 2.787918219837593e-06
. O 0 1.7977148445424973e-06

The O 0 4.941097131450078e-07
encoded O 0 1.2419427264376282e-07
protein O 0 4.808369453712658e-07
has O 0 5.167290151320003e-09
a O 0 1.6651918732790705e-09
unique O 0 2.9304232374016692e-09
organization O 0 1.1662072196827467e-08
of O 0 1.0860696875170106e-07
EGF O 1 0.6085300445556641
and O 0 6.302701081040141e-07
LDLR O 1 0.9998475313186646
repeats O 0 1.4011959592608036e-07
; O 0 5.89922777294305e-09
therefore O 0 2.0780811738063676e-08
, O 0 1.1122998522239413e-08
LRP5 O 1 0.9370765686035156
likely O 0 8.190629330329102e-08
represents O 0 1.801835480819136e-08
a O 0 4.040811241168285e-09
new O 0 2.4716251267875577e-09
category O 0 2.9225319053693966e-08
of O 0 2.436363288893517e-08
the O 0 1.4271216741690296e-07
LDLR O 1 0.9966552257537842
family O 0 2.0937982299074065e-06
. O 0 1.6803818425614736e-06

Both O 0 7.946596838337427e-07
human O 0 6.376544661179651e-07
and O 0 9.344522311494075e-08
mouse O 0 4.981997676622996e-07
LRP5 O 0 0.00035864373785443604
cDNAs O 0 1.3282261761560221e-06
have O 0 2.0906152364830177e-09
been O 0 1.833763030312241e-09
isolated O 0 1.4290631789037889e-08
and O 0 1.1768047647464641e-09
the O 0 4.613994075697292e-09
encoded O 0 4.1457592914184715e-09
mature O 0 6.051000145390617e-09
proteins O 0 1.2716722119776591e-09
are O 0 3.1372704434318166e-10
95 O 0 1.526080239955263e-08
% O 0 5.17024534296695e-10
identical O 0 1.567995178142212e-09
, O 0 2.958253642049158e-10
indicating O 0 4.379788087760517e-09
a O 0 1.1848134695569001e-09
high O 0 1.3606573645574827e-08
degree O 0 1.659979353973995e-08
of O 0 5.084792586984577e-09
evolutionary O 0 6.594637369516931e-08
conservation O 0 8.311111798775528e-08
. O 0 2.679355581847176e-08
. O 0 3.046032759357331e-07

The O 0 3.858018317259848e-06
APC B-Disease 0 2.9796874514431693e-06
variants O 0 2.3811152516373113e-07
I1307K O 0 3.8521729948115535e-06
and O 0 1.503389590595816e-08
E1317Q O 0 5.695400204785983e-07
are O 0 2.005327903731313e-09
associated O 0 1.551700279378565e-06
with O 1 0.9980282187461853
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.9629582100105836e-09
but O 0 3.7704803168558954e-10
not O 0 4.291454136495787e-10
always O 0 2.367288143290125e-09
with O 0 7.13049674860855e-10
a O 0 1.3444922508654145e-08
family O 0 2.4945062904180304e-08
history O 0 3.2389058901571843e-07
. O 0 6.269907544265152e-07

Classical O 1 0.998630166053772
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.9610383787949104e-06
FAP B-Disease 0 9.210987627739087e-06
) O 0 3.133880932537636e-09
is O 0 1.2299777862878614e-09
a O 0 1.6246897160954177e-08
high O 1 0.9605392217636108
- O 1 0.999998927116394
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
that O 0 8.031098008842719e-10
predisposes O 0 4.014096077753493e-08
to O 0 7.469405094440162e-10
hundreds O 0 4.018828381191497e-09
or O 0 6.417780751277746e-10
thousands O 0 1.4157127026237504e-08
of O 0 4.347249102920614e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 1.1979755072388798e-06
carcinoma I-Disease 1 1.0
and O 0 2.581594715778124e-09
that O 0 1.9500237535829967e-10
results O 0 2.869033677299626e-09
from O 0 1.365774249251217e-08
truncating O 0 1.0171378761469896e-07
mutations O 0 2.0027679070722115e-08
in O 0 3.545913562774672e-09
the O 0 4.9306656535463844e-08
APC B-Disease 0 8.096207579910697e-07
gene O 0 5.328026873030467e-07
. O 0 1.6267600813080207e-06

A O 0 1.086978954845108e-06
variant O 0 1.1570609785849229e-06
of O 0 2.5530488301228615e-07
FAP B-Disease 0 2.329599556105677e-05
is O 0 7.406210755789289e-08
attenuated B-Disease 1 0.9892910122871399
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9982361793518066
coli I-Disease 1 0.9999921321868896
, O 0 5.311161288545918e-09
which O 0 2.955495848055989e-10
results O 0 1.2461200959990038e-09
from O 0 3.105195878205791e-09
germ O 0 1.8878736227634363e-06
- O 0 3.53229097527219e-07
line O 0 2.3600316012561962e-07
mutations O 0 2.085366324067195e-09
in O 0 9.981127035985082e-10
the O 0 1.0592687615940122e-08
5 O 0 1.2112235658889858e-08
and O 0 4.2977776892882957e-10
3 O 0 5.888300957934689e-09
regions O 0 6.0676885738075725e-09
of O 0 6.329263868565249e-08
the O 0 2.9627216235894593e-07
APC B-Disease 0 1.3935401739217923e-06
gene O 0 2.473598499364016e-07
. O 0 1.5138712115003727e-06

Attenuated B-Disease 1 0.9999984502792358
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999203681945801
coli I-Disease 1 0.9999899864196777
patients O 0 7.858423600737297e-08
have O 0 6.63682775403629e-10
" O 0 2.2337280913831137e-09
multiple O 0 9.742412743207751e-08
" O 0 7.689403719268739e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.33825739168492e-09
typically O 0 6.001617536277593e-10
fewer O 0 1.1248484366177536e-09
than O 0 1.0453864163206816e-10
100 O 0 6.361645654706649e-10
) O 0 1.5219154061996143e-11
without O 0 2.516078456693549e-10
the O 0 3.626584144100775e-09
florid O 0 4.95345830131555e-07
phenotype O 0 1.3005595178583462e-07
of O 0 5.720043105839068e-08
classical O 0 1.9288427210994996e-06
FAP B-Disease 0 3.9477810787502676e-05
. O 0 1.4956207223804086e-06

Another O 0 3.9328921275227913e-07
group O 0 5.181880879945311e-08
of O 0 4.16672101266613e-08
patients O 0 6.003349817262915e-09
with O 0 1.1622273143885309e-09
multiple O 0 2.9712175546592334e-06
adenomas B-Disease 1 0.9999607801437378
has O 0 2.8625017911565465e-09
no O 0 8.215577107506533e-10
mutations O 0 2.3165687146331493e-09
in O 0 7.167859084056261e-10
the O 0 1.3293861123031547e-08
APC B-Disease 0 3.070432086360597e-08
gene O 0 2.63471222616829e-09
, O 0 2.246640429248714e-09
and O 0 9.608683848583155e-10
their O 0 1.3145845523254707e-09
phenotype O 0 4.783916907058483e-08
probably O 0 5.997752960951175e-09
results O 0 2.7484237108410525e-09
from O 0 6.638641192324712e-09
variation O 0 9.661472688549111e-08
at O 0 1.4360280076175513e-08
a O 0 6.86679779704491e-09
locus O 0 1.4112508495145448e-08
, O 0 2.232501516985508e-09
or O 0 2.8052946632328712e-09
loci O 0 1.850608377651497e-08
, O 0 2.20521712002153e-09
elsewhere O 0 3.0945020768058384e-08
in O 0 3.919911506500284e-09
the O 0 7.355011888421359e-08
genome O 0 3.3352122841279197e-07
. O 0 5.89140427109669e-07

Recently O 0 2.226992364739999e-06
, O 0 2.5548555271370788e-08
however O 0 1.5681694165436966e-08
, O 0 9.517049370799668e-10
a O 0 1.3023306877357754e-09
missense O 0 9.33976522787816e-08
variant O 0 1.4360655598011363e-07
of O 0 2.452975138567126e-07
APC B-Disease 0 9.059688750312489e-07
( O 0 1.1539645683456001e-08
I1307K O 0 6.122703553046449e-07
) O 0 1.2916414604546844e-09
was O 0 7.990001549273984e-09
described O 0 1.1044161141171571e-09
that O 0 1.4418835569962596e-10
confers O 0 1.8400564627540916e-08
an O 0 3.9598269108154227e-10
increased O 0 4.1588505972356415e-09
risk O 0 2.052908172345269e-07
of O 1 0.9328418970108032
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.0182140403335325e-08
including O 0 2.4177617685694486e-09
multiple O 0 1.1479588124529982e-07
adenomas B-Disease 0 2.696621413633693e-05
, O 0 2.4206148196981303e-08
in O 0 4.682867782435096e-08
Ashkenazim O 0 0.0004380031896289438
. O 0 3.994035978394095e-06

We O 0 2.9598098194583145e-07
have O 0 2.1180333931170026e-08
studied O 0 5.5056037950862446e-08
a O 0 1.903334601038864e-09
set O 0 4.636101280652838e-09
of O 0 6.088486159683271e-09
164 O 0 1.9658749295103917e-08
patients O 0 1.4400318715246385e-09
with O 0 1.560470641592815e-09
multiple O 1 0.995996356010437
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 5.660328952217242e-07
/ I-Disease 0 0.00015662098303437233
or I-Disease 0 4.284917395125376e-06
carcinoma I-Disease 1 1.0
and O 0 1.2565314122525706e-08
analyzed O 0 6.382519046610469e-08
codons O 0 3.7796726815031434e-07
1263 O 0 5.251162292552181e-06
- O 0 5.959247459941253e-07
1377 O 0 4.10057646149653e-06
( O 0 3.0945606965815387e-08
exon O 0 1.0159416063970639e-07
15G O 0 1.3197752650739858e-06
) O 0 1.324695353410732e-09
of O 0 1.228452095602961e-08
the O 0 2.3055058306908904e-08
APC B-Disease 0 4.055993940710323e-08
gene O 0 4.071804671212931e-09
for O 0 1.3786459973630372e-08
germ O 0 9.195626626024023e-05
- O 0 9.698593203211203e-06
line O 0 2.2123015241959365e-06
variants O 0 4.339138968134648e-07
. O 0 9.639575182518456e-07

Three O 0 2.542814172556973e-07
patients O 0 1.3107070095941253e-08
with O 0 9.189540239873395e-10
the O 0 7.484853625783217e-09
I1307K O 0 1.4668593451006018e-07
allele O 0 8.9433092043123e-09
were O 0 1.70312719482979e-09
detected O 0 7.588347172848842e-10
, O 0 1.0846398085240239e-10
each O 0 2.055953879365191e-10
of O 0 2.06507788647059e-08
Ashkenazi O 0 2.4923388082243036e-06
descent O 0 4.3185241338505875e-06
. O 0 1.0294431831425754e-06

Four O 0 1.0910418950516032e-06
patients O 0 9.319887794845272e-08
had O 0 3.3395401999314345e-08
a O 0 8.019790165292306e-09
germ O 0 3.1287574984162347e-06
- O 0 5.763981789641548e-07
line O 0 2.3590189357491909e-07
E1317Q O 0 2.260219957861409e-07
missense O 0 8.262209405529575e-08
variant O 0 2.2794806042725213e-08
of O 0 3.7980495193323804e-08
APC O 0 3.724602493093698e-08
that O 0 5.72564773371198e-10
was O 0 3.2279263706413985e-09
not O 0 1.8593987460846506e-10
present O 0 8.635375747800822e-10
in O 0 3.071155274536608e-10
controls O 0 6.159738497046874e-09
; O 0 5.794642543577311e-10
one O 0 1.4292451666619854e-09
of O 0 3.23153592773906e-09
these O 0 5.761909838142287e-10
individuals O 0 2.4868611614436986e-09
had O 0 5.0138844187586074e-08
an O 0 1.8762471576394546e-09
unusually O 0 6.866012203232685e-09
large O 0 2.7224098531064556e-09
number O 0 1.2688865957954931e-08
of O 0 2.1309195119556534e-07
metaplastic B-Disease 0 0.17559178173542023
polyps I-Disease 0 1.2198711374367122e-06
of I-Disease 0 2.9170445259296685e-07
the I-Disease 0 6.535310035360453e-07
colorectum I-Disease 0 0.00012342588161118329
. O 0 1.717421469038527e-06

There O 0 3.4396987302898197e-07
is O 0 3.27657034837614e-09
increasing O 0 6.7003504966578475e-09
evidence O 0 1.3699042789028226e-08
that O 0 6.852102218957157e-10
there O 0 1.528975501763341e-09
exist O 0 3.238051382581375e-09
germ O 0 4.746244997022586e-07
- O 0 3.054847041994435e-08
line O 0 1.3408556931437943e-08
variants O 0 5.445466300102453e-09
of O 0 1.974856900233135e-08
the O 0 2.8373680294180303e-08
APC B-Disease 0 7.315389893847168e-08
gene O 0 2.861862968828177e-09
that O 0 2.16373630124167e-09
predispose O 0 4.116034517664957e-07
to O 0 2.2140467237363737e-09
the O 0 4.536296227541925e-09
development O 0 1.3339785276400562e-08
of O 0 1.8146034008736933e-08
multiple O 1 0.9983295798301697
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.00015441548021044582
carcinoma I-Disease 1 1.0
, O 0 1.57639756803718e-09
but O 0 6.112615968945079e-10
without O 0 3.383882951624173e-09
the O 0 1.199322330336372e-08
florid O 0 4.470640249110147e-07
phenotype O 0 1.2221588008287654e-07
of O 0 2.5339099707366586e-08
classical O 0 4.111695091069123e-07
FAP B-Disease 0 2.6992631774191977e-06
, O 0 2.7039970262876523e-09
and O 0 6.153934029029529e-10
possibly O 0 2.1737631694662696e-09
with O 0 3.3816358047111805e-10
importance O 0 2.0400855760271952e-07
for O 0 1.4114027180767152e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 3.2845687059079864e-08
in O 0 5.888137893927947e-11
the O 0 3.4632691159330875e-10
general O 0 1.3563190570664574e-09
population O 0 4.649045037830035e-10
. O 0 2.4200870196722235e-09
. O 0 8.361324432826223e-08

Genomic O 0 1.140487597695028e-06
structure O 0 3.0235679560064455e-07
of O 0 9.190529226543731e-08
the O 0 2.1331480581920914e-07
human O 1 0.9999983310699463
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.918202817440033
CLD B-Disease 1 1.0
) O 0 2.184467433608006e-07
gene O 0 2.0914712877129205e-06
. O 0 3.66472977475496e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999794960021973
CLD B-Disease 1 1.0
) O 0 1.9667824702196413e-08
is O 0 1.2073249067157121e-09
caused O 0 7.274618685215728e-09
by O 0 1.83779921836269e-10
mutations O 0 5.030923677651344e-09
in O 0 3.570806705877061e-10
a O 0 5.718335249760287e-10
gene O 0 7.277681790540669e-10
which O 0 4.874815551225709e-10
encodes O 0 1.0723317345195937e-08
an O 0 1.029070251234998e-08
intestinal O 0 5.31551677340758e-07
anion O 0 3.921464667655528e-06
transporter O 0 1.6375894119846635e-05
. O 0 1.0604451290419092e-06

We O 0 2.8360003057059657e-07
report O 0 6.390546758439086e-08
here O 0 8.57242987706286e-09
the O 0 3.393746617064153e-09
complete O 0 2.1280586182115258e-09
genomic O 0 3.48355833068581e-08
organization O 0 1.1200746996564703e-08
of O 0 1.858060549864149e-08
the O 0 3.12372527844218e-08
human O 0 4.47516185886343e-07
CLD B-Disease 1 0.9999922513961792
gene O 0 4.5219064048751534e-08
which O 0 9.428450020720902e-09
spans O 0 6.56922836128615e-08
approximately O 0 6.442386624172514e-09
39kb O 0 1.652251967243501e-06
, O 0 1.1197393234851916e-08
and O 0 1.0285109652841129e-08
comprises O 0 4.322700064562923e-08
21 O 0 8.340281851815234e-07
exons O 0 2.973252776428126e-06
. O 0 1.9920680642826483e-06

All O 0 2.5523725071252557e-06
exon O 0 7.124967851268593e-06
/ O 0 7.75934040575521e-06
intron O 0 3.37331789523887e-06
boundaries O 0 9.440257286996712e-08
conform O 0 9.093094632817156e-08
to O 0 2.2624318418706935e-08
the O 0 1.8114016597792215e-07
GT O 0 7.782315151416697e-06
/ O 0 4.057281785208033e-06
AG O 0 0.00012802590208593756
rule O 0 3.239238367314101e-06
. O 0 3.0876653909217566e-06

An O 0 3.249821389772478e-08
analysis O 0 2.2430707957710183e-08
of O 0 3.337044418572077e-08
the O 0 2.5832068928366425e-08
putative O 0 2.136492184945382e-06
promoter O 0 2.893352530008997e-06
region O 0 1.3867006032342033e-07
sequence O 0 2.3661788972617614e-08
shows O 0 4.8844160716043916e-08
a O 0 4.593983859990658e-08
putative O 0 7.994736733962782e-06
TATA O 0 1.8726977941696532e-05
box O 0 1.4412822793019586e-06
and O 0 6.240664873757851e-08
predicts O 0 2.130362872776459e-07
multiple O 0 2.61946091484333e-08
transcription O 0 1.7583851104063797e-06
factor O 0 6.252400339690212e-07
binding O 0 7.15398073225515e-07
sites O 0 5.574488568527158e-06
. O 0 2.6095083285326837e-06

The O 0 9.545177590553067e-07
genomic O 0 5.589637339653564e-07
structure O 0 2.2316005754419166e-07
was O 0 3.715839369533569e-08
determined O 0 2.1417569939785608e-09
using O 0 4.887803495279286e-10
DNA O 0 1.0737049471742921e-08
from O 0 3.280222315993342e-09
several O 0 1.7118031436780257e-09
sources O 0 3.266177017735572e-08
including O 0 1.390996096084507e-09
multiple O 0 2.060187753727405e-08
large O 0 1.7278436814649467e-07
- O 0 1.6357178367343295e-07
insert O 0 2.5741920239852334e-07
libaries O 0 1.966799572983291e-06
and O 0 3.863491304656463e-09
genomic O 0 7.307006111290093e-09
DNA O 0 5.779592626709018e-08
from O 0 8.551008079393796e-08
Finnish O 0 0.0013353893300518394
CLD B-Disease 1 0.9999991655349731
patients O 0 2.826458285198896e-07
and O 0 1.369259621242236e-07
controls O 0 2.6914799491351005e-06
. O 0 9.111008694162592e-07

Exon O 0 1.7771385500964243e-06
- O 0 4.951172059008968e-07
specific O 0 3.95092882854442e-08
primers O 0 1.6130221069943218e-07
developed O 0 1.3167181123208138e-08
in O 0 4.687850108098246e-10
this O 0 2.0074777951073486e-10
study O 0 1.7335007040930606e-10
will O 0 9.252922039681977e-11
facilitate O 0 3.945903603863599e-09
mutation O 0 8.726473987863415e-10
screening O 0 8.694276965037773e-10
studies O 0 9.732376016202693e-10
of O 0 2.2506119190524032e-09
patients O 0 2.7974988991985583e-09
with O 0 2.713327562631207e-09
the O 0 4.878206141256669e-07
disease O 0 1.0987260793626774e-05
. O 0 2.520861244192929e-07

Genomic O 0 6.604909117413627e-07
sequencing O 0 3.4771429113789054e-07
of O 0 3.7910007222308195e-07
a O 0 2.894346948778548e-07
BAC O 0 1.460198745917296e-05
clone O 0 1.286164547309454e-06
H O 1 1.0
_ O 0 3.104048929003511e-08
RG364P16 O 0 1.7493867687790043e-07
revealed O 0 3.754765831587292e-09
the O 0 6.263853880028591e-10
presence O 0 2.084574735050637e-09
of O 0 6.324471168994705e-09
another O 0 1.0556220786384074e-08
, O 0 8.804215689828254e-10
highly O 0 3.1290430246855294e-09
homologous O 0 1.436257335285518e-09
gene O 0 5.943953773623889e-09
3 O 0 2.5990371455009154e-07
of O 0 1.5554797982986202e-07
the O 0 3.915303352641786e-07
CLD B-Disease 0 0.31187090277671814
gene O 0 4.9936133450501075e-08
, O 0 1.3582665658873339e-08
with O 0 6.317125156307668e-10
a O 0 1.0066819600140775e-09
similar O 0 9.33048083240351e-10
genomic O 0 1.4403347847746772e-08
structure O 0 1.3350984318094561e-08
, O 0 2.695274670116987e-09
recently O 0 1.675491856367728e-09
identified O 0 3.196032549723782e-09
as O 0 3.1582676474073423e-09
the O 0 7.759377496086017e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.950886823782639e-07
( O 0 3.9694580777904775e-07
PDS B-Disease 1 0.9561543464660645
) O 0 1.3494146244852345e-08
. O 0 2.3041080154939664e-08
. O 0 3.477073278190801e-07

The O 0 5.257999760033272e-07
APCI1307K O 0 0.14830148220062256
allele O 0 1.3746387139690341e-06
and O 0 3.9403474261234805e-08
cancer B-Disease 0 7.964395649651124e-07
risk O 0 2.0860953853230058e-08
in O 0 3.8093198040378695e-10
a O 0 1.3344053639841036e-09
community O 0 9.715831472689729e-10
- O 0 3.1081528462095775e-09
based O 0 2.4440602874875594e-09
study O 0 6.066053770403812e-10
of O 0 1.153286888211369e-08
Ashkenazi O 0 2.1246776782390953e-07
Jews O 0 1.426453763997415e-06
. O 0 1.1765110912165255e-06

Mutations O 0 1.4675632655780646e-06
in O 0 7.696189641137607e-08
APC O 0 6.860909138595161e-07
are O 0 3.5861724700936293e-09
classically O 0 1.460179390733174e-07
associated O 0 3.124143006516533e-07
with O 0 1.5468481251446065e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.373530262251734e-06
FAP B-Disease 0 1.0169251254410483e-05
) O 0 6.585857414975749e-10
, O 0 1.5317944135340156e-10
a O 0 7.626770326396581e-10
highly O 0 6.288339591264958e-07
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.55191899518104e-07
by O 0 1.307725483457034e-08
multiple O 0 7.515111519751372e-07
intestinal O 1 0.775891900062561
polyps B-Disease 0 7.777455124369226e-08
and O 0 1.1596343885145188e-09
, O 0 1.8370703569470237e-10
without O 0 9.408019918666355e-10
surgical O 0 9.409983903196917e-08
intervention O 0 4.769685446603944e-08
, O 0 5.11855502427494e-10
the O 0 8.869748269191291e-10
development O 0 2.1189431720358698e-07
of O 0 0.012399593368172646
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.3982073571460205e-07
CRC B-Disease 0 8.694439748069271e-05
) O 0 4.612122239677774e-08
. O 0 4.1067886513701524e-07

APC B-Disease 0 5.0077444029739127e-05
is O 0 1.8794381162479112e-07
a O 0 1.8150261382743338e-07
tumour O 1 0.9999570846557617
- O 0 5.584149107562553e-07
suppressor O 0 6.452251568589418e-07
gene O 0 7.219508102451755e-09
, O 0 1.6069189312517551e-09
and O 0 9.168041326113041e-10
somatic O 0 8.005983545444906e-06
loss O 0 9.917258694258635e-07
occurs O 0 1.3337346160824382e-07
in O 0 1.6678635006428522e-07
tumours B-Disease 1 1.0
. O 0 6.038549145159777e-06

The O 0 8.211594831664115e-06
germline O 0 5.107278047944419e-05
T O 0 3.3832313874881947e-06
- O 0 1.6955993942247005e-07
to O 0 1.6502687216757295e-08
- O 0 4.550918220047606e-08
A O 0 5.9256418438735636e-08
transversion O 0 9.256483934905191e-08
responsible O 0 1.3984926550136834e-09
for O 0 6.793774431912425e-10
the O 0 6.4573084657126856e-09
APC O 0 6.978503108712175e-08
I1307K O 0 9.746390361442536e-08
allele O 0 6.383770845275194e-09
converts O 0 1.107156410995458e-08
the O 0 3.2653779680202888e-09
wild O 0 1.555918238693721e-08
- O 0 6.7896586131155345e-09
type O 0 2.854781078198698e-09
sequence O 0 1.357509549215763e-09
to O 0 2.001048660105198e-09
a O 0 3.360036870958538e-08
homopolymer O 0 1.735013211145997e-05
tract O 0 1.7628227624300052e-06
( O 0 3.556916183811154e-08
A8 O 0 1.0876844498852734e-05
) O 0 1.0417959828146195e-09
that O 0 2.8545182884087694e-10
is O 0 5.906610756056807e-10
genetically O 0 9.705189540909487e-08
unstable O 0 0.0004265580209903419
and O 0 1.8011139246709718e-08
prone O 0 1.2003984295461123e-07
to O 0 1.3443051116723836e-08
somatic O 0 0.0001809254172258079
mutation O 0 1.2895247891719919e-06
. O 0 5.748073590439162e-07

The O 0 1.165606704489619e-06
I1307K O 0 4.038828137709061e-06
allele O 0 2.26539683012561e-07
was O 0 7.978294291888233e-08
found O 0 2.687174482929322e-09
in O 0 2.9540379031800512e-09
6 O 0 5.868844255019212e-07
. O 0 3.238757813051052e-07

1 O 0 6.46711259832955e-06
% O 0 6.860333456870649e-08
of O 0 7.993983786036551e-08
unselected O 0 7.638261013198644e-05
Ashkenazi O 0 3.2830223517521517e-07
Jews O 0 9.33087989096748e-08
and O 0 2.5871105258090665e-09
higher O 0 2.6485242443641255e-08
proportions O 0 5.8919102485788244e-08
of O 0 3.757583044716739e-08
Ashkenazim O 0 1.3297027408043505e-06
with O 0 2.317585234834496e-09
family O 0 2.0599991046310606e-08
or O 0 3.105930623803488e-09
personal O 0 3.944972348790543e-08
histories O 0 1.7024663634401804e-07
of O 0 2.4080604816845153e-06
CRC B-Disease 1 0.9999591112136841
( O 0 4.1040871678887925e-07
ref O 0 1.861863893282134e-05
. O 0 2.992546228597348e-07
2 O 0 2.567150886534364e-06
) O 0 1.1329734661558177e-07
. O 0 9.728994427860016e-07

To O 0 1.0790802207338857e-07
evaluate O 0 5.790880663880671e-07
the O 0 1.6160493032657541e-07
role O 0 6.843174560344778e-08
of O 0 1.1796687715559528e-07
I1307K O 0 6.3734046307217795e-06
in O 0 1.8145824398629884e-08
cancer B-Disease 0 9.731193131301552e-07
, O 0 7.467513718495411e-09
we O 0 1.0752234658184534e-08
genotyped O 0 4.596798135025892e-06
5 O 0 3.851236272112146e-07
, O 0 4.503383976839359e-08
081 O 0 4.627318958227988e-06
Ashkenazi O 0 2.554237426011241e-07
volunteers O 0 5.338117503583817e-08
in O 0 2.082706895834008e-09
a O 0 7.608859320384909e-09
community O 0 2.441825053267621e-08
survey O 0 1.5128811980957835e-07
. O 0 3.2697178653506853e-07

Risk O 0 7.315540187846636e-06
of O 0 2.0186046185699524e-06
developing O 0 0.08827836811542511
colorectal B-Disease 1 1.0
, I-Disease 0 1.0881957450692425e-06
breast I-Disease 0 1.2656738590521854e-06
and I-Disease 0 9.885454232971824e-09
other I-Disease 0 3.8062296425778186e-08
cancers I-Disease 0 0.01640269346535206
were O 0 8.102817972144294e-09
compared O 0 2.4592485825536414e-09
between O 0 5.38277378225871e-09
genotyped O 0 4.7656209289925755e-07
I1307K O 0 6.117357287394043e-08
carriers O 0 2.237911633784506e-09
and O 0 1.70315650471764e-09
non O 0 1.4597191899667905e-08
- O 0 7.282573655231772e-09
carriers O 0 4.739773462603125e-09
and O 0 2.8362197035392e-09
their O 0 2.536819643239596e-09
first O 0 3.876328946716967e-08
- O 0 1.6726565377211955e-07
degree O 0 7.873957770243578e-07
relatives O 0 8.636751772428397e-06
. O 0 2.5031577024492435e-06

Sperm O 0 9.433162517780147e-07
DNA O 0 2.985265723509656e-07
analysis O 0 1.0433998198777772e-07
in O 0 1.167858876272021e-08
a O 0 1.5733260738670651e-07
Friedreich B-Disease 1 0.9944224953651428
ataxia I-Disease 1 1.0
premutation O 1 0.9995325803756714
carrier O 0 2.854462195500673e-07
suggests O 0 5.0386567806981475e-08
both O 0 1.3711982660424837e-08
meiotic O 0 8.78907030710252e-07
and O 0 1.625917533942811e-08
mitotic O 0 4.225771874644124e-07
expansion O 0 4.931615649184096e-07
in O 0 1.923682546589589e-08
the O 0 3.3612650440772995e-07
FRDA B-Disease 0 0.0005368504789657891
gene O 0 1.2461063079172163e-06
. O 0 2.2712188183504622e-06

Friedreich B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
is O 0 2.4775604288151953e-06
usually O 0 4.4663956089152634e-08
caused O 0 8.263801731800413e-08
by O 0 5.381806666981959e-10
an O 0 3.4768901646664574e-10
expansion O 0 9.723251537252509e-09
of O 0 7.584647576663883e-09
a O 0 5.2426827323870384e-08
GAA O 1 0.9998726844787598
trinucleotide O 1 0.9999456405639648
repeat O 0 5.023864559916547e-07
in O 0 1.4028294081924741e-08
intron O 0 7.741814442852046e-07
1 O 0 2.1909517045060056e-07
of O 0 4.681956511376484e-08
the O 0 1.6386110246457974e-07
FRDA B-Disease 0 0.0005212960531935096
gene O 0 1.244759232577053e-06
. O 0 3.870149612339446e-06

Occasionally O 0 1.4733632269781083e-06
, O 0 1.7463587909105627e-08
a O 0 6.661155182996481e-09
fully O 0 1.145191852458538e-08
expanded O 0 2.4687651922761233e-09
allele O 0 8.696553699394372e-09
has O 0 5.244187861741523e-10
been O 0 1.473134808582799e-10
found O 0 1.1329546328875395e-10
to O 0 2.4394578024278246e-10
arise O 0 1.0291566709952349e-08
from O 0 5.4113913350306575e-09
a O 0 5.340823783228643e-09
premutation O 0 1.5920450096018612e-06
of O 0 2.0060941352539885e-08
100 O 0 2.6541881581465532e-08
or O 0 8.782684801644791e-09
less O 0 1.5460472013728577e-07
triplet O 0 9.400238013768103e-06
repeats O 0 3.235625854358659e-06
. O 0 1.4230406577553367e-06

We O 0 3.518623543641297e-07
have O 0 1.965319995633763e-08
examined O 0 1.1250683229491187e-07
the O 0 1.5564525668310125e-08
sperm O 0 2.2895200402217597e-08
DNA O 0 6.727860579758271e-08
of O 0 5.333090413728314e-08
a O 0 8.685401553520933e-08
premutation O 0 2.2143314708955586e-05
carrier O 0 1.2204402537463466e-06
. O 0 5.594885124082793e-07

This O 0 9.273625067862667e-08
mans O 0 5.378679361456307e-06
leucocyte O 0 8.54032919050951e-07
DNA O 0 8.396595774229354e-08
showed O 0 2.555957046013191e-08
one O 0 1.6486224607703548e-09
normal O 0 3.553273231204912e-09
allele O 0 3.147851312945704e-09
and O 0 5.328184005115588e-10
one O 0 3.1918029330668674e-10
allele O 0 6.684573339299504e-09
of O 0 5.5171640589435356e-09
approximately O 0 6.633527949162499e-09
100 O 0 7.65613137332366e-08
repeats O 0 4.239018949192541e-07
. O 0 4.663757238176913e-07

His O 0 2.6405150492792018e-06
sperm O 0 1.2513270348790684e-06
showed O 0 1.2846085439832677e-07
an O 0 1.7010429731456611e-09
expanded O 0 2.3402841886621673e-09
allele O 0 5.572868833070288e-09
in O 0 1.2814163063978867e-09
a O 0 2.6890422333281094e-08
tight O 0 4.3911751390623976e-07
range O 0 1.1561056680875481e-06
centering O 0 9.00153054317343e-07
on O 0 3.7231536964554834e-08
a O 0 5.0533888185100295e-09
size O 0 1.9921461813510177e-08
of O 0 5.0714387356265433e-08
approximately O 0 4.969422207068419e-08
320 O 0 3.1335633821072406e-07
trinucleotide O 0 4.5011271140538156e-05
repeats O 0 3.3089147564169252e-06
. O 0 1.5033915587991942e-06

His O 0 4.937610810884507e-06
affected O 0 2.2586891645914875e-05
son O 0 0.0013125838013365865
has O 0 2.0941403278129656e-08
repeat O 0 4.617447757482296e-08
sizes O 0 3.6864591379526246e-07
of O 0 1.6171685501831234e-07
1040 O 0 1.1164262332385988e-06
and O 0 1.725714469102968e-07
540 O 0 2.273377276651445e-06
. O 0 7.677539315409376e-07

These O 0 8.204545309808964e-08
data O 0 1.408876642017276e-07
suggest O 0 2.3676010485473853e-08
that O 0 5.238379729988196e-10
expansion O 0 1.4975626072555315e-08
occurs O 0 1.1677291356093633e-09
in O 0 1.6462743668288482e-10
two O 0 2.74753136908501e-10
stages O 0 2.7206450425865114e-09
, O 0 4.4689646427897856e-10
the O 0 2.6067650260586106e-09
first O 0 4.434222766747098e-09
during O 0 4.093202221611136e-09
meiosis O 0 3.0179151622178324e-08
followed O 0 1.4233154210785415e-08
by O 0 1.3076024707459055e-09
a O 0 1.3023389477950786e-08
second O 0 1.0403395123148584e-07
mitotic O 0 1.758552798492019e-06
expansion O 0 5.245481133897556e-06
. O 0 6.0980873968219385e-06

We O 0 4.3320684994796466e-07
also O 0 4.048450463756126e-08
show O 0 7.65129648527818e-09
that O 0 4.552328791707083e-10
in O 0 5.375476730407058e-10
all O 0 6.966806576080842e-10
informative O 0 1.09492992450555e-08
carrier O 0 3.937686177124533e-09
father O 0 1.3021550948622007e-08
to O 0 1.7614453229342075e-09
affected O 0 1.9856667421436214e-08
child O 0 1.4221159361227365e-08
transmissions O 0 9.013404422830718e-08
, O 0 6.738951063844922e-10
with O 0 1.4556890415295953e-10
the O 0 2.0870174477494174e-09
notable O 0 1.1869856209045793e-08
exception O 0 1.487022682766792e-08
of O 0 2.947516186679877e-08
the O 0 6.466765256618601e-08
premutation O 0 2.880151896533789e-06
carrier O 0 3.473579113233427e-08
, O 0 4.911355766523684e-09
the O 0 1.4342761645025348e-08
expansion O 0 1.3545390231683996e-07
size O 0 8.627152681128791e-08
decreases O 0 4.480944255647046e-07
. O 0 4.559772293077913e-08
. O 0 8.159987032740901e-07

The O 0 8.883324085218192e-07
R496H O 0 6.000071607559221e-06
mutation O 0 8.77647607921972e-08
of O 0 1.1631132679212897e-07
arylsulfatase O 0 3.403568553039804e-05
A O 0 7.36372101073357e-07
does O 0 9.804147715897216e-09
not O 0 2.255223918723459e-08
cause O 0 0.005274641793221235
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.367779638414504e-06

Deficiency B-Disease 1 0.9673241376876831
of I-Disease 0 0.000820813060272485
arylsulfatase I-Disease 1 0.9999997615814209
A I-Disease 1 0.9763696789741516
( O 0 1.388531131851778e-06
ARSA O 0 0.0003693773760460317
) O 0 2.0437575187770562e-08
enzyme O 0 1.190954094454355e-06
activity O 0 1.471571408728778e-06
causes O 0 0.022475671023130417
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.6147951050224947e-06
MLD B-Disease 1 1.0
) O 0 1.3650873142978526e-07
. O 0 3.7688420206904993e-07

A O 0 1.556145889480831e-06
number O 0 2.0442416825972032e-07
of O 0 8.63811635554157e-07
ARSA O 0 6.831685459474102e-05
gene O 0 2.9329808626243903e-07
mutations O 0 2.2869848237405677e-07
responsible O 0 8.111047833381235e-08
for O 0 3.919434732324589e-08
MLD B-Disease 1 1.0
have O 0 2.1915907311154115e-08
been O 0 1.0324301413788817e-08
identified O 0 7.904453269702572e-08
. O 0 1.651560523896478e-07

Recently O 0 1.264889533558744e-06
, O 0 1.8555390113306203e-08
the O 0 1.327341436763163e-08
R496H O 0 7.635451311216457e-07
mutation O 0 2.528811293700528e-08
of O 0 1.4057695807423443e-07
ARSA O 0 0.00017521984409540892
was O 0 9.05854307120535e-08
proposed O 0 5.3778275166394e-09
to O 0 8.011835639365472e-10
be O 0 1.429744100889252e-09
a O 0 7.4867960719871e-09
cause O 0 1.1221594604648999e-06
of O 0 2.101700601997436e-06
MLD B-Disease 1 1.0
( O 0 4.942180567013565e-07
Draghia O 0 2.6589706976665184e-05
et O 0 3.5200368984078523e-06
al O 0 3.2390405522164656e-06
. O 0 2.5633532629854017e-08
, O 0 1.6036191041735037e-08
1997 O 0 3.741948617630442e-08
) O 0 1.8672338342184958e-08
. O 0 3.160324411055626e-07

We O 0 3.9294280895774136e-07
have O 0 3.549840243977087e-08
investigated O 0 1.5099854522304668e-07
the O 0 2.3567608309349453e-08
R496H O 0 2.8198618906571937e-07
mutation O 0 4.7902419808565355e-09
and O 0 7.172905602814694e-10
found O 0 3.2138561256722653e-10
this O 0 9.167477194038653e-11
mutation O 0 1.0423605312226414e-09
at O 0 2.131251175541138e-09
a O 0 6.492279491787656e-10
relatively O 0 2.876556770559091e-09
high O 0 1.5491157245861586e-09
frequency O 0 7.941863833238472e-10
in O 0 1.0280726270295304e-10
an O 0 4.850515544774225e-10
African O 0 7.074197339029809e-10
American O 0 1.3018414124488231e-09
population O 0 4.3163106422383635e-10
( O 0 2.6329374791522753e-10
f O 0 2.372320118126936e-08
= O 0 2.5220533217407137e-08
0 O 0 6.166806088003796e-08
. O 0 1.2935282178716534e-08
09 O 0 3.9124742556850833e-07
, O 0 1.9339466916790116e-08
n O 0 6.70971473937243e-08
= O 0 4.726775841845665e-07
61 O 0 7.816065590304788e-07
subjects O 0 3.850913401493017e-07
) O 0 5.762465349334889e-08
. O 0 5.7266305475423e-07

The O 0 1.7538015526952222e-05
ARSA O 0 5.3399387979879975e-05
enzyme O 0 2.3526743575530418e-07
activity O 0 1.0640256675742421e-07
in O 0 2.335967197453215e-09
subjects O 0 1.8338022655939312e-08
with O 0 2.0998817962247784e-10
and O 0 6.766307514283199e-10
without O 0 2.398260257052698e-09
the O 0 6.375059147245565e-09
R496H O 0 1.0215279644398834e-07
mutation O 0 2.099722617998623e-09
was O 0 3.72586539398867e-09
determined O 0 2.4553394872839363e-09
and O 0 7.55052131928835e-10
found O 0 1.4961399896762373e-09
to O 0 2.3241855107158926e-09
be O 0 2.591181313960078e-08
normal O 0 1.2558327853184892e-06
. O 0 7.340967727031966e-07

It O 0 8.045716981541773e-08
is O 0 6.561649001923797e-09
therefore O 0 1.3861976455586955e-08
concluded O 0 6.367888882863326e-09
that O 0 4.5142842242107406e-10
the O 0 2.6228041960507653e-09
R496H O 0 2.6239945327688474e-07
mutation O 0 8.070289325701197e-09
of O 0 3.1992911431188986e-08
ARSA O 0 8.738825272303075e-06
does O 0 3.6247789214627346e-09
not O 0 2.158768941384892e-09
negatively O 0 2.011957001002429e-08
influence O 0 1.5102237682640407e-08
the O 0 8.278248309068204e-09
activity O 0 3.205026288810586e-08
of O 0 8.10914499993487e-08
ARSA O 0 0.0007064900128170848
and O 0 2.0262946875959642e-08
is O 0 1.358138934648423e-09
not O 0 6.287003140315051e-10
a O 0 1.4924925295645153e-08
cause O 0 1.0658477549441159e-05
of O 0 2.540106106607709e-05
MLD B-Disease 1 1.0

Down O 0 2.3047132344800048e-05
- O 0 1.3359972399484832e-06
regulation O 0 6.93072252033744e-07
of O 0 6.876098836983147e-07
transmembrane O 0 1.127738050854532e-05
carbonic O 0 7.358713628491387e-05
anhydrases O 0 4.1878101910697296e-05
in O 0 1.8403096646579797e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.7383421659469604
lines O 0 1.2696835938186268e-07
by O 0 3.3597657989048457e-09
wild O 0 7.432446835764495e-08
- O 0 1.5237425543546124e-07
type O 0 1.102455030377314e-06
von B-Disease 1 0.999858021736145
Hippel I-Disease 1 0.9999539852142334
- I-Disease 1 0.9998860359191895
Lindau I-Disease 1 0.992355227470398
transgenes O 0 0.00102528790012002
. O 0 1.2395952580845915e-05

To O 0 3.380859823209903e-07
discover O 0 4.35259636333285e-07
genes O 0 1.1736720040289583e-07
involved O 0 7.948342073405001e-08
in O 0 2.8574246968560146e-08
von B-Disease 1 0.9999978542327881
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Lindau I-Disease 1 0.9999996423721313
( O 0 9.562411833030637e-06
VHL B-Disease 1 0.9999995231628418
) O 0 1.47214961998543e-07
- O 0 9.445549267184106e-07
mediated O 0 2.6587982574710622e-05
carcinogenesis O 0 0.00040468090446665883
, O 0 4.880483572833327e-09
we O 0 1.8113794908458658e-09
used O 0 3.2042375863738926e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9939150214195251
lines O 0 1.3829976523993537e-06
stably O 0 6.884766889925231e-07
transfected O 0 2.309890589913266e-07
with O 0 3.8952268077707686e-09
wild O 0 1.000257654482084e-07
- O 0 2.67116149643698e-07
type O 0 1.4838672086625593e-06
VHL O 1 0.9986829161643982
- O 0 6.896683771628886e-05
expressing O 0 1.75484183273511e-06
transgenes O 0 7.038497278699651e-05
. O 0 2.14607371162856e-06

Large O 0 2.794756937873899e-06
- O 0 5.918751071476436e-07
scale O 0 2.647252017595747e-07
RNA O 0 2.348146352915137e-07
differential O 0 3.1034039693622617e-07
display O 0 1.9331315215254108e-08
technology O 0 1.6247703626959265e-08
applied O 0 7.616453245873345e-09
to O 0 4.0440167881072853e-10
these O 0 1.222666079492285e-09
cell O 0 4.706148359900908e-08
lines O 0 1.0820332185801362e-08
identified O 0 5.774983602435668e-09
several O 0 2.754112049530022e-09
differentially O 0 3.1164179858933494e-07
expressed O 0 7.76562281146198e-09
genes O 0 6.46449338503885e-09
, O 0 1.4315204577286522e-09
including O 0 1.4121736002792318e-09
an O 0 1.146675909780015e-08
alpha O 0 9.803741107816677e-08
carbonic O 0 1.3829290992362075e-06
anhydrase O 0 1.5260008012774051e-06
gene O 0 1.5667259845031367e-07
, O 0 2.049224860911636e-07
termed O 0 6.727733762090793e-06
CA12 O 1 0.9979419112205505
. O 0 5.958268957328983e-06

The O 0 2.036914111158694e-06
deduced O 0 1.9879005321854493e-06
protein O 0 2.2232310925573984e-07
sequence O 0 5.4675535210435555e-08
was O 0 2.9908051146776415e-08
classified O 0 1.4377491197592462e-08
as O 0 3.6914733492210416e-09
a O 0 3.3059495141429807e-09
one O 0 7.00967639488681e-09
- O 0 7.241438737537464e-08
pass O 0 3.6120340496381687e-07
transmembrane O 0 2.238262140963343e-06
CA O 0 3.903509878000477e-06
possessing O 0 4.070533918820729e-07
an O 0 1.289351132527372e-07
apparently O 0 1.2697151419160946e-07
intact O 0 4.7791111512651696e-08
catalytic O 0 1.9269837281399305e-08
domain O 0 6.838672561571002e-08
in O 0 1.6164525717954348e-08
the O 0 5.764036359323654e-07
extracellular O 0 0.00040551525307819247
CA O 0 0.00012694446195382625
module O 0 6.627954462601338e-06
. O 0 1.354080836790672e-06

Reintroduced O 0 5.033507477492094e-06
wild O 0 3.94200105802156e-06
- O 0 1.7940292309504002e-06
type O 0 1.408620164511376e-06
VHL B-Disease 0 0.009554426185786724
strongly O 0 1.2188368714305398e-07
inhibited O 0 6.24761966605547e-08
the O 0 5.492521548688956e-09
overexpression O 0 2.433883707908535e-07
of O 0 9.80138104011985e-09
the O 0 1.2426624174111112e-08
CA12 O 0 1.616182089492213e-05
gene O 0 3.0216058544141333e-09
in O 0 1.772614499628844e-09
the O 0 4.0927517375166644e-08
parental O 0 0.0011638414580374956
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999972581863403
lines O 0 1.2032151971652638e-05
. O 0 4.6729550717827806e-07

Similar O 0 7.338196894579596e-08
results O 0 1.3300257251103176e-07
were O 0 1.4008908699736367e-08
obtained O 0 4.176826706725478e-08
with O 0 7.099612897576435e-09
CA9 O 0 1.3474180377670564e-05
, O 0 2.779680929876349e-09
encoding O 0 1.5227627159219992e-08
another O 0 9.300939751710757e-08
transmembrane O 0 2.0073839550605044e-06
CA O 0 5.973523002467118e-06
with O 0 1.3103520046797712e-08
an O 0 6.879766090150952e-08
intact O 0 2.1964099516935676e-07
catalytic O 0 2.642888148329803e-07
domain O 0 1.5470340031242813e-06
. O 0 1.1422226862123352e-06

Although O 0 2.824210980634234e-07
both O 0 4.3238959079872075e-08
domains O 0 3.255119906953041e-07
of O 0 5.603311024060531e-07
the O 0 1.030897237797035e-06
VHL B-Disease 0 0.0035650385543704033
protein O 0 4.945679279444448e-07
contribute O 0 1.3845647295340768e-08
to O 0 1.8912187371711298e-09
regulation O 0 1.0130487027026902e-07
of O 0 5.971387508907355e-07
CA12 O 1 0.9999996423721313
expression O 0 3.0929089689379907e-07
, O 0 5.973344485710186e-09
the O 0 8.34791880066632e-09
elongin O 0 1.1797565235838192e-07
binding O 0 1.4252822921889674e-08
domain O 0 6.292346910186097e-08
alone O 0 1.56144199792152e-08
could O 0 1.5788057083909735e-08
effectively O 0 2.707023156744981e-07
regulate O 0 2.7911053166462807e-06
CA9 O 0 0.015392446890473366
expression O 0 1.4459988960879855e-05
. O 0 4.487111709750025e-06

We O 0 1.812336222428712e-06
mapped O 0 1.3619546734844334e-05
CA12 O 0 0.4576033651828766
and O 0 3.4912488899863092e-06
CA9 O 0 0.006354913581162691
loci O 0 1.912412926685647e-06
to O 0 9.84233707868043e-08
chromosome O 0 2.957434048767027e-07
bands O 0 3.384724323041155e-07
15q22 O 0 6.026789378665853e-06
and O 0 1.3148502375770477e-07
17q21 O 0 2.095761738019064e-05
. O 0 9.737013897392899e-07

2 O 0 6.862924692541128e-06
respectively O 0 4.396630970404658e-07
, O 0 1.074801136979886e-08
regions O 0 2.5371113210326257e-08
prone O 0 3.7697727606200715e-08
to O 0 1.6839337702023727e-09
amplification O 0 1.7570880572748138e-07
in O 0 5.305542227773685e-09
some O 0 5.282642945303451e-08
human O 0 6.184090125316288e-06
cancers B-Disease 1 0.6431043148040771
. O 0 5.33397553681425e-07

Additional O 0 4.804533091373742e-07
experiments O 0 1.238817475268661e-07
are O 0 1.157049456246284e-09
needed O 0 1.1151037426770927e-08
to O 0 1.8574856097686165e-09
define O 0 3.5450231195000015e-08
the O 0 4.586113178106643e-08
role O 0 5.2423626328845785e-08
of O 0 4.976574246029486e-07
CA O 0 4.3991112761432305e-06
IX O 1 0.9999864101409912
and O 0 5.228251211519819e-06
CA O 0 1.69676623045234e-05
XII O 0 0.00011543917935341597
enzymes O 0 1.3380147656505414e-08
in O 0 1.3112688712624276e-09
the O 0 1.8906778365135324e-09
regulation O 0 7.142778368773861e-09
of O 0 4.188106927927038e-08
pH O 0 8.202229651033122e-08
in O 0 3.4970706330739176e-09
the O 0 4.988757851265291e-08
extracellular O 0 1.5447724308614852e-06
microenvironment O 0 6.272231530601857e-06
and O 0 6.438111821438497e-09
its O 0 2.324039183321247e-09
potential O 0 2.072567895083921e-07
impact O 0 2.4676121483935276e-06
on O 0 1.0561828958088881e-06
cancer B-Disease 0 3.6034298318554647e-06
cell O 0 1.7899952581501566e-05
growth O 0 4.7068397179828025e-07
. O 0 2.8140053132119647e-07

A O 0 1.6605088148935465e-06
gene O 0 5.796561097781705e-08
encoding O 0 1.7780068617412326e-07
a O 0 2.139802575129579e-07
transmembrane O 0 3.802866785918013e-07
protein O 0 3.154596583954117e-08
is O 0 3.046749796897785e-10
mutated O 0 2.8805045015900532e-09
in O 0 1.2491582768170417e-10
patients O 0 9.839813408518694e-10
with O 0 5.024767268935193e-09
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.7545148134231567
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.6732102632522583
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 7.037463234382813e-08
. O 0 1.6193042995382712e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00015937472926452756
WFS B-Disease 1 0.954702615737915
; O 0 7.478334396182618e-07
OMIM O 0 0.048936113715171814
222300 O 0 7.010299668763764e-06
) O 0 2.3444302055253274e-09
is O 0 9.449724336363374e-10
an O 0 2.382968311565037e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999996423721313
defined O 0 3.008725357744879e-08
by O 0 1.5525912777647477e-09
young O 0 1.3976139712212898e-07
- O 0 8.792935659585055e-07
onset O 1 0.9999933242797852
non O 1 0.9928447604179382
- O 0 8.38398773339577e-06
immune O 0 4.036950849695131e-05
insulin B-Disease 1 0.850426435470581
- I-Disease 0 0.00023430486908182502
dependent I-Disease 0 0.0021626201923936605
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.5829205040063243e-06
progressive O 1 0.9509926438331604
optic B-Disease 1 0.9999934434890747
atrophy I-Disease 0 0.0014466432621702552
. O 0 2.4396499611611944e-06

Linkage O 0 1.3796562598145101e-05
to O 0 1.5153865717820736e-07
markers O 0 2.244625875391648e-06
on O 0 6.035234605406004e-07
chromosome O 0 1.1710372973539052e-06
4p O 0 5.094985317555256e-05
was O 0 8.274115970152707e-08
confirmed O 0 7.406024238321152e-09
in O 0 1.7790975359588401e-09
five O 0 1.4741425857778268e-08
families O 0 4.7156191840258543e-08
. O 0 3.8382566458494694e-07

On O 0 9.82885467237793e-07
the O 0 3.692736072480329e-08
basis O 0 1.3312211422089604e-07
of O 0 5.3179963543925624e-08
meiotic O 0 3.6393339541973546e-05
recombinants O 1 0.999674916267395
and O 0 1.6826768955979787e-07
disease O 0 2.479971726643271e-06
- O 0 1.0458265364832187e-07
associated O 0 3.5526451824807737e-07
haplotypes O 0 3.0260191579145612e-06
, O 0 6.631921234401261e-09
the O 0 3.6732142660866884e-08
WFS B-Disease 0 1.553536276333034e-05
gene O 0 1.988759734672385e-08
was O 0 3.531592795980032e-08
localized O 0 7.099249899056304e-08
to O 0 4.573165846011307e-09
a O 0 1.1489029105860027e-07
BAC O 0 1.411919674865203e-05
/ O 0 6.88526540670864e-07
P1 O 0 2.1036316866229754e-06
contig O 0 2.2223227915674215e-06
of O 0 1.7854826950269853e-08
less O 0 1.0057804367136214e-08
than O 0 2.1268129479778963e-09
250 O 0 4.324481395201474e-08
kb O 0 6.964362000871915e-06
. O 0 1.0125887683898327e-06

Mutations O 0 9.747103604240692e-07
in O 0 2.1979536413141432e-08
a O 0 1.6424872129050527e-08
novel O 0 3.301048678849838e-08
gene O 0 2.142248156644655e-08
( O 0 3.9589096445524774e-08
WFS1 O 0 4.63585092802532e-05
) O 0 1.2118744896483236e-09
encoding O 0 1.140698824286801e-08
a O 0 3.116298685768015e-08
putative O 0 3.444616254455468e-07
transmembrane O 0 8.006435336938011e-08
protein O 0 1.9694327946240264e-08
were O 0 1.9215216084944586e-09
found O 0 2.7722826811960033e-10
in O 0 1.8409497537508202e-10
all O 0 2.8731775292278883e-10
affected O 0 2.814888766522472e-09
individuals O 0 1.2787690351068193e-10
in O 0 1.1058811644204525e-09
six O 0 2.531233889158102e-08
WFS B-Disease 0 1.8994616766576655e-05
families O 0 6.375824757043347e-09
, O 0 5.89531035100066e-10
and O 0 3.131053472049672e-10
these O 0 5.335537012207681e-10
mutations O 0 3.0440443499202274e-09
were O 0 1.1415123291058649e-09
associated O 0 1.1160399715492986e-08
with O 0 1.4147456539603809e-09
the O 0 8.245207538948307e-08
disease O 0 1.032202362694079e-05
phenotype O 0 4.801610202775919e-07
. O 0 2.367307985196021e-07

WFS1 O 0 0.012448533438146114
appears O 0 4.1773847669901443e-07
to O 0 6.794762974493551e-09
function O 0 6.9766774579704816e-09
in O 0 2.1299630947879677e-09
survival O 0 5.680266212948482e-07
of O 0 5.98406586505007e-08
islet O 0 2.3139341465139296e-07
beta O 0 2.1570706110196625e-07
- O 0 1.3700353918011388e-07
cells O 0 5.901278754549821e-08
and O 0 2.780016572501154e-08
neurons O 0 3.245195046019944e-07
. O 0 3.9383191818842533e-08
. O 0 1.90261729926533e-07

Stable O 0 1.788967892935034e-05
interaction O 0 4.3148006056981103e-07
between O 0 4.1800543471026685e-08
the O 0 4.4916124153360215e-09
products O 0 2.344458138736627e-08
of O 0 1.3422681632846434e-08
the O 0 4.5886068278377934e-08
BRCA1 O 0 9.261760851586587e-07
and O 0 1.265615594547853e-07
BRCA2 O 0 5.659864541485149e-07
tumor B-Disease 0 4.3714825892493536e-07
suppressor O 0 5.066802941655624e-07
genes O 0 9.47714795529464e-09
in O 0 3.0438758180650893e-09
mitotic O 0 6.872460289741866e-07
and O 0 2.509716523491079e-07
meiotic O 0 2.520411362638697e-05
cells O 0 1.898965274449438e-05
. O 0 3.457508455539937e-06

BRCA1 O 0 6.505980127258226e-05
and O 0 2.4894218313420424e-06
BRCA2 O 0 1.235119725606637e-06
account O 0 1.1323054494027929e-08
for O 0 4.319028468202646e-10
most O 0 7.143101665718632e-10
cases O 0 1.4450945995392317e-09
of O 0 7.735716067713838e-09
familial O 0 7.523143352727857e-08
, O 0 1.5811855158531785e-09
early O 0 2.1697793783914676e-08
onset O 0 6.19237562204944e-06
breast B-Disease 0 5.085852876618446e-07
and I-Disease 0 4.1011762164089305e-07
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1469596383761882e-09
encode O 0 1.2283132289070409e-09
products O 0 6.29060448176233e-09
that O 0 5.914546630236828e-10
each O 0 6.243076056122732e-10
interact O 0 8.194391831750636e-09
with O 0 2.2442604219463647e-08
hRAD51 O 0 1.4159243619360495e-05
. O 0 1.3620175423056935e-06

Results O 0 7.470935088349506e-07
presented O 0 5.658471877723059e-07
here O 0 7.008007685271878e-08
show O 0 1.9501708692359898e-08
that O 0 3.8502276922258716e-09
BRCA1 O 0 1.4761407385321945e-07
and O 0 5.819059722966813e-08
BRCA2 O 0 2.844207074303995e-07
coexist O 0 7.124385348333817e-08
in O 0 2.0345387596876208e-09
a O 0 5.733136188013077e-09
biochemical O 0 5.128313205204904e-07
complex O 0 1.0454556331751519e-07
and O 0 1.5050018120632558e-08
colocalize O 0 3.8767539081163704e-06
in O 0 9.055844074623565e-09
subnuclear O 0 5.7948086578107905e-06
foci O 0 6.504494081127632e-07
in O 0 3.027189832138788e-09
somatic O 0 2.2454985071362898e-07
cells O 0 1.957501005733775e-08
and O 0 2.4504924756030277e-09
on O 0 3.785333380079692e-09
the O 0 9.100756259705634e-10
axial O 0 2.900867457356071e-08
elements O 0 6.749373948622406e-09
of O 0 1.12329239243536e-08
developing O 0 2.0252134902420948e-07
synaptonemal O 0 1.857610732258763e-05
complexes O 0 2.7442508780950448e-06
. O 0 2.2881461063661845e-06

Like O 0 6.537705758091761e-06
BRCA1 O 0 3.0935960239730775e-05
and O 0 3.016896471308428e-06
RAD51 O 0 0.03474605828523636
, O 0 8.995797884381318e-07
BRCA2 O 0 3.642576302809175e-06
relocates O 0 1.6079874285424012e-06
to O 0 5.0678128360459596e-08
PCNA O 0 7.203580480563687e-06
+ O 0 3.197022024892249e-08
replication O 0 2.4751587446303347e-09
sites O 0 5.9864158075129126e-09
following O 0 1.5892644977810733e-09
exposure O 0 7.078401154103631e-08
of O 0 6.855559320229077e-08
S O 0 1.6176356893993216e-06
phase O 0 1.1429250434957794e-07
cells O 0 7.547922109552019e-08
to O 0 5.103012412632779e-08
hydroxyurea O 0 9.670128747529816e-06
or O 0 3.706531686020753e-07
UV O 0 0.00030423831776715815
irradiation O 0 7.045990514598088e-06
. O 0 8.694266284692276e-07

Thus O 0 1.1814605613835738e-06
, O 0 1.1583201597886728e-07
BRCA1 O 0 3.127171623873437e-07
and O 0 3.821651617386124e-08
BRCA2 O 0 6.179745781764723e-08
participate O 0 3.421010141835268e-09
, O 0 1.251555636905266e-09
together O 0 2.9972321846649663e-10
, O 0 4.6139744802609073e-10
in O 0 3.02183472689066e-10
a O 0 3.0202691458924846e-09
pathway O 0 1.1170754277145534e-07
( O 0 4.8971284805077175e-09
s O 0 1.9445028698328315e-08
) O 0 2.591588887934648e-10
associated O 0 4.92878227120741e-09
with O 0 7.081932262842372e-10
the O 0 5.994493346150875e-09
activation O 0 6.552859588282445e-08
of O 0 4.2845474723662846e-08
double O 0 1.8402143808771143e-08
- O 0 1.4131288139651588e-07
strand O 0 7.98778003741063e-08
break O 0 7.318725181448826e-08
repair O 0 1.0508288141863886e-06
and O 0 3.584407011203439e-07
/ O 0 2.1764167286164593e-06
or O 0 9.017841051672804e-08
homologous O 0 1.517425687325158e-07
recombination O 0 1.4884903976053465e-07
. O 0 7.353517048613867e-07

Dysfunction O 0 0.0001310544175794348
of O 0 1.3730532373301685e-06
this O 0 3.1772635633586788e-09
pathway O 0 2.050916094731292e-07
may O 0 3.0387712346424678e-09
be O 0 6.533659169249972e-10
a O 0 1.7942931584968846e-09
general O 0 1.116142200885406e-08
phenomenon O 0 3.7534142904860346e-08
in O 0 2.498679874118892e-10
the O 0 1.2872760635218583e-09
majority O 0 1.5633119798685868e-10
of O 0 6.885010339630071e-10
cases O 0 1.7369105043130162e-09
of O 0 2.5293131145076586e-08
hereditary B-Disease 1 0.9998687505722046
breast I-Disease 1 0.9939910769462585
and I-Disease 1 0.9728246927261353
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.459090175932488e-08
. O 0 7.348057096123739e-08

A O 0 9.52736536419252e-06
novel O 0 9.84871803666465e-07
Arg362Ser O 0 5.749637239205185e-06
mutation O 0 3.688054661665774e-08
in O 0 2.2706445612641346e-09
the O 0 1.0009824968904013e-08
sterol O 0 1.1537794080140884e-06
27 O 0 8.994554150376644e-07
- O 0 4.7315930373770243e-07
hydroxylase O 0 3.0564169719582424e-06
gene O 0 2.5932882863344275e-07
( O 0 2.2914035469057126e-07
CYP27 O 1 0.9972692131996155
) O 0 2.8783679884014646e-09
: O 0 1.0729080957005976e-09
its O 0 1.864200793733062e-09
effects O 0 8.423223363251964e-08
on O 0 3.843274143378039e-08
pre O 0 8.004053597687744e-08
- O 0 4.411002052506774e-08
mRNA O 0 8.3946574136462e-08
splicing O 0 1.0359278945770711e-07
and O 0 2.657541564587973e-08
enzyme O 0 2.5492170152574545e-07
activity O 0 7.220570523713832e-07
. O 0 8.124593477987219e-07

A O 0 2.8699712402158184e-06
novel O 0 2.0141384027283493e-07
C O 0 3.483804675852298e-07
to O 0 3.2236440183908144e-09
A O 0 3.562483641417202e-08
mutation O 0 4.0476377805021e-09
in O 0 7.816932656723452e-10
the O 0 7.989986450240849e-09
sterol O 0 5.843082249157305e-07
27 O 0 6.874912514831522e-07
- O 0 2.3344813371295459e-07
hydroxylase O 0 5.644308203045512e-07
gene O 0 9.913402720940212e-08
( O 0 5.5758910377790016e-08
CYP27 O 0 0.016811227425932884
) O 0 1.1058305382505296e-09
was O 0 2.824052325323123e-09
identified O 0 7.345205554898371e-10
by O 0 3.2067595800988613e-10
sequencing O 0 1.4765569211760976e-08
amplified O 0 1.445707766833948e-07
CYP27 O 0 3.156136926918407e-06
gene O 0 3.7387790641219e-09
products O 0 3.9556187658718045e-08
from O 0 8.596694911489067e-09
a O 0 4.032788325503134e-09
patient O 0 1.3339631621533954e-08
with O 0 1.3762131878536366e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 6.787161623833526e-07
CTX B-Disease 0 0.013862148858606815
) O 0 1.7977920663270197e-07
. O 0 9.038416237672209e-07

The O 0 7.993859298949246e-07
mutation O 0 2.4259119868474954e-07
changed O 0 1.525827713066974e-07
the O 0 5.678116821172807e-08
adrenodoxin O 0 2.0633988242479973e-06
cofactor O 0 4.4399465082278766e-07
binding O 0 3.276416578046337e-07
residue O 0 2.9168795663281344e-06
362Arg O 0 1.1996344255749136e-06
to O 0 5.684716697373915e-08
362Ser O 0 1.0872986422327813e-05
( O 0 3.5725003044717596e-07
CGT O 0 0.0003950480022467673
362Arg O 0 4.64064714833512e-06
to O 0 1.502402540154435e-07
AGT O 0 5.86641144764144e-05
362Ser O 0 6.939677632544772e-07
) O 0 1.1069742900104984e-09
, O 0 7.059450801705225e-10
and O 0 8.567275777693339e-10
was O 0 1.1593475512938767e-08
responsible O 0 3.0216287250084406e-09
for O 0 1.109060754345137e-08
deficiency O 1 0.9990580677986145
in O 0 3.312565866053774e-08
the O 0 3.0213888635444164e-07
sterol O 0 3.651849056041101e-06
27 O 0 7.942474553601642e-07
- O 0 1.3575601087723044e-07
hydroxylase O 0 6.602087410101376e-07
activity O 0 4.1873558842553393e-08
, O 0 7.184557393458135e-10
as O 0 3.450497387813556e-10
confirmed O 0 5.819608683843569e-10
by O 0 1.4725055896835926e-10
expression O 0 2.5962654248701256e-09
of O 0 7.233704746312242e-09
mutant O 0 1.3533428599998842e-08
cDNA O 0 8.585081445744436e-08
into O 0 1.7359120363380498e-07
COS O 0 0.0001139914384111762
- O 0 2.3924835659272503e-06
1 O 0 1.209415813718806e-06
cells O 0 7.713522336416645e-07
. O 0 7.894160489740898e-07

Quantitative O 0 1.505572413407208e-06
analysis O 0 2.0897498131944303e-07
showed O 0 4.9409365487917967e-08
that O 0 7.382679467760056e-10
the O 0 3.129580150584843e-09
expression O 0 2.5324700558826407e-08
of O 0 8.64858691329573e-08
CYP27 O 0 8.862652975949459e-06
gene O 0 6.015522302504905e-09
mRNA O 0 5.5087230776962315e-08
in O 0 2.437468227256545e-09
the O 0 9.595209959911699e-09
patient O 0 2.7088303156119764e-08
represented O 0 6.652688000485796e-08
52 O 0 3.0472169783024583e-06
. O 0 8.452794304503186e-07

5 O 0 1.4094264315644978e-06
% O 0 1.8306257842937157e-08
of O 0 1.595783771790593e-08
the O 0 5.3269701538738445e-08
normal O 0 1.1953871990044718e-06
level O 0 2.5588483367755543e-06
. O 0 4.954847554472508e-07

As O 0 1.8126148404462583e-07
the O 0 4.13990584036128e-08
mutation O 0 3.070437770702483e-08
occurred O 0 1.3089410799693724e-07
at O 0 7.41488603850371e-09
the O 0 3.6830269944942984e-09
penultimate O 0 7.344203822867712e-08
nucleotide O 0 4.505265494003652e-08
of O 0 7.168357996079067e-08
exon O 0 6.982816813660975e-08
6 O 0 4.0572712123321253e-07
( O 0 9.141225554287757e-09
- O 0 6.674943620055274e-08
2 O 0 8.821285035764959e-08
position O 0 1.0261130256594697e-07
of O 0 7.512718269708785e-08
exon O 0 1.3357229988741892e-07
6 O 0 2.029987172136316e-06
- O 0 1.0057939334728871e-06
intron O 0 1.6764761312515475e-06
6 O 0 6.20669084128167e-07
splice O 0 4.592012885495933e-07
site O 0 9.427733260736204e-08
) O 0 6.795433660222727e-10
of O 0 1.3827067490979061e-08
the O 0 1.7168002131029425e-08
gene O 0 7.459542317178602e-09
, O 0 8.461704226192523e-09
we O 0 2.255321707167468e-09
hypothesized O 0 9.431075476129536e-09
that O 0 3.29752808392314e-10
the O 0 1.807017757649021e-09
mutation O 0 5.522438950578135e-09
may O 0 4.226615946123502e-09
partially O 0 5.8511908207492525e-08
affect O 0 8.246446192572421e-09
the O 0 8.798914485907972e-09
normal O 0 4.260155783697428e-09
splicing O 0 1.706041174998063e-08
efficiency O 0 1.722461462350111e-08
in O 0 2.1329105148737426e-09
exon O 0 3.056245390098411e-08
6 O 0 1.2558011519558931e-07
and O 0 2.244588737099207e-09
cause O 0 9.359342634240875e-09
alternative O 0 1.0457184451695412e-08
splicing O 0 2.9034024962015792e-08
elsewhere O 0 2.5580201068464703e-08
, O 0 6.495933235761697e-10
which O 0 1.3261684805865315e-10
resulted O 0 3.316813046438938e-09
in O 0 5.77029035664367e-10
decreased O 0 2.4109384710868653e-08
transcript O 0 5.1406626511152353e-08
in O 0 1.9788903848905193e-09
the O 0 3.173812856971381e-08
patient O 0 1.3787149555355427e-07
. O 0 5.177849971005344e-07

Transfection O 0 6.232097075553611e-05
of O 0 3.9696051317150705e-06
constructed O 0 1.926041477418039e-06
minigenes O 0 2.762327312666457e-05
, O 0 7.53638129680212e-09
with O 0 2.508583896165817e-10
or O 0 5.723594931339449e-10
without O 0 1.5931735930507784e-09
the O 0 1.301019736388298e-09
mutation O 0 7.969039872435246e-10
, O 0 4.627793981359929e-10
into O 0 9.024841318705512e-09
COS O 0 4.46471203758847e-05
- O 0 2.8802816132156295e-07
1 O 0 7.754272957072317e-08
cells O 0 9.534059763893765e-09
confirmed O 0 6.026351417887099e-09
that O 0 5.5597724341049926e-11
the O 0 8.334964385348087e-10
mutant O 0 9.450252136389281e-09
minigene O 0 1.8380434596565465e-07
was O 0 1.0835615071869142e-08
responsible O 0 1.0529008775961302e-09
for O 0 6.302466881713542e-10
a O 0 2.5295625594168314e-09
mRNA O 0 3.4986200603270845e-08
species O 0 6.22148887963192e-10
alternatively O 0 2.457144354650609e-08
spliced O 0 8.180479085240222e-07
at O 0 2.4673548182363447e-07
an O 0 6.097995708387316e-08
activated O 0 5.347034175429144e-07
cryptic O 0 1.6352248621842591e-06
5 O 0 1.0725160848323867e-07
splice O 0 1.1444077472333447e-06
site O 0 4.2733583427434496e-07
88 O 0 3.874260414704622e-07
bp O 0 1.1273000666278676e-07
upstream O 0 2.0542300660508772e-07
from O 0 1.502758806282145e-08
the O 0 3.749721955159657e-08
3 O 0 1.0191652677349339e-07
end O 0 6.058716195411762e-08
of O 0 1.2022979944958934e-07
exon O 0 5.397858444666781e-07
6 O 0 5.687867542292224e-06
. O 0 1.5452910702151712e-06

Our O 0 4.711097005838383e-07
data O 0 1.2361053336462646e-07
suggest O 0 3.126610437220734e-08
that O 0 1.525194859297585e-09
the O 0 8.991577260530903e-09
C O 0 4.3718532793945997e-08
to O 0 5.659006596658855e-10
A O 0 2.068124871357213e-08
mutation O 0 3.600908904388689e-09
at O 0 4.589015834000065e-09
the O 0 2.8268656304675233e-09
penultimate O 0 3.431788542229697e-08
nucleotide O 0 2.142150279382804e-08
of O 0 1.724262688185263e-08
exon O 0 2.4603052040106377e-08
6 O 0 1.0047606480156901e-07
of O 0 2.0756370844310368e-08
the O 0 8.637492499019572e-08
CYP27 O 0 3.559339893399738e-05
gene O 0 2.5574478090817365e-09
not O 0 1.157122397899002e-09
only O 0 2.2740513916374994e-09
causes O 0 1.9305970511140913e-07
the O 0 3.2059677579354684e-08
deficiency B-Disease 0 1.7350988628095365e-06
in I-Disease 0 7.80510678310975e-09
the I-Disease 0 7.519155076352035e-08
sterol I-Disease 0 1.526127448414627e-06
27 I-Disease 0 3.8269917013167287e-07
- I-Disease 0 1.2335028998222697e-07
hydroxylase I-Disease 0 4.4204904270372936e-07
activity I-Disease 0 5.901717869960521e-08
, O 0 1.7332173474216006e-09
but O 0 3.4913256730106923e-09
also O 0 7.751046915416282e-09
partially O 0 6.251028850101648e-08
leads O 0 6.6029035572512385e-09
to O 0 1.4320502561560033e-09
alternative O 0 3.803950932024236e-08
pre O 0 4.5096498979546595e-08
- O 0 1.3543085763956242e-08
mRNA O 0 2.6810681674760417e-08
splicing O 0 6.583527323300586e-08
of O 0 5.659940427449328e-08
the O 0 3.715803842396781e-08
gene O 0 1.4488105648524652e-07
. O 0 1.7011223008012166e-06

To O 0 1.0255319438101651e-07
our O 0 7.64609140446737e-08
knowledge O 0 1.3487178307514114e-07
, O 0 1.4926569980033833e-09
this O 0 1.5064248459761842e-10
is O 0 2.536392762486628e-10
the O 0 6.552128839487636e-10
first O 0 1.4660299640922858e-09
report O 0 3.793052094636096e-09
regarding O 0 3.192853625932912e-08
effects O 0 9.298119607592525e-08
on O 0 3.526571390466415e-08
pre O 0 3.471387088893607e-08
- O 0 8.392765593612239e-09
mRNA O 0 1.9611036350397626e-08
splicing O 0 1.78533277050974e-08
of O 0 2.16389004492612e-08
a O 0 4.3942809391239734e-09
mutation O 0 3.463918041290981e-09
at O 0 1.1679278877352317e-08
the O 0 2.55041516794563e-08
- O 0 5.489570398253818e-08
2 O 0 1.4306618822956807e-07
position O 0 1.7263234042275144e-07
of O 0 1.8526219491832308e-07
a O 0 2.260219957861409e-07
5 O 0 6.868384616609546e-07
splice O 0 1.0753510650829412e-05
site O 0 6.956986453587888e-06
. O 0 3.179998657287797e-06

ATM O 0 0.0003354797954671085
germline O 0 4.7792902478249744e-05
mutations O 0 6.881405738567992e-07
in O 0 3.975026174884988e-08
classical O 0 0.34069567918777466
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0007207781891338527
in O 0 2.457804182398604e-09
the O 0 3.34716565575377e-09
Dutch O 0 1.4302418094302993e-07
population O 0 4.189311120228467e-09
. O 0 2.195640824709244e-08

Germline O 0 4.029374031233601e-05
mutations O 0 3.9006417296150175e-07
in O 0 1.340308486419417e-08
the O 0 1.7093373827492542e-08
ATM O 0 4.0245038235298125e-07
gene O 0 2.2379500475011582e-09
are O 0 1.1797256227463748e-10
responsible O 0 2.340470595108002e-10
for O 0 2.0305214454285903e-10
the O 0 1.150060825239052e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998278617858887
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3824278255469835e-07
. O 0 2.684261914964736e-07

In O 0 3.468085481017624e-07
our O 0 1.6316656115122896e-07
study O 0 1.23849561717293e-08
, O 0 1.547370453991448e-09
we O 0 5.073648723374902e-10
have O 0 1.4502904432944774e-10
determined O 0 1.3008932819857932e-09
the O 0 5.45098410853484e-09
ATM O 0 4.952461267748731e-07
mutation O 0 1.3010802213386796e-08
spectrum O 0 3.3620622730268224e-08
in O 0 2.3683492944570617e-09
19 O 0 5.332622166065448e-08
classical O 0 2.583266450528754e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.174333684796693e-08
, O 0 7.581895111741233e-10
including O 0 9.962406594121731e-11
some O 0 3.6049960239203926e-10
immigrant O 0 1.808615124332391e-08
populations O 0 4.4614552052735235e-09
, O 0 5.925590573774286e-10
as O 0 3.105178114637397e-09
well O 0 1.872489940879518e-09
as O 0 3.918894542209728e-09
12 O 0 1.572545293981875e-08
of O 0 1.3260105014012424e-08
Dutch O 0 2.76392341902465e-07
ethnic O 0 3.095050615797845e-08
origin O 0 3.9492567793786293e-07
. O 0 5.831931275679381e-07

Both O 0 3.433527524521196e-07
the O 0 1.1628914364791854e-07
protein O 0 2.7939921665165457e-07
truncation O 0 5.553516757572652e-07
test O 0 2.9286869818179184e-08
( O 0 1.076674820410517e-07
PTT O 0 4.098735189472791e-06
) O 0 2.510519125920041e-09
and O 0 9.730853900435932e-10
the O 0 2.319845204823423e-09
restriction O 0 1.745999078650584e-08
endonuclease O 0 1.3621846051137254e-07
fingerprinting O 0 4.388470387084453e-08
( O 0 5.0555129860185843e-08
REF O 0 2.622068450364168e-06
) O 0 1.2274607996687337e-09
method O 0 6.655719086978706e-09
were O 0 1.6241314959586362e-09
used O 0 1.7048172873401768e-09
and O 0 2.072088056692678e-09
compared O 0 3.0040214760163053e-09
for O 0 4.0990366656501465e-10
their O 0 8.872100276668959e-10
detection O 0 2.7683332959327345e-08
efficiency O 0 2.7496939836169076e-08
, O 0 1.0928803417797894e-09
identifying O 0 1.5831357558226955e-08
76 O 0 8.21497465608445e-08
% O 0 7.331726337156397e-10
and O 0 1.4222013844378267e-10
60 O 0 2.735067505810207e-09
% O 0 2.8183147482430115e-10
of O 0 1.0395927452222509e-09
the O 0 8.964503805941604e-09
mutations O 0 2.0169364844946358e-08
, O 0 2.657369257974551e-08
respectively O 0 1.974876369104095e-07
. O 0 8.221837788369157e-07

Most O 0 2.733583528424788e-07
patients O 0 3.4370291501772954e-08
were O 0 8.71631478105428e-09
found O 0 8.047367217045576e-10
to O 0 8.811473217740229e-10
be O 0 5.173611761222219e-09
compound O 0 1.4394140634976793e-06
heterozygote O 0 9.101477917283773e-05
. O 0 1.9144383713864954e-06

Seventeen O 0 5.77205219087773e-06
mutations O 0 2.688130109618214e-07
were O 0 3.3149866851545085e-08
distinct O 0 2.0542627154895854e-08
, O 0 1.6038140815410884e-09
of O 0 3.151070959717117e-09
which O 0 3.3318955927619243e-10
10 O 0 6.0001439372570076e-09
were O 0 4.5118504488073086e-09
not O 0 4.880102100202066e-09
reported O 0 1.4396664482774213e-07
previously O 0 1.8397656731394818e-07
. O 0 4.7658301127739833e-07

Mutations O 0 2.9436534987326013e-06
are O 0 3.193072828366894e-08
small O 0 3.446955432195864e-08
deletions O 0 4.4613301497520297e-07
or O 0 2.386974244927842e-07
point O 0 9.932431339620962e-07
mutations O 0 1.9679107765568915e-07
frequently O 0 9.579414239624384e-08
affecting O 0 2.890628252316674e-07
splice O 0 7.843858838896267e-06
sites O 0 2.773518644971773e-06
. O 0 2.1555067633016733e-06

Moreover O 0 2.194327680626884e-05
, O 0 6.199550171004375e-07
a O 0 5.848344812875439e-07
16 O 0 5.2871464504278265e-06
. O 0 2.836226485669613e-06

7 O 0 2.6327094019507058e-05
- O 0 2.153224386347574e-06
kb O 0 4.526118573267013e-06
genomic O 0 2.138390868822171e-07
deletion O 0 7.195932738568445e-08
of O 0 7.515384226053357e-08
the O 0 1.816882111427276e-08
3 O 0 3.2895592028125975e-08
end O 0 1.0874373401748016e-08
of O 0 1.845265096278581e-08
the O 0 6.26533847025712e-09
gene O 0 1.7345599401252798e-09
, O 0 8.983722099564773e-10
most O 0 3.9473543878010275e-10
likely O 0 1.5079032467113507e-09
a O 0 4.21032847475189e-10
result O 0 4.053315905139243e-09
of O 0 3.252759395167004e-09
recombination O 0 9.00564678385507e-10
between O 0 8.106095350512987e-09
two O 0 1.7764536508479978e-08
LINE O 0 6.750638476660242e-06
elements O 0 3.803529935453298e-08
, O 0 1.4840956907846703e-08
was O 0 1.061210426200887e-07
identified O 0 3.0597513500651985e-07
. O 0 7.884138994995737e-07

The O 0 6.855885317236243e-07
most O 0 2.4659476238753086e-08
frequently O 0 5.467258645808215e-09
found O 0 5.367966626756981e-10
mutation O 0 6.42052300214857e-10
, O 0 2.1547365280927266e-10
identified O 0 1.1216776396594241e-09
in O 0 1.5218640236902559e-10
three O 0 5.32788924090255e-10
unrelated O 0 2.8402812546346468e-08
Turkish O 0 8.799570991868677e-07
A B-Disease 1 1.0
- I-Disease 0 0.10146011412143707
T I-Disease 1 1.0
individuals O 0 1.0967315944299116e-08
, O 0 5.079558107468074e-09
was O 0 1.4426882799511986e-08
previously O 0 1.4111100066216409e-09
described O 0 2.520766650970785e-10
to O 0 1.8825158099033956e-10
be O 0 6.620340942120606e-10
a O 0 5.3508366626431325e-09
Turkish O 0 2.9768614240310853e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
founder O 0 0.0003357960667926818
mutation O 0 3.2853256470843917e-06
. O 0 1.452093215448258e-06

The O 0 5.862708007953188e-07
presence O 0 3.6655231383520004e-07
of O 0 4.082056364040909e-07
a O 0 3.727893371774371e-08
founder O 0 2.2255859732922545e-07
mutation O 0 7.213258879090745e-09
among O 0 2.305583945982903e-09
relatively O 0 2.5849105078634693e-09
small O 0 7.931675871652999e-10
ethnic O 0 4.4663486797880125e-10
population O 0 6.564459392732758e-11
groups O 0 1.1273129998934373e-11
in O 0 3.112230959056994e-11
Western O 0 2.36288988375577e-09
Europe O 0 1.8237487076078196e-09
could O 0 2.595908821234616e-09
indicate O 0 1.643706326603933e-08
a O 0 6.2221805485762616e-09
high O 0 1.8453389927231e-08
carrier O 0 1.5476537829073322e-09
frequency O 0 2.680448307756933e-09
in O 0 5.519550372312665e-10
such O 0 6.7517946789052985e-09
communities O 0 1.4324832875445281e-07
. O 0 1.8335894083065796e-06

In O 0 3.5985966206908415e-08
patients O 0 3.3449061298540528e-09
of O 0 1.645676306338828e-08
Dutch O 0 2.609734508496331e-07
ethnic O 0 6.523924511725454e-09
origin O 0 1.511543601395715e-08
, O 0 1.1227135887637019e-09
however O 0 4.838395017969788e-09
, O 0 2.0538071243692002e-09
no O 0 1.195857191049754e-08
significant O 0 1.4006161563884234e-07
founder O 0 8.19930221496179e-07
effect O 0 1.8527245515542745e-07
could O 0 3.1930241561894945e-08
be O 0 3.107929202883497e-08
identified O 0 9.532987519378366e-07
. O 0 4.820118419956998e-07

The O 0 2.198847397494319e-07
observed O 0 7.095337650753208e-08
genetic O 0 6.300765420519383e-08
heterogeneity O 0 2.8027884013681614e-07
including O 0 2.2315902459268955e-09
the O 0 8.167599929720382e-09
relative O 0 4.444184469321044e-06
high O 0 2.6166978841501987e-06
percentage O 0 2.862293797534221e-07
of O 0 6.634428473262233e-08
splice O 0 2.0038817183376523e-06
- O 0 6.257201903281384e-07
site O 0 3.424642329719063e-07
mutations O 0 8.006496443613287e-08
had O 0 3.9551508734803065e-08
no O 0 1.509739888660988e-08
reflection O 0 9.446291215908786e-08
on O 0 2.6357589888448274e-08
the O 0 8.311840815622418e-08
phenotype O 0 2.5504209588689264e-06
. O 0 1.3196921599956113e-06

All O 0 3.2226378721134097e-07
patients O 0 2.420328293339935e-08
manifested O 0 5.33473851760391e-08
classical O 0 4.3015751316488604e-07
A B-Disease 1 1.0
- I-Disease 0 0.029681069776415825
T I-Disease 1 1.0
and O 0 3.924349556427842e-08
increased O 0 4.848466872431345e-08
cellular O 0 2.7308004746373626e-07
radioresistant O 0 1.8988628198712831e-06
DNA O 0 3.156812056204217e-07
synthesis O 0 3.006740371347405e-06
. O 0 7.36916490495787e-07

Determination O 0 7.087816698003735e-07
of O 0 5.043426085649116e-07
the O 0 3.620386124225661e-08
genomic O 0 1.1344676664748476e-07
structure O 0 5.5823718980718695e-08
of O 0 3.330418607561114e-08
the O 0 5.3753282713842054e-08
COL4A4 O 0 0.002629101974889636
gene O 0 5.415356163496199e-09
and O 0 3.512941493255539e-09
of O 0 5.497017507849478e-09
novel O 0 2.989710168321835e-08
mutations O 0 2.028202970905113e-06
causing O 0 0.0001841234479798004
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.5816365450737067e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.0167092057145055e-07
a O 0 4.224039074074426e-08
progressive O 0 0.0016580705996602774
hematuric B-Disease 1 0.9999523162841797
glomerulonephritis I-Disease 1 1.0
characterized O 0 2.637115130710299e-07
by O 0 3.893623912176736e-08
glomerular B-Disease 1 0.9999483823776245
basement I-Disease 0 0.0613405816257
membrane I-Disease 0 4.480877123569371e-06
abnormalities I-Disease 0 3.852209829346975e-06
and O 0 2.8221947001583203e-09
associated O 0 8.395218031864715e-08
with O 0 5.984223783173093e-09
mutations O 0 5.1918132015771334e-08
in O 0 2.43375164465931e-09
either O 0 1.7939004948175352e-08
the O 0 1.2276983341052983e-07
COL4A3 O 0 0.2196514755487442
or O 0 5.883518561233814e-09
the O 0 4.210003368143589e-08
COL4A4 O 0 7.846912012610119e-06
gene O 0 4.7016328608151525e-09
, O 0 1.793523218829307e-09
which O 0 2.444814350965885e-10
encode O 0 2.166413182180804e-08
the O 0 8.409241303297676e-08
alpha3 O 0 1.6735701137804426e-05
and O 0 1.1392294396728175e-07
alpha4 O 0 6.465595561166992e-06
type O 0 9.323689482698683e-07
IV O 1 0.9997528195381165
collagen O 0 0.00010708221816457808
chains O 0 4.0620598156237975e-05
, O 0 4.1424345909035765e-07
respectively O 0 6.193682793309563e-07
. O 0 7.304737437152653e-07

To O 0 7.476809571471676e-08
date O 0 5.183358666727145e-07
, O 0 4.010573650958804e-09
mutation O 0 3.6194505725895e-10
screening O 0 4.823989541158369e-10
in O 0 2.950364952347684e-10
the O 0 3.314232888129709e-09
two O 0 9.71727698306779e-10
genes O 0 3.4340521537501445e-09
has O 0 9.019983648883567e-10
been O 0 7.066537355271407e-10
hampered O 0 1.5892167581910144e-08
by O 0 3.921988289690148e-10
the O 0 6.899750992772624e-09
lack O 0 1.3623068184642761e-07
of O 0 1.739397781364005e-08
genomic O 0 9.186095439872588e-08
structure O 0 6.851232114968298e-08
information O 0 4.5242103396958555e-07
. O 0 7.585459229630942e-07

We O 0 1.8607281049298763e-07
report O 0 6.227169535577559e-08
here O 0 6.720214162925231e-09
the O 0 2.8179079070156376e-09
complete O 0 4.745970283437373e-09
characterization O 0 2.4118543251461233e-07
of O 0 3.002293169629411e-08
the O 0 2.0470736217248486e-08
48 O 0 1.331673189497451e-07
exons O 0 8.591667466362196e-08
of O 0 9.595689220986969e-08
the O 0 1.4780735568820091e-07
COL4A4 O 0 0.000324806576827541
gene O 0 1.5322694224551014e-08
, O 0 3.40823813615998e-09
a O 0 2.1532173821725564e-09
comprehensive O 0 1.2067523869063734e-08
gene O 0 2.6119011398151315e-09
screen O 0 9.66945492564264e-08
, O 0 4.397198605232688e-09
and O 0 1.0273714101671771e-09
the O 0 3.2166341812356336e-10
subsequent O 0 3.0841457165919905e-10
detection O 0 3.648187973936956e-09
of O 0 3.1497131569580006e-09
10 O 0 2.9972109238940448e-09
novel O 0 1.8713401939152163e-09
mutations O 0 1.2607391797203604e-09
in O 0 3.5138977838578e-10
eight O 0 1.822094652936812e-08
patients O 0 9.148327961838731e-08
diagnosed O 0 3.438712383285747e-06
with O 0 1.1317942494315503e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.446391802863218e-06

Furthermore O 0 2.5486219783488195e-06
, O 0 6.598008894798113e-08
we O 0 1.248642700346636e-08
identified O 0 3.6377258538777824e-08
a O 0 8.787476524219073e-09
glycine O 0 2.0849418191914992e-08
to O 0 1.4328972453014899e-09
alanine O 0 6.717013434354158e-08
substitution O 0 7.214045893988441e-08
in O 0 5.272141390122442e-09
the O 0 1.7872270774432764e-08
collagenous O 0 1.2192396070531686e-06
domain O 0 1.0380734494219723e-08
that O 0 6.285659770455254e-10
is O 0 7.205142593669223e-10
apparently O 0 1.834809992828923e-08
silent O 0 1.1506413599704501e-08
in O 0 3.85038001482485e-10
the O 0 3.0765858749504105e-09
heterozygous O 0 3.7187515289360817e-09
carriers O 0 9.093281683192345e-09
, O 0 5.1313828741683665e-09
in O 0 1.3592099001868974e-08
11 O 0 9.812305279410793e-07
. O 0 1.7051747818186413e-06

5 O 0 8.508088740200037e-07
% O 0 8.888822122798956e-09
of O 0 5.3146669287684745e-09
all O 0 4.865201574943967e-10
control O 0 9.230329833798123e-10
individuals O 0 1.6241955003160058e-10
, O 0 3.1413122103529645e-10
and O 0 1.5771124683983118e-10
in O 0 1.3568332568603125e-10
one O 0 4.530034125593829e-10
control O 0 8.474007606729117e-10
individual O 0 1.6423079562954968e-09
homozygous O 0 5.5135980225884396e-09
for O 0 2.388873987513307e-09
this O 0 2.47463960434402e-09
glycine O 0 1.6424786508650868e-07
substitution O 0 1.1112628044429584e-06
. O 0 1.2003062010990107e-06

There O 0 3.122525811249943e-07
has O 0 1.3034994417182588e-08
been O 0 4.505546602473487e-09
no O 0 8.790388972279572e-10
previous O 0 2.2216737338709436e-09
finding O 0 9.859393301780983e-09
of O 0 5.018790272259821e-09
a O 0 1.1356444673538135e-09
glycine O 0 2.77345835186793e-09
substitution O 0 1.0610158085455623e-08
that O 0 6.34158336954016e-10
is O 0 1.4729044373051892e-10
not O 0 6.222269227640354e-11
associated O 0 2.427196887921923e-09
with O 0 1.2012740802092026e-10
any O 0 1.1955608059111e-08
obvious O 0 7.822695238246524e-07
phenotype O 0 4.094024319556411e-08
in O 0 1.101746138765236e-09
homozygous O 0 2.82229297710046e-08
individuals O 0 2.3122966652522337e-08
. O 0 8.318444884025666e-07

Founder O 0 0.0004233807558193803
BRCA1 O 0 2.4097391360555775e-05
and O 0 4.532985826699587e-07
BRCA2 O 0 2.2323625614717457e-07
mutations O 0 1.526051107703097e-08
in O 0 1.7679009367554954e-09
French O 0 5.385292070059222e-07
Canadian O 0 6.660000508418307e-05
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.90026710811253e-07
. O 0 1.550255035454029e-07

We O 0 1.5206852310711838e-07
have O 0 8.458348688122896e-09
identified O 0 6.818056164092923e-08
four O 0 4.886566262740644e-09
mutations O 0 3.2180904607770344e-09
in O 0 5.840781192034683e-10
each O 0 1.0799461325206039e-09
of O 0 1.2245996572346485e-07
the O 0 2.468935417709872e-05
breast B-Disease 0 0.02485317923128605
cancer I-Disease 0 2.175951885874383e-05
- O 0 5.68096538700047e-07
susceptibility O 0 7.405207611554943e-07
genes O 0 6.953869302606108e-08
, O 0 1.611185673766613e-08
BRCA1 O 0 8.131153350632303e-08
and O 0 2.626099160352169e-08
BRCA2 O 0 1.232947823837094e-07
, O 0 1.5632052319247691e-09
in O 0 6.543161568117739e-10
French O 0 7.729258300059882e-07
Canadian O 0 2.9447960514517035e-06
breast B-Disease 0 0.0004450698907021433
cancer I-Disease 1 0.7392443418502808
and O 1 0.9999027252197266
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.3904979329358866e-08
from O 0 2.5111715373782317e-08
Quebec O 0 4.718223465260962e-07
. O 0 3.180715850703564e-07

To O 0 4.13136405086334e-07
identify O 0 3.0618200526078e-06
founder O 0 2.9786575396428816e-05
effects O 0 0.000323796208249405
, O 0 2.3450306585459657e-08
we O 0 2.6384034956805635e-09
examined O 0 6.9822547743569885e-09
independently O 0 3.240127277592819e-09
ascertained O 0 1.4342944609779806e-07
French O 0 9.147891688598975e-08
Canadian O 0 2.332006232563799e-08
cancer B-Disease 0 6.511070793635554e-09
families O 0 2.8763358361771907e-10
for O 0 8.945928026138361e-11
the O 0 3.686054239615544e-10
distribution O 0 3.820104677032532e-09
of O 0 4.748360815653996e-09
these O 0 4.016820653873765e-09
eight O 0 1.1618040218763781e-07
mutations O 0 1.1042881169487373e-06
. O 0 9.577821629136452e-07

Mutations O 0 2.4556461539759766e-06
were O 0 1.6082083220680943e-07
found O 0 1.0584245480060872e-08
in O 0 1.7716342837204024e-09
41 O 0 1.7911008853843668e-07
of O 0 1.9920170402087933e-08
97 O 0 6.809945034547127e-07
families O 0 1.1344936723389765e-07
. O 0 7.142977551666263e-07

Six O 0 1.8387165710009867e-06
of O 0 5.263894991003326e-07
eight O 0 7.046811845157208e-08
mutations O 0 5.942505865164094e-08
were O 0 2.1324478183259998e-08
observed O 0 2.4021620248504405e-08
at O 0 2.3148650996063225e-08
least O 0 1.9692599551035528e-08
twice O 0 2.5030237793544075e-07
. O 0 4.033852292195661e-07

The O 0 7.87254703027429e-06
BRCA1 O 0 4.222213192406343e-06
C4446T O 0 3.5864934488927247e-06
mutation O 0 3.187632913181915e-08
was O 0 2.9754312791396842e-08
the O 0 1.6876411379485035e-09
most O 0 2.8057320355934223e-10
common O 0 5.811067738115128e-10
mutation O 0 1.4821430749378806e-09
found O 0 6.773641647583872e-10
, O 0 2.1246507331262876e-10
followed O 0 1.0098512026601725e-09
by O 0 9.098637954174649e-10
the O 0 2.674766221844038e-07
BRCA2 O 0 5.633721229969524e-06
8765delAG O 0 3.3445717235736083e-06
mutation O 0 3.4890578604063194e-07
. O 0 8.721172548575851e-07

Together O 0 1.4247758883811912e-07
, O 0 1.895621970504635e-08
these O 0 5.023760962785673e-09
mutations O 0 2.3171002894173398e-08
were O 0 5.219134013856319e-09
found O 0 1.3317303926285717e-09
in O 0 2.6998112079290593e-10
28 O 0 2.6608690362195375e-08
of O 0 3.797265613059153e-09
41 O 0 1.9116377814043517e-08
families O 0 4.420321331188859e-10
identified O 0 2.7555833170822552e-09
to O 0 1.0953679074887646e-09
have O 0 1.3295300416160671e-09
a O 0 1.3794771547281925e-08
mutation O 0 1.6183719253604067e-07
. O 0 2.980202964408818e-07

The O 0 8.546529670638847e-07
odds O 0 1.1651621889541275e-06
of O 0 5.497982069613272e-09
detection O 0 2.426503620256426e-08
of O 0 4.247142193491982e-09
any O 0 5.508394629316626e-09
of O 0 1.6910873057440767e-07
the O 0 1.255744876971221e-07
four O 0 1.430923930456629e-07
BRCA1 O 0 7.168671345425537e-07
mutations O 0 1.8201431828401837e-07
was O 0 1.004405930871144e-06
18 O 0 1.0121813147634384e-06
. O 0 1.1666453474390437e-06

7x O 0 0.0005403024842962623
greater O 0 2.3125408006308135e-06
if O 0 8.942477336404409e-08
one O 0 5.509014577853577e-09
or O 0 1.9621418378967803e-10
more O 0 9.229726011250605e-11
cases O 0 1.9914536686371775e-09
of O 0 6.218053840711946e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.076684608136702e-08
also O 0 1.972468299804575e-10
present O 0 1.571179714110471e-10
in O 0 2.3685919892102447e-10
the O 0 2.6569232147721777e-08
family O 0 3.408403017601813e-07
. O 0 4.2101001440641994e-07

The O 0 9.561558727000374e-07
odds O 0 2.210960246884497e-06
of O 0 9.868047712302541e-09
detection O 0 2.2637353325194454e-08
of O 0 7.664398005147177e-09
any O 0 6.36100594419986e-09
of O 0 2.2977276614710718e-07
the O 0 2.526440141537023e-07
four O 0 1.1353075990427897e-07
BRCA2 O 0 4.223660710067634e-07
mutations O 0 4.1074070367130844e-08
was O 0 2.4002002874112804e-07
5 O 0 6.874788027744216e-07
. O 0 4.308670042973972e-07

3x O 0 1.5348676242865622e-05
greater O 0 2.576938129550399e-07
if O 0 5.537862435289753e-08
there O 0 3.0094025049720585e-08
were O 0 2.009134547620306e-08
at O 0 3.262974779261185e-09
least O 0 5.44931821888639e-10
five O 0 1.734307697454085e-10
cases O 0 1.7243012573331384e-09
of O 0 8.337865864405103e-08
breast B-Disease 0 0.00013488030526787043
cancer I-Disease 0 1.0549725629971363e-05
in O 0 1.775287583605234e-09
the O 0 6.364673055259118e-08
family O 0 1.1400598509681004e-07
. O 0 1.8817463853793015e-07

Interestingly O 0 3.9559545257361606e-06
, O 0 3.087910016574824e-08
the O 0 1.8755967445827082e-08
presence O 0 9.435522940748342e-08
of O 0 1.1640291859293939e-06
a O 0 6.399109224730637e-07
breast B-Disease 0 1.8380084156888188e-06
cancer I-Disease 0 7.505757793069279e-08
case O 0 5.662507795989313e-09
< O 0 7.788748312975713e-09
36 O 0 9.051008831306717e-09
years O 0 4.344972992509355e-10
of O 0 1.9753683133671984e-09
age O 0 5.315701656627425e-09
was O 0 3.5561478206602715e-09
strongly O 0 2.6170313138784707e-10
predictive O 0 3.6078042775500307e-09
of O 0 2.0618298179897465e-09
the O 0 1.2939124216515552e-09
presence O 0 4.037128853440208e-09
of O 0 6.8138406028595e-09
any O 0 8.24905743712634e-09
of O 0 1.1813563816076567e-07
the O 0 7.67437811077798e-08
eight O 0 4.253070073900744e-08
mutations O 0 1.4044161389392684e-07
screened O 0 7.336026897064585e-07
. O 0 4.61793206341099e-07

Carriers O 0 1.0167673281102907e-07
of O 0 1.2875472066298244e-07
the O 0 1.9647353965979164e-08
same O 0 1.5049838042457964e-09
mutation O 0 1.076548628020646e-09
, O 0 7.167267473962013e-11
from O 0 4.315279383826365e-11
different O 0 1.1233684815703526e-10
families O 0 1.8463977013993826e-09
, O 0 4.2277828460335343e-10
shared O 0 5.313660622618954e-10
similar O 0 3.6213290699471656e-10
haplotypes O 0 4.947933973653562e-08
, O 0 9.070170170488723e-10
indicating O 0 5.793971524781227e-09
that O 0 2.3021597128636273e-10
the O 0 1.7047913081214006e-09
mutant O 0 6.703584354283976e-09
alleles O 0 1.959076456614639e-09
were O 0 3.925747282806924e-09
likely O 0 3.970295647803823e-09
to O 0 5.502396316359182e-10
be O 0 3.8250899669911576e-10
identical O 0 1.2694960638270913e-09
by O 0 4.560445909795874e-10
descent O 0 5.644337885968298e-09
for O 0 4.159404209946871e-10
a O 0 2.5620565669015605e-09
mutation O 0 3.0138929130174574e-09
in O 0 1.3424927836069855e-09
the O 0 3.905159573491801e-08
founder O 0 7.690113648095576e-07
population O 0 2.6264499908279504e-08
. O 0 1.6924586532240937e-07

The O 0 1.2707418228785627e-08
identification O 0 1.761889656393123e-08
of O 0 2.831972167882668e-08
common O 0 8.946486218519567e-08
BRCA1 O 0 3.286713990746648e-06
and O 0 4.953193410983658e-07
BRCA2 O 0 5.454813845062745e-07
mutations O 0 1.2673603499990804e-08
will O 0 7.237924704028842e-10
facilitate O 0 4.805286391018626e-09
carrier O 0 1.3966693357403415e-09
detection O 0 4.06076017256396e-09
in O 0 1.1606036132150166e-09
French O 0 9.136049357039155e-07
Canadian O 0 1.7313220723735867e-06
breast B-Disease 0 0.006369325798004866
cancer I-Disease 1 0.8927052021026611
and O 1 0.9892296195030212
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.446847193165013e-07
. O 0 1.2968637008725636e-07

Are O 0 4.036969869503082e-07
Dp71 O 0 5.954822336207144e-05
and O 0 1.9129880968193902e-07
Dp140 O 0 1.1849398106278386e-05
brain O 0 4.91466607854818e-06
dystrophin O 0 2.4371408926526783e-06
isoforms O 0 1.8210458563316934e-07
related O 0 2.886275041191766e-08
to O 0 3.797641756619896e-09
cognitive B-Disease 0 2.5744724553078413e-05
impairment I-Disease 1 0.9988676309585571
in O 0 8.566497058382083e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999978542327881

Molecular O 0 3.6815370094700484e-06
study O 0 5.112910983484653e-08
and O 0 3.747818055899188e-09
neuropsychological O 0 7.300140936195021e-08
analysis O 0 3.0774327086646736e-08
were O 0 1.6239029676512473e-08
performed O 0 2.4224147132656526e-09
concurrently O 0 9.236656772770857e-09
on O 0 8.674504670125316e-09
49 O 0 5.845066652909736e-08
patients O 0 2.264684439978737e-09
with O 0 1.633757484853504e-08
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999750852584839
DMD B-Disease 1 1.0
) O 0 1.2659029380301945e-09
in O 0 7.273570634680482e-11
order O 0 4.0218783858847473e-10
to O 0 1.551024864099304e-10
find O 0 2.86603119015183e-09
a O 0 7.771886467722311e-10
molecular O 0 9.437409964618837e-09
explanation O 0 9.466036843264192e-09
for O 0 6.394589302516351e-10
the O 0 9.479660612043972e-09
cognitive B-Disease 0 4.52945687356987e-06
impairment I-Disease 0 2.676251142474939e-06
observed O 0 1.5253032614737094e-08
in O 0 1.4071833698281466e-09
most O 0 5.5889557870614226e-08
DMD B-Disease 1 1.0
patients O 0 2.3969087692421454e-07
. O 0 5.149691446604265e-07

Complete O 0 5.922545653902489e-08
analysis O 0 7.172638305519285e-08
of O 0 6.530998319931314e-08
the O 0 2.376164864870134e-08
dystrophin O 0 6.270601033975254e-07
gene O 0 3.9489098213607576e-08
was O 0 2.52568383984908e-07
performed O 0 1.4864569297667884e-10
to O 0 1.5653407736682112e-10
define O 0 3.089299038805393e-09
the O 0 5.768180599829975e-09
localization O 0 3.3608256444495055e-07
of O 0 3.377668278403689e-08
deletions O 0 2.48819645776166e-07
and O 0 2.022583878158457e-08
duplications O 0 3.481336818822456e-07
in O 0 6.171074762306716e-09
relation O 0 5.2530928940086596e-08
to O 0 5.79665782041161e-09
the O 0 6.581179690101635e-08
different O 0 2.6557384558145714e-07
DMD B-Disease 1 1.0
promoters O 0 0.00013761343143414706
. O 0 8.443686056125443e-06

Qualitative O 0 1.3665101050719386e-06
analysis O 0 7.592017681190555e-08
of O 0 1.4365929246196174e-07
the O 0 1.0066213462778251e-07
Dp71 O 0 5.475262241816381e-06
transcript O 0 1.6830877314077952e-07
and O 0 1.1914534914225783e-09
testing O 0 2.3126914272530996e-10
for O 0 4.417834986725211e-10
the O 0 2.4834294620745823e-09
specific O 0 4.059660163591161e-09
first O 0 1.0995067079022647e-08
exon O 0 1.95613516495996e-08
of O 0 8.276673213458707e-08
Dp140 O 0 1.6481286593261757e-06
were O 0 7.758282549730211e-08
also O 0 1.6881152475889394e-08
carried O 0 9.75544764969527e-08
out O 0 9.639384757065272e-08
. O 0 1.1497253353809356e-06

Neuropsychological O 0 5.325250185705954e-06
analysis O 0 5.894456194255326e-07
assessed O 0 1.239253833773546e-06
verbal O 0 7.424483783324831e-07
and O 0 6.494551740843235e-08
visuospatial O 0 5.467852588481037e-06
intelligence O 0 4.591723836711026e-07
, O 0 2.6888523407819775e-08
verbal O 0 4.843041665480996e-07
memory O 0 0.008798877708613873
, O 0 1.4623255140122637e-07
and O 0 5.531581592777002e-08
reading O 0 1.8089657487507793e-06
skills O 0 3.797923000092851e-06
. O 0 3.7158295072003966e-06

Comparison O 0 4.878917934547644e-06
of O 0 5.11323321461532e-07
molecular O 0 1.4508115100397845e-06
and O 0 4.238202322426332e-08
psychometric O 0 9.668594884715276e-07
findings O 0 1.424943008032642e-07
demonstrated O 0 3.8690977532951365e-08
that O 0 2.6264137531484266e-09
deletions O 0 1.3098677698053507e-07
and O 0 8.069442891667222e-09
duplications O 0 1.5996501190329582e-07
that O 0 2.559404466140336e-09
were O 0 3.2498816970871758e-09
localized O 0 1.4349907928590255e-07
in O 0 1.1730397764253553e-09
the O 0 9.975765102865353e-09
distal O 0 2.475817098002153e-07
part O 0 6.362862237097033e-09
of O 0 8.519327820977196e-08
the O 0 7.179070848906122e-08
gene O 0 1.6178743678096907e-08
seemed O 0 9.920742627400614e-08
to O 0 1.0161015362442072e-09
be O 0 1.0788118176563444e-09
preferentially O 0 1.472349797637662e-08
associated O 0 2.6447784406968822e-08
with O 0 1.283178008293362e-08
cognitive B-Disease 1 0.7072374820709229
impairment I-Disease 1 0.9967425465583801
. O 0 2.4211469735746505e-06

Two O 0 1.535434080324194e-06
altered O 0 2.1354042019083863e-06
Dp71 O 0 1.5102350516826846e-05
transcripts O 0 6.056487222849682e-07
and O 0 2.1085769574824553e-08
two O 0 3.9893790493295e-09
deleted O 0 4.379230844619997e-08
Dp140 O 0 3.874311360618776e-08
DNA O 0 2.5093891409255775e-09
sequences O 0 1.0682238427150992e-09
were O 0 9.75720726437146e-10
found O 0 1.827013679234213e-10
in O 0 1.0424475171966208e-10
four O 0 3.704689610639633e-10
patients O 0 5.410006331807438e-10
with O 0 1.863077692121351e-09
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 3.46012097907078e-06

These O 0 1.1604430483203032e-07
findings O 0 7.526860201778618e-08
suggest O 0 1.5607273695650292e-08
that O 0 2.1803726879543461e-10
some O 0 6.720826672967917e-10
sequences O 0 7.540159607799524e-10
located O 0 2.1287973606121113e-09
in O 0 2.671861343284121e-10
the O 0 4.546898857427095e-09
distal O 0 1.0609109324377641e-07
part O 0 2.6494424432144115e-09
of O 0 2.8362210358068296e-08
the O 0 1.117386094762196e-08
gene O 0 3.609263332648993e-09
and O 0 1.7574157240574095e-08
, O 0 1.054108467180015e-09
in O 0 2.8645757987888487e-10
particular O 0 4.418553523066748e-09
, O 0 1.000233895709357e-09
some O 0 4.533519781801942e-09
DMD B-Disease 1 0.9999995231628418
isoforms O 0 1.2218465883506724e-07
expressed O 0 1.774130709009114e-08
in O 0 1.3238995455466807e-09
the O 0 2.1221499224566287e-08
brain O 0 2.563847942838038e-07
may O 0 1.6459047458283749e-09
be O 0 1.6948110970194108e-10
related O 0 1.236672653170956e-09
to O 0 3.907219547905072e-10
the O 0 9.27310850329377e-09
cognitive B-Disease 0 2.939955720648868e-06
impairment I-Disease 0 3.040360752493143e-06
associated O 0 5.850118895978085e-07
with O 0 1.7117297090862849e-07
DMD B-Disease 1 1.0
. O 0 2.9254999844852136e-07
. O 0 1.10490123006457e-06

I1307K O 0 7.57581801735796e-05
APC O 0 6.024318281561136e-06
and O 0 1.261336848301653e-07
hMLH1 O 0 1.2174073162896093e-06
mutations O 0 4.035652523270983e-08
in O 0 4.921623997233837e-09
a O 0 1.6164555916020618e-08
non O 0 2.5316933260910446e-07
- O 0 5.029516003673962e-08
Jewish O 0 4.7315569418060477e-07
family O 0 2.0397697753082866e-08
with O 0 4.799891151208158e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.076029199495679e-06

We O 0 1.3655885311436577e-07
describe O 0 8.057495648472468e-08
a O 0 1.933773319251486e-08
French O 0 2.668162437657884e-07
Canadian O 0 4.698453324181173e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.647842383245006e-07
HNPCC B-Disease 1 0.9312812685966492
) O 0 1.8364650911095737e-09
kindred O 0 3.039312161945418e-07
which O 0 3.766635059410106e-10
carries O 0 6.340353131406573e-09
a O 0 5.610514275389278e-10
novel O 0 4.325147351380565e-09
truncating O 0 1.074358806363307e-07
mutation O 0 1.0031671493493377e-08
in O 0 1.2109255820291764e-08
hMLH1 O 0 1.0360309715906624e-05
. O 0 1.8452425365467207e-06

Interestingly O 0 4.085299224243499e-06
, O 0 5.611194353605242e-08
the O 0 6.160081511552562e-08
I1307K O 0 7.550987675131182e-07
APC O 0 7.752528574656026e-08
polymorphism O 0 1.1128302723761863e-08
, O 0 1.9221668701163708e-09
associated O 0 4.858221380743544e-09
with O 0 2.8274571572950435e-10
an O 0 2.7271429559050375e-10
increased O 0 2.7200846020036806e-09
risk O 0 1.1300815572212741e-07
of O 0 0.019380459561944008
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.6866789076530608e-09
is O 0 1.0481335938061775e-10
also O 0 9.548207363652139e-11
present O 0 2.463895198978605e-10
in O 0 3.8865119456055197e-10
this O 0 2.8431199616818503e-09
family O 0 1.5307743694847886e-07
. O 0 6.500277436316537e-07

The O 0 9.78354478320398e-07
I1307K O 0 1.3649691936734598e-06
polymorphism O 0 6.844688726914683e-08
has O 0 6.0878941887665405e-09
previously O 0 2.5355328947540556e-09
only O 0 5.875934738774902e-10
been O 0 5.335485941948548e-10
identified O 0 1.1222189844062314e-09
in O 0 1.1518039993996254e-10
individuals O 0 2.244669311535219e-10
of O 0 4.6169368772552843e-08
self O 0 2.919343558005494e-07
- O 0 1.0065500646305736e-06
reported O 0 3.104123038610851e-07
Ashkenazi O 0 1.623968728381442e-07
Jewish O 0 3.017173355601699e-07
origins O 0 1.0309365734428866e-06
. O 0 4.977595153832226e-07

In O 0 6.148085418544724e-08
addition O 0 4.6428375810592115e-08
, O 0 2.1398949279216595e-09
in O 0 2.4540272591799805e-10
this O 0 3.75660474949413e-10
family O 0 5.138709013863263e-09
, O 0 4.428380162568857e-10
there O 0 2.1595830679288497e-10
appears O 0 6.353932935354578e-10
to O 0 1.5838468037099318e-10
be O 0 7.138661328731644e-10
no O 0 4.49138104485769e-09
relationship O 0 2.0066057704326568e-09
between O 0 6.020469456302635e-09
the O 0 9.50620471229513e-09
I1307K O 0 5.656778512275196e-08
polymorphism O 0 4.182620472192866e-09
and O 0 8.784422633745237e-10
the O 0 2.252390052248643e-09
presence O 0 1.3531879616834885e-08
or O 0 2.87117583042118e-08
absence O 0 6.812078936491162e-05
of O 0 9.268882763535657e-07
cancer B-Disease 0 1.5997583204807597e-06
. O 0 6.207602609720198e-08
. O 0 3.5428269029580406e-07

Identification O 0 3.7135376373953477e-07
of O 0 1.1992541715244442e-07
a O 0 6.245675532312589e-09
novel O 0 9.219425223250255e-09
mutation O 0 3.888241728589037e-09
of O 0 1.5912064554868266e-08
the O 0 8.08044262612384e-08
CPO O 0 3.903279321093578e-06
gene O 0 8.529827510983523e-09
in O 0 5.08700415124963e-09
a O 0 2.663189313523162e-08
Japanese O 0 1.7811341876949882e-06
hereditary B-Disease 1 0.999197781085968
coproporphyria I-Disease 1 0.9816556572914124
family O 0 2.3191664695332292e-06
. O 0 1.149136664935213e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 3.891926826327108e-05
HCP B-Disease 1 1.0
) O 0 1.2352310818641854e-07
is O 0 1.070100541511465e-08
an O 0 3.289879657586425e-08
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999963045120239
characterized O 0 1.4798324787790307e-09
by O 0 1.2826652240338632e-10
a O 0 1.982184638649187e-09
deficiency B-Disease 0 1.561292083351873e-05
of I-Disease 0 1.2059917935403064e-05
coproporphyrinogen I-Disease 0 0.0002082058199448511
oxidase I-Disease 0 2.9183721039771626e-07
( O 0 2.6621684412475588e-08
CPO O 0 1.7860704701888608e-06
) O 0 3.74557246329843e-10
caused O 0 4.340320547413512e-09
by O 0 3.7012573561590045e-10
a O 0 1.0663021576817755e-09
mutation O 0 2.164660672931973e-09
in O 0 1.319352072037816e-09
the O 0 9.890399610412715e-08
CPO O 0 1.9106166291749105e-05
gene O 0 4.585571105053532e-07
. O 0 1.5158561836869922e-06

Only O 0 2.5356317223668157e-07
11 O 0 2.0704304404262075e-07
mutations O 0 2.6382890538911852e-08
of O 0 4.762422278759004e-08
the O 0 7.8518125334881e-09
gene O 0 4.365942718465021e-09
have O 0 3.698944484042954e-09
been O 0 2.1931787497209143e-09
reported O 0 5.570541805610674e-09
in O 0 3.6662688440713964e-09
HCP B-Disease 1 1.0
patients O 0 1.318773797720496e-06
. O 0 1.4962969316911767e-06

We O 0 3.5638774420476693e-07
report O 0 8.617400482080484e-08
another O 0 1.5209600690013758e-08
mutation O 0 6.539946362238425e-09
in O 0 1.6717092155005275e-09
a O 0 1.1924043086253278e-08
Japanese O 0 3.9068217461135646e-07
family O 0 2.614539766909729e-07
. O 0 4.850150503443729e-07

Polymerase O 0 1.9631622762972256e-06
chain O 0 1.0875711495828e-06
reaction O 0 2.228635764822684e-07
- O 0 1.3927919439993275e-07
single O 0 3.653563895866796e-09
strand O 0 5.958745052936365e-09
conformational O 0 2.1154564766590056e-09
polymorphism O 0 1.5101654371463269e-09
and O 0 2.6862403967875537e-10
direct O 0 1.963430529272614e-09
sequence O 0 7.476901875413944e-10
analyses O 0 5.300342831304761e-09
demonstrated O 0 2.554561673306921e-09
a O 0 5.1579949200686315e-09
C O 0 4.425885435921373e-08
to O 0 2.3695694295611247e-09
T O 0 1.733085852606564e-08
substitution O 0 5.500678135206272e-09
in O 0 4.936024367019343e-10
exon O 0 2.9472786433615283e-09
1 O 0 1.0758594903848007e-08
of O 0 8.416361829688412e-09
the O 0 3.8222857767777896e-08
CPO O 0 4.367161352547555e-07
gene O 0 2.3465416276735596e-09
at O 0 1.6269380509470466e-08
nucleotide O 0 1.896602164208616e-08
position O 0 2.0688428747916987e-08
85 O 0 2.7621728904136944e-08
, O 0 4.5361209233263367e-10
which O 0 4.4137163368596077e-10
lies O 0 1.4477159915315951e-08
in O 0 6.335127977763477e-10
the O 0 2.2396164922611206e-08
putative O 0 1.6645200275888783e-06
presequence O 0 9.302852959081065e-07
for O 0 6.892661552626578e-09
targeting O 0 1.0880062717433248e-07
to O 0 4.6088509009223344e-08
mitochondria O 0 1.2917741514684167e-05
. O 0 3.1232361834554467e-06

This O 0 1.4063980202649873e-08
mutation O 0 1.8473603091706536e-08
changes O 0 7.484968200799358e-09
the O 0 8.785163707614174e-09
codon O 0 2.3959298545150887e-08
for O 0 2.41325603944631e-09
glutamine O 0 1.3112220642597094e-08
to O 0 1.9384216454199077e-09
a O 0 8.749211133363133e-09
termination O 0 3.936156929285062e-07
codon O 0 9.051846632246452e-07
at O 0 3.4148908412134915e-07
amino O 0 2.2804466937031975e-07
acid O 0 1.6607305042271037e-07
position O 0 4.2194332650069555e-07
29 O 0 5.13960731041152e-06
. O 0 1.4939000720914919e-06

MaeI O 0 4.3094354623463005e-05
restriction O 0 1.0913623782471404e-06
analysis O 0 1.6218699272485537e-07
showed O 0 7.691743775239956e-08
two O 0 1.3992290659459172e-09
other O 0 5.22189957941066e-10
carriers O 0 2.374935581528348e-09
in O 0 8.05142008619697e-10
the O 0 1.9646078541768475e-08
family O 0 1.5175876910689112e-07
. O 0 1.9737240108952392e-07

The O 0 4.205014647595817e-06
C O 0 0.050622936338186264
- O 0 9.72462585195899e-05
T O 0 5.366965979192173e-06
mutation O 0 1.0167437558550318e-08
is O 0 6.477399727700117e-10
located O 0 1.3789397401708925e-09
within O 0 5.891601095875387e-10
a O 0 1.935388294072027e-09
recently O 0 1.0468435007737753e-09
proposed O 0 6.407713804001958e-10
putative O 0 2.9315481597791404e-08
alternative O 0 6.896369697528826e-09
translation O 0 8.761218417419059e-09
initiation O 0 6.544762953808458e-09
codon O 0 8.467989687233057e-08
( O 0 2.941989407645451e-08
TIC O 0 1.636318529563141e-07
- O 0 1.1208980055243956e-07
1 O 0 8.009978813561247e-08
) O 0 7.266682811035707e-10
, O 0 5.741548902982174e-10
supporting O 0 9.43646827344935e-10
that O 0 8.019479524890016e-10
TIC O 0 2.4982583113342116e-08
- O 0 9.18635478797114e-09
1 O 0 1.737567423276687e-08
is O 0 7.813742430862192e-10
the O 0 9.523408728284721e-09
real O 0 5.709153469979356e-07
TIC O 0 1.0984780374201364e-07
rather O 0 6.050099976562251e-09
than O 0 7.001979440701689e-09
TIC O 0 3.1970438385542366e-07
- O 0 2.0325157379375014e-07
2 O 0 2.742419553669606e-07
. O 0 3.0055993249789026e-08
. O 0 1.6464336738408747e-07

Human B-Disease 0 1.5297499089683697e-07
complement I-Disease 0 7.670030299777864e-07
factor I-Disease 0 9.975489774660673e-06
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999948740005493
associated O 1 0.9999535083770752
with O 1 0.9999955892562866
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999982118606567

This O 0 2.6083082360628396e-08
study O 0 1.053694997921184e-08
reports O 0 1.2989179509759197e-08
on O 0 2.0666017785941904e-09
six O 0 3.2097946522924303e-10
cases O 0 6.754599102265502e-10
of O 0 1.036623142880444e-08
deficiency B-Disease 0 1.57179147208808e-05
in I-Disease 0 1.7569858901111957e-09
the I-Disease 0 5.4130433468913e-09
human I-Disease 0 3.215133270728643e-09
complement I-Disease 0 6.4921961140385065e-09
regulatory I-Disease 0 1.1139579925156795e-08
protein I-Disease 0 6.237035421463588e-08
Factor I-Disease 0 4.952466170493608e-08
H I-Disease 1 0.9999998807907104
( O 0 2.947235167027884e-08
FH O 0 8.097605359580484e-07
) O 0 2.591257763917554e-10
in O 0 6.778782396521521e-11
the O 0 1.537769217518914e-10
context O 0 3.210139265519274e-09
of O 0 1.6069006125718488e-09
an O 0 2.5175546980449326e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.962052465387387e-06

Five O 0 6.767228910575795e-07
of O 0 6.244546568723308e-08
the O 0 5.658631341276532e-09
cases O 0 2.752672978445503e-09
were O 0 1.0088828661380944e-09
observed O 0 9.758955865635244e-10
in O 0 1.2042562780312238e-10
children O 0 1.0648388837353195e-09
presenting O 0 2.808251409192053e-08
with O 0 1.0033856767677207e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
HUS B-Disease 1 1.0
) O 0 1.1309993169561494e-05
. O 0 9.968928679882083e-06

Two O 0 9.686012703014057e-08
of O 0 4.6026489286532524e-08
the O 0 1.6953947579168016e-08
children O 0 1.0971166197748516e-08
exhibited O 0 8.508091298153886e-08
a O 0 1.7254865980476097e-08
homozygous O 0 4.7064983732525434e-07
deficiency O 0 8.76683770911768e-06
characterized O 0 7.527331646883795e-09
by O 0 7.628283560379145e-10
the O 0 2.7615302045091994e-08
absence O 0 2.7501430395204807e-06
of O 0 7.36455731953356e-08
the O 0 1.5551943732816653e-08
150 O 0 1.2385452663465912e-08
- O 0 1.5258619256997008e-08
kD O 0 1.8878571594882487e-08
form O 0 9.770317888069258e-10
of O 0 1.3478069327277353e-08
Factor O 0 1.2710744101696037e-07
H O 1 1.0
and O 0 4.55607747085196e-08
the O 0 8.087782532584242e-08
presence O 0 1.7937807683665596e-08
, O 0 1.1460062898649426e-09
upon O 0 1.1975051172896656e-08
immunoblotting O 0 8.584653414800414e-07
, O 0 2.5010749027387646e-09
of O 0 1.862680498732061e-08
the O 0 6.511370997941412e-08
42 O 0 2.6805219022207893e-07
- O 0 1.181366542368778e-07
kD O 0 2.3418844818934303e-07
Factor O 0 6.816716080493279e-08
H O 0 0.014195101335644722
- O 0 5.767093398389989e-07
like O 0 2.131366194646489e-08
protein O 0 5.216360250415164e-07
1 O 0 6.402955250450759e-07
( O 0 1.295987939187171e-08
FHL O 0 5.0790699788194615e-06
- O 0 1.266152906964635e-07
1 O 0 3.165035522556536e-08
) O 0 2.0618523555171464e-10
and O 0 4.033024747496228e-10
other O 0 2.605179405534841e-09
FH O 0 3.783387398925697e-07
- O 0 2.789342978815057e-08
related O 0 4.084181526309294e-08
protein O 0 4.096602879144484e-07
( O 0 3.23770130705725e-08
FHR O 0 0.0003907042555510998
) O 0 9.827476610269059e-09
bands O 0 2.8986366373828787e-07
. O 0 5.657668111780367e-07

Southern O 0 5.735955710406415e-06
blot O 0 3.6347062177810585e-06
and O 0 8.972286913433436e-09
PCR O 0 1.681700645406181e-08
analysis O 0 6.572208111066402e-09
of O 0 3.154823735584955e-09
DNA O 0 5.90994941873646e-09
of O 0 1.1608788597072817e-08
one O 0 1.86570203730696e-09
patient O 0 8.564257747423198e-09
with O 0 4.472258563481546e-09
homozygous O 0 3.6181157270220865e-07
deficiency O 0 0.10534624755382538
ruled O 0 2.7916698286389874e-07
out O 0 5.026549843023531e-09
the O 0 1.958291750980834e-09
presence O 0 3.744260013149869e-09
of O 0 3.4185638764228088e-09
a O 0 9.560277014486473e-10
large O 0 1.9399750694759632e-09
deletion O 0 3.11164072286374e-09
of O 0 1.586170306211443e-08
the O 0 3.706997731001138e-08
FH O 0 1.078758714356809e-06
gene O 0 3.661202674365427e-09
as O 0 1.1464551086248775e-08
the O 0 2.1129695326749243e-08
underlying O 0 8.394719657189853e-07
defect O 0 7.04377498550457e-08
for O 0 2.6552717358185873e-08
the O 0 9.064692676474806e-06
deficiency O 1 0.9999942779541016
. O 0 7.414779247483239e-06

The O 0 2.417883422367595e-07
other O 0 1.3329509052084632e-08
four O 0 4.980987622360544e-09
children O 0 1.2422969319914046e-09
presented O 0 7.228781129242634e-09
with O 0 2.4037880574923065e-09
heterozygous O 0 7.090088871564149e-08
deficiency O 0 5.3769854275742546e-05
and O 0 2.0833596181546454e-08
exhibited O 0 3.528492982241005e-07
a O 0 8.421870312247393e-09
normal O 0 6.935972862720519e-08
immunoblotting O 0 1.2041263062201324e-06
pattern O 0 3.4449310959416835e-08
of O 0 7.558248249495136e-09
proteins O 0 5.3805053745747955e-09
of O 0 8.753622182666732e-08
the O 0 4.852852271142183e-07
FH O 0 0.000616442586760968
family O 0 9.13293149551464e-07
. O 0 1.1488539257697994e-06

Factor B-Disease 0 0.0014781322097405791
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
is O 0 3.3287292922068445e-08
the O 0 2.476765637027256e-08
only O 0 1.0306263931170179e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.00042430171743035316
with O 0 5.484651524056972e-07
HUS B-Disease 1 1.0
. O 0 1.7536309314891696e-05

These O 0 4.2859613813561737e-07
observations O 0 8.529844990334823e-07
suggest O 0 4.8505391703201894e-08
a O 0 2.1788908455278033e-08
role O 0 2.414274646866943e-08
for O 0 1.8363714104907558e-08
FH O 0 7.348262897721725e-06
and O 0 6.418202502800341e-08
/ O 0 2.5967281658267893e-07
or O 0 2.8077586478048033e-08
FH O 0 1.8844971236831043e-06
receptors O 0 6.471255886708605e-08
in O 0 2.203611071394107e-09
the O 0 1.0772311931361855e-08
pathogenesis O 0 0.0009895622497424483
of O 0 5.674440899383626e-07
idiopathic O 1 0.9999514818191528
HUS B-Disease 1 1.0
. O 0 1.1527237120390055e-06
. O 0 1.923352328958572e-06

Further O 0 3.2554987683397485e-07
evidence O 0 2.7201022589906643e-07
for O 0 6.8362839833469025e-09
a O 0 4.132882036600449e-09
major O 0 1.718021991337082e-08
ancient O 0 6.21127398403587e-08
mutation O 0 3.2755511369941814e-07
underlying O 0 1.4829463452770142e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.2964614743159473e-07
linkage O 0 1.4081351764616556e-06
disequilibrium O 0 1.0265226819683448e-06
studies O 0 3.2903610946988238e-09
in O 0 4.330659442164375e-10
the O 0 2.862971415495963e-09
Japanese O 0 4.26812825082834e-08
population O 0 4.830833510993671e-09
. O 0 8.797207584620992e-08

The O 0 1.5331794202211313e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0014785975217819214
DM B-Disease 1 1.0
) O 0 1.0681591611216845e-08
mutation O 0 7.031369264609566e-09
is O 0 8.857355959790425e-10
an O 0 3.605286513774786e-09
unstable O 0 8.430068305642635e-07
( O 0 4.7349153931008914e-08
CTG O 0 3.518162338878028e-05
) O 0 4.561735877928186e-09
n O 0 1.4694180983099159e-08
repeat O 0 1.903059576591204e-08
, O 0 2.1131818517261536e-09
present O 0 2.3359316703164268e-09
at O 0 3.74156172711082e-09
a O 0 2.1433085861666257e-10
copy O 0 2.9490554442901384e-09
number O 0 2.944311905395125e-09
of O 0 6.078542114096308e-09
5 O 0 1.966249740803505e-08
- O 0 2.8593710510449455e-08
37 O 0 6.428150811643718e-08
repeats O 0 1.6913704214971403e-08
on O 0 1.3794982933745814e-08
normal O 0 9.957135560512143e-09
chromosomes O 0 4.678383902501082e-09
but O 0 1.644768654607276e-09
amplified O 0 8.589057465258065e-09
to O 0 2.652891017973502e-09
50 O 0 2.149213784718995e-08
- O 0 1.0994963162147542e-08
3000 O 0 8.569797316226868e-09
copies O 0 4.041044476821298e-08
on O 0 5.920998091824003e-07
DM B-Disease 1 0.9999997615814209
chromosomes O 0 2.2448057279689237e-06
. O 0 1.4615825421060435e-06

Previous O 0 1.1390571899028146e-06
findings O 0 1.3596927317394147e-07
in O 0 5.956051651878624e-09
Caucasian O 0 7.491298248396561e-08
populations O 0 6.106431804653312e-09
of O 0 9.291981406533978e-09
a O 0 1.0172503550620604e-07
DM B-Disease 1 1.0
founder O 0 0.0001123901383834891
chromosome O 0 1.5930413610476535e-07
raise O 0 1.1803705568524947e-08
a O 0 1.1500483898529978e-09
question O 0 1.7051489109576323e-09
about O 0 1.9213446111887578e-10
the O 0 3.8003497571104106e-10
molecular O 0 2.3573620833161613e-09
events O 0 6.902893256999221e-10
involved O 0 7.23440529704078e-10
in O 0 5.12699716015419e-10
the O 0 1.0552637874639004e-08
expansion O 0 2.7573310035222676e-07
mutation O 0 2.4031663770074374e-07
. O 0 7.676821951463353e-07

To O 0 1.0173609155117447e-07
investigate O 0 1.4735599052073667e-07
whether O 0 1.72423639810404e-08
a O 0 1.478913347341404e-08
founder O 0 1.4085192390211887e-07
chromosome O 0 5.5026929679513614e-09
for O 0 8.910171489517893e-10
the O 0 1.485568379422375e-08
DM B-Disease 1 1.0
mutation O 0 9.388373412022588e-10
exists O 0 2.5260898928181064e-10
in O 0 5.1167958758924215e-11
the O 0 4.5631431966342006e-10
Japanese O 0 3.685184157831145e-09
population O 0 1.4354405164507256e-10
, O 0 4.5051062880219206e-10
we O 0 3.274571280798e-09
genotyped O 0 5.91272566907719e-07
families O 0 4.264627317951408e-09
using O 0 2.1832911034636027e-09
polymorphic O 0 3.780905188932593e-08
markers O 0 2.7895086418538995e-07
near O 0 1.8883022221416468e-06
the O 0 8.268025339930318e-07
( O 0 1.9030019871024706e-07
CTG O 0 2.9421655199257657e-05
) O 0 1.5762900318350148e-08
n O 0 4.647045770411751e-08
repeat O 0 1.7922815231941058e-07
region O 0 6.31942043582967e-07
and O 0 1.5663256647258095e-07
constructed O 0 3.228126843168866e-06
haplotypes O 0 2.5946192181436345e-05
. O 0 3.6669111977971625e-06

Six O 0 6.376234864546859e-07
different O 0 7.74705952721888e-08
haplotypes O 0 1.0219172281722422e-06
were O 0 1.3352155825430145e-08
found O 0 4.5738981491183495e-09
and O 0 1.3502591045266854e-08
DM B-Disease 1 1.0
alleles O 0 4.762831196103434e-08
were O 0 4.1186172694551715e-08
always O 0 6.564468435499293e-08
haplotype O 0 1.777831698746013e-06
A O 0 5.093559138913406e-06
. O 0 1.742308654684166e-06

To O 0 1.5506744333038114e-08
find O 0 8.649556626494359e-09
an O 0 5.004659464624694e-10
origin O 0 5.817635706506508e-09
of O 0 1.0854521725889299e-08
the O 0 4.810479126149403e-08
( O 0 2.194355630535938e-08
CTG O 0 6.173100700834766e-06
) O 0 1.820273487496138e-09
n O 0 5.5168589696563686e-09
repeat O 0 7.702794846409233e-09
mutation O 0 4.169875555959379e-09
and O 0 5.042719020131869e-10
to O 0 3.4474778587423316e-10
investigate O 0 2.7438771255106076e-09
the O 0 1.9054919864203157e-09
mechanism O 0 7.857836159530507e-09
of O 0 2.287502187670043e-09
the O 0 1.7812638031244887e-09
expansion O 0 6.5251937186872055e-09
mutation O 0 5.174349282377477e-10
in O 0 1.0488995783042299e-10
the O 0 1.122726356328485e-09
Japanese O 0 7.3553594326369875e-09
population O 0 2.999371306877663e-10
we O 0 3.5346486848553127e-10
have O 0 4.378015450168249e-10
studied O 0 8.493267422693407e-09
90 O 0 1.3431594503288125e-08
Japanese O 0 1.1147873379968587e-07
DM B-Disease 1 0.9999985694885254
families O 0 8.184394495458491e-09
comprising O 0 2.5013087157077507e-09
190 O 0 9.26197163408915e-09
affected O 0 6.269355257160214e-09
and O 0 3.1011888612653138e-09
130 O 0 3.5599295955535126e-08
unaffected O 0 7.007686804172408e-07
members O 0 2.820613964615859e-08
. O 0 4.7527447577522253e-07

The O 0 1.0483364576430176e-06
results O 0 3.313451202302531e-07
suggest O 0 8.58657216440406e-08
that O 0 5.112135714746557e-10
a O 0 1.1210359307511908e-09
few O 0 2.2239716734873127e-09
common O 0 1.0854764864731692e-09
ancestral O 0 2.38200499325103e-08
mutations O 0 2.098465623490142e-09
in O 0 6.437518851321045e-10
both O 0 2.5125117542046382e-09
Caucasian O 0 7.33778771078164e-09
and O 0 4.74508154990616e-10
Japanese O 0 7.239377541878866e-09
populations O 0 4.378909179703072e-10
have O 0 7.199575657867996e-11
originated O 0 6.790095152808817e-10
by O 0 1.4759164723709972e-10
expansion O 0 2.0980943205017866e-08
of O 0 1.1206132022323345e-08
an O 0 1.6095885513323083e-08
ancestral O 0 3.254616842696123e-07
n O 0 5.740448472124626e-08
= O 0 1.2319416953232576e-07
5 O 0 7.284452152589438e-08
repeat O 0 2.3720938102655964e-08
to O 0 3.358281119858475e-08
n O 0 1.2997807630199532e-07
= O 0 6.25133907306008e-07
19 O 0 1.5594278011121787e-06
- O 0 4.606908987625502e-07
37 O 0 3.991296182448423e-07
copies O 0 2.8115186978538986e-07
. O 0 4.5034875029159593e-07

These O 0 2.6377909634334173e-08
data O 0 2.5125991953700577e-08
support O 0 4.799332486982166e-09
multistep O 0 2.2762596074699104e-07
models O 0 2.0755447849296615e-07
of O 0 1.6475364361667744e-07
triplet O 0 1.6075151734185056e-06
repeat O 0 2.0789701693502138e-07
expansion O 0 9.629569603930577e-07
that O 0 4.548946552773714e-09
have O 0 1.1682326217510308e-09
been O 0 1.0369824998690547e-09
proposed O 0 1.5971470812559119e-09
for O 0 2.403709897791373e-09
both O 0 2.003532699745847e-07
DM B-Disease 1 1.0
and O 0 2.1475600533449324e-06
Friedreichs B-Disease 0 0.0008313799626193941
ataxia I-Disease 1 0.9999673366546631
. O 0 1.0395018534836709e-06
. O 0 2.9918546715634875e-06

The O 0 1.393326130028072e-07
molecular O 0 4.069897272529488e-07
basis O 0 4.4186273839841306e-07
of O 0 9.981761650124099e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.9892981423529363e-09
the O 0 2.505410101605321e-09
western O 0 9.222731911506798e-09
Cape O 0 1.7988549316783065e-08
, O 0 1.634224200408596e-09
South O 0 1.2900984280861394e-08
Africa O 0 6.143267938796271e-08
. O 0 4.3892407575185644e-07

Deficiency B-Disease 0 0.48414623737335205
of I-Disease 0 0.00017920488608069718
the I-Disease 0 3.989812000781967e-07
sixth I-Disease 0 6.035695037098776e-07
component I-Disease 0 3.6180813367536757e-07
of I-Disease 0 4.515192841836324e-08
human I-Disease 0 1.0428005126073003e-08
complement I-Disease 0 5.371085620708982e-08
( O 0 1.1898461771409075e-08
C6 O 0 0.002642527222633362
) O 0 6.712678746190193e-10
has O 0 2.1678288331106188e-10
been O 0 1.7711805633258138e-10
reported O 0 2.5842192274971865e-10
in O 0 2.281625929856368e-11
a O 0 9.568590364494867e-11
number O 0 3.374085177920705e-10
of O 0 5.054813789762136e-10
families O 0 5.299248262424783e-10
from O 0 1.1810366018494278e-09
the O 0 1.907623170538386e-09
western O 0 3.094944744930217e-08
Cape O 0 2.65066688598381e-08
, O 0 2.6535893482559914e-09
South O 0 2.618107508567391e-08
Africa O 0 9.470862494254106e-08
. O 0 7.601767606502108e-07

Meningococcal B-Disease 0 0.005045468918979168
disease I-Disease 0 0.001604742370545864
is O 0 2.846663127442639e-09
endemic O 0 6.346920211619533e-10
in O 0 8.42529934708125e-11
the O 0 1.0712415399183328e-09
Cape O 0 8.1317086397803e-09
and O 0 1.6834834914991603e-10
almost O 0 8.233680404146071e-10
all O 0 1.911154706712992e-10
pedigrees O 0 3.420952765509355e-08
of O 0 4.1515615833986885e-08
total O 0 2.4247240162367234e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.022537266086147e-07
C6Q0 O 1 0.9999154806137085
) O 0 9.525039645907896e-10
have O 0 1.8714248206652684e-10
been O 0 2.0680201995304515e-10
ascertained O 0 5.2645173553855784e-08
because O 0 3.3316942538164085e-09
of O 0 4.050736635008434e-08
recurrent O 0 0.00028543765074573457
disease O 0 2.9600138077512383e-05
. O 0 8.616345894552069e-07

We O 0 1.5860227620123624e-07
have O 0 5.6716413787682995e-09
sequenced O 0 9.474996787162127e-09
the O 0 6.931025087197895e-09
expressed O 0 1.2967297458033045e-08
exons O 0 1.2101398283448361e-07
of O 0 1.5680444676036132e-07
the O 0 1.5546997644833027e-07
C6 O 0 6.3084708017413504e-06
gene O 0 2.91470891866652e-09
from O 0 4.5438648399453996e-09
selected O 0 2.8656264028370515e-09
cases O 0 9.706569992218306e-10
and O 0 5.180135764781824e-10
have O 0 2.0672709377667076e-10
found O 0 5.248600998264408e-10
three O 0 1.0827098106958033e-09
molecular O 0 1.1076558621425647e-06
defects O 0 0.07432553917169571
leading O 0 7.757437856525939e-07
to O 0 7.867673623707105e-09
total O 0 1.766419472915004e-07
deficiency O 0 0.00025019177701324224
879delG O 0 8.785502359387465e-06
, O 0 2.689348521656143e-09
which O 0 3.98765048759131e-10
is O 0 1.2108387903442264e-10
the O 0 6.659424123256485e-10
common O 0 3.6987750640093964e-09
defect O 0 1.6648369793870188e-08
in O 0 1.355414003256783e-09
the O 0 1.9439836407286748e-08
Cape O 0 3.660171188357708e-08
and O 0 3.829121464349328e-09
hitherto O 0 2.943168908586813e-07
unreported O 0 8.314646038343199e-07
, O 0 1.5986344470420022e-09
and O 0 4.265196640318436e-09
1195delC O 0 1.9897315439720842e-07
and O 0 1.2153751782761901e-08
1936delG O 0 1.9845995780087833e-07
, O 0 2.2334554206082657e-09
which O 0 1.2093530621370974e-09
have O 0 1.524525838902946e-09
been O 0 3.4609066723589876e-09
previously O 0 8.269127604876303e-09
reported O 0 5.884955189827679e-09
in O 0 2.7904165644798695e-09
African O 0 3.250013591582501e-08
- O 0 3.453550050380727e-07
Americans O 0 1.6156947424406098e-07
. O 0 9.327069392384146e-07

We O 0 8.850370818436204e-07
also O 0 1.0311612186342245e-07
show O 0 1.492612078379807e-08
that O 0 9.926544031202411e-10
the O 0 6.8135812547609476e-09
879delG O 0 3.461503297330637e-07
and O 0 1.3251584718432241e-08
1195delC O 0 6.27457711743773e-06
defects O 0 0.00031426624627783895
are O 0 7.258250445119074e-09
associated O 0 3.0532976325048367e-07
with O 0 6.462141044494274e-08
characteristic O 1 0.9999436140060425
C6 O 1 1.0
/ O 0 0.002197894034907222
C7 O 0 0.0003950975078623742
region O 0 1.0645473480508372e-07
DNA O 0 1.6925265811096324e-07
marker O 0 8.803448849903361e-07
haplotypes O 0 3.562086874353554e-07
, O 0 3.5082610150283244e-09
although O 0 2.6135507091851196e-09
small O 0 3.1079747664364277e-09
variations O 0 1.1449367320892634e-07
were O 0 3.366124090575795e-08
observed O 0 2.2865312132580584e-07
. O 0 6.573112614205456e-07

The O 0 8.413667273998726e-07
1936delG O 0 4.810442987945862e-06
defect O 0 1.9356350549060153e-06
was O 0 1.2630727042051149e-07
observed O 0 5.447886586296136e-09
only O 0 1.4675715087619778e-09
once O 0 2.3905786239453164e-09
in O 0 2.0041225623490533e-10
the O 0 7.227967557810189e-09
Cape O 0 3.525979508367527e-08
, O 0 4.759511673668726e-10
but O 0 4.550922416690639e-10
its O 0 3.9906100646192044e-10
associated O 0 1.6262276858469704e-08
haplotype O 0 1.516826557690365e-07
could O 0 3.2713266762129933e-08
be O 0 8.620622793387156e-08
deduced O 0 1.2291737220948562e-05
. O 0 1.817840825424355e-06

The O 0 5.993203444631945e-08
data O 0 2.4869857284670616e-08
from O 0 7.930076151296817e-09
the O 0 5.994619023397263e-09
haplotypes O 0 2.6779156314660213e-07
indicate O 0 1.801667082190761e-08
that O 0 4.2841097336321354e-10
these O 0 1.2976394403452218e-09
three O 0 2.417890998529515e-09
molecular O 0 3.026700881036959e-07
defects O 0 2.1318965082173236e-06
account O 0 7.396029566564266e-09
for O 0 3.6760299249039008e-09
the O 0 1.4576820603906526e-06
defects O 1 0.995712399482727
in O 0 4.454559388022972e-09
all O 0 3.0031621633952454e-09
the O 0 1.9296026110282583e-08
38 O 0 4.8849379652438074e-08
unrelated O 0 3.914548685202135e-08
C6Q0 O 0 9.061961463885382e-06
individuals O 0 1.4102544687588647e-09
we O 0 5.3101381070064235e-09
have O 0 2.098105245096349e-09
studied O 0 2.172707347369851e-08
from O 0 7.277796587601415e-09
the O 0 6.396583529522104e-08
Cape O 0 8.579251584706071e-07
. O 0 4.1129817418550374e-07

We O 0 3.7880300851611537e-07
have O 0 3.211702548355788e-08
also O 0 1.0316408172172942e-08
observed O 0 4.769528327841499e-09
the O 0 8.360315995048495e-09
879delG O 0 3.842585556412814e-07
defect O 0 1.5628953065061069e-07
in O 0 9.097393949275556e-09
two O 0 7.242792321449087e-08
Dutch O 1 0.9999157190322876
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 1.7711283362586983e-05
, O 0 3.515320923241916e-09
but O 0 7.017993963742697e-10
the O 0 5.1216826335576116e-09
879delG O 0 2.0778165321644337e-07
defect O 0 7.146147140701942e-08
in O 0 2.7224462684216633e-09
the O 0 4.401497122330511e-08
Cape O 0 4.2849805481637304e-08
probably O 0 4.654681085014545e-09
did O 0 1.1399501342879148e-09
not O 0 9.266208911284934e-10
come O 0 7.094793641471142e-09
from O 0 1.2281546446502034e-08
The O 0 2.752160099817047e-08
Netherlands O 0 1.7717373168579797e-07
. O 0 1.1444891612200081e-07
. O 0 1.0434589512442471e-06

Complement B-Disease 1 0.9998254179954529
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.3697202777839266e-07
seven O 0 4.6312955248595244e-08
further O 0 8.055175726440211e-08
molecular O 0 1.4757504686713219e-05
defects O 1 0.982291579246521
and O 0 2.3386165892702593e-08
their O 0 1.8317644290277713e-08
associated O 0 7.979639121913351e-06
marker O 0 0.00021967712382320315
haplotypes O 0 8.393278403673321e-05
. O 0 4.501890998653835e-06

Seven O 0 5.694797664546059e-07
further O 0 9.030060965642406e-08
molecular O 0 1.9785144900197338e-07
bases O 0 6.819615805397916e-07
of O 0 0.2578938901424408
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.80056488829905e-07
described O 0 3.8778904354330734e-07
. O 0 3.7222770288281026e-07

All O 0 8.893456282521583e-08
these O 0 1.9479216462059412e-08
new O 0 2.4492601724546148e-08
molecular O 0 6.738892466273683e-07
defects O 0 8.436598477601365e-07
involve O 0 1.1892449691686124e-08
single O 0 1.9855267652246766e-08
- O 0 5.752198006803155e-08
nucleotide O 0 4.083316795799874e-08
events O 0 2.303967328032286e-08
, O 0 3.637543377621455e-09
deletions O 0 2.752411987216874e-08
and O 0 1.4674315096385726e-09
substitutions O 0 1.352976308766074e-08
, O 0 1.1460631332838034e-09
some O 0 2.9524886979714893e-09
of O 0 5.67613547275414e-08
which O 0 5.148519388598061e-09
alter O 0 1.844375390191999e-07
splice O 0 1.5525054095633095e-06
sites O 0 3.9702376852801535e-07
, O 0 2.060439285855864e-08
and O 0 3.098742595852855e-08
others O 0 1.284664961076487e-07
codons O 0 9.149074685410596e-06
. O 0 5.411504844232695e-06

They O 0 8.830055264752446e-08
are O 0 4.705140721483758e-09
distributed O 0 2.3241954139052723e-08
along O 0 2.1692207141654762e-08
the O 0 8.016872499183592e-08
C7 O 0 1.407723448210163e-05
gene O 0 2.2083792572402672e-08
, O 0 8.661145578514606e-09
but O 0 1.920898551333039e-09
predominantly O 0 1.6255011781041162e-09
towards O 0 1.5766810079753668e-08
the O 0 7.236657939557745e-09
3 O 0 1.499784190173159e-07
end O 0 2.6405302833154565e-07
. O 0 7.712146725680213e-07

All O 0 1.6177854433863104e-07
were O 0 2.999259862690451e-08
found O 0 4.466188752161315e-09
in O 0 1.3766849882301813e-09
compound O 0 9.881348717044602e-08
heterozygous O 0 5.202628372558138e-08
individuals O 0 1.4489315525167967e-08
. O 0 2.886716288230673e-07

The O 0 4.9058635340770707e-05
C6 O 1 0.9999608993530273
/ O 0 0.00018962174362968653
C7 O 0 0.0001992608158616349
marker O 0 9.115075840782083e-07
haplotypes O 0 7.23910375199921e-07
associated O 0 9.948787038638329e-08
with O 0 1.4794295566389337e-08
most O 0 2.313279765076004e-06
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 1.45821161368076e-07
tabulated O 0 1.7180667555294349e-06
. O 0 2.0766000830008124e-07
. O 0 9.81314769887831e-07

A O 0 9.358768693346065e-06
genome O 0 7.005481847954798e-07
- O 0 1.872869859198545e-07
wide O 0 2.7844421879308356e-08
search O 0 4.288748023384414e-09
for O 0 1.0835422559196672e-09
chromosomal O 0 5.017835746912169e-07
loci O 0 3.1988216164791083e-07
linked O 0 9.711557140690275e-07
to O 0 7.577879657105768e-09
mental O 0 0.16565024852752686
health O 0 2.9221206432339386e-07
wellness O 0 6.268042085366687e-08
in O 0 5.512248990591218e-10
relatives O 0 8.987088051526371e-08
at O 0 1.4079411414513743e-08
high O 0 5.053266605159479e-08
risk O 0 2.0132084443957865e-08
for O 0 1.0085465795839355e-08
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 3.731006017915206e-06
the O 0 7.504898746901745e-08
Old O 0 9.089123409466993e-08
Order O 0 5.390214852241115e-08
Amish O 0 4.589360742102144e-06
. O 0 2.9766542866127566e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.00048100415733642876
BPAD B-Disease 1 1.0
; O 0 2.2168755094753578e-05
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 9.651596855064781e-09
is O 0 5.50638534768666e-10
characterized O 0 3.144033366986321e-10
by O 0 2.1139953676474477e-10
episodes O 0 3.0473845669121147e-09
of O 0 7.659312295515974e-09
mania B-Disease 0 1.3040805413311318e-07
and O 0 2.4178783419870342e-08
/ O 0 2.7163073923475167e-07
or O 0 6.578945743740405e-08
hypomania B-Disease 0 1.140974745794665e-05
interspersed O 0 1.1849976999656064e-07
with O 0 1.0043957887617694e-09
periods O 0 1.266467961613671e-07
of O 0 2.0175392023702443e-07
depression B-Disease 0 5.7911956901079975e-06
. O 0 7.83739039889042e-07

Compelling O 0 2.3115662770578638e-06
evidence O 0 2.71753521019491e-07
supports O 0 2.5344318643760744e-08
a O 0 1.403511085129594e-09
significant O 0 2.443146573938293e-09
genetic O 0 1.3376269869525004e-08
component O 0 5.1984624604983765e-08
in O 0 3.504199708181943e-10
the O 0 3.951816207603542e-09
susceptibility O 0 2.3235512003338954e-07
to O 0 2.2030111068715996e-08
develop O 0 6.338775165204424e-06
BPAD B-Disease 1 1.0
. O 0 8.368027010874357e-06

To O 0 6.078926872987722e-08
date O 0 4.74543895734314e-07
, O 0 9.445477289204973e-09
however O 0 1.2602253463001034e-08
, O 0 2.9067477314015377e-09
linkage O 0 1.4479817878054746e-07
studies O 0 5.5638516016642825e-09
have O 0 3.3886737860200355e-10
attempted O 0 6.8772965100549754e-09
only O 0 5.355551557784111e-10
to O 0 6.512408390335622e-10
identify O 0 3.305478202264567e-08
chromosomal O 0 1.7859138097264804e-06
loci O 0 1.3085067962492758e-07
that O 0 3.3108462638153924e-09
cause O 0 9.996777805554302e-08
or O 0 1.0822926999054516e-09
increase O 0 8.760795977558189e-10
the O 0 2.9121862699099665e-09
risk O 0 3.093227363137885e-08
of O 0 6.545988640027645e-08
developing O 0 1.2033861821691971e-05
BPAD B-Disease 1 1.0
. O 0 4.900223302684026e-06

To O 0 1.840144214781958e-08
determine O 0 2.5205286746654565e-08
whether O 0 1.172834629414865e-08
there O 0 6.315755030072978e-09
could O 0 3.7246576933824826e-09
be O 0 1.2935176263439985e-09
protective O 0 1.9004550821932753e-08
alleles O 0 5.293240512571629e-09
that O 0 5.25691656871885e-10
prevent O 0 4.9868811302644644e-09
or O 0 2.352816164119531e-09
reduce O 0 3.647631530157014e-09
the O 0 2.29707719512362e-09
risk O 0 1.3841738422115668e-08
of O 0 1.6779200251448856e-08
developing O 0 5.904994395677932e-07
BPAD B-Disease 1 1.0
, O 0 2.413854449656583e-09
similar O 0 2.0687895840865167e-10
to O 0 5.135159519831234e-10
what O 0 9.967999758941914e-10
is O 0 1.1832185231597236e-10
observed O 0 3.4389927017208777e-10
in O 0 9.689399282919453e-11
other O 0 1.9093748804266397e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 6.934965046667685e-09
we O 0 1.0123930582750518e-09
used O 0 3.762773648219309e-09
mental O 0 4.522097697190475e-06
health O 0 4.710944097041647e-07
wellness O 0 1.5289288057829253e-06
( O 0 4.205226389331074e-09
absence O 0 1.855309648135517e-07
of O 0 3.415131288875273e-08
any O 0 9.724720229087325e-08
psychiatric B-Disease 0 0.009228567592799664
disorder I-Disease 0 7.419105259032222e-07
) O 0 2.754320660436349e-10
as O 0 9.010285295651954e-10
the O 0 1.839420282756521e-09
phenotype O 0 1.4349055277307343e-08
in O 0 8.018500863293809e-10
our O 0 1.7652196149242627e-08
genome O 0 3.128161552012898e-08
- O 0 2.2311367331440124e-07
wide O 0 4.311033023896016e-07
linkage O 0 6.392473324012826e-07
scan O 0 1.2615990385711484e-07
of O 0 1.0183666887542131e-07
several O 0 4.7599066022030456e-08
large O 0 2.8388632244968903e-07
multigeneration O 0 1.531269845145289e-05
Old O 0 2.0332097960817919e-07
Order O 0 4.122554742025386e-08
Amish O 0 6.314577376542729e-07
pedigrees O 0 1.308231503571733e-06
exhibiting O 0 3.4897169598480104e-07
an O 0 1.8749494401504307e-08
extremely O 0 8.712063959137595e-08
high O 0 1.4432037005462917e-06
incidence O 0 0.00012261458323337138
of O 0 1.1449489647930022e-05
BPAD B-Disease 1 1.0
. O 0 2.842779394995887e-05

We O 0 9.436708410248684e-07
have O 0 2.6918288043020766e-08
found O 0 1.4894212974070342e-08
strong O 0 9.689870239526499e-09
evidence O 0 1.5226262917167332e-08
for O 0 1.8406276502958008e-09
a O 0 6.788156703407822e-09
locus O 0 5.85590207435871e-08
on O 0 4.545557530377664e-08
chromosome O 0 3.7593687807202514e-07
4p O 0 5.187093120184727e-05
at O 0 2.956012963295507e-07
D4S2949 O 0 8.663411108500441e-07
( O 0 7.209064012414501e-09
maximum O 0 1.601184038690917e-07
GENEHUNTER O 0 1.6212256014114246e-05
- O 0 7.375443829005235e-07
PLUS O 0 6.92353523845668e-07
nonparametric O 0 1.674593704592553e-06
linkage O 0 4.403470938996179e-07
score O 0 4.2884840922852163e-07
= O 0 2.59634191479563e-07
4 O 0 2.0027762559493567e-07
. O 0 1.772250435294609e-08
05 O 0 1.1244241022723145e-06
, O 0 4.0874468254514795e-08
P O 0 1.564019498800917e-06
= O 0 1.1650449494027271e-07
5 O 0 7.876055718725183e-08
. O 0 4.1423682262120565e-09
22 O 0 4.170601286546116e-08
x O 0 8.329583778277083e-08
10 O 0 1.2311407715515088e-07
( O 0 1.2826005146848729e-08
- O 0 7.773198262839287e-08
4 O 0 9.696234570810702e-08
) O 0 1.7303634081144992e-09
; O 0 6.052569556658227e-09
SIBPAL O 0 6.430053417716408e-06
Pempirical O 0 5.064097763352038e-07
value O 0 4.1981039089478145e-08
< O 0 1.4530496805775783e-08
3 O 0 1.528148274587693e-08
x O 0 1.9298381559451627e-08
10 O 0 2.6138263109487525e-08
( O 0 1.9932284711643433e-09
- O 0 1.0880099488019823e-08
5 O 0 1.10050963897379e-08
) O 0 1.8110746236033037e-10
) O 0 1.0126764010687239e-10
and O 0 1.8083960717785175e-10
suggestive O 0 2.0137143064147267e-09
evidence O 0 5.326459273646833e-09
for O 0 6.338221614221595e-10
a O 0 4.5434918050091255e-09
locus O 0 5.882018072611572e-08
on O 0 9.15836650960955e-08
chromosome O 0 3.3822441309894202e-06
4q O 0 5.290286208037287e-05
at O 0 4.265923223556456e-07
D4S397 O 0 2.8455112897063373e-06
( O 0 1.5511446349592006e-08
maximum O 0 6.178120770528039e-07
GENEHUNTER O 0 5.396176129579544e-05
- O 0 1.3892331480747089e-06
PLUS O 0 2.2487588466901798e-06
nonparametric O 0 1.4084548638493288e-06
linkage O 0 7.570687330371584e-07
score O 0 2.553263129811967e-07
= O 0 2.092747308779508e-07
3 O 0 1.7325645274013368e-07
. O 0 1.0334368916176118e-08
29 O 0 2.9027665959802107e-07
, O 0 2.051834790961493e-08
P O 0 7.193325473053847e-07
= O 0 4.233750416915427e-08
2 O 0 2.3236768953438514e-08
. O 0 1.4699694794728657e-09
57 O 0 8.389036132427918e-09
x O 0 1.4232882428188987e-08
10 O 0 1.636477087174626e-08
( O 0 2.830885303950481e-09
- O 0 1.3786459973630372e-08
3 O 0 1.6061720842230898e-08
) O 0 3.140197823991997e-10
; O 0 1.1364613694553327e-09
SIBPAL O 0 7.261839414240967e-07
Pempirical O 0 9.835974879024434e-08
value O 0 5.316066253868712e-09
< O 0 3.783326540940379e-09
1 O 0 6.374207828230283e-09
x O 0 1.7436761368117004e-08
10 O 0 1.897712920140293e-08
( O 0 1.5525468688437627e-09
- O 0 8.865101541744025e-09
3 O 0 1.2890899903084119e-08
) O 0 1.0614641110517908e-10
) O 0 2.1488784709977615e-11
that O 0 5.601903663166041e-11
are O 0 1.7231760462976808e-10
linked O 0 3.970979634004834e-08
to O 0 1.3680059751663975e-08
mental O 1 0.9999967813491821
health O 0 0.019893456250429153
wellness O 0 4.736233677249402e-05
. O 0 1.2484590570238652e-06

These O 0 2.0908639442041022e-07
findings O 0 1.751179468101327e-07
are O 0 2.4216986194147694e-09
consistent O 0 2.7487288889460615e-08
with O 0 1.8985980843044814e-10
the O 0 8.592526690165414e-10
hypothesis O 0 3.228505018881833e-09
that O 0 2.9030715331668233e-11
certain O 0 7.673638391381132e-10
alleles O 0 2.9929378975168675e-09
could O 0 4.62442617532588e-09
prevent O 0 2.3941026938700816e-08
or O 0 5.160838867368511e-09
modify O 0 2.0633338593256667e-08
the O 0 5.37809397016531e-09
clinical O 0 2.3228704293387636e-08
manifestations O 0 7.334467113651044e-07
of O 0 3.4833462336791854e-07
BPAD B-Disease 1 1.0
and O 0 1.023768714247808e-08
perhaps O 0 7.3851613713316056e-09
other O 0 1.011497996472599e-08
related O 0 6.597696483368054e-06
affective B-Disease 1 1.0
disorders I-Disease 1 0.9999719858169556
. O 0 1.10045102701406e-05

Segregation O 0 6.946669600438327e-05
distortion O 0 0.00043153975275345147
in O 0 4.699762030213606e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005661994218826294

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9969448447227478
DM B-Disease 1 1.0
) O 0 1.43680935593693e-07
is O 0 7.224742137879048e-09
an O 0 8.957581343338461e-09
autosomal B-Disease 0 0.015145842917263508
dominant I-Disease 1 0.9999979734420776
disease I-Disease 1 0.9979411959648132
which O 0 6.482911985017381e-10
, O 0 6.610419850394678e-11
in O 0 3.957861469117141e-11
the O 0 1.2015817230093262e-09
typical O 0 2.6700504918153456e-08
pedigree O 0 5.276590897551614e-08
, O 0 2.2230512985998985e-09
shows O 0 6.268590091451642e-09
a O 0 1.0291958396635437e-08
three O 0 1.1713233938337453e-08
generation O 0 3.875213678838918e-07
anticipation O 0 4.792849722434767e-06
cascade O 0 2.2582757083000615e-05
. O 0 2.5152421585517004e-06

This O 0 5.153628190868176e-09
results O 0 4.711429468784445e-08
in O 0 1.5229399963345713e-08
infertility B-Disease 1 0.9999862909317017
and O 0 0.00010224855213891715
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0026759898755699396
CDM B-Disease 0 2.408156251476612e-05
) O 0 3.916919844026978e-10
with O 0 1.3675402477097975e-10
the O 0 4.706110168228861e-09
disappearance O 0 6.878407248223084e-07
of O 0 8.245897902270372e-07
DM B-Disease 1 1.0
in O 0 2.1874937417010187e-08
that O 0 1.4174662332777643e-08
pedigree O 0 5.153925030754181e-06
. O 0 1.0526001688049291e-06

The O 0 1.024534839189073e-07
concept O 0 8.484786917506426e-08
of O 0 4.9812562963325036e-08
segregation O 0 1.3177161406474625e-07
distortion O 0 7.036086913103645e-07
, O 0 1.8307749760637648e-09
where O 0 1.417105988110734e-09
there O 0 2.149933148176686e-10
is O 0 8.042436855371093e-11
preferential O 0 1.88693838332199e-09
transmission O 0 5.015766468829952e-09
of O 0 2.7253503898094777e-09
the O 0 2.119814546119869e-09
larger O 0 6.823309028902713e-09
allele O 0 2.013200628425693e-08
at O 0 8.091019410016997e-09
the O 0 3.444832330501413e-08
DM B-Disease 1 1.0
locus O 0 6.4665307775158e-08
, O 0 2.924041453411519e-09
has O 0 9.47710687704273e-10
been O 0 9.591801797270705e-10
put O 0 1.0436860264917414e-08
forward O 0 4.123467078898102e-08
to O 0 1.2477451072356871e-08
explain O 0 1.9014707675069076e-07
partially O 0 2.736455257945636e-07
the O 0 1.193182441738827e-08
maintenance O 0 1.6442935191207653e-07
of O 0 2.3895913159321935e-07
DM B-Disease 1 1.0
in O 0 1.7180614264589167e-08
the O 0 7.304264215690637e-08
population O 0 2.0982424686621926e-08
. O 0 9.370759812554752e-08

In O 0 3.385847335835024e-08
a O 0 2.9624519726212384e-08
survey O 0 2.5255721070038817e-08
of O 0 5.0098790893571277e-08
DM B-Disease 1 1.0
in O 0 1.4732318476262662e-08
Northern O 0 9.037574244530333e-08
Ireland O 0 1.6755469900431308e-08
, O 0 2.695239942340777e-08
59 O 0 2.955328000098234e-07
pedigrees O 0 8.648717084724922e-07
were O 0 1.6633046584502154e-07
ascertained O 0 2.383115133852698e-05
. O 0 2.1404691779025597e-06

Sibships O 0 4.5730441343039274e-05
where O 0 8.457094224922912e-08
the O 0 4.0575085513694376e-09
status O 0 3.404106330151535e-09
of O 0 7.311439009782816e-09
all O 0 7.936609147662921e-10
the O 0 2.981849656080726e-09
members O 0 4.684828636136729e-10
had O 0 1.8902091003525356e-09
been O 0 5.412534864746021e-10
identified O 0 1.7617275416270672e-09
were O 0 4.95831153912718e-10
examined O 0 9.22698528693644e-10
to O 0 1.432962082326128e-10
determine O 0 2.8278577257623283e-09
the O 0 2.3946264970930997e-09
transmission O 0 2.925750131055338e-08
of O 0 6.130717711272382e-09
the O 0 6.831697874076781e-08
DM B-Disease 1 1.0
expansion O 0 2.2787378384236945e-07
from O 0 9.283017909922364e-09
affected O 0 1.8809528157248678e-08
parents O 0 1.0804369843242512e-08
to O 0 1.0839459996248024e-08
their O 0 1.3362669903926871e-07
offspring O 0 7.2797402026480995e-06
. O 0 2.2663896288577234e-06

Where O 0 3.1459026672564505e-07
the O 0 7.330278606332286e-08
transmitting O 0 2.178688646381488e-06
parent O 0 1.9435985620930296e-07
was O 0 2.18510493255053e-07
male O 0 3.0490376445868606e-08
, O 0 1.4750031418486742e-08
58 O 0 3.398652665964619e-07
. O 0 2.0184495497233002e-07

3 O 0 1.3081914858048549e-06
% O 0 1.0575325504191824e-08
of O 0 4.931321573309333e-09
the O 0 5.807192948736883e-09
offspring O 0 2.2620350037527714e-08
were O 0 7.988401939940104e-09
affected O 0 1.4335787668073863e-08
, O 0 7.014447356290532e-10
and O 0 2.0283305590673706e-10
in O 0 1.4044583551697798e-10
the O 0 1.1187631931974806e-09
case O 0 2.6678297349036484e-09
of O 0 7.952554170742587e-09
a O 0 1.0776174619309131e-08
female O 0 1.0003072503650401e-07
transmitting O 0 2.0628633592423284e-06
parent O 0 2.2277306754858728e-07
, O 0 6.626082438287995e-08
68 O 0 1.4880037042530603e-06
. O 0 7.287536618605372e-07

7 O 0 1.8049582649837248e-05
% O 0 1.2328914067438745e-07
were O 0 5.288772442213485e-08
affected O 0 4.762295304772124e-07
. O 0 5.487895009537169e-07

Studies O 0 9.040226700562926e-07
on O 0 1.6687417314642516e-07
meiotic O 0 1.0507105798751581e-06
drive O 0 4.974496050635935e-07
in O 0 3.5891783767283414e-08
DM B-Disease 1 1.0
have O 0 3.320636432491142e-09
shown O 0 6.922856177205006e-10
increased O 0 4.849905477222194e-10
transmission O 0 3.109860591266056e-09
of O 0 6.145723374650913e-10
the O 0 1.0092197078037657e-09
larger O 0 3.990558994360072e-09
allele O 0 8.365420356426512e-09
at O 0 9.684198332138294e-09
the O 0 4.9220020059692615e-08
DM B-Disease 1 1.0
locus O 0 6.225792503755656e-08
in O 0 1.1209039030291024e-08
non O 0 7.843433195375837e-06
- O 0 0.00012969970703125
DM O 1 1.0
heterozygotes O 0 1.3470867088472005e-05
for O 0 4.882721214016783e-07
CTGn O 0 0.00014429344446398318
. O 0 2.9028822154941736e-06

This O 0 6.533004182074365e-08
study O 0 1.1454648785047539e-08
provides O 0 4.616335758100831e-09
further O 0 2.310012181538923e-09
evidence O 0 1.6568794336535575e-08
that O 0 3.0340336909517873e-09
the O 0 1.9924050320696551e-07
DM B-Disease 1 1.0
expansion O 0 1.7330482933175517e-06
tends O 0 1.6500585786616284e-07
to O 0 5.686220827527677e-09
be O 0 2.866480741658961e-08
transmitted O 0 1.750852192117236e-07
preferentially O 0 6.660775966338406e-07
. O 0 5.47668037143012e-07

Diagnosis O 0 0.003104917239397764
of O 0 0.004985144827514887
hemochromatosis B-Disease 1 1.0
. O 1 0.9333750009536743

If O 0 6.046703674655873e-06
untreated O 1 0.9999998807907104
, O 0 2.15862854702209e-07
hemochromatosis B-Disease 1 1.0
can O 0 4.206431754028017e-07
cause O 1 0.9999997615814209
serious O 1 0.9840774536132812
illness O 1 0.9660576581954956
and O 0 7.701086990330452e-10
early B-Disease 0 1.0540286865534654e-08
death I-Disease 0 8.645107385518713e-08
, O 0 6.67957411604192e-10
but O 0 9.247457244399016e-10
the O 0 1.7560319420795167e-08
disease O 0 3.084861361912772e-07
is O 0 8.94994300892904e-10
still O 0 1.817487826905051e-09
substantially O 0 5.021473725719261e-08
under O 0 6.994947057137324e-07
- O 0 0.00020095452782697976
diagnosed O 0 7.2167126745625865e-06
. O 0 8.603520313954505e-07

The O 0 2.5083959371841047e-06
cornerstone O 0 1.4352757716551423e-05
of O 0 9.495335717701892e-08
screening O 0 5.974620798099295e-09
and O 0 9.713052584459092e-10
case O 0 1.2311912600537767e-09
detection O 0 1.1624097240314768e-08
is O 0 3.301347806239363e-10
the O 0 6.980306888060284e-10
measurement O 0 6.368935601130943e-08
of O 0 3.651461710774129e-08
serum O 0 2.5582892249076394e-07
transferrin O 0 4.350075414549792e-06
saturation O 0 8.162352855833888e-07
and O 0 2.8912781502299367e-08
the O 0 6.56312835189965e-08
serum O 0 1.5063536693560309e-06
ferritin O 0 3.136435407213867e-05
level O 0 7.543052561231889e-06
. O 0 2.481164074197295e-06

Once O 0 6.139947572592064e-07
the O 0 5.440444539317468e-08
diagnosis O 0 4.5754103439321625e-07
is O 0 4.922056096035021e-09
suspected O 0 1.5230305905333807e-07
, O 0 3.935170855839942e-09
physicians O 0 3.644293533611176e-09
must O 0 4.663968322660139e-09
use O 0 2.036356683277063e-08
serum O 0 2.1784519503853517e-06
ferritin O 0 6.475861300714314e-05
levels O 0 1.9342492123541888e-06
and O 0 2.6030608069049777e-07
hepatic O 1 0.9999998807907104
iron O 0 0.009564709849655628
stores O 0 2.2192366486706305e-06
on O 0 3.736799669695756e-07
liver O 0 9.807927199290134e-07
biopsy O 0 1.4358417566029402e-08
specimens O 0 4.0408574264461095e-09
to O 0 1.0734811928259091e-09
assess O 0 6.853506562265466e-08
patients O 0 7.4016321960357345e-09
for O 0 3.1488363028131516e-09
the O 0 5.048729079248915e-08
presence O 0 9.57847987592686e-07
of O 0 2.0603803932317533e-05
iron B-Disease 1 0.9873942136764526
overload I-Disease 1 0.9998972415924072
. O 0 2.2152100427774712e-05

Liver O 0 0.00039061150164343417
biopsy O 0 7.482539331249427e-06
is O 0 2.826813094713998e-08
also O 0 1.0955831797332394e-09
used O 0 2.758474282327228e-10
to O 0 1.694161616550005e-10
establish O 0 4.658420316161482e-09
the O 0 6.319394341147699e-09
presence O 0 1.6856956719379923e-08
or O 0 8.983657373562437e-09
absence O 0 1.4654765436716843e-06
of O 0 1.540050647008684e-07
cirrhosis B-Disease 1 0.996866762638092
, O 0 8.893600300652338e-10
which O 0 2.1058900456782936e-10
can O 0 1.4682911553265399e-09
affect O 0 7.039543561404571e-07
prognosis O 1 0.9843611717224121
and O 0 3.004418829277711e-07
management O 0 6.279769877437502e-07
. O 0 1.5592804629704915e-06

A O 0 2.8344149995973567e-06
DNA O 0 2.6454503654349537e-07
- O 0 8.62195435047397e-08
based O 0 5.61974911050811e-09
test O 0 5.158110605307797e-10
for O 0 1.4534285996958829e-09
the O 0 3.7804145591735505e-08
HFE O 0 4.949665708409157e-06
gene O 0 1.2869722176844789e-08
is O 0 1.0088654356366078e-09
commercially O 0 1.974373997626344e-09
available O 0 1.1626020146593419e-09
, O 0 2.6465873936842854e-10
but O 0 3.483169030982225e-10
its O 0 4.346415172218343e-10
place O 0 3.987812302597149e-09
in O 0 5.860533169865789e-10
the O 0 5.029081595608886e-09
diagnosis O 0 2.891648591685225e-07
of O 0 1.6425883586634882e-07
hemochromatosis B-Disease 1 1.0
is O 0 4.434081688486913e-07
still O 0 5.729892649242174e-08
being O 0 2.920576136489217e-08
evaluated O 0 2.3441278074187721e-07
. O 0 7.049109740364656e-07

Currently O 0 2.823327633905137e-07
, O 0 7.200406493268474e-09
the O 0 6.272213859404019e-09
most O 0 9.791678579063046e-10
useful O 0 1.2806936844356187e-08
role O 0 2.4474984261502186e-09
for O 0 6.359558990531866e-10
this O 0 2.0315907289791824e-10
test O 0 2.6632726579656207e-10
is O 0 2.406708998758944e-10
in O 0 3.908894735671353e-11
the O 0 1.8683576907818633e-10
detection O 0 1.1610470806999729e-08
of O 0 5.3726836313217063e-08
hemochromatosis B-Disease 1 1.0
in O 0 2.146059685514956e-08
the O 0 4.92273457552983e-08
family O 0 4.104084627698512e-09
members O 0 4.804935893609752e-10
of O 0 9.776996989785403e-09
patients O 0 8.18220602383235e-10
with O 0 2.023083645052992e-10
a O 0 1.6333951968761085e-09
proven O 0 2.854793557105495e-08
case O 0 1.6537537561589488e-08
of O 0 5.4852062447707794e-08
the O 0 3.1875967465566646e-07
disease O 0 2.7805683657788904e-06
. O 0 3.834853714579367e-07

It O 0 3.968435535739445e-08
is O 0 6.9952248438198694e-09
crucial O 0 1.852731656981632e-07
to O 0 3.719327779094783e-08
diagnose O 0 0.12949217855930328
hemochromatosis B-Disease 1 1.0
before O 1 0.9999257326126099
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 2.2703042645844107e-07
because O 0 4.4728643011637814e-09
phlebotomy O 0 3.7872857205911714e-07
therapy O 0 3.425822292513203e-09
can O 0 6.785279560439506e-10
avert O 0 6.437367574108066e-06
serious O 1 0.987572431564331
chronic O 1 1.0
disease O 0 0.027736082673072815
and O 0 1.024139217875586e-09
can O 0 1.229545493197648e-10
even O 0 2.1042128039994168e-09
lead O 0 5.485214060740873e-09
to O 0 1.7658922102370411e-09
normal O 0 8.982906507526423e-08
life O 0 2.2306979374775437e-08
expectancy O 0 3.091870723892498e-07
. O 0 3.778461277192946e-08
. O 0 4.3238216562713205e-07

Prevalence O 0 7.346266102103982e-06
of O 0 2.1493782753623236e-07
the O 0 8.565045561681472e-08
I1307K O 0 1.3296926226757932e-06
APC B-Disease 0 2.8017241859856767e-08
gene O 0 6.410244557386591e-10
variant O 0 3.196337416966344e-09
in O 0 1.8467385953790938e-10
Israeli O 0 9.04969699178082e-09
Jews O 0 3.468334286438335e-09
of O 0 4.571889811177954e-10
differing O 0 1.9270929296766326e-09
ethnic O 0 7.345513641787704e-10
origin O 0 2.4708002310802613e-09
and O 0 1.903868174224499e-09
risk O 0 1.851233975003197e-07
for O 0 4.639271082851337e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.942328935911064e-06

BACKGROUND O 0 0.00019032674026675522
& O 0 4.5185456656327005e-06
AIMS O 0 1.8058061641568202e-06
Israeli O 0 9.35967307214014e-07
Jews O 0 1.279175734225646e-07
of O 0 2.8768218029995296e-08
European O 0 2.5889582033755687e-08
birth O 0 3.0377125881386746e-07
, O 0 2.0656331756185864e-08
i O 0 1.8685733849110875e-08
. O 0 4.607029424619213e-09
e O 0 9.297920655626513e-09
. O 0 3.114015489913413e-09
, O 0 3.8849581329714056e-09
Ashkenazim O 0 1.2346132507445873e-06
, O 0 3.2679323691553464e-09
have O 0 3.924263136667605e-10
the O 0 1.3435590417998355e-08
highest O 0 0.00034647996653802693
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.2422547115420457e-06
of O 0 1.4684394811226298e-09
any O 0 3.597167896884912e-09
Israeli O 0 2.937340923381271e-06
ethnic O 0 1.7965786014428886e-07
group O 0 9.144002177663424e-08
. O 0 2.0112247511860915e-07

The O 0 2.9776622341159964e-06
I1307K O 0 1.589876046637073e-05
APC B-Disease 0 6.131527356956212e-07
gene O 0 2.0359140151526844e-08
variant O 0 1.5700854305578105e-07
was O 0 4.675772302675796e-08
found O 0 3.3328189097403538e-09
in O 0 5.865870456034372e-09
6 O 0 8.401183322348516e-07
. O 0 3.1721492632641457e-07

1 O 0 9.409712333763309e-07
% O 0 8.026691311613376e-09
of O 0 5.650014678337811e-09
American O 0 4.182795887430757e-09
Jews O 0 1.8032794812938846e-08
, O 0 1.1389372778225493e-09
28 O 0 2.123404918563665e-08
% O 0 6.109189265579573e-10
of O 0 3.3055331805087462e-09
their O 0 8.060475806814793e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.0714975573478114e-08
, O 0 9.491230024138986e-11
but O 0 6.684184455929554e-11
not O 0 1.0021371926738354e-10
in O 0 1.9984551791196736e-09
non O 0 1.5439108835835214e-07
- O 0 2.159186465178209e-07
Jews O 0 1.293019636250392e-06
. O 0 8.73217459229636e-07

We O 0 2.566619912158785e-07
assessed O 0 7.793371423758799e-07
the O 0 4.3116248349406305e-08
I1307K O 0 1.0672538337530568e-06
prevalence O 0 2.0726462324205386e-08
in O 0 2.3081039857153485e-10
Israeli O 0 2.1367432267993536e-08
Jews O 0 8.037384091608146e-09
of O 0 1.332279175869644e-09
differing O 0 4.086166516259482e-09
ethnic O 0 1.8029484571968624e-09
origin O 0 9.49364764579741e-09
and O 0 3.7071092862106525e-09
risk O 0 1.9377688431632123e-07
for O 0 6.841347385488916e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.8392657895892626e-06

METHODS O 0 1.3581754956248915e-06
DNA O 0 1.748948079693946e-07
samples O 0 1.6632245802838952e-08
from O 0 8.444904331383896e-09
500 O 0 2.146942845726585e-09
unrelated O 0 6.97952495798404e-09
Jews O 0 4.81993644996237e-09
of O 0 3.5222402772205896e-09
European O 0 8.562102138398586e-09
or O 0 3.1428000202282647e-09
non O 0 1.5268371456045315e-08
- O 0 2.0689168156451387e-09
European O 0 2.328156334385767e-09
origin O 0 6.572622002209982e-09
, O 0 4.51517101485166e-10
with O 0 8.901419878970529e-11
or O 0 4.171480383341475e-10
without O 0 1.558635331910807e-09
a O 0 2.2738344540584876e-09
personal O 0 2.9166905335387128e-08
and O 0 1.677472027949989e-08
/ O 0 6.306657240884306e-08
or O 0 8.731174006015863e-09
family O 0 7.555682302040623e-09
history O 0 2.0015688662056164e-08
of O 0 2.6878732128921e-08
neoplasia B-Disease 0 1.0023829872807255e-06
, O 0 7.117510580911812e-09
were O 0 5.989613249823833e-09
examined O 0 1.6339756214733825e-08
for O 0 1.30511579321535e-09
the O 0 9.737858519542897e-09
I1307K O 0 8.324263944814447e-08
variant O 0 6.628987136991782e-09
by O 0 9.455566329918952e-10
the O 0 6.235367777662759e-09
allele O 0 1.1499174057405526e-08
- O 0 2.0609659756587462e-08
specific O 0 1.1557399481887387e-08
oligonucleotide O 0 1.0934251122307614e-06
( O 0 1.6184088735826663e-07
ASO O 0 9.827788744587451e-06
) O 0 7.000029889070447e-09
method O 0 2.3177106811544945e-07
. O 0 5.549874231292051e-07

RESULTS O 0 5.3654821385862306e-06
In O 0 1.5325207769478766e-08
persons O 0 3.574619356072617e-08
at O 0 9.835952496928257e-09
average O 0 1.1285237633273937e-08
risk O 0 3.2880038247640186e-08
for O 0 1.8071294505261903e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.79120973398517e-09
I1307K O 0 8.658820860318883e-08
was O 0 6.967581178685123e-09
found O 0 6.277620645533943e-10
in O 0 2.6175965839314586e-09
5 O 0 3.734391498255718e-07
. O 0 5.059038699073426e-07

0 O 0 3.4114771096938057e-06
% O 0 2.7879973885092113e-08
of O 0 1.1620727491390426e-08
120 O 0 3.6161008409862916e-08
European O 0 4.031336686693976e-08
and O 0 3.407122051157785e-08
1 O 0 1.6171112520169117e-06
. O 0 5.995925107527e-07

6 O 0 1.0778973773994949e-05
% O 0 3.701077488926785e-08
of O 0 2.9613731911126706e-08
188 O 0 3.7249154871688006e-08
non O 0 7.896918674532571e-08
- O 0 3.084148758603078e-08
European O 0 3.417665794813729e-08
Jews O 0 1.7050075484803529e-07
( O 0 1.4691349470297155e-08
P O 0 5.874936732652714e-07
= O 0 4.3474809530152925e-08
0 O 0 6.085168280378639e-08
. O 0 4.375362738784361e-09
08 O 0 1.0625350910231646e-07
) O 0 5.248903978127828e-09
. O 0 9.705763659439981e-08

It O 0 7.055244566345209e-08
occurred O 0 6.804102667956613e-07
in O 0 2.5879904441694634e-08
15 O 0 1.2572359082696494e-06
. O 0 8.494217809129623e-07

4 O 0 3.68755263480125e-06
% O 0 3.1271593314841084e-08
of O 0 1.772892588292052e-08
52 O 0 1.0044617226867558e-07
Ashkenazi O 0 1.5460206270745402e-07
Israelis O 0 2.1990737764099322e-07
with O 0 1.4204297293929358e-08
familial O 0 3.8807306736998726e-06
cancer B-Disease 0 2.1333229597075842e-05
( O 0 1.8981619831492935e-08
P O 0 1.4552861102856696e-06
= O 0 2.145503152917172e-08
0 O 0 1.447020370193286e-08
. O 0 1.2880029265360804e-09
02 O 0 1.0222175106378018e-08
) O 0 6.302920685374858e-11
and O 0 2.6386740015205135e-10
was O 0 2.0993382587874976e-09
not O 0 2.4558582945033436e-10
detected O 0 5.165299743481455e-09
in O 0 1.16679843564782e-09
51 O 0 5.627786237027976e-08
non O 0 7.46320267808187e-08
- O 0 2.0130393352246756e-08
European O 0 2.7023382642710203e-08
Jews O 0 2.924958835137659e-07
at O 0 3.988392194287371e-08
increased O 0 8.809683293975468e-08
cancer B-Disease 0 6.02595775944792e-07
risk O 0 3.259962966239982e-07
. O 0 2.667391356681037e-07

Colorectal B-Disease 0 0.000801653484813869
neoplasia I-Disease 0 0.00030321264057420194
occurred O 0 1.852310924732592e-05
personally O 0 4.485442062218681e-08
or O 0 8.008733676234669e-10
in O 0 1.763495044437846e-10
the O 0 6.29340968227865e-10
families O 0 5.863328156330283e-10
of O 0 2.2504746954865595e-09
13 O 0 7.918211863966462e-09
of O 0 4.6298382017084805e-08
20 O 0 1.9122346373023902e-07
Ashkenazi O 0 1.8293174264272238e-07
I1307K O 0 1.9681658613990294e-07
carriers O 0 5.767333721706791e-09
, O 0 1.0294387564613316e-09
8 O 0 1.0689499951865855e-08
of O 0 3.262403680537318e-08
whom O 0 3.1864601623965427e-07
also O 0 7.618969988243407e-08
had O 0 1.3211508331778532e-08
a O 0 4.86199436267043e-09
personal O 0 1.982482871198954e-07
or O 0 2.0125249022839853e-08
family O 0 3.1451342863419995e-08
history O 0 1.4544616533385124e-07
of O 0 7.406987378999474e-07
noncolonic O 0 0.0002509861660655588
neoplasia B-Disease 0 0.001709149917587638
. O 0 8.858901310304645e-06

CONCLUSIONS O 0 0.00019314352539367974
The O 0 1.4571511428584927e-06
I1307K O 0 1.9100261852145195e-05
APC O 0 1.041720906869159e-06
variant O 0 1.8200563545178738e-07
may O 0 1.2792704673358912e-08
represent O 0 1.133649618623167e-08
a O 0 8.496718884032362e-09
susceptibility O 0 1.2823991824006953e-07
gene O 0 2.123040587775904e-08
for O 0 1.836960592527248e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.1535904675952224e-08
or I-Disease 0 1.8636925336323884e-09
other I-Disease 0 2.302421009403588e-08
, I-Disease 0 1.2937502624765784e-08
cancers I-Disease 0 1.1618261197554602e-07
in O 0 1.7382594252879358e-09
Ashkenazi O 0 1.0831816865675137e-07
Jews O 0 3.4305656981814536e-07
, O 0 6.599214952274224e-09
and O 0 1.1317139225752726e-08
partially O 0 1.4569050676982442e-07
explains O 0 1.1588833004338994e-08
the O 0 1.4661390990156065e-09
higher O 0 5.516324819154761e-08
incidence O 0 4.400231318868464e-06
of O 0 4.713474481832236e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.5759826776928776e-09
European O 0 1.6141202152653022e-08
Israelis O 0 2.7258778345640167e-07
. O 0 1.7584828526651108e-07

Systematic O 0 3.179278280640574e-07
analysis O 0 1.1099880481424407e-07
of O 0 1.386246992751694e-07
coproporphyrinogen O 0 4.975481715518981e-06
oxidase O 0 8.553468546779186e-07
gene O 0 2.0700801997008966e-06
defects O 1 0.9989553689956665
in O 0 5.931940449954709e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
and O 0 4.7601794506135775e-08
mutation O 0 2.822373623700969e-08
update O 0 4.7590717144885275e-07
. O 0 5.472039106280135e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 6.717687028867658e-06
HC B-Disease 1 1.0
) O 0 2.1154292539904418e-08
is O 0 1.6012343673210694e-09
an O 0 5.890480547776633e-09
acute O 1 0.9999990463256836
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.00023171689826995134
autosomal O 1 0.9999997615814209
dominant O 1 0.9999997615814209
inheritance O 0 3.339631439303048e-05
caused O 0 1.0200185442954535e-06
by O 0 3.5444664980843754e-09
deficient B-Disease 0 1.7131276308646193e-07
activity I-Disease 0 2.4763169292896237e-08
of I-Disease 0 1.6884502684888503e-08
coproporphyrinogen I-Disease 0 1.1030629138986114e-06
III I-Disease 0 0.00014561701391357929
oxidase I-Disease 0 1.9658693872770527e-06
( O 0 3.7834954014215327e-07
CPO O 0 2.2640093447989784e-05
) O 0 5.057682983533596e-08
. O 0 5.029209546592028e-07

Clinical O 0 2.4783048502285965e-06
manifestations O 0 0.0002683677012100816
of O 0 7.984168064467667e-07
the O 0 9.342651452470818e-08
disease O 0 2.21585310100636e-06
are O 0 1.0485615153932315e-10
characterized O 0 2.537307308703163e-10
by O 0 1.4156248395735815e-10
acute O 0 1.969171535165515e-06
attacks O 0 1.562913887198647e-08
of O 0 9.400329759046144e-07
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999998807907104
often O 0 2.7617936382284825e-08
precipitated O 0 1.9603781709065515e-08
by O 0 3.3193933712816204e-10
drugs O 0 5.222778654001559e-09
, O 0 2.126565368243405e-09
fasting O 0 6.392583173919775e-08
, O 0 3.591287622839445e-08
cyclical O 0 0.36445167660713196
hormonal O 0 6.711828063998837e-06
changes O 0 3.2968964092106035e-07
, O 0 1.4243750001696753e-07
or O 0 1.6251831311819842e-06
infectious B-Disease 0 0.4640311300754547
diseases I-Disease 0 0.00030529973446391523
. O 0 1.1562975714696222e-06

Skin O 1 0.9999620914459229
photosensitivity O 1 0.9999995231628418
may O 0 5.062589480075985e-06
also O 0 6.60614389857983e-08
be O 0 1.2747472410978844e-08
present O 0 5.243652978492719e-08
. O 0 5.634568083223712e-07

The O 0 2.3551262984256027e-06
seven O 0 5.594991989710252e-07
exons O 0 1.9461858755676076e-06
, O 0 4.133640985060083e-08
the O 0 4.1321587929132875e-08
exon O 0 1.451875704105987e-07
/ O 0 1.7581625399998302e-07
intron O 0 1.6887503306861618e-07
boundaries O 0 2.0418793766907584e-08
and O 0 2.5264379477363264e-09
part O 0 1.910816616046418e-09
of O 0 2.2873374305731886e-08
3 O 0 3.062454112523483e-08
noncoding O 0 3.434892548170865e-08
sequence O 0 6.038824551524158e-09
of O 0 4.96857914811244e-08
the O 0 1.769103334936517e-07
CPO O 0 1.8478467609384097e-06
gene O 0 1.1009295697306243e-08
were O 0 3.8408778380016884e-08
systematically O 0 2.9715744531699784e-08
analyzed O 0 5.290131888102678e-09
by O 0 8.148239305505456e-10
an O 0 3.068252762972179e-09
exon O 0 3.934637948788122e-09
- O 0 1.2747472410978844e-08
by O 0 8.699208464690855e-09
- O 0 3.329114122152532e-07
exon O 0 2.5746044229890686e-07
denaturing O 0 1.428388168278616e-05
gradient O 0 2.355040805923636e-06
gel O 0 1.0808480510604568e-06
electrophoresis O 0 3.4770138768180914e-07
( O 0 9.00235690437512e-08
DGGE O 0 0.00013866429799236357
) O 0 1.7858461376363266e-09
strategy O 0 3.2657516690903776e-09
followed O 0 7.732201545707085e-10
by O 0 1.0513431097924908e-10
direct O 0 1.9680348462003394e-09
sequencing O 0 2.2023505241719477e-09
in O 0 9.836885750402757e-10
seven O 0 1.5326726554576453e-08
unrelated O 0 3.5877823734153935e-07
heterozygous O 0 9.355097319030392e-08
HC B-Disease 0 0.0001007280225167051
patients O 0 1.031270890905489e-08
from O 0 1.5550401855080054e-08
France O 0 4.7297611160956876e-08
, O 0 6.9197838570289605e-09
Holland O 0 6.159693555218837e-08
, O 0 8.948087604210286e-09
and O 0 1.0113629045349626e-08
Czech O 0 1.8179033531851019e-06
Republic O 0 1.0057296094601043e-05
. O 0 1.0483920959813986e-05

Seven O 0 9.942485803549062e-07
novel O 0 2.9087800612614956e-07
mutations O 0 6.352399850584334e-08
and O 0 5.1262176725686e-09
two O 0 3.460550068723478e-09
new O 0 7.274105318089141e-09
polymorphisms O 0 4.951842811351526e-07
were O 0 1.0272155748225487e-07
detected O 0 1.0197014717050479e-06
. O 0 4.635767254512757e-07

Among O 0 4.99961743116728e-07
these O 0 2.5353505961334122e-08
mutations O 0 3.980184715146606e-08
two O 0 1.0214982637535286e-08
are O 0 2.253369713045572e-09
missense O 0 4.2165692093476537e-07
( O 0 9.87548443021069e-09
G197W O 0 8.29938812785258e-07
, O 0 1.0119650006856773e-08
W427R O 0 1.968524543372041e-07
) O 0 6.218689452275328e-10
, O 0 8.867954703895009e-10
two O 0 1.5231830241546618e-09
are O 0 1.893182277612482e-09
nonsense O 0 3.317710195460677e-07
( O 0 1.9947810514509e-08
Q306X O 0 2.67177574642119e-06
, O 0 2.0861191885046537e-08
Q385X O 0 3.1527716259915906e-07
) O 0 1.4283757510114015e-09
, O 0 2.115117414547285e-09
two O 0 4.601760306144342e-09
are O 0 3.4466840492797246e-09
small O 0 5.84252539681529e-08
deletions O 0 7.054395609884523e-07
( O 0 7.820727176977016e-08
662de14bp O 0 3.66409358321107e-06
; O 0 6.539872998700957e-08
1168del3bp O 0 3.356192337378161e-06
removing O 0 2.888495203023922e-07
a O 0 4.84704330006025e-08
glycine O 0 8.663760553417887e-08
at O 0 7.548282354719049e-08
position O 0 8.700722275989392e-08
390 O 0 1.9363493919399843e-08
) O 0 2.7264304702789843e-10
, O 0 3.47009282419819e-10
and O 0 1.0167858777165861e-09
one O 0 2.5343724896487174e-09
is O 0 8.043253840739339e-10
a O 0 2.5305422202137606e-09
splicing O 0 1.8146418767628347e-07
mutation O 0 8.66399147980701e-08
( O 0 4.042879098165031e-08
IVS1 O 0 1.4400607142306399e-05
- O 0 3.780068880132603e-07
15c O 0 9.182152211906214e-07
- O 0 1.0894412127981923e-07
- O 0 9.22233027722541e-08
> O 0 2.701699308715888e-08
g O 0 2.4763357586721213e-08
) O 0 8.998161105111535e-10
which O 0 4.229565586655326e-10
creates O 0 9.630046093889177e-09
a O 0 2.5506763368099428e-09
new O 0 3.969341744181065e-09
acceptor O 0 1.686362196551272e-07
splice O 0 1.283127858187072e-05
site O 0 4.678931418311549e-06
. O 0 1.9850890566885937e-06

The O 0 4.269614635177277e-07
pathological O 0 3.6076248761673924e-06
significance O 0 9.392856554768514e-07
of O 0 1.6403214431193192e-07
the O 0 1.306546693058408e-07
point O 0 4.052619431149651e-07
mutations O 0 7.934831103284523e-08
G197W O 0 1.2458567653084174e-06
, O 0 7.573775384628334e-09
W427R O 0 4.031352602851257e-07
, O 0 3.75071440572583e-09
and O 0 2.9913627130895293e-09
the O 0 2.4228411277249506e-08
in O 0 6.7218297594706655e-09
- O 0 1.1730118387731636e-07
frame O 0 4.726000781829498e-07
deletion O 0 2.8718218914036697e-08
390delGly O 0 1.0704254549409598e-07
were O 0 3.848979357456983e-09
assessed O 0 1.4203241249788334e-08
by O 0 9.37538269241145e-10
their O 0 4.260025665558942e-09
respective O 0 1.1638410768455287e-07
expression O 0 5.667199687309221e-08
in O 0 1.621395240292145e-09
a O 0 3.2970202124005255e-09
prokaryotic O 0 1.0809976913606079e-08
system O 0 3.311098728531192e-09
using O 0 5.042057438231495e-09
site O 0 1.3388475395004207e-07
- O 0 1.2962802031779574e-07
directed O 0 1.2991574749321444e-07
mutagenesis O 0 7.627855211467249e-06
. O 0 1.0863343504752265e-06

These O 0 1.1905003560741534e-07
mutations O 0 8.962882702689967e-08
resulted O 0 9.875319761931678e-08
in O 0 1.6261275659346097e-09
the O 0 7.070369623107808e-09
absence O 0 6.962270049371e-08
or O 0 8.879430524189047e-10
a O 0 9.569909309448121e-10
dramatic O 0 3.0269543316308045e-08
decrease O 0 1.946796857055233e-07
of O 0 4.42216418150565e-07
CPO O 0 0.00019591645104810596
activity O 0 2.5234305667254375e-06
. O 0 1.4821630429651123e-06

The O 0 6.422709475373267e-07
two O 0 4.1091542613003185e-08
polymorphisms O 0 1.467353172301955e-07
were O 0 7.493653697565605e-09
localized O 0 5.320228169125585e-08
in O 0 4.4863701642583464e-10
noncoding O 0 2.5406754033951984e-08
part O 0 2.0461825567252845e-09
of O 0 1.0295218011435736e-08
the O 0 5.222818622030445e-09
gene O 0 1.2229411927577871e-09
1 O 0 1.6092998933459057e-08
) O 0 1.1334064242696229e-10
a O 0 1.493488444026525e-09
C O 0 7.631128795537734e-08
/ O 0 9.023567670851662e-09
G O 0 1.9450482113825274e-08
polymorphism O 0 2.602998927514477e-09
in O 0 2.078920591230826e-09
the O 0 2.4848333168847603e-08
promotor O 0 4.245619948051171e-06
region O 0 1.4568146866622556e-07
, O 0 1.274674410467469e-08
142 O 0 1.130745559407842e-07
bp O 0 1.2295707563225733e-07
upstream O 0 3.8891565168341913e-07
from O 0 3.442192308966696e-08
the O 0 4.561024979921058e-08
transcriptional O 0 3.1715379122942977e-07
initiation O 0 5.617009080083335e-08
site O 0 3.6240069789528206e-07
( O 0 1.2188341891317123e-08
- O 0 1.404721530207098e-07
142C O 0 1.3348358152143192e-06
/ O 0 5.103898459424272e-08
G O 0 2.0156218738520693e-07
) O 0 2.2597397286716614e-09
, O 0 2.1960711027446678e-09
and O 0 2.197504178624854e-09
2 O 0 1.5030597211307395e-08
) O 0 2.7127156077000336e-10
a O 0 5.987306206378662e-09
6 O 0 5.1376826348814575e-08
bp O 0 8.64907878650456e-09
deletion O 0 7.795075696037657e-10
polymorphism O 0 3.8728980022995074e-09
in O 0 8.091354253281224e-10
the O 0 1.0534598970934894e-08
3 O 0 1.5707227518646505e-08
noncoding O 0 3.204861087624522e-08
part O 0 3.4133189608098746e-09
of O 0 2.36871215975043e-08
the O 0 2.049484777444377e-07
CPO O 0 5.0005460252577905e-06
gene O 0 2.1513956838248305e-08
, O 0 2.1028418117907677e-08
574 O 0 2.408183945590281e-07
bp O 0 1.0772911451795153e-07
downstream O 0 4.6479414095301763e-07
of O 0 3.6799463032366475e-08
the O 0 1.311649810986637e-08
last O 0 2.6248210271972994e-09
base O 0 8.02125832422007e-09
of O 0 2.03883532279292e-09
the O 0 3.0894873326303696e-09
normal O 0 2.731794701560375e-08
termination O 0 1.4643377710399363e-07
codon O 0 4.894081939710304e-07
( O 0 1.528344313328489e-07
+ O 0 2.4520516035408946e-06
574 O 0 7.033422662061639e-06
delATTCTT O 0 9.453765414946247e-06
) O 0 6.795465168352166e-08
. O 0 6.815988058406219e-07

Five O 0 3.777675829041982e-06
intragenic O 0 3.797244426095858e-05
dimorphisms O 0 1.9033526768907905e-05
are O 0 1.1725013848717936e-08
now O 0 5.144161097092592e-09
well O 0 2.0601709227463516e-09
characterized O 0 2.5664586011941992e-09
and O 0 2.846037572279414e-10
the O 0 1.3820179445289682e-09
high O 0 1.213980471703735e-08
degree O 0 1.2798000881275584e-08
of O 0 4.660802410683118e-09
allelic O 0 2.509831347197178e-07
heterogeneity O 0 7.187716164480662e-07
in O 0 1.2843777597026929e-08
HC B-Disease 1 0.9999985694885254
is O 0 1.9809419882221846e-08
demonstrated O 0 1.7722909362305472e-08
with O 0 7.341899865842549e-10
seven O 0 2.396870257825867e-09
new O 0 1.0508124370645078e-09
different O 0 3.0517743887514825e-10
mutations O 0 2.908766782994121e-09
making O 0 1.396142090825947e-09
a O 0 7.693951586951187e-10
total O 0 1.6823029636015008e-09
of O 0 1.3633226103593188e-08
nineteen O 0 1.9408439584367443e-06
CPO O 0 3.8233192753978074e-05
gene B-Disease 0 5.487230509970686e-07
defects I-Disease 1 0.9726381301879883
reported O 0 1.8736380980044487e-07
so O 0 9.659737010281333e-09
far O 0 3.811576831935781e-08
. O 0 3.1222125329577466e-08
. O 0 3.604828009429184e-07

Coincidence O 0 1.2239998795848805e-05
of O 0 8.262381356871629e-07
two O 0 3.282126570525179e-08
novel O 0 5.990575147052368e-08
arylsulfatase O 0 2.280882426930475e-06
A O 0 1.372085733919448e-07
alleles O 0 1.878392907883608e-08
and O 0 9.965590130889268e-09
mutation O 0 3.83921516800001e-08
459 O 0 1.0999246313758704e-07
+ O 0 1.0849558407244331e-07
1G O 0 4.549539880827069e-06
> O 0 7.875004115476258e-08
A O 0 5.416960391357861e-08
within O 0 3.186865216164847e-09
a O 0 3.394652781096852e-09
family O 0 6.05265082498363e-09
with O 0 2.931507703252123e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 2.0457378013816196e-09
molecular O 0 1.8018869951674787e-08
basis O 0 1.535010341058296e-08
of O 0 1.5452654267278376e-08
phenotypic O 0 2.065093667624751e-06
heterogeneity O 0 0.00011110367631772533
. O 0 8.357452315976843e-06

In O 0 7.06312093257111e-08
a O 0 3.1341816253416255e-08
family O 0 1.637045166091866e-08
with O 0 2.8208759772496705e-09
three O 0 1.3391024289433062e-08
siblings O 0 1.666874283046127e-07
, O 0 2.8529412166022894e-09
one O 0 9.225119557143557e-10
developed O 0 1.480001787790286e-09
classical O 0 4.985809454183254e-08
late O 0 2.9027935397607507e-06
infantile O 1 0.9999998807907104
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.1526209675594146e-07
MLD B-Disease 1 1.0
) O 0 5.812645031966213e-09
, O 0 7.312638494738621e-09
fatal O 0 5.323034883986111e-07
at O 0 5.4624980094786224e-08
age O 0 3.8004696278903793e-08
5 O 0 3.2404258831775223e-08
years O 0 3.7839185118571095e-09
, O 0 1.3947473176401104e-09
with O 0 2.304414659093368e-09
deficient O 0 4.962981279277301e-07
arylsulfatase O 0 9.292158210882917e-06
A O 0 4.9425766519561876e-06
( O 0 8.807482743122819e-08
ARSA O 0 8.026318027987145e-06
) O 0 2.0932846567234265e-09
activity O 0 1.0946584971804896e-08
and O 0 1.9835575404414385e-09
increased O 0 2.4751269478429094e-08
galactosylsulfatide O 0 8.669214366818778e-06
( O 0 1.9210942525660357e-07
GS O 1 1.0
) O 0 9.165583492176665e-08
excretion O 0 8.473561479149794e-07
. O 0 3.1770295549904404e-07

The O 0 7.204708936114912e-07
two O 0 4.695532496157284e-08
other O 0 2.0099625075431504e-08
siblings O 0 9.638682740842341e-07
, O 0 1.9967719921965e-08
apparently O 0 5.194577283873514e-07
healthy O 0 5.596113439310102e-08
at O 0 3.8949313108105343e-08
12 O 0 1.5517512608198558e-08
( O 0 4.378107598679293e-10
1 O 0 2.1114907156061236e-08
/ O 0 5.2703721387104e-09
2 O 0 8.431931597385756e-09
) O 0 4.321177096699991e-11
and O 0 1.3129750064955203e-10
15 O 0 1.062315235778044e-09
years O 0 1.2118284153928016e-09
, O 0 5.908300515500287e-10
respectively O 0 1.3873528992291995e-09
, O 0 3.9967193443679605e-10
and O 0 6.645314298836524e-10
their O 0 4.593954994192018e-09
father O 0 2.1330270101316273e-06
, O 0 4.082631477331233e-08
apparently O 0 3.957823082600953e-07
healthy O 0 7.114334010793755e-09
as O 0 5.550443660240489e-09
well O 0 5.906793720811265e-09
, O 0 3.471299026003294e-09
presented O 0 1.7841625776782166e-07
ARSA O 0 0.00041837868047878146
and O 0 3.21027613381375e-07
GS O 1 1.0
values O 0 2.468700799340695e-08
within O 0 2.4310609081368284e-09
the O 0 4.731590230733218e-09
range O 0 1.5214888549053285e-07
of O 0 2.3199199006285198e-07
MLD B-Disease 1 1.0
patients O 0 3.6195515917825105e-07
. O 0 5.415327564151085e-07

Mutation O 0 7.866177043069911e-08
screening O 0 1.5488890170445302e-08
and O 0 2.0042956183630167e-09
sequence O 0 1.8627153153261133e-09
analysis O 0 2.9413596003280418e-09
disclosed O 0 2.5880794396471174e-08
the O 0 3.329083231307095e-09
involvement O 0 1.6641893196833735e-08
of O 0 1.722251141700326e-08
three O 0 7.531118506598489e-10
different O 0 3.730316944228207e-09
ARSA O 0 1.4148877198749688e-05
mutations O 0 1.7123754858516804e-08
being O 0 1.5223872162906105e-09
the O 0 7.761487008650647e-10
molecular O 0 5.3491633345004175e-09
basis O 0 1.0512599679657342e-08
of O 0 1.80431172225326e-08
intrafamilial O 0 1.2628871445485856e-05
phenotypic O 0 3.074750566156581e-06
heterogeneity O 0 0.00017665786435827613
. O 0 1.0177711374126375e-05

The O 0 8.128669719553727e-07
late O 0 3.049646875297185e-05
infantile O 0 0.04076465964317322
patient O 0 1.2361455503651086e-07
inherited O 0 9.952713071470498e-07
from O 0 8.618535218829493e-08
his O 0 1.9451748300980398e-07
mother O 0 1.20747557730283e-07
the O 0 2.2300639557215618e-08
frequent O 0 1.2425984685648928e-08
0 O 0 1.8279344260463404e-07
- O 0 1.2800958870684553e-07
type O 0 2.1031389962899993e-07
mutation O 0 1.9726289224308857e-07
459 O 0 1.7236436633538688e-07
+ O 0 8.932743611467231e-08
1G O 0 1.5871560208324809e-06
> O 0 4.2509373798793604e-08
A O 0 1.2686015793406114e-07
, O 0 2.360398987377721e-09
and O 0 1.1773164665385139e-09
from O 0 6.3270890748867714e-09
his O 0 4.5028254902490517e-08
father O 0 1.20521619351166e-07
a O 0 8.11076539264377e-09
novel O 0 2.1776443759335962e-08
, O 0 1.5579011414246224e-09
single O 0 9.38574640230172e-09
basepair O 0 4.0464387893734965e-06
microdeletion O 0 4.402078047860414e-06
of O 0 3.2952306128208875e-07
guanine O 0 5.706878027922357e-07
at O 0 1.932431672457824e-07
nucleotide O 0 1.6548082726330904e-07
7 O 0 2.1278573569816217e-07
in O 0 5.5124727005306795e-09
exon O 0 1.521451054031786e-07
1 O 0 4.7278308556997217e-07
( O 0 3.213865440443442e-08
7delG O 0 1.3796083067063591e-06
) O 0 4.690850730071361e-08
. O 0 4.0466755990564707e-07

The O 0 5.570054781856015e-07
two O 0 1.7288640208334982e-07
clinically O 0 0.002298845676705241
unaffected O 0 4.106767391931498e-06
siblings O 0 3.8376856537070125e-07
carried O 0 5.871559949355287e-08
the O 0 4.287793231583237e-08
maternal O 0 1.9719902866199845e-06
mutation O 0 1.1949684619594336e-07
459 O 0 2.7693693027686095e-07
+ O 0 1.4480453103260515e-07
1G O 0 2.513939989512437e-06
> O 0 5.0092957337710686e-08
A O 0 1.3668589815551968e-07
and O 0 4.248276397333939e-09
, O 0 1.0640774927850316e-09
on O 0 2.7980646688519073e-09
their O 0 1.8765728970748796e-09
paternal O 0 1.4162982324705808e-06
allele O 0 6.637694127675786e-08
, O 0 3.832328676622865e-09
a O 0 2.3742201538112795e-09
novel O 0 6.921459849706935e-09
cytosine O 0 4.5214556543271556e-09
to O 0 1.8844279470187075e-09
thymidine O 0 6.542194341818686e-07
transition O 0 4.5500985379476333e-07
at O 0 1.653180419225464e-07
nucleotide O 0 6.934649832146533e-07
2435 O 0 1.0598855624266434e-05
in O 0 1.7970235077768848e-08
exon O 0 8.128036910193259e-08
8 O 0 1.5994503144156624e-07
, O 0 1.6214323217411675e-09
resulting O 0 4.188656088643938e-09
in O 0 1.6989409878931383e-10
substitution O 0 1.64307003558406e-08
of O 0 2.841906976414066e-08
alanine O 0 4.83446797261422e-07
464 O 0 1.06092261376034e-06
by O 0 1.3966572964818624e-07
valine O 0 9.12315008463338e-05
( O 0 2.3382780511838064e-07
A464V O 0 1.4973081306379754e-05
) O 0 1.1490770646105375e-07
. O 0 6.450073328778672e-07

The O 0 3.3215994790225523e-06
fathers O 0 4.630483999790158e-06
genotype O 0 9.575885542290052e-07
thus O 0 3.212597619040025e-07
was O 0 6.707462603117165e-07
7delG O 0 1.1964550139964558e-05
/ O 0 4.294441168894991e-06
A464V O 0 5.8370031183585525e-05
. O 0 1.8277111166753457e-06

Mutation O 0 2.2307203835225664e-06
A464V O 0 9.496541679254733e-06
was O 0 9.638373654752286e-08
not O 0 8.029704123835302e-10
found O 0 1.3283107946904238e-09
in O 0 7.003845836628386e-10
18 O 0 2.7495573817759578e-08
unrelated O 0 1.2663354027608875e-06
MLD B-Disease 1 1.0
patients O 0 3.753714850063261e-08
and O 0 7.094969500798243e-09
50 O 0 4.607453618632462e-08
controls O 0 3.950160589738516e-07
. O 0 3.24577655419489e-07

A464V O 0 0.00019938548211939633
, O 0 2.16567414668134e-07
although O 0 7.79065345568597e-08
clearly O 0 1.9266646233973006e-07
modifying O 0 1.8838089772543753e-06
ARSA O 0 0.007534367963671684
and O 0 1.522642719464784e-06
GS O 1 1.0
levels O 0 2.3036523089103866e-06
, O 0 1.1341298566946989e-08
apparently O 0 1.4445376450566982e-07
bears O 0 2.9437191528813855e-07
little O 0 8.142230889518487e-09
significance O 0 3.0284386554058074e-08
for O 0 1.8567595239105117e-09
clinical O 0 4.9981391470055314e-08
manifestation O 0 2.0240049707354046e-05
of O 0 1.991088083741488e-06
MLD B-Disease 1 1.0
, O 0 1.0978538256267711e-07
mimicking O 0 9.788921033759834e-07
the O 0 4.326453506564576e-07
frequent O 0 6.664768079645e-06
ARSA O 0 0.00897875614464283
pseudodeficiency O 0 0.0002510649210307747
allele O 0 1.72550389834214e-05
. O 0 6.517622750834562e-06

Our O 0 7.171003062467207e-07
results O 0 6.459553247850636e-08
demonstrate O 0 1.8669025436679476e-08
that O 0 3.752594346373428e-10
in O 0 1.2083795075668036e-10
certain O 0 3.4691016725929558e-09
genetic O 0 1.9324721733937622e-07
conditions O 0 6.716423968100571e-07
MLD B-Disease 1 1.0
- O 0 3.9520778045698535e-06
like O 0 1.9883354696048627e-07
ARSA O 0 0.0003635321918409318
and O 0 4.80895664622949e-07
GS O 1 1.0
values O 0 2.4855159708181418e-08
need O 0 4.401797149000686e-09
not O 0 9.742702200554731e-10
be O 0 1.1290742785163843e-09
paralleled O 0 9.728022831723138e-08
by O 0 2.3169000051836974e-09
clinical O 0 1.3636118012527731e-07
disease O 0 7.12906114586076e-07
, O 0 7.429279968995672e-10
a O 0 7.127967660558454e-10
finding O 0 4.772950035203394e-09
with O 0 5.036931982616011e-10
serious O 0 6.436259525344212e-08
diagnostic O 0 4.112079352580622e-07
and O 0 6.178815681323613e-08
prognostic O 1 0.9999948740005493
implications O 0 3.999352702521719e-05
. O 0 4.8309007070201915e-06

Moreover O 0 5.1583110689534806e-06
, O 0 1.3466177506415988e-07
further O 0 1.0160748615817283e-06
ARSA O 0 0.0006809361511841416
alleles O 0 2.2662891296931775e-07
functionally O 0 1.1006191869000759e-07
similar O 0 1.0966348940044668e-09
to O 0 1.1043445047320688e-09
A464V O 0 1.9069551626671455e-07
might O 0 3.54679308145478e-09
exist O 0 5.587940776763389e-09
which O 0 1.926751203029653e-09
, O 0 1.4726214692117878e-09
together O 0 9.315649363017542e-10
with O 0 1.556232032129401e-09
0 O 0 1.447606337023899e-07
- O 0 5.227036936616969e-08
type O 0 6.138126451560311e-08
mutations O 0 3.639224743778868e-08
, O 0 3.3449187863965335e-09
may O 0 7.015026781687084e-09
cause O 0 2.146415454262751e-06
pathological O 0 0.01597762107849121
ARSA O 1 0.8277915716171265
and O 0 1.1684480796247954e-06
GS O 1 1.0
levels O 0 5.585758344750502e-07
, O 0 1.0259849636540253e-09
but O 0 1.900967994128422e-10
not O 0 1.5855576573908792e-10
clinical O 0 5.2398512195850344e-09
outbreak O 0 5.0784368710310446e-08
of O 0 1.6432142757594193e-08
the O 0 9.507115095175322e-08
disease O 0 5.340164648259815e-07
. O 0 1.976175667550706e-08
. O 0 2.7851814365931205e-07

Human O 0 0.194505512714386
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.010911463759839535
to O 0 7.323584441110143e-07
hematological B-Disease 1 0.9999996423721313
malignancy I-Disease 1 0.9987008571624756
and O 0 1.06711695480044e-07
neurofibromatosis B-Disease 1 0.9993268251419067
type I-Disease 0 3.372583523741923e-05
1 I-Disease 0 7.579806697322056e-05
. O 0 1.3666025324710063e-06

Heterozygous O 0 1.3982421478431206e-06
germ O 0 2.0617522750399075e-05
- O 0 2.110944706146256e-06
line O 0 2.740877107498818e-07
mutations O 0 6.447856915059447e-09
in O 0 4.941713704909034e-10
the O 0 2.597890347288967e-09
DNA O 0 2.2036715563444886e-07
mismatch O 0 6.853897502878681e-05
repair O 0 3.7654863263014704e-06
genes O 0 5.857107794327021e-07
lead O 0 1.1830030643977807e-06
to O 0 2.463975761202164e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9041943914999138e-06

The O 0 1.8452374206390232e-07
disease O 0 6.881977014927543e-07
susceptibility O 0 1.6627305399197212e-07
of O 0 2.2127389698312072e-08
individuals O 0 1.2577897612331412e-09
who O 0 5.632404054267681e-08
constitutionally O 0 2.6608992342858073e-08
lack O 0 1.81166768697949e-07
both O 0 5.3092672480659076e-09
wild O 0 6.436125232767154e-08
- O 0 5.1317474714096534e-08
type O 0 3.622064781438894e-08
alleles O 0 1.121062176423493e-08
is O 0 4.145988441450754e-09
unknown O 0 1.1450451893324498e-06
. O 0 5.077623654869967e-07

We O 0 2.05586658807988e-07
have O 0 1.3636398676908357e-08
identified O 0 8.809833929035449e-08
three O 0 3.4458427222716637e-09
offspring O 0 1.3284534361446276e-08
in O 0 7.968173898476039e-10
a O 0 2.7804142987974956e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.028446364325646e-08
who O 0 1.517852510346529e-09
developed O 0 4.44852243930427e-09
hematological B-Disease 0 0.0004059628990944475
malignancy I-Disease 0 3.364145231898874e-05
at O 0 1.5458194724260466e-08
a O 0 1.575384600549512e-09
very O 0 8.343648549846705e-10
early O 0 9.833795111546806e-09
age O 0 1.2894884271474893e-08
, O 0 4.766215755402925e-10
and O 0 1.2181897712792988e-09
at O 0 2.992504022358844e-09
least O 0 1.7424286458123106e-09
two O 0 1.7216524872409877e-09
of O 0 2.5563406946815803e-09
them O 0 2.2631989615717885e-09
displayed O 0 5.112647727401054e-07
signs O 0 1.2164185818619444e-06
of O 0 7.484671016300126e-08
neurofibromatosis B-Disease 0 0.06287765502929688
type I-Disease 0 1.255042207048973e-05
1 I-Disease 0 7.603094854857773e-05
( O 0 7.352163606810791e-07
NF1 B-Disease 0 0.004141481593251228
) O 0 5.111458563078486e-07
. O 0 1.2535424502857495e-06

DNA O 0 5.857276050846849e-07
sequence O 0 5.7490936455906194e-08
analysis O 0 4.80494932730835e-08
and O 0 4.1885281909515015e-09
allele O 0 7.69782992904311e-09
- O 0 3.0950493279391367e-09
specific O 0 8.490995684340419e-10
amplification O 0 9.251166943613498e-09
in O 0 1.3362085882206998e-09
two O 0 8.638346038480904e-09
siblings O 0 4.72300030196493e-07
revealed O 0 5.756588095096049e-08
a O 0 4.81113993089366e-08
homozygous O 0 7.369882268903893e-07
MLH1 O 0 0.00017463872791267931
mutation O 0 3.486230752969277e-07
( O 0 3.950958671339322e-08
C676T O 0 2.6590430479700444e-06
- O 0 8.004486176105274e-07
- O 0 1.7092548887376324e-06
> O 0 8.101505954982713e-07
Arg226Stop O 0 5.570061603066279e-06
) O 0 3.69652006781962e-08
. O 0 1.7095599957883678e-07

Thus O 0 1.6584529021201888e-06
, O 0 2.9033804693767706e-08
a O 0 2.2007432320947373e-08
homozygous O 0 1.5656864604807197e-07
germ O 0 3.0374447305803187e-05
- O 0 5.452688583318377e-06
line O 0 2.553665353843826e-06
MLH1 O 0 6.67487911414355e-05
mutation O 0 3.875856080526319e-08
and O 0 8.045129895606351e-09
consequent O 0 0.000363785627996549
mismatch O 1 0.999995231628418
repair O 1 0.9999947547912598
deficiency O 1 1.0
results O 0 2.7079008759756107e-06
in O 0 8.49728643004255e-09
a O 0 2.6623206750286954e-08
mutator O 0 4.432138211996062e-06
phenotype O 0 5.320228169125585e-08
characterized O 0 1.927526804834656e-09
by O 0 7.746490671145523e-10
leukemia B-Disease 0 0.04166809096932411
and O 0 1.2095819101887173e-06
/ O 1 0.9990296363830566
or O 0 0.0017641463782638311
lymphoma B-Disease 1 1.0
associated O 0 0.11055852472782135
with O 0 2.4063352199732435e-08
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.00018427798931952566
1 I-Disease 0 6.6217503444931936e-06
. O 0 3.088180733357149e-08
. O 0 2.0209071749377472e-07

Missense O 0 3.5891131119569764e-05
mutations O 0 1.1134903843412758e-06
in O 0 2.713153257616341e-08
the O 0 1.8135445145617268e-08
most O 0 2.1261434834940474e-09
ancient O 0 1.598159649063291e-08
residues O 0 7.581352434726796e-08
of O 0 3.027237482911005e-08
the O 0 8.863397482627988e-08
PAX6 O 0 0.0009850008646026254
paired O 0 2.596708270630188e-07
domain O 0 1.2736056476114754e-07
underlie O 0 2.8193454681968433e-07
a O 0 5.902683231084893e-09
spectrum O 0 3.6950294202142686e-07
of O 0 2.1738973998708389e-07
human O 1 0.9999997615814209
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.00023520288232248276

Mutations O 0 1.9851952401950257e-06
of O 0 4.0563816128269536e-07
the O 0 3.5423600053263726e-08
human O 0 9.664680078458332e-08
PAX6 O 0 0.00019631213217508048
gene O 0 1.8242041051053093e-06
underlie O 1 0.998751163482666
aniridia B-Disease 1 1.0
( O 1 0.9999879598617554
congenital B-Disease 1 1.0
absence I-Disease 1 1.0
of I-Disease 1 0.9919183850288391
the I-Disease 0 2.9617795007652603e-06
iris I-Disease 0 1.0176371688430663e-05
) O 0 2.178216496062646e-09
, O 0 5.273094183522176e-10
a O 0 1.7028414234232514e-09
rare O 0 1.6563160443183733e-07
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.9999990463256836
the I-Disease 1 0.9778866767883301
eye I-Disease 1 0.9999988079071045
. O 0 2.6411726139485836e-06

The O 0 4.865475489168603e-07
spectrum O 0 3.52619940713339e-06
of O 0 1.305850560129329e-06
PAX6 O 0 0.0004787102516274899
mutations O 0 7.448724659298023e-07
in O 0 4.8603187252638236e-08
aniridia B-Disease 1 1.0
patients O 0 1.3628078221472606e-08
is O 0 8.159654618644652e-10
highly O 0 3.969993223051915e-09
biased O 0 7.22967996580337e-08
, O 0 7.847227312396399e-10
with O 0 2.1352540569008482e-10
92 O 0 3.0697407282787026e-08
% O 0 3.5138242315824186e-10
of O 0 4.6406989362424156e-10
all O 0 9.62926849368273e-10
reported O 0 9.045762361381549e-09
mutations O 0 1.0399918259906826e-08
leading O 0 1.8350899466668125e-08
to O 0 1.6450917295074419e-09
premature O 0 5.408983838606218e-07
truncation O 0 2.1217183530097827e-06
of O 0 6.048724117135862e-07
the O 0 2.0483496143697266e-07
protein O 0 8.939815074882063e-07
( O 0 1.70047620429159e-08
nonsense O 0 2.020806988412005e-07
, O 0 9.218088514728606e-09
splicing O 0 4.866905101152952e-08
, O 0 7.126992329631321e-09
insertions O 0 6.4050439618768e-08
and O 0 8.174097843038908e-09
deletions O 0 6.176941269586678e-08
) O 0 1.438488994587317e-09
and O 0 3.4104101764853567e-09
just O 0 7.947914326678074e-09
2 O 0 1.8078253560815938e-08
% O 0 4.296564770633893e-10
leading O 0 4.171702983057912e-10
to O 0 2.4397820569399542e-11
substitution O 0 4.212378890144919e-09
of O 0 1.584555597844428e-08
one O 0 8.756557257072473e-09
amino O 0 7.819948244502939e-09
acid O 0 1.7778120087186267e-09
by O 0 1.1606390293295021e-09
another O 0 9.004434531334482e-08
( O 0 8.003014784208062e-08
missense O 0 5.447460353025235e-06
) O 0 1.3202897264363855e-07
. O 0 9.89720888355805e-07

The O 0 6.545077440023306e-07
extraordinary O 0 4.595618463554274e-07
conservation O 0 3.8647135625069495e-07
of O 0 7.494999465507135e-08
the O 0 7.93218219996561e-08
PAX6 O 0 1.573537156218663e-05
protein O 0 6.090858732932247e-07
at O 0 4.276114040635548e-08
the O 0 1.4188051622454623e-08
amino O 0 5.7811138987062805e-08
acid O 0 2.043157287801023e-08
level O 0 5.2987587650932255e-08
amongst O 0 7.211789210259667e-08
vertebrates O 0 1.326814214053229e-07
predicts O 0 3.562103145782203e-08
that O 0 1.1962146828636833e-09
pathological O 0 5.834679654981301e-07
missense O 0 1.0893918442889117e-06
mutations O 0 5.084901744112358e-08
should O 0 3.386000591021343e-09
in O 0 1.0400726946357963e-09
fact O 0 2.1928021620709615e-09
be O 0 6.507491212559557e-10
common O 0 5.831909399844903e-10
even O 0 1.2995070575172463e-09
though O 0 1.6650266720930063e-09
they O 0 6.842619804103833e-10
are O 0 8.425304343084861e-10
hardly O 0 1.4259707370456454e-07
ever O 0 2.2533063415153265e-08
seen O 0 1.2675204175138788e-07
in O 0 5.330771557510161e-08
aniridia B-Disease 1 1.0
patients O 0 3.5596653447100834e-07
. O 0 6.859704626549501e-07

This O 0 3.1242738174341866e-08
indicates O 0 1.5299366395993275e-07
that O 0 1.4384231583619567e-09
there O 0 3.2000524452513446e-09
is O 0 5.712056383444519e-10
a O 0 1.6780695721863026e-09
heavy O 0 6.929182632120501e-07
ascertainment O 0 3.174909943481907e-05
bias O 0 4.1542077156009327e-07
in O 0 7.478584973519276e-10
the O 0 2.716455282936181e-09
selection O 0 6.80089629057079e-09
of O 0 5.717018858319989e-09
patients O 0 9.427905123260416e-10
for O 0 3.5634670769724153e-09
PAX6 O 0 6.576601663255133e-06
mutation O 0 6.9205627895030375e-09
analysis O 0 4.628220029445629e-09
and O 0 6.983237321733782e-10
that O 0 3.957003336108045e-10
the O 0 1.5606619996333393e-08
missing O 0 2.8148797355243005e-06
PAX6 O 0 0.00018937746062874794
missense O 0 4.264472863724222e-06
mutations O 0 2.284458417989299e-07
frequently O 0 6.419867304430227e-08
may O 0 3.080674204625211e-08
underlie O 0 1.164761579275364e-05
phenotypes O 0 5.819142188556725e-06
distinct O 0 2.44590438569503e-07
from O 0 1.3364670792270772e-07
textbook O 0 1.3356277122511528e-05
aniridia B-Disease 1 1.0
. O 0 4.863332378590712e-06

Here O 0 6.857467838017328e-07
we O 0 3.139889770409354e-08
present O 0 2.5993587726702572e-08
four O 0 2.4161957767887543e-08
novel O 0 1.6310494288518385e-07
PAX6 O 0 3.008708154084161e-05
missense O 0 2.0787726953130914e-06
mutations O 0 1.9120777494663344e-07
, O 0 1.4035439477311229e-08
two O 0 3.4836893370027155e-09
in O 0 1.0152394480655857e-09
association O 0 8.05887623300805e-09
with O 0 3.3993698966838792e-09
atypical O 0 2.8808851766370935e-06
phenotypes O 0 1.5953461343087838e-06
ectopia B-Disease 0 8.272384548035916e-06
pupillae I-Disease 0 6.710816251143115e-06
( O 0 8.071012302934832e-09
displaced B-Disease 0 2.777913152840483e-07
pupils I-Disease 0 5.1014652058256615e-08
) O 0 5.259225499543163e-09
and O 0 6.490728083008435e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999991655349731
( O 0 4.2693741875154956e-08
searching B-Disease 0 4.647506557375891e-07
gaze I-Disease 0 1.3758478871750413e-06
) O 0 3.737936071779302e-10
, O 0 1.0811064266036396e-09
and O 0 4.925812646661143e-09
two O 0 1.2631298673682068e-08
in O 0 5.267015712462353e-09
association O 0 6.896345894347178e-08
with O 0 1.0517954507349714e-08
more O 0 4.8470710112269444e-08
recognizable O 1 0.999332845211029
aniridia B-Disease 1 1.0
phenotypes O 0 1.76657904376043e-05
. O 0 1.716740257506899e-06

Strikingly O 0 3.233812458347529e-05
, O 0 1.2561210382955323e-07
all O 0 2.7247384792872253e-08
four O 0 1.7893828641035725e-08
mutations O 0 2.464424220249839e-08
are O 0 1.227006718451662e-09
located O 0 8.668219031449098e-09
within O 0 3.739049958539908e-09
the O 0 1.3627848716168955e-07
PAX6 O 0 5.2214909374015406e-05
paired O 0 1.5750045179174776e-07
domain O 0 5.7116377405463936e-08
and O 0 1.000053195809869e-08
affect O 0 5.503115474425613e-08
amino O 0 4.989367141661205e-08
acids O 0 2.525191611368882e-08
which O 0 1.6593389995378516e-09
are O 0 4.268775333216013e-10
highly O 0 4.539741027542732e-09
conserved O 0 2.1799715810288944e-08
in O 0 2.198816462239961e-09
all O 0 8.649787552883481e-09
known O 0 6.970334709421877e-08
paired O 0 1.0732139799074503e-07
domain O 0 1.46669975720215e-07
proteins O 0 2.1961105289847183e-07
. O 0 1.0286148608429357e-06

Our O 0 5.437642585093272e-07
results O 0 9.583928317624668e-08
support O 0 2.593782255644328e-08
the O 0 8.053912203820346e-09
hypothesis O 0 1.1097759156086795e-08
that O 0 7.360038967174631e-11
the O 0 7.227909382123698e-10
under O 0 1.7013220832140519e-09
- O 0 3.3954559164328657e-09
representation O 0 1.1499920127278074e-08
of O 0 3.510605495193886e-08
missense O 0 8.169626539711317e-07
mutations O 0 6.096588833770511e-08
is O 0 3.3404048416230125e-09
caused O 0 2.250227026934226e-08
by O 0 5.3501940655564795e-09
ascertainment O 1 0.9733308553695679
bias O 0 2.3180447897175327e-05
and O 0 9.435430214921325e-09
suggest O 0 1.710276720245929e-08
that O 0 8.095198400503989e-10
a O 0 2.7603386243413297e-09
substantial O 0 1.3589978209438414e-07
burden O 0 5.970424354018178e-06
of O 0 7.830487447790802e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9978805780410767
related I-Disease 1 0.9996403455734253
disease I-Disease 1 0.9999997615814209
remains O 0 2.1443948128307966e-07
to O 0 1.1966962976117657e-09
be O 0 4.34121449899294e-09
uncovered O 0 4.5224587097436597e-07
. O 0 4.490047089689142e-08
. O 0 2.820187319230172e-07

The O 0 2.642993877088884e-07
chromosomal O 0 6.048244927114865e-07
order O 0 1.076752909057177e-07
of O 0 1.8797196332798194e-07
genes O 0 1.9497137770940753e-07
controlling O 0 3.40817314281594e-06
the O 0 5.674694989465934e-07
major O 0 7.572087952212314e-07
histocompatibility O 0 1.619851536815986e-05
complex O 0 5.315967541719147e-07
, O 0 5.180711415420092e-09
properdin O 0 1.923055634733828e-07
factor O 0 1.6406836778060097e-08
B O 0 2.3698333961874596e-07
, O 0 1.1293112001098393e-09
and O 0 1.5299616018538131e-09
deficiency B-Disease 1 0.945348858833313
of I-Disease 1 0.999958872795105
the I-Disease 0 0.00012382066051941365
second I-Disease 0 1.0120809292857302e-06
component I-Disease 0 9.082102678803494e-07
of I-Disease 0 2.0240240417024324e-07
complement I-Disease 0 1.222423975377751e-06
. O 0 3.608065298976726e-06

The O 0 2.6591217761051666e-07
relationship O 0 2.4849185820130515e-08
of O 0 5.624621124411533e-08
the O 0 4.99261076924995e-09
genes O 0 9.70316493820178e-10
coding O 0 1.1153526102702926e-08
for O 0 2.5042061757574174e-09
HLA O 0 1.4957947769289603e-07
to O 0 1.5547783061009568e-09
those O 0 1.1863490190222592e-09
coding O 0 2.1650294002029113e-08
for O 0 4.161722966244952e-09
properdin O 0 4.3847640540661814e-07
Factor O 0 1.7427185028395797e-08
B O 0 1.7185372769290552e-07
allotypes O 0 1.2500800039561e-07
and O 0 7.976095894868251e-10
for O 0 1.6347542208805521e-09
deficiency B-Disease 0 3.464691189947189e-06
of I-Disease 0 2.628620904943091e-06
the I-Disease 0 4.114016505241125e-08
second I-Disease 0 1.2045148878314649e-08
component I-Disease 0 3.909907064780782e-08
of I-Disease 0 5.511950007530686e-08
complement I-Disease 0 8.602111023492398e-08
( O 0 2.5191301489257967e-08
C2 O 0 4.5713105123468267e-07
) O 0 1.3629735118314557e-09
was O 0 8.85359430213839e-09
studied O 0 4.625237526312276e-09
in O 0 9.526669730863802e-11
families O 0 1.5331105274185575e-09
of O 0 7.670306167995022e-09
patients O 0 2.47564635458275e-08
with O 0 3.473586787094973e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 9.59302815317642e-06

Patients O 0 8.00383972432428e-08
were O 0 7.706908888849284e-09
selected O 0 3.746417398531321e-09
because O 0 8.044834798326406e-10
they O 0 2.125688375320678e-10
were O 0 1.3219213501614036e-09
heterozygous O 0 9.091599473265433e-09
or O 0 1.3472594595498322e-08
homozygous O 0 6.073851182009093e-07
for O 0 6.319122803688515e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.1289186406647786e-05

12 O 0 5.322117431205697e-06
families O 0 7.369770571585832e-08
with O 0 8.744239998748071e-09
15 O 0 1.1484273443329585e-07
matings O 0 8.211932822632662e-07
informative O 0 1.5443246184076997e-06
for O 0 1.7171265653814771e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 8.442683565590414e-07
found O 0 1.029887499726101e-07
. O 0 2.9844972004866577e-07

Of O 0 4.860302942688577e-05
57 O 0 1.698139021755196e-05
informative O 0 3.74572323380562e-06
meioses O 0 1.7210519217769615e-05
, O 0 2.0306087478161317e-08
two O 0 6.773360983203247e-09
crossovers O 0 1.5716496193363128e-07
were O 0 4.884292525986211e-09
noted O 0 2.0697228819699376e-08
between O 0 3.012739213659188e-08
the O 0 2.6331765184295364e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.9814596186051858e-08
and O 0 8.043243404642908e-09
the O 0 2.527644404892726e-08
HLA O 0 1.3732287698076107e-06
- O 0 2.355323886149563e-06
B O 0 3.245518200856168e-06
gene O 0 2.4665578468585636e-09
, O 0 1.33809585634026e-09
with O 0 4.67532852710395e-11
a O 0 3.759744182652014e-10
recombinant O 0 1.031669749629316e-09
fraction O 0 1.5229515426540274e-08
of O 0 6.341831237932638e-08
0 O 0 1.625559775675356e-06
. O 0 6.627598168051918e-07

035 O 0 0.015190616250038147
. O 0 0.00012082370813004673

A O 0 1.615285327716265e-05
lod O 0 4.901014472125098e-05
score O 0 5.445364195111324e-07
of O 0 1.4692197680687968e-07
13 O 0 9.151382585059764e-08
was O 0 4.178633439266832e-09
calculated O 0 2.5915851686875158e-09
for O 0 7.710493354906589e-10
linkage O 0 2.545061079217703e-06
between O 0 1.5529556549154222e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.1662922361210804e-07
HLA O 0 1.9596753190853633e-05
- O 0 3.7809772038599476e-05
B O 0 0.0001840244367485866
at O 0 2.3552764183421004e-09
a O 0 9.106863180230462e-11
maximum O 0 7.256087397600197e-10
likelihood O 0 2.654034991778076e-09
value O 0 2.7522528700529847e-09
of O 0 1.37873990002646e-09
the O 0 2.027488399392041e-09
recombinant O 0 6.861181400807936e-09
fraction O 0 4.315228707696406e-08
of O 0 1.1628692675458296e-07
0 O 0 2.120848421327537e-06
. O 0 1.2792895631719148e-06

04 O 0 0.0060660517774522305
. O 0 8.949403854785487e-05

18 O 0 6.573641712748213e-06
families O 0 1.1068907213029888e-07
with O 0 1.887349654339232e-08
21 O 0 5.003128080716124e-07
informative O 0 2.0712757020646677e-07
matings O 0 5.59086402063258e-07
for O 0 2.4690869793175807e-08
both O 0 8.906884119141978e-08
properdin O 0 8.565193638787605e-06
Factor O 0 5.260432658360514e-07
B O 0 2.0999734715587692e-06
allotype O 0 1.2524072872110992e-06
and O 0 2.1517815085303482e-08
HLA O 0 3.3668934520392213e-06
- O 0 1.090800651581958e-05
B O 0 0.0004051649593748152
were O 0 5.273220082813168e-08
found O 0 2.4815273391709525e-08
. O 0 1.3102875584536378e-07

Of O 0 4.291763616492972e-05
72 O 0 1.0517579539737199e-05
informative O 0 2.8378067327139433e-06
meioses O 0 2.7281994334771298e-05
, O 0 2.1213324430391367e-08
three O 0 1.2186481157527851e-08
recombinants O 0 4.8395882004115265e-06
were O 0 2.184412650763079e-08
found O 0 5.8895817112158966e-09
, O 0 1.0104909131669615e-09
giving O 0 1.198482535436085e-09
a O 0 1.8945511826018446e-09
recombinant O 0 6.144366793137124e-09
fraction O 0 5.2419629525957134e-08
of O 0 8.576227372714129e-08
0 O 0 3.1366209896077635e-06
. O 0 1.4585998542315792e-06

042 O 0 0.007860698737204075
. O 0 9.602299542166293e-05

A O 0 1.4968341019994114e-05
lod O 0 4.214001455693506e-05
score O 0 6.790567113057477e-07
of O 0 1.7574835453615378e-07
16 O 0 3.114489857125591e-07
between O 0 8.980079968523569e-08
HLA O 0 3.364518079251866e-06
- O 0 3.0442834031418897e-06
B O 0 2.3195248104457278e-06
and O 0 2.329551218593906e-09
Factor O 0 1.310894504058524e-08
B O 0 2.555197227138706e-07
allotypes O 0 1.1897206775302038e-07
was O 0 6.120739470816261e-09
calculated O 0 2.7634043942015296e-09
at O 0 4.2710232572851226e-10
a O 0 6.687014830752958e-11
maximum O 0 1.160457507864976e-09
likelihood O 0 6.136800845268908e-09
value O 0 1.1653555453960962e-08
of O 0 7.001872859291325e-09
the O 0 3.1538127664987314e-09
recombinant O 0 4.120721097677915e-09
fraction O 0 6.07228756166478e-08
of O 0 1.1688287315791968e-07
0 O 0 2.348008138142177e-06
. O 0 1.2738014447677415e-06

04 O 0 0.003993974067270756
. O 0 6.567504897248e-05

A O 0 1.627126266612322e-06
crossover O 0 5.275443868413277e-07
was O 0 4.37373017803111e-08
shown O 0 7.324695294741446e-10
to O 0 4.822103827351043e-10
have O 0 4.905221229201118e-10
occurred O 0 1.2687873862660126e-08
between O 0 1.2187010289821387e-09
genes O 0 1.1568442870313334e-09
for O 0 1.2123831938382068e-09
Factor O 0 1.3264784826105824e-08
B O 0 1.87534354267882e-07
and O 0 1.263134841167357e-08
HLA O 0 2.635850478327484e-06
- O 0 6.4486243900319096e-06
D O 0 2.0731740733026527e-06
, O 0 1.697996765415155e-08
in O 0 3.860876063299656e-09
which O 0 4.130202846397424e-09
HLA O 0 7.592421411573014e-07
- O 0 2.2140113742352696e-06
D O 0 1.0257211897624074e-06
segregared O 0 2.8673832730419235e-06
with O 0 1.6064630514733835e-08
HLA O 0 2.9952491331641795e-06
- O 0 2.3374402644549264e-06
A O 0 1.002689987217309e-05
and O 0 6.636921767722015e-08
B O 0 1.3837397091265302e-05
. O 0 2.74610982842205e-07

These O 0 1.1838454838652979e-07
studies O 0 2.5631432976069846e-08
suggest O 0 1.3696403122764877e-08
that O 0 8.028508968749293e-10
the O 0 1.2535099624955137e-09
genes O 0 1.2718760489249803e-09
for O 0 9.570529924118887e-10
Factor O 0 5.8939001235103206e-08
B O 0 0.19334016740322113
and O 0 0.00011262594489380717
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.7064726843283324e-09
located O 0 3.695094008548949e-09
outside O 0 5.228041111138282e-09
those O 0 4.77564321421653e-10
for O 0 2.3955311068135643e-09
HLA O 0 6.805507291574031e-05
, O 0 2.1400254901493554e-09
that O 0 1.3048961911010792e-10
the O 0 7.618759512162399e-10
order O 0 4.478609039182402e-09
of O 0 4.8092683613276677e-08
genese O 0 1.8679445474845124e-06
is O 0 1.1698631396939163e-08
HLA O 0 6.219702868293098e-07
- O 0 6.305550641627633e-07
A O 0 5.227433575782925e-06
, O 0 2.918359953696381e-08
- O 0 8.35150615330349e-08
B O 0 1.0608255252009258e-06
, O 0 1.6040353045809752e-08
- O 0 8.362361114677697e-08
D O 0 8.165110898517014e-08
, O 0 6.294841092824299e-09
Factor O 0 4.0146627355852615e-08
B O 0 1.2773299204127397e-05
allotype O 0 0.0002030134928645566
, O 0 6.48320519758272e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.7001936242498914e-09
that O 0 6.631724336347844e-11
the O 0 3.7105876704579543e-10
genes O 0 1.8178413219160916e-09
coding O 0 7.198459428536808e-08
for O 0 2.510142849132535e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.002612368798509e-08
Factor O 0 1.4737524622887577e-07
B O 0 2.3959837562870234e-06
allotypes O 0 5.637174922412669e-07
are O 0 2.6964674937346444e-09
approximately O 0 4.366592420979032e-09
3 O 0 1.581638819914133e-08
- O 0 1.2981154817737206e-08
- O 0 4.2771581831857475e-08
5 O 0 3.8240870026129414e-08
centimorgans O 0 2.271161747557926e-07
from O 0 1.4424020200465293e-08
the O 0 1.5726204338761818e-08
HLA O 0 2.06989341222652e-07
- O 0 9.271892054130149e-08
A O 0 2.6439721523274784e-07
and O 0 1.172440988739254e-08
HLA O 0 4.669845452554e-07
- O 0 2.9313983418433054e-07
B O 0 3.005874589234736e-07
loci O 0 5.536708425069037e-09
, O 0 6.379166639369771e-10
and O 0 6.994924778291889e-11
that O 0 1.8943614038535728e-11
the O 0 2.3194236808965485e-10
apparent O 0 3.368481316101679e-08
lack O 0 2.1431226571166917e-08
of O 0 3.85757825682731e-09
recombinants O 0 2.7962954618487856e-07
between O 0 3.88684062713196e-09
the O 0 5.253190327181301e-09
Factor O 0 2.9934589917957055e-08
B O 0 8.083570151029562e-07
gene O 0 3.239833006318804e-07
and O 1 0.9999936819076538
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.091724730732494e-08
suggests O 0 3.096084100207008e-08
that O 0 2.479708105518341e-10
these O 0 5.15745113283117e-10
two O 0 1.32748512182701e-09
genes O 0 1.3816205957084549e-08
lie O 0 1.2801251614291687e-07
in O 0 3.115049107549339e-09
close O 0 1.2118941583594278e-07
proximity O 0 1.1189130191269214e-06
to O 0 1.38650442238486e-08
one O 0 1.0134139927231445e-07
another O 0 4.124761971979751e-07
. O 0 1.1545565712367534e-06

Distribution O 0 1.2856776265834924e-06
of O 0 1.1152652632517857e-06
emerin O 0 2.0801551727345213e-05
and O 0 4.07141058644811e-08
lamins O 0 1.605516445124522e-05
in O 0 1.2616514943886159e-08
the O 0 2.526160756133322e-07
heart O 0 7.598803222208517e-07
and O 0 1.1329492899392335e-08
implications O 0 2.5582744456187356e-07
for O 0 3.1439288505907825e-08
Emery B-Disease 1 0.999528169631958
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.3335855305194855

Emerin O 0 0.0001378629676764831
is O 0 1.5491082194785122e-07
a O 0 3.262478287524573e-08
nuclear O 0 2.915840298101102e-07
membrane O 0 1.095795241212727e-07
protein O 0 1.4228204747723794e-07
which O 0 4.124770747182538e-09
is O 0 3.5256144670370304e-09
missing O 0 1.468793726644435e-07
or O 0 1.9063072898006794e-08
defective O 0 2.150293994418462e-06
in O 0 4.049856272558827e-08
Emery B-Disease 1 0.9999866485595703
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
EDMD B-Disease 1 1.0
) O 0 7.429612196574453e-07
. O 0 8.367041459678148e-07

It O 0 2.2753539496989106e-08
is O 0 4.884432414087314e-09
one O 0 2.3712105612361256e-09
member O 0 4.0825982594583365e-09
of O 0 2.1264609628701692e-08
a O 0 1.1895965990049717e-08
family O 0 1.1959124890381645e-07
of O 0 6.084426331653958e-07
lamina O 1 0.9999990463256836
- O 0 0.0001364127965644002
associated O 0 2.406396106380271e-06
proteins O 0 3.531734193984448e-08
which O 0 2.9777234011874043e-09
includes O 0 9.10256581221347e-09
LAP1 O 0 0.4349820911884308
, O 0 9.923675037271096e-08
LAP2 O 0 0.3268541097640991
and O 0 3.6371153555592173e-07
lamin O 0 0.00023462231911253184
B O 0 0.00014664632908534259
receptor O 0 0.00013512645091395825
( O 0 9.089537343243137e-06
LBR O 1 0.9999946355819702
) O 0 6.948618533897388e-07
. O 0 2.273867266922025e-06

A O 0 1.2249925021023955e-05
panel O 0 1.149809691014525e-06
of O 0 2.715794380492298e-07
16 O 0 1.1744848649186679e-07
monoclonal O 0 8.672357409977849e-08
antibodies O 0 3.6931091074166034e-08
( O 0 8.384684946349807e-09
mAbs O 0 1.2302839991207293e-07
) O 0 7.299006399286156e-10
has O 0 7.59199536570776e-10
been O 0 7.478856423048796e-10
mapped O 0 2.1639796621286678e-09
to O 0 1.0582624776489524e-09
six O 0 2.5271031933726817e-09
specific O 0 3.3536835530867393e-09
sites O 0 3.728185049567401e-08
throughout O 0 2.0368617015265045e-08
the O 0 9.454890204096955e-08
emerin O 0 1.1001927759934915e-06
molecule O 0 6.680023201255381e-09
using O 0 6.427534948727498e-09
phage O 0 1.3255123221256326e-08
- O 0 1.8535722290380363e-08
displayed O 0 1.5043992718233312e-08
peptide O 0 3.3678113631196993e-09
libraries O 0 5.846959361122117e-09
and O 0 2.141601784799718e-09
has O 0 5.83200931991712e-10
been O 0 4.434423661603404e-10
used O 0 2.956330458214751e-10
to O 0 2.3412261018762592e-09
localize O 0 2.715726623137016e-06
emerin O 0 1.0046616807812825e-05
in O 0 1.3241527874185977e-08
human O 0 1.529831621382982e-07
and O 0 6.450799219237524e-07
rabbit O 0 4.989290118828649e-06
heart O 0 5.341368705558125e-06
. O 0 2.205993951065466e-06

Several O 0 3.461804226390086e-06
mAbs O 0 1.4649213881057221e-05
against O 0 2.2963212131799082e-07
different O 0 7.795856760139941e-08
emerin O 0 7.126190666895127e-06
epitopes O 0 1.1735874068108387e-06
did O 0 2.9641137544444973e-08
not O 0 5.244740641785484e-09
recognize O 0 3.0350193469530495e-08
intercalated O 0 2.7129362933919765e-07
discs O 0 6.171418220901614e-08
in O 0 3.630307165991553e-09
the O 0 7.422530501344227e-08
heart O 0 2.2761922480185603e-07
, O 0 3.5129279485346387e-09
though O 0 2.4559576594640475e-09
they O 0 1.6522961887588394e-09
recognized O 0 4.122036045828281e-08
cardiomyocyte O 0 7.632029905835225e-07
nuclei O 0 8.772640853749181e-07
strongly O 0 2.7058920437639244e-08
, O 0 4.88242957175089e-09
both O 0 1.6181212814103674e-08
at O 0 1.619722951318181e-07
the O 0 2.1549918471919227e-07
rim O 0 1.280027845496079e-06
and O 0 1.1459128756996506e-08
in O 0 1.706933083767126e-08
intranuclear O 0 9.618125477572903e-05
spots O 0 3.803298113780329e-06
or O 0 3.053018247101136e-07
channels O 0 2.1484490844159154e-06
. O 0 1.317800638389599e-06

A O 0 3.077944347751327e-05
polyclonal O 0 4.4401120248949155e-05
rabbit O 0 2.2852457277622307e-06
antiserum O 0 6.6530960793897975e-06
against O 0 4.5710839913226664e-07
emerin O 0 1.2610962585313246e-05
did O 0 2.657896480684485e-08
recognize O 0 2.35899140221818e-08
both O 0 1.721863540637969e-08
nuclear O 0 4.883586939286033e-07
membrane O 0 1.3705346191272838e-07
and O 0 4.078450022149127e-09
intercalated O 0 8.870010503869707e-08
discs O 0 2.9212223751073907e-08
but O 0 6.024696741491198e-09
, O 0 1.1886706063890529e-09
after O 0 1.6661259039096876e-09
affinity O 0 4.2992147619713705e-09
purification O 0 6.9970402805097365e-09
against O 0 6.1910458981628835e-09
a O 0 1.4382319335481952e-08
pure O 0 2.506133682800282e-07
- O 0 1.3894951678139478e-07
emerin O 0 2.169454319300712e-06
band O 0 3.034446294236659e-08
on O 0 1.603313393161443e-08
a O 0 3.4413893956752872e-09
western O 0 6.082986914179855e-08
blot O 0 1.309362232859712e-06
, O 0 5.869866370744603e-09
it O 0 2.9491566966299843e-09
stained O 0 2.0198910988256102e-06
only O 0 1.7362356885541885e-08
the O 0 3.9431142795365304e-08
nuclear O 0 4.261956291884417e-06
membrane O 0 7.697392902628053e-06
. O 0 1.0743133316282183e-06

These O 0 7.315613714808933e-08
results O 0 2.055077885643186e-08
would O 0 3.4483345068281324e-09
not O 0 1.0671893369007535e-09
be O 0 1.5227648031412855e-09
expected O 0 1.5514022067009137e-08
if O 0 2.3263066140088995e-08
immunostaining O 0 5.986937139823567e-06
at O 0 6.336559721376034e-08
intercalated O 0 1.6731557650473405e-07
discs O 0 8.895712255707622e-08
were O 0 8.88155238243371e-09
due O 0 1.025590279368771e-08
to O 0 5.256394763897276e-10
a O 0 9.930652966616549e-10
product O 0 6.369382798965262e-09
of O 0 1.930427018237424e-08
the O 0 1.708239061315453e-08
emerin O 0 7.03072714713926e-07
gene O 0 7.416329328435722e-09
and O 0 2.4627608397054246e-08
, O 0 1.746531252955208e-09
therefore O 0 5.919978729451714e-09
, O 0 1.0469193290063572e-09
cast O 0 4.144012244466921e-09
some O 0 1.2434679952377792e-09
doubt O 0 3.123112080061219e-08
upon O 0 9.219776941904456e-09
the O 0 2.157986678241741e-09
hypothesis O 0 3.5404617904077895e-08
that O 0 1.5348543547233362e-09
cardiac B-Disease 0 6.024829053785652e-05
defects I-Disease 1 0.5466173887252808
in O 0 1.5444365430994367e-07
EDMD B-Disease 1 1.0
are O 0 5.675634628943271e-09
caused O 0 9.378859999742417e-08
by O 0 3.4593756748080295e-09
absence O 0 1.0031796591647435e-05
of O 0 3.0435928692895686e-06
emerin O 0 0.009401613846421242
from O 0 1.4318524108603015e-06
intercalated O 0 1.2947895811521448e-05
discs O 0 1.1724982869054656e-05
. O 0 4.011450982943643e-06

Although O 0 5.147103934177721e-07
emerin O 0 1.765898741723504e-05
was O 0 2.0198474715016346e-07
abundant O 0 2.0953673640633497e-07
in O 0 3.0333047185138184e-09
the O 0 3.003805559842476e-08
membranes O 0 2.7189844331587665e-07
of O 0 1.6097044408525107e-07
cardiomyocyte O 0 1.2893059420093778e-06
nuclei O 0 1.967515800060937e-06
, O 0 7.761728149091596e-09
it O 0 8.985984178977446e-10
was O 0 2.1991027665535512e-08
absent O 0 3.169675011349682e-08
from O 0 4.2300354330393475e-09
many O 0 5.154376037097563e-09
non O 0 3.037782221326779e-07
- O 0 1.7968356758046866e-07
myocyte O 0 2.2269498458626913e-06
cells O 0 2.719956349039876e-08
in O 0 6.282714348770924e-09
the O 0 9.38686000040434e-08
heart O 0 1.2405084817146417e-06
. O 0 4.870643124377239e-07

This O 0 5.893019849878556e-09
distribution O 0 1.0208287193336218e-07
of O 0 1.1619491857572939e-07
emerin O 0 1.0829874554474372e-05
was O 0 1.233596602645548e-08
similar O 0 1.9842789911184155e-10
to O 0 1.9391564742843315e-10
that O 0 4.657494390158945e-10
of O 0 1.538994354177703e-08
lamin O 0 6.265488082135562e-06
A O 0 1.7487107015767833e-06
, O 0 3.3063907167729667e-09
a O 0 4.218352334106612e-09
candidate O 0 1.1960967327695471e-08
gene O 0 2.688661071559295e-09
for O 0 1.0699964470006762e-08
an O 0 1.2204950827765515e-08
autosomal O 0 4.154412991397294e-08
form O 0 4.345905679770112e-08
of O 0 1.952560523932334e-05
EDMD B-Disease 1 1.0
. O 0 1.2641136891033966e-05

In O 0 3.182484817898512e-07
contrast O 0 1.9277908904768992e-06
, O 0 2.890347161610407e-07
lamin O 0 0.0012439507991075516
B1 O 1 0.9705556035041809
was O 0 2.8394335913617397e-06
absent O 0 2.5312951947853435e-06
from O 0 1.3892791628222767e-07
cardiomyocyte O 0 3.0657381557830377e-06
nuclei O 0 2.214023879787419e-06
, O 0 9.725031446805588e-09
showing O 0 3.1398176503216746e-08
that O 0 9.71453850695525e-09
lamin O 0 3.8315651181619614e-05
B1 O 0 1.64998145919526e-05
is O 0 7.909045640630552e-10
not O 0 2.0968719816050196e-10
essential O 0 6.4912306640962925e-09
for O 0 1.0173368814037076e-09
localization O 0 2.412989260847098e-06
of O 0 2.2011006706179614e-07
emerin O 0 6.17159957982949e-06
to O 0 2.2873637206544117e-08
the O 0 2.3451184461009689e-07
nuclear O 0 3.1356277759186924e-05
lamina O 1 0.9997598528862
. O 0 7.3111741585307755e-06

Lamin O 0 0.02767924778163433
B1 O 0 0.20670528709888458
is O 0 2.543410744237917e-07
also O 0 4.8912873751305597e-08
almost O 0 3.502385581555245e-08
completely O 0 3.754531689992291e-07
absent O 0 2.6879147299041506e-06
from O 0 3.044371510441124e-07
skeletal O 0 2.670314279384911e-05
muscle O 0 4.456007900444092e-06
nuclei O 1 0.8495087027549744
. O 0 1.687145299911208e-06

In O 0 1.3478887694873265e-06
EDMD B-Disease 1 1.0
, O 0 3.8961129433801034e-08
the O 0 3.1759608276615836e-09
additional O 0 1.7494926396466326e-08
absence O 0 3.361537608270737e-07
of O 0 8.967873554865946e-07
lamin O 0 0.004354376345872879
B1 O 1 0.8243727684020996
from O 0 3.7688562315452145e-06
heart O 1 0.999481737613678
and O 0 5.1605533371912315e-05
skeletal O 1 0.9999849796295166
muscle O 0 6.2433000493911095e-06
nuclei O 1 0.9999706745147705
which O 0 5.99153509028838e-08
already O 0 1.3397001730197644e-08
lack O 0 2.1957754370305338e-07
emerin O 0 3.230557013012003e-06
may O 0 3.569500917066648e-09
offer O 0 3.6817064952288092e-09
an O 0 3.8423467185744187e-10
alternative O 0 4.4608507998589175e-09
explanation O 0 3.989411823113187e-08
of O 0 1.4268489501034765e-08
why O 0 1.9293153741273272e-08
these O 0 1.3992031533405225e-08
tissues O 0 1.015155106642851e-07
are O 0 3.770554091175882e-09
particularly O 0 2.7714186501270888e-08
affected O 0 5.413934189846259e-08
. O 0 3.9575883903353315e-08
. O 0 3.45521698363882e-07

Genetic O 0 8.662229333822324e-07
mapping O 0 6.813063464505831e-07
of O 0 5.734051455874578e-07
the O 0 8.350835400960932e-07
copper B-Disease 0 1.9921342754969373e-05
toxicosis I-Disease 0 0.0002701333141885698
locus O 0 2.0265621003545675e-07
in O 0 2.2565190604950658e-08
Bedlington O 0 2.1447525796247646e-05
terriers O 0 6.591621513507562e-06
to O 0 6.204358982131453e-08
dog O 0 2.3089964429345855e-07
chromosome O 0 1.2491243239765026e-07
10 O 0 7.012434366515663e-08
, O 0 1.854922326849362e-09
in O 0 4.4331974202727054e-10
a O 0 3.507759194221194e-09
region O 0 3.121277813988854e-08
syntenic O 0 1.2494953125496977e-06
to O 0 1.0659205074148304e-08
human O 0 6.111945083375758e-08
chromosome O 0 8.119667427308741e-07
region O 0 5.014381940782187e-07
2p13 O 0 8.261945367848966e-06
- O 0 3.199131697328994e-06
p16 O 0 6.8635595198429655e-06
. O 0 1.6155512412296957e-06

Abnormal O 1 0.999998927116394
hepatic B-Disease 1 1.0
copper I-Disease 0 8.311156125273556e-05
accumulation I-Disease 0 0.00020357909670565277
is O 0 2.5787847413027976e-09
recognized O 0 2.02070893351447e-09
as O 0 2.045526859006941e-09
an O 0 6.662298268622635e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 4.333125858124731e-08
man O 0 4.363439813914738e-07
, O 0 3.07212921768496e-09
mouse O 0 3.8185184791927895e-08
, O 0 1.4428368722008145e-08
rat O 0 1.3831557055254962e-07
and O 0 4.230295402862794e-08
dog O 0 6.52305573112244e-07
. O 0 1.1815722018582164e-06

The O 0 3.293377233148931e-07
major O 0 1.7970120325117023e-06
cause O 0 0.03748064488172531
of O 0 0.0014243365731090307
hepatic B-Disease 1 1.0
copper I-Disease 0 0.0015063644386827946
accumulation I-Disease 1 0.9956122636795044
in O 0 7.464782925126201e-08
man O 0 5.879230229766108e-06
is O 0 3.114181801322502e-09
a O 0 1.2102697510840699e-08
dysfunctional O 0 1.2944854006491369e-06
ATP7B O 1 0.5437811017036438
gene O 0 1.0441424080909201e-07
, O 0 2.057776349317919e-08
causing O 0 4.0699542296351865e-06
Wilson B-Disease 0 5.898453991903807e-07
disease I-Disease 0 0.07315348833799362
( O 0 1.337954103064476e-07
WD B-Disease 0 0.00414117518812418
) O 0 1.457466538568042e-07
. O 0 6.015926601321553e-07

Mutations O 0 1.3450073765852721e-06
in O 0 7.322872619397458e-08
the O 0 1.3813313159971585e-07
ATP7B O 0 0.0015951860696077347
genes O 0 3.482043453573169e-08
have O 0 2.1880892653314277e-09
also O 0 2.602472681800805e-09
been O 0 8.274771423621985e-10
demonstrated O 0 1.5404737485624764e-09
in O 0 1.702685548110594e-09
mouse O 0 1.7041101330050878e-07
and O 0 1.749740619061413e-07
rat O 0 2.6557077035249677e-06
. O 0 5.553717983275419e-07

The O 0 2.5071476557059214e-06
ATP7B O 0 0.0016119112260639668
gene O 0 9.748416829324924e-08
has O 0 1.3421555422610254e-08
been O 0 2.2912705066602257e-09
excluded O 0 9.391261102109638e-09
in O 0 1.0279588291695063e-10
the O 0 4.2029629776507704e-10
much O 0 9.163985126292573e-10
rarer O 0 4.973092586624261e-07
human O 0 6.930881824018797e-08
copper B-Disease 0 1.431296823284356e-06
overload I-Disease 0 0.0002357722696615383
disease O 0 1.7802678485168144e-05
non B-Disease 0 1.075943964679027e-05
- I-Disease 0 3.7888611359448987e-07
Indian I-Disease 0 1.2851276487424457e-08
childhood I-Disease 0 2.5771739728952525e-06
cirrhosis I-Disease 1 0.9999945163726807
, O 0 5.119046075918732e-09
indicating O 0 4.757483296202736e-08
genetic O 0 3.0840905651530193e-07
heterogeneity O 0 1.1170386642334051e-05
. O 0 1.1290295560684172e-06

By O 0 2.5095722833157197e-08
investigating O 0 9.459344596507435e-08
the O 0 5.221078325234885e-08
common O 0 2.550525266542536e-07
autosomal O 0 0.24083170294761658
recessive O 1 0.9998928308486938
copper B-Disease 1 0.9420458078384399
toxicosis I-Disease 1 0.9418489933013916
( O 0 1.4916507495854603e-07
CT B-Disease 0 9.181808309222106e-06
) O 0 1.5493668570343289e-09
in O 0 4.174387502331456e-09
Bedlington O 0 3.7691690522478893e-05
terriers O 0 6.306185241555795e-05
, O 0 1.0940594208364018e-08
we O 0 4.234636641342604e-09
have O 0 1.0997726063166624e-09
identified O 0 4.752266136165417e-09
a O 0 7.635299614783264e-10
new O 0 1.4520293856179478e-09
locus O 0 2.591708625487854e-09
involved O 0 2.0547163970263682e-09
in O 0 1.2124809600777553e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.492925711474527e-07

We O 0 4.221977292218071e-07
examined O 0 4.4287398281994683e-07
whether O 0 3.8500829191434605e-08
the O 0 1.1506462982424637e-07
WD B-Disease 0 1.6326195691362955e-05
gene O 0 3.7753062542833504e-07
ATP7B O 1 0.9999961853027344
was O 0 4.624560574484349e-07
also O 0 3.4710874174948003e-09
causative O 0 3.001440163075131e-08
for O 0 2.622914108130203e-09
CT B-Disease 0 6.038533229002496e-07
by O 0 2.82826762010302e-09
investigating O 0 2.967038170709202e-08
the O 0 6.419769960075428e-08
chromosomal O 0 2.662128508745809e-06
co O 0 3.912586237220239e-07
- O 0 5.081072913526441e-07
localization O 0 1.6039110050769523e-05
of O 0 3.4915121887024725e-06
ATP7B O 1 0.9987665414810181
and O 0 6.957451148537075e-08
C04107 O 0 6.547206226059643e-07
, O 0 2.2939423693912886e-09
using O 0 9.277066892465768e-10
fluorescence O 0 2.207431926137815e-08
in O 0 5.9270401919775395e-09
situ O 0 3.8807240798632847e-07
hybridization O 0 9.648250909322087e-08
( O 0 2.317780989358198e-08
FISH O 0 5.600033091468504e-06
) O 0 4.513823981255882e-08
. O 0 3.461179858277319e-07

C04107 O 0 0.0002590816584415734
is O 0 1.1857143533688941e-07
an O 0 2.1616829215531652e-08
anonymous O 0 3.393321890143852e-07
microsatellite O 0 2.6234067718178267e-06
marker O 0 7.465358748959261e-07
closely O 0 1.0372387038160014e-07
linked O 0 1.4546991451425129e-06
to O 0 2.452028127208905e-07
CT B-Disease 0 0.0009802075801417232
. O 0 1.2783358442902681e-06

However O 0 8.919180800148752e-06
, O 0 1.1877848464791896e-06
BAC O 0 4.112351598450914e-05
clones O 0 9.033935270963411e-07
containing O 0 3.9067955981408886e-07
ATP7B O 0 0.0014176855329424143
and O 0 2.1697504237749854e-08
C04107 O 0 5.448813453767798e-07
mapped O 0 1.887968892333447e-08
to O 0 4.757009453015826e-09
the O 0 4.8213824044296416e-08
canine O 0 5.847296620231646e-07
chromosome O 0 2.0063050953922357e-07
regions O 0 9.716673332604842e-08
CFA22q11 O 0 3.7499371501326095e-06
and O 0 3.4193611497812526e-08
CFA10q26 O 0 8.174612958100624e-06
, O 0 1.0306240305624215e-08
respectively O 0 9.949257417929402e-09
, O 0 1.9695369779526573e-09
demonstrating O 0 7.973209648071133e-09
that O 0 7.43235917255447e-09
WD B-Disease 0 6.186107384564821e-06
cannot O 0 6.939467311894987e-08
be O 0 1.5214590476375633e-08
homologous O 0 6.911700722866954e-08
to O 0 2.8665775175795716e-07
CT B-Disease 0 0.00023505065473727882
. O 0 2.050115426754928e-06

The O 0 1.0436518095957581e-05
copper O 0 8.792467269813642e-06
transport O 0 2.2723106667399406e-06
genes O 0 9.521629635855788e-07
CTR1 O 0 0.13085751235485077
and O 0 9.153756508339939e-08
CTR2 O 1 0.9999635219573975
were O 0 5.135978042858369e-08
also O 0 2.78397349617876e-09
excluded O 0 1.5829364485853148e-08
as O 0 3.858247943355764e-09
candidate O 0 4.632043637542438e-09
genes O 0 3.692008698763516e-09
for O 0 6.4280252232151724e-09
CT B-Disease 0 3.938780537282582e-06
since O 0 7.511225419420953e-09
they O 0 2.6284934229181545e-09
both O 0 5.352653875689839e-09
mapped O 0 3.538645643175187e-08
to O 0 1.6894036392045564e-08
canine O 0 4.987358806829434e-06
chromosome O 0 7.851373993617017e-06
region O 0 8.973623152996879e-06
CFA11q22 O 0 0.00042894991929642856
. O 0 6.623669833061285e-06

2 O 0 0.00014808848209213465
- O 0 3.384704905329272e-05
22 O 0 2.4545632186345756e-05
. O 0 2.4247285637102323e-06

5 O 0 0.00022793072275817394
. O 0 1.967271964531392e-05

A O 0 6.348200258798897e-06
transcribed O 0 3.6493250377134245e-07
sequence O 0 5.440942629775236e-08
identified O 0 7.014761393975277e-08
from O 0 2.4086036276571576e-08
the O 0 2.1613820067045708e-08
C04107 O 0 3.36315366666895e-07
- O 0 1.799273441349669e-08
containing O 0 1.018428363863677e-08
BAC O 0 2.5298106720583746e-07
was O 0 2.582210223422976e-09
found O 0 9.136370132667437e-11
to O 0 1.0273237815994207e-10
be O 0 2.989763991934069e-10
homologous O 0 1.1639511576788664e-09
to O 0 6.035643651536304e-10
a O 0 1.8175015936705563e-09
gene O 0 5.938061597987598e-09
expressed O 0 2.2863169135689532e-08
from O 0 1.476061317617905e-08
human O 0 1.4790091817928896e-08
chromosome O 0 7.743322072428782e-08
2p13 O 0 3.249313635933504e-07
- O 0 4.5595893283234545e-08
p16 O 0 3.5599295955535126e-08
, O 0 7.053878592344631e-10
a O 0 5.716198070437883e-10
region O 0 5.7148930032724365e-09
devoid O 0 3.6936449987479136e-07
of O 0 2.4393100872543982e-09
any O 0 1.4450896479445419e-08
positional O 0 7.824926797184162e-06
candidate O 0 4.70563281851355e-06
genes O 0 4.085190084879287e-06
. O 0 6.573478913196595e-06

Molecular O 0 5.761964416706178e-07
analysis O 0 1.0801201000276706e-07
of O 0 3.0666660677525215e-07
the O 0 1.297289315971284e-07
APC B-Disease 0 1.3669007614680595e-07
gene O 0 2.4148305577398332e-09
in O 0 1.7254198070304483e-09
205 O 0 2.9830897751992325e-09
families O 0 7.311198313431078e-10
: O 0 1.950857114740856e-10
extended O 0 1.0246477444297852e-08
genotype O 0 3.660785452552773e-08
- O 0 3.3731302551132103e-07
phenotype O 0 8.62644569110671e-08
correlations O 0 1.8108386257154052e-07
in O 0 4.132393538469614e-09
FAP B-Disease 0 1.1446747549825886e-07
and O 0 2.6128366137356807e-10
evidence O 0 2.79277001524747e-09
for O 0 2.8803329166215974e-10
the O 0 2.302885437899249e-09
role O 0 7.545629898686457e-09
of O 0 4.52326105460088e-08
APC B-Disease 0 1.0378739290217709e-07
amino O 0 1.2679769234580363e-08
acid O 0 4.4432311163689064e-09
changes O 0 6.361163595869357e-09
in O 0 1.0012422535510268e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999730587005615
. O 0 6.608058811252704e-07

BACKGROUND O 0 0.0006620283238589764
/ O 0 3.825630301435012e-06
AIMS O 0 1.469564608669316e-06
The O 0 1.3293759870691702e-08
development O 0 1.230600759072331e-07
of O 0 1.2786011211574078e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1293436186221584e-09
a O 0 1.881736710895865e-10
variable O 0 4.08599509782448e-09
range O 0 6.27597129820856e-09
of O 0 3.1459364002728307e-09
extracolonic O 0 5.79609104534029e-06
manifestations O 0 2.6115492801181972e-05
in O 0 1.2507716462550889e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.0518597782247525e-07
FAP B-Disease 0 5.495921413967153e-06
) O 0 6.036932620467894e-10
is O 0 1.3757184280649426e-10
the O 0 5.085992738074196e-10
result O 0 3.6857605856255304e-09
of O 0 1.5478020642945012e-08
the O 0 1.0953100648691816e-08
dominant O 0 1.5551950127701275e-06
inheritance O 0 1.4058278793527279e-05
of O 0 1.4785100574954413e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 1.0
( O 0 7.541035529357032e-07
APC B-Disease 0 1.2704360869975062e-06
) O 0 1.3323638192730414e-08
gene O 0 5.845022243988751e-08
mutations O 0 1.3207195479481015e-06
. O 0 1.3830095895173145e-06

In O 0 2.7691042348010342e-08
this O 0 1.3610874649572224e-09
study O 0 7.054510864357155e-10
, O 0 7.444922456301128e-11
direct O 0 2.5951699123005767e-10
mutation O 0 1.766400081759656e-10
analysis O 0 3.135445791890845e-10
of O 0 1.4219659894010306e-09
the O 0 8.653616490050808e-09
APC B-Disease 0 4.082460236531915e-08
gene O 0 4.596593328187737e-09
was O 0 3.6888430088311e-08
performed O 0 1.6499648869405803e-10
to O 0 2.846607394246803e-10
determine O 0 2.023807255113752e-08
genotype O 0 2.8891838610434206e-07
- O 0 4.413190879404283e-07
phenotype O 0 2.450099430006958e-07
correlations O 0 3.027653576737066e-07
for O 0 1.617423883715219e-08
nine O 0 3.004195434641588e-07
extracolonic O 0 7.646100129932165e-06
manifestations O 0 5.549969728235737e-07
and O 0 1.467756360895578e-09
to O 0 4.405977804822214e-10
investigate O 0 7.2456356470240735e-09
the O 0 9.282345558858651e-09
incidence O 0 7.869940645832685e-07
of O 0 3.327599173985618e-08
APC B-Disease 0 1.7140493469014473e-07
mutations O 0 2.5224766275755428e-08
in O 0 1.613895506125118e-08
non O 1 0.9999998807907104
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.494827870374138e-06

METHODS O 0 1.117822921514744e-05
The O 0 1.4660665783594595e-06
APC B-Disease 0 1.015409338833706e-06
gene O 0 3.822519190066487e-08
was O 0 8.222043845762528e-08
analysed O 0 1.78120345140087e-08
in O 0 1.6312874384638576e-09
190 O 0 1.3959030376042847e-08
unrelated O 0 5.0408484497665995e-08
FAP B-Disease 0 3.9008128283057886e-07
and O 0 5.015747372993928e-09
15 O 0 1.3392536857281812e-07
non O 0 0.014467461034655571
- O 1 0.9999783039093018
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.8935824847309277e-09
using O 0 2.6765347715951293e-09
denaturing O 0 1.048676494974643e-06
gradient O 0 2.1709307418404933e-07
gel O 0 7.182536165828424e-08
electrophoresis O 0 3.1800663435888055e-08
, O 0 3.4977043483763737e-09
the O 0 1.1415324685515316e-08
protein O 0 4.267094766419177e-08
truncation O 0 5.593723173547005e-08
test O 0 7.271608204462154e-09
, O 0 6.12094952501252e-09
and O 0 5.5525402054001916e-09
direct O 0 8.588570210577018e-08
sequencing O 0 4.814509111383813e-07
. O 0 1.4316599390440388e-06

RESULTS O 0 5.49973665329162e-05
Chain O 0 1.5170696769928327e-06
terminating O 0 1.1550785075087333e-06
signals O 0 2.4459905034746043e-07
were O 0 9.463979822044166e-09
only O 0 1.0188553334344874e-09
identified O 0 3.921735824974348e-09
in O 0 3.0141730777977216e-10
patients O 0 5.195472940755508e-10
belonging O 0 2.996433767776807e-09
to O 0 1.1425556056821051e-09
the O 0 3.801789105750686e-08
FAP B-Disease 0 2.7885962481377646e-06
group O 0 7.801445711663746e-09
( O 0 2.97782554170567e-09
105 O 0 1.1669865074281915e-07
patients O 0 3.5236382700531976e-09
) O 0 7.54597540009172e-09
. O 0 3.1041673764775624e-07

Amino O 0 6.920432156221068e-07
acid O 0 4.861866997885045e-08
changes O 0 7.273355695502914e-09
were O 0 3.0425639785391922e-09
identified O 0 3.5331406689209643e-09
in O 0 1.701973562084902e-10
four O 0 3.1568084257749263e-10
patients O 0 1.0499603964042592e-10
, O 0 6.080171088829189e-11
three O 0 2.330118875626397e-10
of O 0 4.98450631880587e-08
whom O 0 5.523041295418807e-07
belonged O 0 2.284720540046692e-05
to O 0 4.029789835158226e-09
the O 0 1.1445131775644768e-07
non O 0 1.3708317965210881e-06
- O 0 2.598829098587885e-07
FAP O 0 2.875643622246571e-05
group O 0 2.462907104927581e-07
of O 1 0.9978700876235962
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.5177165550994687e-06
. O 0 1.533650078044957e-07

Genotype O 0 5.452563982544234e-06
- O 0 4.443252237251727e-06
phenotype O 0 2.0231827591032925e-07
correlations O 0 1.3684579869277513e-07
identified O 0 1.0331294042487116e-08
significant O 0 1.0583113940754174e-08
differences O 0 1.2756862233231914e-08
in O 0 5.312434936399768e-10
the O 0 1.671355276400277e-09
nature O 0 3.2801783511615668e-09
of O 0 2.184690650608445e-09
certain O 0 1.8421177472305317e-08
extracolonic O 0 1.3082041732559446e-05
manifestations O 0 2.0816483470298408e-07
in O 0 1.6710046679691004e-09
FAP B-Disease 0 3.049875658689416e-07
patients O 0 3.6966432692686624e-10
belonging O 0 2.2688089185152194e-09
to O 0 1.544734118397173e-09
three O 0 8.026982634135038e-09
mutation O 0 1.985932414072522e-07
subgroups O 0 2.817090035023284e-06
. O 0 5.078437084193865e-07

CONCLUSIONS O 0 3.4394244721625e-05
Extended O 0 1.9397707546886522e-06
genotype O 0 1.5440065226357547e-06
- O 0 1.156296434601245e-06
phenotype O 0 2.385627055900841e-07
correlations O 0 3.284437752881786e-07
made O 0 6.352433690182124e-09
in O 0 3.087524125255925e-10
this O 0 7.061574935907089e-11
study O 0 1.1928490140089565e-10
may O 0 1.6892215404240574e-10
have O 0 2.608663562941871e-10
the O 0 1.7830859011525035e-09
potential O 0 9.269624179353286e-09
to O 0 6.068078817200728e-10
determine O 0 1.049302866817925e-08
the O 0 1.0177759079965654e-08
most O 0 1.411468164569385e-09
appropriate O 0 1.1013937317727596e-08
surveillance O 0 2.9055078343276364e-08
and O 0 7.158326376099922e-09
prophylactic O 0 2.3065446441705717e-07
treatment O 0 1.0621618251605014e-08
regimens O 0 5.6836073625277095e-09
for O 0 5.660604207591291e-10
those O 0 1.8110719590680446e-09
patients O 0 6.85411449818929e-10
with O 0 1.4793068159324463e-10
mutations O 0 3.6430982675028645e-09
associated O 0 2.625893991137218e-08
with O 0 1.2470188215374378e-09
life O 0 3.819844707209086e-08
threatening O 0 1.15973216452403e-06
conditions O 0 2.566074044807465e-06
. O 0 1.5291446970877587e-06

This O 0 6.248966855082472e-08
study O 0 9.74620117943914e-09
also O 0 6.079849956819317e-10
provided O 0 2.4588402425251843e-09
evidence O 0 3.0940519035738134e-09
for O 0 5.423157478645635e-10
the O 0 4.634332917419215e-09
pathological O 0 8.609084716226789e-07
nature O 0 2.408116550611794e-08
of O 0 2.293164769184841e-08
amino O 0 2.2666043264507607e-08
acid O 0 5.14467179968392e-09
changes O 0 1.6952614867449256e-09
in O 0 2.712649882496976e-09
APC O 0 1.2759981871113268e-07
associated O 0 5.637401301328282e-08
with O 0 6.280294062577241e-09
both O 0 1.883943667735366e-08
FAP B-Disease 0 1.710475407890044e-05
and O 0 8.352302671710277e-08
non O 1 0.9999988079071045
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.2203163635149394e-07
. O 0 4.017862487160073e-09
. O 0 4.4549267386173597e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 4.7975963752833195e-06
cancer B-Disease 1 0.9596393704414368
risk O 0 5.970192091808713e-07
of O 0 6.946710584543325e-08
the O 0 5.32542578923767e-08
APC O 0 1.214548774441937e-06
I1307K O 0 1.4758664974579006e-06
polymorphism O 0 3.781720465667604e-07
. O 0 5.146504804542928e-07

Germ O 0 7.839690806576982e-05
- O 0 1.1370968422852457e-05
line O 0 1.6745043467381038e-06
and O 0 5.086480570071217e-09
somatic O 0 4.532303137239069e-07
truncating O 0 1.441426320525352e-07
mutations O 0 1.9990507027500826e-08
of O 0 5.3467076099877886e-08
the O 0 1.617269695941559e-08
APC B-Disease 0 3.981156737609126e-08
gene O 0 3.5795231223545443e-09
are O 0 8.967235287649089e-10
thought O 0 2.928294273729648e-09
to O 0 2.1881019218739084e-09
initiate O 0 2.270360539569083e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.6364635939680738e-06
formation O 0 4.844113377089343e-08
in O 0 3.503140888483358e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.3647349987877533e-06
sporadic O 1 0.999998927116394
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 3.078193344663305e-07
respectively O 0 3.5768161410487664e-07
. O 0 5.031502610108873e-07

Recently O 0 4.1510220398777165e-06
, O 0 7.62049623403982e-08
an O 0 8.884690316790511e-08
isoleucine O 0 3.449179985182127e-06
- O 0 6.277613806560112e-07
- O 0 1.2361047083686572e-06
> O 0 5.589530474026105e-07
lysine O 0 9.612017493054736e-07
polymorphism O 0 5.9123085094370254e-08
at O 0 6.253902995467797e-08
codon O 0 2.1215959122855566e-07
1307 O 0 1.3776124205833185e-06
( O 0 1.0821446849718086e-08
I1307K O 0 2.504723966012534e-07
) O 0 6.080209113967783e-10
of O 0 1.4716114549173653e-08
the O 0 3.432377582157642e-08
APC B-Disease 0 3.872028386808779e-08
gene O 0 3.67998653771906e-09
has O 0 3.226953815271827e-09
been O 0 7.107792687754966e-10
identified O 0 1.4426682071189134e-09
in O 0 5.365929367506794e-10
6 O 0 1.5586866908279262e-08
% O 0 7.61403828875018e-10
- O 0 1.4512486767870314e-09
7 O 0 8.40197422746769e-09
% O 0 6.83424650205211e-10
of O 0 1.116407744028436e-09
the O 0 3.9950140973132875e-09
Ashkenazi O 0 3.74236286404539e-08
Jewish O 0 4.651914409237179e-08
population O 0 5.117825718770064e-09
. O 0 8.519815963836663e-08

To O 0 3.5127889930208767e-08
assess O 0 2.667796081823326e-07
the O 0 5.221914989306242e-08
risk O 0 8.466745526902741e-08
of O 0 6.397606000518863e-09
this O 0 6.206270497521871e-10
common O 0 6.3072800315921995e-09
APC B-Disease 0 1.282537311908527e-07
allelic O 0 1.2349377698228636e-07
variant O 0 1.7206659208568453e-07
in O 0 5.1151641144997484e-08
colorectal O 1 1.0
carcinogenesis O 1 0.9999916553497314
, O 0 4.869040637345279e-08
we O 0 8.045867083694702e-09
have O 0 1.990507980664802e-09
analyzed O 0 1.0024441721157018e-08
a O 0 3.738764853267185e-09
large O 0 1.2898942358674503e-08
cohort O 0 3.3016785749850897e-08
of O 0 3.566426798329303e-08
unselected O 0 6.724751438014209e-05
Ashkenazi O 0 7.491868814213376e-07
Jewish O 0 1.3915681620346732e-06
subjects O 0 7.657963578822091e-07
with O 0 5.348737630583855e-08
adenomatous B-Disease 0 5.540373422263656e-06
polyps I-Disease 0 1.739285835355986e-07
and O 0 5.186455709349502e-09
. O 0 1.4348316312862153e-08
or O 1 0.9909449815750122
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.4524002828485436e-09
for O 0 8.309963273056553e-10
the O 0 3.200450748863659e-08
APC O 0 7.11795337338117e-07
I1307K O 0 1.2801169759768527e-06
polymorphism O 0 3.4024859019154974e-07
. O 0 9.794131301532616e-07

The O 0 1.7878292055684142e-06
APC O 0 3.814475121544092e-06
I1307K O 0 1.2063217127433745e-06
allele O 0 8.415354812996156e-08
was O 0 3.9328241996372526e-08
identified O 0 6.733801960479013e-09
in O 0 1.1036054292645758e-09
48 O 0 6.038860789203682e-08
( O 0 1.701828344913281e-09
10 O 0 5.198568242548163e-09
. O 0 7.1878469842801e-10
1 O 0 2.2810725752719918e-08
% O 0 9.285900381961198e-10
) O 0 9.35713798111415e-11
of O 0 3.990924479779778e-09
476 O 0 1.8144135083275614e-07
patients O 0 1.8710519356091027e-08
. O 0 2.40976675058846e-07

Compared O 0 5.8450776663221404e-08
with O 0 8.536072959586249e-10
the O 0 1.8598325102203717e-09
frequency O 0 1.429850460255011e-09
in O 0 7.274070235041563e-11
two O 0 8.717785521250576e-11
separate O 0 3.252259225816623e-11
population O 0 1.9665283290670743e-11
control O 0 5.687288834321791e-11
groups O 0 5.0340669133230875e-11
, O 0 1.8643563082232362e-10
the O 0 1.7948920127963675e-09
APC O 0 5.7019171606498276e-08
I1307K O 0 6.183401524140208e-08
allele O 0 7.026140558252791e-09
is O 0 4.027021216490567e-10
associated O 0 5.079170417587875e-09
with O 0 4.5401890580443194e-10
an O 0 6.66643906743758e-10
estimated O 0 2.5136956960380985e-09
relative O 0 1.1772277730415226e-07
risk O 0 3.02244878014335e-08
of O 0 1.1331204774478465e-07
1 O 0 3.753977125597885e-06
. O 0 1.1716416565832333e-06

5 O 0 0.00012762279948219657
- O 0 2.209509511885699e-05
1 O 0 1.4324043149827048e-05
. O 0 1.7275353911827551e-06

7 O 0 1.6917187167564407e-05
for O 0 7.217589086394582e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.529076099395752
( O 0 3.7800654695274716e-07
both O 0 5.075759759165521e-07
P O 0 6.191585271153599e-05
= O 0 1.2967540214958717e-06
. O 0 7.18649673103755e-08
01 O 0 3.640766863099998e-06
) O 0 6.083613612872796e-08
. O 0 4.1788908333728614e-07

Furthermore O 0 2.1620146526402095e-06
, O 0 5.5472924032073934e-08
compared O 0 7.404290158774529e-08
with O 0 1.085212009144243e-08
noncarriers O 0 1.0966355148411822e-05
, O 0 3.068821641249997e-08
APC O 0 2.7116948331240565e-07
I1307K O 0 4.833103162127372e-07
carriers O 0 1.0025970276217322e-08
had O 0 2.30643726339963e-09
increased O 0 1.880377853424875e-09
numbers O 0 5.0250354988179424e-09
of O 0 4.204185799494553e-08
adenomas B-Disease 1 0.9484845399856567
and O 0 0.0005933042266406119
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9988621473312378
per O 0 2.6876064040948222e-08
patient O 0 2.0544586476489712e-08
( O 0 1.0151238072353408e-08
P O 0 4.225709744787309e-06
= O 0 9.645931697832566e-08
. O 0 6.964392618158399e-09
03 O 0 6.632277660401087e-08
) O 0 3.8028877269447037e-10
, O 0 6.960829690427772e-10
as O 0 1.6466331631548314e-09
well O 0 1.935189120061409e-09
as O 0 6.6503136331164114e-09
a O 0 2.2123760601289177e-08
younger O 0 1.356756570203288e-06
age O 0 6.214891982381232e-06
at O 0 1.2272107596800197e-06
diagnosis O 0 3.837550138996448e-06
. O 0 8.143194918375229e-07

We O 0 2.3303708474031737e-07
conclude O 0 5.449582545224985e-07
that O 0 1.2577544339364977e-08
the O 0 5.663568813929487e-08
APC O 0 8.258458024101856e-07
I1307K O 0 4.061498941609898e-07
variant O 0 6.770908811404297e-08
leads O 0 3.2998904941905494e-08
to O 0 4.547453968939408e-09
increased O 0 3.0279653628895176e-07
adenoma B-Disease 1 1.0
formation O 0 2.4528605990781216e-07
and O 0 6.878398739473823e-09
directly O 0 6.80717748835491e-09
contributes O 0 1.933735394032965e-09
to O 0 4.722643942578486e-10
3 O 0 1.3497544415486118e-08
% O 0 1.1643929154203647e-09
- O 0 1.5092784799719539e-09
4 O 0 5.709924533192634e-09
% O 0 2.8072041913240753e-10
of O 0 6.448492850807952e-10
all O 0 2.771042062477136e-09
Ashkenazi O 0 5.1465476644807495e-06
Jewish O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.836152005642361e-07

The O 0 1.1613908412755336e-07
estimated O 0 3.5343422410960557e-08
relative O 0 1.9267859840965684e-07
risk O 0 1.4998494890505754e-08
for O 0 9.584816273999763e-10
carriers O 0 7.168683424652045e-09
may O 0 1.7636505589280205e-09
justify O 0 2.2179742487082876e-08
specific O 0 5.800130598032638e-09
clinical O 0 5.384273471520373e-09
screening O 0 3.554091465574061e-10
for O 0 5.029693328495455e-10
the O 0 3.054163588700476e-09
360 O 0 5.052348761580561e-09
, O 0 3.199830955757932e-10
000 O 0 8.65388027904146e-09
Americans O 0 6.291897558519111e-10
expected O 0 2.3972268614613768e-09
to O 0 1.773043933894769e-09
harbor O 0 1.1245083442190662e-07
this O 0 3.4435082563177843e-10
allele O 0 6.94407154000487e-09
, O 0 7.670361013012439e-10
and O 0 4.111455065292091e-10
genetic O 0 1.6211323394799138e-09
testing O 0 4.1949541063068807e-10
in O 0 4.548501575385444e-10
the O 0 3.4369223023134055e-09
setting O 0 1.8478255370268926e-08
of O 0 2.997212433797358e-08
long O 0 1.1191009008371111e-08
- O 0 6.013494413537046e-08
term O 0 1.4942149562102713e-07
- O 0 9.132864420280384e-08
outcome O 0 1.3775583340702724e-07
studies O 0 1.0023867069719472e-08
may O 0 1.487007850187183e-09
impact O 0 2.3122614933868135e-08
significantly O 0 1.1122916987460485e-07
on O 0 9.506680726190098e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 7.78040387672263e-09
in O 0 3.7149762432964195e-11
this O 0 1.1703708835408833e-10
population O 0 2.2256987364244196e-09
. O 0 5.208625353247953e-08

Localization O 0 1.612176674825605e-05
of O 0 1.5918642475298839e-06
human O 0 6.038735023139452e-07
BRCA1 O 0 1.0690926046663662e-06
and O 0 2.0342875828305296e-08
its O 0 6.721676104604057e-09
loss O 0 4.80151385318095e-08
in O 0 8.398162165690337e-09
high O 0 1.1214042388019152e-05
- O 0 1.1304236977593973e-06
grade O 0 4.7331545829365496e-06
, O 0 1.9680513219100249e-07
non B-Disease 1 1.0
- I-Disease 1 1.0
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 2.879908242903184e-05

Although O 0 1.8542040436386742e-07
the O 0 6.976121369461907e-08
link O 0 4.5240290091896895e-07
between O 0 1.6757235243858304e-07
the O 0 5.478701723404811e-07
BRCA1 O 0 8.902796253096312e-06
tumour B-Disease 1 0.9999994039535522
- O 0 4.3008000716326933e-07
suppressor O 0 7.088249844855454e-07
gene O 0 1.062826537889805e-08
and O 0 4.308722978407786e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.112539446296751e-10
established O 0 5.002016023603062e-10
, O 0 9.65604332603398e-11
the O 0 7.943863900017334e-10
role O 0 1.2814456162857368e-09
, O 0 2.0988806526123227e-10
if O 0 6.627239312884114e-10
any O 0 6.3775642544783295e-09
, O 0 3.974493179015326e-09
of O 0 3.616217725266324e-08
BRCA1 O 0 3.007451709891029e-07
in O 0 4.723009183749127e-08
non B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
familial I-Disease 1 0.9999697208404541
cancers I-Disease 1 0.9999960660934448
is O 0 1.5839392020211562e-08
unclear O 0 8.239994144787488e-07
. O 0 4.931610533276398e-07

BRCA1 O 0 1.129426800616784e-05
mutations O 0 3.9354435443783586e-07
are O 0 3.987013830197839e-09
rare O 0 1.21390630880569e-08
in O 0 3.2090676782559058e-09
sporadic B-Disease 0 2.8952546927030198e-05
cancers I-Disease 0 0.00015529803931713104
, O 0 7.184872696797129e-10
but O 0 5.395476287972656e-10
loss O 0 7.715752303738554e-08
of O 0 3.001904360644403e-07
BRCA1 O 0 8.018064789894197e-08
resulting O 0 3.3006273270075326e-08
from O 0 3.051968233691582e-09
reduced O 0 1.0841320730037296e-08
expression O 0 3.957254524067366e-09
or O 0 3.60333407556368e-09
incorrect O 0 6.788081918784883e-08
subcellular O 0 1.780933757800085e-06
localization O 0 4.948443574903649e-07
is O 0 4.637286110664718e-09
postulated O 0 3.404705495313465e-08
to O 0 2.1187354093399335e-09
be O 0 3.197447195901759e-09
important O 0 2.8249427685977935e-08
in O 0 1.66679416935267e-08
non B-Disease 0 0.05968504026532173
- I-Disease 1 0.9764019250869751
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.7454219687351724e-06

Epigenetic O 0 0.00017955161456484348
loss O 0 0.0003150702395942062
, O 0 9.900704611709443e-08
however O 0 7.640916521722829e-08
, O 0 2.341105531655785e-09
has O 0 1.9614046498084292e-10
not O 0 6.057090246036623e-11
received O 0 9.631252462227735e-10
general O 0 2.4703525891567324e-09
acceptance O 0 1.532199256359945e-08
due O 0 4.998927938260067e-09
to O 0 5.158228288948408e-10
controversy O 0 7.410474900382269e-09
regarding O 0 5.2807864747705935e-09
the O 0 6.5640026747360025e-09
subcellular O 0 4.800562237505801e-06
localization O 0 1.2246455298736691e-06
of O 0 2.693593614822021e-07
BRCA1 O 0 4.540791209706185e-08
proteins O 0 8.20030177095532e-09
, O 0 1.4848283713675414e-09
reports O 0 1.3194106252001347e-08
of O 0 8.262158956995336e-09
which O 0 5.374358735821261e-10
have O 0 5.095099897545197e-10
ranged O 0 8.329011791374796e-08
from O 0 2.710798252536506e-09
exclusively O 0 5.2068442890629285e-09
nuclear O 0 5.9042399414011015e-08
, O 0 1.3838774570729129e-09
to O 0 3.1831473012999822e-09
conditionally O 0 1.7029242371791042e-07
nuclear O 0 9.833780012513671e-08
, O 0 1.8053091244141228e-09
to O 0 5.0815351926303265e-09
the O 0 3.644073558461969e-07
ER O 0 0.0001998247462324798
/ O 0 3.710319447236543e-07
golgi O 0 3.616339881773456e-06
, O 0 1.7309750077743047e-08
to O 0 1.8987593719543838e-08
cytoplasmic O 0 6.016057795932284e-06
invaginations O 0 2.0781721104867756e-05
into O 0 1.9840091169953666e-07
the O 0 1.9547705676359328e-07
nucleus O 0 1.914815220516175e-05
. O 0 1.8913623307525995e-06

In O 0 6.500042104562453e-08
an O 0 1.5152384236216676e-08
attempt O 0 3.004493009939324e-08
to O 0 3.2259628302000465e-09
resolve O 0 2.644435603826878e-08
this O 0 1.7770830362806578e-09
issue O 0 1.0783658410673524e-08
, O 0 3.740947551733598e-09
we O 0 6.135654206929075e-09
have O 0 1.0938611794131248e-08
comprehensively O 0 7.757400339869491e-07
characterized O 0 1.4373165413417155e-07
19 O 0 5.700557039745036e-07
anti O 0 9.407934840055532e-07
- O 0 4.178438757662661e-06
BRCA1 O 0 1.3030615946263424e-06
antibodies O 0 4.4731905290973373e-07
. O 0 8.44398812205327e-07

These O 0 7.321880275412695e-07
reagents O 0 6.744061920471722e-06
detect O 0 6.422445721909753e-07
a O 0 1.6745606501444854e-07
220 O 0 1.5229406358230335e-07
- O 0 9.200211081861198e-08
kD O 0 1.0482089862762223e-07
protein O 0 1.9436612319623237e-08
localized O 0 1.5635400529845356e-08
in O 0 2.0249367460589696e-10
discrete O 0 8.24165091728446e-09
nuclear O 0 3.248550939360939e-08
foci O 0 1.4235141065910284e-07
in O 0 1.4009168269879524e-09
all O 0 1.6011519887726422e-09
epithelial O 0 2.128311962223961e-07
cell O 0 3.8013294556549226e-07
lines O 0 2.8847008337606894e-08
, O 0 2.7902236077181897e-10
including O 0 1.0348520651515258e-10
those O 0 8.286285546610372e-10
derived O 0 1.8770968779335817e-07
from O 0 1.8230596197099658e-06
breast B-Disease 0 0.00017077618394978344
malignancies I-Disease 0 6.760952237527817e-05
. O 0 1.4723757431056583e-06

Immunohistochemical O 0 0.0002117952681146562
staining O 0 4.439472468220629e-05
of O 0 4.962062121194322e-06
human O 0 3.5970060707768425e-06
breast O 0 2.5810797978920164e-06
specimens O 0 1.7912802263708727e-07
also O 0 6.938246421839267e-09
revealed O 0 2.8104484073310232e-08
BRCA1 O 0 1.832715526006723e-07
nuclear O 0 6.459343353526492e-07
foci O 0 1.4116949387243949e-05
in O 0 1.072328004170231e-07
benign O 1 1.0
breast O 1 0.9290226101875305
, O 0 1.0054815646753923e-07
invasive B-Disease 0 1.1171163350809366e-05
lobular I-Disease 1 0.9998917579650879
cancers I-Disease 1 0.9999790191650391
and O 0 1.5240318134601694e-05
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.2965096175321378e-05

Conversely O 0 2.201280267399852e-06
, O 0 2.061831594346586e-07
BRCA1 O 0 1.266178202286028e-07
expression O 0 4.900204686464349e-08
was O 0 3.542812621049052e-08
reduced O 0 1.0423132579262528e-08
or O 0 1.4835911388288991e-09
undetectable O 0 1.4187103936080803e-08
in O 0 7.396854656560592e-11
the O 0 6.929394835708536e-10
majority O 0 2.878476623724424e-10
of O 0 1.3006657972880475e-08
high O 0 2.8967263006052235e-06
- O 0 5.540870006370824e-06
grade O 0 5.967134256934514e-06
, O 0 6.10317442806263e-07
ductal B-Disease 1 0.9990148544311523
carcinomas I-Disease 1 1.0
, O 0 3.999710784796662e-09
suggesting O 0 3.5984990542914375e-09
that O 0 1.641765196014333e-10
absence O 0 8.638330086796486e-07
of O 0 1.6458119489470846e-06
BRCA1 O 0 1.1120944520826015e-07
may O 0 3.751007504604331e-09
contribute O 0 2.0052743909815263e-09
to O 0 9.191941652275659e-10
the O 0 6.942707742041421e-09
pathogenesis O 0 8.261032235168386e-06
of O 0 7.067012308681342e-09
a O 0 1.3542613697126171e-09
significant O 0 3.2189880982969044e-08
percentage O 0 7.716310506111768e-07
of O 0 2.9203699796198634e-06
sporadic B-Disease 1 0.9999998807907104
breast I-Disease 1 0.999992847442627
cancers I-Disease 1 0.9999833106994629
. O 0 2.7075500952378206e-07
. O 0 8.613322961537051e-07

